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This book documents the increased number of stem cell-related research,  clinical 
applications, and views for the future. The book covers a wide range of issues in 
cell-based  therapy and regenerative medicine, and includes clinical and preclinical 
chapters from the respected authors involved with stem cell studies and research 
from around the world.  It complements and extends the basics of stem cell 
physiology, hematopoietic stem cells, issues related to clinical problems, tissue typing, 
cryopreservation, dendritic cells, mesenchymal cells, neuroscience, endovascular 
cells and other tissues. In addition, tissue engineering that employs novel methods 
with stem cells is explored. Clearly, the continued use of biomedical engineering 
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Preface 
This book documents the increased number of stem cell-related research,  clinical
applications, and views for the future. The book covers a wide range of issues in cell-
based therapy and regenerative medicine, and includes clinical and preclinical 
chapters from the respected authors involved with stem cell studies and research from
around the world.  It complements and extends the basics of stem cell physiology,
hematopoietic stem cells, issues related to clinical problems, tissue typing, 
cryopreservation, dendritic cells, mesenchymal cells, neuroscience, endovascular cells
and other tissues. In addition, tissue engineering that employs novel methods with
stem cells is explored. Clearly, the continued use of biomedical engineering will 
depend heavily on stem cells, and this book is well positioned to provide 
comprehensive coverage of these developments. 
This book will be the the main source for clinical and preclinical publications for 
scientists working toward cell transplantation therapies with the goal of replacing
diseased cells with donor cells of various organs, and transplanting those cells close to
the injured or diseased target.  With the increased number of publications related to
stem cells and Cell Transplantation, we feel it is important to take this opportunity to
share these new developments and innovations describing stem cell research in the 
cell transplantation field with our worldwide readers.
Stem cells have a unique ability. They are able to self renew with no limit, allowing 
them to replenish themselves, as well as other cells. Another ability of stem cells is
that they are able to differentiate to any cell type. A stem cell does not differentiate 
directly to a specialized cell however- there are often multiple intermediate stages. A 
stem cell will first differentiate to a progenitor cell. A progenitor cell is similar to a 
stem cell, although they are limited in the number of times they can replicate, and 
they are also restricted in which cells they can further differentiate to. Serving as a
sort of repair system for the body, they can theoretically divide without limit in order 
to replenish other cells for the rest of the person or animal's natural life. When a stem 
cell divides, each new cell has the potential to either remain a stem cell, or become 
another type of cell with a more specialized function, such as a muscle cell, a red blood
cell, or a brain cell. 
Because of the unique abilities of stem cells, as opposed to a typical somatic cell, they
are currently the target of ongoing research. Research on stem cells is advancing in the
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knowledge about how an organism develops from a single cell and how healthy cells 
replace damaged cells in adult organisms. This promising area of science is also 
leading scientists to investigate the possibility of cell-based therapies to treat disease 
such as diabetes or heart disease. It is often referred to as regenerative medicine or 
reparative medicine. 
During this last decade, the number of published articles or books investigating the 
role of stem cells in cell transplantation or regenerative medicine increased remarkably 
across all sections of the stem cell related journals. The largest number of stem cell 
articles was published mainly in the field of neuroscience, followed by the bone, 
muscle, cartilage, and hepatocytes. Interestingly, in recent years, the number of stem 
cell articles describing the potential use of stem cell therapy and islet transplantation 
in diabetes is also slowly increasing, even though this field of endeavor could have 
one of the greatest clinical and societal impacts. 
Stem cells could have the potential to diminish the problem of the availability of 
transplantable organs that, today, limits the number of successful large-scale organ 
replacements. Several different methods using stem cells are currently used, but there 
are still several obstacles that need to be resolved before attempting to use stem cells in 
the clinic. Regarding the transplantation of differentiated cells derived from stem cells, 
one can argue that there are several regulatory, scientific, and technical issues, such as 
cell manufacturing procedures, regulatory mechanisms for differentiation, and 
developing screening methods to avoid developing inappropriate differentiated cells. 
One of the next steps in stem cell therapy is the development of treatments that will 
function not only at an early stage of transplantation, but will also remain intact 
throughout the life of the host recipient. 
It will be exciting and interesting for our readers to follow the recent developments in 
the field of stem cells and cell transplantation, via this book, such as authors’ search 
for the clues to what pathways are used by stem cells to repair tissue, or what can 
trigger wound healing, bone growth, and brain repair. Although we are close to 
finding pathways for stem cell therapies in many medical conditions, scientists need to 
be careful how they use stem cells ethically, and should not rush into clinical trials 
without carefully investigating the side effects. Focus must be on Good Manufacturing 
Procedures (GMP) and careful monitoring of the long-term effects of transplanted 
stem cells in the host. 
In conclusion, Cell Transplantation is bridging cell transplantation research in a 
multitude of disease models as methods and technology continue to be refined. The 
use of stem cells in many therapeutic areas will bring hope to many patients awaiting 
replacement of malfunctioning organs, or repairing of damaged tissues. We hope that 
this book will be an important tool and reference guide for all scientists worldwide 
who work in the field of stem cells and cell transplantation. Additionally, we hope that 
it will shed a light upon many important debatable issues in this field. 
        Preface XI 
 
I would like to thank all authors who contributed this book with excellent up to date 
chapters relaying the recent developments in the field of stem cell transplantation to 
our readers. I would like to give special thanks to Masa Vidovic, Publishing Process 
Manager, and all InTech workers for their valuable contribution in order to make this 
book available. 
 
Taner Demirer, MD, FACP 
Professor of Medicine, Hematology/Oncology 
Dept. of Hematology 
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Generation of Patient Specific Stem Cells: 
 A Human Model System 
Stina Simonsson, Cecilia Borestrom and Julia Asp 
Department of Clinical Chemistry and Transfusion Medicine,  
Institute of Biomedicine, University of Gothenburg, Gothenburg 
 Sweden 
1. Introduction 
In 2006, Shinya Yamanaka and colleagues reported that only four transcription factors 
were needed to reprogram mouse fibroblasts back in development into cells similar to 
embryonic stem cells (ESCs). These reprogrammed cells were called induced pluripotent 
stem cells (iPSCs). The year after, iPSCs were successfully produced from human 
fibroblasts and in 2008 reprogramming cells were chosen as the breakthrough of the year 
by Science magazine. In particular, this was due to the establishment of patient-specific 
cell lines from patients with various diseases using the induced pluripotent stem cell 
(iPSC) technique. IPSCs can be patient specific and therefore may prove useful in several 
applications, such as; screens for potential drugs, regenerative medicine, models for 
specific human diseases and in models for patient specific diseases. When using iPSCs in 
academics, drug development, and industry, it is important to determine whether the 
derived cells faithfully capture biological processes and relevant disease phenotypes. This 
chapter provides a summary of cell types of human origin that have been transformed 
into iPSCs and of different iPSC procedures that exist. Furthermore we discuss 
advantages and disadvantages of procedures, potential medical applications and 
implications that may arise in the iPSC field. 
1.1 Preface 
For the last three decades investigation of embryonic stem (ES) cells has resulted in better 
understanding of the molecular mechanisms involved in the differentiation process of ES 
cells to somatic cells. Under specific in vitro culture conditions, ES cells can proliferate 
indefinitely and are able to differentiate into almost all tissue specific cell lineages, if the 
appropriate extrinsic and intrinsic stimuli are provided. These properties make ES cells an 
attractive source for cell replacement therapy in the treatment of neurodegenerative 
diseases, blood disorders and diabetes. Before proceeding to a clinical setting, some 
problems still need to be overcome, like tumour formation and immunological rejection of 
the transplanted cells. To avoid the latter problem, the generation of induced pluripotent 
stem (iPS) cells have exposed the possibility to create patient specific ES-like cells whose 
differentiated progeny could be used in an autologous manner. An adult differentiated cell 
has been considered very stable, this concept has however been proven wrong 
experimentally, during the past decades.  One ultimate experimental proof has been cloning  
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Fig. 1. Schematic picture of establishment of patient-specific induced pluripotent stem cells 
(iPSCs), from which two prospective routes emerge1) in vivo transplantation 2) in vitro human 
model system. Patient-specific induced pluripotent stem cells that are similar to embryonic 
stem cells (ESCs) are produced by first 1) collecting adult somatic cells from the patient, for 
example skin fibroblasts by a skin biopsy, 2) and reprogramming by retroviral transduction of 
defined transcription factors (Oct4, c-Myc, Klf4 and Sox 2 or other combinations) in those 
somatic fibroblast cells. Reprogrammed cells are selected by the detection of endogenous 
expression of a reprogramming marker, for example Oct4. 3) Generated patient-specific iPSCs 
can be genetically corrected of a known mutation that causes the disease. 4) Expansion of 
genetically corrected patient-specific iPSCs theoretically in eternity. First prospective route 
(Route 1): 5) upon external signals (or internal) iPSCs can theoretically be stimulated to 
differentiate into any cell type in the body. 6) In this way patient-specific dopamine producing 
nerve cells or skin cells can be generated and transplanted into individuals suffering from 
Parkinson´s disease or Melanoma respectively. Second route (Route 2): Generated disease-
specific iPSCs can be used as a human in vitro system to study degenerative disorders or any 
disease, cause of disease, screening for drugs or recapitulate development. 
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animals using somatic cell nuclear transfer (SCNT) to eggs. Such experiments can result in a 
new individual from one differentiated somatic cell. The much more recent method to 
reprogram cells was the fascinating finding that mouse embryonic fibroblasts (MEFs) can be 
converted into induced pluripotent stem cells (iPSCs) by retroviral expression of four 
transcription factors: Oct4, c-Myc, Sox2 and Klf4. iPSCs are a type of pluripotent stem cell 
derived from a differentiated somatic cell by overexpression of a set of proteins. Nowadays, 
several ways of generating iPSCs have been developed and includes 1) overexpression of 
different combinations of transcription factors most efficiently in combination with 
retroviruses (step 2 in Figure 1), 2) exposure to chemical compounds in combination with 
the transcription factors Oct4, Klf4 and retroviruses, 3) retroviruses alone, 4) recombinant 
proteins or 5) mRNA. The iPSCs are named pluripotent because of their ability to 
differentiate into all different differentiation pathways. Generation of patient-specific iPSC 
lines capable of giving rise to any desired cell type provides great opportunities to treat 
many disorders either as therapeutic treatment or discovery of patient specific medicines in 
human iPSC model systems (Figure 1). Here, some of this field’s fast progress and results 
mostly concerning human cells are summarized.  
2. Reprogramming-Induced Pluripotent Stem Cells (iPSCs) 
Reprogramming is the process by which induced pluripotent stem cells (iPSCs) are 
generated and is the conversion of adult differentiated somatic cells to an embryonic-like 
state. Takahashi and Yamanaka demonstrated that retrovirus-mediated delivery of Oct4, 
Sox2, c-Myc and Klf4 is capable of inducing pluripotency in mouse fibroblasts (Takahashi 
and Yamanaka, 2006) and one year later was reported the successful reprogramming of 
human somatic fibroblast cells into iPSCs using the same transcription factors (Takahashi et 
al., 2007). Takahashi and Yamanaka came up with those four reprogramming proteins after 
a search for regulators of pluripotency among 24 cherry picked pluripotency-associated 
genes. These initial mouse iPSC lines differed from ESCs in that they had a diverse global 
gene expression pattern compared to ESCs and failed to produce adult chimeric mice. Later 
iPSCs were shown to have the ability to form live chimeric mice and were transmitted 
through the germ line to offspring when using Oct4 or Nanog as selection marker for 
reprogramming instead of Fbx15, which was used in the initial experiments (Meissner et al., 
2007; Okita et al., 2007; Wernig et al., 2007). Various combinations of the genes listed in table 
1 have been used to obtain the induced pluripotent state in human somatic cells. The first 
human iPSC lines were successfully generated by Oct4 and Sox2 combined with either, Klf4 
and c-Myc, as used earlier in the mouse model, or Nanog and Lin28 (Lowry et al., 2008; 
Nakagawa et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007). Subsequent 
reports have demonstrated that Sox2 can be replaced by Sox1, Klf4 by Klf2 and c-Myc by N-
myc or L-myc indicating that they are not fundamentally required for generation of iPSCs 
(Yamanaka, 2009). Oct4 has not yet been successfully replaced by another member of the 
Oct family to generate iPSCs which is logical due to the necessity of Oct4 in early 
development. However, Blx-01294 an inhibitor of G9a histone methyl transferase, which is 
involved in switching off Oct4 during differentiation, enables neural progenitor cells to be 
reprogrammed without exogenous Oct4, although transduction of Klf4, c-Myc and Sox2 
together with endogenous Oct4 was required (Shi et al., 2008). Recently, Oct4 has been 
replaced with steroidogenic factor 1, which controls Oct4 expression in ESCs by binding the 
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animals using somatic cell nuclear transfer (SCNT) to eggs. Such experiments can result in a 
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mostly concerning human cells are summarized.  
2. Reprogramming-Induced Pluripotent Stem Cells (iPSCs) 
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generated and is the conversion of adult differentiated somatic cells to an embryonic-like 
state. Takahashi and Yamanaka demonstrated that retrovirus-mediated delivery of Oct4, 
Sox2, c-Myc and Klf4 is capable of inducing pluripotency in mouse fibroblasts (Takahashi 
and Yamanaka, 2006) and one year later was reported the successful reprogramming of 
human somatic fibroblast cells into iPSCs using the same transcription factors (Takahashi et 
al., 2007). Takahashi and Yamanaka came up with those four reprogramming proteins after 
a search for regulators of pluripotency among 24 cherry picked pluripotency-associated 
genes. These initial mouse iPSC lines differed from ESCs in that they had a diverse global 
gene expression pattern compared to ESCs and failed to produce adult chimeric mice. Later 
iPSCs were shown to have the ability to form live chimeric mice and were transmitted 
through the germ line to offspring when using Oct4 or Nanog as selection marker for 
reprogramming instead of Fbx15, which was used in the initial experiments (Meissner et al., 
2007; Okita et al., 2007; Wernig et al., 2007). Various combinations of the genes listed in table 
1 have been used to obtain the induced pluripotent state in human somatic cells. The first 
human iPSC lines were successfully generated by Oct4 and Sox2 combined with either, Klf4 
and c-Myc, as used earlier in the mouse model, or Nanog and Lin28 (Lowry et al., 2008; 
Nakagawa et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007). Subsequent 
reports have demonstrated that Sox2 can be replaced by Sox1, Klf4 by Klf2 and c-Myc by N-
myc or L-myc indicating that they are not fundamentally required for generation of iPSCs 
(Yamanaka, 2009). Oct4 has not yet been successfully replaced by another member of the 
Oct family to generate iPSCs which is logical due to the necessity of Oct4 in early 
development. However, Blx-01294 an inhibitor of G9a histone methyl transferase, which is 
involved in switching off Oct4 during differentiation, enables neural progenitor cells to be 
reprogrammed without exogenous Oct4, although transduction of Klf4, c-Myc and Sox2 
together with endogenous Oct4 was required (Shi et al., 2008). Recently, Oct4 has been 
replaced with steroidogenic factor 1, which controls Oct4 expression in ESCs by binding the 
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Oct4 proximal promoter, and iPSCs were produced without exogenous Oct4 (Heng et al., 
2010). Remarkably, exogenous expression of E-cadherin was reported to be able to replace 
the requirement for Oct4 during reprogramming in the mouse system (Redmer et al., 
2011). iPSCs are similar to embryonic stem cells (ESCs) in morphology, proliferation and 
ability to form teratomas. In mice, pluripotency of iPSCs has been proven by tetraploid 
complementation (Zhao et al., 2009). Both ESCs and iPSCs can be used as the pluripotent 
starting cells for the generation of differentiated cells or tissues in regenerative medicine. 
However, the ethical dilemma associated with ESCs is avoided when using iPSCs since no 
embryos are destroyed when iPSCs are obtained. Moreover, iPSCs can be patient-specific 
and as such patient-specific drugs can be screened and in personalized regenerative 
medicine therapies immune rejection could be circumvented. However the question 
surrounding the potential immunogenicity remains unclear due to recent reports that 
iPSCs do not form teratomas probably because iPSCs are rejected by the immune system 
(Zhao et al., 2011). 
 
Genes Description
Oct4 Transcription factor expressed in undifferentiated pluripotent 
embryonic stem cells and germ cells during normal 
development. Together with Nanog and Sox 2, is required for 
the maintenance of pluripotent potential.
Sox2 Transcription factor expressed in undifferentiated pluripotent 
embryonic stem cells and germ cells during development. 
Together with Oct4 and Nanog, is necessary for the maintenance 
of pluripotent potential.
Myc family Proto-oncogenes, including c-Myc, first used for generation of 
human and mouse iPSCs.
Klf family Zinc-finger-containing transcription factor Kruppel-like factor 4 
(KLF4) was first used for generation of human and mouse iPSCs  
Nanog Homeodomain-containing transcription factor essential for 
maintenance of pluripotency and self-renewal in embryonic 
stem cells. Expression is controlled by a network of factors 
including the key pluripotency regulator Oct4.
Lin 28 Conserved RNA binding protein and stem cell marker. Inhibitor 
of microRNA processing in embryonic stem (ES) and carcinoma 
(EC) cells. 
Table 1. Combinations of the genes that have been used to obtain the induced pluripotent 
state in human somatic cells 
2.1 Differentiation of iPSCs into cells of the heart  
After the cells have been reprogrammed, it will be possible to differentiate them towards a 
wide range of specialized cells, using existing protocols for differentiation of hESCs. 
Differentiation of beating heart cells, the cardiomyocytes, from hESCs has now been 
achievable through various protocols for a decade (Kehat et al., 2001; Mummery et al., 2002). 
In 2007, human iPSCs were first reported to differentiate into cardiomyocytes (Takahashi et 
al., 2007), using a protocol including activin A and BMP4 which was described for 
differentiation of hESCs the same year (Laflamme et al., 2007).  A comparison between the 
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cardiac differentiation potential of hESCs and iPSCs concluded that the difference between 
the two cell sources were no greater than the known differences between different hESC 
lines and that iPSCs thus should be a viable alternative as an autologous cell source (Zhang 
et al., 2009). Furthermore, a recent study demonstrated that reprogramming excluding c-
MYC yielded iPSCs which efficiently up-regulated a cardiac gene expression pattern and 
showed spontaneous beating in contrast to iPSCs reprogrammed with four factors including 
c-MYC (Martinez-Fernandez et al., 2010). On the transcriptional level, beating clusters from 
both iPSCs and hESCs were found to be similarly enriched for cardiac genes, although a 
small difference in their global gene expression profile was noted (Gupta et al., 2010). Taken 
together, these results indicate that cardiomyocytes differentiated from both hESCs and 
iPSCs are highly similar, although differences exist.  
2.2 Additional methods to achieve reprogramming- 1.cloning = Somatic Cell Nuclear 
Transfer (SCNT) 2.cell fusion 3.egg extract 
In addition to the iPSC procedure other ways exist to reprogram somatic cells including: 1) 
somatic cell nuclear transfer (SCNT), 2) cell fusion of somatic adult cells with pluripotent 
ESCs to generate hybrid cells and 3) cell extract from ESCs or embryo carcinoma cells (ECs). 
From the time when successful SCNT experiments, more commonly known as cloning, in 
the frog Xenopus Laevis (Gurdon et al., 1958) to the creation of the sheep Dolly (Wilmut et al., 
1997), it has been proven that an adult cell nucleus transplanted into an unfertilized egg can 
support development of a new individual, and researchers have focused on identifying the 
molecular mechanisms that take place during this remarkable process. Even though SCNT 
has been around for 50 years, the molecular mechanisms that take place inside the egg 
remain largely unknown. The gigantic egg cell receiving a tiny nucleus is extremely difficult 
to study. Single cell analysis are required and gene knock-out of egg proteins is very 
challenging. In 2007 a report that the first primate ESCs were isolated from SCNT blastula 
embryos of the species Rhesus Monkey was published (Byrne et al., 2007). The reason why it 
took so long to perform successful SCNT in Rhesus Monkey was a technical issue; to 
enucleate the egg, modified polarized light was used instead of traditional methods using 
either mechanical removal of DNA or UV light mediated DNA destruction. The first reliable 
publication of successful human SCNT reported generation of a single cloned blastocyst 
(Stojkovic et al., 2005). Unfortunately, the dramatic advances in human SCNT reported by 
Hwang and colleagues in South Korea were largely a product of fraud (Cho et al., 2006). In 
human SCNT reports, left over eggs from IVF (in vitro fertilization) that failed to fertilize 
have been used, indicating poor egg quality. However, human SCNT using 29 donated eggs 
(oocytes) of good quality, and not leftovers from IVF, from three young women were 
reported to develop into cloned blastocysts, at a frequency as high as 23% (French et al., 
2008). Theoretically, hESC lines can be derived in vitro from SCNT generated blastocysts. 
However, so far no established hESC line using the SCNT procedure has been reported. The 
shortage of donated high quality human eggs for research is a significant impediment for 
this field.  
Other methods that have been used to elucidate the molecular mechanism of 
reprogramming are 2) fusion of somatic adult cells with pluripotent ESCs to generate hybrid 
cells or 3) cell extract from ESCs or ECs (Bhutani et al., 2010; Cowan et al., 2005; Freberg et 
al., 2007; Taranger et al., 2005; Yamanaka and Blau, 2010). 
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Oct4 proximal promoter, and iPSCs were produced without exogenous Oct4 (Heng et al., 
2010). Remarkably, exogenous expression of E-cadherin was reported to be able to replace 
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complementation (Zhao et al., 2009). Both ESCs and iPSCs can be used as the pluripotent 
starting cells for the generation of differentiated cells or tissues in regenerative medicine. 
However, the ethical dilemma associated with ESCs is avoided when using iPSCs since no 
embryos are destroyed when iPSCs are obtained. Moreover, iPSCs can be patient-specific 
and as such patient-specific drugs can be screened and in personalized regenerative 
medicine therapies immune rejection could be circumvented. However the question 
surrounding the potential immunogenicity remains unclear due to recent reports that 
iPSCs do not form teratomas probably because iPSCs are rejected by the immune system 
(Zhao et al., 2011). 
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of microRNA processing in embryonic stem (ES) and carcinoma 
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state in human somatic cells 
2.1 Differentiation of iPSCs into cells of the heart  
After the cells have been reprogrammed, it will be possible to differentiate them towards a 
wide range of specialized cells, using existing protocols for differentiation of hESCs. 
Differentiation of beating heart cells, the cardiomyocytes, from hESCs has now been 
achievable through various protocols for a decade (Kehat et al., 2001; Mummery et al., 2002). 
In 2007, human iPSCs were first reported to differentiate into cardiomyocytes (Takahashi et 
al., 2007), using a protocol including activin A and BMP4 which was described for 
differentiation of hESCs the same year (Laflamme et al., 2007).  A comparison between the 
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cardiac differentiation potential of hESCs and iPSCs concluded that the difference between 
the two cell sources were no greater than the known differences between different hESC 
lines and that iPSCs thus should be a viable alternative as an autologous cell source (Zhang 
et al., 2009). Furthermore, a recent study demonstrated that reprogramming excluding c-
MYC yielded iPSCs which efficiently up-regulated a cardiac gene expression pattern and 
showed spontaneous beating in contrast to iPSCs reprogrammed with four factors including 
c-MYC (Martinez-Fernandez et al., 2010). On the transcriptional level, beating clusters from 
both iPSCs and hESCs were found to be similarly enriched for cardiac genes, although a 
small difference in their global gene expression profile was noted (Gupta et al., 2010). Taken 
together, these results indicate that cardiomyocytes differentiated from both hESCs and 
iPSCs are highly similar, although differences exist.  
2.2 Additional methods to achieve reprogramming- 1.cloning = Somatic Cell Nuclear 
Transfer (SCNT) 2.cell fusion 3.egg extract 
In addition to the iPSC procedure other ways exist to reprogram somatic cells including: 1) 
somatic cell nuclear transfer (SCNT), 2) cell fusion of somatic adult cells with pluripotent 
ESCs to generate hybrid cells and 3) cell extract from ESCs or embryo carcinoma cells (ECs). 
From the time when successful SCNT experiments, more commonly known as cloning, in 
the frog Xenopus Laevis (Gurdon et al., 1958) to the creation of the sheep Dolly (Wilmut et al., 
1997), it has been proven that an adult cell nucleus transplanted into an unfertilized egg can 
support development of a new individual, and researchers have focused on identifying the 
molecular mechanisms that take place during this remarkable process. Even though SCNT 
has been around for 50 years, the molecular mechanisms that take place inside the egg 
remain largely unknown. The gigantic egg cell receiving a tiny nucleus is extremely difficult 
to study. Single cell analysis are required and gene knock-out of egg proteins is very 
challenging. In 2007 a report that the first primate ESCs were isolated from SCNT blastula 
embryos of the species Rhesus Monkey was published (Byrne et al., 2007). The reason why it 
took so long to perform successful SCNT in Rhesus Monkey was a technical issue; to 
enucleate the egg, modified polarized light was used instead of traditional methods using 
either mechanical removal of DNA or UV light mediated DNA destruction. The first reliable 
publication of successful human SCNT reported generation of a single cloned blastocyst 
(Stojkovic et al., 2005). Unfortunately, the dramatic advances in human SCNT reported by 
Hwang and colleagues in South Korea were largely a product of fraud (Cho et al., 2006). In 
human SCNT reports, left over eggs from IVF (in vitro fertilization) that failed to fertilize 
have been used, indicating poor egg quality. However, human SCNT using 29 donated eggs 
(oocytes) of good quality, and not leftovers from IVF, from three young women were 
reported to develop into cloned blastocysts, at a frequency as high as 23% (French et al., 
2008). Theoretically, hESC lines can be derived in vitro from SCNT generated blastocysts. 
However, so far no established hESC line using the SCNT procedure has been reported. The 
shortage of donated high quality human eggs for research is a significant impediment for 
this field.  
Other methods that have been used to elucidate the molecular mechanism of 
reprogramming are 2) fusion of somatic adult cells with pluripotent ESCs to generate hybrid 
cells or 3) cell extract from ESCs or ECs (Bhutani et al., 2010; Cowan et al., 2005; Freberg et 
al., 2007; Taranger et al., 2005; Yamanaka and Blau, 2010). 
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3. Molecular mechanisms of reprogramming 
The mechanisms of nuclear reprogramming are not yet completely understood. The crucial 
event during reprogramming is the activation of ES- and the silencing of differentiation 
markers, while the genetic code remains intact. Major reprogramming of gene expression 
takes place inside the egg and genes that have been silenced during embryo development 
are awakened. In contrast, genes that are expressed in, and are specific for, the donated cell 
nucleus become inactivated most of the time, however some SCNT embryos remember their 
heritage and fail to inactivate somatic-specific genes (Ng and Gurdon, 2008). It has been 
reported that reprogramming involves changes in chromatin structure and chromatin 
components (Jullien et al., 2010; Kikyo et al., 2000). Importantly, initiation of Oct4 expression 
has been found to be crucial for successful nuclear transfers (Boiani et al., 2002; Byrne et al., 
2003) and important for iPSC creation; all other reprogramming iPSC transcription factors 
have been replaced with other factors or chemical compounds, but only one report so far 
could exclude Oct4. In murine ES cells, Oct4 must hold a precise level to maintain them as 
just ES cells (Niwa et al., 2000) and therefore understanding the control of the Oct4 level will 
be key if one wants to understand pluripotency and reprogramming at the molecular level. 
A recent report demonstrated that Oct4 expression is regulated by scaffold attachment 
factor A (SAF-A). SAF-A was found on the Oct4 promoter only when the gene is actively 
transcribed in murine ESCs, depending on LIF, and gene silencing of SAF-A in ESCs 
resulted in down regulation of Oct4 (Vizlin-Hodzic et al., 2011). Other Oct4 modulators have 
been reported that in similarity with SAF-A are in complex with RNA polymerase II (Ding 
et al., 2009; Ponnusamy et al., 2009). Post-translational modifications have been shown to be 
able to modify the activity of Oct4, such as sumoylation (Wei et al., 2007) and ubiquitination 
(Xu et al., 2004). During the reprogramming process epigenetic marks are changed such as 
the removal of methyl groups on DNA (DNA demethylation) of the Oct4 promoter which 
has been shown during SCNT (Simonsson and Gurdon, 2004) and has also been observed in 
mouse (Yamazaki et al., 2006). The growth arrest and DNA damage inducible protein 
Gadd45a and deaminase Aid was shown to promote DNA demethylation of the Oct4 and 
Nanog promoters (Barreto et al., 2007; Bhutani et al., 2010). Consistent with those findings 
is that Aid together with Gadd45 and Mbd4 has been shown to promote DNA 
demethylation in zebrafish (Rai et al., 2008). Translational tumor protein (Tpt1) has been 
proposed to control Oct4 and shown to interact with nucleophosmin (Npm1) during 
mitosis of ESCs and such complexes are involved in cell proliferation (Johansson et al., 
2010b; Koziol et al., 2007). Furthermore, phosphorylated nucleolin (Ncl-P) interacts with 
Oct4 during interphase in both murine and human ESCs (Johansson et al., 2010a). Core 
transcription factors, Oct4, Sox2 and Nanog, were shown to individually form complexes 
with nucleophosmin (Npm1) to control ESCs (Johansson and Simonsson, 2010). ESCs also 
display high levels of telomerase activity which maintain the length of the telomeres. The 
telomerase activity or Tert gene expression is rapidly down regulated during 
differentiation and are much lower or absent in somatic cells. Therefore, reestablishment 
of high telomerase activity (or reactivation of Tert gene) is important for reprogramming. 
In SCNT animals, telomere length in somatic cells has been reported to be comparable to 
that in normally fertilized animals (Betts et al., 2001; Lanza et al., 2000; Tian et al., 2000). A 
telomere length-resetting mechanism has been identified in the Xenopus egg (Vizlin-
Hodzic et al., 2009). 
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When iPSCs first were introduced many thought that the molecular mechanism of 
reprogramming was solved once and for all. It was soon shown that to generate iPSC 
colonies one could use different combinations of transcription factors most efficiently 
together with retroviruses or more recently, exposure to chemical compounds together with 
the transcription factors, Oct4 and Klf4, and with retroviruses (Zhu et al., 2010) or 
retroviruses alone (Kane et al., 2010). What retroviruses do for the reprogramming process is 
unknown and the efficiency by which the egg reprograms the somatic cells is far more 
efficient than the iPSC procedure. Moreover, mutagenic effects have been documented in 
both laboratory and clinical gene therapy studies, principally as a result of a dysregulated 
host gene expression in the proximity of gene integration sites. So the first question to ask is 
whether all iPSC experiments so far forgot the obvious control of using only virus. The 
answer is probably no because the efficiency is very low with viruses alone as compared to 
using transcription factors combined with virus or identified reprogramming compounds. 
Reprogramming an adult somatic frog cell nucleus to generate a normal “clonal“ new 
individual is far less efficient (0.1-3%) than reprogramming to create a blastocyst, from 
which ESCs are isolated (efficiency 20-40%) (Gurdon, 2008) and is comparable with blastula 
formation after human SCNT (23%). This number could be compared with iPSC procedure 
that has reported 0.5 % success rate at most with human cells (table 1). The low efficiency 
and slow kinetics of iPSC derivation suggest that there are other procedures that are more 
efficient, yet to decipher. There is a belief that there are different levels of pluripotency when 
it comes to ESC and also that reprogramming follows an organized sequence of events, 
beginning with downregulation of somatic markers and activation of pluripotency markers 
alkaline phosphatase, SSEA-4, and Fbxo15 before pluripotency endogenous genes such as 
Oct4, Nanog, Tra1-60 and Tra-1-80 become expressed and cells gain independence from 
exogenous transcription factor expression (Brambrink et al., 2008; Stadtfeld et al., 2008a). 
Only a small subset of somatic cells expressing the reprogramming factors down-regulates 
somatic markers and activates pluripotency genes (Wernig et al., 2008a). 
3.1 History of reprogramming 
SCNT has been around for more than fifty years although it was already proposed in 1938 
by Hans Spemann (Spemann, 1938), an embryologist who received the Nobel Prize in 
Medicine for his development of new embryological micro surgery techniques. Spemann 
anticipated that “transplanting an older nucleus into an egg would be a fantastic 
experiment”. Later on, Robert Briggs and Thomas King were the first to put the nuclear 
transfer technique into practice. However, they only managed to obtain viable offspring 
through nuclear transfer of undifferentiated cells in the frog species Rana pipiens (Briggs and 
King, 1952). During the 1950s to the 1970s a series of pioneering somatic nuclear transfer 
experiments performed by John Gurdon showed that nuclei from differentiated amphibian 
cells, for example tadpole intestinal or adult skin cells could generate cloned tadpoles 
(Gurdon, 1962; Gurdon et al., 1958; Gurdon et al., 1975). In 1997, the successful cloning of a 
mammal was first achieved. The sheep Dolly was produced by using the nuclei of cells 
cultured from an adult mammary gland (Wilmut et al., 1997). Following the cloning of 
Dolly, researchers have reported successful cloning of a number of species including cow, 
pig, mouse, rabbit, cat (named Copycat) and monkey. In 2006, reprogrammed murine iPSCs 
were reported by Takahashi and Yamanaka (Takahashi and Yamanaka, 2006) and in 2007 
human iPSCs were reported (Takahashi et al., 2007; Yu et al., 2009). 
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The mechanisms of nuclear reprogramming are not yet completely understood. The crucial 
event during reprogramming is the activation of ES- and the silencing of differentiation 
markers, while the genetic code remains intact. Major reprogramming of gene expression 
takes place inside the egg and genes that have been silenced during embryo development 
are awakened. In contrast, genes that are expressed in, and are specific for, the donated cell 
nucleus become inactivated most of the time, however some SCNT embryos remember their 
heritage and fail to inactivate somatic-specific genes (Ng and Gurdon, 2008). It has been 
reported that reprogramming involves changes in chromatin structure and chromatin 
components (Jullien et al., 2010; Kikyo et al., 2000). Importantly, initiation of Oct4 expression 
has been found to be crucial for successful nuclear transfers (Boiani et al., 2002; Byrne et al., 
2003) and important for iPSC creation; all other reprogramming iPSC transcription factors 
have been replaced with other factors or chemical compounds, but only one report so far 
could exclude Oct4. In murine ES cells, Oct4 must hold a precise level to maintain them as 
just ES cells (Niwa et al., 2000) and therefore understanding the control of the Oct4 level will 
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Nanog promoters (Barreto et al., 2007; Bhutani et al., 2010). Consistent with those findings 
is that Aid together with Gadd45 and Mbd4 has been shown to promote DNA 
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When iPSCs first were introduced many thought that the molecular mechanism of 
reprogramming was solved once and for all. It was soon shown that to generate iPSC 
colonies one could use different combinations of transcription factors most efficiently 
together with retroviruses or more recently, exposure to chemical compounds together with 
the transcription factors, Oct4 and Klf4, and with retroviruses (Zhu et al., 2010) or 
retroviruses alone (Kane et al., 2010). What retroviruses do for the reprogramming process is 
unknown and the efficiency by which the egg reprograms the somatic cells is far more 
efficient than the iPSC procedure. Moreover, mutagenic effects have been documented in 
both laboratory and clinical gene therapy studies, principally as a result of a dysregulated 
host gene expression in the proximity of gene integration sites. So the first question to ask is 
whether all iPSC experiments so far forgot the obvious control of using only virus. The 
answer is probably no because the efficiency is very low with viruses alone as compared to 
using transcription factors combined with virus or identified reprogramming compounds. 
Reprogramming an adult somatic frog cell nucleus to generate a normal “clonal“ new 
individual is far less efficient (0.1-3%) than reprogramming to create a blastocyst, from 
which ESCs are isolated (efficiency 20-40%) (Gurdon, 2008) and is comparable with blastula 
formation after human SCNT (23%). This number could be compared with iPSC procedure 
that has reported 0.5 % success rate at most with human cells (table 1). The low efficiency 
and slow kinetics of iPSC derivation suggest that there are other procedures that are more 
efficient, yet to decipher. There is a belief that there are different levels of pluripotency when 
it comes to ESC and also that reprogramming follows an organized sequence of events, 
beginning with downregulation of somatic markers and activation of pluripotency markers 
alkaline phosphatase, SSEA-4, and Fbxo15 before pluripotency endogenous genes such as 
Oct4, Nanog, Tra1-60 and Tra-1-80 become expressed and cells gain independence from 
exogenous transcription factor expression (Brambrink et al., 2008; Stadtfeld et al., 2008a). 
Only a small subset of somatic cells expressing the reprogramming factors down-regulates 
somatic markers and activates pluripotency genes (Wernig et al., 2008a). 
3.1 History of reprogramming 
SCNT has been around for more than fifty years although it was already proposed in 1938 
by Hans Spemann (Spemann, 1938), an embryologist who received the Nobel Prize in 
Medicine for his development of new embryological micro surgery techniques. Spemann 
anticipated that “transplanting an older nucleus into an egg would be a fantastic 
experiment”. Later on, Robert Briggs and Thomas King were the first to put the nuclear 
transfer technique into practice. However, they only managed to obtain viable offspring 
through nuclear transfer of undifferentiated cells in the frog species Rana pipiens (Briggs and 
King, 1952). During the 1950s to the 1970s a series of pioneering somatic nuclear transfer 
experiments performed by John Gurdon showed that nuclei from differentiated amphibian 
cells, for example tadpole intestinal or adult skin cells could generate cloned tadpoles 
(Gurdon, 1962; Gurdon et al., 1958; Gurdon et al., 1975). In 1997, the successful cloning of a 
mammal was first achieved. The sheep Dolly was produced by using the nuclei of cells 
cultured from an adult mammary gland (Wilmut et al., 1997). Following the cloning of 
Dolly, researchers have reported successful cloning of a number of species including cow, 
pig, mouse, rabbit, cat (named Copycat) and monkey. In 2006, reprogrammed murine iPSCs 
were reported by Takahashi and Yamanaka (Takahashi and Yamanaka, 2006) and in 2007 
human iPSCs were reported (Takahashi et al., 2007; Yu et al., 2009). 
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4. Producing iPSCs from other cell types than fibroblasts 
The most studied somatic cell type that has been reprogrammed into iPSCs is fibroblasts. 
The different human somatic cell types that have been transformed into iPSCs so far are 
summarized in table 2. The efficiency of fibroblast reprogramming does not exceed 1-5% but 
generally is extremely inefficient (0.001-0.1%) and occurs at a slow speed (> 2 weeks). In 
order to use iPSCs in clinical applications, improved efficiency, suitable factor delivery 
techniques and identification of true reprogrammed cells are crucial. In the fast growing 
field of regenerative medicine, patient-specific iPSCs offer a unique source of autologous 
cells for clinical applications. Although promising, using somatic cells of an adult individual 
as starting material for reprogramming in this context has also raised concern. Acquired 
somatic mutations that have been accumulated during an individual’s life time will be 
transferred to the iPSCs, and there is a fear that these mutations may be associated with 
adverse events such as cancer development. As an alternative, iPSCs have been generated 
from human cord blood. These cells have been shown to differentiate into all three germ 
layers including spontaneous beating cardiomyocytes (Haase et al., 2009). Reprogrammed 
cells from cord blood have not only the advantage to come from a juvenescent cell source. In 
addition, cord blood is already routinely harvested for clinical use.  
Another issue that has been raised in this field is a wish to harvest cells for 
reprogramming without surgical intervention. Therefore, reprogramming experiments 
have also been performed using plucked human hair follicle keratinocytes. These iPSCs 
were also able to differentiate into cells from all three germ layers including 
cardiomyocytes (Novak et al., 2010). 
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Mobilized peripheral blood 0.01% OKSM (Loh et al., 2009) 
Table 2. Different somatic cell types that human iPSCs have been generated from  
4.1 iPSC as a disease model 
The introduction of iPSC technology holds a great promise for disease modelling. By 
differentiating iPSCs from patients into various cell lineages there is hope to be able to 
follow the disease progression and to identify new prognostic markers as well as to use the 
differentiated cells for drug screening in both toxicological testing and the development of 
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new treatment. This approach has already been tested for monogenic diseases using 
genetically modified hESCs or hESCs from embryos carrying these diseases (reviewed in 
(Stephenson et al., 2009)). However, diseases with a more complex genetic background 
involving several or unknown genes have not been able to be studied in this way before 
iPSCs became available. An additional advantage with iPSCs is that since many diseases 
differ in both clinical symptoms and penetrance between patients, iPSCs derived from 
patients will offer the opportunity to reveal a clinical history as well. It could also provide a 
model for late-onset degenerative diseases such as Alzheimer’s disease  or osteoarthritis. 
Recent work on cardiac arrhythmias has fully shown the potential of disease modelling 
using iPSCs. Long QT syndrome (LQTS) is characterized by rapid irregular heart beats due 
to abnormal ion channel function and the condition can lead to sudden death. So far, 
various mutations in at least 12 different genes have been associated with LQTS and the 
disease is subdivided into different types depending on which gene is affected (reviewed in 
(Bokil et al., 2010)). Fibroblasts from patients with LQTS1 (Moretti et al., 2010) and LQTS2 
(Itzhaki et al., 2011; Matsa et al., 2011) were reprogrammed and differentiated into the 
cardiac lineage. These cells displayed the electrophysiological pattern characteristic to the 
disease. Moreover, the cells responded appropriately when treated with pharmacological 
compounds, which further extends the usability of these cells. 
iPSCs have also been generated from fibroblasts from patients suffering from the LEOPARD 
syndrome, an autosomal-dominant developmental disorder where one of the major disease 
phenotypes includes hyperthropic cardiomyopathy. The authors showed that 
cardiomyocytes derived from those iPSCs were larger with another intracellular 
organization compared to cardiomyocytes derived from hESCs or iPSCs generated from a 
healthy sibling (Carvajal-Vergara et al., 2010). Today many laboratories and hospitals 
worldwide are producing iPSC lines from patients with various diseases. Patient-specific 
iPSC lines can be used as 1) a human modelling system for studying the molecular cause of, 
and in the long run for 2) the treatment of, degenerative diseases with autologous 
transplantation, which refers to the transplantation to a patient of his/her own cells. The 
therapeutic potential of iPSCs in combination with genetic repair has already been 
successfully shown in mouse models of sickle cell anemia (Hanna et al., 2007), Duchenne 
muscular dystrophy (DMD) (Kazuki et al., 2010), hemophilia A (Xu et al., 2009) and, in a rat 
model, Parkinson’s disease (Wernig et al., 2008c). For diseases where animal and human 
physiology differ, disease-specific iPSC lines capable of differentiation into the tissue 
affected by the disease could recapitulate tissue formation and thereby enable determination 
of the cause of the disease and could provide cues to drug targets. Therefore iPSC lines from 
patients suffering from a variety of genetic diseases with either Mendelian or complex 
inheritance have been secured for future research, and include deaminase deficiency-related 
severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond syndrome 
(SBDS), Gaucher disease (GD) type III, Duchenne (DMD) and Becker muscular dystrophy 
(BMD), Parkinson disease (PD), Huntington disease (HD), juvenile-onset (type1) diabetes 
mellitus (JDM), Downs syndrome (DS)/trisomy21 and Lesch-Nyhan syndrome (Park et al., 
2008a). Furthermore, iPSCs derived from amyotrophic lateral sclerosis (ALS) patients were 
terminally differentiated into motor neurons (Dimos et al., 2008). 
4.2 Procedures to produce iPSCs 
In the first iPSC reprogramming studies, retroviral or lentiviral vectors were used to 
introduce the transcription factors into somatic cells. By using these viral delivery systems,  
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cardiac lineage. These cells displayed the electrophysiological pattern characteristic to the 
disease. Moreover, the cells responded appropriately when treated with pharmacological 
compounds, which further extends the usability of these cells. 
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Fig. 2. Methods for producing induced pluripotent stem cells (iPSCs) by non-integrating 
vectors. Several different methods exist to generate iPSCs by non-integrating vectors: for 
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example by plasmid, episomal, adenoviral minicircle vectors and mRNA. a) A combination 
of expression plasmid vectors for defined reprogramming factors is transfected into somatic 
cells. Plasmid vectors are not integrated into the genome of transfected cells and are 
gradually lost during reprogramming. This method therefore requires multiple transfection 
steps. b) Somatic cells can be transfected by episomal vectors expressing defined 
reprogramming factors. These vectors can replicate themselves autonomously in cells 
during reprogramming under drug selection and are not integrated into the genome. Upon 
withdrawal of drug selection, the episomal vectors are lost. c) Adenovirus carrying defined 
reprogramming factors can be infected into somatic cells to transiently express these factors. 
This method requires multiple transductions since adenoviral vectors are lost upon 
celldivision. d) The minicircle vector method is based on PhiC31-vector intra molecular 
recombinant system that allows the bacterial elements of the vector to be degraded in 
bacteria. Minicircle vector containing only defined reprogramming factors is not degraded 
and is delivered into somatic cells by nucleofection. This strategy requires multiple 
transfection steps since minicircle vectors are lost upon cell division. e) Reprogramming 
using mRNA reprogramming factors have been achieved.  
the transduced viral vectors and transgenes are randomly and permanently integrated 
into the genome of infected somatic cells and remains in the iPSCs. The vector integration 
into the host genome is a limitation of this technology if it is going to be used in human 
therapeutic applications due to increased risk of tumor formation (Okita et al., 2007). 
Approaches to derive transgene-free iPSCs are therefore critical. The first strategy was by 
using non-integrating (Figure 2) vectors. Efforts have been made to derive iPSCs by 
repeated plasmid transfections (Gonzalez et al., 2009; Okita et al., 2008) (Figure 2a), 
adenoviral (Stadtfeld et al., 2008b) (Figure 2b) and episomal vectors (Yu et al., 2009) 
(Figure 2c). Recently, minicircle vectors (Figure 2d) have been used to generate iPSCs (Jia 
et al., 2010). Unfortunately, reprogramming with these techniques has extremely low 
efficiency as compared to integrating viral vectors. Another promising alternative is the 
use of excisable integrating vectors, allowing for the generation of transgene-free iPSCs. A 
classical expression-excision system uses vectors with inserts flanked with recognition 
sites, loxP sites, for Cre-recombinase (Figure 3a). Consequently, DNA is excised upon Cre-
recombinase expression in the cells. Cre-loxP-based approaches have been used to 
reprogram human somatic cells from individuals with Parkinson’s disease by four 
different vectors (Soldner et al., 2009) or by a single, polycistronic lentiviral vector 
encoding reprogramming factors (Chang et al., 2009). Though, a potential limitation of 
Cre-loxP-based approaches is that a long terminal repeat (LTR) will remain after Cre-
mediated excision which may interfere with the expression of endogenous genes. An 
alternative integration-free strategy is based on the piggy-Bac transposon (Figure 3b), a 
mobile genetic element from insects that integrates into the genome of mammalian cells 
and, most importantly, can be entirely removed by a transposase. Two research teams 
generated iPSCs using this system to deliver a single polycistron encoding four 
reprogramming factors into somatic cells (Woltjen et al., 2009; Yusa et al., 2009). 
Interestingly, the latest development indicates that gene transfection may not even be 
needed for the generation of iPSCs and that direct delivery of four recombinant 
reprogramming proteins that can penetrate the plasma membrane of somatic cells is 
sufficient (Zhou et al., 2009), or mRNA (Angel &Yanik, 2010; Plews et al., 2010; Warren et 
al. 2010; Yakoba et al., 2010; Zhou et al.,2009).  
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Fig. 3. Methods for production of induced pluripotent stem cells (iPSCs) by excisable 
integrating vectors. Two different methods exist today to generate iPSCs by excisable 
integrating vectors: by Cre-loxP and Piggy-Bac vectors. a) In the Cre-loxP viral delivery 
system, defined reprogramming factors are cloned into vectors flanked by recognition sites, 
loxP sites, for Cre-recombinase. Upon transduction into somatic cells, the loxP site is 
duplicated and reprogramming factos are stably integrated into the genome flanked by loxP 
sites. When Cre-recombinase is expressed, the integrated reprogramming factors are excised 
from the genome but one loxP site is left behind integrated into the genome of iPSCs. b) The 
Piggy-Bac transposon gene delivery system is based on a mobile genetic element that 
efficiently integrates into the genome of mammalian cells. When fusion gene encoding 
defined reprogramming factors in the transposon expression vector as well as transposase 
expression vector are transfected into somatic cells, the fusion gene is stably integrated into 
the genome. When transposase is expressed, the interated genetic material is excised from 
the genome resulting in transgene- and vector free iPSCs. 
The therapeutic application of iPSCs is limited by another concern due to the use of 
potential oncogenes when iPSCs are produced. C-Myc is an oncogene and as such causes 
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tumor formation, which has been observed in iPSC-derived chimeric mice (Okita et al., 
2007). As a major step towards solving this issue, several studies have demonstrated that 
mouse and human iPSCs can be derived without C-Myc but the efficiency of 
reprogramming is reduced (Nakagawa et al., 2008; Wernig et al., 2008b; Yu et al., 2007). 
Although the oncogenic potential of C-Myc is mostly discussed, Oct4, Sox2 and Klf4 are also 
associated with multiple types of cancer (Bass et al., 2009; Gidekel et al., 2003; Wei et al., 
2006). To circumvent this problem, a recent trend is to avoid the transduction of some of the 
oncogenes by 1) reprogramming somatic cells which already endogenously express 
sufficient levels of some of the reprogramming factors (Tsai et al., 2010), 2) replacing one or 
more reprogramming factors by small molecules like histone deacetylase inhibitor vaporic 
acid, the DNA methyltransferase inhibitor 5-aza-cytidine, the Wnt signaling component 
WNT3a, the L-channel calcium channel agonist Bayk8644 (Huangfu et al., 2008a; Huangfu et 
al., 2008b), or 3) dual inhibition of mitogen activated protein kinase signaling and glycogen 
synthase kinase-3 (Silva et al., 2008). It has been reported that Sox2 can be replaced by Sox1, 
Klf4 by Klf2 and c-Myc by N-myc or L-myc indicating that they are not fundamentally 
required for generation of iPSCs (Yamanaka, 2009). Tet-on™ technology has been used to 
express exogenously reprogramming factors in presence of Doxycycline. Removal of 
Doxycycline results in that iPSC colonies that endogenously express pluripotent genes and 
colonies that are truly reprogrammed remains. 
5. Transplanting cells 
In order to make cell therapy (route 1 in Figure 1) using iPSCs a reality in medicine many 
obstacles need to be overcome. Organ transplantation between individuals is complicated 
due to the limited availability of matched tissues and consequently the requirement for life-
long treatment with immunosuppressive drugs that can cause serious side effects. The hope 
is that iPSCs that are already genetically matched with the patient would circumvent these 
issues. Another advantage of iPSCs over current transplantation approaches is the 
opportunity of repairing mutations that cause the disease by homologous recombination, 
which has not been very successful in adult stem cells due to difficulties in propagating 
those cells in vitro. In mouse, iPSC technology combined with correction of a known disease-
causing mutation has been proven successful. In human autologous cell therapy has been 
used since the mid 90´s for the treatment of focal cartilage lesions, using the patient’s 
chondrocytes transplanted into the injured knee (Brittberg et al., 1994), thereby alleviated 
osteoarthritic symptoms and induction of tissue repair. The cell therapy gives stable long-
term results up to 20 years after surgery in some patients but is less successful in others 
(Lindahl et al., 2003; Peterson et al., 2010). One drawback with this technique is the supply 
of cells. Large injuries require large amounts of cells, and there is a limit of the size of the 
biopsies that can be taken out from the patient. Introducing the iPSC technique in such 
system might improve the process. Since the iPSCs have theoretically an unlimited 
proliferation capacity, these cells can be used to reach larger quantities of cells. When 
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can be made from a regular skin fibroblast. Before this somewhat futuristic scenario can 
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can form teratoma in vivo (Fairchild, 2010). The iPSCs have however, been shown to retain 
their epigenic memory from the tissue from which they originate. It would therefore be 
easier to differentiate an iPSC to a chondrocyte if the donor cell was a chondrocyte (Kim et 
al., 2010), and maybe terminally so, thus avoiding risk for terratoma formation. A biopsy 
would thus be needed, but a relatively small cell harvest could with the iPSC technique 
result in the treatment of larger injuries. The iPSC procedure could also lead to a therapy-
outcome that is more predicted and constant due to that chondrogenic differentiation of 
iPSC probably result in a more homogeneous cell-population. Since cartilage lacks 
vascularisation and thus is immunoprivileged the derivation of a universal donor 
chondrocytes cell line based on the iPSC technology could be an interesting option. If such 
cells are combined with a suitable matrix scaffold a cartilage regeneration therapy could 
potentially have a much wider application and be more cost effective than current 
autologous procedures.  
5.1 Directprogramming of somatic cells into another cell type 
Switching from one somatic cell type into another cell type, not necessarily via a 
pluripotent cell state was first demonstrated when fibroblasts formed myofibers after 
transduction with retroviral vectors expressing the skeletal muscle factor MyoD (Davis et 
al., 1987). Further, it has been reported that pancreatic acinar cells could be transformed 
into insulin-producing β cells by overexpression of the pancreatic factors Pdx1, MafA and 
Ngn3 in vivo (Zhou et al., 2008) as well as that ESCs could be directly differentiated into 
specific dopamine neurons by overexpression of only one factor, Lmx1 (Friling et al., 
2009). These experiments proved that transdifferentiation do not require reprogramming 
into a pluripotent state, although all such experiments have used some kind of 
retroviruses and if only virus in itself can contribute to pluripotency as has recently been 
shown one cannot completely rule out that the switch hasn’t passed via a pluripotent 
state.  
6. Final remarks 
To date, clinically valid iPSCs do not yet exist, but are under development worldwide. 
Some will argue that the complexity of reprogramming is solved by the iPSC technology, 
however apart from the defined reprogramming factors, retroviruses help in the 
reprogramming process in an unknown way, and is still inefficient compared to SCNT 
which argues for that more can be learnt about reprogramming. Also the fact that 
different combinations of reprogramming factors, or replacement with chemicals, have 
been used successfully indicates that there exist reprogramming molecules yet to be 
discovered. Therefore, further investigations are needed to learn more about the 
molecular mechanisms of iPSCs and how to prevent tumor formation following in vivo 
transplantation. Awaiting in vivo safety, these techniques offer exciting possibilities for 
mapping mechanisms of different diseases and screening for patient-specific therapies 
and drugs. To derive iPSCs from the patient’s own cells following differentiation into the 
disease-causing cells means recapitulating the disease in a test tube for genomic, 
proteomic and epigenomic analysis. The iPSC as a human in vitro disease modeling 
system is a new promising and fast expanding research area. 
 
Generation of Patient Specific Stem Cells: A Human Model System 17 
7. References 
Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilic, 
J., Pekarik, V., Tiscornia, G., et al. (2008). Efficient and rapid generation of induced 
pluripotent stem cells from human keratinocytes. Nat Biotechnol 26, 1276-1284. 
Angel, M. & Yanik, M. F. (2010). Innate immune suppression enables frequent transfection 
with RNA encoding reprogramming proteins. PLoS One 5, e11756. 
Aoki, T., Ohnishi, H., Oda, Y., Tadokoro, M., Sasao, M., Kato, H., Hattori, K., and Ohgushi, 
H. (2010). Generation of induced pluripotent stem cells from human adipose-
derived stem cells without c-MYC. Tissue Eng Part A 16, 2197-2206. 
Barreto, G., Schafer, A., Marhold, J., Stach, D., Swaminathan, S.K., Handa, V., Doderlein, G., 
Maltry, N., Wu, W., Lyko, F., et al. (2007). Gadd45a promotes epigenetic gene 
activation by repair-mediated DNA demethylation. Nature 445, 671-675. 
Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim, S.Y., 
Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009). SOX2 is an amplified lineage-
survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 
41, 1238-1242. 
Betts, D., Bordignon, V., Hill, J., Winger, Q., Westhusin, M., Smith, L., and King, W. (2001). 
Reprogramming of telomerase activity and rebuilding of telomere length in cloned 
cattle. Proc Natl Acad Sci U S A 98, 1077-1082. 
Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., and Blau, H.M. (2010). 
Reprogramming towards pluripotency requires AID-dependent DNA 
demethylation. Nature 463, 1042-1047. 
Boiani, M., Eckardt, S., Scholer, H.R., and McLaughlin, K.J. (2002). Oct4 distribution and 
level in mouse clones: consequences for pluripotency. Genes Dev 16, 1209-1219. 
Bokil, N.J., Baisden, J.M., Radford, D.J., and Summers, K.M. (2010). Molecular genetics of 
long QT syndrome. Mol Genet Metab 101, 1-8. 
Brambrink, T., Foreman, R., Welstead, G.G., Lengner, C.J., Wernig, M., Suh, H., and 
Jaenisch, R. (2008). Sequential expression of pluripotency markers during direct 
reprogramming of mouse somatic cells. Cell Stem Cell 2, 151-159. 
Briggs, R., and King, T.J. (1952). Transplantation of Living Nuclei From Blastula Cells into 
Enucleated Frogs' Eggs. Proc Natl Acad Sci U S A 38, 455-463. 
Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L. (1994). 
Treatment of deep cartilage defects in the knee with autologous chondrocyte 
transplantation. N Engl J Med 331, 889-895. 
Byrne, J.A., Pedersen, D.A., Clepper, L.L., Nelson, M., Sanger, W.G., Gokhale, S., Wolf, D.P., 
and Mitalipov, S.M. (2007). Producing primate embryonic stem cells by somatic cell 
nuclear transfer. Nature 450, 497-502. 
Byrne, J.A., Simonsson, S., Western, P.S., and Gurdon, J.B. (2003). Nuclei of adult 
mammalian somatic cells are directly reprogrammed to oct-4 stem cell gene 
expression by amphibian oocytes. Curr Biol 13, 1206-1213. 
Carvajal-Vergara, X., Sevilla, A., D'Souza, S.L., Ang, Y.S., Schaniel, C., Lee, D.F., Yang, L., 
Kaplan, A.D., Adler, E.D., Rozov, R., et al. (2010). Patient-specific induced 
pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808-812. 
Chang, C.W., Lai, Y.S., Pawlik, K.M., Liu, K., Sun, C.W., Li, C., Schoeb, T.R., and Townes, 
T.M. (2009). Polycistronic lentiviral vector for "hit and run" reprogramming of 
adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27, 1042-1049. 
 
New Advances in Stem Cell Transplantation 16
can form teratoma in vivo (Fairchild, 2010). The iPSCs have however, been shown to retain 
their epigenic memory from the tissue from which they originate. It would therefore be 
easier to differentiate an iPSC to a chondrocyte if the donor cell was a chondrocyte (Kim et 
al., 2010), and maybe terminally so, thus avoiding risk for terratoma formation. A biopsy 
would thus be needed, but a relatively small cell harvest could with the iPSC technique 
result in the treatment of larger injuries. The iPSC procedure could also lead to a therapy-
outcome that is more predicted and constant due to that chondrogenic differentiation of 
iPSC probably result in a more homogeneous cell-population. Since cartilage lacks 
vascularisation and thus is immunoprivileged the derivation of a universal donor 
chondrocytes cell line based on the iPSC technology could be an interesting option. If such 
cells are combined with a suitable matrix scaffold a cartilage regeneration therapy could 
potentially have a much wider application and be more cost effective than current 
autologous procedures.  
5.1 Directprogramming of somatic cells into another cell type 
Switching from one somatic cell type into another cell type, not necessarily via a 
pluripotent cell state was first demonstrated when fibroblasts formed myofibers after 
transduction with retroviral vectors expressing the skeletal muscle factor MyoD (Davis et 
al., 1987). Further, it has been reported that pancreatic acinar cells could be transformed 
into insulin-producing β cells by overexpression of the pancreatic factors Pdx1, MafA and 
Ngn3 in vivo (Zhou et al., 2008) as well as that ESCs could be directly differentiated into 
specific dopamine neurons by overexpression of only one factor, Lmx1 (Friling et al., 
2009). These experiments proved that transdifferentiation do not require reprogramming 
into a pluripotent state, although all such experiments have used some kind of 
retroviruses and if only virus in itself can contribute to pluripotency as has recently been 
shown one cannot completely rule out that the switch hasn’t passed via a pluripotent 
state.  
6. Final remarks 
To date, clinically valid iPSCs do not yet exist, but are under development worldwide. 
Some will argue that the complexity of reprogramming is solved by the iPSC technology, 
however apart from the defined reprogramming factors, retroviruses help in the 
reprogramming process in an unknown way, and is still inefficient compared to SCNT 
which argues for that more can be learnt about reprogramming. Also the fact that 
different combinations of reprogramming factors, or replacement with chemicals, have 
been used successfully indicates that there exist reprogramming molecules yet to be 
discovered. Therefore, further investigations are needed to learn more about the 
molecular mechanisms of iPSCs and how to prevent tumor formation following in vivo 
transplantation. Awaiting in vivo safety, these techniques offer exciting possibilities for 
mapping mechanisms of different diseases and screening for patient-specific therapies 
and drugs. To derive iPSCs from the patient’s own cells following differentiation into the 
disease-causing cells means recapitulating the disease in a test tube for genomic, 
proteomic and epigenomic analysis. The iPSC as a human in vitro disease modeling 
system is a new promising and fast expanding research area. 
 
Generation of Patient Specific Stem Cells: A Human Model System 17 
7. References 
Aasen, T., Raya, A., Barrero, M.J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilic, 
J., Pekarik, V., Tiscornia, G., et al. (2008). Efficient and rapid generation of induced 
pluripotent stem cells from human keratinocytes. Nat Biotechnol 26, 1276-1284. 
Angel, M. & Yanik, M. F. (2010). Innate immune suppression enables frequent transfection 
with RNA encoding reprogramming proteins. PLoS One 5, e11756. 
Aoki, T., Ohnishi, H., Oda, Y., Tadokoro, M., Sasao, M., Kato, H., Hattori, K., and Ohgushi, 
H. (2010). Generation of induced pluripotent stem cells from human adipose-
derived stem cells without c-MYC. Tissue Eng Part A 16, 2197-2206. 
Barreto, G., Schafer, A., Marhold, J., Stach, D., Swaminathan, S.K., Handa, V., Doderlein, G., 
Maltry, N., Wu, W., Lyko, F., et al. (2007). Gadd45a promotes epigenetic gene 
activation by repair-mediated DNA demethylation. Nature 445, 671-675. 
Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim, S.Y., 
Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009). SOX2 is an amplified lineage-
survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 
41, 1238-1242. 
Betts, D., Bordignon, V., Hill, J., Winger, Q., Westhusin, M., Smith, L., and King, W. (2001). 
Reprogramming of telomerase activity and rebuilding of telomere length in cloned 
cattle. Proc Natl Acad Sci U S A 98, 1077-1082. 
Bhutani, N., Brady, J.J., Damian, M., Sacco, A., Corbel, S.Y., and Blau, H.M. (2010). 
Reprogramming towards pluripotency requires AID-dependent DNA 
demethylation. Nature 463, 1042-1047. 
Boiani, M., Eckardt, S., Scholer, H.R., and McLaughlin, K.J. (2002). Oct4 distribution and 
level in mouse clones: consequences for pluripotency. Genes Dev 16, 1209-1219. 
Bokil, N.J., Baisden, J.M., Radford, D.J., and Summers, K.M. (2010). Molecular genetics of 
long QT syndrome. Mol Genet Metab 101, 1-8. 
Brambrink, T., Foreman, R., Welstead, G.G., Lengner, C.J., Wernig, M., Suh, H., and 
Jaenisch, R. (2008). Sequential expression of pluripotency markers during direct 
reprogramming of mouse somatic cells. Cell Stem Cell 2, 151-159. 
Briggs, R., and King, T.J. (1952). Transplantation of Living Nuclei From Blastula Cells into 
Enucleated Frogs' Eggs. Proc Natl Acad Sci U S A 38, 455-463. 
Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L. (1994). 
Treatment of deep cartilage defects in the knee with autologous chondrocyte 
transplantation. N Engl J Med 331, 889-895. 
Byrne, J.A., Pedersen, D.A., Clepper, L.L., Nelson, M., Sanger, W.G., Gokhale, S., Wolf, D.P., 
and Mitalipov, S.M. (2007). Producing primate embryonic stem cells by somatic cell 
nuclear transfer. Nature 450, 497-502. 
Byrne, J.A., Simonsson, S., Western, P.S., and Gurdon, J.B. (2003). Nuclei of adult 
mammalian somatic cells are directly reprogrammed to oct-4 stem cell gene 
expression by amphibian oocytes. Curr Biol 13, 1206-1213. 
Carvajal-Vergara, X., Sevilla, A., D'Souza, S.L., Ang, Y.S., Schaniel, C., Lee, D.F., Yang, L., 
Kaplan, A.D., Adler, E.D., Rozov, R., et al. (2010). Patient-specific induced 
pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465, 808-812. 
Chang, C.W., Lai, Y.S., Pawlik, K.M., Liu, K., Sun, C.W., Li, C., Schoeb, T.R., and Townes, 
T.M. (2009). Polycistronic lentiviral vector for "hit and run" reprogramming of 
adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27, 1042-1049. 
 
New Advances in Stem Cell Transplantation 18
Cho, M.K., McGee, G., and Magnus, D. (2006). Research conduct. Lessons of the stem cell 
scandal. Science 311, 614-615. 
Cowan, C.A., Atienza, J., Melton, D.A., and Eggan, K. (2005). Nuclear reprogramming of 
somatic cells after fusion with human embryonic stem cells. Science 309, 1369-1373. 
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single transfected cDNA 
converts fibroblasts to myoblasts. Cell 51, 987-1000. 
Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, W., Croft, 
G.F., Saphier, G., Leibel, R., Goland, R., et al. (2008). Induced pluripotent stem cells 
generated from patients with ALS can be differentiated into motor neurons. Science 
321, 1218-1221. 
Ding, L., Paszkowski-Rogacz, M., Nitzsche, A., Slabicki, M.M., Heninger, A.K., de Vries, I., 
Kittler, R., Junqueira, M., Shevchenko, A., Schulz, H., et al. (2009). A genome-scale 
RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic 
stem cell identity. Cell Stem Cell 4, 403-415. 
Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T., Mostoslavsky, G., Hock, H., 
and Hochedlinger, K. (2009). Differentiation stage determines potential of 
hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat 
Genet 41, 968-976. 
Fairchild, P.J. (2010). The challenge of immunogenicity in the quest for induced 
pluripotency. Nat Rev Immunol 10, 868-875. 
Freberg, C.T., Dahl, J.A., Timoskainen, S., and Collas, P. (2007). Epigenetic reprogramming 
of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol 
Biol Cell 18, 1543-1553. 
French, A.J., Adams, C.A., Anderson, L.S., Kitchen, J.R., Hughes, M.R., and Wood, S.H. 
(2008). Development of human cloned blastocysts following somatic cell nuclear 
transfer with adult fibroblasts. Stem Cells 26, 485-493. 
Friling, S., Andersson, E., Thompson, L.H., Jonsson, M.E., Hebsgaard, J.B., Nanou, E., 
Alekseenko, Z., Marklund, U., Kjellander, S., Volakakis, N., et al. (2009). Efficient 
production of mesencephalic dopamine neurons by Lmx1a expression in 
embryonic stem cells. Proc Natl Acad Sci U S A 106, 7613-7618. 
Gidekel, S., Pizov, G., Bergman, Y., and Pikarsky, E. (2003). Oct-3/4 is a dose-dependent 
oncogenic fate determinant. Cancer Cell 4, 361-370. 
Giorgetti, A., Montserrat, N., Aasen, T., Gonzalez, F., Rodriguez-Piza, I., Vassena, R., Raya, 
A., Boue, S., Barrero, M.J., Corbella, B.A., et al. (2009). Generation of induced 
pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem 
Cell 5, 353-357. 
Gonzalez, F., Barragan Monasterio, M., Tiscornia, G., Montserrat Pulido, N., Vassena, R., 
Batlle Morera, L., Rodriguez Piza, I., and Izpisua Belmonte, J.C. (2009). Generation 
of mouse-induced pluripotent stem cells by transient expression of a single 
nonviral polycistronic vector. Proc Natl Acad Sci U S A 106, 8918-8922. 
Gupta, M.K., Illich, D.J., Gaarz, A., Matzkies, M., Nguemo, F., Pfannkuche, K., Liang, H., 
Classen, S., Reppel, M., Schultze, J.L., et al. (2010). Global transcriptional profiles of 
beating clusters derived from human induced pluripotent stem cells and 
embryonic stem cells are highly similar. BMC Dev Biol 10, 98. 
Gurdon, J. (2008). Primate therapeutic cloning in practice. Nat Biotechnol 26, 64-65. 
 
Generation of Patient Specific Stem Cells: A Human Model System 19 
Gurdon, J.B. (1962). The developmental capacity of nuclei taken from intestinal epithelium 
cells of feeding tadpoles. J Embryol Exp Morphol 10, 622-640. 
Gurdon, J.B., Elsdale, T.R., and Fischberg, M. (1958). Sexually mature individuals of 
Xenopus laevis from the transplantation of single somatic nuclei. Nature 182, 64-65. 
Gurdon, J.B., Laskey, R.A., and Reeves, O.R. (1975). The developmental capacity of nuclei 
transplanted from keratinized skin cells of adult frogs. J Embryol Exp Morphol 34, 
93-112. 
Haase, A., Olmer, R., Schwanke, K., Wunderlich, S., Merkert, S., Hess, C., Zweigerdt, R., 
Gruh, I., Meyer, J., Wagner, S., et al. (2009). Generation of induced pluripotent stem 
cells from human cord blood. Cell Stem Cell 5, 434-441. 
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P., Beard, C., 
Brambrink, T., Wu, L.C., Townes, T.M., et al. (2007). Treatment of sickle cell anemia 
mouse model with iPS cells generated from autologous skin. Science 318, 1920-
1923. 
Heng, J.C., Feng, B., Han, J., Jiang, J., Kraus, P., Ng, J.H., Orlov, Y.L., Huss, M., Yang, L., 
Lufkin, T., et al. (2010). The nuclear receptor Nr5a2 can replace Oct4 in the 
reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell 6, 167-
174. 
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, 
D.A. (2008a). Induction of pluripotent stem cells by defined factors is greatly 
improved by small-molecule compounds. Nat Biotechnol 26, 795-797. 
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W., 
and Melton, D.A. (2008b). Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26, 1269-1275. 
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., 
Gepstein, A., Arbel, G., Hammerman, H., et al. (2011). Modelling the long QT 
syndrome with induced pluripotent stem cells. Nature 471, 225-229. 
Jia, F., Wilson, K.D., Sun, N., Gupta, D.M., Huang, M., Li, Z., Panetta, N.J., Chen, Z.Y., 
Robbins, R.C., Kay, M.A., et al. (2010). A nonviral minicircle vector for deriving 
human iPS cells. Nat Methods 7, 197-199. 
Johansson, H., and Simonsson, S. (2010). Core transcription factors, Oct4, Sox2 and Nanog, 
individually form complexes with nucleophosmin (Npm1) to control embryonic 
stem (ES) cell fate determination. Aging (Albany NY) 2, 815-822. 
Johansson, H., Svensson, F., Runnberg, R., Simonsson, T., and Simonsson, S. (2010a). 
Phosphorylated nucleolin interacts with translationally controlled tumor protein 
during mitosis and with Oct4 during interphase in ES cells. PLoS One 5, e13678. 
Johansson, H., Vizlin-Hodzic, D., Simonsson, T., and Simonsson, S. (2010b). Translationally 
controlled tumor protein interacts with nucleophosmin during mitosis in ES cells. 
Cell Cycle 9. 
Jullien, J., Astrand, C., Halley-Stott, R.P., Garrett, N., and Gurdon, J.B. (2010). 
Characterization of somatic cell nuclear reprogramming by oocytes in which a 
linker histone is required for pluripotency gene reactivation. Proc Natl Acad Sci U 
S A 107, 5483-5488. 
Kane, N.M., Nowrouzi, A., Mukherjee, S., Blundell, M.P., Greig, J.A., Lee, W.K., Houslay, 
M.D., Milligan, G., Mountford, J.C., von Kalle, C., et al. (2010). Lentivirus-mediated 
 
New Advances in Stem Cell Transplantation 18
Cho, M.K., McGee, G., and Magnus, D. (2006). Research conduct. Lessons of the stem cell 
scandal. Science 311, 614-615. 
Cowan, C.A., Atienza, J., Melton, D.A., and Eggan, K. (2005). Nuclear reprogramming of 
somatic cells after fusion with human embryonic stem cells. Science 309, 1369-1373. 
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single transfected cDNA 
converts fibroblasts to myoblasts. Cell 51, 987-1000. 
Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, W., Croft, 
G.F., Saphier, G., Leibel, R., Goland, R., et al. (2008). Induced pluripotent stem cells 
generated from patients with ALS can be differentiated into motor neurons. Science 
321, 1218-1221. 
Ding, L., Paszkowski-Rogacz, M., Nitzsche, A., Slabicki, M.M., Heninger, A.K., de Vries, I., 
Kittler, R., Junqueira, M., Shevchenko, A., Schulz, H., et al. (2009). A genome-scale 
RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic 
stem cell identity. Cell Stem Cell 4, 403-415. 
Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T., Mostoslavsky, G., Hock, H., 
and Hochedlinger, K. (2009). Differentiation stage determines potential of 
hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat 
Genet 41, 968-976. 
Fairchild, P.J. (2010). The challenge of immunogenicity in the quest for induced 
pluripotency. Nat Rev Immunol 10, 868-875. 
Freberg, C.T., Dahl, J.A., Timoskainen, S., and Collas, P. (2007). Epigenetic reprogramming 
of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol 
Biol Cell 18, 1543-1553. 
French, A.J., Adams, C.A., Anderson, L.S., Kitchen, J.R., Hughes, M.R., and Wood, S.H. 
(2008). Development of human cloned blastocysts following somatic cell nuclear 
transfer with adult fibroblasts. Stem Cells 26, 485-493. 
Friling, S., Andersson, E., Thompson, L.H., Jonsson, M.E., Hebsgaard, J.B., Nanou, E., 
Alekseenko, Z., Marklund, U., Kjellander, S., Volakakis, N., et al. (2009). Efficient 
production of mesencephalic dopamine neurons by Lmx1a expression in 
embryonic stem cells. Proc Natl Acad Sci U S A 106, 7613-7618. 
Gidekel, S., Pizov, G., Bergman, Y., and Pikarsky, E. (2003). Oct-3/4 is a dose-dependent 
oncogenic fate determinant. Cancer Cell 4, 361-370. 
Giorgetti, A., Montserrat, N., Aasen, T., Gonzalez, F., Rodriguez-Piza, I., Vassena, R., Raya, 
A., Boue, S., Barrero, M.J., Corbella, B.A., et al. (2009). Generation of induced 
pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem 
Cell 5, 353-357. 
Gonzalez, F., Barragan Monasterio, M., Tiscornia, G., Montserrat Pulido, N., Vassena, R., 
Batlle Morera, L., Rodriguez Piza, I., and Izpisua Belmonte, J.C. (2009). Generation 
of mouse-induced pluripotent stem cells by transient expression of a single 
nonviral polycistronic vector. Proc Natl Acad Sci U S A 106, 8918-8922. 
Gupta, M.K., Illich, D.J., Gaarz, A., Matzkies, M., Nguemo, F., Pfannkuche, K., Liang, H., 
Classen, S., Reppel, M., Schultze, J.L., et al. (2010). Global transcriptional profiles of 
beating clusters derived from human induced pluripotent stem cells and 
embryonic stem cells are highly similar. BMC Dev Biol 10, 98. 
Gurdon, J. (2008). Primate therapeutic cloning in practice. Nat Biotechnol 26, 64-65. 
 
Generation of Patient Specific Stem Cells: A Human Model System 19 
Gurdon, J.B. (1962). The developmental capacity of nuclei taken from intestinal epithelium 
cells of feeding tadpoles. J Embryol Exp Morphol 10, 622-640. 
Gurdon, J.B., Elsdale, T.R., and Fischberg, M. (1958). Sexually mature individuals of 
Xenopus laevis from the transplantation of single somatic nuclei. Nature 182, 64-65. 
Gurdon, J.B., Laskey, R.A., and Reeves, O.R. (1975). The developmental capacity of nuclei 
transplanted from keratinized skin cells of adult frogs. J Embryol Exp Morphol 34, 
93-112. 
Haase, A., Olmer, R., Schwanke, K., Wunderlich, S., Merkert, S., Hess, C., Zweigerdt, R., 
Gruh, I., Meyer, J., Wagner, S., et al. (2009). Generation of induced pluripotent stem 
cells from human cord blood. Cell Stem Cell 5, 434-441. 
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P., Beard, C., 
Brambrink, T., Wu, L.C., Townes, T.M., et al. (2007). Treatment of sickle cell anemia 
mouse model with iPS cells generated from autologous skin. Science 318, 1920-
1923. 
Heng, J.C., Feng, B., Han, J., Jiang, J., Kraus, P., Ng, J.H., Orlov, Y.L., Huss, M., Yang, L., 
Lufkin, T., et al. (2010). The nuclear receptor Nr5a2 can replace Oct4 in the 
reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell 6, 167-
174. 
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, 
D.A. (2008a). Induction of pluripotent stem cells by defined factors is greatly 
improved by small-molecule compounds. Nat Biotechnol 26, 795-797. 
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W., 
and Melton, D.A. (2008b). Induction of pluripotent stem cells from primary human 
fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26, 1269-1275. 
Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., 
Gepstein, A., Arbel, G., Hammerman, H., et al. (2011). Modelling the long QT 
syndrome with induced pluripotent stem cells. Nature 471, 225-229. 
Jia, F., Wilson, K.D., Sun, N., Gupta, D.M., Huang, M., Li, Z., Panetta, N.J., Chen, Z.Y., 
Robbins, R.C., Kay, M.A., et al. (2010). A nonviral minicircle vector for deriving 
human iPS cells. Nat Methods 7, 197-199. 
Johansson, H., and Simonsson, S. (2010). Core transcription factors, Oct4, Sox2 and Nanog, 
individually form complexes with nucleophosmin (Npm1) to control embryonic 
stem (ES) cell fate determination. Aging (Albany NY) 2, 815-822. 
Johansson, H., Svensson, F., Runnberg, R., Simonsson, T., and Simonsson, S. (2010a). 
Phosphorylated nucleolin interacts with translationally controlled tumor protein 
during mitosis and with Oct4 during interphase in ES cells. PLoS One 5, e13678. 
Johansson, H., Vizlin-Hodzic, D., Simonsson, T., and Simonsson, S. (2010b). Translationally 
controlled tumor protein interacts with nucleophosmin during mitosis in ES cells. 
Cell Cycle 9. 
Jullien, J., Astrand, C., Halley-Stott, R.P., Garrett, N., and Gurdon, J.B. (2010). 
Characterization of somatic cell nuclear reprogramming by oocytes in which a 
linker histone is required for pluripotency gene reactivation. Proc Natl Acad Sci U 
S A 107, 5483-5488. 
Kane, N.M., Nowrouzi, A., Mukherjee, S., Blundell, M.P., Greig, J.A., Lee, W.K., Houslay, 
M.D., Milligan, G., Mountford, J.C., von Kalle, C., et al. (2010). Lentivirus-mediated 
 
New Advances in Stem Cell Transplantation 20
reprogramming of somatic cells in the absence of transgenic transcription factors. 
Mol Ther 18, 2139-2145. 
Kazuki, Y., Hiratsuka, M., Takiguchi, M., Osaki, M., Kajitani, N., Hoshiya, H., Hiramatsu, K., 
Yoshino, T., Kazuki, K., Ishihara, C., et al. (2010). Complete genetic correction of ips 
cells from Duchenne muscular dystrophy. Mol Ther 18, 386-393. 
Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, 
O., Itskovitz-Eldor, J., and Gepstein, L. (2001). Human embryonic stem cells can 
differentiate into myocytes with structural and functional properties of 
cardiomyocytes. J Clin Invest 108, 407-414. 
Kikyo, N., Wade, P.A., Guschin, D., Ge, H., and Wolffe, A.P. (2000). Active remodeling of 
somatic nuclei in egg cytoplasm by the nucleosomal ATPase ISWI. Science 289, 
2360-2362. 
Kim, J.B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Arauzo-Bravo, M.J., Ruau, 
D., Han, D.W., Zenke, M., et al. (2008). Pluripotent stem cells induced from adult 
neural stem cells by reprogramming with two factors. Nature 454, 646-650. 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji, H., Ehrlich, L.I., 
et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-
290. 
Koziol, M.J., Garrett, N., and Gurdon, J.B. (2007). Tpt1 activates transcription of oct4 and 
nanog in transplanted somatic nuclei. Curr Biol 17, 801-807. 
Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A., Dupras, S.K., 
Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al. (2007). Cardiomyocytes 
derived from human embryonic stem cells in pro-survival factors enhance function 
of infarcted rat hearts. Nat Biotechnol 25, 1015-1024. 
Lanza, R.P., Cibelli, J.B., Blackwell, C., Cristofalo, V.J., Francis, M.K., Baerlocher, G.M., Mak, 
J., Schertzer, M., Chavez, E.A., Sawyer, N., et al. (2000). Extension of cell life-span 
and telomere length in animals cloned from senescent somatic cells. Science 288, 
665-669. 
Li, C., Zhou, J., Shi, G., Ma, Y., Yang, Y., Gu, J., Yu, H., Jin, S., Wei, Z., Chen, F., et al. (2009). 
Pluripotency can be rapidly and efficiently induced in human amniotic fluid-
derived cells. Hum Mol Genet 18, 4340-4349. 
Lindahl, A., Brittberg, M., and Peterson, L. (2003). Cartilage repair with chondrocytes: 
clinical and cellular aspects. Novartis Found Symp 249, 175-186; discussion 186-
179, 234-178, 239-141. 
Liu, H., Ye, Z., Kim, Y., Sharkis, S., and Jang, Y.Y. (2010). Generation of endoderm-derived 
human induced pluripotent stem cells from primary hepatocytes. Hepatology 51, 
1810-1819. 
Loh, Y.H., Agarwal, S., Park, I.H., Urbach, A., Huo, H., Heffner, G.C., Kim, K., Miller, J.D., 
Ng, K., and Daley, G.Q. (2009). Generation of induced pluripotent stem cells from 
human blood. Blood 113, 5476-5479. 
Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R., Clark, A.T., and 
Plath, K. (2008). Generation of human induced pluripotent stem cells from dermal 
fibroblasts. Proc Natl Acad Sci U S A 105, 2883-2888. 
Martinez-Fernandez, A., Nelson, T.J., Ikeda, Y., and Terzic, A. (2010). c-MYC independent 
nuclear reprogramming favors cardiogenic potential of induced pluripotent stem 
cells. J Cardiovasc Transl Res 3, 13-23. 
 
Generation of Patient Specific Stem Cells: A Human Model System 21 
Matsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., and Denning, C. 
(2011). Drug evaluation in cardiomyocytes derived from human induced 
pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 
32, 952-962. 
Meissner, A., Wernig, M., and Jaenisch, R. (2007). Direct reprogramming of genetically 
unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 25, 1177-1181. 
Moretti, A., Bellin, M., Welling, A., Jung, C.B., Lam, J.T., Bott-Flugel, L., Dorn, T., Goedel, A., 
Hohnke, C., Hofmann, F., et al. (2010). Patient-specific induced pluripotent stem-
cell models for long-QT syndrome. N Engl J Med 363, 1397-1409. 
Mummery, C., Ward, D., van den Brink, C.E., Bird, S.D., Doevendans, P.A., Opthof, T., 
Brutel de la Riviere, A., Tertoolen, L., van der Heyden, M., and Pera, M. (2002). 
Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 
200, 233-242. 
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., 
Mochiduki, Y., Takizawa, N., and Yamanaka, S. (2008). Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nat 
Biotechnol 26, 101-106. 
Ng, R.K., and Gurdon, J.B. (2008). Epigenetic memory of an active gene state depends on 
histone H3.3 incorporation into chromatin in the absence of transcription. Nat Cell 
Biol 10, 102-109. 
Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-376. 
Novak, A., Shtrichman, R., Germanguz, I., Segev, H., Zeevi-Levin, N., Fishman, B., Mandel, 
Y.E., Barad, L., Domev, H., Kotton, D., et al. (2010). Enhanced reprogramming and 
cardiac differentiation of human keratinocytes derived from plucked hair follicles, 
using a single excisable lentivirus. Cell Reprogram 12, 665-678. 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent induced 
pluripotent stem cells. Nature 448, 313-317. 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008). Generation of 
mouse induced pluripotent stem cells without viral vectors. Science 322, 949-953. 
Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., 
Cowan, C., Hochedlinger, K., and Daley, G.Q. (2008a). Disease-specific induced 
pluripotent stem cells. Cell 134, 877-886. 
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., Lensch, M.W., 
and Daley, G.Q. (2008b). Reprogramming of human somatic cells to pluripotency 
with defined factors. Nature 451, 141-146. 
Peterson, L., Vasiliadis, H.S., Brittberg, M., and Lindahl, A. (2010). Autologous chondrocyte 
implantation: a long-term follow-up. Am J Sports Med 38, 1117-1124. 
Plews, J. R., Li, J., Jones, M., Moore, H. D., Mason, C., Andrews, P. W. & Na, J. (2010). 
Activation of pluripotency genes in human fibroblast cells by a novel mRNA based 
approach. PLoS One 5, e14397. 
Ponnusamy, M.P., Deb, S., Dey, P., Chakraborty, S., Rachagani, S., Senapati, S., and Batra, 
S.K. (2009). RNA polymerase II associated factor 1/PD2 maintains self-renewal by 
its interaction with Oct3/4 in mouse embryonic stem cells. Stem Cells 27, 3001-
3011. 
 
New Advances in Stem Cell Transplantation 20
reprogramming of somatic cells in the absence of transgenic transcription factors. 
Mol Ther 18, 2139-2145. 
Kazuki, Y., Hiratsuka, M., Takiguchi, M., Osaki, M., Kajitani, N., Hoshiya, H., Hiramatsu, K., 
Yoshino, T., Kazuki, K., Ishihara, C., et al. (2010). Complete genetic correction of ips 
cells from Duchenne muscular dystrophy. Mol Ther 18, 386-393. 
Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, 
O., Itskovitz-Eldor, J., and Gepstein, L. (2001). Human embryonic stem cells can 
differentiate into myocytes with structural and functional properties of 
cardiomyocytes. J Clin Invest 108, 407-414. 
Kikyo, N., Wade, P.A., Guschin, D., Ge, H., and Wolffe, A.P. (2000). Active remodeling of 
somatic nuclei in egg cytoplasm by the nucleosomal ATPase ISWI. Science 289, 
2360-2362. 
Kim, J.B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Arauzo-Bravo, M.J., Ruau, 
D., Han, D.W., Zenke, M., et al. (2008). Pluripotent stem cells induced from adult 
neural stem cells by reprogramming with two factors. Nature 454, 646-650. 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji, H., Ehrlich, L.I., 
et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-
290. 
Koziol, M.J., Garrett, N., and Gurdon, J.B. (2007). Tpt1 activates transcription of oct4 and 
nanog in transplanted somatic nuclei. Curr Biol 17, 801-807. 
Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A., Dupras, S.K., 
Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al. (2007). Cardiomyocytes 
derived from human embryonic stem cells in pro-survival factors enhance function 
of infarcted rat hearts. Nat Biotechnol 25, 1015-1024. 
Lanza, R.P., Cibelli, J.B., Blackwell, C., Cristofalo, V.J., Francis, M.K., Baerlocher, G.M., Mak, 
J., Schertzer, M., Chavez, E.A., Sawyer, N., et al. (2000). Extension of cell life-span 
and telomere length in animals cloned from senescent somatic cells. Science 288, 
665-669. 
Li, C., Zhou, J., Shi, G., Ma, Y., Yang, Y., Gu, J., Yu, H., Jin, S., Wei, Z., Chen, F., et al. (2009). 
Pluripotency can be rapidly and efficiently induced in human amniotic fluid-
derived cells. Hum Mol Genet 18, 4340-4349. 
Lindahl, A., Brittberg, M., and Peterson, L. (2003). Cartilage repair with chondrocytes: 
clinical and cellular aspects. Novartis Found Symp 249, 175-186; discussion 186-
179, 234-178, 239-141. 
Liu, H., Ye, Z., Kim, Y., Sharkis, S., and Jang, Y.Y. (2010). Generation of endoderm-derived 
human induced pluripotent stem cells from primary hepatocytes. Hepatology 51, 
1810-1819. 
Loh, Y.H., Agarwal, S., Park, I.H., Urbach, A., Huo, H., Heffner, G.C., Kim, K., Miller, J.D., 
Ng, K., and Daley, G.Q. (2009). Generation of induced pluripotent stem cells from 
human blood. Blood 113, 5476-5479. 
Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R., Clark, A.T., and 
Plath, K. (2008). Generation of human induced pluripotent stem cells from dermal 
fibroblasts. Proc Natl Acad Sci U S A 105, 2883-2888. 
Martinez-Fernandez, A., Nelson, T.J., Ikeda, Y., and Terzic, A. (2010). c-MYC independent 
nuclear reprogramming favors cardiogenic potential of induced pluripotent stem 
cells. J Cardiovasc Transl Res 3, 13-23. 
 
Generation of Patient Specific Stem Cells: A Human Model System 21 
Matsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., and Denning, C. 
(2011). Drug evaluation in cardiomyocytes derived from human induced 
pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 
32, 952-962. 
Meissner, A., Wernig, M., and Jaenisch, R. (2007). Direct reprogramming of genetically 
unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 25, 1177-1181. 
Moretti, A., Bellin, M., Welling, A., Jung, C.B., Lam, J.T., Bott-Flugel, L., Dorn, T., Goedel, A., 
Hohnke, C., Hofmann, F., et al. (2010). Patient-specific induced pluripotent stem-
cell models for long-QT syndrome. N Engl J Med 363, 1397-1409. 
Mummery, C., Ward, D., van den Brink, C.E., Bird, S.D., Doevendans, P.A., Opthof, T., 
Brutel de la Riviere, A., Tertoolen, L., van der Heyden, M., and Pera, M. (2002). 
Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 
200, 233-242. 
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., 
Mochiduki, Y., Takizawa, N., and Yamanaka, S. (2008). Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nat 
Biotechnol 26, 101-106. 
Ng, R.K., and Gurdon, J.B. (2008). Epigenetic memory of an active gene state depends on 
histone H3.3 incorporation into chromatin in the absence of transcription. Nat Cell 
Biol 10, 102-109. 
Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372-376. 
Novak, A., Shtrichman, R., Germanguz, I., Segev, H., Zeevi-Levin, N., Fishman, B., Mandel, 
Y.E., Barad, L., Domev, H., Kotton, D., et al. (2010). Enhanced reprogramming and 
cardiac differentiation of human keratinocytes derived from plucked hair follicles, 
using a single excisable lentivirus. Cell Reprogram 12, 665-678. 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent induced 
pluripotent stem cells. Nature 448, 313-317. 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008). Generation of 
mouse induced pluripotent stem cells without viral vectors. Science 322, 949-953. 
Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., 
Cowan, C., Hochedlinger, K., and Daley, G.Q. (2008a). Disease-specific induced 
pluripotent stem cells. Cell 134, 877-886. 
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., Lensch, M.W., 
and Daley, G.Q. (2008b). Reprogramming of human somatic cells to pluripotency 
with defined factors. Nature 451, 141-146. 
Peterson, L., Vasiliadis, H.S., Brittberg, M., and Lindahl, A. (2010). Autologous chondrocyte 
implantation: a long-term follow-up. Am J Sports Med 38, 1117-1124. 
Plews, J. R., Li, J., Jones, M., Moore, H. D., Mason, C., Andrews, P. W. & Na, J. (2010). 
Activation of pluripotency genes in human fibroblast cells by a novel mRNA based 
approach. PLoS One 5, e14397. 
Ponnusamy, M.P., Deb, S., Dey, P., Chakraborty, S., Rachagani, S., Senapati, S., and Batra, 
S.K. (2009). RNA polymerase II associated factor 1/PD2 maintains self-renewal by 
its interaction with Oct3/4 in mouse embryonic stem cells. Stem Cells 27, 3001-
3011. 
 
New Advances in Stem Cell Transplantation 22
Rai, K., Huggins, I.J., James, S.R., Karpf, A.R., Jones, D.A., and Cairns, B.R. (2008). DNA 
demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, 
and gadd45. Cell 135, 1201-1212. 
Redmer, T., Diecke, S., Grigoryan, T., Quiroga-Negreira, A., Birchmeier, W., and Besser, D. 
(2011). E-cadherin is crucial for embryonic stem cell pluripotency and can replace 
OCT4 during somatic cell reprogramming. EMBO Rep 12, 720-726. 
Shi, Y., Do, J.T., Desponts, C., Hahm, H.S., Scholer, H.R., and Ding, S. (2008). A combined 
chemical and genetic approach for the generation of induced pluripotent stem cells. 
Cell Stem Cell 2, 525-528. 
Silva, J., Barrandon, O., Nichols, J., Kawaguchi, J., Theunissen, T.W., and Smith, A. (2008). 
Promotion of reprogramming to ground state pluripotency by signal inhibition. 
PLoS Biol 6, e253. 
Simonsson, S., and Gurdon, J. (2004). DNA demethylation is necessary for the epigenetic 
reprogramming of somatic cell nuclei. Nat Cell Biol 6, 984-990. 
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., 
Cooper, O., Mitalipova, M., et al. (2009). Parkinson's disease patient-derived 
induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-
977. 
Spemann, H. (1938). Embryonic Development and Induction. New Haven: Yale University 
Press. 
Stadtfeld, M., Maherali, N., Breault, D.T., and Hochedlinger, K. (2008a). Defining molecular 
cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 
2, 230-240. 
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008b). Induced 
pluripotent stem cells generated without viral integration. Science 322, 945-949. 
Stephenson, E.L., Mason, C., and Braude, P.R. (2009). Preimplantation genetic diagnosis as a 
source of human embryonic stem cells for disease research and drug discovery. 
BJOG 116, 158-165. 
Stojkovic, M., Stojkovic, P., Leary, C., Hall, V.J., Armstrong, L., Herbert, M., Nesbitt, M., 
Lako, M., and Murdoch, A. (2005). Derivation of a human blastocyst after 
heterologous nuclear transfer to donated oocytes. Reprod Biomed Online 11, 226-
231. 
Sugii, S., Kida, Y., Kawamura, T., Suzuki, J., Vassena, R., Yin, Y.Q., Lutz, M.K., Berggren, 
W.T., Izpisua Belmonte, J.C., and Evans, R.M. (2010). Human and mouse adipose-
derived cells support feeder-independent induction of pluripotent stem cells. Proc 
Natl Acad Sci U S A 107, 3558-3563. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, 
S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. Cell 131, 861-872. 
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 
Taranger, C.K., Noer, A., Sorensen, A.L., Hakelien, A.M., Boquest, A.C., and Collas, P. 
(2005). Induction of dedifferentiation, genomewide transcriptional programming, 
and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. 
Mol Biol Cell 16, 5719-5735. 
 
Generation of Patient Specific Stem Cells: A Human Model System 23 
Tian, X.C., Xu, J., and Yang, X. (2000). Normal telomere lengths found in cloned cattle. Nat 
Genet 26, 272-273. 
Tsai, S.Y., Clavel, C., Kim, S., Ang, Y.S., Grisanti, L., Lee, D.F., Kelley, K., and Rendl, M. 
(2010). Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem 
cells. Stem Cells 28, 221-228. 
Vizlin-Hodzic, D., Johansson, H., Ryme, J., Simonsson, T., and Simonsson, S. (2011). SAF-A 
Has a Role in Transcriptional Regulation of Oct4 in ES Cells Through Promoter 
Binding. Cell Reprogram. 
Vizlin-Hodzic, D., Ryme, J., Simonsson, S., and Simonsson, T. (2009). Developmental studies 
of Xenopus shelterin complexes: the message to reset telomere length is already 
present in the egg. FASEB J 23, 2587-2594. 
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, W., Mandal, P. K., 
Smith, Z. D. & other authors (2010). Highly efficient reprogramming to 
pluripotency and directed differentiation of human cells with synthetic modified 
mRNA. Cell Stem Cell 7, 618‐630. 
Wei, D., Kanai, M., Huang, S., and Xie, K. (2006). Emerging role of KLF4 in human 
gastrointestinal cancer. Carcinogenesis 27, 23-31. 
Wei, F., Scholer, H.R., and Atchison, M.L. (2007). Sumoylation of Oct4 enhances its stability, 
DNA binding, and transactivation. J Biol Chem 282, 21551-21560. 
Wernig, M., Lengner, C.J., Hanna, J., Lodato, M.A., Steine, E., Foreman, R., Staerk, J., 
Markoulaki, S., and Jaenisch, R. (2008a). A drug-inducible transgenic system for 
direct reprogramming of multiple somatic cell types. Nat Biotechnol 26, 916-924. 
Wernig, M., Meissner, A., Cassady, J.P., and Jaenisch, R. (2008b). c-Myc is dispensable for 
direct reprogramming of mouse fibroblasts. Cell Stem Cell 2, 10-12. 
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, 
B.E., and Jaenisch, R. (2007). In vitro reprogramming of fibroblasts into a 
pluripotent ES-cell-like state. Nature 448, 318-324. 
Wernig, M., Zhao, J.P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V., Constantine-
Paton, M., Isacson, O., and Jaenisch, R. (2008c). Neurons derived from 
reprogrammed fibroblasts functionally integrate into the fetal brain and improve 
symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 105, 5856-
5861. 
Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable 
offspring derived from fetal and adult mammalian cells. Nature 385, 810-813. 
Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., Cowling, 
R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009). piggyBac transposition 
reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770. 
Xu, D., Alipio, Z., Fink, L.M., Adcock, D.M., Yang, J., Ward, D.C., and Ma, Y. (2009). 
Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. 
Proc Natl Acad Sci U S A 106, 808-813. 
Xu, H.M., Liao, B., Zhang, Q.J., Wang, B.B., Li, H., Zhong, X.M., Sheng, H.Z., Zhao, Y.X., 
Zhao, Y.M., and Jin, Y. (2004). Wwp2, an E3 ubiquitin ligase that targets 
transcription factor Oct-4 for ubiquitination. J Biol Chem 279, 23495-23503. 
Yakubov, E., Rechavi, G., Rozenblatt, S. & Givol, D. (2010). Reprogramming of human 
fibroblasts to pluripotent stem cells using mRNA of four transcription factors. 
Biochem Biophys Res Commun 394, 189‐193. 
 
New Advances in Stem Cell Transplantation 22
Rai, K., Huggins, I.J., James, S.R., Karpf, A.R., Jones, D.A., and Cairns, B.R. (2008). DNA 
demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, 
and gadd45. Cell 135, 1201-1212. 
Redmer, T., Diecke, S., Grigoryan, T., Quiroga-Negreira, A., Birchmeier, W., and Besser, D. 
(2011). E-cadherin is crucial for embryonic stem cell pluripotency and can replace 
OCT4 during somatic cell reprogramming. EMBO Rep 12, 720-726. 
Shi, Y., Do, J.T., Desponts, C., Hahm, H.S., Scholer, H.R., and Ding, S. (2008). A combined 
chemical and genetic approach for the generation of induced pluripotent stem cells. 
Cell Stem Cell 2, 525-528. 
Silva, J., Barrandon, O., Nichols, J., Kawaguchi, J., Theunissen, T.W., and Smith, A. (2008). 
Promotion of reprogramming to ground state pluripotency by signal inhibition. 
PLoS Biol 6, e253. 
Simonsson, S., and Gurdon, J. (2004). DNA demethylation is necessary for the epigenetic 
reprogramming of somatic cell nuclei. Nat Cell Biol 6, 984-990. 
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., 
Cooper, O., Mitalipova, M., et al. (2009). Parkinson's disease patient-derived 
induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-
977. 
Spemann, H. (1938). Embryonic Development and Induction. New Haven: Yale University 
Press. 
Stadtfeld, M., Maherali, N., Breault, D.T., and Hochedlinger, K. (2008a). Defining molecular 
cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 
2, 230-240. 
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008b). Induced 
pluripotent stem cells generated without viral integration. Science 322, 945-949. 
Stephenson, E.L., Mason, C., and Braude, P.R. (2009). Preimplantation genetic diagnosis as a 
source of human embryonic stem cells for disease research and drug discovery. 
BJOG 116, 158-165. 
Stojkovic, M., Stojkovic, P., Leary, C., Hall, V.J., Armstrong, L., Herbert, M., Nesbitt, M., 
Lako, M., and Murdoch, A. (2005). Derivation of a human blastocyst after 
heterologous nuclear transfer to donated oocytes. Reprod Biomed Online 11, 226-
231. 
Sugii, S., Kida, Y., Kawamura, T., Suzuki, J., Vassena, R., Yin, Y.Q., Lutz, M.K., Berggren, 
W.T., Izpisua Belmonte, J.C., and Evans, R.M. (2010). Human and mouse adipose-
derived cells support feeder-independent induction of pluripotent stem cells. Proc 
Natl Acad Sci U S A 107, 3558-3563. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, 
S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. Cell 131, 861-872. 
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 
Taranger, C.K., Noer, A., Sorensen, A.L., Hakelien, A.M., Boquest, A.C., and Collas, P. 
(2005). Induction of dedifferentiation, genomewide transcriptional programming, 
and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. 
Mol Biol Cell 16, 5719-5735. 
 
Generation of Patient Specific Stem Cells: A Human Model System 23 
Tian, X.C., Xu, J., and Yang, X. (2000). Normal telomere lengths found in cloned cattle. Nat 
Genet 26, 272-273. 
Tsai, S.Y., Clavel, C., Kim, S., Ang, Y.S., Grisanti, L., Lee, D.F., Kelley, K., and Rendl, M. 
(2010). Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem 
cells. Stem Cells 28, 221-228. 
Vizlin-Hodzic, D., Johansson, H., Ryme, J., Simonsson, T., and Simonsson, S. (2011). SAF-A 
Has a Role in Transcriptional Regulation of Oct4 in ES Cells Through Promoter 
Binding. Cell Reprogram. 
Vizlin-Hodzic, D., Ryme, J., Simonsson, S., and Simonsson, T. (2009). Developmental studies 
of Xenopus shelterin complexes: the message to reset telomere length is already 
present in the egg. FASEB J 23, 2587-2594. 
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, W., Mandal, P. K., 
Smith, Z. D. & other authors (2010). Highly efficient reprogramming to 
pluripotency and directed differentiation of human cells with synthetic modified 
mRNA. Cell Stem Cell 7, 618‐630. 
Wei, D., Kanai, M., Huang, S., and Xie, K. (2006). Emerging role of KLF4 in human 
gastrointestinal cancer. Carcinogenesis 27, 23-31. 
Wei, F., Scholer, H.R., and Atchison, M.L. (2007). Sumoylation of Oct4 enhances its stability, 
DNA binding, and transactivation. J Biol Chem 282, 21551-21560. 
Wernig, M., Lengner, C.J., Hanna, J., Lodato, M.A., Steine, E., Foreman, R., Staerk, J., 
Markoulaki, S., and Jaenisch, R. (2008a). A drug-inducible transgenic system for 
direct reprogramming of multiple somatic cell types. Nat Biotechnol 26, 916-924. 
Wernig, M., Meissner, A., Cassady, J.P., and Jaenisch, R. (2008b). c-Myc is dispensable for 
direct reprogramming of mouse fibroblasts. Cell Stem Cell 2, 10-12. 
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, 
B.E., and Jaenisch, R. (2007). In vitro reprogramming of fibroblasts into a 
pluripotent ES-cell-like state. Nature 448, 318-324. 
Wernig, M., Zhao, J.P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V., Constantine-
Paton, M., Isacson, O., and Jaenisch, R. (2008c). Neurons derived from 
reprogrammed fibroblasts functionally integrate into the fetal brain and improve 
symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 105, 5856-
5861. 
Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable 
offspring derived from fetal and adult mammalian cells. Nature 385, 810-813. 
Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., Cowling, 
R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009). piggyBac transposition 
reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766-770. 
Xu, D., Alipio, Z., Fink, L.M., Adcock, D.M., Yang, J., Ward, D.C., and Ma, Y. (2009). 
Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. 
Proc Natl Acad Sci U S A 106, 808-813. 
Xu, H.M., Liao, B., Zhang, Q.J., Wang, B.B., Li, H., Zhong, X.M., Sheng, H.Z., Zhao, Y.X., 
Zhao, Y.M., and Jin, Y. (2004). Wwp2, an E3 ubiquitin ligase that targets 
transcription factor Oct-4 for ubiquitination. J Biol Chem 279, 23495-23503. 
Yakubov, E., Rechavi, G., Rozenblatt, S. & Givol, D. (2010). Reprogramming of human 
fibroblasts to pluripotent stem cells using mRNA of four transcription factors. 
Biochem Biophys Res Commun 394, 189‐193. 
 
New Advances in Stem Cell Transplantation 24
Yamanaka, S. (2009). A fresh look at iPS cells. Cell 137, 13-17. 
Yamanaka, S., and Blau, H.M. (2010). Nuclear reprogramming to a pluripotent state by three 
approaches. Nature 465, 704-712. 
Yamazaki, Y., Fujita, T.C., Low, E.W., Alarcon, V.B., Yanagimachi, R., and Marikawa, Y. 
(2006). Gradual DNA demethylation of the Oct4 promoter in cloned mouse 
embryos. Mol Reprod Dev 73, 180-188. 
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, II, and Thomson, J.A. (2009). 
Human induced pluripotent stem cells free of vector and transgene sequences. 
Science 324, 797-801. 
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., 
Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell 
lines derived from human somatic cells. Science 318, 1917-1920. 
Yusa, K., Rad, R., Takeda, J., and Bradley, A. (2009). Generation of transgene-free induced 
pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 6, 363-369. 
Zhang, J., Wilson, G.F., Soerens, A.G., Koonce, C.H., Yu, J., Palecek, S.P., Thomson, J.A., and 
Kamp, T.J. (2009). Functional cardiomyocytes derived from human induced 
pluripotent stem cells. Circ Res 104, e30-41. 
Zhao, H.X., Li, Y., Jin, H.F., Xie, L., Liu, C., Jiang, F., Luo, Y.N., Yin, G.W., Wang, J., Li, L.S., 
et al. (2010). Rapid and efficient reprogramming of human amnion-derived cells 
into pluripotency by three factors OCT4/SOX2/NANOG. Differentiation 80, 123-
129. 
Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced pluripotent 
stem cells. Nature 474, 212-215. 
Zhao, X.Y., Li, W., Lv, Z., Liu, L., Tong, M., Hai, T., Hao, J., Guo, C.L., Ma, Q.W., Wang, L., et 
al. (2009). iPS cells produce viable mice through tetraploid complementation. 
Nature 461, 86-90. 
Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., 
et al. (2009). Generation of induced pluripotent stem cells using recombinant 
proteins. Cell Stem Cell 4, 381-384. 
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., and Melton, D.A. (2008). In vivo 
reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455, 627-632. 
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K., and Ding, S. 
(2010). Reprogramming of human primary somatic cells by OCT4 and chemical 
compounds. Cell Stem Cell 7, 651-655. 
2 
Importance of Non-HLA Gene Polymorphisms 
 in Hematopoietic Stem Cell Transplantation 
Jeane Visentainer and Ana Sell 
Maringa State University  
Brazil 
1. Introduction  
In the last 10 years, non-HLA genotypes have been investigated for their potential roles in 
the occurrence and severity of graft-versus-host disease (GvHD) as well as for their 
contribution to overall transplant-related mortality, infectious episodes, and overall 
survival. 
These non-HLA-encoded genes include polymorphisms within the regulatory sequences of 
the cytokine genes, or genes associating with innate immunity: KIR (killer immunoglobulin-
like receptor) genes, MIC (MHC class I chain-related) genes, and others. 
The first studied non-HLA genes were polymorphisms in regulatory cytokine genes because 
of cytokine role in GvHD immunopathogenesis. Single nucleotide polymorphisms in several 
regions of cytokine genes were correlated with the transplant overcome in several studies 
(Kim et al., 2005; Laguila Visentainer et al., 2005; Lin et al., 2003; Mlynarczewska et al., 2004; 
Viel et al., 2007; reviewed in Dickinson, 2008). 
2. Role of cytokines in graft-versus-host disease after allogeneic stem cell 
transplantation 
The pathophysiology of acute GvHD can be considered a cytokine storm (Ferrara, 2000), 
initializing with the transplant conditioning regimen that damages and activates host 
tissues. Activated host cells secrete inflammatory cytokines, such as tumor necrosis factor 
(TNF)- and interleukin (IL)-1. This initial cytokine release is further amplified in the second 
phase by presentation of host antigens to donor T cells and the subsequent proliferation and 
differentiation of these activated T cells. These cells secrete a variety of cytokines, such as IL-
2, TNF-, interferon (IFN)-γ, IL-4, IL-6, IL-10, and transforming growth factor-beta (TGF)-1. 
Several reports have demonstrated the increase of these cytokines in the serum from 
patients with acute GvHD (Kayaba et al., 2000; Liem et al., 1998; Sakata et al., 2001; 
Visentainer et al., 2003). 
Although chronic GvHD remains a frequent complication of hematopoietic stem cell 
transplantation (HSCT), the pathogenesis is still unclear. However, it is known that 
cytokines also play an important role in its development (Iwasaki, 2004; Letterio & Roberts, 
1998; Liem et al., 1999; Margolis & Vogelsang, 2000; Zhang et al., 2006). Chronic GvHD is a 
multisystem alloimmune and autoimmune disorder characterized by immune 
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1998; Liem et al., 1999; Margolis & Vogelsang, 2000; Zhang et al., 2006). Chronic GvHD is a 
multisystem alloimmune and autoimmune disorder characterized by immune 
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dysregulation, immunodeficiency, impaired organ function and decreased survival (Baird & 
Pavletic, 2006). It starts with the expansion of donor T cells in response to allo or auto-
antigens that escape assessment thymus and the mechanisms of deletion. T cells induce 
damage in target organs by attacking cytolytic, inflammatory cytokines and fibrosis by 
activating B cells, with production of autoantibodies (Pérez-Simón et al., 2006). 
Thus multiple cytokines are important in GvHD pathogenesis and regulation (Ferrara & 
Krenger, 1998; Jung et al., 2006; Kappel et al., 2009; Reddy et al., 2003; Tawara et al., 2008; 
Visentainer et al., 2005; Yi et al., 2008). Furthermore, the timing and duration of cytokine 
expression may be a critical factor determining the induction of the graft-versus-host (GvH) 
reaction, and cytokine dysregulation could potentially contribute to the severity of GvHD. 
Recently, Choi et al. (2010) and Paczesny et al. (2010) reviewed the biology of acute GvHD, 
and concluded that the underlying mechanisms of GvHD have emerged as a complex 
network of immune interactions where the key players are the naive T cells, the host and 
donor APCs, CTLs and regulatory T cells, along with new players such as Plasmacytoid DCs 
(pDCs), B cells and Th17 cells. 
2.1 Cytokine gene polymorphisms 
The production of some cytokines is under genetic control. Polymorphisms in the regulatory 
regions of several cytokine genes may cause inter-individual differences in cytokine 
production (Wilson et al., 1997; Turner et al., 1997; Awad et al., 1998; Fishman et al., 1998; 
Pravica et al., 1999). As these polymorphisms segregate independently, each person is a 
mosaic of high-, intermediate-, and low-producing phenotypes. These cytokine 
polymorphisms are known to have functional relevance in post-transplant outcome, 
rejection and GvHD, following solid organ (Benza et al., 2009; Fernandes et al., 2002; Hahn 
et al., 2001; Karimi et al., 2011; Reviron et al., 2001) and hematopoietic stem cell 
transplantation (Ambruzova et al., 2009; Karimi et al., 2010; Laguila Visentainer et al., 2005; 
Leffell et al., 2001; Takahashi et al., 2000; Tambur et al., 2001), respectively. 
2.2 Impact of cytokine gene polymorphisms on graft-vs-host disease 
Many studies in recent years have focused on correlating donor and/or recipient 
genotype with GvHD risk. Table 1 summarizes the various polymorphisms in genes 
encoding both pro- and anti-inflammatory factors and their receptors that have been 
studied in GvHD. 
3. Killer immunoglobulin-like receptors and hematopoietic stem cell 
transplantation 
Natural killer (NK) cell effector function is regulated by a balance between activating 
receptors and inhibitory receptors for major histocompatibility complex (MHC) class I 
molecules (Joyce & Sun, 2011; Parham et al., 2006; Yokoyama et al., 2006). In the setting of 
allogeneic HSCT, donor NK cells may attack recipient cells that lack the appropriate HLA 
class I ligands for the donor KIR. Several studies have shown that certain combinations of 
killer immunoglobulin-like receptors and human leukocyte antigens (in both donors and 
recipients) can affect the chances of survival of transplant patients, particularly in relation to 
the graft-versus-leukemia effect, which may be associated to decreased relapse rates in 
certain groups (reviewed in Franceschi et al., 2011). 
 




Acute Chronic  
SNP/Genotype References 
 IL1A-889*2 Cullup et al. (2003)
IL6-174 G/C IL6-174 GG Lin et al. (2003)
 IL6-174 CC Laguila Visentainer et al. (2005) 
TNF-308 GG/GA Takahashi et al. (2000)
 TNF-238 GA Viel et al. (2007)
IL2-330 GT Macmillan et al. (2003)
 IL10-1082,-819,-592 ATA/ATA Kim et al. (2005) 
IL10-592 A/A Lin et al. (2003)
IL-10RB A/A IL-10RB A/A Sivula et al. (2009)
TGFB1+869,+915 TG/GG Leffell et al. (2001)
TGFB1+869 T Hattori et al. (2002)
TGF- beta1 codon 25 GG Rashidi-Nezhad et al. (2010) 
IFN-γ T+874A Karimi et al. (2010)
IL-7RA Shamim et al. (2011)
Table 1. Polymorphisms in genes encoding both pro- and anti-inflammatory factors and 
their receptors in GvHD 
3.1 Killer immunoglobulin-like receptors 
The group of KIR genes comprises a region of approximately 150 Kb in the leukocyte 
receptor complex (LRC) on chromosome 19q13.4 (Uhrberg et al., 1997). KIRs are members of 
a group of regulatory molecules on the surface of NK cells, in subgroups of Tγ+ 
lymphocytes, effector T+ lymphocytes and memory lymphocytes (Rajagopalan & Long, 
2005). The KIR family includes activating and inhibitory molecules. Inhibitory KIRs (2DL 
and 3DL) have a long cytoplasmic tail containing tyrosine-based inhibitory motifs (ITIMs) 
that trigger inhibitory events of cytotoxicity. In contrast, activating KIRs (2DS and 3DS) 
interact with the DAP12 molecule, which has tyrosine-based activation motifs (ITAMs) that 
cause a cascade that results in an increase in cytoplasmic granulation and the production of 
cytokines and chemokines, thereby initiating immune response (McVicar et al., 2001). 
The balance between activation and inhibition of NK cells occurs through the binding of 
KIRs with HLA class I molecules present in all nucleated cells of an individual. Most KIRs 
bind to HLA-C molecules. It is worth remembering the importance of the dimorphism of 
amino acids, such as residue 80 of -helix-1, in the definition of this HLA receptor. On this 
basis, HLA-C alleles may be defined as "Group 1" or "Group 2": C1 – HLA-Cw*01, *03, *07, 
*08, *12, *13, *14, and *16 and C2 – HLA-Cw*02, *04, *05, *06, *07, *15, *17, and *18, which are 
specific for KIR2DL2/2DL3/2DS2 and KIR2DL1/2DS1, respectively (Boyton & Altmann, 
2007). Evidence suggests that HLA-Cw4 is a receptor for KIR2DS4 (Katz et al., 2001). The 
KIR2DL4, for example, specificity binds to the HLA-G molecule (Rajagopalan & Long, 1999), 
while the KIR3DL1 receptor binds to a subset of HLA molecules with the Bw4 epitope, 
present in approximately one third of all HLA-B molecules. The KIR3DS1 is highly 
homologous with 3DL1 and seems to share the Bw4 epitope as ligand, although this needs 
to be experimentally verified. The KIR3DL2 receptor is still being discussed, but studies 
suggest that HLA-A3 and HLA-A11 perform this role (O'Connor et al., 2006). 
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dysregulation, immunodeficiency, impaired organ function and decreased survival (Baird & 
Pavletic, 2006). It starts with the expansion of donor T cells in response to allo or auto-
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Krenger, 1998; Jung et al., 2006; Kappel et al., 2009; Reddy et al., 2003; Tawara et al., 2008; 
Visentainer et al., 2005; Yi et al., 2008). Furthermore, the timing and duration of cytokine 
expression may be a critical factor determining the induction of the graft-versus-host (GvH) 
reaction, and cytokine dysregulation could potentially contribute to the severity of GvHD. 
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certain groups (reviewed in Franceschi et al., 2011). 
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Based on the genetic content and pattern of segregation at the population level, KIR 
haplotypes are divided into two groups, A and B, varying in the type and number of genes 
present. The KIR group A haplotype is uniform in terms of gene content (3DL3, 2DL3, 2DL1, 
2DP1, 3DP1, 2DL4, 3DL1, 2DS4, and 3DL2), of which all but 1 encode inhibitory receptors. In 
contrast, the KIR group B haplotype is more diverse in the KIR genes it contains, has more 
activating receptors, and is characterized by the 2DL2, 2DS1, 2DS2, 2DS3, and 2DS5 genes 
(Uhrberg et al., 1997). 
3.2 Impact of killer immunoglobulin-like receptors and hematopoietic stem cell 
transplantation 
Previous studies have examined the effect of donor and recipient KIR genotypes on the 
outcome of allogeneic HSCT (Bishara et al., 2004; Gagne et al., 2002; Sun et al., 2005). One 
study found a 100% risk of GvHD after unrelated donor BMT, when the donor contained 
KIR genes absent in the recipient, compared to a 60% risk of GvHD with other combinations 
(Gagne et al., 2002).  
In 2004, one study carried out KIR-HLA genotyping of 220 related HLA identical donor-
recipient pairs (112 for myeloid diseases and 108 lymphoid diseases) (Cook et al., 2004). For 
patients with myeloid diseases, survival was lower in those homozygous for Group 2 (C2) 
HLA-C compared to patients with Group 1 (C1). This effect was observed only when the 
donor had the KIR2DS2 gene. As KIR2DS2 is in strong linkage disequilibrium with KIR2DL2 
(receptor inhibited by C1), this would indirectly indicate lower survival in patients who do 
not have the receptor for KIR2DL2, an opposite result to the model in which this lack of 
inhibition  could result in NK cell alloreactivity with a consequent elimination of residual 
leukemic cells (Witt et al., 2006). In 178 patients with AML, CML, ALL and primary 
myelodysplastic syndrome (MDS) who received HSCT with T cell depletion from HLA-
identical related donors, some authors observed that the disease-free survival was 
significantly higher in patients with AML and MDS that did not have the HLA ligand for 
the inhibitory KIR of the donor (Hsu et al., 2005). Moreover, the relapse rate was lower in 
these individuals, which may be related to higher survival rates. The results differ from a 
study in which T cell depletion was not performed (Cook et al., 2004). In another study 
(Schellekens et al., 2008) involving 83 patients with different types of hematologic 
malignancies who received HSCT from related HLA-identical donors without T cell 
depletion, a high relapse rate was found when high numbers of activating KIRs were 
present in both the patient and donor. According to the authors, a consequence of this 
finding may be an increased alloreactivity of the host against graft, impairing the response 
of donor cells resulting in an insufficient graft-versus-leukemia effect and increased risk of 
leukemic relapse.  
Nowadays, there is no unequivocal evidence that polymorphic genes for KIR involved in 
innate immunity sufficiently influence GvHD and transplant outcome to change clinical 
practice (Davies et al., 2002; Cooley et al., 2009; Giebel et al., 2003; Hsu et al., 2005; Ludajic et 
al., 2009; Miller et al., 2007; Moretta et al., 2009; Schellekens et al., 2008; Symons et al., 2010; 
Witt et al., 2006).  
Using a large cohort of patients, Venstrom et al. (2010) demonstrated that individual donor 
activating KIR, recipient HLA class I ligands, and donor KIR gene copy number all impact 
KIR-driven NK effects. They also showed that not all KIR B haplotypes have equivalent 
clinical impact, and they proposed that future studies consider specific B haplotype subsets 
or individual KIR genes in their analyses. 
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However, there are conflicting results in many studies, which may be due to the 
heterogeneity in HSCT protocols employed, differences in inclusion criteria, the HSCT 
preparative regimen and graft content, the degree of donor HLA-incompatibility, and 
posttransplant immunosuppression. Beside of this, according to early studies, Symons et al. 
(2010) have described 4 models of NK cell alloreactivity to predict HSCT outcomes: 1) KIR 
ligand incompatibility; 2) receptor-ligand model; 3) missing ligand model; and 4) KIR gene-
gene model. And, contradictory results obtained from these models have made it difficult to 
conclude which model is most predictive of transplant outcome. 
4. MICA and MICB matching in bone marrow transplantation 
Retrospective and prospective studies have shown that matching donors and recipients for 
non-HLA DNA sequences in the MHC (beta and delta block matching) can result in 
improved patient survival and less severe GvHD (Tay et al., 1995; Witt et al., 2000). One of 
these blocks, the beta block, spans about 300 kb and contains the immunologically relevant 
HLA-B, HLA-C, MICA, and MICB genes (Kitcharoen et al., 2006). The polymorphic MICA 
molecule likely may be a target for specific antibodies and T cells in solid organ grafts or in 
GvHD (Zhang & Stastny, 2006). 
4.1 MICA and MICB genes 
In 1994, two new polymorphic families of MHC class I related genes, termed MHC class I-
related chain A (MICA) and B (MICB) were described (Bahram et al., 1994). These genes are 
highly polymorphic with at least 76 alleles for MICA and 31 alleles for MICB (IMGT/HLA 
database; http://www.ebi.ac.uk/imgt/hla/stats.html), and are located in the MHC classical 
class I region (Horton et al., 2004), 46.4 and 141.2 kb centromeric to HLA-B, respectively 
(Bahram et al., 1994; Bahram et al., 2000; Leelayuwat et al., 1994). They encode cell surface 
glycoproteins that do not associate with 2-microglobulin. These molecules function as 
restriction elements for intestinal γ T cells and they behave as cell stress molecules. MICA 
is expressed in endothelial cells, keratinocytes and monocytes, but not in CD4+, CD8+ or 
CD19+ lymphocytes (Zwirner et al., 1999).  
The MICA gene products have been shown to play a role in some aspects of antigen 
presentation and T-cell recognition, and appear to be important in innate immunity as 
ligands to NKG2D receptor expressed on most γ T cells, CD8  T cells, and NK cells 
(Tieng et al., 2002). 
4.2 MICA and MICB and relevance to stem cell transplantation outcome 
Several studies have shown that the highly polymorphic MIC antigens are expressed in 
transplanted organs and may cause early graft rejection (Hankey  et al., 2002; Mizutani et al., 
2006; Narayan et al., 2011; Panigrahi et al., 2007; Sumitran-Holgersson, 2008; Terasaki et al., 
2007). The polymorphisms of MICA and MICB may be involved in allogeneic BMT and 
GvHD (Gannage et al., 2008; Murai et al., 2003; Parmar et al. 2009; Przepiorka et al., 1995) 
because they are augmented by stress in epithelia (Groh et al., 1996) and are recognized by a 
subpopulation of intestinal γ T cells (Zou et al. 2007). In addition to classical HLA class I 
and II matching, matches at MICA and MICB loci have been shown to increase patient 
survival (Kitcharoen et al., 2006). 
Recent review has discussed the genetics and biology of the MICA gene and its products, 
and their importance in disease related to NK activity and allograft rejection or GvHD 
 
New Advances in Stem Cell Transplantation 
 
28
Based on the genetic content and pattern of segregation at the population level, KIR 
haplotypes are divided into two groups, A and B, varying in the type and number of genes 
present. The KIR group A haplotype is uniform in terms of gene content (3DL3, 2DL3, 2DL1, 
2DP1, 3DP1, 2DL4, 3DL1, 2DS4, and 3DL2), of which all but 1 encode inhibitory receptors. In 
contrast, the KIR group B haplotype is more diverse in the KIR genes it contains, has more 
activating receptors, and is characterized by the 2DL2, 2DS1, 2DS2, 2DS3, and 2DS5 genes 
(Uhrberg et al., 1997). 
3.2 Impact of killer immunoglobulin-like receptors and hematopoietic stem cell 
transplantation 
Previous studies have examined the effect of donor and recipient KIR genotypes on the 
outcome of allogeneic HSCT (Bishara et al., 2004; Gagne et al., 2002; Sun et al., 2005). One 
study found a 100% risk of GvHD after unrelated donor BMT, when the donor contained 
KIR genes absent in the recipient, compared to a 60% risk of GvHD with other combinations 
(Gagne et al., 2002).  
In 2004, one study carried out KIR-HLA genotyping of 220 related HLA identical donor-
recipient pairs (112 for myeloid diseases and 108 lymphoid diseases) (Cook et al., 2004). For 
patients with myeloid diseases, survival was lower in those homozygous for Group 2 (C2) 
HLA-C compared to patients with Group 1 (C1). This effect was observed only when the 
donor had the KIR2DS2 gene. As KIR2DS2 is in strong linkage disequilibrium with KIR2DL2 
(receptor inhibited by C1), this would indirectly indicate lower survival in patients who do 
not have the receptor for KIR2DL2, an opposite result to the model in which this lack of 
inhibition  could result in NK cell alloreactivity with a consequent elimination of residual 
leukemic cells (Witt et al., 2006). In 178 patients with AML, CML, ALL and primary 
myelodysplastic syndrome (MDS) who received HSCT with T cell depletion from HLA-
identical related donors, some authors observed that the disease-free survival was 
significantly higher in patients with AML and MDS that did not have the HLA ligand for 
the inhibitory KIR of the donor (Hsu et al., 2005). Moreover, the relapse rate was lower in 
these individuals, which may be related to higher survival rates. The results differ from a 
study in which T cell depletion was not performed (Cook et al., 2004). In another study 
(Schellekens et al., 2008) involving 83 patients with different types of hematologic 
malignancies who received HSCT from related HLA-identical donors without T cell 
depletion, a high relapse rate was found when high numbers of activating KIRs were 
present in both the patient and donor. According to the authors, a consequence of this 
finding may be an increased alloreactivity of the host against graft, impairing the response 
of donor cells resulting in an insufficient graft-versus-leukemia effect and increased risk of 
leukemic relapse.  
Nowadays, there is no unequivocal evidence that polymorphic genes for KIR involved in 
innate immunity sufficiently influence GvHD and transplant outcome to change clinical 
practice (Davies et al., 2002; Cooley et al., 2009; Giebel et al., 2003; Hsu et al., 2005; Ludajic et 
al., 2009; Miller et al., 2007; Moretta et al., 2009; Schellekens et al., 2008; Symons et al., 2010; 
Witt et al., 2006).  
Using a large cohort of patients, Venstrom et al. (2010) demonstrated that individual donor 
activating KIR, recipient HLA class I ligands, and donor KIR gene copy number all impact 
KIR-driven NK effects. They also showed that not all KIR B haplotypes have equivalent 
clinical impact, and they proposed that future studies consider specific B haplotype subsets 
or individual KIR genes in their analyses. 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
29 
However, there are conflicting results in many studies, which may be due to the 
heterogeneity in HSCT protocols employed, differences in inclusion criteria, the HSCT 
preparative regimen and graft content, the degree of donor HLA-incompatibility, and 
posttransplant immunosuppression. Beside of this, according to early studies, Symons et al. 
(2010) have described 4 models of NK cell alloreactivity to predict HSCT outcomes: 1) KIR 
ligand incompatibility; 2) receptor-ligand model; 3) missing ligand model; and 4) KIR gene-
gene model. And, contradictory results obtained from these models have made it difficult to 
conclude which model is most predictive of transplant outcome. 
4. MICA and MICB matching in bone marrow transplantation 
Retrospective and prospective studies have shown that matching donors and recipients for 
non-HLA DNA sequences in the MHC (beta and delta block matching) can result in 
improved patient survival and less severe GvHD (Tay et al., 1995; Witt et al., 2000). One of 
these blocks, the beta block, spans about 300 kb and contains the immunologically relevant 
HLA-B, HLA-C, MICA, and MICB genes (Kitcharoen et al., 2006). The polymorphic MICA 
molecule likely may be a target for specific antibodies and T cells in solid organ grafts or in 
GvHD (Zhang & Stastny, 2006). 
4.1 MICA and MICB genes 
In 1994, two new polymorphic families of MHC class I related genes, termed MHC class I-
related chain A (MICA) and B (MICB) were described (Bahram et al., 1994). These genes are 
highly polymorphic with at least 76 alleles for MICA and 31 alleles for MICB (IMGT/HLA 
database; http://www.ebi.ac.uk/imgt/hla/stats.html), and are located in the MHC classical 
class I region (Horton et al., 2004), 46.4 and 141.2 kb centromeric to HLA-B, respectively 
(Bahram et al., 1994; Bahram et al., 2000; Leelayuwat et al., 1994). They encode cell surface 
glycoproteins that do not associate with 2-microglobulin. These molecules function as 
restriction elements for intestinal γ T cells and they behave as cell stress molecules. MICA 
is expressed in endothelial cells, keratinocytes and monocytes, but not in CD4+, CD8+ or 
CD19+ lymphocytes (Zwirner et al., 1999).  
The MICA gene products have been shown to play a role in some aspects of antigen 
presentation and T-cell recognition, and appear to be important in innate immunity as 
ligands to NKG2D receptor expressed on most γ T cells, CD8  T cells, and NK cells 
(Tieng et al., 2002). 
4.2 MICA and MICB and relevance to stem cell transplantation outcome 
Several studies have shown that the highly polymorphic MIC antigens are expressed in 
transplanted organs and may cause early graft rejection (Hankey  et al., 2002; Mizutani et al., 
2006; Narayan et al., 2011; Panigrahi et al., 2007; Sumitran-Holgersson, 2008; Terasaki et al., 
2007). The polymorphisms of MICA and MICB may be involved in allogeneic BMT and 
GvHD (Gannage et al., 2008; Murai et al., 2003; Parmar et al. 2009; Przepiorka et al., 1995) 
because they are augmented by stress in epithelia (Groh et al., 1996) and are recognized by a 
subpopulation of intestinal γ T cells (Zou et al. 2007). In addition to classical HLA class I 
and II matching, matches at MICA and MICB loci have been shown to increase patient 
survival (Kitcharoen et al., 2006). 
Recent review has discussed the genetics and biology of the MICA gene and its products, 
and their importance in disease related to NK activity and allograft rejection or GvHD 
 
New Advances in Stem Cell Transplantation 
 
30
(Choy & Phipps, 2010). According to Parmar et al. (2009), some HSCT cases with matched 
HLA but mismatched MICA showed an increased incidence of GvHD, and according to 
Boukouaci et al. (2009), MICA-129 valine and soluble MICA are risk factors for chronic 
GvHD, whereas the presence of anti-MICA antibodies that can neutralize soluble MICA 
confers protection. 
A methionine to valine change at position 129 of the 2-heavy chain domain categorized the 
MICA alleles into strong (MICA-129 met) and weak (MICA-129 val) binders of NKG2D 
receptor (Steinle et al., 2001).  Varying affinities of MICA alleles for NKG2D may affect 
thresholds of NK-cell triggering and T-cell modulation. According to Boukouaci et al. (2009), 
in the context of cGVHD, the weak engagement of NKG2D receptors by the weak binder 
MICA-129 val allele may impair NK/cytotoxic T lymphocyte cell activation/costimulation, 
possibly skewing the TH1 pathway toward TH2 with consequent B-cell activation and Ab 
production. 
5. Conclusion 
Analysis of non-HLA genetics may permit more accurate assessment of transplant-related 
complications, improve donor selection and individualized prophylaxis, and aid in the 
development of a prognostic risk index. Overall, this type of analysis could potentially 
define high- and low-risk patient groups, and to result in effective therapeutic strategies for 
GvHD. 
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(Choy & Phipps, 2010). According to Parmar et al. (2009), some HSCT cases with matched 
HLA but mismatched MICA showed an increased incidence of GvHD, and according to 
Boukouaci et al. (2009), MICA-129 valine and soluble MICA are risk factors for chronic 
GvHD, whereas the presence of anti-MICA antibodies that can neutralize soluble MICA 
confers protection. 
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MICA alleles into strong (MICA-129 met) and weak (MICA-129 val) binders of NKG2D 
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define high- and low-risk patient groups, and to result in effective therapeutic strategies for 
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6. References 
Ambruzova, Z.; Mrazek, F.; Raida, L.; Jindra, P.; Vidan-Jeras, B.; Faber, E.; Pretnar, J.; Indrak, 
K. & Petrek, M. (2009). Association of IL6 and CCL2 gene polymorphisms with the 
outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow 
Transplantation, Vol.44, No.4, (August 2009), pp.227-235, ISSN 0268-3369 
Awad, M.R.; El-Gamel, A.; Hasleton, P.; Turner, D.M.; Sinnott, P.J. & Hutchinson, I.V. 
(1998). Genotypic variation in the transforming growth factorb1 gene. 
Transplantation, Vol.66, No.8, (October 1998), pp.1014-1020, ISSN 0041-1337 
Bahram, S. (2000). MIC genes: from genetics to biology. Advances in Immunology, Vol.76, 
(2000), pp.1-60, ISSN 0065-2776 
Bahram, S.; Bresnahan, M.; Geraghty, D.E. & Spies, T. (1994). A second lineage of 
mammalian major histocompatibility complex class I genes. Proceedings of the 
National Academy of Sciences of the United States of America, Vol.91, No.14, (Jul 1994), 
pp. 6259-6263, ISSN 0027-8424 
Baird, K. & Pavletic, S.Z. Chronic graft versus host disease. (2006). Current Opinion in 
Hematology, Vol.13, No.6, (November 2006), pp. 426-435, ISSN 1065-6251 
Benza, R.L.; Coffey, C.S.; Pekarek, D.M.; Barchue J.P.; Tallaj, J.A.; Passineau, M.J. & Grenett, 
H.E. (2009). Transforming growth factor-beta polymorphisms and cardiac allograft 
rejection. The Journal of Heart and Lung Transplantation, Vol.28, No.10, (October 
2009), pp.1057-1062, ISSN 1053-2498 
Bishara, A; De Santis, D.; Witt C.C.; Brautbar, C.; Christiansen, F.T.; Or, R.& Nagler, A., 
Slavin, S. (2004). The beneficial role of inhibitory KIR genes of HLA class I NK 
epitopes in haploidentically mismatched stem cell allografts may be masked by 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
31 
residual donor-alloreactive T cells causing GVHD. Tissue Antigens, Vol.63, (March 
2004), pp.204-211, ISSN 0001-2815 
Boukouaci, W.; Busson, M.; Peffault de Latour, R.; Rocha, V.; Suberbielle, C.; Bengoufa, D.; 
Dulphy, N.; Haas, P.; Scieux, C.; Amroun, H.; Gluckman, E.; Krishnamoorthy, R.; 
Toubert, A.; Charron, D.; Socié, G. & Tamouza, R. (2009). MICA-129 genotype, 
soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-
host disease. Blood, Vol.114, No.25, (December 2009), pp.5216–5224, ISSN 0006-4971 
Boyton, R.J. & Altmann, D.M. (2007). Natural killer cells, killer immunoglobulin like 
receptors and human leukocyte antigen class I in disease. Clinical of Experimental 
Immunology, Vol.149, No.1, (January 2007), pp.1-8, ISSN 0009-9104 
Choi, S.W.; Levine, J.E. & Ferrara, J.L. (2010). Pathogenesis and Management of Graft-
versus-Host Disease.  Immunology and Allergy Clinics of North America, Vol.30, No.1, 
(February 2010), pp.75–101, ISSN 0889-8561 
Choy, M.K. & Phipps, M.E. (2010). MICA polymorphism: biology and importance in 
immunity and disease. Trends in Molecular Medicine, Vol.16, No.3, (March 2010), 
pp.97-106, ISSN 1471-4914 
Cook, M.A.; Milligan, D.W.; Fegan, C.D.; Darbyshire, P.J.; Mahendra, P.; Craddock, C.F.; 
Moss, P.A. & Briggs, D.C. (2004). The impact of donor KIR and patient HLA-C 
genotypes on outcome following HLA-identical sibling hematopoietic stem cell 
transplantation for myeloid leukemia. Blood, Vol.103, No.4, (February 2004), 
pp.1521-1526, ISSN 0006-4971 
Cullup, H.; Dickinson, A.M.; Cavet, J.; Jackson, G.H. & Middleton, P.G. (2003). 
Polymorphisms of interleukin-1alpha constitute independent risk factors for 
chronic graft-versus-host disease after allogeneic bone marrow transplantation. 
British Journal of Haematology, Vol.122, No.5, (September 2003), pp.778-787, ISSN 
0007-1048 
Davies, S.M.; Ruggieri, L.; DeFor, T.; Wagner, J.E.; Weisdorf, D.J.; Miller, J.S.; Velardi, A. & 
Blazar, B.R. (2002). Evaluation of KIR ligand incompatibility in mismatched 
unrelated donor hematopoietic transplants. Blood, Vol.100, No.10, (November 
2002), pp.3825-3827, ISSN 0006-4971 
Fernandes, H.; Koneru, B.; Fernandes, N.; Hameed, M.; Cohen, MC.; Raveche, E. & Cohen, S. 
(2002). Investigation of promoter polymorphisms in the tumor necrosis factor-a and 
interleukin-10 genes in liver transplant patients. Transplantation, Vol.73, No.12, 
(June 2002), pp.1886-1891, ISSN 0041-1337 
Ferrara, J.L. & Krenger, W. (1998). Graft-versus-host disease: the influence of type 1 and type 
2 T cell cytokines. Transfusion Medicine Reviews, Vol.12, No.1, (January 1998), pp.1–
17, ISSN 0887-7963 
Ferrara, J.L. (2000). Pathogenesis of acute graft-versus-host disease: cytokines and cellular 
effectors. Journal of Hematotherapy & Stem Cell Research, Vol.9, No.3, (June 2000), pp. 
299–306, ISSN 1061-6128 
Fishman, D.; Faulds, G.; Jeffery, R.; Mohamedali, V.; Yudkin, J.S.; Humphries, S. & Woo, P. 
(1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 
transcription and plasma IL-6 levels, and an association with systemic-onset 
juvenile chronic arthritis. The Journal of Clinical Investigation, Vol.102, No.7, (October 
1998), pp.1369-1376, ISSN 0021-9738 
 
New Advances in Stem Cell Transplantation 
 
32
Franceschi, D.S.;de Souza, C.A.; Aranha, F.J.; Cardozo, D.M.; Sell, A.M. & Visentainer, J.E. 
(2011). Importance of killer immunoglobulin-like receptors in allogeneic 
hematopoietic stem cell transplantation. Revista Brasileira de Hematologia e 
Hemoterapia, Vol.33, No.2, (April 2011), ISSN 1516-8484 
Gagne, K.; Brizard, G.; Gueglio. B.; Milpied, N. ; Herry, P.; Bonneville, F.; Chéneau, M.L.; 
Schleinitz, N.; Cesbron, A.; Folléa, G.; Harrousseau, J.L & Bignon, J.D. (2002). 
Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. 
Human Immunology, Vol.63, (April 2002), pp.271-280, ISSN 0198-8859 
Gannage, M.; Buzyn, A. ; Bogiatzi, S.I.; Lambert, M.; Soumelis, V; Dal Cortivo, L.; 
Cavazzana-Calvo, M.; Brousse, N. & Caillat-Zucman, S. (2008). Induction of 
NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may 
participate in the tissue damage during acute graft-versus-host disease. 
Transplantation, Vol.85, No.6, (March 2008), pp.911-915, ISSN 0041-1337 
Gasser, S. & Raulet, D.H. (2006). Activation and self-tolerance of natural killer cells. 
Immunological Reviews, Vol.214, No.1, (December 2006), pp.130-142, ISSN: 0105-2896 
Giebel, S.; Locatelli, F.; Lamparelli, T.; Velardi, A.; Davies, S.; Frumento, G.; Maccario, R.; 
Bonetti, F.; Wojnar, J.; Martinetti, M.; Frassoni, F.; Giorgiani, G.; Bacigalupo, A. & 
Holowiecki, J. (2003). Survival advantage with KIR ligand incompatibility in 
hematopoietic stem cell transplantation from unrelated donors. Blood, Vol.102, 
No.3, (August 2003), pp.814-819, ISSN 0006-4971 
Groh, V.; Bahram, S; Bauer, S.; Herman, A.; Beauchamp, M. & Spies T. (1996). Cell stress-
regulated human major histocompatibility complex class I gene expressed in 
gastrointestinal epithelium. Proceedings of the National Academy of Sciences of the 
United States of America, Vol.93, No.22 (October 1996), pp. 12445-12450, ISSN 0027-
8424 
Hahn, A.B.; Kasten-Jolly, J.C.; Constantino, D.M.; Graffunder, E. & Conti, D.J. (2001). TNF-
alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 
receptor a-chain variant Q576R: effects on renal allograft outcome. Transplantation, 
Vol.72, No.4, (August 2001), pp.660-665, ISSN 0041-1337 
Hankey, K.G.; Drachenberg, C.B.; Papadimitriou, J.C.; Klassen, D.K.; Philosophe, B.; Bartlett, 
S.T.; Groh, V.; Spies, T. & Mann, D.L. (2002). MIC expression in renal and 
pancreatic allografts. Transplantation Vol.73, No.2, (January 2002), pp. 304-306, ISSN 
0041-1337 
Hattori, H.; Matsuzaki, A.; Suminoe, A.; Ihara, K.; Nagatoshi, Y.; Sakata, N.; Kawa, K.; 
Okamura, J. & Hara, T. (2002). Polymorphisms of transforming growth factor-beta1 
and transforming growth factor-beta1 type II receptor genes are associated with 
acute graft-versus-host disease in children with HLA matched sibling bone marrow 
transplantation. Bone Marrow Transplanation, Vol.30, No.10, (November 2002), 
pp.665-671, ISSN 0268-3369 
Horton, R.; Wilming, L.; Rand, V.; Lovering R.C.; Bruford, E.A.; Khodiyar, V.K.; Lush, M.; 
Povey, S.; Talbot, C.C. Jr.; Wright, M.W.; Wain, H.M.; Trowsdale, J.; Ziegler, A. & 
Beck, S. (2004). Gene map of the extended human MHC. Nature Reviews Genetics, 
Vol.5, No.12, (December 2004), pp.889-899, ISSN 1471-0056 
Hsu, K.C.; Keever-Taylor, C.A.; Wilton, A.; Pinto, C.; Heller, G.; Arkun, K.; O'Reilly, R.J.; 
Horowitz, M.M. & Dupont, B. (2005). Improved outcome in HLA-identical sibling 
hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
33 
by KIR and HLA genotypes. Blood, Vol.105, No.12, (June 2005), pp.4878-4884, ISSN 
0006-4971 
Iwasaki, T. (2004). Recent advances in the treatment of graft-versus-host disease. Clinical 
Medicine & Research, Vol.2, No.4, (November 2004), pp.243-252, ISSN 1539-4182 
Joyce, M.G. & Sun, P.D. (2011). The structural basis of ligand recognition by natural killer 
cell receptors. Journal of Biomedicine and Biotechnology, Vol.2011, (May 2011), pp.1-15, 
ISSN 1110-7243 
Jung, U.; Foley, J.E.; Erdmann, A.A.; Toda, Y.; Borenstein, T.; Mariotti, J. & Fowler, D.H. 
(2006). Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 effector T cells with 
enhanced in vivo function and differential sensitivity to post-transplant rapamycin 
therapy. Biology of Blood and Marrow Transplantation, Vol.12, No.9, (September 2006), 
pp.905–918, ISSN 1083-8791 
Kappel, L.W.;  Goldberg, G.L.; King, C.G.; Suh, D.Y.; Smith, O.M.; Ligh, C.; Holland, A.M.; 
Grubin, J.; Mark, N.M.; Liu, C.; Iwakura, Y.; Heller, G. & van den Brink, M.R. 
(2009). IL-17 contributes to CD4-mediated graft-versushost disease. Blood, Vol.113, 
No.4, (January 2009), pp.945–952, ISSN 0006-4971 
Karimi, M.H.; Daneshmandi, S.; Pourfathollah, A.A.; Geramizadeh, B.; Ramzi, M.; Yaghobi, 
R. & Ebadi, P. (2010). The IFN-γ Allele Correlated to Moderate-to-Severe Acute 
Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant. Experimental and 
Clinical Transplantation, Vol.8, No.2, (June 2010), pp.125-129, ISSN 1304-0855 
Karimi, M.H.; Daneshmandi, S.; Pourfathollah, A.A.; Geramizadeh, B.; Yaghobi, R.; Rais-
Jalali, G.A.; Roozbeh, J. & Bolandparvaz, S. (2011). A study of the impact of 
cytokine gene polymorphism in acute rejection of renal transplant recipients. 
Molecular Biology Reports, [Epub ahead of print], (May 2011), ISSN 0301-4851 
Katz, G.; Markel, G.; Mizrahi, S.; Arnon, T.I. & Mandelboim, O. (2001). Recognition of HLA-
Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-
domain short tail number 4. Journal of Immunology, Vol.166, No.12, (June 2001), 
pp.7260-7267, ISSN 0022-1767 
Kayaba, H.; Hirokawa, M.; Watanabe, A.; Saitoh, N.; Changhao, C.; Yamada, Y.; Honda, K., 
Kobayashi, Y.; Urayama, O. & Chihara, J. (2000). Serum markers of graft-versus-
host disease after bone marrow transplantation. The Journal of Allergy and Clinical 
Immunology, Vol.106, No.2, (July 2000), pp. S40-S44, ISSN 00917-6749 
Kim, D.H.; Lee, N.Y.; Sohn, S.K.; Baek, J.H.; Kim, J.G.; Suh, J.S.; Lee, K.B. & Shin, I.H. (2005). 
IL-10 promoter gene polymorphism associated with the occurrence of chronic 
GVHD and its clinical course during systemic immunosuppressive treatment for 
chronic GVHD after allogeneic peripheral blood stem cell transplantation. 
Transplantation, Vol.79, No.11, (June 2005), pp.1615-1622, ISSN 0041-1337   
Kitcharoen, K.; Witt, C.S.; Romphruk, A.V.; Christiansen, F.T. & Leelayuwat, C. (2006). 
MICA, MICB, and MHC beta block matching in bone marrow transplantation: 
relevance to transplantation outcome. Human Immunology, Vol.67, No.3, (March 
2006), pp.238–246, ISSN 0198-8859 
Laguila Visentainer, J.E.; Lieber, S.R.; Lopes Persoli, L.B.; Dutra Marques, S.B.; Vigorito, 
A.C.; Penteado Aranha, F.J.; de Brito Eid, K.A.; Oliveira, G.B.; Martins Miranda, 
E.C.; Bragotto, L. & de Souza, C.A. (2005). Relationship between cytokine gene 
polymorphisms and graft-versus-host disease after allogeneic stem cell 
 
New Advances in Stem Cell Transplantation 
 
32
Franceschi, D.S.;de Souza, C.A.; Aranha, F.J.; Cardozo, D.M.; Sell, A.M. & Visentainer, J.E. 
(2011). Importance of killer immunoglobulin-like receptors in allogeneic 
hematopoietic stem cell transplantation. Revista Brasileira de Hematologia e 
Hemoterapia, Vol.33, No.2, (April 2011), ISSN 1516-8484 
Gagne, K.; Brizard, G.; Gueglio. B.; Milpied, N. ; Herry, P.; Bonneville, F.; Chéneau, M.L.; 
Schleinitz, N.; Cesbron, A.; Folléa, G.; Harrousseau, J.L & Bignon, J.D. (2002). 
Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. 
Human Immunology, Vol.63, (April 2002), pp.271-280, ISSN 0198-8859 
Gannage, M.; Buzyn, A. ; Bogiatzi, S.I.; Lambert, M.; Soumelis, V; Dal Cortivo, L.; 
Cavazzana-Calvo, M.; Brousse, N. & Caillat-Zucman, S. (2008). Induction of 
NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may 
participate in the tissue damage during acute graft-versus-host disease. 
Transplantation, Vol.85, No.6, (March 2008), pp.911-915, ISSN 0041-1337 
Gasser, S. & Raulet, D.H. (2006). Activation and self-tolerance of natural killer cells. 
Immunological Reviews, Vol.214, No.1, (December 2006), pp.130-142, ISSN: 0105-2896 
Giebel, S.; Locatelli, F.; Lamparelli, T.; Velardi, A.; Davies, S.; Frumento, G.; Maccario, R.; 
Bonetti, F.; Wojnar, J.; Martinetti, M.; Frassoni, F.; Giorgiani, G.; Bacigalupo, A. & 
Holowiecki, J. (2003). Survival advantage with KIR ligand incompatibility in 
hematopoietic stem cell transplantation from unrelated donors. Blood, Vol.102, 
No.3, (August 2003), pp.814-819, ISSN 0006-4971 
Groh, V.; Bahram, S; Bauer, S.; Herman, A.; Beauchamp, M. & Spies T. (1996). Cell stress-
regulated human major histocompatibility complex class I gene expressed in 
gastrointestinal epithelium. Proceedings of the National Academy of Sciences of the 
United States of America, Vol.93, No.22 (October 1996), pp. 12445-12450, ISSN 0027-
8424 
Hahn, A.B.; Kasten-Jolly, J.C.; Constantino, D.M.; Graffunder, E. & Conti, D.J. (2001). TNF-
alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 
receptor a-chain variant Q576R: effects on renal allograft outcome. Transplantation, 
Vol.72, No.4, (August 2001), pp.660-665, ISSN 0041-1337 
Hankey, K.G.; Drachenberg, C.B.; Papadimitriou, J.C.; Klassen, D.K.; Philosophe, B.; Bartlett, 
S.T.; Groh, V.; Spies, T. & Mann, D.L. (2002). MIC expression in renal and 
pancreatic allografts. Transplantation Vol.73, No.2, (January 2002), pp. 304-306, ISSN 
0041-1337 
Hattori, H.; Matsuzaki, A.; Suminoe, A.; Ihara, K.; Nagatoshi, Y.; Sakata, N.; Kawa, K.; 
Okamura, J. & Hara, T. (2002). Polymorphisms of transforming growth factor-beta1 
and transforming growth factor-beta1 type II receptor genes are associated with 
acute graft-versus-host disease in children with HLA matched sibling bone marrow 
transplantation. Bone Marrow Transplanation, Vol.30, No.10, (November 2002), 
pp.665-671, ISSN 0268-3369 
Horton, R.; Wilming, L.; Rand, V.; Lovering R.C.; Bruford, E.A.; Khodiyar, V.K.; Lush, M.; 
Povey, S.; Talbot, C.C. Jr.; Wright, M.W.; Wain, H.M.; Trowsdale, J.; Ziegler, A. & 
Beck, S. (2004). Gene map of the extended human MHC. Nature Reviews Genetics, 
Vol.5, No.12, (December 2004), pp.889-899, ISSN 1471-0056 
Hsu, K.C.; Keever-Taylor, C.A.; Wilton, A.; Pinto, C.; Heller, G.; Arkun, K.; O'Reilly, R.J.; 
Horowitz, M.M. & Dupont, B. (2005). Improved outcome in HLA-identical sibling 
hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
33 
by KIR and HLA genotypes. Blood, Vol.105, No.12, (June 2005), pp.4878-4884, ISSN 
0006-4971 
Iwasaki, T. (2004). Recent advances in the treatment of graft-versus-host disease. Clinical 
Medicine & Research, Vol.2, No.4, (November 2004), pp.243-252, ISSN 1539-4182 
Joyce, M.G. & Sun, P.D. (2011). The structural basis of ligand recognition by natural killer 
cell receptors. Journal of Biomedicine and Biotechnology, Vol.2011, (May 2011), pp.1-15, 
ISSN 1110-7243 
Jung, U.; Foley, J.E.; Erdmann, A.A.; Toda, Y.; Borenstein, T.; Mariotti, J. & Fowler, D.H. 
(2006). Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 effector T cells with 
enhanced in vivo function and differential sensitivity to post-transplant rapamycin 
therapy. Biology of Blood and Marrow Transplantation, Vol.12, No.9, (September 2006), 
pp.905–918, ISSN 1083-8791 
Kappel, L.W.;  Goldberg, G.L.; King, C.G.; Suh, D.Y.; Smith, O.M.; Ligh, C.; Holland, A.M.; 
Grubin, J.; Mark, N.M.; Liu, C.; Iwakura, Y.; Heller, G. & van den Brink, M.R. 
(2009). IL-17 contributes to CD4-mediated graft-versushost disease. Blood, Vol.113, 
No.4, (January 2009), pp.945–952, ISSN 0006-4971 
Karimi, M.H.; Daneshmandi, S.; Pourfathollah, A.A.; Geramizadeh, B.; Ramzi, M.; Yaghobi, 
R. & Ebadi, P. (2010). The IFN-γ Allele Correlated to Moderate-to-Severe Acute 
Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant. Experimental and 
Clinical Transplantation, Vol.8, No.2, (June 2010), pp.125-129, ISSN 1304-0855 
Karimi, M.H.; Daneshmandi, S.; Pourfathollah, A.A.; Geramizadeh, B.; Yaghobi, R.; Rais-
Jalali, G.A.; Roozbeh, J. & Bolandparvaz, S. (2011). A study of the impact of 
cytokine gene polymorphism in acute rejection of renal transplant recipients. 
Molecular Biology Reports, [Epub ahead of print], (May 2011), ISSN 0301-4851 
Katz, G.; Markel, G.; Mizrahi, S.; Arnon, T.I. & Mandelboim, O. (2001). Recognition of HLA-
Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-
domain short tail number 4. Journal of Immunology, Vol.166, No.12, (June 2001), 
pp.7260-7267, ISSN 0022-1767 
Kayaba, H.; Hirokawa, M.; Watanabe, A.; Saitoh, N.; Changhao, C.; Yamada, Y.; Honda, K., 
Kobayashi, Y.; Urayama, O. & Chihara, J. (2000). Serum markers of graft-versus-
host disease after bone marrow transplantation. The Journal of Allergy and Clinical 
Immunology, Vol.106, No.2, (July 2000), pp. S40-S44, ISSN 00917-6749 
Kim, D.H.; Lee, N.Y.; Sohn, S.K.; Baek, J.H.; Kim, J.G.; Suh, J.S.; Lee, K.B. & Shin, I.H. (2005). 
IL-10 promoter gene polymorphism associated with the occurrence of chronic 
GVHD and its clinical course during systemic immunosuppressive treatment for 
chronic GVHD after allogeneic peripheral blood stem cell transplantation. 
Transplantation, Vol.79, No.11, (June 2005), pp.1615-1622, ISSN 0041-1337   
Kitcharoen, K.; Witt, C.S.; Romphruk, A.V.; Christiansen, F.T. & Leelayuwat, C. (2006). 
MICA, MICB, and MHC beta block matching in bone marrow transplantation: 
relevance to transplantation outcome. Human Immunology, Vol.67, No.3, (March 
2006), pp.238–246, ISSN 0198-8859 
Laguila Visentainer, J.E.; Lieber, S.R.; Lopes Persoli, L.B.; Dutra Marques, S.B.; Vigorito, 
A.C.; Penteado Aranha, F.J.; de Brito Eid, K.A.; Oliveira, G.B.; Martins Miranda, 
E.C.; Bragotto, L. & de Souza, C.A. (2005). Relationship between cytokine gene 
polymorphisms and graft-versus-host disease after allogeneic stem cell 
 
New Advances in Stem Cell Transplantation 
 
34
transplantation in a Brazilian population. Cytokine, Vol.32, No.3-4, (November 
2005), pp.171-177, ISSN: 1043-4666 
Lanier, L.L. (2008). Up on the tightrope: natural killer cell activation and inhibition. Nature 
Immunology, Vol.9, No.5, (May 2008), pp.495-502, ISSN 1529-2908 
Leelayuwat, C.; Townend, D.C.; Degli-Esposti, M.A.; Abraham, L.J. & Dawkins, R.L. (1994). 
A new polymorphic and multicopy RL: A new polymorphic and multicopy MHC 
gene family related to non mammalian class I. Immunogenetics, Vol.40, No.51, 
(1994), pp. 339-351, ISSN 0093-7711 
Leffell, M.S.; Vogelsang, G.B.; Lucas, D.P.; Delaney, N.L. & Zachary, A.A. (2001). Association 
between TGF-beta expression and severe GVHD in allogeneic bone marrow 
transplantation. Transplantation Proceedings, Vol.33, No.1-2, (February-March 2001), 
pp.485-486, ISSN 0041-1345 
Letterio, J.J. & Roberts, A.B. (1998). Regulation of immune responses by TGFbeta. Annual 
Review of Immunology, Vol.16, (April 1998), pp.137-161, ISSN 15453278 
Liem, L.M.; Fibbe, W.E.; van Houwelingen, H.C. & Golmy, E. (1999). Serum transforming 
growth factor-b1 levels in bone marrow transplant recipients correlate with blood 
cell counts and chronic graft-versus-host disease. Transplantation, Vol.67, No.1, 
(January 1999), pp. 59-65, ISSN 0041-1337 
Liem, L.M.; van Houwelingen, H.C. & Goulmy, E. (1998). Serum cytokine levels after HLA-
identical bone marrow transplantation. Transplantation, Vol.66, No.7, (October 
1998), pp.863-871, ISSN 0041-1337 
Lin, M.T., Storer, B., Martin, P.J., Tseng, L.H., Gooley, T., Chen, P.J. & Hansen, J.A. (2003). 
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease 
and survival after hematopoietic-cell transplantation. The New England Journal of 
Medicine, Vol.349, No.23, (December 2003), pp.2201-2210, ISSN 0028-4793 
Ludajic, K.; Balavarca, Y.; Bickeböller, H.; Rosenmayr, A.; Fae, I.; Fischer, G.F.; Kouba, M.; 
Pohlreich, D.; Kalhs, P. & Greinix, H.T. (2009). KIR genes and KIR ligands affect 
occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic 
stem cell transplantation. Bone Marrow Transplantation, Vol.44, No.2, (July 2009), 
pp.97–103, ISSN 0268-3369 
Macmillan, M.L.; Radloff, G.A.; Kiffmeyer, W.R.; Defor, T.E.; Weisdorf, D.J. & Davies, S.M. 
(2003). High-producer interleukin-2 genotype increases risk for acute graft-versus-
host disease after unrelated donor bone marrow transplantation. Transplantation, 
Vol.76, No.12, (December 2003), pp.1758-1762, ISSN 0041-1337 
Margolis, J. & Vogelsang, G. (2000). Chronic graft-versus-host disease. Journal of 
Hematotherapy & Stem Cell Research, Vol.9, No.3, (June 2000), pp.339-346, ISSN 1061-
6128 
McVicar, D.W. & Burshtyn, D.N. (2001). Intracellular signaling the killer immunoglobulin-
like receptors and Ly49. Sciences´s STKE: signal transduction knowledge environment, 
Vol.2001, No.75, (March 2001), pp. re1, ISSN 1945-0877 
Mlynarczewska, A.; Wysoczanska, B.; Karabon, L.; Bogunia-Kubik, K. & Lange, A. (2004) 
Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and 
intensity of conditioning regimen influences the risk of aGVHD manifestation after 
HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow 
Transplantation, Vol.34, No.4, (August 2004), pp.339-344, ISSN 0268-3369 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
35 
Miller, J.S.; Cooley, S.; Parham, P.; Farag, S.S.; Verneris, M.R.; McQueen, K.L.; Guethlein, 
L.A.; Trachtenberg, E.A.; Haagenson, M.; Horowitz, M.M.; Klein, J.P. & Weisdorf, 
D.J. (2007).  Missing KIR-ligands are associated with less relapse and increased 
graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 
Vol.109, No.11, (June 2007), pp.5058–5061, ISSN 0006-4971 
Mizutani,  K.; Terasaki, P.I.; Shih, R.N.; Pei, R. Ozawa, M. & Lee, J. (2006). Frequency of MIC 
Antibody in Rejected Renal Transplant Patients without HLA Antibody. Human 
Immunology, Vol.67, No.3, (March 2006) pp. 223–229, ISSN 0198-8859 
Moretta, A.; Pende, D.; Locatelli, F. & Moretta, L. (2009). Activating and inhibitory killer 
immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell 
transplantation to cure high-risk leukaemias. Clinical Experimental of Immunology, 
Vol.157, No.3, (September 2009), pp.325–331, ISSN 0093-9104 
Murai, M.; Yoneyama, H.; Ezaki, T.; Suematsu, M.; Terashima, Y.; Harada, A.; Hamada, H.; 
Asakura, H.; Ishikawa, H & Matsushima, K. (2003). Peyer’s patch is the essential 
site in initiating murine acute and lethal graft-versus-host reaction. Nature 
Immunology, Vol.4, No.2, (February 2003), pp. 3154-3160, ISSN 1529-2908 
Narayan, S.; Tsai, E.W.; Zhang, Q.; Wallace, W.D.; Reed, E.F. & Ettenger, R.B. (2011). Acute 
rejection associated with donor specific anti-MICA antibody in a highly sensitized 
pediatric renal transplant recipient. Pediatric Transplantation, Vol.15, No.1, 
(February 2011), pp.E1-7, ISSN 1397-3142 
O'Connor, G.M.; Hart, O.M. & Gardiner, C.M. (2006). Putting the natural killer cell in its 
place. Immunology, Vol.117, No.1, (January 2006), pp.1-10, ISSN 0019-2805 
Paczesny, S.; Hanauer, D.; Sun, Y. & Reddy, P. (2010). New perspectives on the biology of 
acute GVHD. Bone Marrow Transplantation, Vol.45, No.1, (January 2010), pp.1–11, 
ISSN 0268-3369 
Panigrahi, A.; Gupta, N.; Siddiqui, J.A.; Margoob, A.; Bhowmik, D.; Guleria, S. & Mehra, 
N.K. (2007). Post Transplant Development of MICA and Anti-HLA Antibodies is 
Associated with Acute Rejection Episodes and Renal Allograft Loss. Human 
Immunology, Vol.68, No.5, (May 2007), pp.362–367, ISSN 0198-8859 
Parham, P. (2006). Taking license with natural killer cell maturation and repertoire 
development. Immunological Reviews, Vol.214, No.1, (December 2006), pp.155-160, 
ISSN 1529-2908 
Parmar, S.; Del Lima, M.; Zou, Y.; Patah, P.A.; Liu, P.; Cano, P.; Rondon, G.; Pesoa, S.; de 
Padua Silva, L.; Qazilbash, M.H.; Hosing, C.; Popat, U.; Kebriaei, P.; Shpall, E.J.; 
Giralt, S.; Champlin, R.E.; Stastny, P. & Fernandez-Vina, M. (2009). Donor-recipient 
mismatches in MHC class I chain-related gene A in unrelated donor transplantation 
lead to increased incidence of acute graft-versus-host disease. Blood, (October 2009), 
Vol.114, No.14, pp.2884–2887, ISSN 0006-4971 
Pérez-Simón, J.A.; Sánchez-Abarca, I.; Díezcampelo, M.; Caballero, D. & San Miguel, J. 
(2006). Chronic Graft-Versus-Host Disease Pathogenesis and Clinical Management. 
Drugs, Vol.66, No.8, (2006), pp. 1041-1057, ISSN 0012-6667 
Pravica, V.; Asderakis, A.; Perrey, C.; Hajeer, A.; Sinnott, P.J. & Hutchinson, I.V. (1999). In 
vitro production of IFN-gamma correlates with CA repeat polymorphism in the 
human IFN-gamma gene. European Journal of Immunogenetics, Vol.26, No.1, 
(February 1999), pp.1-3, ISSN 0960-7420 
 
New Advances in Stem Cell Transplantation 
 
34
transplantation in a Brazilian population. Cytokine, Vol.32, No.3-4, (November 
2005), pp.171-177, ISSN: 1043-4666 
Lanier, L.L. (2008). Up on the tightrope: natural killer cell activation and inhibition. Nature 
Immunology, Vol.9, No.5, (May 2008), pp.495-502, ISSN 1529-2908 
Leelayuwat, C.; Townend, D.C.; Degli-Esposti, M.A.; Abraham, L.J. & Dawkins, R.L. (1994). 
A new polymorphic and multicopy RL: A new polymorphic and multicopy MHC 
gene family related to non mammalian class I. Immunogenetics, Vol.40, No.51, 
(1994), pp. 339-351, ISSN 0093-7711 
Leffell, M.S.; Vogelsang, G.B.; Lucas, D.P.; Delaney, N.L. & Zachary, A.A. (2001). Association 
between TGF-beta expression and severe GVHD in allogeneic bone marrow 
transplantation. Transplantation Proceedings, Vol.33, No.1-2, (February-March 2001), 
pp.485-486, ISSN 0041-1345 
Letterio, J.J. & Roberts, A.B. (1998). Regulation of immune responses by TGFbeta. Annual 
Review of Immunology, Vol.16, (April 1998), pp.137-161, ISSN 15453278 
Liem, L.M.; Fibbe, W.E.; van Houwelingen, H.C. & Golmy, E. (1999). Serum transforming 
growth factor-b1 levels in bone marrow transplant recipients correlate with blood 
cell counts and chronic graft-versus-host disease. Transplantation, Vol.67, No.1, 
(January 1999), pp. 59-65, ISSN 0041-1337 
Liem, L.M.; van Houwelingen, H.C. & Goulmy, E. (1998). Serum cytokine levels after HLA-
identical bone marrow transplantation. Transplantation, Vol.66, No.7, (October 
1998), pp.863-871, ISSN 0041-1337 
Lin, M.T., Storer, B., Martin, P.J., Tseng, L.H., Gooley, T., Chen, P.J. & Hansen, J.A. (2003). 
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease 
and survival after hematopoietic-cell transplantation. The New England Journal of 
Medicine, Vol.349, No.23, (December 2003), pp.2201-2210, ISSN 0028-4793 
Ludajic, K.; Balavarca, Y.; Bickeböller, H.; Rosenmayr, A.; Fae, I.; Fischer, G.F.; Kouba, M.; 
Pohlreich, D.; Kalhs, P. & Greinix, H.T. (2009). KIR genes and KIR ligands affect 
occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic 
stem cell transplantation. Bone Marrow Transplantation, Vol.44, No.2, (July 2009), 
pp.97–103, ISSN 0268-3369 
Macmillan, M.L.; Radloff, G.A.; Kiffmeyer, W.R.; Defor, T.E.; Weisdorf, D.J. & Davies, S.M. 
(2003). High-producer interleukin-2 genotype increases risk for acute graft-versus-
host disease after unrelated donor bone marrow transplantation. Transplantation, 
Vol.76, No.12, (December 2003), pp.1758-1762, ISSN 0041-1337 
Margolis, J. & Vogelsang, G. (2000). Chronic graft-versus-host disease. Journal of 
Hematotherapy & Stem Cell Research, Vol.9, No.3, (June 2000), pp.339-346, ISSN 1061-
6128 
McVicar, D.W. & Burshtyn, D.N. (2001). Intracellular signaling the killer immunoglobulin-
like receptors and Ly49. Sciences´s STKE: signal transduction knowledge environment, 
Vol.2001, No.75, (March 2001), pp. re1, ISSN 1945-0877 
Mlynarczewska, A.; Wysoczanska, B.; Karabon, L.; Bogunia-Kubik, K. & Lange, A. (2004) 
Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and 
intensity of conditioning regimen influences the risk of aGVHD manifestation after 
HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow 
Transplantation, Vol.34, No.4, (August 2004), pp.339-344, ISSN 0268-3369 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
35 
Miller, J.S.; Cooley, S.; Parham, P.; Farag, S.S.; Verneris, M.R.; McQueen, K.L.; Guethlein, 
L.A.; Trachtenberg, E.A.; Haagenson, M.; Horowitz, M.M.; Klein, J.P. & Weisdorf, 
D.J. (2007).  Missing KIR-ligands are associated with less relapse and increased 
graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood, 
Vol.109, No.11, (June 2007), pp.5058–5061, ISSN 0006-4971 
Mizutani,  K.; Terasaki, P.I.; Shih, R.N.; Pei, R. Ozawa, M. & Lee, J. (2006). Frequency of MIC 
Antibody in Rejected Renal Transplant Patients without HLA Antibody. Human 
Immunology, Vol.67, No.3, (March 2006) pp. 223–229, ISSN 0198-8859 
Moretta, A.; Pende, D.; Locatelli, F. & Moretta, L. (2009). Activating and inhibitory killer 
immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell 
transplantation to cure high-risk leukaemias. Clinical Experimental of Immunology, 
Vol.157, No.3, (September 2009), pp.325–331, ISSN 0093-9104 
Murai, M.; Yoneyama, H.; Ezaki, T.; Suematsu, M.; Terashima, Y.; Harada, A.; Hamada, H.; 
Asakura, H.; Ishikawa, H & Matsushima, K. (2003). Peyer’s patch is the essential 
site in initiating murine acute and lethal graft-versus-host reaction. Nature 
Immunology, Vol.4, No.2, (February 2003), pp. 3154-3160, ISSN 1529-2908 
Narayan, S.; Tsai, E.W.; Zhang, Q.; Wallace, W.D.; Reed, E.F. & Ettenger, R.B. (2011). Acute 
rejection associated with donor specific anti-MICA antibody in a highly sensitized 
pediatric renal transplant recipient. Pediatric Transplantation, Vol.15, No.1, 
(February 2011), pp.E1-7, ISSN 1397-3142 
O'Connor, G.M.; Hart, O.M. & Gardiner, C.M. (2006). Putting the natural killer cell in its 
place. Immunology, Vol.117, No.1, (January 2006), pp.1-10, ISSN 0019-2805 
Paczesny, S.; Hanauer, D.; Sun, Y. & Reddy, P. (2010). New perspectives on the biology of 
acute GVHD. Bone Marrow Transplantation, Vol.45, No.1, (January 2010), pp.1–11, 
ISSN 0268-3369 
Panigrahi, A.; Gupta, N.; Siddiqui, J.A.; Margoob, A.; Bhowmik, D.; Guleria, S. & Mehra, 
N.K. (2007). Post Transplant Development of MICA and Anti-HLA Antibodies is 
Associated with Acute Rejection Episodes and Renal Allograft Loss. Human 
Immunology, Vol.68, No.5, (May 2007), pp.362–367, ISSN 0198-8859 
Parham, P. (2006). Taking license with natural killer cell maturation and repertoire 
development. Immunological Reviews, Vol.214, No.1, (December 2006), pp.155-160, 
ISSN 1529-2908 
Parmar, S.; Del Lima, M.; Zou, Y.; Patah, P.A.; Liu, P.; Cano, P.; Rondon, G.; Pesoa, S.; de 
Padua Silva, L.; Qazilbash, M.H.; Hosing, C.; Popat, U.; Kebriaei, P.; Shpall, E.J.; 
Giralt, S.; Champlin, R.E.; Stastny, P. & Fernandez-Vina, M. (2009). Donor-recipient 
mismatches in MHC class I chain-related gene A in unrelated donor transplantation 
lead to increased incidence of acute graft-versus-host disease. Blood, (October 2009), 
Vol.114, No.14, pp.2884–2887, ISSN 0006-4971 
Pérez-Simón, J.A.; Sánchez-Abarca, I.; Díezcampelo, M.; Caballero, D. & San Miguel, J. 
(2006). Chronic Graft-Versus-Host Disease Pathogenesis and Clinical Management. 
Drugs, Vol.66, No.8, (2006), pp. 1041-1057, ISSN 0012-6667 
Pravica, V.; Asderakis, A.; Perrey, C.; Hajeer, A.; Sinnott, P.J. & Hutchinson, I.V. (1999). In 
vitro production of IFN-gamma correlates with CA repeat polymorphism in the 
human IFN-gamma gene. European Journal of Immunogenetics, Vol.26, No.1, 
(February 1999), pp.1-3, ISSN 0960-7420 
 
New Advances in Stem Cell Transplantation 
 
36
Przepiorka, D.; Weisdorf, D.; Martin, P.; Klingemann, H.G.; Beatty, P.; Hows, J & Thomas, 
E.D. (1995). 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow 
Transplantation, Vol.15, No.6, (June 1995), pp. 825-828, ISSN 0268-3369 
Rajagopalan, S. & Long, E.O. (1999). A human histocompatibility leukocyte antigen (HLA)-
G-specific receptor expressed on all natural killer cells. Journal of Experimental 
Medicine, Vol.189, No.7, (1999), pp.1093-1100. ISSN 0022-1007 
Rajagopalan, S. & Long, E.O. (2005). Understanding how combinations of HLA and KIR 
genes influence disease. The Journal of Experimental Medicine, Vol.201, No.7, (April 
2005), pp.1025-1029, ISSN 0022-1007 
Rashidi-Nezhad, A.; Azimi, C.; Alimoghaddam, K.; Ghavamzadeh, A.; Hossein-Nezhad, A.; 
Izadi, P.; Sobhani, M.; Noori-Daloii, A.R. & Noori-Daloii, M.R. (2010). TGF-Beta 
codon 25 polymorphism and the risk of graft-versus-host disease after allogenic 
hematopoietic stem cell transplantation. Iranian Journal of Allergy, Asthma and 
Immunology, Vol.9, No.1, (March 2010), pp.1-6, ISSN 1735-1502 
Reddy, P. & Ferrara, J.L. (2003). Immunobiology of acute graft-versus-host disease. Blood 
Reviews, (December 2003), Vol.17, No.4, pp.187–194, ISSN 0268-960X 
Reviron, D.; Dussol, B.; Andre, M.; Brunet, P.; Mercier, P. & Berland, Y. (2001). TNF-alpha 
and IL-6 gene polymorphism and rejection in kidney transplantation recipients. 
Transplantation Proceedings, Vol.33, No.1-2, (February-March 2001), pp.350-351, 
ISSN 0041-1345 
Sakata, N; Yasui, M.; Okamura, T.; Inoue, M.; Yumura-Yagi, K. & Kawa, K. (2001). Kinetics 
of plasma cytokines after hematopoietic stem cell transplantation from unrelated 
donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in 
severe acute graft-versus-host disease. Bone Marrow Transplantation, Vol.27, No.11, 
(June 2001), pp. 1153-1161, ISSN 0268-3369 
Schellekens, J.; Rozemuller, E.H.; Petersen, E.J.; van den Tweel, J.G.; Verdonck, L.F. & 
Tilanus, M.G. (2008). Activating KIRs exert a crucial role on relapse and overall 
survival after HLA-identical sibling transplantation. Molecular Immunology, Vol.45, 
No.8, (April 2008), pp.2255-2261, ISSN 0161-5890 
Shamim, Z.; Ryder, L.P.; Christensen, I.J.; Toubert, A.; Norden, J.; Collin, M.; Jackson, G.; 
Dickinson, A.M. & Müller, K. (2011). Prognostic Significance of Interleukin-7 
Receptor- Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A 
Confirmatory Study. Transplantation, (April 2011), Vol.91, No.7, pp.731–736, ISSN 
0041-1337 
Sivula, J.; Turpeinen, H.; Volin, L. & Partanen, J. (2009). Association of IL-10 and IL-10Rβ 
gene polymorphisms with graft-versus-host disease after haematopoietic stem cell 
transplantation from an HLA-identical sibling donor. BMC Immunology, Vol.10, 
(May 2009), pp.24-30, ISSN 1471-2172 
Steinle, A.; Li, P.; Morris, D.L.; Groh, V.; Lanier, L.L.; Strong, R.K. & Spies, T. (2001). 
Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the 
mouse RAE-1 protein family. Immunogenetics, Vol.53, No.4, (May-June 2001), 
pp.279-287, ISSN: 0093-7711 
Sumitran-Holgersson, S. (2008). Relevance of MICA and other non- HLA antibodies in 
clinical transplantation. Current Opinion of Immunology, Vol.20, No.5 (October 2008), 
pp.607–613, ISSN 0952-7915 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
37 
Sun, J.Y.; Gaidulis, L.; Dagis, A.; Palmer, J.; Rodriguez, R.; Miller, M.M.; Forman, S.J. & 
Senitzer, D. (2005). Killer Ig-like receptor (KIR) compatibility plays a role in the 
prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. 
Bone Marrow Transplantation, Vol.36, No.6, (September 2005), pp.525-530, ISSN 
0268-3369 
Symons, H.J.; Leffell, M.S.; Rossiter, N.D.; Zahurak, M.; Jones, R.J. & Fuchs, E.J. (2010). 
Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene 
Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-
Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow 
Transplantation, Vol.16, No.4, (April 2010), pp.533-542, ISSN 1083-8791 
Takahashi, H.; Furukawa, T.; Hashimoto, S.; Susuki, N.; Yamazaki, F.; Inano, K.; Takahashi, 
M.; Aizawa, Y. & Koike, T. (2000). Contribution of TNF-alpha and IL-10 gene 
polymorphisms to graftversus-host disease following allo-hematopoietic stem cell 
transplantation. Bone Marrow Transplantation, Vol.26, No.12, (December 2000), 
pp.1317-1323, ISSN 0268-3369 
Tambur, A.R.; Yaniv, I.; Stein, J.; Lapidot, M.; Shabtai, E.; Kfir, B. & Klein, T. (2001). Cytokine 
gene polymorphism in patients with graft-versus-host disease. Transplantation 
Proceedings, Vol.33, No.1-2, (February-March 2001), pp.502-503, ISSN 0041-1345 
Tawara, I.; Maeda, Y.; Sun, Y.; Lowler, K.P.; Liu, C.; Toubai, T.; McKenzie, A.N & Reddy, P. 
(2008). Combined Th2 cytokine deficiency in donor T cells aggravates experimental 
acute graft-vs-host disease. Experimental Hematology, Vol.36, No.8, (August 2008), 
pp.988–996, ISSN 0301-472X 
Tay, G.K.; Witt, C.S.; Christiansen, F.T.; Charron, D.; Baker, D.; Herrmann, R.; Smith, L.K.; 
Diepeveen, D.; Mallal, S. & McCluskey, J. (1995). Matching for MHC haplotypes 
results in improved survival following unrelated bone marrow transplantation. 
Bone Marrow Transplantation, Vol.15, No.3, (March 1995), pp.381–385, ISSN 0268-
3369 
Terasaki, P.I.; Ozawa, M. & Castro R. (2007). Four-year follow-up of a prospective trial of 
HLA an MICA antibodies on kidney graft survival. American Journal of 
Transplantation, Vol.7, No.2, (February 2007), pp. 408–415, ISSN 1600-6135 
Tieng, V.; Le Bouguenec, C. ; du Merle, L.; Bertheau, P.; Desreumaux, P.; Janin, A.; Charron, 
D. & Toubert, A. (2002). Binding of Escherichia coli adhesin AfaE to CD55 triggers 
cell-surface expression of the MHC class I-related molecule MICA. Proceedings of the 
National Academy of Sciences of the United States of America, Vol.99, No.5, (March 
2002), pp.2977-2982, ISSN 0027-8424 
Turner, D.M.; Williams, D.M.; Sankaran, D.; Lazarus, M.; Sinnott, P.J. & Hutchinson, I.V. 
(1997). An investigation of polymorphism in the interleukin-10 gene promoter. 
European Journal of Immunogenetics, Vol.24, No.1, (February 1997), pp.1-8, ISSN 0960-
7420 
Uhrberg, M.; Valiante, N.M.; Shum, B.P.; Shilling, H.G.; Lienert-Weidenbach, K.; Corliss, B.; 
Tyan, D.; Lanier, L.L. & Parham, P. (1997). Human diversity in killer cell inhibitory 
receptor genes. Immunity, Vol.7, No.6, (December 1997), pp.753-763, ISSN 1074-7613 
Venstrom, J.M., Ted, A. Gooley, T.A.; Spellman, S.; Pring, J.; Malkki, M.; Dupont, B.; 
Petersdorf, E. & Hsu, K.C. (2010). Donor activating KIR3DS1 is associated with 
decreased acute GVHD in unrelated allogeneic hematopoietic stem cell 
transplantation. Blood, Vol.115, No.15, (April 2010), pp.3162-3165, ISSN 0006-4971 
 
New Advances in Stem Cell Transplantation 
 
36
Przepiorka, D.; Weisdorf, D.; Martin, P.; Klingemann, H.G.; Beatty, P.; Hows, J & Thomas, 
E.D. (1995). 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow 
Transplantation, Vol.15, No.6, (June 1995), pp. 825-828, ISSN 0268-3369 
Rajagopalan, S. & Long, E.O. (1999). A human histocompatibility leukocyte antigen (HLA)-
G-specific receptor expressed on all natural killer cells. Journal of Experimental 
Medicine, Vol.189, No.7, (1999), pp.1093-1100. ISSN 0022-1007 
Rajagopalan, S. & Long, E.O. (2005). Understanding how combinations of HLA and KIR 
genes influence disease. The Journal of Experimental Medicine, Vol.201, No.7, (April 
2005), pp.1025-1029, ISSN 0022-1007 
Rashidi-Nezhad, A.; Azimi, C.; Alimoghaddam, K.; Ghavamzadeh, A.; Hossein-Nezhad, A.; 
Izadi, P.; Sobhani, M.; Noori-Daloii, A.R. & Noori-Daloii, M.R. (2010). TGF-Beta 
codon 25 polymorphism and the risk of graft-versus-host disease after allogenic 
hematopoietic stem cell transplantation. Iranian Journal of Allergy, Asthma and 
Immunology, Vol.9, No.1, (March 2010), pp.1-6, ISSN 1735-1502 
Reddy, P. & Ferrara, J.L. (2003). Immunobiology of acute graft-versus-host disease. Blood 
Reviews, (December 2003), Vol.17, No.4, pp.187–194, ISSN 0268-960X 
Reviron, D.; Dussol, B.; Andre, M.; Brunet, P.; Mercier, P. & Berland, Y. (2001). TNF-alpha 
and IL-6 gene polymorphism and rejection in kidney transplantation recipients. 
Transplantation Proceedings, Vol.33, No.1-2, (February-March 2001), pp.350-351, 
ISSN 0041-1345 
Sakata, N; Yasui, M.; Okamura, T.; Inoue, M.; Yumura-Yagi, K. & Kawa, K. (2001). Kinetics 
of plasma cytokines after hematopoietic stem cell transplantation from unrelated 
donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in 
severe acute graft-versus-host disease. Bone Marrow Transplantation, Vol.27, No.11, 
(June 2001), pp. 1153-1161, ISSN 0268-3369 
Schellekens, J.; Rozemuller, E.H.; Petersen, E.J.; van den Tweel, J.G.; Verdonck, L.F. & 
Tilanus, M.G. (2008). Activating KIRs exert a crucial role on relapse and overall 
survival after HLA-identical sibling transplantation. Molecular Immunology, Vol.45, 
No.8, (April 2008), pp.2255-2261, ISSN 0161-5890 
Shamim, Z.; Ryder, L.P.; Christensen, I.J.; Toubert, A.; Norden, J.; Collin, M.; Jackson, G.; 
Dickinson, A.M. & Müller, K. (2011). Prognostic Significance of Interleukin-7 
Receptor- Gene Polymorphisms in Allogeneic Stem-Cell Transplantation: A 
Confirmatory Study. Transplantation, (April 2011), Vol.91, No.7, pp.731–736, ISSN 
0041-1337 
Sivula, J.; Turpeinen, H.; Volin, L. & Partanen, J. (2009). Association of IL-10 and IL-10Rβ 
gene polymorphisms with graft-versus-host disease after haematopoietic stem cell 
transplantation from an HLA-identical sibling donor. BMC Immunology, Vol.10, 
(May 2009), pp.24-30, ISSN 1471-2172 
Steinle, A.; Li, P.; Morris, D.L.; Groh, V.; Lanier, L.L.; Strong, R.K. & Spies, T. (2001). 
Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the 
mouse RAE-1 protein family. Immunogenetics, Vol.53, No.4, (May-June 2001), 
pp.279-287, ISSN: 0093-7711 
Sumitran-Holgersson, S. (2008). Relevance of MICA and other non- HLA antibodies in 
clinical transplantation. Current Opinion of Immunology, Vol.20, No.5 (October 2008), 
pp.607–613, ISSN 0952-7915 
 
Importance of Non-HLA Gene Polymorphisms in Hematopoietic Stem Cell Transplantation 
 
37 
Sun, J.Y.; Gaidulis, L.; Dagis, A.; Palmer, J.; Rodriguez, R.; Miller, M.M.; Forman, S.J. & 
Senitzer, D. (2005). Killer Ig-like receptor (KIR) compatibility plays a role in the 
prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. 
Bone Marrow Transplantation, Vol.36, No.6, (September 2005), pp.525-530, ISSN 
0268-3369 
Symons, H.J.; Leffell, M.S.; Rossiter, N.D.; Zahurak, M.; Jones, R.J. & Fuchs, E.J. (2010). 
Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene 
Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-
Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow 
Transplantation, Vol.16, No.4, (April 2010), pp.533-542, ISSN 1083-8791 
Takahashi, H.; Furukawa, T.; Hashimoto, S.; Susuki, N.; Yamazaki, F.; Inano, K.; Takahashi, 
M.; Aizawa, Y. & Koike, T. (2000). Contribution of TNF-alpha and IL-10 gene 
polymorphisms to graftversus-host disease following allo-hematopoietic stem cell 
transplantation. Bone Marrow Transplantation, Vol.26, No.12, (December 2000), 
pp.1317-1323, ISSN 0268-3369 
Tambur, A.R.; Yaniv, I.; Stein, J.; Lapidot, M.; Shabtai, E.; Kfir, B. & Klein, T. (2001). Cytokine 
gene polymorphism in patients with graft-versus-host disease. Transplantation 
Proceedings, Vol.33, No.1-2, (February-March 2001), pp.502-503, ISSN 0041-1345 
Tawara, I.; Maeda, Y.; Sun, Y.; Lowler, K.P.; Liu, C.; Toubai, T.; McKenzie, A.N & Reddy, P. 
(2008). Combined Th2 cytokine deficiency in donor T cells aggravates experimental 
acute graft-vs-host disease. Experimental Hematology, Vol.36, No.8, (August 2008), 
pp.988–996, ISSN 0301-472X 
Tay, G.K.; Witt, C.S.; Christiansen, F.T.; Charron, D.; Baker, D.; Herrmann, R.; Smith, L.K.; 
Diepeveen, D.; Mallal, S. & McCluskey, J. (1995). Matching for MHC haplotypes 
results in improved survival following unrelated bone marrow transplantation. 
Bone Marrow Transplantation, Vol.15, No.3, (March 1995), pp.381–385, ISSN 0268-
3369 
Terasaki, P.I.; Ozawa, M. & Castro R. (2007). Four-year follow-up of a prospective trial of 
HLA an MICA antibodies on kidney graft survival. American Journal of 
Transplantation, Vol.7, No.2, (February 2007), pp. 408–415, ISSN 1600-6135 
Tieng, V.; Le Bouguenec, C. ; du Merle, L.; Bertheau, P.; Desreumaux, P.; Janin, A.; Charron, 
D. & Toubert, A. (2002). Binding of Escherichia coli adhesin AfaE to CD55 triggers 
cell-surface expression of the MHC class I-related molecule MICA. Proceedings of the 
National Academy of Sciences of the United States of America, Vol.99, No.5, (March 
2002), pp.2977-2982, ISSN 0027-8424 
Turner, D.M.; Williams, D.M.; Sankaran, D.; Lazarus, M.; Sinnott, P.J. & Hutchinson, I.V. 
(1997). An investigation of polymorphism in the interleukin-10 gene promoter. 
European Journal of Immunogenetics, Vol.24, No.1, (February 1997), pp.1-8, ISSN 0960-
7420 
Uhrberg, M.; Valiante, N.M.; Shum, B.P.; Shilling, H.G.; Lienert-Weidenbach, K.; Corliss, B.; 
Tyan, D.; Lanier, L.L. & Parham, P. (1997). Human diversity in killer cell inhibitory 
receptor genes. Immunity, Vol.7, No.6, (December 1997), pp.753-763, ISSN 1074-7613 
Venstrom, J.M., Ted, A. Gooley, T.A.; Spellman, S.; Pring, J.; Malkki, M.; Dupont, B.; 
Petersdorf, E. & Hsu, K.C. (2010). Donor activating KIR3DS1 is associated with 
decreased acute GVHD in unrelated allogeneic hematopoietic stem cell 
transplantation. Blood, Vol.115, No.15, (April 2010), pp.3162-3165, ISSN 0006-4971 
 
New Advances in Stem Cell Transplantation 
 
38
Viel, D.O.; Tsuneto, L.T.; Sossai, C.R.; Lieber, S.R.; Marques, S.B.; Vigorito, A.C.; Aranha, F.J.; 
De Brito Eid, K.A.; Oliveira, G.B.; Miranda, E.C.; De Souza, C.A. & Visentainer, J.E. 
(2007). IL2 and TNFA gene polymorphisms and the risk of graft-versus-host 
disease after allogeneic stem cell transplantation. Scandinavian Journal of 
Immunology, Vol.66, No.6, (December 2007), pp.703-710, ISSN 0300-9475 
Visentainer, J.E.; Lieber, S.R.; Persoli, L.B.; Vigorito, A.C.; Aranha, F.J.; Eid, K.A.; Oliveira, 
G.B.; Miranda, E.C. & de Souza, C.A. (2003). Serum cytokine levels and acute graft-
versus-host disease after HLA-identical hematopoietic stem cell transplantation. 
Experimental Hematology, Vol.31, No.11, (November 2003), pp. 1044-1050, ISSN 0301-
472X 
Wilson, A.G.; Symons, J.A.; Mcdowell, T.L.; Mcdevitt, H.O. & Duff, G.W. (1997). Effects of a 
polymorphism in the human tumor necrosis factor alpha promoter on 
transcriptional activation. Proceedings of the National Academy of Sciences of the United 
States of America, Vol.94, No.7, (April 1997), pp.3195-319, ISSN 1091-6490 
Witt, C.; Sayer, D.; Trimboli, F.; Saw, M.; Herrmann, R.; Cannell, P.; Baker, D. & 
Christiansen, F. (2000). Unrelated donors selected prospectively by block-matching 
have superior bone marrow transplant outcome. Human Immunology, Vol. 61, No.2, 
(February 2000), pp.85-91, ISSN 0198-8859 
Witt, C.S. & Christiansen, F.T. (2006). The relevance of natural killer cell human leukocyte 
antigen epitopes and killer cell immunoglobulinlike receptors in bone marrow 
transplantation. Vox Sanguinis, Vol.90, No.1, (January 2006), pp.10-20, ISSN 0042-
9007 
Yi, T.; Zhao, D.; Lin, C.L.; Zhang, C.; Chen, Y.; Todorov, I.; LeBon, T.; Kandeel, F.; Forman, S. 
& Zeng, D. (2008). Absence of donor Th17 leads to augmented Th1 differentiation 
and exacerbated acute graft-versus-host disease. Blood, Vol.112, No.5, (September 
2008), pp.2101–2110, ISSN 0006-4971 
Yokoyama, W.M. & Kim, S. (2006). Licensing of natural killer cells by self major 
histocompatibility complex class I. Immunological Reviews, Vol.214, No.1, (December 
2006), pp.143-154, ISSN 1529-2908 
Zhang, C.; Todorov, I.; Zhang, Z.; Liu, Y.; Kandeel, F.; Forman, S.; Strober, S. & Zeng, D. 
(2006). Donor CD4+ T and B cells in transplants induce chronic graft-versus-host 
disease with autoimmune manifestations. Blood, Vol.107, No.7, (April 2006), 
pp.2993-3001, ISSN 0006-4971 
Zhang, Y. & Stastny, P. (2006). MICA antigens stimulate T cell proliferation and cell-
mediated cytotoxicity. Human Immunology, Vol.67, No.3, (March 2006), pp.215–222, 
ISSN 0198-8859 
Zou, Y.; Stastny, P.; Susal, C.; Dohler, B. & Opelz G. (2007). Antibodies against MICA 
antigens and kidneytransplant rejection. The New England Journal of Medicine, 
Vol.357, No.13, (September 2007), pp. 1293-1300, ISSN 0028-4793 
Zwirner, N.W.; Dole, K. & Stastny, P. (1999). Differential surface expression of MICA by 
endothelial cells, fibroblasts, keratinocytes, and monocytes. Human Immunology, 
Vol.60, No.4, (April 1999), pp.323–330, ISSN 0198-8859 
3 
Relevance of HLA Expression Variants  
in Stem Cell Transplantation 
Britta Eiz-Vesper and Rainer Blasczyk 
Institute for Transfusion Medicine, Hannover Medical School, Hannover 
Germany 
1. Introduction  
Matching the donor and recipient for class I and II human leukocyte antigens (HLA) is 
pivotal to the success of allogeneic hematopoietic stem cell transplantation (HSCT). 
Transplantation across HLA barriers will lead to the development of T-cell responses to the 
mismatched HLA molecules, resulting in T-cell–mediated graft-versus-host disease (GvHD) 
or graft rejection in patients with insufficient immune suppression. The accuracy of testing 
and matching criteria has an important impact on the transplant outcome, but exact 
matching across multiple HLA loci (e.g., HLA-A, HLA-B, HLA-C, and HLA-DRB1) is a 
challenging task. Today, serological HLA diagnostic tests are being replaced by DNA-based 
typing methods considering only selected regions of the genes. Therefore, HLA null alleles 
or expression variants bearing their variation outside of these regions may be misdiagnosed 
as normally expressed variants, resulting in HLA mismatches that are highly likely to 
stimulate allogeneic T cells and trigger GvHD. This chapter will address the relevance, 
genetics, prevalence and diagnosis of HLA expression, variants of HLA class I loci and will 
discuss their clinical implications for transplantation.  
2. The human major histocompatibility complex 
The human major histocompatibility complex (MHC), also referred to as the human 
leukocyte antigen (HLA) complex, is encoded on the short arm of chromosome 6 (6p21) and 
is extremely polymorphic (Parham et al. 1988). HLA class I molecules are expressed on most 
nucleated cells. The HLA class I region comprises the gene loci for the heavy chains of the 
three classical human leukocyte antigens, HLA-A, -B, and -C. They consist of a heavy chain 
(44 kDa) and a non-covalently bound β2 microglobulin (β2m) light chain (12 kDa) encoded 
by chromosome 15. The heavy chain is made up of three extracellular domains: α1, α2, and 
α3. The highly polymorphic region of HLA class I molecules is located in the DNA and 
amino acid sequences of the α1 and α 2 domains, which form the peptide-binding groove. 
Endogenous 8 to 12 amino acid peptides are presented to CD8+ cytotoxic T lymphocytes 
(CTLs) (Natarajan et al. 1999). The α3 domain is mainly invariant and contains the binding 
site for the co-receptor CD8. Because of the MHC’s role in recognizing pathogenic and 
cancerous peptides, these genes are under high environmental pressure to be very 
polymorphic. A total of 4,946 HLA class I alleles have been identified to date 
(http://www.ebi.ac uk/imgt/hla; released April 2011).  
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amino acid sequences of the α1 and α 2 domains, which form the peptide-binding groove. 
Endogenous 8 to 12 amino acid peptides are presented to CD8+ cytotoxic T lymphocytes 
(CTLs) (Natarajan et al. 1999). The α3 domain is mainly invariant and contains the binding 
site for the co-receptor CD8. Because of the MHC’s role in recognizing pathogenic and 
cancerous peptides, these genes are under high environmental pressure to be very 
polymorphic. A total of 4,946 HLA class I alleles have been identified to date 
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HLA class I molecules are stabilized by disulfide bonds located in the α2 and α3 domains 
between cysteine (C) residues at amino acid positions 101/164 and 203/259. These bonds 
are essential for the correct processing and function of the molecules (Solheim 1999). Amino 
acid substitutions in these crucial C residues are likely to cause aberrant expression of the 
respective HLA class I molecules and may also change the affinity of the peptide-binding 
groove towards endogenous peptides (Warburton et al. 1994; Hirv et al. 2006; Hinrichs et al. 
2009; Hinrichs et al. 2010). 
HLA class II molecules (DR, DQ, DP) are mainly expressed on hematopoietic cells 
(macrophages, dendritic cells, T cells and B cells). The heterodimers are formed by two 
membrane-bound chains (α and β), each consisting of two domains (α1/α2 or β1/β2, 
respectively) encoded by two genes co-located in the centromeric part of the MHC. The 
antigenic peptide (up to 30 amino acids) is presented to CD4+ T helper cells (Th cells) in a 
cleft formed by the outermost α1 and β1 domains. Nearly all of the polymorphisms occur 
at exon 2 of the respective A or B genes. Peptides presented by HLA class II molecules are 
derived from exogenous proteins as well as from epitopes of plasma membranes or 
endosomes ( Rudensky et al. 1991; Chicz et al. 1993; Sant 1994). The nonpolymorphic β2 
domain contains the binding site for the T cell co-receptor CD4. More than 1,457 HLA 
class II alleles have been identified to date (http://www.ebi.ac uk/imgt/hla; released 
April 2011). 
2.1 Peptide presentation by HLA 
The ability to recognize and distinguish between self and non-self is primarily mediated by 
T lymphocytes, which survey the protein environment of cell surfaces for binding partners, 
i.e. for signs of foreign invasion. T cells do not recognize proteins directly; instead, they 
recognize imprints of ongoing protein metabolism in the form of peptides presented by 
HLA molecules. This phenomenon is called MHC restriction. The biological function of 
HLA molecules is to present antigenic peptides to T cells. Therefore, HLA molecules play a 
central role in T cell-mediated adoptive immunity. MHC class I molecules present peptides 
from endogenously synthezised proteins, whereas MHC class II molecules present peptides 
from incorporated exogenous proteins. All of these peptides originate from foreign or host 
cell proteins and are generated by proteasomal cleavage (class I pathway) or lysosomal 
processing (class II pathway). It has been estimated that about 0.5% of presented peptides 
are bound to MHC molecules, whereas more than 99% are ignored. Consequently, peptide 
binding to HLA is the single most selective event involved in antigen processing and 
presentation (Yewdell, Norbury, and Bennink 1999; Yewdell and Bennink 2001). A T cell-
mediated immune response occurs when the T-cell receptor recognizes a specific peptide-
MHC complex and thus identifies cells that have been infected by intracellular parasites or 
viruses or cells containing abnormal proteins (e.g., tumor cells). The peptides beeing part of 
a certain peptide-MHC complex triggering T-cell recognition are important tools for 
diagnosis and treatment of infectious, autoimmune, allergic and neoplastic diseases (Ferrari 
et al. 2000; Haselden, Kay, and Larche 2000; Singh 2000; Wang, Phan, and Marincola 2001).  
Different polymorphic HLA molecules have different peptide binding specificities (Falk et 
al. 1991; Sette et al. 1994; Bade-Doeding et al. 2007; Bade-Doeding et al. 2011). Peptides 
presented by MHC class I molecules are derived from cytoplasmic proteins by proteolytic 
degradation in the proteasome. Therefore, the MHC class I presentation pathway is often 
called the cytosolic or endogenous pathway. The MHC class I crystal structure features a 
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unique peptide-binding groove at the outer polymorphic α2 and α3 domains (Bjorkman et 
al. 1987, Madden et al. 1991). This groove can be subdivided into six pockets (A-F) of 
different size, shape, and function (Garrett et al. 1989; Matsumura et al. 1992). A pocket is 
defined as a unit having an affinity for a certain peptide side chain (e.g., affinity of pocket A 
for peptide position P1 and pocket B for P2). Some pockets have a well-shaped structure 
with an affinity for only one side chain, whereas others have an affinity for a group of side 
chains. In some cases, the boundaries between pockets are unclear. The most important 
residues and positions of a peptide are known as anchor residues and anchor positions. The 
identity and spacing of these primary anchors constitutes the peptide motif of an HLA 
specificity (Sette et al. 1987; Sette et al. 1989; Jardetzky et al. 1991; Ruppert et al. 1994; 
Rammensee, Friede, and Stevanoviic 1995). A typical peptide is 8 to 12 amino acids in length 
and binds in the peptide-binding groove, exhibiting an extended conformation with its 
terminal amino group bound to a pocket at one end of the groove and its terminal carboxyl 
group bound to a pocket at the other end of the groove.  
Peptide binding motifs generally contain two to three anchor positions (Rammensee, Friede, 
and Stevanoviic 1995). Other features such as secondary anchors and disfavored residues 
have also been described as playing an important role in defining the peptide-MHC 
interaction (Ruppert et al. 1993). The peptide-binding cleft of HLA class II molecules is 
formed by the outer α1 and β1 domains. Since it does not narrow at the ends, it can 
accommodate longer peptides containing up to 30 but usually 13 to 17 amino acids. The 
peptides presented by class II molecules are derived from extracellular proteins internalized 
by endophagocytosis and degraded in an endocytic compartment. Hence, the MHC class II-
dependent pathway of antigen presentation is called the endocytic or exogenous pathway. 
2.2 HLA nomenclature and typing methods 
According to the World Health Organization (WHO) Committee on Nomenclature for 
Factors of the HLA System (Holdsworth et al. 2009), each HLA allele name has a unique 
number corresponding to up to four sets of digits separated by colons. The 2-digits before 
the first colon describe the type, which often corresponds to the serological antigen carried 
by an allotype. The next set of digits are used to list the subtypes, numbers being assigned in 
the order in which DNA sequences have been determined. Broad families of alleles are 
clustered into serotypes (e.g., HLA-A1). 
There are two levels of typing: low-resolution (2-digits) and high-resolution (at least 4-
digits). Low-resolution typing delivers results equivalent to serological typing and can be 
achieved by serological (microlymphocytotoxicity test) or molecular techniques. Due to its 
simplicity and low cost, serologic typing is still used in some laboratories. High-resolution 
typing can only be achieved by DNA-based techniques allowing classification of the 
individual alleles within each serotype (e.g., HLA-A*01:01). A number of HLA typing 
methods based on PCR technology have been developed. PCR with sequence-specific 
primers (PCR-SSP), PCR followed by sequence-specific oligonucleotide probing (PCR-SSO) 
and PCR followed by sequencing-based typing (PCR-SBT) are currently the most commonly 
used molecular methods for low- and high-resolution HLA typing. These methods have 
displaced serology in most laboratories because of a much greater accuracy.  
2.2.1 Types and nomenclature of HLA expression variants 
To label HLA alleles with an alternative expression pattern the WHO Nomenclature 
Committee for Factors of the HLA System defined suffixes (’N’, ’L’, ’S’, ’C’, ’A’, ’Q’), that are 
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unique peptide-binding groove at the outer polymorphic α2 and α3 domains (Bjorkman et 
al. 1987, Madden et al. 1991). This groove can be subdivided into six pockets (A-F) of 
different size, shape, and function (Garrett et al. 1989; Matsumura et al. 1992). A pocket is 
defined as a unit having an affinity for a certain peptide side chain (e.g., affinity of pocket A 
for peptide position P1 and pocket B for P2). Some pockets have a well-shaped structure 
with an affinity for only one side chain, whereas others have an affinity for a group of side 
chains. In some cases, the boundaries between pockets are unclear. The most important 
residues and positions of a peptide are known as anchor residues and anchor positions. The 
identity and spacing of these primary anchors constitutes the peptide motif of an HLA 
specificity (Sette et al. 1987; Sette et al. 1989; Jardetzky et al. 1991; Ruppert et al. 1994; 
Rammensee, Friede, and Stevanoviic 1995). A typical peptide is 8 to 12 amino acids in length 
and binds in the peptide-binding groove, exhibiting an extended conformation with its 
terminal amino group bound to a pocket at one end of the groove and its terminal carboxyl 
group bound to a pocket at the other end of the groove.  
Peptide binding motifs generally contain two to three anchor positions (Rammensee, Friede, 
and Stevanoviic 1995). Other features such as secondary anchors and disfavored residues 
have also been described as playing an important role in defining the peptide-MHC 
interaction (Ruppert et al. 1993). The peptide-binding cleft of HLA class II molecules is 
formed by the outer α1 and β1 domains. Since it does not narrow at the ends, it can 
accommodate longer peptides containing up to 30 but usually 13 to 17 amino acids. The 
peptides presented by class II molecules are derived from extracellular proteins internalized 
by endophagocytosis and degraded in an endocytic compartment. Hence, the MHC class II-
dependent pathway of antigen presentation is called the endocytic or exogenous pathway. 
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According to the World Health Organization (WHO) Committee on Nomenclature for 
Factors of the HLA System (Holdsworth et al. 2009), each HLA allele name has a unique 
number corresponding to up to four sets of digits separated by colons. The 2-digits before 
the first colon describe the type, which often corresponds to the serological antigen carried 
by an allotype. The next set of digits are used to list the subtypes, numbers being assigned in 
the order in which DNA sequences have been determined. Broad families of alleles are 
clustered into serotypes (e.g., HLA-A1). 
There are two levels of typing: low-resolution (2-digits) and high-resolution (at least 4-
digits). Low-resolution typing delivers results equivalent to serological typing and can be 
achieved by serological (microlymphocytotoxicity test) or molecular techniques. Due to its 
simplicity and low cost, serologic typing is still used in some laboratories. High-resolution 
typing can only be achieved by DNA-based techniques allowing classification of the 
individual alleles within each serotype (e.g., HLA-A*01:01). A number of HLA typing 
methods based on PCR technology have been developed. PCR with sequence-specific 
primers (PCR-SSP), PCR followed by sequence-specific oligonucleotide probing (PCR-SSO) 
and PCR followed by sequencing-based typing (PCR-SBT) are currently the most commonly 
used molecular methods for low- and high-resolution HLA typing. These methods have 
displaced serology in most laboratories because of a much greater accuracy.  
2.2.1 Types and nomenclature of HLA expression variants 
To label HLA alleles with an alternative expression pattern the WHO Nomenclature 
Committee for Factors of the HLA System defined suffixes (’N’, ’L’, ’S’, ’C’, ’A’, ’Q’), that are 
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added to an allele name to indicate its expression status (Holdsworth et al. 2009). Alleles 
shown to be not expressed ('Null' alleles) are given the suffix 'N'. The alteration does not 
necessarily imply the lack of production of an internal partial product which might be a T-
cell target (Elsner and Blasczyk 2004). HLA alleles with ‘Low’ cell surface expression of an 
intact antigen compared to normal levels are indicated using the suffix ‘L’. The suffix 'S' is 
used to denote an allele specifying a protein which is exclusively expressed as a 'Secreted' 
molecule but not as a cell surface protein. A 'Q' suffix is used when the expression of an 
allele is 'Questionable' given that the mutation seen in the allele has previously been 
shown to affect normal expression levels. The suffix 'C' is used to denote an allele product 
found in the 'Cytoplasm' but not on the cell surface, and the suffix ‘A’ indicates 'Aberrant' 
expression.  
Currently, 197 HLA class I alleles (168 N, 5 L, 24 Q and 1 S allele) and 21 HLA class II alleles 
(all null alleles) with variant expression are listed in the IMGT/HLA database on the HLA 
nomenclature website (www.ebi.ac.uk/imgt/hla; released April 2011). As of April 2011, no 
alleles have been named with a 'C' or 'A' suffix. Most of these alleles carry mutations causing 
stop codons, leaving no doubt about their non-expression. Examples include HLA-
A*02:82N, HLA-A*23:08N, HLA-A*24:132N, HLA-B*14:07N, HLA-B*39:40N, HLA-
B*46:07N, HLA-B*56:190N, or HLA-C*06:49N. In the case of HLA-A*03:03N, a frame 
deletion is responsible for non-expression (Lienert et al. 1996).  
Only four HLA-A alleles (HLA-A*01:01:38L, HLA-A*02:01:01:02L, HLA-A*24:02:01:02L, 
HLA-A*30:14L) and one HLA-B allele (HLA-B*39:01:01:02L) with low-expression patterns 
have been identified up to now (Balas et al. 1994; Magor et al. 1997; Laforet et al. 1997; Dunn 
et al. 2004; Hirv et al. 2006; Perrier et al. 2006). Low expression of these alleles is usually 
associated with a low expression of the corresponding mRNA. However, the alteration 
causing the low expression of HLA*A-30:14L is not associated with a reduced mRNA level, 
but rather seems to result from the loss of the disulfide bond between the cysteine residues 
at positions 101 and 164 in the α2 domain (Hirv et al. 2006; Hinrichs et al. 2009). 
The only soluble secreted allele (S) known so far is HLA-B*44:02:01:02S (Dubois et al. 2004). 
This HLA-B44 variant was typed as a null allele by microlymphocytotoxicity, whereas the 
B*44:02:01:01 allele was identified by PCR-SSP. DNA sequencing revealed a single 
nucleotide difference at the end of intron 4 in the acceptor splicing site, leading to a splicing 
error characterized by the deletion of exon 5 (transmembrane domain of the HLA antigen).  
All known HLA class I Q alleles (7 HLA-A, 9 HLA-B and 8 HLA-C) and the HLA-A*30:14L 
allele have cysteine residue mutations at amino acid position 101 or 164 affecting the 
101/164 disulfide bridge in the α2 domain. Point mutations altering codon 101 have been 
described for HLA-C*02:25Q and HLA-C*03:22Q (Middleton et al. 2006). In the case of HLA-
A*02:293Q, HLA-A*11:50Q, HLA-A*30:14L (Hirv et al. 2006), HLA-A*32:11Q (Tang et al. 
2006), HLA-B*15:218Q, HLA-B*35:65Q (Elsner et al. 2006), HLA-B*37:16Q, HLA-B*39:38Q 
(Tang et al. 2006), HLA-B*40:133Q, HLA-C*04:59Q, HLA-C*07:121Q, HLA-C*12:42Q, HLA-
C*15:32Q and HLA-C*16:16Q, point mutations in codon 164 result in a replacement of the 
Cys residue, causing disruption of the disulfide bond in the 2 domain. HLA-A*30:14L is 
the only one of these alleles described as having a low expression pattern not affecting the 
corresponding mRNA levels (Hirv et al. 2006; Hinrichs et al. 2009). There are no known 
alleles with an amino acid mutation at positions 203 or 259 affecting the bridge in the α3 
domain.  
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2.3 HLA in transplantation 
The best donor is an HLA genotypically matched sibling identified by family typing. When 
no identical sibling donor is available, transplantation of stem cells from an HLA-matched 
unrelated donor can result in comparable disease–free survival, particularly for good-risk 
patients (Petersdorf et al. 2004; Petersdorf 2007; 2008). Nevertheless, unrelated 
transplantation is associated with a higher frequency of post-transplant complications than 
in genotypically matched sibling HSCT, mainly because of undefined HLA 
incompatibilities. The negative impact of HLA mismatches on the outcome of hematopoietic 
stem cell transplantation has been demonstrated in a variety of studies (Mickelson et al. 
2000; Ottinger et al. 2003; Schaffer et al. 2003). Most allele mismatches affect differences in 
the T-cell receptor contact area of the heavy chain or the peptide-binding site causing a 
change in the peptide binding repertoire both leading to a T cell-mediated allorecognition.  
HistoCheck (www.histocheck.org) is an online tool which helps clinicians and researchers 
visualize the amino acid substitutions of HLA alleles so that they can make informed 
judgments about their functional similarity (Elsner et al. 2004). Because exact HLA matching 
is often not possible, it is important to understand which alleles are the most similar. 
HistoCheck provides crystallography-based 3-dimensional (3D) visualizations of the allelic 
mismatches by highlighting amino acid mismatches, positions, and functions. The user is 
provided with dissimilarity scores (DSSs) for the amino acids involved as well as an over-all 
DSS for the two alleles. However, scoring HLA mismatches by HistoCheck has not been 
shown to predict clinical outcome in unrelated hematopoietic stem cell transplantation.  
Several large-scale studies have shown that high-resolution matching of patients and 
unrelated donors significantly improves post-transplant survival (Bray et al. 2008), the 
incidence and severity of acute and chronic GVHD (Morishima et al. 2002; Morishima et al. 
2007), and engraftment (Petersdorf et al. 2001; Flomenberg et al. 2004; Lee et al. 2007; 
Petersdorf 2008). Regarding cord blood transplantation, several studies have shown that the 
degree of HLA match is important as well, but a large cell dose may be at least equally 
important (Laughlin et al. 2004; Rocha, Sanz, and Gluckman 2004; Arcese et al. 2006; Eapen 
et al. 2007). 
The National Marrow Donor Program (NMDP¸ www.marrow.org) proposed minimum 
HLA matching requirements for adult donors for HLA-A, -B, -C and -DRB1 (8/8) typed, at 
high resolution by DNA-based methods and cord blood units (CBU) for HLA-A, -B, (low 
resolution) and -DRB1 (high resolution) (Table 1) (Bray et al. 2008; Kamani et al. 2008). 
Considering HLA allele and haplotype frequencies can be very useful when interpreting 
typing results and finding appropriate donors. Simply knowing that a patient's haplotype is 
extremely rare can prevent futile registry searches. Considering allele frequency alone is 
insufficient, because a rare allele can be acceptable when it is found in its most common 
haplotype. Being aware of rare alleles and haplotypes is also an important factor in quality 
control. Furthermore, typing results in registries are often incomplete. In the case where 
there are two matching donors, but each donor typing is incomplete with respect to 
different alleles, then haplotype frequencies can help choose the donor who is most likely to 
be an exact match. To overcome these limitations the new matching algorithm HapLogic 
(www.marrow.org) and Haplocheck (www.haplocheck.org) were developed. HapLogic a new 
enhanced matching algorithm that automatically identifies the donors or CBUs with the 
highest potential to match the patient, was established by the NMDP to accelerate and 
improve the efficiency of searches. The new matching algorithm analyzes the haplotypes of 
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millions of donors on NMDP's Be The Match Registry. HapLogic uses advanced logic to 
predict a donor’s or CBU’s high-resolution match and builds upon mathematical formulas 
that predict DR match in AB donors (Hurley et al. 2006).  
 
HLA locus Tissue type patient? Match donor and patient? 
A Yes, allele level Yes 
B Yes, allele level Yes 
C Yes, allele level Yes 
DRA No No 
DRB1 Yes, allele level Yes 
DRB3, 4, and 5 Yes (DRB1 association) Unknown 
DQA1 No No 
DQB1 Yes (DRB1 association) Uncertain 
DPA1 No No 
DPB1 No Uncertain 
Table 1. HLA tissue typing recommended by the NMDP (from www.marrow.org) (Bray et 
al. 2008; Kamani et al. 2008) 
The web tool HaploCheck is addressing this chance by ranking typing results based upon 
haplotype frequencies. The user enters the typing results for a patient, for which the cis/trans 
phase is unknown. The result is a list of separated haplotypes, ordered by frequency. Very rare 
alleles and associations are highlighted to inform the user of potential problems when 
searching registries, or to identify potential typing errors. For the case that a single mismatch is 
unavoidable, the user is presented with a list of mismatch-containing haplotypes and their 
frequencies. This can not only prevent futile registry searches, but also enable the clinician to 
make decisions about accepted mismatches before initiating a registry search. 
3. Prevalence and allogenicity of HLA class I expression variants  
Few investigators have systematically addressed the prevalence of HLA null and 
alternatively expressed alleles, which has been shown to be about 0.003% and 0.3%, 
respectively (Noreen et al. 2001; Elsner and Blasczyk 2004; Smith et al. 2005). Considering 
that most studies indicate that the prevalence of these alleles is around 1 per 1000 
individuals, these alleles are not particularly rare. Consequently, it was recommended that 
laboratories typing unrelated bone marrow patients and donors should have a strategy to 
identify these expression variants (Elsner and Blasczyk 2004). 
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HLA null and expression variants are typically identified by the discrepancy between 
serological and molecular typing results. As molecular typing techniques have nearly 
displaced serological methods and are focusing on selected regions of the HLA genes many 
expression variants are likely to be overlooked. In solid organ transplantation, HLA 
expression variants are not considered in the matching procedure. In allogeneic HSCT, 
expression variants make an essential difference and can strongly affect transplant-related 
mortality since HLA mismatches are the major cause of severe GvHD or graft rejection. 
Thus, in contrast to solid organ transplantation, excluding HLA expression variants is 
required in the matching process for HSCT (Elsner and Blasczyk 2004; Hirv et al. 2006; 
Hinrichs et al. 2009).  
Overlooking an HLA null allele in the donor would result in a T cell-mediated 
allorecognition of the recipient’s HLA and may lead to the development of acute severe 
GvHD (Elsner and Blasczyk 2004). In the reverse setting (recipient null allele, donor 
expressed allele), allogeneic recognition of the recipient's stem cells may lead to their 
destruction and subsequent graft failure. Accordingly, mismatches between expressed and 
non-expressed HLA variants should be avoided in HSCT. In case of a recipient with an HLA 
null allele having no HLA-identical donor with the same null variant, matching must be 
performed as if the patient would be homozygous for the expressed allele of the respective 
HLA locus (Figure 1). 
 
 
Fig. 1. Haplotypes in a recipient-donor combination with a null allele in one of the 
recipient’s haplotypes. Shadowed boxes indicate normally expressed variants. The 
recipient carries an HLA-B null allele (white box). In the donor search the recipient's 
haplotype h2 has to be ‘replaced’ by haplotype (h3) containing the expressed HLA-B allele 
(var1). However, such a haplotype may be rare and a matching donor hard to find (Elsner 
and Blasczyk 2004). 
On the other hand, an incomplete HLA molecule may be generated, as has been shown for 
HLA-B*44:02:01:02S, which might be presented via the indirect allogeneic recognition 
pathway (Magor et al. 1997; Dubois et al. 2004). Provided that the HLA-derived peptides fit 
into the peptide-binding groove and are capable of triggering a strong T-cell response, they 
may act as minor histocompatibility antigens (mHags). This could also apply to those HLA 
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expression variants where the transcription of a truncated mRNA is known and/or 
translation is probable. It also shows that premature stop codons do not automatically lead 
to the interruption of transcription (Balas et al. 1994; Laforet et al. 1997; Magor et al. 1997; 
Dunn et al. 2004; Hirv et al. 2006; Perrier et al. 2006; Eiz-Vesper, Blasczyk, and Horn 2007). 
In the light of countless non-HLA mHags this is probably of inferior importance. 
4. Characterization of HLA expression variants by cytokine-induced HLA 
secretion 
Because of the clinical importance of expresion variants an HLA secretion assay was 
designed capable of discriminating between low-expression (L) and non-expressed (N) HLA 
variant alleles and assigning questionably expressed (Q) alleles to either group (Hinrichs et 
al. 2009).  
All of the aforementioned HLA class I alleles with an unknown expression profile (Q alleles; 
7 HLA-A, 9 HLA-B and 8 HLA-C) and HLA-A*30:14L, have a mutation of cysteine residue 
101 or 164 affecting disulfide bridge 101/164 in the α2 domain. Because HLA-A*30:14L is 
the only one of these alleles described to have a low expression pattern with no effect on 
mRNA levels (Hirv et al. 2006; Hinrichs et al. 2009), A*30:14L was used as an expression 
model. HLA-A*30:14L was reported to be non-expressed under normal conditions and to 
show weak aberrant expression after cultivation of the corresponding B-lymphoblastoid cell 
line at 30°C (Hirv et al. 2006).  
HLA-A*30:14L was originally identified in a patient suffering from chronic myeloid 
leukemia (Hirv et al. 2006). The sequence of this allele is identical to that of HLA-A*30:01 
except for a transversion at nucleotide position 563 in exon 3 (guanine to cytosine 
substitution), resulting in a replacement of cysteine by serine at position 164, impairing 
disulfide bridge formation in the α2 domain of the mature polypeptide. This alteration of 
the secondary structure presumably decreases expression, rendering HLA-A*30:14L 
basically undetectable by serology.  
Human cell lines (HEK293, C1R and K562) expressing recombinant soluble HLA (sHLA) 
molecules (Table 2) were incubated with interferon (IFN)- and/or tumor necrosis factor 
(TNF)-α (Hinrichs et al. 2009). These pro-inflammatory cytokines are known to enhance the 
expression of HLA molecules by affecting the interaction of DNA-binding proteins with the 
HLA-A promoter regions, resulting in the increased transcription of heavy and light chain 
genes (Girdlestone 1996; Gobin et al. 1997; Gobin et al. 1998; Gobin et al. 1999; Johnson 
2003). In addition, these cytokines induce the transcription of proteasome subunits, peptide 
transporters and chaperones that promote the expresson of HLA class I molecules by 
providing peptides for presentation (Ma et al. 1997; Lankat-Buttgereit and Tampe 2002).  
Expression of soluble HLA-A*30:14L and HLA-A*30:01 was measured in the 
supernatants of transfected and untransfected cells incubated with or without IFN- 
and/or TNF-α using a W6/32 and anti-β2-microglobulin-based sandwich ELISA (Figure 
1) (Bade-Doeding et al. 2007). HLA-A*30:14L was not detected in the supernatant of 
unstimulated transfectants. Stimulation with IFN- and/or TNF-α increased HLA-
A*30:14L secretion to detectable levels and increased HLA-A*30:01 expression up to 8-
fold, but did not result in any difference between mRNA levels of HLA-A*30:14L and 
A*30:01 (Figure 2).  
 




Day  Expression level (ng/ml) 
  HEK293 C1R K562 
1 HLA-A*30:01 31.3 ± 10.3 98.0 ± 14.7 155.8 ± 73.9 
 HLA-A*30:14L 0 3.2 ± 1.7 0 
3 HLA-A*30:01 383.2 ± 56.5 225.8 ± 177.5 143.5 ± 40.8 
 HLA-A*30:14L 1.8 ± 1.4 0 0 
7 HLA-A*30:01 160.4 ± 3.2 253.6 ± 16.1 175.9 ± 74.7 
 HLA-A*30:14L 0 9.7 ± 4.9 0 
Table 2. Soluble HLA-A*30:01 and HLA-A*30:14L expression levels (ng/ml) in the 













Fig. 2. Secretion of soluble HLA-A*30:01 and HLA-A*30:14L by transfected K562 cells 
Expression of mRNA transcripts of both alleles was determined by real-time PCR. For 
control, Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (B-LCL) 
expressing HLA-A*30:14L was established from cells of the patient’s mother (genotype 
HLA-A*30:14L,*02:01) (Hirv et al. 2006). The positive control was a B-LCL expressing HLA-
A*30:01 (genotype HLA-A*30:01,*02:01). In both B-LCLs and HEK293 cells, the mRNA level 
of HLA-A*30:14L was nearly identical to that of HLA-A*30:01 (Figure 3). This finding 
suggests that the mRNA transcription rate of sHLA-A*30:14L is not affected by the mutation 
at nucleotide position 563 (G->C). The mRNA levels of both alleles clearly increased in 
response to combined stimulation with IFN- and TNF-α. In view of this lack of any 
difference in mRNA transcription, the protein expression defect is most likely caused by the 
missing disulfide bond in the α2 domain. 
                         untreated    IFN-       TNF-α      IFN-+                untreated    IFN-      TNF-α      IFN- +               untreated   IFN-      TNF- α      IFN- +                     
                                                                                          TNF- α                                                                                 TNF- α                                                                                TNF- α 
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expression variants where the transcription of a truncated mRNA is known and/or 
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Expression of soluble HLA-A*30:14L and HLA-A*30:01 was measured in the 
supernatants of transfected and untransfected cells incubated with or without IFN- 
and/or TNF-α using a W6/32 and anti-β2-microglobulin-based sandwich ELISA (Figure 
1) (Bade-Doeding et al. 2007). HLA-A*30:14L was not detected in the supernatant of 
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fold, but did not result in any difference between mRNA levels of HLA-A*30:14L and 
A*30:01 (Figure 2).  
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expressing HLA-A*30:14L was established from cells of the patient’s mother (genotype 
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A*30:01 (genotype HLA-A*30:01,*02:01). In both B-LCLs and HEK293 cells, the mRNA level 
of HLA-A*30:14L was nearly identical to that of HLA-A*30:01 (Figure 3). This finding 
suggests that the mRNA transcription rate of sHLA-A*30:14L is not affected by the mutation 
at nucleotide position 563 (G->C). The mRNA levels of both alleles clearly increased in 
response to combined stimulation with IFN- and TNF-α. In view of this lack of any 
difference in mRNA transcription, the protein expression defect is most likely caused by the 
missing disulfide bond in the α2 domain. 
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Fig. 3. Detection of mRNA levels of HLA-A*30 alleles in B-LCLs and HEK293 cells 
mRNA expression of the HLA-A*30 alleles in transfected cell lines and B-LCLs was 
determined by real-time PCR. Shown are representative results for HEK293 cells measured 
after 3 days of culture in the presence (“treated”) or absence (“untreated”) of the cytokines 
IFN- and/or TNF-α. Data were acquired using a probe specific for the HLA-A30 sequence. 
Similar results were achieved for all transfected cell lines. Lanes: a) sHLA-A*30:01-
transfected HEK293, b) sHLA-A*30:14L-transfected HEK293, c) EBRCC-256 (HLA-A*30:01), 
d) EBRCC-1818 (HLA-A*30:14L), 1 untreated, 2 IFN--treated, 3 TNF-α-treated, 4 IFN- plus 
TNF-α-treated 
The observation that HLA-A*30:14L protein accumulates inside the cells indicates that HLA-
A*30:14L translation is not affected. Consequently, the lack of protein secretion in the 
supernatant is best explained by post-translational instability of the HLA-A*30:14L 
molecules because of the missing disulfide bridge (Hinrichs et al. 2009). Based on these 
findings, it is likely that the intracellular enriched HLA-A*30:14L protein is a major substrate 
for proteasomal cleavage and that it provides a flood of peptide fragments presented to 
cytotoxic T lymphocytes. As a result of this indirect surface expression by the presentation 
of peptide fragments, it is possible that GvHD or graft rejection might be promoted in the 
event of mismatching (Benichou 1999). Consequently, considering HLA-A*30:14L as null 
allele is, in case of a mismatch with any other HLA-A allele, potentially more dangerous in 
terms of GvHD and graft rejection than a mismatch with its most related allele HLA-
A*30:01. Indeed, mistyping HLA-A*30:14L as an N allele has led to a severe GvHD in a 
patient transplanted with hematopoietic stem cells from an HLA-A*02:01 homozygous 
donor (Hirv et al. 2006).  
In recent studies, the cytokine-based HLA secretion assay was used to classify the 
expression patterns of HLA-A*32:11Q (Tang et al. 2006) and HLA-B*35:65Q (Elsner et al. 
2006). Both alleles undergo cysteine substitution at amino acid position 164 and thus lack 
the disulfide bond between the cysteine residues at amino acid positions 101 and 164 in 
the 2 domain of the mature protein. This interferes with HLA maturation inside the ER 
and therefore impairs cell surface expression. In concordance with the results of Hinrichs 
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et al. (Hinrichs et al. 2009), IFN-γ and TNF-α increased the expression of the HLA 
expression variants, making HLA-A*32:11Q and HLA-B*35:65Q distinctly detectable. 
Compared to HLA-A*32:01 and HLA-B*35:01, the variants have very weak protein levels, 
indicating a low expression status. Consequently, they should be handled as low 
expression variants (L alleles). 
5. The nature of peptides presented by HLA class I expression variants 
The functional integrity of HLA low-expression variants is a prerequisite for considering 
them as essential in hematopoietic stem cell donor and recipient matching to diminish the 
risk of serious complications such as GvHD or graft rejection. HLA class I molecules 
present endogenous peptides 8-12 amino acids in length to CD8+ cytotoxic T lymphocytes 
(Natarajan et al. 1999). Most amino acid polymorphisms of different HLA class I 
molecules are located in the peptide-binding region shaped by parts of the α1 and α2 
domains; these polymorphisms determine the characteristics of presented peptides. 
Peptide motifs have been reported for the most common HLA-A and B alleles and for 
some rare variants. Importantly, differences in peptide binding among the alleles of a 
serological group have also been described (Prilliman et al. 1999; Bade-Doeding et al. 
2011,). Identification and comparison of allele-specific peptide-binding motifs provide 
important information for donor-recipient matching and prediction of HLA subtype 
allogenicity in allogeneic HSCT. 
In order to determine the functionality of HLA low-expression alleles, peptides from 
recombinant truncated HLA-A*30:14L molecules secreted in the supernatant of a human cell 
line were eluted and sequenced (Hinrichs et al 2010). The suitability of the monoclonal anti-
HLA class I antibody W6/32 for purifying recombinant HLA-A*30:14L molecules suggested 
its proper folding and assembly. Presumably, more soluble HLA-A*30:14L is produced and 
secreted into the supernatant that might not be correctly folded because of the lack of a 
disulfide bridge in the α2 domain. 
Edman pool sequencing of eluted peptides corroborated the hypothesis that peptides are 
presented by HLA low expression variants and showed idential peptide motifs in HLA-
A*30:01 and HLA-A*30:14L confirming the previously described peptide motif of A*30:01 
(Lamberth et al. 2008; Sidney et al. 2008). The C-terminal position (P) was identified as a 
primary anchor position. The preferred residues of the HLA-A*30 peptide epitopes at this 
position are lysine (K), valine (V) or arginine (R). The preference for lysine as the top amino 
acid at the P position of the bound peptides, like described by positional scanning 
combinatorial peptide libraries (PSCPL) analysis, could be consolidated by the obtained 
peptide sequence data (Lamberth et al. 2008; Sidney et al. 2008). Position P3 of the peptides 
was identified as a primary-secondary anchor showing a high preference for the basic amino 
acids K and R. Six amino acids are reportedly favored at position P2: phenylalanine (F), 
serine (S), threonine (T), valine (V), isoleucine (I) or leucine (L).  
The size of the obtained peptides ranged from 8 to 14 amino acids, but most had a length of 
9 to 10 aa. The sequences of 200 HLA-A*30:01 ligands and of 100 HLA-A*30:14L ligands 
were identified. The following three peptide epitopes (3%) were presented by both HLA-
A*30:01 and HLA-A*30:14L: 1) VLDTPGPPV, a nonameric peptide derived from titin 
(isoform N2-A, aa position 19783-19791), a protein of human muscle ultrastructure and 
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event of mismatching (Benichou 1999). Consequently, considering HLA-A*30:14L as null 
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A*30:01. Indeed, mistyping HLA-A*30:14L as an N allele has led to a severe GvHD in a 
patient transplanted with hematopoietic stem cells from an HLA-A*02:01 homozygous 
donor (Hirv et al. 2006).  
In recent studies, the cytokine-based HLA secretion assay was used to classify the 
expression patterns of HLA-A*32:11Q (Tang et al. 2006) and HLA-B*35:65Q (Elsner et al. 
2006). Both alleles undergo cysteine substitution at amino acid position 164 and thus lack 
the disulfide bond between the cysteine residues at amino acid positions 101 and 164 in 
the 2 domain of the mature protein. This interferes with HLA maturation inside the ER 
and therefore impairs cell surface expression. In concordance with the results of Hinrichs 
    a-1           a-2           a-3           a-4           b-1           b-2           b-3          b- 4          c-1           d-1 
 
Relevance of HLA Expression Variants in Stem Cell Transplantation 
 
49 
et al. (Hinrichs et al. 2009), IFN-γ and TNF-α increased the expression of the HLA 
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indicating a low expression status. Consequently, they should be handled as low 
expression variants (L alleles). 
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The size of the obtained peptides ranged from 8 to 14 amino acids, but most had a length of 
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were identified. The following three peptide epitopes (3%) were presented by both HLA-
A*30:01 and HLA-A*30:14L: 1) VLDTPGPPV, a nonameric peptide derived from titin 
(isoform N2-A, aa position 19783-19791), a protein of human muscle ultrastructure and 
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elasticity; 2) EITALAPSTMK, an 11-mer peptide derived from human muscle protein 
ACTA1 (actin, alpha 1, skeletal muscle; aa position 301-311); and 3) DNIQGITKPAIR, a 12-




1    2    3   4    5   6    7   8    9   10   11  12 Source 
Ligand V   L   D   T   P   G   P   P  V 
E    I    T   A   L   A   P   S  T   M   K 
D   N   I    Q  G   I    T   K  P   A    I     R 
Titin (TTN titin isoform N2-A) 
Actin (ACTA1) 
Histone (HIST2H4A) 
Table 3. Shared peptide epitopes of HLA-A*30:14L and HLA-A*30:01 
To verify the presentation of naturally presented peptides from recombinant HLA-
A*30:01/30:14L molecules, peptide binding was analyzed by flow cytometry ( Storkus et al. 
1993; Zeh et al. 1994; Maeurer et al. 1996) in three EBV-transformed B-LCLs expressing 
either HLA-A*30:14L,*02:01 (Ulm-241539), HLA-A*30:01,*02:01 (EBRCC-256) or HLA-
A*02:01 (EBRCC-2296) ( Warburton et al. 1994; Hirv et al. 2006; Hinrichs et al. 2009; 2010). 
Acid treatment of the cell lines resulted in the dissociation of the naturally bound peptides 
and the release of β2 microglobulin from the HLA class I heavy chain. The HLA class I 
molecules were then reconstituted by adding fluorescein isothiocyanate (FITC)-labeled HLA 
peptide ligands and recombinant β2 microglobulin. The synthetic FITC-labeled peptide 
EITALAK(FITC)PSTMK (HLA-A*30:01/30:14L) and the immunodominant HLA-A*02:01-
restricted CMVpp65495-503 peptide (NLVPMK(FITC)VATV) were used. Reconstitution of 
HLA with the HLA-A*30 ligand mounted up to 51% (Ulm-241539) and 74% (EBRCC-256), 
respectively, compared to 25% for the HLA-A*02:01 homozygous cell line (EBRCC-2296). 
Binding on cells expressing the normal HLA-A*30:01 allele was higher than on those 
expressing HLA-A*30:14L, the low expression variant (Figure 4). The results confirm that 
the A*30 peptide previously isolated binds to HLA-A*30 on the cell surface. Peptide binding 
was found for the A*30:01 specific peptide on the HLA-A*30:14L-expressing cell line (Ulm-
241539), indicating the stability of HLA-A*30:14L cell surface expression. 
 




A*30 peptide/A*02 peptide binding [%]  
Fig. 4. Relative A*30/A*02:01 peptide-binding intensities for different HLA-expressing B-LCLs  
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Homology-based modeling for each HLA-A*30 alleles with the shared 9, 11 and 12-mer 
peptide epitopes revealed only marginal differences between the two HLA-A*30 alleles. The 
HLA-A*30:01 and HLA-A*30:14L models were essentially identical with the Cys164 Ser 
substitution, but simply adopted an alternate rotamer conformation upon breakage of the 
disulfide bond. Therefore, only the HLA-A*30:14L model is illustrated (Figure 5).  
Although the models look identical and the alleles appear to bind identical peptides, the 
Cys164Ser variation could potentially generate additional flexibility within the peptide-
binding groove, thereby influencing binding kinetics, particularly in peptides of lower 
affinity. Such an effect could stimulate a T-cell immune response and have serious 
implications in allogeneic HSCT.  
 
 
Fig. 5. Homology-based model of HLA-A*30:14L with the three shared peptide ligands 
Modeling of the HLA-A*30:01 and HLA-A*30:14L structures was carried out using the 
SCWRL homology-based modeling server (Wang, Canutescu, and Dunbrack 2008) while 
employing the crystal structure of the closely related HLA-A*11:01 (1Q94) as a template. 
Peptide templates for 9-mer (1Q94), 11-mer (2BVO) and 12-mer (3BW9) were superimposed 
and merged with the HLA-A*30:14L model. Peptide mutagenesis was then performed using 
DeepView (Guex and Peitsch 1997) and the rotamer library to find the best side chain 
orientations with minimum steric clashes. Each model was then subjected to energy 
minimization using DeepView software. The graphics program PyMOL 
(http://www.pymol.org) was used to generate the structural models.  
6. Conclusions 
Since HLA mismatches are the main cause of severe GvHD and graft rejection, 
misinterpretation of HLA null alleles and expression variants as irrelevant could strongly 
affect transplant-related mortality.  
The cytokine-based HLA secretion assay can be used to distinguish between low-expressed 
and non-expressed HLA alleles in order to classify alleles with a currently undefined 
expression status (questionable alleles, Q) as well as to re-classify certain alleles which have 
been assigned as null variants (N). Additionally, discrimination between cytokine inducible 
and non-inducible defect alleles may be important in allotransplant settings in which a 
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elasticity; 2) EITALAPSTMK, an 11-mer peptide derived from human muscle protein 
ACTA1 (actin, alpha 1, skeletal muscle; aa position 301-311); and 3) DNIQGITKPAIR, a 12-
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A*30:01/30:14L molecules, peptide binding was analyzed by flow cytometry ( Storkus et al. 
1993; Zeh et al. 1994; Maeurer et al. 1996) in three EBV-transformed B-LCLs expressing 
either HLA-A*30:14L,*02:01 (Ulm-241539), HLA-A*30:01,*02:01 (EBRCC-256) or HLA-
A*02:01 (EBRCC-2296) ( Warburton et al. 1994; Hirv et al. 2006; Hinrichs et al. 2009; 2010). 
Acid treatment of the cell lines resulted in the dissociation of the naturally bound peptides 
and the release of β2 microglobulin from the HLA class I heavy chain. The HLA class I 
molecules were then reconstituted by adding fluorescein isothiocyanate (FITC)-labeled HLA 
peptide ligands and recombinant β2 microglobulin. The synthetic FITC-labeled peptide 
EITALAK(FITC)PSTMK (HLA-A*30:01/30:14L) and the immunodominant HLA-A*02:01-
restricted CMVpp65495-503 peptide (NLVPMK(FITC)VATV) were used. Reconstitution of 
HLA with the HLA-A*30 ligand mounted up to 51% (Ulm-241539) and 74% (EBRCC-256), 
respectively, compared to 25% for the HLA-A*02:01 homozygous cell line (EBRCC-2296). 
Binding on cells expressing the normal HLA-A*30:01 allele was higher than on those 
expressing HLA-A*30:14L, the low expression variant (Figure 4). The results confirm that 
the A*30 peptide previously isolated binds to HLA-A*30 on the cell surface. Peptide binding 
was found for the A*30:01 specific peptide on the HLA-A*30:14L-expressing cell line (Ulm-
241539), indicating the stability of HLA-A*30:14L cell surface expression. 
 




A*30 peptide/A*02 peptide binding [%]  
Fig. 4. Relative A*30/A*02:01 peptide-binding intensities for different HLA-expressing B-LCLs  
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Homology-based modeling for each HLA-A*30 alleles with the shared 9, 11 and 12-mer 
peptide epitopes revealed only marginal differences between the two HLA-A*30 alleles. The 
HLA-A*30:01 and HLA-A*30:14L models were essentially identical with the Cys164 Ser 
substitution, but simply adopted an alternate rotamer conformation upon breakage of the 
disulfide bond. Therefore, only the HLA-A*30:14L model is illustrated (Figure 5).  
Although the models look identical and the alleles appear to bind identical peptides, the 
Cys164Ser variation could potentially generate additional flexibility within the peptide-
binding groove, thereby influencing binding kinetics, particularly in peptides of lower 
affinity. Such an effect could stimulate a T-cell immune response and have serious 
implications in allogeneic HSCT.  
 
 
Fig. 5. Homology-based model of HLA-A*30:14L with the three shared peptide ligands 
Modeling of the HLA-A*30:01 and HLA-A*30:14L structures was carried out using the 
SCWRL homology-based modeling server (Wang, Canutescu, and Dunbrack 2008) while 
employing the crystal structure of the closely related HLA-A*11:01 (1Q94) as a template. 
Peptide templates for 9-mer (1Q94), 11-mer (2BVO) and 12-mer (3BW9) were superimposed 
and merged with the HLA-A*30:14L model. Peptide mutagenesis was then performed using 
DeepView (Guex and Peitsch 1997) and the rotamer library to find the best side chain 
orientations with minimum steric clashes. Each model was then subjected to energy 
minimization using DeepView software. The graphics program PyMOL 
(http://www.pymol.org) was used to generate the structural models.  
6. Conclusions 
Since HLA mismatches are the main cause of severe GvHD and graft rejection, 
misinterpretation of HLA null alleles and expression variants as irrelevant could strongly 
affect transplant-related mortality.  
The cytokine-based HLA secretion assay can be used to distinguish between low-expressed 
and non-expressed HLA alleles in order to classify alleles with a currently undefined 
expression status (questionable alleles, Q) as well as to re-classify certain alleles which have 
been assigned as null variants (N). Additionally, discrimination between cytokine inducible 
and non-inducible defect alleles may be important in allotransplant settings in which a 
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cytokine storm usually occurs following pre-transplant myeloablative conditioning or post-
transplant immunosuppressive therapy. 
The fact that the monoclonal anti-HLA class I antibody W6/32 is a conformational antibody 
implies that only correctly folded, β2 microglobulin-assembled and peptide-loaded MHC 
complexes can be detected. This suggests that parts of soluble HLA-A*30:14L molecules are 
assembled correctly and secreted by transfectants. Presumably, more soluble HLA-A*30:14L 
is produced and secreted into the supernatant, but it might not be correctly folded because 
of the lack of the disulfide bridge in the α2 domain. Therefore, these molecules are not 
detected by the conformational anti-HLA-ABC mAb. This assumption arose after comparing 
mRNA and associated protein levels of HLA-A*30:14L and HLA-A*30:01 alleles (Hinrichs et 
al. 2009). Additionally, it was found that HLA-A*30:14L accumulates inside the cells; 
therefore, it might be a major substrate for proteasomal cleavage and could provide a flood 
of peptide fragments presented to cytotoxic T lymphocytes. As a result of this indirect 
allorecognition pathway, GvHD or graft rejection might be promoted in the event of a 
severe mismatch. 
It was shown for the first time that an HLA low expression allele (HLA-A*30:14L) presents 
peptides with identical features to those of its most closely related relative, HLA-A*30:01 
(Hinrichs et al. 2010). The results indicate that a mismatch at amino acid position 164 might 
be permissive. Therefore, mismatching of these alleles will presumably be of low 
allogenicity in allogeneic HSCT. The fact that a low expression variant is not only functional 
and able to present peptides, but also shares epitopes with its related variant leads to the 
conclusion that low expression variants need to be considered in donor selection as 
permissive or non-permissive mismatches, respectively. Increasing knowledge of the 
expression behavior of HLA expression variants, such as L and Q alleles, will help to 
improve HLA allogenicity prediction algorithms by delivering proof that these variants are 
fully functional. Taking all relevant factors into account, the results shown allow to predict 
the immunogenicity of aberrantly expressed alleles in a transplant setting. 
In the case of HLA-A*30:14L misinterpreting it as a null allele is, in case of a mismatch with 
any other HLA-A allele, potentially more dangerous in terms of GvHD and graft rejection 
according to the direct and indirect allo-recognition pathway than a mismatch with its most 
related allele HLA-A*30:01. Indeed, mistyping HLA-A*30:14L as an N allele has led to a 
severe GvHD in a patient transplanted with hematopoietic stem cells from an HLA-A*02:01 
homozygous donor (Hirv et al. 2006).  
In order to predict the relevance of similar alleles with disulfide bridge rearrangements (e.g., 
HLA-A*32:11Q and B*35:65Q) in allogeneic HSCT, it is important to know their surface 
expression as well as their peptide binding of HLA variants. From a clinical perspective, 
HLA variants with similar disulfide bridge variations need to be considered as functionally 
active in an allogeneic HSCT setting as long as the opposite has not been shown.  
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complexes can be detected. This suggests that parts of soluble HLA-A*30:14L molecules are 
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detected by the conformational anti-HLA-ABC mAb. This assumption arose after comparing 
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allorecognition pathway, GvHD or graft rejection might be promoted in the event of a 
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be permissive. Therefore, mismatching of these alleles will presumably be of low 
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1. Introduction  
1.1 Background (Schmid, Schmetzer) 
Highly specialized and sensitive defence against infections as well as tumors is provided in 
great part by the adaptive, T-cell-mediated part of our immune system. Those T-cell 
specialists arise out of a cell pool of 25-100 million distinct naïve T-cell clones, after a very 
efficient priming phase by dendritic cells (DC), that present antigens in the context of major 
histocompatibility complexes (MHC), T-cell receptors (TCR) and costimulatory signals. It is 
well known, that T-cells are most important  effectors of cellular tumor immunity and carry 
long lasting  memory. Therefore recent tumor research has focused on the development and 
improvement of T-cell based immunotherapies (Barrett & Le Blanc, 2010; Smits et al., 2011). 
The T-lymphocyte pool includes naïve (Tnaive), effector (Teff), effector memory (Tem) and 
central memory (Tcm), either CD8 or CD4 T-cells. After an antigen driven TCR engagement 
Tnaive proliferate and give rise to large numbers of Teff. Most of them die after depleting 
target cells. Some ‘memory T-cells’ of either Tcm or Tem phenotype remain, persist and can 
differentiate to Teff after a re-challenge with antigens. It has been demonstrated that memory 
T-cells are able to self-renewal and differentiation (Sallusto et al., 2005). However antitumor 
immunity is limited by regulatory T-cells (Treg) that are in general responsible for the 
prevention of autoimmunity, regulation of inflammatory antimicrobial or antitumor 
reactions and are regarded as the mediators of tolerance (Vignali et al., 2008). Treg reactions 
can be either mediated by inhibitory cytokines (IL-10, IL-35, TGF-ß), Granzyme A/B 
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1. Introduction  
1.1 Background (Schmid, Schmetzer) 
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histocompatibility complexes (MHC), T-cell receptors (TCR) and costimulatory signals. It is 
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long lasting  memory. Therefore recent tumor research has focused on the development and 
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target cells. Some ‘memory T-cells’ of either Tcm or Tem phenotype remain, persist and can 
differentiate to Teff after a re-challenge with antigens. It has been demonstrated that memory 
T-cells are able to self-renewal and differentiation (Sallusto et al., 2005). However antitumor 
immunity is limited by regulatory T-cells (Treg) that are in general responsible for the 
prevention of autoimmunity, regulation of inflammatory antimicrobial or antitumor 
reactions and are regarded as the mediators of tolerance (Vignali et al., 2008). Treg reactions 
can be either mediated by inhibitory cytokines (IL-10, IL-35, TGF-ß), Granzyme A/B 
dependent cytolysis, CD25 dependent IL-2 deprivation-mediated apoptosis, adenosine 
receptor mediated immunosuppression of  DCs’ maturation (Vignali et al., 2008). Treg 
subtypes can be identified by their expression profiles and be subdivided in resting or 
activated Tregs of either CD4 or CD8 subtype (Miyora et al., 2009; Jordanova et al., 2008; 
Schick et al., 2011). Resting Tregs can convert to activated Tregs after proliferation. The 
functional repertoire of T-cells depends on their survival and their cooperation via cellular 
contact and the secretion of humoral factors. Improved knowledge of these properties 
should contribute to detect or select T-cells with defined markers or functional profiles for 
adoptive therapy. 
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In the past the potential of adoptively transferred T-cells to eradicate tumor cells has been 
intensively studied in patients with melanoma, EBV-associated tumors and especially in 
the context of a transplantation of allogeneic hematopoietic stem cells including 
immunocompetent cells in patients with lymphoid- or myeloid-derived malignant 
diseases (Kahl et al., 2007; Kolb et al., 2004; Schmid et al., 2011; Parmar et al., 2011; 
Moosmann et al., 2010). 
In patients with acute myeloid leukemia (AML), a malignant clonal disease of the 
hematopoietic stem cells, conventional chemotherapy induces remission in 60- 80% of 
patients. However, relapse occurs in the majority of patients in the following two years 
(Buechner et al., 2003). Allogeneic stem cell transplantation (SCT) is considered as a curative 
therapy for patients with AML: Following engraftment of donor cells, the established 
hematopoietic chimerism persists even after discontinuation of immunsuppressive therapy, 
reflecting tolerance both in Graft-versus-Host and Host-versus-Graft direction (Kolb et al., 
2004; Schmid et al., 2011). T-cells of the healthy donor mediate the ‘graft versus leukemia’ 
(GvL), effect which was perceived in principle as early as in the 1960ies. Clinical evidence 
for the efficacy of GvL reactions in AML came from the observation, that  leukemia relapse 
after allogeneic SCT, the most frequent reason of treatment failure in AML, occurred most 
frequently in patients who had either been transplanted from a syngeneic twin, or had 
received a graft which had been depleted from donor T-cells prior to transfusion. In 
contrast, relapse incidence was lowest in patients developing acute or chronic Graft-versus-
Host Disease (GvHD), which represents the second clinical manifestation of the allogeneic 
immune reaction mediated by donor T-cells (Hemmati et al., 2011; Schmid et al., 2007; 
Schmid et al., 2011;  van den Brink et al., 2010). Based on these observations, the infusion of 
donor lymphocytes (DLI) was developed as a form of immunotherapy for relapsed disease 
after allogeneic SCT. However, up to now, not every patient, in particular those with rapidly 
proliferating AML, responds to or permanently benefits from those T-cell based 
immunotherapy.  
1.2 Aims (Schmetzer) 
The ability of T-cells to eliminate tumor cells and even to cure tumors has been 
demonstrated in experimental animal models. In man the development of effective T-cell 
therapies to treat human tumors remains still a challenge. Tumor antigens that elicit curative 
responses have been identified in animal models; in man tumor associated antigens are also 
known, but their use is limited due to HLA-restriction and limited duration of responses. 
This applies also to hematological malignancies as AML. In the last years several 
approaches have been made to further characterize T-cells and to explore the role of soluble 
and cellular factors on the regulation and mediation of antitumor reactions in AML-patients. 
Known tumor antigens may help to identify specific T-cells and their subtypes. This could 
be monitored in the course of treatment and they could be prepared for further treatment. 
However the majority of potential tumor antigens is unknown. Their presence may be 
deduced from T-cell reactions initiated and mediated by leukemia-derived dendritic cells 
(DC), presenting the whole antigenic repertoire of the leukemic cell. In analogy to T-cell 
reactions against known tumor antigens DC-stimulated T-cells reacting against unknown 
tumor antigens may be analysed against healthy cells before further use. In addition the 
identification of possible immune escape phenomena in cases without successful SCT or DLI 
or without antileukemic functions ex vivo could contribute to develop strategies to overcome 
those immunological barriers.  
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In this chapter we want to present experimental and clinical results of our group with a 
special focus on the following topics and discuss perspectives for future therapies: 
 T-cells addressing known (leukemia-) specific antigens 
 T-cells addressing unknown leukemia-specific antigens 
 T-cell profiles to predict antileukemic reactions and prognosis 
 Clinical use of donor T-cells for prevention and treatment of AML relapse after 
allogeneic SCT 
 Perspectives for future therapies: adoptive transfer or in vivo activation of antileukemic 
T-cells? 
2. Research methods (Schmetzer) 
Cellular characterizations (especially of T-cells, leukemic blasts and dendritic cells) were 
performed by Flow Cytometric Analyses applying a panel of marker-specific, fluorochrome 
labelled monoclonal antibodies: T-cells: Naïve T-cells (Tnaive) CD45RO-CCR7+; non-naïve T-
cells (Tnon-naïve) CD45RO+; central memory T-cells (Tcm) CD45RO+CCR7+CD8+; Effector 
memory T-cells (Tem) CD45RO+CCR7-CD27+; Effector T-cells (Teff) CD45RO+CCR7-CD27-; 
Regulatory T-cells (CD8+Treg) CD8+CD25+CD127low; (CD4+Treg) CD4+CD25+CD127low; (Tnaive 
reg) CD25+CD127lowCCR7+CD45RO-; (Tcm reg) CD25+CD127lowCCR7+CD45RO+; (Teff/em reg) 
CD25+CD127lowCCR7-CD45RO+ (Liepert et al., 2010; Vogt  et al., 2011; Schick et al., 2011). 
Blasts: Myeloid cells co-expressing patient-specific markers (e.g. CD34, CD117, CD56, 
CD65); DC: DC co-expressing DC-antigens; Mature DC: DC coexpressing CD83; DCleu: DC 
coexpressing DC-antigens (e.g. CD80, CD86, CD40) with blast-markers; (Schmetzer et al., 
2007; Kremser et al., 2010). Untouched or touched CD4+, CD8+ or CD3+ T-cells were isolated 
by Magnetic labelled cell sorting (MACS) (Schick et al., 2011; Vogt et al., 2011; Grabrucker et 
al., 2010), leukemia-antigen specific T-cells by Interferon gamma (IFN-γ) capture assay 
(Neudorfer et al., 2007) or by MHC-multimer  (Streptamers) staining for several described 
leukemia associated antigens  (Knabel et al., 2002). In some cases spectratyping analyses were 
performed to observe clonal restriction among T-cells characterized by defined T-cell receptor- 
Vß chains (Schuster et al., 2008). The expression of leukemia-associated antigens (LAA; e.g. 
WT1, PRAME, PR1) was evaluated by PCR-technology (Steger et al., 2011). ‘Taq man low 
density arrays’ were used to study expressions of most of the known protein-coding Y-
chromosome genes (Liu et al., 2005). To predict the HLA-A0201 binding potential of selected 
peptides a HLA-A0201 peptide binding assay was performed by using the HLA-A0201 
positive TAP-deficient T2 cell line system (Nijman et al., 1993; Saller et al., 1985). Leukemic 
blasts were cultured in ‘DC-media’ containing a cocktail of immune-modulators and 
cytokines, (thereby converting blasts to leukemia-derived DC (DCleu), theoretically presenting 
the whole leukemic antigen spectrum (Kremser et al., 2010; Schmetzer et al., 2007).  
Alternatively LAA/HA1 or ‘male specific’ antigens were loaded as peptides or full length 
proteins on either unmanipulated or irradiated antigen presenting cells (APC; e.g. MNCs or 
CD4 cell depleted cell fraction (Adhikary et al., 2008),  EBV-transformed B-cells ‘mini-LCL’ 
or DC (Moosmann et al., 2002) were irradiated with 45/80 Gray and used for T-cell 
stimulations as given in figure 3.1.3-1 ( Steger et al., 2012; Bund et al., 2011). Antileukemic 
reactivity of T-effector cells was measured by chromium release-, IFN-γ ELISPOT assays or 
non-radioactive Fluorolysis assays (Bund et al., 2011; Kremser et al., 2010). Intracellular 
cytokine staining (ICS) and cytokine release profiles were performed by FACS (Cytometric 
Bead arrays (CBA)), ELISA or ELISPOT (Elbaz & Shaltout 2001; Schmittel 2000;  Fischbacher 
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et al., 2011; Merle et al., 2011; Bund et al., 2011). In a dog model we performed in addition an 
in vivo immunisation with antigen positive cells (Bund et al., 2011). 
Using these methods we could evaluate antigen expression profiles on T-cells, antigen 
presenting cells or blast cells as well as cytokine secretion profiles assigning these profiles to 
cellular subtypes and correlate them with antileukemic reaction profiles or the clinical 
response to immunotherapies. Moreover we could contribute and quantify reaction profiles 
of ‘antigen stimulated’ or ‘-unstimulated’ as well as of (specifically) selected, enriched or 
cloned T-cells against blast targets. Statistical evaluations were performed with standard 
excel programmes or SPSS software.  
3. Experimental key results 
In the following chapter the most important experimental  results generated by our group 
are summarized. Responsible co-workers and cooperation partners are given and their 
contributions listed below. 
3.1 T-cells addressing known (leukemia-) specific antigens  
3.1.1 Y-chromosome encoded proteins overexpressed in acute myeloid leukemia and 
CD8+ T-cell reactions (Groupleaders: Kolb, Adamski; Scientists: Bund, Gallo)  
In haploidentical SCT we and others observed that female-donors (especially mothers) show 
a higher GvL reactivity against male-patients (particularly sons) compared to all other 
haploidentical donor-recipient combinations for AML patients (Stern et al., 2008). These 
effects could be due to Y-chromosome-encoded male minor histocompatibility antigens 
(minor-H-Ags, mHAs) recognized by female alloimmune effector (memory) T-cells, 
immunized during pregnancy, in the context of a GvL-reaction (Ofran et al., 2010). We 
studied the expression profiles of Y-chromosome genes in healthy male stem cell donors 
compared to male AML patients in order to possibly detect new AML-typical Y-restricted 
expression patterns. Blasts from male patients with acute (myelo) monocytic leukemia and 
monocytes from healthy male donors as the healthy control counterpart were used to 
determine and compare the expression profiles of Y-chromosome genes. We could detect 
several genes being up-regulated in male AML-cells. Among those, we focused on PCDH11, 
VCY, TGIF2LY, known to be expressed only in male tissues and its X-chromosome-encoded 
homolog TGIF2LX (Blanco-Arias et al., 2002; Skaletsky et al., 2003; Gallo et al., 2011). In a 
next step, we studied the immunological impact of the identified Y-encoded genes. We 
analyzed the proteins encoded by those four genes for the presence of nonameric peptides 
that could potentially bind HLA-A0201 molecules. Such analysis was performed with the 
help of publicly available peptide-motif scoring systems (http://bimas.dcrt.nih.gov/molbio/ 
hla_bind/ and http://www.syfpeithi.de; Rammensee et al., 1995). High-scoring peptides were 
not found for PCDH11, whereas HLA-A0201-binding peptides could be identified in silico 
for the VCY, TGIF2LY and TGIF2LX genes. Their effective binding efficacy was determined 
in a standard HLA-A0201-T2 binding assay: Two peptides derived from VCY as well as 
from TGIF2LX and one derived from TGIF2LY were able to bind to the HLA-A0201-
molecules of the T2 cells. Furthermore these peptides were tested for their ability to induce a 
CD8+ T-cell response: we selected CD3+ T-cells from female volunteers and cultured them 
in the presence of T2 cells loaded with the different Y-chromosome-encoded peptides for 
four weeks. We could show that the VCY-encoded peptide G54 stimulated female effector T-
cells as shown by a specific lysis of G54-loaded T2 target cells in a chromium release assay 
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(Figure 3.1.1-1). Further research will focus on the immunogenic G54-peptid particularly 
with respect to our assumption that mothers (who had given birth to a son) bear CD8+ T-
cells being reactive to male-specific antigens, leading to a strong GvL effect. Moreover, 
peptides restricted to other HLA-types will also be investigated. 
In conclusion we identified three new potentially antileukemic, male-specific human genes 
being upregulated in blasts of male AML-patients. These might be valuable targets for T-cells.  
As a rule Y-chromosome coded antigens are expressed in all cells of the organism. However 
some data have been reported, that differentially spliced forms of the Y-linked UTY 
(ubiquitously-transcribed tetratricopeptide-repeat-gene, Skaletsky et al., 2003) may be 
restricted in a tissue restricted fashion (Warren et al., 2000). UTY is highly conserved in man 
and animal species. We worked out in a dog model in vitro and in vivo that the Y-
chromosome coded mHA UTY might be a promising candidate target-structure to improve 
GvL immune reactions after SCT: female T-cells were stimulated with either autologous 
(female) DCs, loaded with three different UTY-derived (male) peptides or with allogeneic, 
donor-matched male cells (PBMCs) endogenously expressing UTY. We identified 3 out of 15 
identified UTY-encoded peptides bearing immunological potential to stimulate ‘antimale’-
(i.e. anti-UTY-) directed immune reactions. Amongst those, W248 showed highest 
immunogenic potential in both in vitro and in vivo settings: In vitro expanded CTLs 
specifically recognized mainly bone-marrow (BM) from DLA-identical male littermates in 
an MHC-I-restricted manner (Figure 3.1.1-2; in vitro). In vivo, comparable W248-(UTY-) 
specific reactivity against BM was also obtained after stimulation and immunization of a 
female dog with DLA-identical male PBMCs (Table 3.1.1-1; in vivo (Bund et al., 2001)).  
 
 
T2-cells were loaded with the VCY-derived G54-peptide and incubated with female HLA-A0201+ T-cells 
for 4 weeks. Cytotoxic activity of the generated G54-specific CTLs were tested in Chromium release assays 
(E:T = 8.75:1 to 50:1). T-cells specifically lysed T2-cells loaded with the cognate peptides G54 (G54, ● red). 
T2-cells alone (T20, ○), T2-cells loaded with I540S (non-HLA-A0201 binding; HFLLWKLIA; T2+I540S, ▲) 
and K562-cells (NK-cell target, ×) were not recognized or only to a low extent 
Fig. 3.1.1-1. Female T-cells stimulated with the Y-chromosomally encoded G54-peptid can 
specifically lyse T2-cells loaded with G54 in vitro.  
 
New Advances in Stem Cell Transplantation 
 
62
et al., 2011; Merle et al., 2011; Bund et al., 2011). In a dog model we performed in addition an 
in vivo immunisation with antigen positive cells (Bund et al., 2011). 
Using these methods we could evaluate antigen expression profiles on T-cells, antigen 
presenting cells or blast cells as well as cytokine secretion profiles assigning these profiles to 
cellular subtypes and correlate them with antileukemic reaction profiles or the clinical 
response to immunotherapies. Moreover we could contribute and quantify reaction profiles 
of ‘antigen stimulated’ or ‘-unstimulated’ as well as of (specifically) selected, enriched or 
cloned T-cells against blast targets. Statistical evaluations were performed with standard 
excel programmes or SPSS software.  
3. Experimental key results 
In the following chapter the most important experimental  results generated by our group 
are summarized. Responsible co-workers and cooperation partners are given and their 
contributions listed below. 
3.1 T-cells addressing known (leukemia-) specific antigens  
3.1.1 Y-chromosome encoded proteins overexpressed in acute myeloid leukemia and 
CD8+ T-cell reactions (Groupleaders: Kolb, Adamski; Scientists: Bund, Gallo)  
In haploidentical SCT we and others observed that female-donors (especially mothers) show 
a higher GvL reactivity against male-patients (particularly sons) compared to all other 
haploidentical donor-recipient combinations for AML patients (Stern et al., 2008). These 
effects could be due to Y-chromosome-encoded male minor histocompatibility antigens 
(minor-H-Ags, mHAs) recognized by female alloimmune effector (memory) T-cells, 
immunized during pregnancy, in the context of a GvL-reaction (Ofran et al., 2010). We 
studied the expression profiles of Y-chromosome genes in healthy male stem cell donors 
compared to male AML patients in order to possibly detect new AML-typical Y-restricted 
expression patterns. Blasts from male patients with acute (myelo) monocytic leukemia and 
monocytes from healthy male donors as the healthy control counterpart were used to 
determine and compare the expression profiles of Y-chromosome genes. We could detect 
several genes being up-regulated in male AML-cells. Among those, we focused on PCDH11, 
VCY, TGIF2LY, known to be expressed only in male tissues and its X-chromosome-encoded 
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not found for PCDH11, whereas HLA-A0201-binding peptides could be identified in silico 
for the VCY, TGIF2LY and TGIF2LX genes. Their effective binding efficacy was determined 
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in the presence of T2 cells loaded with the different Y-chromosome-encoded peptides for 
four weeks. We could show that the VCY-encoded peptide G54 stimulated female effector T-
cells as shown by a specific lysis of G54-loaded T2 target cells in a chromium release assay 
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(Figure 3.1.1-1). Further research will focus on the immunogenic G54-peptid particularly 
with respect to our assumption that mothers (who had given birth to a son) bear CD8+ T-
cells being reactive to male-specific antigens, leading to a strong GvL effect. Moreover, 
peptides restricted to other HLA-types will also be investigated. 
In conclusion we identified three new potentially antileukemic, male-specific human genes 
being upregulated in blasts of male AML-patients. These might be valuable targets for T-cells.  
As a rule Y-chromosome coded antigens are expressed in all cells of the organism. However 
some data have been reported, that differentially spliced forms of the Y-linked UTY 
(ubiquitously-transcribed tetratricopeptide-repeat-gene, Skaletsky et al., 2003) may be 
restricted in a tissue restricted fashion (Warren et al., 2000). UTY is highly conserved in man 
and animal species. We worked out in a dog model in vitro and in vivo that the Y-
chromosome coded mHA UTY might be a promising candidate target-structure to improve 
GvL immune reactions after SCT: female T-cells were stimulated with either autologous 
(female) DCs, loaded with three different UTY-derived (male) peptides or with allogeneic, 
donor-matched male cells (PBMCs) endogenously expressing UTY. We identified 3 out of 15 
identified UTY-encoded peptides bearing immunological potential to stimulate ‘antimale’-
(i.e. anti-UTY-) directed immune reactions. Amongst those, W248 showed highest 
immunogenic potential in both in vitro and in vivo settings: In vitro expanded CTLs 
specifically recognized mainly bone-marrow (BM) from DLA-identical male littermates in 
an MHC-I-restricted manner (Figure 3.1.1-2; in vitro). In vivo, comparable W248-(UTY-) 
specific reactivity against BM was also obtained after stimulation and immunization of a 
female dog with DLA-identical male PBMCs (Table 3.1.1-1; in vivo (Bund et al., 2001)).  
 
 
T2-cells were loaded with the VCY-derived G54-peptide and incubated with female HLA-A0201+ T-cells 
for 4 weeks. Cytotoxic activity of the generated G54-specific CTLs were tested in Chromium release assays 
(E:T = 8.75:1 to 50:1). T-cells specifically lysed T2-cells loaded with the cognate peptides G54 (G54, ● red). 
T2-cells alone (T20, ○), T2-cells loaded with I540S (non-HLA-A0201 binding; HFLLWKLIA; T2+I540S, ▲) 
and K562-cells (NK-cell target, ×) were not recognized or only to a low extent 
Fig. 3.1.1-1. Female T-cells stimulated with the Y-chromosomally encoded G54-peptid can 
specifically lyse T2-cells loaded with G54 in vitro.  
 









In vitro 80:1 
BM 85 
BM + <anti MHC-I antibody> 24 
In vivo 20:1 
BM 45 
BM +  <anti MHC-I antibody> 25 
BM + W248-peptide 35 
BM + W248-peptide + 
<anti MHC-I antibody> 15 
BM bone marrow; <MHC-I>=<MHC-I>-antibody. 
* E:T= Effector-to-target-ratio 
**number of UTY-specific spots per 100,000 T-cells 
T-cells from female dog(s) were expanded using autologous DCs pulsed with the UTY-encoded peptide 
W248 (in vitro; n=3/6) or male DLA-identical PBMCs (in vivo; n=1). Female UTY-specific T-cell 
recognition was determined in IFN-γ-ELISPOT-assays (day 21-28 (E:T = 80:1) and day 49 (E:T = 20:1), 
respectively). Female T-cells mainly recognized male DLA-identical BM in vitro and in vivo verifying the 
male-specific UTY-presentation. T-cells` MHC-I-restriction was shown by an anti-MHC-class-I-mAb. 
Table 3.1.1-1 Female dog T-cells stimulated with UTY (W248)-peptides loaded on 
autologous DC in vitro or male DLA-identical PBMC in vivo specifically recognized  ‘male’ 
target cells 
Taken together we could demonstrate, that female dog effector T-cells could be specifically 
stimulated against male, UTY-gene product specific cells meaning in turns, that UTY seems 
to be a promising candidate antigen to improve GvL reactions after SCT.  
3.1.2 LAA-specific CD8+ T-cells (Groupleaders: Busch, Borkhardt, Kolb; scientists: 
Doessinger, Steger, Schuster) 
Between 60-90% of AML cases overexpress leukemia-associated antigens (LAA), that means 
antigens that are absent or only weakly expressed in normal tissues (e.g. WT1, PR1 or 
PRAME (Greiner et al., 2006; Steger et al., 2011)). Therefore T-cell based immunotherapeutic 
strategies addressing those LAA-expressing cells could be promising. Alternatively mHAs, 
preferentially expressed on hematopoietic cells, could qualify as T-cell targets in a GvL 
reaction (Mutis & Goulmy, 2002). Principally T-cell based strategies could be based on a 
vaccination with LAA/mHAs or by identification, selection and transfer of LAA/mHAs 
specific T-cells already present in the donor. LAA/mHAs specific T-cells can be found at a 
low frequency in normal persons implying a low level of immunity. Vice versa a long 
lasting immunity against leukemic cells overexpressing LAA or mHAs should imply the 
presence of specific T-cells. Therefore our experimental approach was to detect LAA-specific 
T-cells by MHC-multimer technology in AML patients after SCT. We constructed human 
HLA-A2 peptide multimers (Knabel et al., 2002) and tested CD8+ T-cells in 5 AML- and 2 
MDS-patients after SCT for antigen specificity, as given in table 3.1.2-1 
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t (8;22) 0 nd nd nd nd nd ICS, LAA, CD4+  exp. 
nd not done; CR complete remission; Rel. relapse; MDS myelodysplastic syndrome; RAEB Refractory 
Anaemia with Excess Blasts; AML-M3 acute myeloid leukemia FAB M2; CMML Chronic 
Myelomonocytic Leukemia; LAA leukemia associated antigen, overexpression analyses compared to 
healthy controls, detected by the RQ= 2-ΔΔct method in MNCs; dgn. diagnosis; ICS intracellular staining; 
CD4+ exp. CD4+ experiments 
Table 3.1.2-1 Patients’characteristics I:  
In all of these 7 cases we could detect LAA-specific CD8+ T-cells (that means more than 
0.1% T-cells with LAA specificity) –although not directed against all given LAA, suggesting 
the persistence of T-cells with antileukemic potential (table 3.1.2-1 and fig 3.1.2-2). Four of 
five cases with two different types of LAA- specific CD8+ T-cells (pt 1149, 1151, 1152, 1153) 
were characterized by long-lasting clinical remissions for more than 2 years. One patient 
with two different types of LAA-specific CD8+ T-cells relapsed after 9 months (pt 1151) and 
in addition the patient with only one type of LAA-specific T-cells, who relapsed after one 
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year (pt 1147). One patient could not be analysed under a clinical point of view since he died 










staining (% of 
specific CD8+ T- 
cells) 
Cytokine profile 
(IFN-γ, IL-2) after 
LAA-stimulation 
Time to relapse or 
last follow up 
CD 4+/C8+ T-cells  
pt 1147 nd 
A2/WT1 0.11 
A2/PR1 0.13  
A2/PRAME 0.034 
NR/NR 
04/07 local rel.; 
08/09  systemic 
rel., 05/11 CR after 
2nd SCT, DLI and 
3th rel. 





03/06 death with 
infect in CR after 
SCT




NR/NR until 02/11 in CR after SCT 




NR/NR until 03/11 in CR after SCT 





11/06 rel; 04/07 
death  after  3th 
DLI, rel. and 2nd 
SCT  























nd NR/NR until 07/11 in CR after SCT 
No LAA overexpression (-), 1–10x LAA overexpression (+), compared to healthy controls, analysed by 
the RQ= 2-ΔΔct method; nd not done  
Bold: > 0.1% CD8+ T-cells defined as ‘LAA-specific T-cells present’; * restricted T-cells by spectratyping 
in PRAME- MHC multimer selected T-cells detectable 
Table 3.1.2-2 Anti-LAA-peptide reactive T-cells are detectable by MHC-Multimer staining in 
all given PB samples from AML/MDS patients after allogeneic SCT 
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In one case (pt 1152) we performed spectratyping in T-cells selected for PRAME-specificity 
and could demonstrate a highly restricted TCR-repertoire. This points to a specific clonal 
expansion of CD8+ cells after (in vivo) PRAME challenge by residual PRAME overexpressing 




a) representative FACS-plot shows MHC-Multimer staining from peripheral blood of an AML-patient 
after SCT. 
b) LAA-specific T-cells from PBMCs from AML-pts after SCT were labelled with MHC multimers 
binding T-cells, that recognize frequently overexpressed LAA antigens. PBMCs were analyzed by 
FACS. Healthy donors served as controls and multimer-staining revealed a threshold value of 0.11% 
multimer-positive cells in the CD8 cell fraction.  
c) MHC-multimer positive CD8+ T-cells from peripheral blood of an AML-patient after SCT were 
enriched by FACS sorting. RNA was extracted and Spectratyping of the Vβ-composition reveals strong 
clonal restriction among TCR-species (1rd row: Vß3-Jß1.5; 2nd row: Vß3-Jß2.1; 3rd row: Vß3-Jß2.5) 
 
Fig. 3.1.2-1. LAA-specific T-cells can be isolated from AML-patients after SCT by MHC 
multimer technique. Selected T-cells are highly Vß restricted 
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Upon in vitro peptide-challenge we could not detect secretion of IFN-γ or IL-2 in T-cells by 
intracellular cytokine staining in 7 out of 8 patients tested (table 3.1.2-2). This however does 
not exclude a cytokine-independent functionality of multimer positive T-cells. Interestingly 
we could detect an IFN-γ response in CD4+ T-cells in one case (pt 1153) with PRAME 
overexpressing leukemic blasts detectable during persisting relapse after SCT. This is very 
surprising as the peptide triggering this response is MHC class I restricted and could 
indicate a CD8 coreceptor independent binding of a MHC I directed TCR and an unusual 
involvement of CD4+ T-cells in the leukemia directed immune response.  
In summary that means, that in general LAA-specific, HLA-A2-restricted CD8+ T-cells can 
be prepared by MHC multimer technology from most of the patients after SCT at various 
time points. Possibly the simultaneous detection of two different LAA-specific CD8+ T-cells 
correlates with a higher chance of longlasting remissions. Optimal time points have to be 
evaluated for the preparation of (sufficient) LAA-specific CD8+ T-cells that could be used 
for adoptive transfer and concerning minimal amounts needed for maintenance of 
remission. 
3.1.3 LAA-specific CD4+ T-cells (Groupleaders: Buhmann, Milosevic, Kolb, 
Schmetzer; scientists: Steger) 
CD8+ T-cells recognize HLA-class I restricted peptides, therefore they can mediate strong 
cytotoxic, antileukemic reactions, but also severe graft versus host (GvH) disease. In contrast 
CD4+ T-cells recognize HLA class II restricted peptides that are mainly expressed by cells of 
the haematopoetic system and absent from other organs. In order to further analyse the 
antileukemic function of CD4+ T-cells we prepared (untouched) CD4+ T-cells from 6 
patients, as given in table 3.1.3-1, after SCT or DLI immunotherapies and stimulated them 
with LAA-proteins (WT1, PRAME, PR1 and the mHA HA-1), that were loaded on the CD4 
depleted cell fraction (containing monocytes and DC as antigen presenting cells (APCs)) or 
on ‘mini-LCL’. 
During the stimulation phase the cells lost their naïve (and central memory) T-cell 
phenotype and gained an effector memory or effector cell phenotype (data not shown). 
As already shown for CD8 selected T-cells cytokine release assays for IFN-γ (ELISPOT, ICS) 
or GM-CSF (ELISA) did not reveal  clear and specific cytokine release profiles of LAA or 
HA-1 stimulated, expanded or cloned CD4+ T-cells (data not shown).  
Therefore we performed  a functional Fluorolysis assay in case pt 1158: blast cells of the 
patient, that were characterized by a overexpression of WT1, PRAME and PR1 at first 
diagnosis served as leukemic target and  fibroblasts, effector cells or non-blast cells of the 
patient as negative controls. Effector cells (E) used for these assays were: unstimulated  MNC, 
CD3+ or CD4+ T-cells obtained in different stages of the disease, LAA or HA-1 stimulated 
CD4+ T-cells in different stimulation phases, enriched proliferating and CD40L+ CD4+ cells 
before or after single cell cloning (table 3.1.3-2).  
We could demonstrate that most of the CD4+ T- cell containing effector cell fractions (except 
MNCs before SCT, CD4+ T-cells after 16 stimulation rounds (E11) and two of the CD4+ T-
cell clones (E13, E15)) were able to regularly and specifically lyse leukemic blasts, but not 
fibroblasts or non-blast-cells of the patient. Highest antileukemic activity was demonstrated 
for enriched proliferating and CD40L+CD4+ T-cells followed by one of the three tested 
clones. Unfortunately despite of provable (CD4+) immunity against leukemic cells the 
patient died two years after SCT in hematological CR from a myocardial chloroma. 
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Patients (pt) Dgn. 









 in addition 
 to CD4+experiments 
pt 1153 MDS-CMML Pers after SCT 8 
CD4+,  CD8+, 
MNCs 
ICS, IFN-γ  ELISPOT, 
MHC-Multimer  
staining, LAA analyses  
pt 1154 MDS-RAEB II CR after SCT 0 
CD4+,  CD8+, 
MNCs
ICS, IFN-γ  ELISPOT, 
LAA analyses 




CR after SCT 0 CD4+,  CD8+, MNCs 
ICS, IFN-γ  ELISPOT,  






CR after SCT 0 CD4+ IFN-γ  ELISPOT 
pt 1157 AML-M4 CR after SCT 0 CD4+ IFN-γ  ELISPOT 
pt 1158 a (‘E1’) AML-M4 CR before SCT 0 MNCs 
LAA analyses, 
Fluorolysis assay 
pt 1158 b (‘E2’) AML-M4 
CR after 1st
SCT and 1st 
DLI
0 CD4+  Fluorolysis assay 
pt 1158 c (‘E3’) 
pt 1158 d (‘E12’: after P5) 
pt 1158 e (’E11’: after P16) 
pt 1158 f (‘E6’: after P17,FACS-
Sort,  P14) 
pt 1158 g, h, i (‘E13, 14, 15’ clones, 
after FACS-Sort,  P14)
AML-
M4 
CR after 1st 
SCT and 1st 
DLI 
0 CD4+ 
ICS, IFN-γ  ELISPOT, 
GM-CSF ELISA , 
Fluorolysis assay 
pt 1158 p (‘blast targets’) AML-M4
Rel. after 1st SCT 
and  2nd DLI 34 
CD3 depleted 
blasts  Fluorolysis assay 
pt 1158 j (‘E4’) AML-M4
Rel. after 1st SCT 
and 2nd DLI nd CD4+ Fluorolysis assay 
pt 1158 k (‘E5’) AML-M4
CR after 2nd SCT 
and 4th DLI 0 CD4+ Fluorolysis assay 
pt 1158 l (‘E16’) AML-M4
CR after 2nd SCT 
and 4th DLI 0 CD4+ Fluorolysis assay 
pt 1158 m, n, o (‘E7, 8, 9’) AML-M4
CR after 2nd SCT 





Dgn. diagnosis; Pers persistant disease; Rel. relapse;  CR complete remission; MDS myelodysplastic 
syndrome; RAEB Refractory Anaemia with Excess Blasts; AML-M3 acute myeloid leukemia FAB M3; 
CMML Chronic Myelomonocytic Leukemia; LAA leukemia associated antigen, overexpression 
analyses compared to healthy controls, detected by the RQ= 2-ΔΔct method in MNCs; E effector cells 
prepared at different time points in the course of the disease or after stimulation with CD4 depleted 
LAA/HA1 protein loaded APCs; P passage after x stimulations with CD4 depleted LAA/HA1 
protein loaded APCs, nd not done; 
Table 3.1.3-1 Patients´ characteristics II:  
A flow chart with the methodological strategy to create LAA-presenting nonCD4+ cells or 
mini-LCL is given in figure 3.1.3-1. We could demonstrate that in general it is possible to 
stimulate untouched CD4+ T-cells using the CD4 depleted fraction or ‘mini-LCL’ as 
stimulator fraction. Furthermore we enriched LAA-stimulated cells from these stimulation 
settings by either enrichment of proliferating, CD40L+CD4+ T-cells or by T-cell single-cell 
cloning after repeated stimulation with LAA- and HA-1-  loaded stimulator cells. Resulting 
cells were characterized by proliferation, CD40L upregulation and cellular expansion.  
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Table 3.1.3-1 Patients´ characteristics II:  
A flow chart with the methodological strategy to create LAA-presenting nonCD4+ cells or 
mini-LCL is given in figure 3.1.3-1. We could demonstrate that in general it is possible to 
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I. Untouched CD4+ T-cells prepared from AML patients’ PBMNC after SCT were stimulated (6-16 
stimulations with 20 U IL2 twice a month) with irradiated (43 Gy, 80 Gy by mini-LCLs), LAA/HA1 
protein loaded nonCD4 cells (as APCs) for 24h. Alternative stimulation of the nonCD4+ cell fraction 
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• 51 Cr  Chromium-release assay  
II. Stimulated CD4+ T-cells were characterized by ELISPOTS, ELISAS or ICS for secretion of IFN-γ or 
GM-CSF before or after single cell cloning or sorting of CD40L+ CFSElow cells. Moreover some cases 
were tested for antileukemic activity in a chromium-release or fluorolysis assay. 
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pt 1158 j 
(‘E4’) 
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SCT and 2nd 
DLI 
CD4+ 61 pt 1158 g (‘E13’) 





pt 1158 k 
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CR after 2nd 
SCT and 4th 
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MNCs 22 pt 1158 i (‘E15’) 0 
 
pt 1158 n 
(‘E8’) 
 
CD3+ 19 (38, 4h) 
pt 1158 l 
(‘E16’) 
CR after 2nd 




pt 1158 o 
(‘E9’) 
 
CD4+ 9 pt 1158 q  Myocardial Chloroma 
E effector cells prepared at different time points in the course of the disease or after stimulation with 
CD4 depleted LAA/HA1 protein loaded APCs (table 3.1.3-1); P passage after x stimulations with CD4 
depleted LAA/HA1 protein loaded APCs;  Exitus letalis 
Table 3.1.3-2 Antileukemic functionality (demonstrated by fluorolysis assay) of different 
CD4+ effector cells prepared before or after specific stimulation, enrichment or sorting  
In summary this means that the cytokine release of IFN-γ or GM-CSF is no reliable tool to 
detect specificity in T-cell fractions. We could demonstrate however, that CD4+ T-cells in 
general can mediate cytotoxic reactions and that certain enriched CD4+ subtypes might be 
even more promising candidates for GvL- without GvH reactions.  
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In summary this means that the cytokine release of IFN-γ or GM-CSF is no reliable tool to 
detect specificity in T-cell fractions. We could demonstrate however, that CD4+ T-cells in 
general can mediate cytotoxic reactions and that certain enriched CD4+ subtypes might be 
even more promising candidates for GvL- without GvH reactions.  
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3.2 T-cells addressing unknown leukemia-specific antigens 
3.2.1 Establishment and maintenance of protective immunity by dendritic cells 
derived from leukemic blasts (Groupleaders: Borkhardt, Buhmann, Schmetzer; 
Scientists: Fischbacher, Freudenreich, Grabrucker, Liepert, Merle, Reuther, Schick, 
Schuster, Vogt) 
Although technically possible the preparation of LAA-specific T-cells is cumbersome, in case 
of MHC-Multimer technology HLA-A2 restricted and moreover restricted to defined LAAs. 
Therefore we wanted to study the antileukemic activity of T-cells stimulated with DC 
derived from leukemic blasts (DCleu), as those DC bear the advantage of potentially 
presenting the whole (including as yet unknown) and patient-typical antigen pool of the 
leukemic cells. We have already established the methods to generate sufficient amounts of 
DC and especially of DCleu in every given case with AML: in a minimalized assay we 
cultured DC in three different media and choose the DC generation method with the 
quantitatively highest DC/DCleu counts (Kremser et al., 2010;  Schmetzer et al., 2007). In a 
next step we study the functional profiles of DC/DCleu-stimulated T-cells. We could 
demonstrate, that isolated unstimulated T-cells were able to lyse blasts in 47% of cases, 
whereas only 26% of those T-cells showed antileukemic activity after a 10 days culture with 
blasts – pointing to an establishment of a T-cell inhibitory microenvironment in the presence 
of blasts. However, stimulation of T-cells with blasts after their conversion to DCleu resulted 
in a blast lytic activity in 58% of all cases. These data suggest, that the inhibitory (blast-
induced) atmosphere could be abolished after blast-conversion to DCleu, although not 
completely: even a DC/DCleu stimulation of T-cells was not effective to induce antileukemic 
T-cells in every case (Schmetzer  et al., 2011; Grabrucker et al., 2010). Therefore we analysed 
potential conditions and factors being responsible for these impaired immune reactions. We 
could demonstrate that the quality of DC – especially with respect to proportions of mature 
DC and DCleu – is predictive for their activation capacity for antileukemic T-cells. Those 
DC/DCleu induce an ‚antileukemically effective’ T-cell composition of DC-stimulated T-cells, 
characterized by higher proportions of CD4+ and non-naive T-cells (Grabrucker et al., 2010; 
Liepert  et al., 2010). A detailed analysis of T-cells’ compositions in cases with compared to 
those without antileukemic activity revealed significantly higher proportions of naïve (Tnaive)  
and central memory T-cells (Tcm) and lower proportions of effector memory regulatory 
(Teff/em reg) as well as CD8+ regulatory T-cells (CD8+ Treg) (Schick et al., 2011; Vogt et al., 
2011). Moreover we could define soluble factors that are predictive for the mediation of 
antileukemic activity of DC/DCleu-stimulated T-cells: A higher release of ‘inflammatory’ 
chemokines (CXCL8, CCL2) in DC culture supernatants or of ‘T-cell-promoting’ cytokines 
(IFN-γ, IL-6) in mixed lymphocyte culture (MLC) supernatants of T-cells with DC clearly 
correlated with antileukemic activity of DC-stimulated T-cells (Fischbacher et al., 2011; 
Merle et al., 2011; Schmetzer  et al., 2011).  
Detailed studies of T-cell subsets via spectratyping analysis could verify that especially after 
DC-stimulation CD4+ as well as CD8+ T-cells were characterized by a highly restricted Vß 
T-cell-receptor (TCR) repertoire (Schuster et al., 2008). Interestingly, in one patient studied 
comprehensively in vitro stimulation with DC/DCleu resulted into an identical TCR  chain 
restriction pattern which could be identified in vivo in the patient’s T-cells 3 months after 
allo-SCT (Reuther et al., 2011). 
In summary, DCleu are promising candidates to stimulate and enrich antileukemic T-cells 
without knowledge of defined antigen targets which is attended with the creation of an 
‘antileukemic cellular microenvironment’ and could contribute to develop strategies to 
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overcome immunological resistances. With our experimental in vitro models combining 
culture methods and functional flow cytometry with spectratyping we can moreover 
provide explanations for clinical observations and might provide predictive information 
about T-cellular response patterns in vivo. Further studies of selected T-cells (e.g. by their Vß 
type) for their phenotype and function will allow to understand clinical responses and to 
prepare T-cells for treatment. 
3.2.2 Antileukemic T-cell profiles to predict antileukemic reactions of DC/DCleu 
stimulated T-cells and prognosis of patients (Groupleaders: Schmetzer; Scientists: 
Fischbacher, Freudenreich, Grabrucker, Liepert, Merle, Schick, Vogt) 
Since not every AML patient responds to immunotherapy (SCT, DLI) in vivo and since not 
every ex vivo T-cell stimulation with DCleu results in antileukemia effector T-cells we wanted 
to elucidate responsible cells or soluble factors. We could evaluate ‘cut-off values’ for DC- or 
T-cell subtypes in the cellular settings and in addition amounts of soluble factors that allow 
a prediction of the antileukemic function of T-cells in this cellular or microenvironmental context 
or a prediction of the clinical response to immunotherapy. We could demonstrate, that T-cells 
stimulated with DCleu in a ‘favorable cellular and soluble chemokine/cytokine context’ 
(with >45% mature DC and >65% DCleu with a release of >200pg CXCL8, >100pg CCL2, 
>10pg IFN-γ  or >15pg  IL-6, resulting in >65% CD4+, Tnon-naive and <60% CD8+ T-cells and 
especially >3% Tnaive  , >11% Tcm and  low proportions of CD8+ Treg after the DC stimulation) 
had a more than 75% chance to gain antileukemic ex vivo activity. In addition we could 
demonstrate, that clinical responders to  immunotherapy were characterized by a higher ex 
vivo generability of DCleu and mature DC, a better ex vivo T-cell proliferation and CD4:CD8 
and Tnon-naive : Tnaive ratios>1 and in addition by a high release of CCL2, IFN-γ  and IL-6 
(Liepert et al., 2010; Schmetzer et al., 2011; Fischbacher et al., 2011; Merle et al., 2011; 
Grabrucker et al., 2010).  
That means, that we can not only associate cellular subtypes of T-cells and DC or 
cytokine/chemokine release patterns with antileukemic functions of T-cells in ex vivo 
settings and in the context of a clinical response to immunotherapies, but in addition define 
predictive ‘cut-off values’ , that means proportions of cells with certain cellular subtypes or 
concentrations of soluble factors, that allow a correlation with cellular responses or the 
clinical course of the disease after immunotherapy. 
4. Clinical key results 
4.1 Clinical use of donor T-cells for prevention and treatment of AML relapse after 
allogeneic SCT ( Schmetzer, Schmid) 
Donor lymphocyte infusion (DLI) for treatment of leukemic relapse after allogeneic 
hematopoietic stem cell transplantation (SCT) has been introduced in the early nineties 
(Kolb et al., 1990). Being extremely effective in chronic myeloid leukemia, the procedure was 
less successful in AML, although remissions were observed in selected cases (Kolb et al., 
1995; Collins et al., 1997). Therefore, on behalf of the Acute leukemia Working Party of the 
European Group of Blood and Marrow Transplantation (EBMT) our group performed a 
retrospective analysis of patients who had been transplanted for AML in complete 
remission, and had suffered from leukemia relapse post SCT (Schmid et al., 2007). The 
analysis was based on the EBMT transplant registry, and included 399 adult patients who 
had received (n=171) or not (n=228) DLI as part of their treatment. With a median follow up 
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of 27 and 40 months in the both groups, overall survival (OS) at two years was 21±3% for 
patients receiving, and 9±2% for patients not receiving DLI. After adjustment for differences 
between the groups, better outcome was associated with younger age (p= 0.008), remission 
duration >5 months after SCT (p<0.0001), and use of DLI (p=0.04). Among DLI recipients, a 
lower tumour burden at relapse (<35% of bone marrow blasts; p=0.006), female gender 
(p=0.02), favorable cytogenetics (p=0.004) and remission at time of DLI (p<0.0001) were 
predictive for survival in a multivariate analysis. Two-year survival was 5610%, if DLI was 
performed in remission or with favourable karyotype, and 153% if DLI was given in 
aplasia or with active disease. Therefore, an algorithm for the clinical use of DLI in the 
treatment of relapsed AML after allogeneic SCT was developed, comprising the sequence of 
cytoreductive chemotherapy for disease control or induction of complete remission, 
followed by DLI for long term control of the leukemia based on cellular immune effects  
(Schmid et al., 2011).  
In an approach to increase the antileukemic efficacy of donor T-cells against myeloid 
leukemias, systemic application of GM-CSF was studied after DLI for relapse of AML or 
MDS after SCT (Schmid et al., 2004). GM-CSF was chosen due to its capacity to contribute in 
vitro to the generation of antigen-presenting cells (APC) from leukemic blasts 
(Woiciechowsky et al., 2001; Kufner  et al., 2005;  Kremser et al., 2010; Dreyssig et al., 2011). 
As described above, blasts from myeloid leukemias should have the full genetic repertoire 
for effective antigen presentation, but might be ineffective stimulators or even induce 
specific anergy, due to inferior or aberrant expression of co-stimulatory molecules, such as 
CD80 or CD86. GM-CSF has been shown to induce up-regulation of these molecules on 
the surface of leukemia blasts and to improve cytotoxic efficacy of autologous and 
allogeneic T-cells. In a clinical pilot trial for AML relapse after SCT, mild chemotherapy 
with low dose AraC, infusion of donor T-cells together with stem cells for reconstitution 
of haematopoiesis, and s.c. or i.v. application of GM-CSF, was studied. Overall response 
rate was 67% among evaluable patients’, overall survival at 2 years was 29%. Long term 
survival was associated with longer remission post transplant, disease control by low 
dose AraC and development of chronic GvHD. These results confirm the proposed 
strategy of initial cytoreduction by chemotherapy and induction of a GvL reaction for 
long term disease control. Systemic application of GM-CSF was safe in this setting, 
however, its clinical efficacy remains to be evaluated in randomised studies. Nevertheless, 
in accompanying ex vivo experiments we could demonstrate, that cases in which DC could 
be generated ex vivo using GM-CSF-based protocols showed a more favourable outcome 
after in vivo immunotherapy (Freudenreich et al., 2011).  
Since overall, the outcome of patients with AML who relapse after allogeneic SCT is poor, 
strategies to prevent occurrence of overt haematological relapse are of increasing interest. 
Intensive monitoring of minimal residual disease and donor chimerism in different cellular 
compartments (CD34+, CD3+) of bone marrow or peripherial blood has gained in 
importance by allowing early interventions (chemotherapy, DLI, second SCT) before 
haematological relapse has occurred (Bornhauser et al., 2009). Our group has developed a 
protocol for the use of prophylactic or preemptive DLI (pDLI) for patients with high-risk 
AML. Starting from day +120 after SCT, patients in haematologic remission, free of 
immunosuppression for at least 30 days without clinically evident GvHD, and free of 
infections receive up to 3 courses of DLI in 4 weeks’ intervals,  using an escalating cell dose 
schedule. Patients receiving prophylactic DLI have been compared to a control group of 
high-risk AML patients, who were treated according to the same transplant protocol,  would 
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have fulfilled the criteria for pDLI, but did not receive the cells since their transplant centres 
did not take part at this part of the study (Schmid et al.,  2005; Schleuning et al., unpublished 
results). Hence, patients receiving pDLI showed a significantly lower incidence of relapse 
and achieved a longer overall survival as compared to controls without pDLI. The treatment 
was also safe and induction of severe GvHD was a rare event in this setting.   
In summary, although less effective as in CML, the clinical use of DLI for AML patients after 
SCT is an effective therapeutic tool for prevention or as part of treatment of relapses after 
SCT in AML. 
5. Perspectives for future therapies: Adoptive transfer or in vivo activation of 
antileukemic T-cells? (Schmetzer, Schmid) 
We could clearly demonstrate, that it is possible to detect and monitor leukemia specific T-
cells by  LAA-peptid specific (HLA-A2 restricted) MHC-Multimer analyses or LAA-protein 
specific CD4+ T-cells, especially if combined with spectratyping and cellular subtype 
analyses. Concerning ‘known’ (leukemia-) specific antigens we can conclude from our data, 
that LAA-peptide specific CD8+ T-cells can be prepared by MHC multimer-technology,  
LAA-protein specific CD4+ T-cells  by preparation of (enriched) proliferating CD40L+ or 
cloned CD4+ cells and both cell types could be used for adoptive therapies. Moreover we 
could work out in vitro as well as in a dog model, that male specific antigens might be 
promising candidate antigens for immunotherapies. In addition we could show, that 
(enriched) T-cells addressing known as well as unknown leukemia-associated antigens, as 
demonstrated after DC/DCleu-stimulation, can mediate cytotoxic reactions. Those cells 
could be promising candidates for adoptive immunotherapies in selected patients. 
Since the manipulation and selection of antigen-specific T-cells is not only an oncological 
challenge, but has to be approved by special committees before a clinical application another 
strategy circumventing T-cell manipulations could be more promising: applicating immune-
modulators  and cytokines like GM-CSF or IFN-α in vivo could possibly induce the 
conversion of (residual) blasts in patients to DCleu. In a small patients’ cohort we could 
already show, that patients receiving GM-CSF in the context of a DLI-relapse therapy had a 
better chance to respond to this relapse therapy compared to patients without additionally 
applicated GM-CSF (Freudenreich et al., 2011). Moreover we could show, that the 
convertibility of blasts to DCleu in ex vivo settings correlated with the clinical response and 
outcome to immunotherapies, what can be interpretated by an ‘ex vivo simulation’ of the 
DC-generating potential out of blasts. We could even demonstrate, that cases, in that higher 
proportions of DCleu could be generated ex vivo had a longer overall survival compared to 
cases with lower DCleu proportions.  
Our ex vivo focus in the future will therefore be to thoroughly investigate and optimize in 
vivo strategies with allo SCT applying different donor transplants or ex vivo ‘manipulated’ 
grafts. We further want to develop and test different ‘immune modulating cocktails’ 
(Ansprenger et al., 2011; Deen et al., 2011) that can be applicated to patients with the aim 
to induce leukemia-derived DC in vivo and in consequence to stimulate the generation of 
leukemia-specific T-cells in vivo. In parallel we want  to further enlighten the role of 
different (enriched, selected) effector cells – e.g. CD4+, CD8+, NK, NK-T- cells) in the 
mediation of antileukemic reactions in order to find promising candidates for adoptive T-
cell transfer. 
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1. Introduction 
Allogeneic hematopoietic cell transplantation emerges as a therapy option to treat the 
sequels of exposure to radiation, a great concern at the beginning of the atomic age and cold 
war (Welniak et al., 2007). Hematopoietic cell transplantation emerged as a rescue strategy 
since there were already antecedents, like the study of Lorenz et al. in 1952 (as cited by 
Welniak et al., 2007), who showed that infusion of the bone marrow after lethal irradiation 
healed radiation disease in mice. This lay the foundations for the current consideration of 
allogeneic hematopoietic cell transplantation as the first-line therapy for many life-
threatening oncological and hematological diseases. Today, it is primarily used to treat 
patients with hereditary anemias or immunological deficiencies through replacement of the 
hematopoietic system with cells from a healthy individual. It also allows cancer patients to 
be treated with myeloablative radiation and/or chemotherapy (known as myeloablative 
conditioning) in an attempt to eliminate tumoral cells, and although this strategy brings loss 
of bone marrow function, the latter can be recovered with infusion of normal hematopoietic 
cells (Jenq & Van den Brink, 2010). 
2. Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation is today a simple procedure involving infusion of 
these cells intravenously. Once in the bloodstream, stem cells are able to migrate to the bone 
marrow in order to thus restore hematopoiesis during the first two weeks following 
transplantation (Léger & Nevill, 2004). 
Stem cells giving rise to hematopoietic cells are known as hematopoietic stem cells due to 
their capacity for self-renewal, division and differentiation into a variety of specialized 
hematopoietic cells. This is the principle underlying hematopoietic stem cell transplantation 
(Hows, 2005). 
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One of the major difficulties in using hematopoietic stem cells has been their identification, 
since they are morphologically very similar to lymphocytes. This problem was solved with 
the use of biomarkers such as CD34, a transmembrane glycoprotein expressed by 
hematopoietic stem cells which is currently the main biomarker used to identify these cells. 
Hematopoietic cell transplantations are classified as isotransplantation, allotransplantation 
or autotransplantation. These are not the only types of transplantation, but they are the most 
commonly used in medical practice. It calls allotransplantation when donor and recipient 
are the same species but are not identical twins. The advantages of this type of 
transplantation compared to the allogeneic type are that the cells infused are normal cells 
and therefore the incidence of relapse is lower, as well as the fact that the graft cell is infused 
with immunocompetent cells that are able to induce a graft-versus-leukemia effect. The 
major concern with this type of transplantation is development of graft-versus-host disease 
(GVHD) or infections caused by opportunistic microorganisms, since patients are treated 
with immunosuppressant drugs (Léger & Neville, 2004; Vela-Ojeda et al., 2005). 
2.1 Hematopoietic stem cell mobilization by G-CSF 
At present peripheral blood hematopoietic stem cells are preferably used since grafting 
(particularly of blood platelets) is faster. This procedure is not excessively invasive – as is 
bone marrow procurement – and better results are obtained when mobilized peripheral 
blood is used as the hematopoietic stem cells source (Jaime et al., 2004). Normally, 
peripheral blood contains only a small amount of hematopoietic stem cells (<0.1% of 
nucleated cells). Different methods are therefore used to induce their egress from the bone 
marrow into the bloodstream in order to be able to collect them by apheresis for subsequent 
infusion in the patient. Hematopoietic stem cells mobilization was an innovative 
development in the 1990s, in particular after it was seen that the number of stem cells 
obtained from mobilized peripheral blood contained 1-log more lymphocytes than the 
number obtained from bone marrow (Champlin, 2000). The established, widely-used 
method of mobilization involves the use of G-CSF, which induces mobilization by initiating 
a stress process through neutrophil and osteoclast activation. This results in dissociation of 
the cell membrane unions between stem cells and the stroma cells as well as stem cell 
proliferation and activation and/or adhesion molecule degradation. Hematopoietic stem 
cells mobilization is also seen when chemotherapy is exclusively used (Devetten & 
Armitage, 2007). 
The mechanism through which G-CSF mobilizes CD34+ hematopoietic stem cells from the 
bone marrow into the peripheral blood involves a series of steps. First of all, there is 
increased hematopoietic stem cell proliferation followed by exit of these cells from the bone 
marrow. Increased proliferation has been shown to occur with cytokines such as GM-CSF 
that temporarily increase the cell adhesion of CD34+ hematopoietic stem cells to the bone 
marrow stroma, a process that in turn increases cell proliferation. The mobilization of 
hematopoietic stem cells from the bone marrow to peripheral blood comprises several 
mechanisms. One hypothesis is modification of the cellular interactions occurring between 
hematopoietic stem cells and the bone marrow stroma. Analyses of peripheral blood 
mononuclear cells mobilized by G-CSF reveal a decrease in the expression of VLA-4 (Very 
late antigen 4 [CD49d/CD29]) integrin which normally binds firmly to its ligand VCAM-1 
(Vascular cell adhesion molecule-1) as well as to an extracellular-matrix fibronectine fragment. 
Other molecules in which a marked decrease occurs are LFA-1 (Leucocyte functional antigen 1 
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[CD11aCD18]) and c-kit. These molecules are expressed in most hematopoietic stem cells 
and are involved in binding of these cells to bone marrow stroma, a process that is 
expressed by the ligands of cells of the latter VCAM-1, ICAM-1 (Intercellular adhesion 
molecule-1) and ICAM-2 for LFA-1 and c-kitL. G-CSF can also initiate mobilization through 
neutrophils, by secretion of gelatinase B, breaking extracellular matrix molecules and  
 
 
Fig. 1. Mechanism of hematopoietic stem cell mobilization from bone marrow to peripheral 
blood by stimulation with G-CSF. This process involves several steps, including 
modification of interactions occurring between stem cells and the stroma. Affected 
interactions include decreased expression of VLA-4 integrin, which normally binds to its 
ligand VCAM-1 and to FNT. Another molecule in which expression is decreased is c-kit; this 
process reduces the bond between this molecule and its ligand kit-L-. Decreased expression 
of these molecules reduces the bond between stem cells and the stromal cells. Another 
means by which G-CSF promotes stem cell mobilization is through neutrophils, by releasing 
gelatinase B, breaking extracellular matrix molecules and weakening adhesive interactions 
between stem cells and stroma cells. Yet another mechanism is stem cell secretion of 
gelatinase B, promoting faster migration of these cells to peripheral blood. A further 
mechanism involves indirect interaction of G-CSF with ligands, receptors/factors and 
stimulation of stem cell proliferation. PB: peripheral blood. G-CSF: granulocytic-colony 
stimulating factor. VCAM-1: vascular cell adhesion molecule-1, VLA-4: very late antigen 4 
[CD49d/CD29] FNT: fibronectina (Modified from Gyger et al., 2000) 
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weakening adhesive interactions between stem cells and stroma cells. Stem cells have also 
been shown to secrete gelatinase B, a mechanism which may improve migration of these 
cells to peripheral blood (Figure 1). Finally, experimental evidence indicates that G-CSF may 
interact indirectly with a stem cell ligand to stimulate proliferation of these cells (Cashen et 
al., 2007; Cottler-Fox et al., 2003; Gyger et al., 2000). 
In recent years, it has been demonstrated that G-CSF is also able to break one of the most 
important interactions between stem cells and stromal cells, which is formed by CXCL12 
(formerly called SDF-1) and CXCR4 (Cashen et al., 2007). 
2.1.1 Which stem cell source is best: bone marrow or mobilized peripheral blood? 
This is one of the most commonly asked questions, since using mobilized peripheral blood 
rather than bone marrow in allogeneic transplantation is increasingly frequent. A 
retrospective study by Champlin et al. in 2000 examined the evolution of 288 allogeneic 
transplants in which mobilized peripheral blood was used and 536 in which bone marrow 
was used. They were followed-up during one year. The study found that in patients who 
had received mobilized peripheral blood, neutrophil engraftment was faster (14 days vs. 19) 
as was also platelet engraftment (19 days vs. 25). No significant differences were observed in 
development of acute GVHD. Chronic GVHD development was significantly higher in 
patients receiving mobilized blood, with a mean of 65% vs. 53%. The incidence of relapse 
did not differ significantly. Treatment-related mortality and leukemia-free survival were 
higher with mobilized blood transplants and hospitalization time was shorter. Additional 
studies similar to this one examining the benefits and drawbacks of allogeneic 
hematopoietic cell transplantation set the basis for mobilized peripheral blood being 
currently the most commonly used source in hematopoietic stem cell transplantation. 
2.2 Points to consider before hematopoietic stem cell transplantation 
When considering transplantation in patients in remission, two important aspects should be 
taken into account: whether medical evidence indicates that hematopoietic stem cells 
transplantation is more likely to heal the disease than other therapy forms and whether a 
suitable donor is available as a stem cell source. Although these are the major aspects to 
consider they are not the only ones. Other factors requiring consideration include biological 
characteristics at diagnosis, the specific disease that is being treated, presence of 
comorbidities that may complicate transplantation, and patient age (Deeg, 2010; Léger & 
Nevill, 2004). 
2.3 Immunological typing of human leukocyte antigens 
One reason for the progress that has taken place in hematopoietic cell transplantation is 
human leukocyte antigen (HLA) immunotyping. This is one of the major points to consider 
in allogeneic hematopoietic cell transplantation since, as already stated, it is important to 
have a suitable donor. 
HLA proteins were first identified in 1950 by Jean Dausset upon observing that in many 
individuals, particularly those who previously received multiple blood transfusions or who 
were multiparous women, blood serum contained antibodies that reacted against a new 
kind of glycoprotein present on the outer surface of leukocytes of other members of the 
population; these glycoproteins were named human leukocyte antigens (HLAs). The latter 
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behave as immunogenic markers making a person’s cells distinct and are the major barrier 
to histocompatibility; they are therefore also called major histocompatibility complex (MHC) 
molecules. The importance of HLA molecules is not limited to the histocompatibility barrier, 
they are also essential in T-cell activation since HLA-molecules bind peptides to be 
presented to T cells. HLA class I molecules present peptides primarily to CD8+ T cells while 
CD4+ T cells recognize mainly peptides presented by class II molecules (Appelbaum, 2001; 
Bleakley & Riddell, 2004). 
MHC genes are encoded on the short arm of chromosome 6 at locus p21. There are three 
different groups of genes called HLA-A, HLA-B and HLA-C, which individually code for 
the  chain of MHC class I. Similarly, there are three loci for the genes of class II MHC 
molecules known as HLA-DP, HLA-DQ and HLA-DR. Each of these includes genes coding 
for the  polypeptide chain and at least one  polypeptide chain. A person normally inherits 
two copies of the locus of each gene, one from each parent. Statistical data provided by the 
European Bioinformatics Institute (EBI) and the International Immunogenetics Organization 
Database (IMGT) suggest that the number of HLA class I and class II alleles discovered is on 
the increase. These data indicate that in human population there are 4,946 different class I 
alleles and 1,457 class II alleles, of which 1,601 are known alleles for HLA-A, 2,125 for HLA-
B, 1,102 for HLA-C and 1,027 for HLA-DRβ of which 928 are HLA-DRβ1 alleles (these are 
the ones most commonly used to determine histocompatibility due to their high 
polymorphism) (Table 1). 
 
Numbers of HLA Alleles  
HLA Class I Alleles 4,946 
HLA Class II Alleles 1,457 
HLA Alleles 6,403 
  
HLA Class I
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Alleles 1,601 2,125 1,102 10 22 47  
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HLA Class II 
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HLA Class II- DRB Alleles 
Gene DRB1 DRB2 DRB3 DRB4 DRB5 DRB6 DRB7 DRB8 DRB9  
Alleles 928 1 57 15 19 3 2 1 1  
Proteins 704 0 46 8 16 0 0 0 0  
(Modified from http://www.ebi.ac.uk/imgt/hla/stats.html) 
Table 1. Statistical data from the European Bioinformatics Institute (EBI) and the 
International Immunogenetics Organization database (IMGT) showing the number of each 
of the HLA alleles. 
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weakening adhesive interactions between stem cells and stroma cells. Stem cells have also 
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behave as immunogenic markers making a person’s cells distinct and are the major barrier 
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Historically, HLA immunotyping was performed by serological methods but now, with the 
advent of polymerase chain reaction (PCR), molecular immunotyping of the donor and 
recipient is possible. A study by Petersdorf et al. in 2001 examined patients who had 
previously undergone transplantation and were compatible by serological methods. When 
reexamined by molecular immunotyping, about 30%of these individuals were found to be 
incompatible in one or more alleles. These differences were correlated with increased GVHD 
and poor survival, indicating that a compatible donor and reliable HLA immunotyping are 
extremely important. The number of class I and class II HLA antigens is relatively large and 
therefore the probability of HLA matching between the recipient and an unrelated donor is 
extremely small. 
2.4 Graft-versus-host disease and Th1/Th2/Th17 cytokines 
Graft-versus-host disease (GVHD) may develop after hematopoietic stem cell 
transplantation. It is a reaction of immune cells from the donor against tissues of the host. 
Damage induced on epithelial cells of the host by activated T cells occurs after an 
inflammatory cascade that is unleashed by the conditioning regimen. Approximately 35-
50%of allogenic hematopoietic cell transplantation recipients develop GVHD. The risk of 
developing the disease depends on several factors, primarily the stem cell source and donor 
cytokines, patient age, existing conditions and GVHD prophylaxis. GVHD involves mainly 
the skin, liver and gastrointestinal tract. Despite GVHD-related morbility and mortality, its 
development is often desirable since it has been found to be associated with a lower 
recurrence of malignant disease, in other words, it is important for establishment of the 
graft-versus-tumor effect (Ferrara & Levine, 2008; Léger & Nevill, 2004; Saliba et al., 2007; 
Weisdorf 2007). 
The physiopathology of acute GVHD described by Ferrara & Levine (2008) is a three-stage 
phenomenon. The initial stage involves damage to tissues of the host due to inflammation 
derived from chemo- and/or radiotherapy during the recipient conditioning. In the second 
stage, antigen-presenting cells (APC) of both donor and recipient as well as inflammatory 
cytokines unleash the activation of donor-derived T cells, with expansion and differentiation 
of the latter into effector cells. Antigens (Ag) of the minor histocompatibility complex have a 
central role in this activation. The pathway of T-cell activation results in activation of genes 
coding for cytokines such as IL-2 and interferon gamma (IFN). Cells that produce these 
cytokines are considered to be Th1 profile, as opposed to cells producing predominantly IL-
4, IL-5, IL-10 and IL-13 which are considered to be Th2 phenotype and are assumed to be the 
ones that modulate GVHD. During the third stage, also known as the effector stage, donor-
derived activated T cells mediate cytotoxicity against target cells of the recipient through 
FasL-Fas, perforin and granzyme B interactions as well as additional production of tumor 
necrosis factor  (TNF). This cytokine is produced by monocytes and macrophages, and 
secondarily by T lymphocytes and natural killer (NK) cells (Figure 2). (Ferrara & Levine, 
2008; Jacobsohn & Vogelsang, 2007; Socie & Blazar 2009). 
TNF is firmly involved in GVHD physiopathology at several steps of the process including 
induction of apoptosis in target tissues through the TNF receptor. It also induces the 
activation of macrophages, neutrophils, eosinophils, and B and T cells; stimulates 
production of inflammatory cytokines such as IL-1, IL-6, IL-12 and TNF itself; increases the 
expression of HLA molecules; and promotes lysis by T lymphocytes. High levels of TNF 
are associated with a higher incidence of GVHD in bone marrow transplant recipients. This 
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allogeneic dysregulation, in addition to dysregulation of cytokines, leads to the acute tissue 
damage produced by GVHD.  
 
 
Fig. 2. Physiopathology of graft-versus-host disease. (I) Damage to host tissues by 
inflammation derived from the chemotherapy and/or radiotherapy conditioning regimen. 
(II) Antigen-presenting cells (APC) of both donor and recipient as well as inflammatory 
cytokines unleash the activation of donor-derived T cells, with expansion and differentiation 
of the latter into effector cells. The pathway of T-cell activation results in activation of the 
genes coding for cytokines such as IL-2 and IFN. (III) Effector stage: donor-derived 
activated T cells mediate cytotoxicity against target cells of the recipient through FasL-Fas, 
perforin and granzyme B interactions as well as additional production of tumor necrosis 
factor  (TNF) (Modified from Ferrara & Levine, 2008). 
In our laboratory, we have studied patients who underwent allogenic hematopoietic cell 
transplantation and developed GVHD, finding a correlation between these patients and an 
increased of CD14+ TNF+ cells. Up to 32% of CD14+ cells secreting TNF were found in a 
patient with stage II GVHD, increasing to 47% when the patient progressed to stage III, 
while in patients who did not develop GVHD this behavior was not observed. In patients 
with GVHD development, TNF may promote increased expression of adhesion molecules 
such as VCAM-1, ICAM-1 and E-selectin in endothelium, therefore also promoting 
diapedesis of leukocytes in affected areas and degranulation of these cells with subsequent 
damage to tissues in which they are infiltrated (Aggarwal et al., 2000). On the other hand, 
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activation of endothelium, release of nitric oxide, vasodilation and increased vascular 
permeability, and blood platelet activation are also promoted and, most importantly, 
increased expression of MHC-I and MHC-II molecules as well as co-stimulatory molecules 
such as CD40, CD80 and CD86 in dendritic cells, thus also activating T lymphocytes and 
giving rise to more effective antigen presentation, and along with this, more effective 
allorecognition (Steinman et al., 1998). 
In addition to this, TNF has a major role in the promotion of apoptosis (De Freitas et al., 
2004) and due to the previously mentioned properties, TNF overexpression contributes to 
GVHD emergence and severity (Figure 3). Recent studies reveal an increase not only in 
TNF levels but also in TNF receptors (TNFR1 and TNFR2), and the latter are more stable 
and easier to quantify (Choi et al., 2009; Kitko et al., 2008). 
The role of other cytokines such as those of the Th1 profile is worth noting. Diverse research 
groups initially correlated this profile with GVHD emergence, since large quantities of 
cytokines such as IFN, IL-2 and IL-12 were found in patients with GVHD development and 
this is correlated with GVHD severity (Das et al., 2001; Ju et al., 2005). However, these 
cytokines have a controversial role as they are necessary for development of both GVHD 
and the graft-versus-leukemia effect. We have found that mononuclear cells from patients 
with GVHD development in co-culture secrete large amounts of IFN and IL-2, but we have 
also observed that the capacity of these cells to secrete these cytokines is correlated with 
graft success unaccompanied by relapse or development of infections by opportunistic 
microorganisms, which tells us these cytokines have a dual role. Regarding the significance 
of the Th2 cytokine profile in GVHD control, some study teams point to the overexpression 
of IL-4, IL-5 and IL-10 as a positive prognostic factor (Das et al., 2001; Ju et al., 2005). In our 
laboratory, however, a correlation has been observed only between the overexpression of IL-
10 by mononuclear cells of patients and control of GVHD. 
There are new lymphocyte subsets to which great significance has been ascribed in 
inflammatory processes as well as in many pathologies previously thought to be associated 
with the Th1 profile. The subpopulation of Th17 cells discovered in 2005 is now known to 
have a controversial role as they are implicated in rejection of solid organ grafts (Kappel et 
al., 2008; Carlson 2009; Coghill et al., 2010). 
In murine models, differences in GVHD development have been found between mice that 
were transferred CD4+ IL-17-/- T cells and mice that were transferred normal CD4+ cells. In 
the former, GVHD development took longer. However, no significant differences were 
noted between these groups in relation to mortality due to GVHD or in graft-versus-tumor 
activity. Another major finding was the fact that mice that were transferred CD4+ IL17-/- 
cells had fewer Th1 cells during early stages of GVHD. Also, a reduction occurred in the 
number of IFN-secreting macrophages and granulocytes as well as a decrease in the 
amount of pro-inflammatory cytokines. IL-17 is therefore believed to be essential for GVHD 
development and graft-versus-leukemia activity as it promotes pro-inflammatory cytokine 
production – all this in murine models (Kappel et al., 2008). These data and others showing 
the importance of the Th17 profile in inflammatory processes made several researchers think 
that this profile might be involved in GVHD development and severity in humans (Coghill, 
2011). Our study team recently found that the Th17 profile is not relevant for GVHD 
development. We conducted a pilot study on the importance of this profile in six patients 
who underwent allogenic hematopoietic cell transplantation, following them for six months. 
This group was divided into patients with GVHD development and patients without 
GVHD. Peripheral blood and mononuclear cell cultures were analyzed at 30, 60, 100 and 180 
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Fig. 3. The role of TNF in GVHD emergence and exacerbation.  
days after transplantation. Overproduction of Th17 profile was not observed neither in 
patients with GVHD nor in individuals without GVHD, as opposed to its production in 
healthy volunteers and in a patient who received a syngeneic transplant. Few months after 
concluding our study, Broady et al. (2010) published a similar study on patients who 
underwent allogenic hematopoietic cell transplantation, in which they evaluated Th1 and 
Th17 cells in tissue and peripheral blood in a cohort of 34 patients, of which 20 developed 
acute GVHD and 14 did not develop GVHD. The authors did not find an increase in the 
number of Th17 cells in patients with acute cutaneous GVHD as compared to healthy 
donors, but they did detect increased production of IFN-secreting cells (Broady, 2010). 
GVHD diagnosis is suspected when the recipient develops all or some of the signs and 
symptoms that are characteristic of this disease such as dermatitis (rash), epidermal 
blistering, stomach cramps, abdominal pain with or without diarrhea which may be 
accompanied by passage of blood, nausea, persistent vomiting, and hepatitis (elevated 
bilirubins and/or liver enzymes). Typically, these signs and symptoms occur 100 days after 
allogenic hematopoietic cell transplantation but may also appear later. Because many of 
them are not specific of this complication, diagnosis must be supported with suitable 
biopsies, particularly if the symptoms are atypical or involve only the liver or 
gastrointestinal tract, since histological confirmation is extremely useful. A further reason 
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days after transplantation. Overproduction of Th17 profile was not observed neither in 
patients with GVHD nor in individuals without GVHD, as opposed to its production in 
healthy volunteers and in a patient who received a syngeneic transplant. Few months after 
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for biopsy-taking is to help differentiate GVHD from other diseases with similar symptoms, 
such as viral infections or reactions to pharmaceutical agents (Ferrara & Levine 2008; 
Jacobsohn & Vogelsang, 2007). 
In GVHD, mature T cells of the donor that accompany the graft attack host tissues, 
particularly the skin, liver and gastrointestinal tract. This explains the signs and symptoms 
that characterize this disease. To prevent GVHD development, all patients receive some 
type of prophylaxis with immunosuppressors and in some cases T cell depletion , being one 
of the most commonly used methods although its effectiveness has not been fully proven 
since T-cell elimination contributes to absence of GVHD development but patients die from 
relapse because lack of GVT effect. Another prophylactic method involves pharmacological 
treatment with agents that affect T-cell function. These types of prophylaxis elicit adverse 
effects since mature T cells of the donor have a major role in mediating the reconstitution of 
the adaptive immune system, particularly in adults with low thymus function (Jacobsohn & 
Vogelsang, 2007). 
GVHD is classified according to the number and extent of the organs involved (Table 2). In 
the current classification system, established in 1994, GVHD is divided into four groups (I – 
IV). Skin damage is evaluated by the percentage of the body surface area involved, liver 
damage by elevated bilirubins, and gastrointestinal tract damage by the amount of diarrhea 
(Jacobsohn & Vogelsang, 2007; Vela-Ojeda et al., 2008). 
 
Stage Skin Liver 
(bilirubin) 
Gut (stool output/day) 
0 No GVHD rash < 2 mg/dl < 500 ml/day or 
persistent nausea 
1 Maculopapular rash < 25% BSA 2-3 mg/dl 500-999 ml/day 
2 Maculopapular rash < 25 - 50% 
BSA 
3.1-6 mg/dl 1000-1500 ml/day 
3 Maculopapular rash > 50% BSA 6.1-15 mg/dl Adult: >1500 ml/day 
4 Generalized erythroderma plus 
bullous formation 
>15 mg/dl Severe abdominal pain 
with or without ileus 
Grade 
I Stage 1-2 None None 
II Stage 3 or Stage 1 or Stage 1 
III - Stage 2-3 or Stage 2-4 
IV Stage 4 or Stage 4 - 
(Modified from Jacobsohn & Volgelsang 2007). 
Table 2. Classification of acute graft-versus-host disease. 
Chronic GVHD (cGVHD) is one of the most common and significant problems affecting 
recipients of allogenic hematopoietic cell transplantation at long term. It appears 
approximately 100 days after allogenic hematopoietic cell transplantation, which is the 
critical time at which close to 50% of patients develop some degree of cGVHD. Increased use 
of hematopoietic stem cells obtained from peripheral blood rather than bone marrow, 
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increased age of recipients, and the use of busulfan in the conditioning regimen have led to 
a higher incidence of cGVHD. Other clinical risk factors for cGVHD development include 
previous acute graft-versus-host disease (aGVHD) and a second transplant. cGVHD most 
commonly affects the skin, liver, eyes and mouth, although other sites may also be affected. 
Death from severe cGVHD is generally a result of infectious complications. The standard 
treatment for severe cGVHD is a combination of cyclosporine and prednisone. An 
alternating daily regimen of these two agents prolongs survival and reduces drug-related 
adverse effects. Topical therapy in affected areas is recommended for patients with grade 1-2 
cutaneous disease. Survival at 10 years in patients who develop light aGVHD is 
approximately 80%, but it is drastically reduced in patients with severe cGVHD, in whom 
this rate is reported to be 5% (Horwitz & Sullivan 2006; Lee 2005; Vela-Ojeda et al., 2008). 
Alloreactivity is the basis for cGVHD pathogenesis. However, the exact phenotype and 
the origin of alloreactive cells remain somewhat ambiguous. Donor-derived alloreactive 
T-cells transplanted with hematopoietic stem cells play a key role in acute and chronic 
GVHD. Current animal models of cGVHD implicate Th2 cells as the first cell type to 
induce damage. However, in humans with cGVHD, Th1/Th2-polarized CD4+ cells have 
alloreactive properties. The formation of antibodies has been observed in experimental 
models and clinical studies of cGVHD. This suggests that B cells are implicated in the 
physiopathology of cGVHD as shown by antibody production in allogenic hematopoietic 
cell transplantation patients with donor of different sex, since antibodies against minor 
histocompatibility antigens are encoded in the Y chromosome. The presence of anti-
nuclear, anti-double strand DNA and anti-smooth muscle antibodies in a frequency range 
of 11-62% has also been detected in patients with cGVHD as well as the presence of anti-
cytoskeletal and anti-nucleolar antibodies. However, despite these findings, the role of 
antibodies in cGVHD remains unclear (Horwitz & Sullivan 2006; Lee 2005; Vela-Ojeda et 
al., 2008). 
cGVHD can be classified according to type of clinical manifestations or extent of the disease. 
Most patients with cGVHD have previously had aGVHD. cGVHD may also be observed 
after achieving control of aGVHD. Similarly, patients may develop cGVHD without a 
previous history of aGVHD (de novo cGVHD). Classification according to the type and 
extent of clinical manifestations is shown in Table 3. 
The International Center for Research on Bone Marrow and Blood Cell Transplantation 
estimates that 50,000 – 60,000 hematopoietic cell transplantations are performed each year 
throughout the world. Bone marrow is the main source of grafts for transplantation in 
children, although peripheral and umbilical cord blood are being increasingly used. 
Between 2004 and 2008 peripheral blood accounted for 27% and umbilical cord blood for 
32% of transplants in patients fewer than 20 years in age. In patients over 20 years the most 
common source for allogenic hematopoietic cell transplantation is peripheral blood. 
Currently, very few adults receive grafts of umbilical cord blood but its use, although 
infrequent, increased 2-4% between 2004 and 2008. Mobilized peripheral blood is the main 
source for autologous transplantation, representing 91% of autotransplantations in children 
and 98% in adults. In recent years the number of hematopoietic cell transplantations, both 
allogeneic and autologous, in patients over 50 years old has increased. Approximately 40% 
of allogeneic transplants are unrelated donor transplantations. There has been a change 
lately: before 2002 the most commonly used source of hematopoietic stem cells was bone 
marrow but its use has declined since 2003 and peripheral and umbilical cord blood have 
been increasingly used.  
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for biopsy-taking is to help differentiate GVHD from other diseases with similar symptoms, 
such as viral infections or reactions to pharmaceutical agents (Ferrara & Levine 2008; 
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Stage Skin Liver 
(bilirubin) 
Gut (stool output/day) 
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(Modified from Jacobsohn & Volgelsang 2007). 
Table 2. Classification of acute graft-versus-host disease. 
Chronic GVHD (cGVHD) is one of the most common and significant problems affecting 
recipients of allogenic hematopoietic cell transplantation at long term. It appears 
approximately 100 days after allogenic hematopoietic cell transplantation, which is the 
critical time at which close to 50% of patients develop some degree of cGVHD. Increased use 
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Classification of GVHD 
Limited chronic GVHD  
Either or both:  
1 Localized skin involvement 
2 Hepatic dysfunction due to chronic GVHD 
Extensive chronic GVHD  
Either:  
1 Generalized skin involvement, or 
2 Localized skin involvement and/or hepatic dysfunction 
due to chronic GVHD 
Plus:  
3a Liver histology showing chronic aggressive hepatitis, 
bridging necrosis, or cirrhosis, or 
b Involvement of eye (Schirmer test with <5-mm wetting), 
or 
c Involvement of minor salivary glands or oral mucosa 
demonstrated on labial biopsy, or 
d Involvement of any other target organ 
Table 3. Classification of chronic graft-versus-host disease (Horwitz & Sullivan, 2006) 
The most common cause of death after allogenic hematopoietic cell transplantation is 
relapse, although in unrelated donor transplants it is followed by GVHD and in HLA-
matched sibling transplants by death from infections. Another major cause of death is 
interstitial pneumonitis (Pasquini & Wang, 2007). 
2.5 Graft-versus-tumor effect 
Existence of the graft-versus-tumor effect was first suggested in 1956 by Barnes et al., upon 
noting eradication of leukemia in irradiated mice receiving allogeneic bone marrow 
transplants, but not in those that after irradiation received syngeneic bone marrow 
transplants. The first evidence of this also occurring in humans came from studies reporting 
that the incidence of relapse was markedly lower in patients who developed GVHD than in 
those who did not (as cited in Appelbaum, 2001), and that just as in murine models, human 
allogenic hematopoietic cell transplantation recipients were at lower risk of relapse than 
recipients of syngeneic stem cell transplantations or allogenic hematopoietic cell 
transplantations in which T cells are previously depleted. Male patients receiving allogenic 
hematopoietic cell transplantation grafts from female donors are also seen to be a special 
group in that donor-derived T cells specific for receptors of minor histocompatibility 
antigens may contribute to development of the graft-versus-tumor or the graft-versus-
leukemia effect as well as GVHD since the graft-versus-leukemia effect is associated with 
presence of GVHD. The potential impact of the graft-versus-leukemia effect can be observed 
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when the patient is administered infusions of donor-derived lymphocytes. Graft versus 
tumor effect formed the basis of the so-called non-myeloablative transplants in which 
intensive chemotherapy regimen are substituted by the antitumoral effect of lymphocytes 
(Jacobsohn & Vogelsang, 2007). 
Factors inducing GVHD or the graft-versus-leukemia effect are not well defined and may to 
some extent be considered speculative. Minor histocompatibility antigens have been 
suggested to play a key role since some of them have limited expression in hematopoietic 
cells, including leukemic cells. These antigens are perhaps targeted by the selective effect of 
the graft-versus-leukemia effect while minor histocompatibility antigens that are expressed 
in general may be targeted by GVHD, but this is still not firmly established (Jacobsohn & 
Vogelsang 2007; Kolb, 2008; Riddell & Appelbaum, 2007). 
Various minor histocompatibility antigens are encoded in Y-chromosome genes that exhibit 
significant polymorphism with their homologues genes of the X chromosome. The former 
genes are responsible for the immune reactions occurring between men and women. 
Differential expression of the genes encoding for minor histocompatibility antigens in 
tissues has been proposed for potential use as a basis to separate the graft-versus-leukemia 
effect from GVHD. Cells that recognize minor histocompatibility antigens which are 
expressed only in hematopoietic cell receptors, including leukemic cells, may have a major 
role in the elimination of the latter without GVHD development. Several minor 
histocompatibility antigens such as HA-1, HA-2, HB-1 and BCL2A1 are expressed by 
hematopoietic cells and are therefore being examined as potential targets in order to 
promote the graft-versus-leukemia effect (Randolph et al., 2004; Kolb, 2008). 
2.6 Clinical relevance of regulation and induction of tolerance after allogenic 
hematopoietic cell transplantation 
The potential benefits of allogenic hematopoietic cell transplantation are offset by the 
moderate survival rate of the graft at long term. This is to a large extent due to 
immunosuppressant agents that unspecifically inhibit immune response in order to prevent 
rejection, but bring multiple adverse effects which are responsible for chronic rejection. 
Therefore, one of the major goals of allogenic hematopoietic cell transplantation is to achieve 
absence of immune response in the face of donor-derived alloantigens without requiring 
prolonged administration of immunosuppressants and to promote the graft-versus-
leukemia effect. To this end, research has focused on the study of regulatory T cells (Treg), 
particularly those of the CD4+CD25highFoxP3+ phenotype (natural Treg, nTreg) as they 
have been shown to be able to control immune response in the face of donor-derived 
alloantigens and therefore possess great potential to establish in vivo tolerance to the 
transplant. These cells have been studied the most but are not the only ones described as 
having a regulatory role since regulatory functions have also been observed in other 
subpopulations of CD4+ cells, in T CD8+ cells, T cells, NK cells and CD3+CD4-CD8-
CD16+56+ cells, also known as NKT cells. The latter have been shown to have a powerful 
anti-tumoral effect and are important in the maintenance of tolerance. This is why many 
studies are focusing on transfer of these cells. The strategy that is being sought for use in the 
near future is ex vivo stimulation of Treg purified with alloantigens of the donor or even 
FoxP3-mediated transfection of alloreactive CD4+CD25¯ cells (Bryceson & Ljunggren, 2007; 
Fehérvari & Sakaguchi, 2005). 
 




Classification of GVHD 
Limited chronic GVHD  
Either or both:  
1 Localized skin involvement 
2 Hepatic dysfunction due to chronic GVHD 
Extensive chronic GVHD  
Either:  
1 Generalized skin involvement, or 
2 Localized skin involvement and/or hepatic dysfunction 
due to chronic GVHD 
Plus:  
3a Liver histology showing chronic aggressive hepatitis, 
bridging necrosis, or cirrhosis, or 
b Involvement of eye (Schirmer test with <5-mm wetting), 
or 
c Involvement of minor salivary glands or oral mucosa 
demonstrated on labial biopsy, or 
d Involvement of any other target organ 
Table 3. Classification of chronic graft-versus-host disease (Horwitz & Sullivan, 2006) 
The most common cause of death after allogenic hematopoietic cell transplantation is 
relapse, although in unrelated donor transplants it is followed by GVHD and in HLA-
matched sibling transplants by death from infections. Another major cause of death is 
interstitial pneumonitis (Pasquini & Wang, 2007). 
2.5 Graft-versus-tumor effect 
Existence of the graft-versus-tumor effect was first suggested in 1956 by Barnes et al., upon 
noting eradication of leukemia in irradiated mice receiving allogeneic bone marrow 
transplants, but not in those that after irradiation received syngeneic bone marrow 
transplants. The first evidence of this also occurring in humans came from studies reporting 
that the incidence of relapse was markedly lower in patients who developed GVHD than in 
those who did not (as cited in Appelbaum, 2001), and that just as in murine models, human 
allogenic hematopoietic cell transplantation recipients were at lower risk of relapse than 
recipients of syngeneic stem cell transplantations or allogenic hematopoietic cell 
transplantations in which T cells are previously depleted. Male patients receiving allogenic 
hematopoietic cell transplantation grafts from female donors are also seen to be a special 
group in that donor-derived T cells specific for receptors of minor histocompatibility 
antigens may contribute to development of the graft-versus-tumor or the graft-versus-
leukemia effect as well as GVHD since the graft-versus-leukemia effect is associated with 
presence of GVHD. The potential impact of the graft-versus-leukemia effect can be observed 
Determination of Th1/Th2/Th17 Cytokines in Patients  
Undergoing Allogeneic Hematopoietic Stem Cell Transplantation 
 
95 
when the patient is administered infusions of donor-derived lymphocytes. Graft versus 
tumor effect formed the basis of the so-called non-myeloablative transplants in which 
intensive chemotherapy regimen are substituted by the antitumoral effect of lymphocytes 
(Jacobsohn & Vogelsang, 2007). 
Factors inducing GVHD or the graft-versus-leukemia effect are not well defined and may to 
some extent be considered speculative. Minor histocompatibility antigens have been 
suggested to play a key role since some of them have limited expression in hematopoietic 
cells, including leukemic cells. These antigens are perhaps targeted by the selective effect of 
the graft-versus-leukemia effect while minor histocompatibility antigens that are expressed 
in general may be targeted by GVHD, but this is still not firmly established (Jacobsohn & 
Vogelsang 2007; Kolb, 2008; Riddell & Appelbaum, 2007). 
Various minor histocompatibility antigens are encoded in Y-chromosome genes that exhibit 
significant polymorphism with their homologues genes of the X chromosome. The former 
genes are responsible for the immune reactions occurring between men and women. 
Differential expression of the genes encoding for minor histocompatibility antigens in 
tissues has been proposed for potential use as a basis to separate the graft-versus-leukemia 
effect from GVHD. Cells that recognize minor histocompatibility antigens which are 
expressed only in hematopoietic cell receptors, including leukemic cells, may have a major 
role in the elimination of the latter without GVHD development. Several minor 
histocompatibility antigens such as HA-1, HA-2, HB-1 and BCL2A1 are expressed by 
hematopoietic cells and are therefore being examined as potential targets in order to 
promote the graft-versus-leukemia effect (Randolph et al., 2004; Kolb, 2008). 
2.6 Clinical relevance of regulation and induction of tolerance after allogenic 
hematopoietic cell transplantation 
The potential benefits of allogenic hematopoietic cell transplantation are offset by the 
moderate survival rate of the graft at long term. This is to a large extent due to 
immunosuppressant agents that unspecifically inhibit immune response in order to prevent 
rejection, but bring multiple adverse effects which are responsible for chronic rejection. 
Therefore, one of the major goals of allogenic hematopoietic cell transplantation is to achieve 
absence of immune response in the face of donor-derived alloantigens without requiring 
prolonged administration of immunosuppressants and to promote the graft-versus-
leukemia effect. To this end, research has focused on the study of regulatory T cells (Treg), 
particularly those of the CD4+CD25highFoxP3+ phenotype (natural Treg, nTreg) as they 
have been shown to be able to control immune response in the face of donor-derived 
alloantigens and therefore possess great potential to establish in vivo tolerance to the 
transplant. These cells have been studied the most but are not the only ones described as 
having a regulatory role since regulatory functions have also been observed in other 
subpopulations of CD4+ cells, in T CD8+ cells, T cells, NK cells and CD3+CD4-CD8-
CD16+56+ cells, also known as NKT cells. The latter have been shown to have a powerful 
anti-tumoral effect and are important in the maintenance of tolerance. This is why many 
studies are focusing on transfer of these cells. The strategy that is being sought for use in the 
near future is ex vivo stimulation of Treg purified with alloantigens of the donor or even 
FoxP3-mediated transfection of alloreactive CD4+CD25¯ cells (Bryceson & Ljunggren, 2007; 
Fehérvari & Sakaguchi, 2005). 
 
New Advances in Stem Cell Transplantation 
 
96
Natural regulatory T cells (nTreg) express from the time of their differentiation in the 
thymus, CD4+, CD25+ and FoxP3 (forkhead box P3 transcription factor) expression patterns. 
They were identified by Sakaguchi et al. (1995) as a natural subset of CD4+ T lymphocytes 
(approximately 5-10% of the T lymphocytes present in peripheral blood) that 
constitutively express the CD25 molecule and suppress the response of effector T 
lymphocytes (CD4+ and CD8+) in vivo. Another lymphocyte subpopulation in peripheral 
blood are CD4+CD25¯ cells, which through the action of TGF- and IL-2 may come  
to express CD25 and FoxP3, and are known as induced Treg (iTreg). Treg lymphocytes  
are also associated with low expression of CD127 which is positively correlated  
with regulatory function acquisition and negatively correlated with expression of  
FoxP3 (Curiel et al., 2004, Horwitz et al., 2008; Korn 2009; Liu et al., 2006; Seddiki et al.,  
2006). 
CD4+CD25+FoxP3+ Treg cells have a key role in the maintenance of peripheral tolerance, 
and Treg deficiencies give rise to progressive autoimmune disorders. Similarly, improved 
Treg function can prevent graft rejection and suppress tumor immunity. In other words, 
an adequate balance between Treg and effector T cells is essential for maintenance of 
tolerance. In the context of allogenic hematopoietic cell transplantation, Treg have also 
been shown to have a major role in the establishment of tolerance between tissues of the 
recipient and donor-derived immunity. This was initially shown to occur in murine 
models where Treg depletion in the stem cell graft produced increased in GVHD and 
increased Treg numbers resulted in suppression of GVHD after transplantation (Lee 
2005). In humans, patients with active cGVHD are reported to have a lower frequency of 
Treg than patients without cGVHD. These findings suggest that robust reconstitution of 
Treg post-allogenic hematopoietic cell transplantation is required to establish immune 
balance in order to be able to maintain adequate levels of peripheral tolerance. However, 
the mechanisms responsible for Treg reconstitution post-allogenic hematopoietic cell 
transplantation have not been adequately characterized and the factors contributing to 
inadequate recovery of Treg in patients who develop cGVHD are unknown (Matsuoka 
2010). 
Based on data obtained by Matsuoka et al. (2010) in patients examined during the first year 
after allogenic hematopoietic cell transplantation, thymus-dependent generation of Treg 
was considerably affected, but this subpopulation maintained high levels of cell 
proliferation in comparison to constitutive T cells. Such in vivo proliferation is apparently 
driven mainly by lymphopenia of CD4 cells. Among other findings, this study team has also 
shown that high levels of Treg proliferation were offset by higher susceptibility to apoptosis. 
Depletion of Treg in periphery in these patients was associated with development of 
extensive cGVHD. 
On the other hand and in reference to lymphocyte populations that may take part in 
development of tolerance to alloantigens, the subpopulation of CD8+ Treg has been recently 
characterized. These lymphocytes, despite a long history in the field of immunology as 
described by Gershon & Kondo in 1970, have been difficult to characterize, and this factor 
combined with the discovery of CD4 Treg by Hall et al. (1990) and Sakaguchi et al. (1995) 
have considerably limited this area. The importance of CD8 Treg lies in the regulatory role 
observed in experimental autoimmune encephalitis (Lu & Cantor, 2008; Wang & Alexander 
2009; Zheng et al., 2004). 
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The latter subpopulation has been said to be increased in peripheral blood analyses and 
infiltrated tissue of patients with colorectal cancer. Increased expression of TGF-β has also 
been found in these lymphocytes as compared to samples from healthy donors. These cells 
were able to suppress CD4+CD25- cell proliferation and cytokine Th1 production. The paper 
mentions the significance of immunological vigilance and the fact that CD8 Treg may 
promote tumoral growth. It also describes this cell subpopulation in patients with multiple 
sclerosis in whom lower numbers of these cells were correlated with relapse, a fact that may 
evidence their immunosuppressant role in the control of autoimmune diseases (Giovanni 
Frisullo, 2010; Chaput, 2009; Kiniwa, 2007). 
Recently described populations of CD8+ Treg include CD8+ IL-10+ cells present in ovarian 
carcinoma, which are induced by plasmocytoid dendritic cells infiltrating the tumor. This 
differentiation towards CD8+ Treg was shown to be independent of CD4+ Treg. All these 
antecedents combined with the generation of CD8+ Treg through continuous antigen 
stimulation may indicate the importance of the latter in GVHD control. 
3. Conclusions 
TNF levels have a major role in development and severity of graft-versus-host disease and 
can be used as a negative prognostic factor. 
Th1 response is essential and required in post-transplant patients to prevent relapse, graft 
loss and appearance of infections caused by opportunistic microorganisms. 
The Th17 profile has no essential role in development or severity of GVHD and is therefore 
not a target for therapy in these patients. 
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mentions the significance of immunological vigilance and the fact that CD8 Treg may 
promote tumoral growth. It also describes this cell subpopulation in patients with multiple 
sclerosis in whom lower numbers of these cells were correlated with relapse, a fact that may 
evidence their immunosuppressant role in the control of autoimmune diseases (Giovanni 
Frisullo, 2010; Chaput, 2009; Kiniwa, 2007). 
Recently described populations of CD8+ Treg include CD8+ IL-10+ cells present in ovarian 
carcinoma, which are induced by plasmocytoid dendritic cells infiltrating the tumor. This 
differentiation towards CD8+ Treg was shown to be independent of CD4+ Treg. All these 
antecedents combined with the generation of CD8+ Treg through continuous antigen 
stimulation may indicate the importance of the latter in GVHD control. 
3. Conclusions 
TNF levels have a major role in development and severity of graft-versus-host disease and 
can be used as a negative prognostic factor. 
Th1 response is essential and required in post-transplant patients to prevent relapse, graft 
loss and appearance of infections caused by opportunistic microorganisms. 
The Th17 profile has no essential role in development or severity of GVHD and is therefore 
not a target for therapy in these patients. 
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1. Introduction 
Allogeneic stem cell transplantation (SCT) is often the final treatment modality for patients 
with leukemia or other hematological malignancies (Schaap et al., 1997; Thomas & Blume, 
1999). However, relapse of the underlying malignancy is still a major complication post SCT. 
To prevent the occurrence of relapse post SCT, patients are treated with pre-emptive donor 
lymphocyte infusions (DLI) consisting of donor-derived T cells from the same donor used 
for allogeneic SCT in order to boost the donor-derived immune system to terminally 
eradicate residual tumour cells (Barge et al., 2003; Peggs et al., 2004; Schaap et al., 2001). 
Unfortunately, DLI treatment using donor-derived T cells does not only provoke graft-
versus-leukemia (GVL) reactivity, but also increases the risk for the development of graft-
versus-host disease (GVHD). Thus, post allogeneic SCT, long-term remission is still greatly 
dependent on effective GVL reactivity, while strictly controlling GVHD. Therefore, the 
development of treatment strategies augmenting GVL reactivity while reducing GVHD is of 
clinical importance. 
In allogeneic SCT, natural killer (NK) cells have shown to play an important role in GVL 
reactivity within the first months after transplantation (Cook et al., 2004; Giebel et al., 
2006; Ruggeri et al., 2002; van der Meer et al., 2008). Ruggeri et al. showed that alloreactive 
donor NK cells were able to lyse recipient tumour cells in vitro, implying that these NK 
cells may be able to provide immune reactivity by targeting residual tumour cells still 
present in the recipient (Ruggeri et al., 1999). Moreover, fast recovery of NK cells and 
predicted GVL reactivity towards host tumour cells has been associated with reduced 
GVHD, decreased relapse rates, and better overall survival of the patient (Kim et al., 
2005a; Kim et al., 2006; Ruggeri et al., 2007; Savani et al., 2007). Altogether, this makes NK 
cells important candidates for immunotherapeutic use in the treatment of leukemia and 
other malignancies. 
2. Natural Killer cells 
NK cells are members of the innate immune system. They are important in the initial phase 
of defense against infections and play an important role in tumour surveillance. Their name 
was based on their ability to kill target cells without prior sensitization (Kiessling et al., 
1975a; Kiessling et al., 1975b). As they are morphologically recognized as relatively large 
lymphocytes containing azurophilic granules, they have also been known as large granular 
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lymphocytes (LGL) (Herberman, 1986). NK cells comprise approximately 5-15% of the 
peripheral blood lymphocyte (PBL) population and are also found in lymph nodes, spleen, 
bone marrow, lung, liver, intestine, omentum and placenta (Vivier, 2006). NK cells are 
believed to originate from the same common lymphoid progenitor lineage as T and B cells in 
bone marrow (Spits et al., 1995). However, they do not rearrange T cell receptor genes or 
immunoglobulin (Ig) like, respectively, T and B cells do. 
Resting NK cells can be recognized based on their expression of CD56 (neural cell adhesion 
molecule; NCAM). Since CD56 is also expressed by other immune cells, NK cells are 
identified by the expression of CD56 combined with the lack of CD3, which are both present 
on NKT cells. NK cells can be further characterized based on their expression of CD56 in 
combination with CD16, a low affinity Fc receptor (Figure 1) (Cooper et al., 2001).  
In peripheral blood, approximately 90% of NK cells shows low expression of CD56 and high 
expression of CD16 on the cell surface. These cells are collectively referred to as the 
CD56dimCD16+ or CD56dim NK cell subset. The other 10% of NK cells shows a high level of 
CD56 expression and almost no expression of CD16 on the cell surface. Together, these cells 
are known as the CD56brightCD16+/- or CD56bright NK cell subset. The CD56dim NK cell subset 
is characterized by a highly cytolytic behaviour towards target cells, whereas CD56bright NK 
cells abundantly produce cytokines, such as IFN- and TNF-, upon activation. The 
production of cytokines by NK cells influences the TH1/TH2 bias of the adaptive immune 
response by activating TH1 cells. Thereby, NK cells form a bridge between innate and 
adaptive immunity (Seaman, 2000). 
 
 
Fig. 1. Natural Killer cell subsets. NK cells can be divided in two major subsets based on 
their expression of CD56 and CD16. CD56bright NK cells have a high CD56 and low CD16 
expression profile, and are specialized in cytokine secretion (e.g. TNF-, IFN-). In addition 
they highly express inhibitory receptor NKG2A. CD56dim NK cells have a low CD56 and 
high CD16 expression profile, and are highly cytolytic. Their function is predominantly 
inhibited through KIR. 
NK cells lyse susceptible target cells (e.g. virus infected cells, malignant transformed cells) 
by one of two mechanisms: “natural killing” (no prior sensitization) or antibody dependent 
cellular cytotoxicity (ADCC). Natural killing is initiated by activating signals from a variety 
of stimulatory receptors that can be inhibited by a variety of inhibitory receptors. In ADCC, 
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the activating receptor FcRIII (CD16) binds to the Fc piece of antibodies bound to target 
cells. In both mechanisms, target cells are lysed by the release of cytolytic proteins (i.e. 
granzymes and perforines) or by the induction of apoptosis (Bossi & Griffiths, 1999). 
2.1 NK cell receptors 
The NK cell receptor repertoire forms the basis for NK cell immune surveillance and NK cell 
activity. NK cell immune surveillance is regulated through the recognition of HLA class I 
molecules by inhibitory receptors. Subsequent activation of NK cells is triggered through 
the recognition of activating ligands by stimulatory receptors. 
2.1.1 Inhibitory receptors 
NK cells survey potential target cells for the absence or loss of expression of classical HLA 
class I molecules or non-classical HLA class I specific signals through inhibitory killer cell 
immunoglobulin-like receptors (KIRs) and lectin-like receptors (Farag & Caligiuri, 2006; 
Papamichail et al., 2004). The cytoplasmic domains of all inhibitory NK cell receptors 
contain an immunoreceptor tyrosine-based inhibitory motif (ITIM) (Burshtyn et al., 1996; 
Fry et al., 1996; Vivier & Daeron, 1997). These domains recruit intracellular tyrosine 
phosphatases SHP-1 or SHP-2 that mediate the inhibition of cytotoxicity and cytokine 
release (Burshtyn et al., 1996; Fry et al., 1996; Le et al., 1998; Olcese et al., 1996). 
The lectin-like receptor complex CD94:NKG2A forms an inhibitory receptor that recognizes 
non-classical HLA-E molecules (Braud et al., 1998). As the expression of HLA-E is promoted 
by the binding of signal sequence-derived peptides from HLA class I molecules, it is 
thought that HLA-E expression serves as a barometer of classical HLA class I expression 
(Braud et al., 1997). The purpose of the inhibitory CD94:NKG2A receptor complex may, 
therefore, be to monitor the overall HLA class I expression. KIRs, on the other hand, allow 
for a more subtle immune surveillance as these receptors scan the presence of specific 
classical HLA class I molecules. 
KIRs are encoded by a family of polymorphic and highly homologous genes, and recognize 
polymorphic epitopes present on HLA-A, -B, or -C molecules; HLA-A3 and -A11 are 
recognized by KIR3DL2, HLA-Bw4 is recognized by KIR3DL1 and receptors KIR2DL1, 
KIR2DL2, and KIR2DL3 are able to distinguish HLA-C into HLA group C1 and HLA group 
C2 molecules (Parham, 2005). The various KIRs are classified by the number of 
immunoglobulin-like (Ig) extracellular domains as 2-domain (2D) or 3-domain (3D). They 
are further subdivided on the basis of the length of their cytoplasmic tail L (long) or S (short) 
(Vilches & Parham, 2002). Different KIRs sharing the same number of Ig domains and length 
of the cytoplasmic tail are distinguished by number at the end of their name, e.g. KIR2DL2 
or KIR2DL3. KIRs are clonally distributed among NK cells within each individual, which 
creates a complex combinatorial repertoire of NK cell specificities for HLA class I molecules 
(Vilches & Parham, 2002). 
2.1.2 Stimulatory receptors 
Some members of the CD94:NKG2 receptor and KIR family have stimulatory properties. 
NKG2C is a stimulatory member of the CD94:NKG2 family and competes with 
CD94:NKG2A for the recognition of HLA-E (Braud et al., 1998; Houchins et al., 1997). 
KIR2DS and KIR3DS are stimulatory members of the KIR family (Biassoni et al., 1996; 
Bottino et al., 1996; Moretta et al., 1995). Instead of ITIM, these stimulatory receptors contain 
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lymphocytes (LGL) (Herberman, 1986). NK cells comprise approximately 5-15% of the 
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the activating receptor FcRIII (CD16) binds to the Fc piece of antibodies bound to target 
cells. In both mechanisms, target cells are lysed by the release of cytolytic proteins (i.e. 
granzymes and perforines) or by the induction of apoptosis (Bossi & Griffiths, 1999). 
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(Braud et al., 1997). The purpose of the inhibitory CD94:NKG2A receptor complex may, 
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KIR2DL2, and KIR2DL3 are able to distinguish HLA-C into HLA group C1 and HLA group 
C2 molecules (Parham, 2005). The various KIRs are classified by the number of 
immunoglobulin-like (Ig) extracellular domains as 2-domain (2D) or 3-domain (3D). They 
are further subdivided on the basis of the length of their cytoplasmic tail L (long) or S (short) 
(Vilches & Parham, 2002). Different KIRs sharing the same number of Ig domains and length 
of the cytoplasmic tail are distinguished by number at the end of their name, e.g. KIR2DL2 
or KIR2DL3. KIRs are clonally distributed among NK cells within each individual, which 
creates a complex combinatorial repertoire of NK cell specificities for HLA class I molecules 
(Vilches & Parham, 2002). 
2.1.2 Stimulatory receptors 
Some members of the CD94:NKG2 receptor and KIR family have stimulatory properties. 
NKG2C is a stimulatory member of the CD94:NKG2 family and competes with 
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Bottino et al., 1996; Moretta et al., 1995). Instead of ITIM, these stimulatory receptors contain 
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a positively charged amino acid residue in their transmembrane domain that associates with 
the negatively charged DAP-12 molecule. DAP-12 contains an immunoreceptor tyrosine-
based activating motif (ITAM) (Lanier et al., 1998). There is evidence that the stimulatory 
KIRs bind self-HLA class I molecules with lower affinity as compared with the inhibitory 
receptors (Vales-Gomez et al., 1998a; Vales-Gomez et al., 1998b). Thus autoimmunity can be 
prevented by a balance towards negative NK cell regulation. Similar to the inhibitory 
receptors, the HLA class I-specific stimulatory receptors are expressed in a variegated and 
predominantly stochastic fashion by NK cells (Raulet et al., 2001). 
Besides stimulatory members of the CD94:NKG2 receptor and KIR family, NK cells also 
express a variety of other stimulatory receptors. The biological roles of many of these 
receptors are not well understood, primarily because the ligands for these receptors have 
not been fully identified. The main triggering receptors for NK cell activity are the natural 
cytotoxicity receptors (NCR) and NKG2D (Arnon et al., 2001; Bauer et al., 1999; Mandelboim 
et al., 2001; Sivori et al., 1997). Their stimulation causes direct killing of target cells and their 
stimulatory signals can even override the inhibition of NK cells. 
NCR consist of three members; NKp30, NKp44, and NKp46. NCR belong to the 
immunoglobulin superfamily and molecular cloning of NCR confirmed that they are 
structurally distinct (Bottino et al., 2000; Pende et al., 1999). The ligands for NCR remain 
controversial. Some groups have proposed viral antigens as being the ligands for NCR 
based on their role in the lysis of virus infected cells (Arnon et al., 2001; Arnon et al., 2005; 
Mandelboim et al., 2001). NCR have also been shown to mediate lysis of tumour cells and 
that NK cells with a NCRdull phenotype are unable to kill tumour cells, suggesting that their 
ligands may be upregulated or induced upon malignant transformation of cells (Bottino et 
al., 2005; Fauriat et al., 2005; Fauriat et al., 2007). NKp30 and NKp46 are both uniquely 
expressed on resting and activated NK cells, whereas NKp44 is only present on IL-2 
activated NK cells (Cantoni et al., 1999). 
Unlike NKG2A, NKG2D is not associated with CD94, but is a homodimer that needs 
association to the adaptor molecule DAP10 for stable cell surface expression (Wu et al., 
1999). NKG2D recognizes HLA class I-like molecules, such as MIC A and MIC B. It has been 
shown that the expression of NKG2D ligands, i.e. MIC A/B, ULPB1, ULPB2, and ULPB3, are 
upregulated by cells in times of stress, virus infection, and malignant transformation (Bauer 
et al., 1999; Cosman et al., 2001; Farrell et al., 2000). NKG2D is constitutively expressed on all 
human NK cells and can be upregulated through stimulation by IL-15, IL-12 and IFN- 
(Diefenbach et al., 2000; Sutherland et al., 2006). Stimulation of NKG2D complements NCR 
activation in mediating NK cell lysis of tumour cells (Pende et al., 2001). Similarly, 
cooperation between NKG2D and stimulatory KIRs has been shown for both cytolytic 
activity and IFN- secretion (Wu et al., 2000). Therefore, it is possible that NKG2D may serve 
both as a primary stimulatory receptor, whose engagement triggers cytotoxicity, and also as 
a co-stimulatory receptor, which cooperates with other activating receptors (e.g. activating 
KIR or NCR) for cytokine secretion. A similar phenomenon is seen on cytomegalovirus-
specific T cells, where NKG2D acts as a co-stimulatory receptor for TCR-dependent signals 
(Das et al., 2001; Groh et al., 2001; Ugolini & Vivier, 2001).  
Other stimulatory receptors that are involved in NK cell activation are co-stimulatory 
receptors NKp80 and 2B4 (CD244) (Biassoni et al., 2001). NKp80 and 2B4 both function 
synergistically with NCR (Sivori et al., 2000; Vitale et al., 2001). In addition, CD16, CD69 and 
DNAM-1 have been shown to trigger NK cell-mediated lysis in redirected cytotoxicity 
assays (Lanier et al., 1988; Moretta et al., 1991; Shibuya et al., 1996). 
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2.2 NK cell allorecognition 
2.2.1 The “missing self” hypothesis 
In 1976, Snell et al. observed a correlation between the susceptibility of target cells to NK cell 
lysis and the absence or loss of expression of HLA class I molecules on the target cells (Snell, 
1976). Absent or low expression of HLA class I molecules is common in virus infected and 
malignant transformed cells, which are the usual targets for NK cell lysis. Therefore, they 
proposed that NK cell receptors may not only interact with HLA class I molecules, but that 
these receptors are also able to detect a decrease in HLA class I expression. 
It was not until 10 years later that Kärre and Ljunggren demonstrated the regulation of NK 
cell activity (Kärre et al., 1986a). They showed that murine lymphoma cells with low, or 
absent, MHC class I expression were less malignant than wild-type cells after low dose 
inoculation in syngeneic mice, and that the rejection of these cells was regulated through 
innate immunity, preferably through NK cell-mediated lysis (Kärre et al., 1986b). Resistance 
to NK cell-mediated lysis of tumours with low MHC class I expression could be restored by 
reintroduction of MHC class I molecules (Franksson et al., 1993; Ljunggren et al., 1990). 
Based on these data, they proposed the “missing self” hypothesis, which is nowadays still 
appreciated as the basic model for NK cell activation (Figure 2) (Ljunggren & Kärre, 1990). 
2.2.2 Licensed to kill 
As the KIR repertoire of NK cells is encoded by a set of highly polymorphic genes and 
segregates independently from HLA class I genes during NK cell development, it is 
essential that the KIR repertoire of NK cells properly corresponds with the HLA 
environment to provide self-tolerance and prevent autoimmunity. There have been several 
hypotheses on the acquisition of self-tolerance by NK cells. Raulet et al. proposed that an 
individual NK cell can simultaneously express multiple inhibitory KIRs in a stochastic 
fashion (Raulet et al., 2001). The only rule appears to be that every NK cell has at least one 
inhibitory KIR specific for self-HLA class I in order to avoid autoreactivity. This is referred 
to as the “at least one receptor” model (Raulet et al., 2001). Others have suggested a 
“receptor calibration” model in which the acquisition of the KIR repertoire may be related to 
changes in the HLA class I environment and is dependent on the HLA class I haplotype 
(Salcedo et al., 1997; Sentman et al., 1995; Valiante et al., 1997). However, these studies 
involved in vitro cultures that could alter the intrinsic features of NK cells that may be 
different from the in vivo situation.  
Recently, the acquisition of self-tolerance was demonstrated in an in vivo murine study. Kim 
et al. showed that NK cells from MHC-deficient mice were functionally immature as they 
were defective in cytokine secretion upon ex vivo stimulation as compared with wild type 
NK cells, indicating that MHC-specific receptors are involved in the acquisition of 
functional competence (Kim et al., 2005b). They also found a correlation between the 
expression of an inhibitory receptor for self-MHC class I and the capacity of an individual 
naive NK cell to be activated to produce cytokines and lyse susceptible target cells. Based on 
their findings they proposed the “licensing” model, in which NK cells acquire functional 
competence through “licensing” by self-HLA class I molecules, resulting in two types of 
self-tolerant NK cells: licensed or unlicensed. This model was confirmed by others, both in 
mice and human, demonstrating that NK cells without expression of known self-receptors 
were found to be hyporesponsive (Cooley et al., 2007; Fernandez et al., 2005). Thus, in order 
for NK cells to get their “license to kill”, they need to fulfil the requirement of HLA class I-
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a positively charged amino acid residue in their transmembrane domain that associates with 
the negatively charged DAP-12 molecule. DAP-12 contains an immunoreceptor tyrosine-
based activating motif (ITAM) (Lanier et al., 1998). There is evidence that the stimulatory 
KIRs bind self-HLA class I molecules with lower affinity as compared with the inhibitory 
receptors (Vales-Gomez et al., 1998a; Vales-Gomez et al., 1998b). Thus autoimmunity can be 
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receptors, the HLA class I-specific stimulatory receptors are expressed in a variegated and 
predominantly stochastic fashion by NK cells (Raulet et al., 2001). 
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receptors are not well understood, primarily because the ligands for these receptors have 
not been fully identified. The main triggering receptors for NK cell activity are the natural 
cytotoxicity receptors (NCR) and NKG2D (Arnon et al., 2001; Bauer et al., 1999; Mandelboim 
et al., 2001; Sivori et al., 1997). Their stimulation causes direct killing of target cells and their 
stimulatory signals can even override the inhibition of NK cells. 
NCR consist of three members; NKp30, NKp44, and NKp46. NCR belong to the 
immunoglobulin superfamily and molecular cloning of NCR confirmed that they are 
structurally distinct (Bottino et al., 2000; Pende et al., 1999). The ligands for NCR remain 
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ligands may be upregulated or induced upon malignant transformation of cells (Bottino et 
al., 2005; Fauriat et al., 2005; Fauriat et al., 2007). NKp30 and NKp46 are both uniquely 
expressed on resting and activated NK cells, whereas NKp44 is only present on IL-2 
activated NK cells (Cantoni et al., 1999). 
Unlike NKG2A, NKG2D is not associated with CD94, but is a homodimer that needs 
association to the adaptor molecule DAP10 for stable cell surface expression (Wu et al., 
1999). NKG2D recognizes HLA class I-like molecules, such as MIC A and MIC B. It has been 
shown that the expression of NKG2D ligands, i.e. MIC A/B, ULPB1, ULPB2, and ULPB3, are 
upregulated by cells in times of stress, virus infection, and malignant transformation (Bauer 
et al., 1999; Cosman et al., 2001; Farrell et al., 2000). NKG2D is constitutively expressed on all 
human NK cells and can be upregulated through stimulation by IL-15, IL-12 and IFN- 
(Diefenbach et al., 2000; Sutherland et al., 2006). Stimulation of NKG2D complements NCR 
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cooperation between NKG2D and stimulatory KIRs has been shown for both cytolytic 
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a co-stimulatory receptor, which cooperates with other activating receptors (e.g. activating 
KIR or NCR) for cytokine secretion. A similar phenomenon is seen on cytomegalovirus-
specific T cells, where NKG2D acts as a co-stimulatory receptor for TCR-dependent signals 
(Das et al., 2001; Groh et al., 2001; Ugolini & Vivier, 2001).  
Other stimulatory receptors that are involved in NK cell activation are co-stimulatory 
receptors NKp80 and 2B4 (CD244) (Biassoni et al., 2001). NKp80 and 2B4 both function 
synergistically with NCR (Sivori et al., 2000; Vitale et al., 2001). In addition, CD16, CD69 and 
DNAM-1 have been shown to trigger NK cell-mediated lysis in redirected cytotoxicity 
assays (Lanier et al., 1988; Moretta et al., 1991; Shibuya et al., 1996). 
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specific receptor engagement by self-HLA. There appears to be one exception to this rule: 
Orr et al. showed in a mouse model that, contrary to the licensing hypothesis, unlicensed NK 
cells were the main mediators of NK cell-mediated control of mouse cytomegalovirus 
infection (MCMV) in vivo (Orr et al., 2010). It would be highly relevant to check whether 
such a cell population harbours increased allo- or tumour reactivity. 
 
 
Fig. 2. “Missing self” hypothesis. NK cell activity depends on a balance between inhibitory 
(i.e. KIR, CD94/NKG2A) and stimulatory (e.g. NCR, NKG2D) signals. In steady state, NK 
cells are inhibited from activation by the recognition of self-HLA class I molecules, which 
overrules potential stimulatory signals (self recognition). In case of virus infection or 
malignant transformation, cells may downregulate self-HLA class I molecules, while 
upregulating activating ligands that trigger NK cells to respond resulting in lysis of the 
infected/transformed cells (missing self).  After allogeneic SCT, donor NK cells may be 
triggered by host leukemic cells due to reduced HLA-matched class I molecules (HLA-
matched SCT), or the presence of non-self HLA class I molecules (HLA-mismatched SCT), 
combined with strong stimulation by upregulated activating ligands. 
3. NK cells and their therapeutic role in SCT 
3.1 Evidence for GVL 
Deficient HLA class I expression has been described for leukemic cells making them 
susceptible targets for NK cell-mediated lysis. However, this phenomenon was not 
ubiquitously observed in the autologous setting for patients with different forms of 
leukemia. In CML, NK cell numbers and NK cell function have been shown to decrease 
progressively during the spontaneous course of the disease, but could be recovered upon 
IFN- treatment (Pawelec et al., 1995; Pierson & Miller, 1996). Moreover, activated 
autologous NK cells were shown to suppress the growth of primitive CML progenitors in 
long-term in vitro cultures (Cervantes et al., 1996). In AML, however, autologous NK cells 
were demonstrated to be impaired in their cytolytic function, which correlated with a low 
NCR cell surface density (NCRdull) (Fauriat et al., 2007). Moreover, these NK cells were 
impaired in regulating DC physiology (killing the surplus of immature DCs), which could 
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lead to specific T cell tolerization by expanded immature DCs expressing leukemia-derived 
antigens (Fauriat et al., 2005). Allogeneic SCT may overcome the impairment of NK cell-
mediated lysis. 
In different allogeneic SCT settings, NK cells have been shown to play an important role in 
the anti-tumour response within the first months after transplantation (Cook et al., 2004; 
Giebel et al., 2006; Ruggeri et al., 2002; van der Meer et al., 2008). In haploidentical SCT, 
Ruggeri et al. showed that donor alloreactive NK cells isolated from peripheral blood of the 
recipient were able to lyse tumour cells derived from the recipient, implying that within one 
month after SCT, NK cells may be able to provide some degree of immune reactivity by 
targeting residual tumour cells still present in the recipient (Ruggeri et al., 1999). Moreover, 
fast recovery of NK cells and predicted GVL reactivity towards host tumour cells has been 
associated with decreased relapse rates and better overall survival of the patient (Kim et al., 
2006; Ruggeri et al., 2007; Savani et al., 2007). Altogether these data suggest that NK cells 
play an important role in the control and clearance of leukemic cells after allogeneic SCT. 
3.2 Evidence for the prevention of GVHD 
The haploidentical transplantations performed by Ruggeri et al. additionally suggested that 
NK cells may prevent the development of GVHD (Ruggeri et al., 2002). For patients, the 
prevalence of GVHD was significantly lower using grafts with potential NK cell 
alloreactivity in the GVL direction as compared with grafts without potential NK cell 
alloreactivity. In a murine model, they demonstrated that mice transplanted with non-T cell 
depleted grafts could be rescued from GVHD upon infusion of alloreactive NK cells. Mice 
infused with non-alloreactive NK cells died as they were not protected from GVHD. They 
also demonstrated that alloreactive NK cells are able to lyse recipient antigen presenting 
cells (APCs), thereby preventing interaction with donor T cells which otherwise would 
initiate GVHD. Recently, a novel mechanism for NK cell-mediated GVHD reduction was 
demonstrated, whereby alloreactive donor NK cells were able to inhibit and lyse alloreactive 
donor T cells during the initiation of GVHD (Olson et al., 2010). Overall, these studies 
demonstrate that alloreactive NK cells may, directly or indirectly, reduce or prevent the 
occurrence of GVHD while retaining GVL reactivity.  
4. Exploitation of NK cell alloreactivity 
4.1 Infusion of mature donor NK cells as part of the graft 
Immediately after allogeneic SCT, alloreactive NK cells have been shown to be beneficial not 
only for boosting the anti-tumour response, but also for the prevention of GVHD as well as 
infections. In these cases, optimal functional activity of NK cells already in the early phase 
after SCT is essential, and therefore the presence of NK cells in the graft appears to be 
beneficial for transplant outcome (Bethge et al., 2006; Kim et al., 2005a).  
As part of a prospective randomized phase III study, we directly compared the alloreactive 
potential of allogeneic donor NK cells between patients having either received a 
CD3+/CD19+ cell depleted graft (containing substantial NK cell numbers) or a conventional 
CD34+ selected graft (devoid of NK cells) in the setting of HLA-matched SCT (Eissens et al., 
2010a). Results demonstrate that patients having received a CD3+/CD19+ cell depleted graft, 
exhibited a faster recovery of NK cells and a functional NK cell receptor repertoire of 
inhibitory and stimulatory receptors as compared with patients having received a 
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specific receptor engagement by self-HLA. There appears to be one exception to this rule: 
Orr et al. showed in a mouse model that, contrary to the licensing hypothesis, unlicensed NK 
cells were the main mediators of NK cell-mediated control of mouse cytomegalovirus 
infection (MCMV) in vivo (Orr et al., 2010). It would be highly relevant to check whether 
such a cell population harbours increased allo- or tumour reactivity. 
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lead to specific T cell tolerization by expanded immature DCs expressing leukemia-derived 
antigens (Fauriat et al., 2005). Allogeneic SCT may overcome the impairment of NK cell-
mediated lysis. 
In different allogeneic SCT settings, NK cells have been shown to play an important role in 
the anti-tumour response within the first months after transplantation (Cook et al., 2004; 
Giebel et al., 2006; Ruggeri et al., 2002; van der Meer et al., 2008). In haploidentical SCT, 
Ruggeri et al. showed that donor alloreactive NK cells isolated from peripheral blood of the 
recipient were able to lyse tumour cells derived from the recipient, implying that within one 
month after SCT, NK cells may be able to provide some degree of immune reactivity by 
targeting residual tumour cells still present in the recipient (Ruggeri et al., 1999). Moreover, 
fast recovery of NK cells and predicted GVL reactivity towards host tumour cells has been 
associated with decreased relapse rates and better overall survival of the patient (Kim et al., 
2006; Ruggeri et al., 2007; Savani et al., 2007). Altogether these data suggest that NK cells 
play an important role in the control and clearance of leukemic cells after allogeneic SCT. 
3.2 Evidence for the prevention of GVHD 
The haploidentical transplantations performed by Ruggeri et al. additionally suggested that 
NK cells may prevent the development of GVHD (Ruggeri et al., 2002). For patients, the 
prevalence of GVHD was significantly lower using grafts with potential NK cell 
alloreactivity in the GVL direction as compared with grafts without potential NK cell 
alloreactivity. In a murine model, they demonstrated that mice transplanted with non-T cell 
depleted grafts could be rescued from GVHD upon infusion of alloreactive NK cells. Mice 
infused with non-alloreactive NK cells died as they were not protected from GVHD. They 
also demonstrated that alloreactive NK cells are able to lyse recipient antigen presenting 
cells (APCs), thereby preventing interaction with donor T cells which otherwise would 
initiate GVHD. Recently, a novel mechanism for NK cell-mediated GVHD reduction was 
demonstrated, whereby alloreactive donor NK cells were able to inhibit and lyse alloreactive 
donor T cells during the initiation of GVHD (Olson et al., 2010). Overall, these studies 
demonstrate that alloreactive NK cells may, directly or indirectly, reduce or prevent the 
occurrence of GVHD while retaining GVL reactivity.  
4. Exploitation of NK cell alloreactivity 
4.1 Infusion of mature donor NK cells as part of the graft 
Immediately after allogeneic SCT, alloreactive NK cells have been shown to be beneficial not 
only for boosting the anti-tumour response, but also for the prevention of GVHD as well as 
infections. In these cases, optimal functional activity of NK cells already in the early phase 
after SCT is essential, and therefore the presence of NK cells in the graft appears to be 
beneficial for transplant outcome (Bethge et al., 2006; Kim et al., 2005a).  
As part of a prospective randomized phase III study, we directly compared the alloreactive 
potential of allogeneic donor NK cells between patients having either received a 
CD3+/CD19+ cell depleted graft (containing substantial NK cell numbers) or a conventional 
CD34+ selected graft (devoid of NK cells) in the setting of HLA-matched SCT (Eissens et al., 
2010a). Results demonstrate that patients having received a CD3+/CD19+ cell depleted graft, 
exhibited a faster recovery of NK cells and a functional NK cell receptor repertoire of 
inhibitory and stimulatory receptors as compared with patients having received a 
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conventional CD34+ graft. Furthermore, transplantation with a CD3+/CD19+ cell depleted 
graft resulted in the development of a functionally different NK cell population that was 
more prone to activation via the CD94:NKG2C receptor complex and less sensitive to 
inhibition via the CD94:NKG2A receptor complex. Although it was demonstrated that 
human cytomegalovirus (CMV) infection may result in increased CD94:NKG2C expression 
levels and subsequent loss of CD94:NKG2A expression (Guma et al., 2004; Guma et al., 2006; 
van Stijn et al., 2008), this phenomenon remained present in the CD3/19 depletion group 
after exclusion of CMV positive patients from analysis. Unfortunately, later interim analysis 
on 25 patients per group showed that the primary objectives of this clinical study could not 
be reached resulting in early termination of the study. Thus, the alternative reconstitution of 
the NK cell receptor repertoire using CD3+/19+ depleted grafts, characterized by the change 
in balance of CD94:NKG2A+ NK cells to more CD94:NKG2C+ NK cells, and its impact on 
clinical outcomes after HLA-matched SCT remains a subject for further study. 
Recently, the reconstitution of allogeneic donor NK cells was evaluated in haploidentical 
SCT after reduced intensity conditioning (RIC) using CD3+/19+ depleted grafts (Federmann 
et al., 2011). Data showed similar results as compared with our study, including fast 
recovery of NK cells and fast immune reconstitution of the NK cell receptor repertoire. In 
addition, a similar decrease of NKG2A+ NK cells was seen post SCT. However, the 
expression of NKG2C was not evaluated. Nevertheless, this study confirms our findings 
that different graft manipulation methods may trigger differential NK cell reconstitution, 
which may be beneficial for transplant outcome. Previously, Gentilini et al. even showed a 
significant faster and sustained recovery of NK cells in a group of patients after RIC 
allogeneic SCT with CD3+/CD19+ depleted grafts in comparison with patients with 
myeloablative allogeneic SCT with CD34+ selected grafts combined with adoptive NK cell 
infusion two days post SCT (Gentilini et al., 2007).  
Overall, these studies suggest that the use of NK cell rich grafts is favourable for the 
facilitation of fast and sustained NK cell recovery and differential reconstitution of the NK 
cell receptor repertoire, which may lead to improved donor NK cell alloreactivity in the 
GVL direction (Eissens et al., 2010a). Further prospective comparisons of the different graft 
manipulation methods for allogeneic SCT in the HLA-matched or haploidentical setting are 
warranted for more detailed analysis of the impact of graft composition on immune 
reconstitution. Subsequently, the impact of adoptive NK cell infusions after allogeneic SCT 
for boosting GVL reactivity needs to be studied in further detail. 
4.2 Skewing donor NK cell alloreactivity before SCT 
In allogeneic SCT, donor NK cell alloreactivity can be facilitated by allowing mismatches for 
specific HLA molecules (e.g. HLA-C) between donor and recipient. This is referred to as the 
“ligand-ligand” model. The introduction of certain HLA mismatches has been shown to 
induce NK cell-mediated GVL reactivity, without inducing severe GVHD, and to contribute to 
decreased relapse, better engraftment and improved overall survival (Ruggeri et al., 1999; 
Ruggeri et al., 2004; Ruggeri et al., 2007). However, others state that the induction of NK cell 
alloreactivity is not dependent on HLA mismatching, but is rather induced by the presence of 
an inhibitory KIR in the donor’s genotype with the absence of the corresponding KIR-ligand in 
the recipient’s HLA repertoire (“receptor-ligand” model) (Hsu et al., 2005; Leung et al., 2004; 
Leung et al., 2005). This makes the exploitation of NK cell alloreactivity not only feasible for 
HLA-mismatched settings, but may also be promising for HLA-matched settings. 
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For further exploitation, however, the “licensing/education” model needs to be considered 
as well. Upon maturation, NK cells obtain their “license to kill” through interactions of 
inhibitory KIRs with self-HLA class I molecules (Parham, 2006; Raulet & Vance, 2006; Vivier 
et al., 2008). NK cells that fail to interact with self-HLA class I molecules remain functionally 
immature and will reside in a hyporesponsive state. Recently, it was shown that the strength 
of response by an individual NK cell is even quantitatively controlled by the extent of 
inhibitory signals that are received from HLA class I molecules during NK cell education 
(Brodin et al., 2009). Concerning adoptive transfer of mature NK cells for 
immunotherapeutic purposes, this suggests that the presence of inhibitory KIR on donor NK 
cells in absence of its cognate ligand in the recipient (“receptor-ligand” model) as well as the 
HLA-background of the donor NK cells (“licensing/education” model) are two key factors 
that need to be taken into account for the successful exploitation of alloreactive donor NK 
cell responses. 
4.3 Interference by immunosuppressive drugs 
For optimal NK cell-mediated GVL reactivity, NK cells need to be fully functional in the 
early phase after allogeneic SCT, despite that at this stage a high level of 
immunosuppressive treatment is given. Among the various immunosuppressive drugs 
(ISDs), cyclosporin A (CsA), rapamycin (Rapa) and mycophenolate mofetil (MMF) have 
successfully been applied for the prevention of GVHD (Cutler et al., 2007; Haentzschel et al., 
2008; Neumann et al., 2005; Schleuning et al., 2008; Vogelsang & Arai, 2001). Therefore, we 
studied the influence of CsA, Rapa and mycophenolic acid (MPA; the active metabolite of 
MMF) on NK cell phenotype and function in an in vitro cytokine-based culture system 
(Eissens et al., 2010b). Results showed that the modulation of the NK cell receptor repertoire 
during culture was arrested by Rapa and MPA treatment. This was reflected in the cytolytic 
activity, as MPA- and Rapa-treated NK cells, in contrast to CsA-treated NK cells, lost their 
cytotoxicity against leukemic target cells. In contrast, IFN- production was not only 
impaired by MPA and Rapa, but also by CsA upon target encounter. A recent study, 
however, suggested that IFN- production upon target encounter may be limited to the 
CD56dim NK cell subset, whereas the CD56bright NK cell subset produces IFN- upon 
cytokine-stimulation (Fauriat et al., 2010). Thus, as CD56bright NK cells were still abundantly 
present in the CsA-treated cultures, in contrast to MPA- and Rapa-treated cultures, the IFN-
 production upon cytokine stimulation may largely be preserved after CsA treatment. This 
was confirmed in a study showing sustained IFN- production by CsA-treated NK cell 
cultures upon IL-12 and IL-18 stimulation (Wang et al., 2007), suggesting that IFN--
mediated GVL reactivity after allogeneic SCT should remain intact when using CsA as 
GVHD prophylaxis. 
Our findings on the effect of CsA and MPA on the cytolytic response by in vitro cytokine-
stimulated NK cells are in concert with previous findings on this subject (Ohata et al., 2011). 
Besides CsA and MPA, they also evaluated the effect of tacrolimus (TAC) and methotrexate 
(MTX), which are also successfully used as GVHD prophylaxis after allogeneic SCT (Alyea 
et al., 2008; Cutler et al., 2007; Ho et al., 2009). Both ISDs did not interfere with NK cell-
mediated cytolytic activity against different leukemic cell lines. However, a dose range of 
each ISD is lacking in this study, which would be more appropriate when studying the 
effect of ISDs on NK cell functionality.    
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conventional CD34+ graft. Furthermore, transplantation with a CD3+/CD19+ cell depleted 
graft resulted in the development of a functionally different NK cell population that was 
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For further exploitation, however, the “licensing/education” model needs to be considered 
as well. Upon maturation, NK cells obtain their “license to kill” through interactions of 
inhibitory KIRs with self-HLA class I molecules (Parham, 2006; Raulet & Vance, 2006; Vivier 
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mediated cytolytic activity against different leukemic cell lines. However, a dose range of 
each ISD is lacking in this study, which would be more appropriate when studying the 
effect of ISDs on NK cell functionality.    
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Overall, these in vitro studies clearly suggest that the choice of immunosuppressive 
treatment might affect the outcome of NK cell immunotherapy in vivo after transplantation. 
Additional studies on NK cell phenotype and function of patients after allogeneic SCT using 
different immunosuppressive strategies are warranted to survey the in vivo effect of the 
different immunosuppressive regimens in more detail.  
4.4 Clinical grade NK cell products for adoptive cancer immunotherapy 
4.4.1 Development of clinical grade NK cell products 
The facilitation of donor NK cell alloreactivity is not restricted to HLA-
matched/mismatched allogeneic SCT, but may also be exploited for adoptive 
immunotherapy in non-transplantation settings. Previously, several clinical studies have 
examined the feasibility of allogeneic NK cells for adoptive immunotherapy using 
allogeneic NK cells selected from leukapheresis products by immunomagnetic beads 
selection protocols (Iyengar et al., 2003; Klingemann & Martinson, 2004; Koehl et al., 2005; 
McKenna, Jr. et al., 2007; Meyer-Monard et al., 2009; Passweg et al., 2004). In all these 
studies, the adoptive transfer of allogeneic NK cells proved to be safe and well tolerated by 
patients. Nevertheless, for optimal exploitation of NK cell adoptive immunotherapy, the 
development of innovative strategies producing allogeneic NK cell products with high cell 
numbers, high purity and functionality are needed. In this respect, recent studies have 
developed culture systems for large scale ex vivo expansion of allogeneic NK cells using 
either hematopoietic progenitor cells from bone marrow or UCB (Carayol et al., 1998; Kao et 
al., 2007; Miller et al., 1992). However, most of these culture systems are unsuitable for 
clinical application due to the use of animal sera, animal-derived proteins, and/or 
supportive feeder cells. 
Previously, in our centre a cytokine-based method for high log-scale ex vivo expansion of 
functional allogeneic NK cells from hematopoietic stem and progenitor cells from umbilical 
cord blood (UCB) using a novel clinical grade medium was developed (Spanholtz et al., 
2010). The ex vivo generated NK cell products are of high purity and contain 
developmentally mature NK cell populations expressing inhibitory NKG2A and KIRs, and a 
variety of stimulatory receptors. Furthermore, these NK cell products show the ability to 
efficiently kill myeloid leukemia and melanoma tumour cell lines. The findings in this study 
provide an important advance for the clinical application of ex vivo generated NK cell 
products to be exploited for adoptive immunotherapy either following allogeneic SCT for 
boosting NK cell-mediated GVL reactivity or in the non-transplant setting following 
lymphodepleting immunosuppressive regimens. In addition, human in vitro studies and in 
vivo evidence in mice suggest that NK cell-based immunotherapy may also be beneficial for 
patients with melanoma or renal cell carcinoma when applied in the setting of the “receptor-
ligand” model (Burke et al., 2010; Igarashi et al., 2004; Lakshmikanth et al., 2009). Overall, 
further exploitation of this culture system may provide a broad clinical application for NK 
cell-based immunotherapy against hematological and non-hematological malignancies.  
4.4.2 Clinical feasibility of ex vivo generated NK cells: a phase I trial 
Recently, the NK cell generation protocol described by Spanholtz et al. was transferred to 
clinical applicable conditions (Spanholtz et al., 2011) and medical ethical approval was given 
to study the feasibility of adoptive transfer of ex vivo generated NK cell products in elderly 
patients diagnosed with poor prognosis AML (Spanholtz et al., 2010). In the second quartile 
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of 2011, a phase I dose-escalating study has started for a group of 12 AML patients (age >65 
years), not eligible for allogeneic SCT, who have achieved clinical remission after standard 
remission-induction chemotherapy and who have completed consolidation chemotherapy. 
Patients will receive allogeneic NK cells generated ex vivo from CD34+ UCB cells in a single 
escalating dose up to 10x107 donor NK cells/kg body weight after completing standard 
chemotherapy and preparative immunosuppressive conditioning consisting of fludarabine 
and cyclophosphamide in order to prevent rejection. The primary goal is to evaluate the 
safety and dose-limiting toxicity of adoptive transfer of the allogeneic ex vivo generated NK 
cells. Secondly, the in vivo lifespan of the adoptively transferred allogeneic NK cells will be 
evaluated together with an assessment of NK cell-mediated GVL reactivity in study 
participants.  
5. Towards NK cell immunotherapy 
Within the last decade, different NK cell-based immunotherapy strategies have successfully 
been developed. They have either already been proved safe in clinical phase I/II trials or are 
currently under clinical evaluation. Today, applications for NK cell-based immunotherapy 
can generally be divided into three main categories: (1) the use of enriched NK cell grafts for 
allogeneic SCT; (2) administering NK-DLI after allogeneic SCT and; (3) adoptive NK cell 
transfer in non-transplantation settings (Figure 3).  
 
 
Fig. 3. Applications for NK cell-based immunotherapy. In the allogeneic SCT setting, 
patients are first treated with a conditioning regimen to eradicate healthy hematopoietic 
recipient cells and to minimize the tumour burden within the recipient. Subsequently, 
enriched NK cell grafts (1) and/or NK-DLI (2) may be applied in the further course of 
allogeneic SCT in order to facilitate alloreactive donor NK cell-mediated GVL reactivity. In 
the non-transplant setting (e.g. patients no longer eligible for allogeneic SCT or with solid 
tumours), adoptive NK cell transfer can be used as a NK cell-based immunotherapeutic 
strategy in patients after completing standard chemotherapy and preparative 
immunosuppressive conditioning in order to prevent rejection. 
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5.1 Allogeneic SCT setting 
The use of enriched NK cell grafts for allogeneic SCT has shown to be beneficial for 
transplant outcome and provides enhanced GVL reactivity directly after transplantation as 
compared with conventional grafts that lack NK cells (Bethge et al., 2006; Eissens et al., 
2010a; Kim et al., 2006). In addition, the head start in GVL reactivity may lead to better 
outcomes in terms of infectious events and overall survival after allogeneic SCT (Kim et al., 
2005a). Altogether, this indicates the immunotherapeutic value of the exploitation of donor 
NK cells in the allogeneic SCT setting. In order to further increase the beneficial effects of 
such NK cell-based immunotherapy strategies in the setting of allogeneic SCT, donor NK 
cells can also be administered as part of the conditioning regimen prior to transplantation 
instead of, or in combination with, the use of enriched NK cell grafts. This can have three 
potential beneficial effects. First, NK cell-mediated GVL reactivity could provide anti-
tumour activity prior to allogeneic SCT (Lundqvist et al., 2007; Ruggeri et al., 2002). Second, 
NK cell-mediated depletion of host dendritic cells before transplantation could prevent the 
development of acute GVHD allowing for a less stringent depletion of T cells in the graft 
(Lundqvist et al., 2007; Ruggeri et al., 2002). Third, NK cells may facilitate better engraftment 
through eradication of host T cells, thereby reducing the need for toxic myeloablative 
regimens and shortening the neutropenic period (Ruggeri et al., 2002). However, to be able 
to implement the combinatorial strategy of NK cell infusions as part of the conditioning 
regimen together with the use of enriched NK cell grafts in the clinic, the necessary amount 
of NK cells used for infusion prior to allogeneic SCT to provoke beneficial 
immunotherapeutic effects still needs to be established. Insufficient numbers may cause the 
necessity to choose between the use of NK cell infusions as part of the conditioning regimen 
and the use of enriched NK cell grafts. In this respect, also in case of the combinatorial 
strategy, it is important that more research is performed on the effects of conditioning and 
immunosuppressive regimens on NK cells in exploiting NK cell-mediated (GVL) reactivity 
in the allogeneic SCT setting. 
The use donor T cells for DLI after allogeneic SCT has developed into an effective treatment 
of recurrent hematological malignancy as well as prophylactic treatment in high-risk 
leukemia and lymphoma (Kolb et al., 2004). Still, the main risk of T-DLI is the induction of 
life-threatening GVHD. To minimize the risk of GVHD, studies have been initiated to 
modify conventional DLI by using donor NK cells instead of donor T cells (Passweg et al., 
2004; Passweg et al., 2005). Additionally, the administration of NK-DLI may facilitate 
engraftment and induce NK cell-mediated GVL reactivity (Passweg et al., 2004; Passweg et 
al., 2005). Although no firm conclusions can be drawn on the clinical efficacy of NK-DLI 
after allogeneic SCT at this point, data indicate that NK-DLI is safe and well tolerated, and 
can generate GVL reactivity and long-term remission in some patients after leukemia 
relapse. As non-malignant tissues generally do not overexpress ligands for activating NK 
cell receptors, NK-DLI should not cause GVHD (Bottino et al., 2005; Ruggeri et al., 2004; 
Ruggeri et al., 2006). Until now, NK-DLI has been tested in the haploidentical SCT setting. 
Thus, further research on the efficacy of NK-DLI in the HLA-matched SCT setting is 
warranted. 
5.2 Non-transplant settings 
In non-transplant settings, donor NK cells can be exploited for immunotherapeutic 
strategies for the treatment of hematological and non-hematological malignancies. 
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Previously, Miller et al. showed that haploidentical donor NK cell infusions after high-dose 
cyclophosphamide and fludarabine treatment resulted in long-term survival and in vivo 
expansion of donor NK cells in patients with metastatic melanoma (n=10), metastatic renal 
cell carcinoma (n=13), refractory non-Hodgkin’s disease (n=1), and poor-prognosis AML 
(n=19) (Miller et al., 2005). The in vivo NK cell expansion was associated with increased 
levels of endogenous IL-15, which were possibly responsible for driving the survival and 
proliferation of donor NK cells. In general, the donor NK cell infusions were well tolerated 
without evidence for the induction of GVHD. Furthermore, 5 out of 19 patients with poor-
prognosis AML achieved complete remission. Only 4 of the 19 AML patients were KIR-
ligand (HLA) mismatched in the graft-versus-host direction. Interestingly, out of these 4 
patients, 3 achieved complete remission. These findings indicate that haploidentical donor 
NK cells can persist and expand in vivo and may have a role in the treatment of (non-
)hematological malignancies in non-transplant settings or in combination with allogeneic 
SCT. In addition, when using haploidentical donors the choice of a KIR-ligand mismatched 
donor, based on the “ligand-ligand” model, may be needed to obtain successful results in 
future clinical trials (Miller et al., 2005). In case of HLA-matched donors, the choice of a 
“receptor-ligand” mismatched donor is preferred. 
In parallel, adoptive transfers are currently being performed with the NK cell line NK-92. 
This cell line can be cultured under good manufacturing practice (GMP) conditions and 
shows significant cytotoxicity against several tumour cell lines (Tam et al., 2003). 
Infusions of NK-92 cells have been administered to more than 20 patients with advanced 
renal-cell carcinoma and malignant melanoma. This proved to be safe and generated anti-
tumor effects in some cases (Klingemann, 2005). Furthermore, NK-92 cells can easily be 
obtained in high numbers during GMP culture providing sufficient amounts of cells for 
adoptive immunotherapeutic strategies. However, to prevent that the success of NK cell 
adoptive immunotherapy is solely based on the use of one NK cell line and the use of 
donor NK cells are still preferred, recent studies have developed culture systems for large 
scale ex vivo expansion of allogeneic NK cells using either hematopoietic progenitor cells 
from bone marrow or UCB (Carayol et al., 1998; Kao et al., 2007; Miller et al., 1992; 
Spanholtz et al., 2010). After transferring these culture systems to GMP conditions, these 
allogeneic donor NK cells may also be proven safe for use in NK cell adoptive 
immunotherapy. 
6. Conclusion 
Several issues remain crucial for the development and implementation of successful NK 
cell-based immunotherapy in the future. In the non-transplant setting , these include issues 
relating to the type of NK cell preparation to be used (activation, degree of enrichment and 
possible selection or skewing of specific subpopulations), criteria for donor selection 
(“ligand-ligand” versus “receptor-ligand” model, KIR genotyping and phenotyping, and 
size of the alloreactive subset), conditioning of patients prior to immunotherapy, clinical 
context of therapy, criteria for patient selection, and strategies for the identification of 
susceptible tumours within patient groups. Besides these issues, the effects of 
immunosuppressive regimens given after allogeneic SCT are also important when 
implementing NK cell-based immunotherapy in the setting of allogeneic SCT. 
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donor NK cells are still preferred, recent studies have developed culture systems for large 
scale ex vivo expansion of allogeneic NK cells using either hematopoietic progenitor cells 
from bone marrow or UCB (Carayol et al., 1998; Kao et al., 2007; Miller et al., 1992; 
Spanholtz et al., 2010). After transferring these culture systems to GMP conditions, these 
allogeneic donor NK cells may also be proven safe for use in NK cell adoptive 
immunotherapy. 
6. Conclusion 
Several issues remain crucial for the development and implementation of successful NK 
cell-based immunotherapy in the future. In the non-transplant setting , these include issues 
relating to the type of NK cell preparation to be used (activation, degree of enrichment and 
possible selection or skewing of specific subpopulations), criteria for donor selection 
(“ligand-ligand” versus “receptor-ligand” model, KIR genotyping and phenotyping, and 
size of the alloreactive subset), conditioning of patients prior to immunotherapy, clinical 
context of therapy, criteria for patient selection, and strategies for the identification of 
susceptible tumours within patient groups. Besides these issues, the effects of 
immunosuppressive regimens given after allogeneic SCT are also important when 
implementing NK cell-based immunotherapy in the setting of allogeneic SCT. 
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2.1 Development of acute graft-versus-host disease following allogeneic 
hematopoietic stem cell transplantation 
A major obstacle that substantially limits the therapeutic potential of allo-HSCT is the 
occurrence of graft-versus-host reactions against healthy host tissues, resulting in graft-
versus-host disease (GVHD). GVHD is a major cause of morbidity and mortality following 
allo-HSCT. The overall incidence lies between 30% and 60% with a mortality rate of 
approximately 50% (Barton-Burke et al., 2008). It is a complex multi-step process, involving 
innate and adaptive immunity and affecting many organs, including skin, liver and the 
gastrointestinal tract (Ball & Egeler, 2008; Ferrara et al., 2009). 
Billingham was the first to describe GVHD (Billingham, 1966). According to the Billingham 
criteria, three conditions must exist in order for GVHD to occur after allogeneic 
transplantation: (1) the donor graft must contain viable and immunologically functional 
effector cells, (2) the donor and recipient must be histoincompatible, and (3) the recipient 
must be immunocompromised.  
The series of events that contribute to the development of acute GVHD (as described by 
Ferrara & Reddy, 2006; Goker et al., 2001) can be divided in three phases (Goker et al., 2001). 
The first phase – conditioning phase – starts before the engraftment. This phase involves 
tissue damage caused by pre-transplantation myeloablative radiation/chemotherapy 
regimens, followed by release of lipopolysaccharide and secretion of proinflammatory 
cytokines, upregulation of adhesion molecules and enhanced expression of major 
histocompatibility complex (MHC) molecules on recipient tissues. The proinflammatory 
environment will also activate APC. The second phase – induction and expansion phase – 
starts with the recognition of the histoincompatible host tissue antigens by donor T cells. 
This phase involves T cell activation, stimulation, proliferation and differentiation. 
Activated host APC play a key role in the second phase of the graft-versus-host reaction by 
presenting mismatched recipient antigens to donor T cells. The first two phases constitute 
the afferent phase of GVHD. Finally, the third phase – effector phase – represents the actual 
clinical phase of acute GVHD and involves direct and indirect damage to host cells 
contributing to aggravation of GVHD. 
From these models, it is clear that donor T cells play a crucial role in evoking GVHD after 
allo-HSCT. Simultaneously, donor T cells represent major mediators of GVL effects. 
Therefore, research efforts are aimed at separating GVL reactions from GVHD (Li et al., 
2009a; Mackinnon et al., 1995; A.R. Rezvani & Storb, 2008). A key question is whether GVL 
activity and GVHD are fundamentally different mechanisms, or whether they are both 
clinical manifestations of similar graft-versus-host reactions.  
Preclinical model systems and clinical trials designed to investigate the possibility of 
selectively activating graft-versus-host reactions that result in GVL effects without GVHD, 
have led to new insights in the pathophysiology of GVL responses and GVHD after allo-
HSCT (Li et al., 2009a; A.R. Rezvani & Storb, 2008). In a more complex model of human 
GVHD and GVL pathophysiology (Li et al., 2009a), differentiation of activated T cells into 
the distinct subsets T helper (Th)1/cytotoxic T cell (Tc)1, Th2/Tc2, Th17 or regulatory T 
(Treg) cells is taken into account. These T cell subsets differ both in cytokine profiles and in 
their graft-versus-host activities. Activated Th1/Tc1 cells can directly attack host tissue and 
initiate specific inflammatory immune responses that lead to both GVL responses and acute 
GVHD.  Th2 cells on the other hand, evoke antigen-specific cellular and humoral immune 
responses resulting in GVL responses, but also in chronic GVHD. Notably, Th2 cytokines 
may inhibit the development of acute GVHD. Activated Th17 cells potentiate inflammation 
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and lead to acute GVHD, whereas the Th1 cytokine interferon (IFN)- can suppress Th17 
responses to decrease GVHD. Donor Treg cells suppress GVHD, but the effect of Treg cells 
on GVL responses remains to be further elucidated. The T cell subsets that are most likely 
associated with shifting the balance away from GVHD towards GVL responses are Th1/Tc1, 
 T and Treg cells (Li et al., 2009a). 
2.2 Dendritic cells in the development of acute graft-versus-host disease 
Early models have mainly focused on the central role of T cell activation and cytokine 
release in the pathophysiologic process of GVHD. The 1966 Billingham criteria clearly 
accounted for the presence of viable and immunologically functional effector cells as a 
prerequisite for the development of GVHD (Billingham, 1966). More recent models of 
GVHD (Choi et al., 2010; Ferrara & Reddy, 2006; Goker et al., 2001;  Li et al., 2009a) also take 
into account the key role of antigen presentation in its development by stating that 
activation of APC precedes activation and clonal expansion of T cells in the immune 
cascade. Host APC play a crucial role in the graft-versus-host reaction by presenting 
mismatched recipient antigens to donor T cells (Goker et al., 2001). In allo-HSCT with a 
histocompatible donor, the relevant antigens are miHC antigens (Falkenburg et al., 2002, 
2003; Ridell et al., 2002, 2003). APC digest miHC antigens into short peptides that are linked 
to MHC molecules and presented on the surface of APC as allopeptide-MHC complexes. 
Physical interaction between the allopeptide-MHC complexes and antigen-specific T cell 
receptors (TCR) then leads to recognition and activation of antigen-specific T cells (Clark & 
Chakraverty, 2002; Goker et al., 2001). 
Following allo-HSCT, a unique situation is created in which both host- and donor-derived 
APC co-exist within the host. Thus, foreign miHC antigens can be presented by either host-
derived or donor-derived APC. The latter case implies effective cross-presentation of 
recipient miHC antigens by donor-derived APC (Shlomchik, 2003). The roles of host- and 
donor-derived APC in the development of GVHD have been examined in experimental 
mouse studies. In a murine allogeneic bone marrow transplantation (BMT) model, 
Shlomchik and colleagues showed that host-derived APC were necessary and sufficient to 
initiate GVHD (Shlomchik et al., 1999). Donor APC on the other hand, while redundant for 
the onset of GVHD, were required to maximize the GVHD (Matte et al., 2004). A model 
focusing on the role of host-derived APC in the effector phase of GVHD demonstrated that 
tissue-resident APC control migration of alloreactive donor T cells into the tissues and 
subsequent local development of GVHD (Zhang et al., 2002). 
APC represent a heterogeneous population of cells with varying antigen-presenting 
capacities. As the most specialized and professional APC of the immune system, DC are 
highly efficient in processing and presenting antigens (Mellman & Steinman, 2001). The role 
of DC in GVHD has been investigated and confirmed in various experimental settings 
(Mohty, 2007; Mohty & Gaugler, 2008; Xu et al., 2008). 
Allo-HSCT can change the origin (host- versus donor-derived), number, lineage and 
activation level of DC in the host (Clark & Chakraverty, 2002). Several studies have 
examined the role of DC counts and subsets in the development and severity of GVHD. 
Based on their immunophenotype and functional properties, DC can be classified into 
myeloid conventional DC (cDC) and plasmacytoid DC (pDC) (Liu, 2001). A murine BMT 
model demonstrated that host-derived DC are necessary and sufficient for priming donor 
T cells to cause acute GVHD (Duffner et al., 2004). In humans, peripheral blood DC 
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chimerism experiments have been performed following allo-HSCT to analyze the 
contribution of different DC subsets to GVHD (Boeck et al., 2006; Chan et al., 2003; Pihusch 
et al., 2005). Findings of Chan et al (Chan et al., 2003) confirmed the importance of host DC, 
because persistence of the DC at day 100 after allo-HSCT was correlated with GVHD. On the 
other hand, graft-versus-host reactions were also detected in patients that had DC 
exclusively of donor origin (Boeck et al., 2006). Lower counts of cDC and pDC in patients 
were associated with an increased risk for acute GVHD (Horváth et al., 2009; Lau et al., 2007; 
Rajasekar et al., 2008; Reddy et al., 2004; Vakkila et al., 2005). In addition, higher numbers of 
donor pDC following allo-HSCT decreased the risk of developing chronic GVHD, but also 
increased the risk of relapse, possibly due to interference with GVL reactions (Waller et al., 
2001). In contrast to these data, higher pDC numbers in the graft or in the recipient after 
allo-HSCT have also been found to correlate with the development of chronic GVHD (Clark 
et al., 2003; Rossi et al., 2002). Next to absolute numbers, also activation status can be 
predictive of GVHD, with activated cDC being highly correlated with acute GVHD (Lau et 
al., 2007). Taken together, experimental data suggest that different DC subsets have different 
effects on GVHD and GVL reactions, but further research is required to unravel the exact 
role of each subset. 
3. Dendritic cell-based therapy and allogeneic hematopoietic stem cell 
transplantation 
Over the past decade several approaches of DC-based  therapy in allo-HSCT settings have 
been scrutinized, yielding some promising results with regard to decreasing GVHD, 
optimizing GVL reactions and restoring protective immunity against pathogens. 
3.1 Dendritic cell-based therapy to reduce graft-versus-host-disease and enhance 
graft-versus-leukemia effects 
Allogeneic T cells have the capacity to kill residual malignant cells in the host, but  also to 
destruct normal host tissue contributing to GVHD, which can be life-threatening and limits 
the use of allo-HSCT. While T cell depletion of the graft is a very effective way of reducing 
the risk of GVHD, it also diminishes the GVL effect, thereby increasing the risk of relapse. 
Hence, a more refined approach is needed to balance graft-versus-host reactions after allo-
HSCT. Given the inherent key regulatory function of DC, DC-based therapy is considered 
an attractive approach to shift the balance in favor of GVL reactions. 
3.1.1 Dendritic cell-based therapy to reduce graft-versus-host-disease 
The finding in murine BMT models that host APC are necessary for GVHD to develop 
(Matte et al., 2004; Shlomchik et al., 1999), led the authors to suggest that depletion of host 
APC before the conditioning regimen should prevent GVHD without the need for 
prolonged immunosuppressive treatment.  
Antibody-mediated depletion of DC was investigated in a chimeric human/mouse model of 
GVHD, in which severe combined immunodeficient (SCID) mice received a xenogeneic 
transplantation with human peripheral blood mononuclear cells (PBMC) (Wilson et al., 
2009). Antibodies against the DC activation marker CD83 were injected in host mice 3 hours 
before injection of human PBMC. This therapeutic intervention almost completely 
prevented lethal GVHD, whereas negative control mice all developed severe GVHD. 
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Moreover, mice treated with anti-CD83 antibodies required no further immunosuppressive 
therapy and possessed functional T cell immunity in vitro (Wilson et al., 2009). 
These data support further investigation of in vivo depletion of host and/or donor APC as a 
way of preventing GVHD in allo-HSCT recipients. This strategy makes redundant both 
T cell depletion, thereby preserving the memory T cell pool, and T cell-targeted 
immunosuppression, which greatly hampers GVL responses and protective immunity. 
However, the effect of DC depletion on GVL responses still needs to be investigated in 
animal allo-HSCT models including in vivo leukemic challenge. Some concern can be raised 
about potential interference of DC depletion with the GVL effect, because in mice studies 
antigen-presentation by host APC has been shown to be important in mediating GVL 
responses following donor lymphocyte infusions (DLI) (Chakraverty et al., 2006; Mapara et 
al., 2002). Furthermore, DC depletion might result in a delayed restorage of immunity 
against pathogens (Clark & Chakraverty, 2002). 
More thorough elucidation of the role of distinct DC subsets in allo-antigen responses after 
allo-HSCT will pave the way to depletion of undesirable or expansion of desirable DC 
subsets. In this context, a study of Li et al. (Li et al., 2009b) has shown that manipulating the 
content of donor APC subsets in allo-HSCT grafts can enhance the GVL effect without 
increasing GVHD. In their study, leukemia-bearing mice that received hematopoietic stem 
cells (HSC) and CD11b-negative donor APC had substantially enhanced survival compared 
to recipients of HSC alone, HSC and T cells, or HSC and CD11b-positive APC. 
Another promising strategy to modulate allo-antigen responses following allo-HSCT 
involves DC engineered to boost their tolerogenic or regulatory capacities.  
In a study of Reichardt et al (Reichardt et al., 2008), DC were isolated directly from mice 
bone marrow and spleen cells using positive magnetic cell selection and exposed to 
rapamycin for 24 hours. Adoptive transfer of rapamycin-treated DC of host origin, but not 
donor origin, administered together with the bone marrow transplant, reduced GVHD 
severity and led to improved survival of recipient mice in a dose-dependent way. The 
reduced expansion of alloreactive T cells could account for the beneficial effects on GVHD 
and survival, but carries the risk of reducing the GVL effect. 
In two other studies with similar methodology (Chorny et al., 2006; Sato et al., 2003), DC 
were generated from murine bone marrow cells using granulocyte macrophage colony-
stimulating factor (GM-CSF) and either interleukin (IL)-10 and transforming growth factor 
(TGF)-β1 or vasoactive intestinal peptide (VIP) for 6 days. Then, lipopolysaccharide (LPS) 
was added for 2 days to induce activation, followed by injection of the DC 2 days after BMT. 
Results of both studies demonstrated that host-matched DC, but not host-mismatched DC, 
prevented the onset of severe GVHD in recipient mice in a dose-dependent way. In order to 
study the effect of DC therapy on GVL responses, mice were challenged with P815 or A20 
malignant cells. BMT recipient mice that received host-matched DC were not only protected 
from lethal GVHD, but also maintained a strong GVL effect and survived significantly 
longer than control animals (Chorny et al., 2006; Sato et al., 2003). 
In conclusion, the administration of specifically engineered DC appears to be a favorable 
means of modulating alloreactivity after allo-HSCT, because they are able to reduce the risk 
of severe GVHD, while maintaining the benefits of the GVL effect. Clinical trials will have to 
show if these beneficial effects can also be seen in humans. Considering that only host-
matched DC were able to protect the recipient from severe GVHD and conserve a strong 
GVL effect in these murine models, it seems likely that the DC will have to be tailored to 
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prolonged immunosuppressive treatment.  
Antibody-mediated depletion of DC was investigated in a chimeric human/mouse model of 
GVHD, in which severe combined immunodeficient (SCID) mice received a xenogeneic 
transplantation with human peripheral blood mononuclear cells (PBMC) (Wilson et al., 
2009). Antibodies against the DC activation marker CD83 were injected in host mice 3 hours 
before injection of human PBMC. This therapeutic intervention almost completely 
prevented lethal GVHD, whereas negative control mice all developed severe GVHD. 
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Moreover, mice treated with anti-CD83 antibodies required no further immunosuppressive 
therapy and possessed functional T cell immunity in vitro (Wilson et al., 2009). 
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way of preventing GVHD in allo-HSCT recipients. This strategy makes redundant both 
T cell depletion, thereby preserving the memory T cell pool, and T cell-targeted 
immunosuppression, which greatly hampers GVL responses and protective immunity. 
However, the effect of DC depletion on GVL responses still needs to be investigated in 
animal allo-HSCT models including in vivo leukemic challenge. Some concern can be raised 
about potential interference of DC depletion with the GVL effect, because in mice studies 
antigen-presentation by host APC has been shown to be important in mediating GVL 
responses following donor lymphocyte infusions (DLI) (Chakraverty et al., 2006; Mapara et 
al., 2002). Furthermore, DC depletion might result in a delayed restorage of immunity 
against pathogens (Clark & Chakraverty, 2002). 
More thorough elucidation of the role of distinct DC subsets in allo-antigen responses after 
allo-HSCT will pave the way to depletion of undesirable or expansion of desirable DC 
subsets. In this context, a study of Li et al. (Li et al., 2009b) has shown that manipulating the 
content of donor APC subsets in allo-HSCT grafts can enhance the GVL effect without 
increasing GVHD. In their study, leukemia-bearing mice that received hematopoietic stem 
cells (HSC) and CD11b-negative donor APC had substantially enhanced survival compared 
to recipients of HSC alone, HSC and T cells, or HSC and CD11b-positive APC. 
Another promising strategy to modulate allo-antigen responses following allo-HSCT 
involves DC engineered to boost their tolerogenic or regulatory capacities.  
In a study of Reichardt et al (Reichardt et al., 2008), DC were isolated directly from mice 
bone marrow and spleen cells using positive magnetic cell selection and exposed to 
rapamycin for 24 hours. Adoptive transfer of rapamycin-treated DC of host origin, but not 
donor origin, administered together with the bone marrow transplant, reduced GVHD 
severity and led to improved survival of recipient mice in a dose-dependent way. The 
reduced expansion of alloreactive T cells could account for the beneficial effects on GVHD 
and survival, but carries the risk of reducing the GVL effect. 
In two other studies with similar methodology (Chorny et al., 2006; Sato et al., 2003), DC 
were generated from murine bone marrow cells using granulocyte macrophage colony-
stimulating factor (GM-CSF) and either interleukin (IL)-10 and transforming growth factor 
(TGF)-β1 or vasoactive intestinal peptide (VIP) for 6 days. Then, lipopolysaccharide (LPS) 
was added for 2 days to induce activation, followed by injection of the DC 2 days after BMT. 
Results of both studies demonstrated that host-matched DC, but not host-mismatched DC, 
prevented the onset of severe GVHD in recipient mice in a dose-dependent way. In order to 
study the effect of DC therapy on GVL responses, mice were challenged with P815 or A20 
malignant cells. BMT recipient mice that received host-matched DC were not only protected 
from lethal GVHD, but also maintained a strong GVL effect and survived significantly 
longer than control animals (Chorny et al., 2006; Sato et al., 2003). 
In conclusion, the administration of specifically engineered DC appears to be a favorable 
means of modulating alloreactivity after allo-HSCT, because they are able to reduce the risk 
of severe GVHD, while maintaining the benefits of the GVL effect. Clinical trials will have to 
show if these beneficial effects can also be seen in humans. Considering that only host-
matched DC were able to protect the recipient from severe GVHD and conserve a strong 
GVL effect in these murine models, it seems likely that the DC will have to be tailored to 
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every individual patient. Although this will be costly and labor-intensive, it can be cost-
effective if proven beneficial in allo-HSCT. 
3.1.2 Dendritic cell-based therapy to enhance the graft-versus-leukemia effect without 
aggravating graft-versus-host-disease 
Donor alloreactive T cells responsible for the GVL effect target a broad range of allogeneic 
antigens and may thereby lead to GVHD. Hence, there is much interest in developing 
strategies that can direct the immune reaction towards specific antigens only or primarily 
expressed on malignant cells, so-called TAA. 
As key regulators of the immune system, DC are inherently capable of inducing tumor-
specific immune responses (Steinman & Banchereau, 2007). Various clinical studies have 
already explored the use of DC loaded with TAA as cellular cancer vaccines for 
hematological malignancies (Smits et al., 2011; Van de Velde et al., 2008). Thus far, results 
are often modest, but there is proof of principle that a DC vaccine can lead to eradication of 
malignant cells in an antigen-specific manner. Promisingly, in a phase I/II study by our 
group, vaccination with autologous monocyte-derived DC loaded with Wilms’ tumor 1 
(WT1) protein-encoding mRNA was able to convert partial remission into complete 
molecular remission in two patients in the absence of any other therapy (Van Tendeloo et 
al., 2010). These clinical responses were correlated with vaccine-associated increases in WT1-
specific CD8+ T cell frequencies. 
While DC vaccines are thoroughly being investigated in clinical trials for their capacity to 
induce tumor-specific immune responses, only few trials addressed their use in the setting 
of HSCT. In the context of autologous hematopoietic stem cell transplantation (auto-HSCT) 
for multiple myeloma (MM), a clinical trial in 27 patients suggested a benefit in overall 
survival of vaccination with autologous idiotype-pulsed APC, given at 4 time points after 
auto-HSCT, compared to historical controls (Lacy et al., 2009). 
In allo-HSCT, the dynamic immunological situation that follows transplantation due to the 
scollision of donor and host immune system adds complexity to the development of DC-
based therapy. Hitherto, it is unclear whether donor- or host-derived DC would be best 
suited for use in immunotherapy aimed at increasing GVL responses. In this regard, murine 
models demonstrated that host APC are crucial for GVL reactions and that donor APC, 
although not strictly necessary, can contribute to the GVL effect (Matte et al., 2004; Reddy et 
al., 2005). This is similar to what is observed in GVHD, which is not surprising given that 
both are manifestations of graft-versus-host immunity. Therefore, avoiding aggravation of 
GVHD is an important concern when developing DC-based strategies aiming to augment 
GVL immunity after allo-HSCT. 
Next to GVHD, another concern regarding DC vaccination to boost GVL responses is its 
effectiveness when given shortly after allo-HSCT, considering the immunosuppressive state 
of patients at that time. Murine vaccination studies have shown, however, that tumor lysate-
pulsed bone marrow-derived DC administered early after auto- or allo-HSCT can elicit 
effective anti-tumor immunity (Asavaroengchai et al., 2002; Moyer et al., 2006). 
Furthermore, DC vaccination around the time of HSCT could have some benefits, such as 
lower tumor burden, donor T cells that are not tolerant to host antigens and low numbers of 
host Treg cells (Hashimoto et al., 2011).   
A total of 6 patients have been involved in three clinical reports of DC vaccines after allo-
HSCT. Donor monocyte-derived DC were used for vaccination, pulsed with recipient tumor 
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cells (Fujii et al., 2001; Tatsugami et al., 2004) or with WT1 peptide (Kitawaki et al., 2008). 
Only one trial reported clinical, but transient responses in 4 relapsed patients with 
hematological malignancies in the absence of GVHD (Fujii et al., 2001). There were no 
detectable responses nor GVHD in the other two cases (renal cell carcinoma and acute 
myeloid leukemia). In the trial reporting clinical responses, patients were infused both with 
donor monocyte-derived DC pulsed with irradiated patient tumor cells and with donor 
T cells primed by these DC, which might both have contributed to the observed responses.  
A fourth study involving 20 MM patients investigated DLI and/or host-derived DC 
vaccination (Levenga et al., 2010). The authors concluded that partial T cell-depleted allo-
HSCT can be combined with pre-emptive DLI and recipient monocyte-derived DC 
vaccination to increase graft-versus-myeloma effects with limited GVHD. 
In conclusion, early results of clinical DC vaccination in the context of HSCT are promising 
with no or limited GVHD, but because of the small study populations and lack of controls, 
further research is required. 
Instead of engineering DC ex vivo and then transferring them to patients, another approach 
is to directly target them in vivo. To our knowledge, this approach has not been tested yet in 
the allo-HSCT setting.  
However, in 8 patients with Hodgkin disease, non-Hodgkin lymphoma or advanced-stage 
breast cancer, auto-HSCT was followed by immunotherapy with fms-like tyrosine kinase 
receptor-3-ligand (Flt3-L) for 6 weeks (Chen et al., 2005). Flt3-L is a hematopoietic growth 
factor, essential for the development of DC from progenitor cells. This phase I study 
demonstrated that vaccination with Flt3-L was safe and well-tolerated, resulting in 
increased frequencies and absolute numbers of circulating immature DC and their 
precursors in patients’ blood without affecting other mature cell lineages. The expanded DC 
were mostly pDC and were shown here to enhance T cell activation and NK cell cytotoxicity 
against tumor cells in vitro after Toll-like receptor 9-ligand administration, but are also 
known to play a role in antiviral immunity and in preventing GVHD (Arpinati et al., 2003). 
In correspondence with these data, others have also suggested that mobilization of specific 
DC subsets through Flt3-L administration might be a feasible way to target DC in vivo (Eto 
et al., 2002; Teshima et al., 2002), but more research is needed to unravel the functional 
diversity of these mobilized DC. 
3.2 Dendritic cell-based therapy to restore protective immunity against pathogens  
Viral and fungal infections are an important cause of morbidity and mortality in patients 
following HSCT (Gratwohl et al., 2005). These patients have increased susceptibility for 
primary infection, reinfection and also reactivation of latent viruses due to hampering of 
their immune system by two main factors (Smits & Berneman, 2010). Firstly, there is the 
immunosuppressed state accompanying HSCT, often further increased by medication given 
to prevent GVHD. Secondly, the intense pre-transplantation chemotherapy conditioning 
regimen, intended to destroy a large part of blood cells, is believed to eliminate memory 
T cells. Furthermore, early after HSCT dysfunctional DC lead to severely impaired 
development of antigen-specific T cells (Safdar, 2006). Considering their central role in 
innate and adaptive immunity, DC seem the ideal candidate for immunotherapy aimed at 
bringing about the swift restoration of immunity against pathogens in this particular setting.  
With regard to DC-based therapy for antifungal immunity after allo-HSCT, much 
knowledge was obtained from research by the group of Romani. They showed in murine 
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every individual patient. Although this will be costly and labor-intensive, it can be cost-
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are often modest, but there is proof of principle that a DC vaccine can lead to eradication of 
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group, vaccination with autologous monocyte-derived DC loaded with Wilms’ tumor 1 
(WT1) protein-encoding mRNA was able to convert partial remission into complete 
molecular remission in two patients in the absence of any other therapy (Van Tendeloo et 
al., 2010). These clinical responses were correlated with vaccine-associated increases in WT1-
specific CD8+ T cell frequencies. 
While DC vaccines are thoroughly being investigated in clinical trials for their capacity to 
induce tumor-specific immune responses, only few trials addressed their use in the setting 
of HSCT. In the context of autologous hematopoietic stem cell transplantation (auto-HSCT) 
for multiple myeloma (MM), a clinical trial in 27 patients suggested a benefit in overall 
survival of vaccination with autologous idiotype-pulsed APC, given at 4 time points after 
auto-HSCT, compared to historical controls (Lacy et al., 2009). 
In allo-HSCT, the dynamic immunological situation that follows transplantation due to the 
scollision of donor and host immune system adds complexity to the development of DC-
based therapy. Hitherto, it is unclear whether donor- or host-derived DC would be best 
suited for use in immunotherapy aimed at increasing GVL responses. In this regard, murine 
models demonstrated that host APC are crucial for GVL reactions and that donor APC, 
although not strictly necessary, can contribute to the GVL effect (Matte et al., 2004; Reddy et 
al., 2005). This is similar to what is observed in GVHD, which is not surprising given that 
both are manifestations of graft-versus-host immunity. Therefore, avoiding aggravation of 
GVHD is an important concern when developing DC-based strategies aiming to augment 
GVL immunity after allo-HSCT. 
Next to GVHD, another concern regarding DC vaccination to boost GVL responses is its 
effectiveness when given shortly after allo-HSCT, considering the immunosuppressive state 
of patients at that time. Murine vaccination studies have shown, however, that tumor lysate-
pulsed bone marrow-derived DC administered early after auto- or allo-HSCT can elicit 
effective anti-tumor immunity (Asavaroengchai et al., 2002; Moyer et al., 2006). 
Furthermore, DC vaccination around the time of HSCT could have some benefits, such as 
lower tumor burden, donor T cells that are not tolerant to host antigens and low numbers of 
host Treg cells (Hashimoto et al., 2011).   
A total of 6 patients have been involved in three clinical reports of DC vaccines after allo-
HSCT. Donor monocyte-derived DC were used for vaccination, pulsed with recipient tumor 
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cells (Fujii et al., 2001; Tatsugami et al., 2004) or with WT1 peptide (Kitawaki et al., 2008). 
Only one trial reported clinical, but transient responses in 4 relapsed patients with 
hematological malignancies in the absence of GVHD (Fujii et al., 2001). There were no 
detectable responses nor GVHD in the other two cases (renal cell carcinoma and acute 
myeloid leukemia). In the trial reporting clinical responses, patients were infused both with 
donor monocyte-derived DC pulsed with irradiated patient tumor cells and with donor 
T cells primed by these DC, which might both have contributed to the observed responses.  
A fourth study involving 20 MM patients investigated DLI and/or host-derived DC 
vaccination (Levenga et al., 2010). The authors concluded that partial T cell-depleted allo-
HSCT can be combined with pre-emptive DLI and recipient monocyte-derived DC 
vaccination to increase graft-versus-myeloma effects with limited GVHD. 
In conclusion, early results of clinical DC vaccination in the context of HSCT are promising 
with no or limited GVHD, but because of the small study populations and lack of controls, 
further research is required. 
Instead of engineering DC ex vivo and then transferring them to patients, another approach 
is to directly target them in vivo. To our knowledge, this approach has not been tested yet in 
the allo-HSCT setting.  
However, in 8 patients with Hodgkin disease, non-Hodgkin lymphoma or advanced-stage 
breast cancer, auto-HSCT was followed by immunotherapy with fms-like tyrosine kinase 
receptor-3-ligand (Flt3-L) for 6 weeks (Chen et al., 2005). Flt3-L is a hematopoietic growth 
factor, essential for the development of DC from progenitor cells. This phase I study 
demonstrated that vaccination with Flt3-L was safe and well-tolerated, resulting in 
increased frequencies and absolute numbers of circulating immature DC and their 
precursors in patients’ blood without affecting other mature cell lineages. The expanded DC 
were mostly pDC and were shown here to enhance T cell activation and NK cell cytotoxicity 
against tumor cells in vitro after Toll-like receptor 9-ligand administration, but are also 
known to play a role in antiviral immunity and in preventing GVHD (Arpinati et al., 2003). 
In correspondence with these data, others have also suggested that mobilization of specific 
DC subsets through Flt3-L administration might be a feasible way to target DC in vivo (Eto 
et al., 2002; Teshima et al., 2002), but more research is needed to unravel the functional 
diversity of these mobilized DC. 
3.2 Dendritic cell-based therapy to restore protective immunity against pathogens  
Viral and fungal infections are an important cause of morbidity and mortality in patients 
following HSCT (Gratwohl et al., 2005). These patients have increased susceptibility for 
primary infection, reinfection and also reactivation of latent viruses due to hampering of 
their immune system by two main factors (Smits & Berneman, 2010). Firstly, there is the 
immunosuppressed state accompanying HSCT, often further increased by medication given 
to prevent GVHD. Secondly, the intense pre-transplantation chemotherapy conditioning 
regimen, intended to destroy a large part of blood cells, is believed to eliminate memory 
T cells. Furthermore, early after HSCT dysfunctional DC lead to severely impaired 
development of antigen-specific T cells (Safdar, 2006). Considering their central role in 
innate and adaptive immunity, DC seem the ideal candidate for immunotherapy aimed at 
bringing about the swift restoration of immunity against pathogens in this particular setting.  
With regard to DC-based therapy for antifungal immunity after allo-HSCT, much 
knowledge was obtained from research by the group of Romani. They showed in murine 
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models of allo-HSCT that DC discriminate between different fungal morphotypes or their 
corresponding RNA with regard to maturation, cytokine production and Th1 cell priming 
both in vitro and in vivo (Bacci et al., 2002; Bozza et al., 2003; d’Ostiani et al., 2000). Similarly, 
also human monocyte-derived DC were found to react differently in terms of cytokine 
production and activation of IFN-γ-producing T cells.  
Subcutaneous vaccination of mice with DC pulsed with Candida yeasts or Aspergillus 
conidia (or transfected with the corresponding RNA) on days 1 and 7 after T cell-depleted 
allo-BMT dramatically increased the recovery of antifungal resistance to subsequent fungal 
challenge (Bacci et al., 2002; Bozza et al., 2003).  
They also demonstrated that Flt3-L-expanded and thymosin α1-treated IL-4-expanded 
monocyte-derived DC were capable of inducing antifungal immunity as well as allogeneic 
transplant tolerance (Romani et al., 2006). Overall, the findings of the group of Romani 
suggest a role for active DC vaccination very shortly after allo-HSCT to restore antifungal 
immunity and show that expansion of distinct DC might allow more specific regulation of 
post-transplantation immunity (Montagnoli et al., 2008; Perruccio et al., 2004). 
Over the last 10 years, DC have established a firm foothold in immune-based strategies 
aimed at restoring antiviral (and especially anti-CMV) immunity following allo-HSCT. 
Monocyte-derived DC from CMV-seropositive HSCT donors pulsed with CMV 
peptide/lysate or transfected with an adenoviral vector encoding CMV-peptide, have been 
used with great success to expand CMV-specific cytotoxic T lymphocytes (CTL) ex vivo 
(Micklethwaite et al., 2008; Peggs et al., 2001; Szmania et al., 2001). Clinical trials examining 
adoptive transfer of these DC-expanded CMV-specific CTL to allo-HSCT recipients 
demonstrated that this is a safe method capable of restoring functional anti-CMV immunity 
early after transplantation (Micklethwaite et al., 2007, 2008; Peggs et al., 2009). Although a 
minority of the patients developed GVHD after adoptive transfer of CMV-specific CTL, this 
was most likely not related to the infusion itself.  
Another study showed that DC transfected with CMV pp65-encoding RNA can successfully 
expand autologous CMV-specific CTL in vitro from both seropositive and -negative patients 
after allo-HSCT, suggesting that CMV-loaded DC vaccination could provide a valid clinical 
alternative to adoptive CTL transfer (Heine et al., 2006).  
Also for measles virus (MV), DC vaccination could be a favorable approach as results of an 
in vitro study with MV-loaded DC from HSCT patients showed that these DC significantly 
induced autologous MV-specific T cells from the naïve repertoire (Nashida et al., 2006). 
Clinical trials are needed, however, to validate whether viral antigen-loaded DC vaccination 
can indeed live up to the promising results obtained with adoptive virus-specific CTL 
transfer. 
4. Conclusion 
DC have been the subject of intensive investigation in mouse models to reduce the 
occurrence of GVHD and enhance GVL reactions following allo-HSCT. Also in humans, it is 
clear that DC play an important role in initiating and balancing graft-versus-host reactions. 
Further clarification of differences between DC subsets in their capacity to shift the balance 
away from GVHD towards GVL and anti-microbial reactions will help to translate the 
promising mouse data into clinical success. Questions to be solved are which would be the 
best time frame and strategy of immunotherapy to use in allotransplant patients. DC-based 
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approaches to be further investigated include DC vaccines, adoptive transfer of in vitro 
primed T cells and in vivo targeting of DC. 
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also human monocyte-derived DC were found to react differently in terms of cytokine 
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Subcutaneous vaccination of mice with DC pulsed with Candida yeasts or Aspergillus 
conidia (or transfected with the corresponding RNA) on days 1 and 7 after T cell-depleted 
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demonstrated that this is a safe method capable of restoring functional anti-CMV immunity 
early after transplantation (Micklethwaite et al., 2007, 2008; Peggs et al., 2009). Although a 
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after allo-HSCT, suggesting that CMV-loaded DC vaccination could provide a valid clinical 
alternative to adoptive CTL transfer (Heine et al., 2006).  
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in vitro study with MV-loaded DC from HSCT patients showed that these DC significantly 
induced autologous MV-specific T cells from the naïve repertoire (Nashida et al., 2006). 
Clinical trials are needed, however, to validate whether viral antigen-loaded DC vaccination 
can indeed live up to the promising results obtained with adoptive virus-specific CTL 
transfer. 
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Further clarification of differences between DC subsets in their capacity to shift the balance 
away from GVHD towards GVL and anti-microbial reactions will help to translate the 
promising mouse data into clinical success. Questions to be solved are which would be the 
best time frame and strategy of immunotherapy to use in allotransplant patients. DC-based 
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1. Introduction 
In recent years it has become evident that mesenchymal stem cells (MSCs), also termed 
mesenchymal stromal cells, have potent immunomodulatory effects in addition to their 
known ability of organ regeneration and recruitment to sites of injured or inflamed tissue 
(Caplan 1991; Garin, Chu et al. 2007; Nauta and Fibbe 2007; Bianco, Robey et al. 2008; Shi, 
Hu et al. 2010). While the ability of MSCs to mediate tissue and organ repair replacing 
damaged tissue has initially been attributed to their multilineage differentiation potential, it 
is now widely attributed to their ability to home to site of injury secreting cytokines and 
growth factors that mediate the repair process inducing proliferation and differentiation of 
progenitor cells (Karp and Leng Teo 2009; Hoogduijn, Popp et al. 2010; Sordi, Melzi et al. 
2010). Whether MSCs migrate from the bone marrow in case of injury or if the stem cell 
niche available in the diseased organ replaces dying cells remains to be elucidated. 
MSCs have been demonstrated to exhibit a profound immunomodulatory effect on T cells, B 
cells, and Natural Killer (NK) cells. This effect has been recently shown to be mediated via 
soluble factors, and this can be enhanced further if direct cell–cell contact between the MSCs 
and immune cells is allowed (Ren, Zhao et al. 2010). Via these factors, MSCs inhibit T cell 
proliferation (Di Nicola, Carlo-Stella et al. 2002; Aggarwal and Pittenger 2005), maturation 
and differentiation of B cells (Corcione, Benvenuto et al. 2006; Tabera, Perez-Simon et al. 
2008; Asari, Itakura et al. 2009), maturation of dendritic cells (DCs) (Nauta, Kruisselbrink et 
al. 2006),  generation of cytotoxic T cells (Angoulvant, Clerc et al. 2004) and proliferation and 
cytotoxic activity of NK cells (Rasmusson, Ringden et al. 2003; Sotiropoulou, Perez et al. 
2006; Spaggiari, Capobianco et al. 2008), while inducing regulatory T cells (Tregs) (Prevosto, 
Zancolli et al. 2007; Di Ianni, Del Papa et al. 2008; Crop, Baan et al. 2010).  
MSCs have been shown to induce immunologic peripheral tolerance, suggesting their 
potential application in a therapeutic approach for immune mediated disorders. In this 
context, MSCs can be used to support the function of standard pharmacological 
immunosuppressants to reduce their dosage or even replace such toxic 
immunosuppressants promoting long-term survival of the transplanted organ (Crop, Baan 
et al. 2009). 
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Limited information is available about the molecular mechanisms responsible for the 
immunomodulation By MSCs and there is no single mechanism responsible for their 
observed tolerogenic effect. However, MSCs have been considered to potentially work 
through multiple mechanisms and have the ability to affect immunological, inflammatory 
and regenerative pathways supporting or replacing current pharmacological agents.  
Considering their immunosuppressive properties in addition to their low inherent 
immunogenicity (Rasmusson, Uhlin et al. 2007) makes MSCs an attractive treatment option 
in cell and organ transplantation potentially improving the graft outcome and eliminating a 
long immunosuppressive treatment regimen (Ryan, Barry et al. 2005; Eggenhofer, 
Steinmann et al. 2011). Both the immunosuppressive effects of MSCs and their regenerative 
potential participate to facilitate grafting of a transplanted organ as well as repair and 
regeneration of the organ after transplantation. 
In both allogeneic hematopoietic stem cell transplantation (AHSCT) and organ 
transplantation setting, major problems exist due to the lack of suitable donors. High histo-
incompatability between donor and recipient is often associated with an increased risk of 
graft rejection or graft versus host disease which MSCs might ameliorate if infusion of MSCs 
along with the organ transplant increases organ engraftment making this immunoprivilege 
useful for transplantation. Indeed, in one of the first in vivo studies showing the 
advantageous immunosuppressive effect of MSCs, allogeneic MSCs were demonstrated to 
prolong (MHC)-mismatched skin allograft survival in baboons (Bartholomew, Sturgeon et 
al. 2002). 
Furthermore, the immunosuppressive properties of MSCs, in addition to their low 
immunogenicity features, have prompted researchers to investigate co-transplantation of 
these cells in AHSCT setting to promote hematopoietic stem cells (HSCs) engraftment and to 
prevent graft versus host reactions as well as host versus graft reactivity. Additionally, 
MSCs provide support for the growth and development of HSCs further promoting 
engraftment. In this, MSCs were shown to interact with HSCs through production of growth 
factors that influence HSCs-homing and –differentiation (Krampera, Cosmi et al. 2006). This 
effect was attributed via either cell-cell contact or production of soluble factors by MSCs 
such as the CXCL12 chemokine which may attract HSCs through its interaction with the 
CXCR4 ligand (Krampera, Cosmi et al. 2006) hence improving HSCs engraftment.  
First clinical trials have been undertaken to assess the safety of MSCs administration as well 
as a potential treatment option for graft versus host disease (GvHD). Encouraging results 
have been obtained in patients with steroid resistant GvHD and in the management of 
chronic GvHD after AHSCT. Interestingly, MSCs treatment improved the overall outcome 
and successfully attenuated GvHD in these patients (Le Blanc, Rasmusson et al. 2004; 
Ringden and Le Blanc 2011).  
MSCs were shown to attenuate graft rejection and in combination with immunosuppressive 
therapy were able to prolong cardiac allograft survival when co-administered with 
immunosuppressive therapy. Indeed, they promote donor-specific graft tolerance and 
ameliorate the alloimmune response where the use of low dose therapy alone was not 
sufficient to maintain the graft; only combination therapy with MSCs maintained the cardio 
graft (Ge, Jiang et al. 2009).  
MSCs have also been suggested as a promising cell immunotherapy tool to promote 
tolerance for organ transplants and to control allograft rejection in post-transplant therapy 
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settings facilitating both transplant acceptance and physiologic functions (Crop, Baan et al. 
2009; Dahlke, Hoogduijn et al. 2009). MSCs have also been recently shown to have an 
ameliorating effect in a model of acute lung injury were transplantation of MSCs resulted in 
a significant increase in the level of  protective/immunomodulatory  Tregs (Sun, Han et al. 
2011). Finally, clinical trials are ongoing to determine the efficacy of MSCs as an effective 
tool for the treatment of autoimmune diseases, such as multiple sclerosis, inflammatory 
bowel diseases, rheumatoid arthritis, and type 1 diabetes.  
2. The biology and originality of mesenchymal stem cells and their 
generation and expansion in vitro for therapeutic use 
MSCs are a self-renewing heterogeneous population of multipotent cells, originally isolated 
from bone marrow as shown in pioneer experiments by Friedenstein and colleagues and 
first referred to as colony-forming unit fibroblasts (Friedenstein, Chailakhyan et al. 1974). 
Since then, MSCs have been isolated from many other adult tissues such a umbilical cord 
blood, placenta, amniotic fluid, peripheral blood, adipose tissue and various other somatic 
tissues sharing the regenerative as well as the immunomodulatory properties of MSCs (In 't 
Anker, Scherjon et al. 2004; Zuk 2010; Bianco 2011) but have mainly been characterized after 
isolation from bone marrow.  
MSCs can be expanded in vitro as plastic adherent cells with a fibroblast-like morphology 
and can be differentiated into cells of mesodermal lineage (osteocytes, chondrocytes and 
adipocytes) (Pittenger, Mackay et al. 1999) as well as cells from other embryonic lineages 
(Sanchez-Ramos 2006; Schwartz, Brick et al. 2008). At present, MSCs lack a definitive marker 
and no single marker has been identified distinguishing MSCs however the International 
Society for Stem Cell Research has outlined minimal criteria to characterize human MSCs, 
these cells have been reported to be positive for CD73, CD90, CD105 and major 
histocompatibility complex class I (HLA-ABC).  They are devoid of the hematopoietic 
markers such as CD14, CD 19, CD34, CD45 and for major histocompatibility complex class 
II, (HLA-DR) (Dominici, Le Blanc et al. 2006).  
An attractive characteristic of MSCs is that they can be easily expanded maintaining a 
relatively stable phenotype and karyotype along with their potential to differentiate into 
multiple mesodermal tissues. The possibility that MSCs might undergo malignant 
transformation does exist, however this might be directly linked to the origin of the tissue. 
Interestingly, it has been shown that human bone marrow derived MSCs could be expanded 
in vitro and despite decreased proliferative capacity upon prolonged expansion and 
eventual cell senescence, no chromosomal abnormalities were detected rendering these cells 
suitable for cell therapeutic approaches (Bernardo, Zaffaroni et al. 2007).   
However, there is a general consensus that MSCs should be used at low passages when 
applied in cell therapy as chromosomal modifications and loss of function can occur after 
prolonged in vitro expansion. 
3. The Immunomodulatory properties of mesenchymal stem cells and their 
role in transplantation 
Understanding the mechanisms by which MSCs exert their immunomodulatory effects will 
have profound therapeutic implications in designing new therapies that can lead to more 
efficient use of these cells in novel treatment regimens. Currently, there is no single clear 
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mechanism which clearly clarifies the immunomodulatory effect of MSCs and several 
mechanisms which sometimes seem paradoxical, have been suggested. Several in vitro 
experimental studies have shown that the immunosuppressive effect of MSCs is sustained 
in transwell experiments suggesting that soluble factors are responsible for such inhibition 
(Di Nicola, Carlo-Stella et al. 2002; Meisel, Zibert et al. 2004; Aggarwal and Pittenger 2005; 
Gao, Wu et al. 2008; Ren, Zhang et al. 2008; Selmani, Naji et al. 2008), while other studies 
have claimed a required cell-cell contact which may be due to the use of different systems 
and cells by the individual research groups (Quaedackers, Baan et al. 2009; Ren, Zhao et al. 
2010).  
MSCs have been shown to modulate the immune response mainly by inhibiting the 
proliferation of effector immune cells preventing further damage to injured tissue allowing 
repair after injury (Uccelli, Moretta et al. 2008). Moreover, MSCs can stimulate the activation 
and proliferation of Tregs which in turn have a beneficial immunosuppressive effect (Crop, 
Baan et al. 2010).  
When MSCs home to site of tissue inflammation or injury, they release various growth 
factors  which enhance repair at site of defect including : fibroblast growth factor, epidermal 
growth factor, platelet-derived growth factor, transforming growth factor-β, vascular 
endothelial growth factor and insulin-like growth factor (Ng, Boucher et al. 2008).  MSCs 
mediated inhibition of effector T cell proliferation seems to be dependent on the 
microenvironment. In this respect, the presence of pro-inflammatory cytokines such as IFN-
γ activates MSCs and this was more effective for the treatment of GvHD (Polchert, Sobinsky 
et al. 2008). Indeed, it has been shown, that the immunosuppressive capacity of MSCs was 
enhanced strongly under inflammatory conditions while their differentiation capacity was 
preserved and suggested that in vitro preconditioning provides MSCs with improved 
properties for immediate clinical immune therapy (Crop, Baan et al. 2010).    
MSCs have been shown to affect almost all cell types of the immune system. It has been 
demonstrated that MSCs can alter the cytokine secretion profile of immune cells such as 
decreasing TNF-α and IFN-γ secretion and increasing the secretion of suppressive cytokines 
(IL-4 and IL-10) and this shift from a pro-inflammatory to a beneficial anti-inflammatory 
response is of therapeutic advantage for the management of GvHD (Dahlke, Hoogduijn et 
al. 2009; Hoogduijn, Popp et al. 2010). Moreover, several studies have demonstrated that the 
MSCs immunoregulatory properties are partially mediated by transforming growth factor  
(TGF-β), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF) and Indoleamine 2, 3-
dioxgenase (IDO) secreted by MSCs in addition to their induction and activation of Tregs all 
of which can lead to amplification of  an effective immunosuppressive response (English, 
Ryan et al. 2009; Kim, Wee et al. 2011). 
3.1 MSC–soluble factors and immunosuppression induction  
Different studies have attributed the immunosuppressive effect of MSCs to several 
immunosuppressive factors leading to different mechanisms of immune cell inhibition. 
These include, IDO (Meisel, Zibert et al. 2004; DelaRosa, Lombardo et al. 2009), PGE2 
(Aggarwal and Pittenger 2005), TGF-β and HGF (Di Nicola, Carlo-Stella et al. 2002), HLA-G 
(Selmani, Naji et al. 2008), nitric oxide (Ren, Zhang et al. 2008), interleukin (IL)-10 (Gao, Wu 
et al. 2008) and haeme oxygenase-1 (Chabannes, Hill et al. 2007). One important mechanism 
is that MSCs suppression is mediated by IDO, a tryptophan catabolising enzyme (Meisel, 
Zibert et al. 2004). In this, activated T cells or NK cells produce elevated levels of IFN-γ 
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which in turn stimulates MSCs to produce IDO. IDO metabolizes tryptophan to kynurenine 
leading to essential tryptophan depletion and accumulation of metabolites in the medium 
which in turn inhibits proliferation of activated T cells and  NK cells (Meisel, Zibert et al. 
2004). Competitive inhibition of IDO activity did not completely abrogate MSC mediated 
immunosuppression and inhibition of IFN-γ was required for complete abrogation 
(Krampera, Cosmi et al. 2006; DelaRosa, Lombardo et al. 2009). This suggests that co-
administration of MSCs with graft T cells-derived IFN-γ activates the immunomodulatory 
properties of MSCs. Furthermore, there is a species variation in the immunosuppressive 
mechanisms mediated by MSCs. It has been shown that while human IDO is a major 
effector molecule for MSCs immunosuppression, mouse MSCs mediate their inhibitory 
effect of immune responses via nitric oxide playing a central role in such 
immunosuppression (Sato, Ozaki et al. 2007; Ren, Zhang et al. 2008).  
3.2 MSC-immune cell interaction and immunosuppression induction  
MSCs have been demonstrated to exhibit a profound immunomodulatory effect on Tregs, 
cytotoxic and T helper cells, NK cells, B cells and dendritic cells.  
3.2.1 Regulatory T cells 
Tregs are a subset of T cells that regulate the immune response by suppressing the 
proliferation and cytokine production of effector T cells. Tregs are thus important for 
protecting our body by suppressing auto-reactive T cells (Thornton and Shevach 1998; Ng, 
Duggan et al. 2001). Tregs were shown to be upregulated in the presence of MSCs 
suggesting that MSCs constitute a suitable niche for Tregs (Crop, Baan et al. 2010). MSCs 
have been suggested to play a role in Tregs recruitment, regulating and maintaining the T 
regulatory phenotype and function over time (Prevosto, Zancolli et al. 2007; Di Ianni, Del 
Papa et al. 2008).  Tregs induction has been suggested to be mediated by PGE2, synthesized 
by cyclooxygenase enzymes (COX) which are expressed by MSCs (Le Blanc and Ringden 
2007). Furthermore, Treg induction has been shown to be mediated by direct cell-cell contact 
between MSCs and CD4+ T cells and the presence of soluble MSC derived factors such as 
TGF-β1 and PGE2 (English, Ryan et al. 2009). In a recent interesting study by (Sundin, 
D'Arcy et al. 2011) it was demonstrated for the first time that MSCs share features with 
regulatory T cells , such as the expression of the Tregs specific transcription factor FOXP3 
(Yagi, Nomura et al. 2004) at variable levels. However,  the MSC immunosuppressive 
function is not as tightly linked to FOXP3 expression as is the case for Tregs (Sundin, D'Arcy 
et al. 2011).  
3.2.2 Cytotoxic T cells and T helper cells 
MSCs were shown to inhibit the proliferation of CD4+ T helper cells (Di Nicola, Carlo-Stella 
et al. 2002; Aggarwal and Pittenger 2005). In addition to indirect inhibitory factors produced 
by MCSs such as TGF-β1, HGF, IL-10, IFN-γ and TNF-α, there is evidence that cell-
membrane interaction between MCSs and T helper cells (Quaedackers, Baan et al. 2009) via 
the intracellular adhesion molecule (ICAM-1) or vascular cell adhesion molecule (VCAM-1) 
play a crucial role in such immunosuppression (Ren, Zhao et al. 2010). MSCs have also been 
shown to suppress the induction of cytotoxic T cell response to allo-antigens (Angoulvant, 
Clerc et al. 2004). However, once cytotoxic T cells are activated, MSCs show no inhibitory 
effect (Rasmusson, Ringden et al. 2003; Le Blanc and Ringden 2007). On the other hand, it is 
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is that MSCs suppression is mediated by IDO, a tryptophan catabolising enzyme (Meisel, 
Zibert et al. 2004). In this, activated T cells or NK cells produce elevated levels of IFN-γ 
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which in turn stimulates MSCs to produce IDO. IDO metabolizes tryptophan to kynurenine 
leading to essential tryptophan depletion and accumulation of metabolites in the medium 
which in turn inhibits proliferation of activated T cells and  NK cells (Meisel, Zibert et al. 
2004). Competitive inhibition of IDO activity did not completely abrogate MSC mediated 
immunosuppression and inhibition of IFN-γ was required for complete abrogation 
(Krampera, Cosmi et al. 2006; DelaRosa, Lombardo et al. 2009). This suggests that co-
administration of MSCs with graft T cells-derived IFN-γ activates the immunomodulatory 
properties of MSCs. Furthermore, there is a species variation in the immunosuppressive 
mechanisms mediated by MSCs. It has been shown that while human IDO is a major 
effector molecule for MSCs immunosuppression, mouse MSCs mediate their inhibitory 
effect of immune responses via nitric oxide playing a central role in such 
immunosuppression (Sato, Ozaki et al. 2007; Ren, Zhang et al. 2008).  
3.2 MSC-immune cell interaction and immunosuppression induction  
MSCs have been demonstrated to exhibit a profound immunomodulatory effect on Tregs, 
cytotoxic and T helper cells, NK cells, B cells and dendritic cells.  
3.2.1 Regulatory T cells 
Tregs are a subset of T cells that regulate the immune response by suppressing the 
proliferation and cytokine production of effector T cells. Tregs are thus important for 
protecting our body by suppressing auto-reactive T cells (Thornton and Shevach 1998; Ng, 
Duggan et al. 2001). Tregs were shown to be upregulated in the presence of MSCs 
suggesting that MSCs constitute a suitable niche for Tregs (Crop, Baan et al. 2010). MSCs 
have been suggested to play a role in Tregs recruitment, regulating and maintaining the T 
regulatory phenotype and function over time (Prevosto, Zancolli et al. 2007; Di Ianni, Del 
Papa et al. 2008).  Tregs induction has been suggested to be mediated by PGE2, synthesized 
by cyclooxygenase enzymes (COX) which are expressed by MSCs (Le Blanc and Ringden 
2007). Furthermore, Treg induction has been shown to be mediated by direct cell-cell contact 
between MSCs and CD4+ T cells and the presence of soluble MSC derived factors such as 
TGF-β1 and PGE2 (English, Ryan et al. 2009). In a recent interesting study by (Sundin, 
D'Arcy et al. 2011) it was demonstrated for the first time that MSCs share features with 
regulatory T cells , such as the expression of the Tregs specific transcription factor FOXP3 
(Yagi, Nomura et al. 2004) at variable levels. However,  the MSC immunosuppressive 
function is not as tightly linked to FOXP3 expression as is the case for Tregs (Sundin, D'Arcy 
et al. 2011).  
3.2.2 Cytotoxic T cells and T helper cells 
MSCs were shown to inhibit the proliferation of CD4+ T helper cells (Di Nicola, Carlo-Stella 
et al. 2002; Aggarwal and Pittenger 2005). In addition to indirect inhibitory factors produced 
by MCSs such as TGF-β1, HGF, IL-10, IFN-γ and TNF-α, there is evidence that cell-
membrane interaction between MCSs and T helper cells (Quaedackers, Baan et al. 2009) via 
the intracellular adhesion molecule (ICAM-1) or vascular cell adhesion molecule (VCAM-1) 
play a crucial role in such immunosuppression (Ren, Zhao et al. 2010). MSCs have also been 
shown to suppress the induction of cytotoxic T cell response to allo-antigens (Angoulvant, 
Clerc et al. 2004). However, once cytotoxic T cells are activated, MSCs show no inhibitory 
effect (Rasmusson, Ringden et al. 2003; Le Blanc and Ringden 2007). On the other hand, it is 
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not clear how helper and cytotoxic T cells affect MSCs development and function. It has 
been shown that MSCs have a low immunophenotype as they express low levels of HLA 
class I, no HLA class II, no co-stimulatory molecules such as CD80 and CD86, and therefore 
do not induce immune responses (Beggs, Lyubimov et al. 2006; Rasmusson, Uhlin et al. 
2007). This should make MSCs transplantable across HLA barriers (Le Blanc, Tammik et al. 
2003). However, in contrast to these data, there is evidence that MSCs are immunogenic and 
can induce memory T-cell responses both in animals (Badillo, Beggs et al. 2007) and human 
studies (Nauta, Westerhuis et al. 2006). Furthermore, it has recently been reported that 
MSCs are susceptible for lysis by CD8+ cytotoxic T cells (Crop, Korevaar et al. 2011). 
Designing tools to escape allogeneic MSCs destruction by cytotoxic T cells should render 
MSCs a promising therapeutic option for transplantation across MHC barriers.   
3.2.3 Natural Killer cells  
MSCs have been shown to inhibit  NK cell proliferation, and cytotoxicity (Sotiropoulou, 
Perez et al. 2006). It has been demonstrated that MSCs can mediate this inhibitory effect 
trough inhibition of cytokine production in addition to the central role played by IDO and 
PGE2 (Spaggiari, Capobianco et al. 2008). Inversely, it has been shown that MSCs are 
susceptible for lysis by NK cells (Spaggiari, Capobianco et al. 2006; Crop, Korevaar et al. 
2011) as MSCs express the activating NK cell-receptor ligands NKG2D and UL16 (Poggi, 
Prevosto et al. 2007). Moreover, intravenously administered MSCs have been demonstrated 
to disappear within days after infusion in immunocompetent mice (Popp, Eggenhofer et al. 
2008). It is possible that lysis by cytotoxic T cells (and not NK cells) is responsible for the 
disappearance of the infused MSCs (Eliopoulos, Stagg et al. 2005). The demonstration of 
tumour engraftment after administration of autologous MSCs in immunodeficient mice (NK 
cells intact) further strengthens this possibility.  
3.2.4 B cells  
MSCs have been shown to suppress B cell terminal differentiation (Asari, Itakura et al. 2009) 
and modulate their function (Corcione, Benvenuto et al. 2006; Tabera, Perez-Simon et al. 
2008). Human MSCs were shown to inhibit antibody production induced in vitro by allo-
stimulation (Comoli, Ginevri et al. 2008; English, French et al. 2010). They have the ability to 
regulate Immunoglobulin production by B cells through soluble factors affecting B cells 
directly or through an indirect MSCs effect by altering the amount of free alloantigen due to 
the overall suppression of graft damage (Ge, Jiang et al. 2009).  
3.2.5 Dendritic cells 
MSCs inhibit monocyte maturation into dendritic cells (Jiang, Zhang et al. 2005), the most 
potent antigen presenting cells,  inhibiting their migration to lymph nodes and thereby 
reducing their ability to activate allo-reactive T cells (Aggarwal and Pittenger 2005). In 
this, MSCs were shown to reduce secretion of pro-inflammatory cytokines such as IFN-γ, 
IL-12 and TNF-α by DCs  while IL-10, a suppressive cytokine, was increased leading to 
the inhibition of DCs maturation and the inability to activate allo-reactive T cells resulting 
in a state of an immunologic tolerance. The inhibitory effect of MSCs on DC 
differentiation is mainly mediated through cell-cell contact involving activation of the 
Notch signalling pathway (Li, Paczesny et al. 2008) as well via soluble factors (Nauta, 
Kruisselbrink et al. 2006). Moreover, PGE2 produced by MSCs following TNF-α or IFN-γ 
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stimulation blocks differentiation of monocytes into DCs and stimulates macrophages to 
produce Il-10.   
3.3 MSCs-Galectins and immunosuppression induction 
Recently, Sioud et al  (Sioud, Mobergslien et al. 2010; Sioud 2011)and Gieseke et al (Gieseke, 
Bohringer et al. 2010) have described another mechanism of MSCs immunosuppression that 
involves a family of beta galactosidase-binding proteins named Galectins which are 
involved in immune tolerance (Garin, Chu et al. 2007). It has been demonstrated that 
Galectin-1, Galectin-3, Galectin-8 and Galectin-9 are constitutively expressed by human 
bone marrow MSCs with Galectin-1 and Galectin -3 being further secreted and expressed on 
the outer plasma membrane (Wada and Makino 2001). New evidence has shown the 
involvement of Galectin-3 as a regulator of MSCs immunosuppression function inhibiting 
allogeneic T cell proliferation by MSCs (Sioud 2011). This group demonstrated that gene 
knockdown of Galectin-3 resulted in less immunosuppressive effect on T cell proliferation 
(Sioud, Mobergslien et al. 2010). Galectins were also shown to regulate the secretion of pro-
inflammatory cytokines and  promote expansion of IL-10 producing peripheral Tregs  
(Sioud 2011). Gieseke et al have also reported that galectin-1 is expressed by MSCs and has 
immunosuppressive activity on both CD4+ and CD8+ T cells (Gieseke, Bohringer et al. 2010). 
4. Clinical prospects of mesenchymal stem cells  
Currently suggested clinical uses of MSCs include; differentiation and repairing of damaged 
tissue e.g. in osteogenesis imperfecta, promoting hematopoietic cell engraftment in AHSCT 
e.g. in leukaemia and their immunosuppressive abilities in autoimmune-induced 
inflammatory bowel disease, GvHD induced upon allogeneic cell or organ transplantation 
as well as autoimmune diseases. Treating autoimmunity with MSCs was first investigated 
for experimental autoimmune encephalomyelitis as a model for multiple sclerosis in 
preclinical studies followed by collagen-induced arthritis, autoimmune type 1 diabetes, 
experimental colitis and lupus nephritis (Uccelli and Prockop 2010). 
Still, very little is known about the mechanisms underlying the MSCs immunomodulatory 
effect in vivo and survival of MSCs upon injection and whether they remain present after 
systemic injection or local transplantation remains unresolved.  However, the clinical 
studies performed so far look encouraging but still the mechanisms as to how the MSCs 
regulate immune cells in vivo are still missing. Furthermore, direct methods to assess MSCs 
mobilization and homing in response to injury or inflammation is essential to eventually 
understand the underlying mechanism (Karp and Leng Teo 2009).  
MSCs are immune-privileged and were shown in most studies to ‘escape’ the immune 
system and be tolerated when transplanted across MHC barriers engrafting and failing to 
induce an immune response. It is important to mention that most of these clinical studies 
have used MSCs from HLA-identical or near identical donors (Le Blanc and Ringden 2007).  
It has been reported that AHSCT recipients have specific tolerance, immune-
unresponsiveness, directed towards MSCs but not to other cells from the MSC donor 
(Sundin, Barrett et al. 2009). This suggests that totally HLA mismatched MSCs from one 
donor can be expanded ex vivo, cryopreserved and used for the treatment of multiple 
patients. Furthermore, the inability of MSCs to induce donor specific tolerance suggests that 
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not clear how helper and cytotoxic T cells affect MSCs development and function. It has 
been shown that MSCs have a low immunophenotype as they express low levels of HLA 
class I, no HLA class II, no co-stimulatory molecules such as CD80 and CD86, and therefore 
do not induce immune responses (Beggs, Lyubimov et al. 2006; Rasmusson, Uhlin et al. 
2007). This should make MSCs transplantable across HLA barriers (Le Blanc, Tammik et al. 
2003). However, in contrast to these data, there is evidence that MSCs are immunogenic and 
can induce memory T-cell responses both in animals (Badillo, Beggs et al. 2007) and human 
studies (Nauta, Westerhuis et al. 2006). Furthermore, it has recently been reported that 
MSCs are susceptible for lysis by CD8+ cytotoxic T cells (Crop, Korevaar et al. 2011). 
Designing tools to escape allogeneic MSCs destruction by cytotoxic T cells should render 
MSCs a promising therapeutic option for transplantation across MHC barriers.   
3.2.3 Natural Killer cells  
MSCs have been shown to inhibit  NK cell proliferation, and cytotoxicity (Sotiropoulou, 
Perez et al. 2006). It has been demonstrated that MSCs can mediate this inhibitory effect 
trough inhibition of cytokine production in addition to the central role played by IDO and 
PGE2 (Spaggiari, Capobianco et al. 2008). Inversely, it has been shown that MSCs are 
susceptible for lysis by NK cells (Spaggiari, Capobianco et al. 2006; Crop, Korevaar et al. 
2011) as MSCs express the activating NK cell-receptor ligands NKG2D and UL16 (Poggi, 
Prevosto et al. 2007). Moreover, intravenously administered MSCs have been demonstrated 
to disappear within days after infusion in immunocompetent mice (Popp, Eggenhofer et al. 
2008). It is possible that lysis by cytotoxic T cells (and not NK cells) is responsible for the 
disappearance of the infused MSCs (Eliopoulos, Stagg et al. 2005). The demonstration of 
tumour engraftment after administration of autologous MSCs in immunodeficient mice (NK 
cells intact) further strengthens this possibility.  
3.2.4 B cells  
MSCs have been shown to suppress B cell terminal differentiation (Asari, Itakura et al. 2009) 
and modulate their function (Corcione, Benvenuto et al. 2006; Tabera, Perez-Simon et al. 
2008). Human MSCs were shown to inhibit antibody production induced in vitro by allo-
stimulation (Comoli, Ginevri et al. 2008; English, French et al. 2010). They have the ability to 
regulate Immunoglobulin production by B cells through soluble factors affecting B cells 
directly or through an indirect MSCs effect by altering the amount of free alloantigen due to 
the overall suppression of graft damage (Ge, Jiang et al. 2009).  
3.2.5 Dendritic cells 
MSCs inhibit monocyte maturation into dendritic cells (Jiang, Zhang et al. 2005), the most 
potent antigen presenting cells,  inhibiting their migration to lymph nodes and thereby 
reducing their ability to activate allo-reactive T cells (Aggarwal and Pittenger 2005). In 
this, MSCs were shown to reduce secretion of pro-inflammatory cytokines such as IFN-γ, 
IL-12 and TNF-α by DCs  while IL-10, a suppressive cytokine, was increased leading to 
the inhibition of DCs maturation and the inability to activate allo-reactive T cells resulting 
in a state of an immunologic tolerance. The inhibitory effect of MSCs on DC 
differentiation is mainly mediated through cell-cell contact involving activation of the 
Notch signalling pathway (Li, Paczesny et al. 2008) as well via soluble factors (Nauta, 
Kruisselbrink et al. 2006). Moreover, PGE2 produced by MSCs following TNF-α or IFN-γ 
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stimulation blocks differentiation of monocytes into DCs and stimulates macrophages to 
produce Il-10.   
3.3 MSCs-Galectins and immunosuppression induction 
Recently, Sioud et al  (Sioud, Mobergslien et al. 2010; Sioud 2011)and Gieseke et al (Gieseke, 
Bohringer et al. 2010) have described another mechanism of MSCs immunosuppression that 
involves a family of beta galactosidase-binding proteins named Galectins which are 
involved in immune tolerance (Garin, Chu et al. 2007). It has been demonstrated that 
Galectin-1, Galectin-3, Galectin-8 and Galectin-9 are constitutively expressed by human 
bone marrow MSCs with Galectin-1 and Galectin -3 being further secreted and expressed on 
the outer plasma membrane (Wada and Makino 2001). New evidence has shown the 
involvement of Galectin-3 as a regulator of MSCs immunosuppression function inhibiting 
allogeneic T cell proliferation by MSCs (Sioud 2011). This group demonstrated that gene 
knockdown of Galectin-3 resulted in less immunosuppressive effect on T cell proliferation 
(Sioud, Mobergslien et al. 2010). Galectins were also shown to regulate the secretion of pro-
inflammatory cytokines and  promote expansion of IL-10 producing peripheral Tregs  
(Sioud 2011). Gieseke et al have also reported that galectin-1 is expressed by MSCs and has 
immunosuppressive activity on both CD4+ and CD8+ T cells (Gieseke, Bohringer et al. 2010). 
4. Clinical prospects of mesenchymal stem cells  
Currently suggested clinical uses of MSCs include; differentiation and repairing of damaged 
tissue e.g. in osteogenesis imperfecta, promoting hematopoietic cell engraftment in AHSCT 
e.g. in leukaemia and their immunosuppressive abilities in autoimmune-induced 
inflammatory bowel disease, GvHD induced upon allogeneic cell or organ transplantation 
as well as autoimmune diseases. Treating autoimmunity with MSCs was first investigated 
for experimental autoimmune encephalomyelitis as a model for multiple sclerosis in 
preclinical studies followed by collagen-induced arthritis, autoimmune type 1 diabetes, 
experimental colitis and lupus nephritis (Uccelli and Prockop 2010). 
Still, very little is known about the mechanisms underlying the MSCs immunomodulatory 
effect in vivo and survival of MSCs upon injection and whether they remain present after 
systemic injection or local transplantation remains unresolved.  However, the clinical 
studies performed so far look encouraging but still the mechanisms as to how the MSCs 
regulate immune cells in vivo are still missing. Furthermore, direct methods to assess MSCs 
mobilization and homing in response to injury or inflammation is essential to eventually 
understand the underlying mechanism (Karp and Leng Teo 2009).  
MSCs are immune-privileged and were shown in most studies to ‘escape’ the immune 
system and be tolerated when transplanted across MHC barriers engrafting and failing to 
induce an immune response. It is important to mention that most of these clinical studies 
have used MSCs from HLA-identical or near identical donors (Le Blanc and Ringden 2007).  
It has been reported that AHSCT recipients have specific tolerance, immune-
unresponsiveness, directed towards MSCs but not to other cells from the MSC donor 
(Sundin, Barrett et al. 2009). This suggests that totally HLA mismatched MSCs from one 
donor can be expanded ex vivo, cryopreserved and used for the treatment of multiple 
patients. Furthermore, the inability of MSCs to induce donor specific tolerance suggests that 
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MSCs co-transplantation with a solid organ most probably facilitates engraftment through 
the immunosuppressive action of MSCs and not by inducing specific tolerance to the 
transplant (Sundin, D'Arcy et al. 2011).  
4.1 Graft versus Host Disease 
GvHD occurs in donated organ recipients and patho-physiologically presents itself as 
damage in skin, mucosa, gastrointestinal tract, the liver, connective tissue and exocrine 
glands. It is considered chronic when it persists more than 100 days after transplantation 
and it is distinguished from acute GvHD which often cannot be ameliorated because of a 
coexistent immunosuppression.   It results from the attack of donor own T cells in the graft 
on recipient tissues after activation by recipient MHC molecules as well as activation of 
cytotoxic T cells, antigen presenting cells and NK cells. In GvHD the observation of an 
increased secretion of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-1, IL-2 and IL-
12 suggests that therapeutic approaches to inhibit these cytokines should lead to a decreased 
severity of GvHD (Aggarwal and Pittenger 2005).  
The immunosuppressive effects of MSCs have been evidenced in a successful clinical trial 
reported by Ringden et al (Ringden and Le Blanc 2011) in patients presented with acute 
GvHD after AHSCT and resistant to conventional immunosuppressive therapy. This study 
showed a dramatic improvement after MSCs infusion with acute GvHD disappearing 
completely in patients with steroid resistant GvHD suggesting that MSCs could be 
considered as a promising alternative immunosuppressive therapy with improved long 
term outcome for the treatment of GvHD (Le Blanc, Rasmusson et al. 2004; English, French 
et al. 2010; Ringden and Le Blanc 2011; Tolar, Villeneuve et al. 2011).  
4.2 Type 1 diabetes  
MSCs have been suggested as a prospective cell therapy of autoimmune type 1 diabetes 
known to be associated with an inflammation in the pancreas and degeneration of β cells. In 
a preclinical study, it has been shown that co-transplantation of bone marrow cells and 
syngeneic or allogeneic MSCs initiated endogenous pancreatic regeneration and improved 
blood glucose levels in streptozotocin induced diabetic mice (Ulicna, Danisovic et al. 2009). 
The success in the treatment was suggested to be due to MSCs aiding in the regeneration of 
recipient derived pancreatic beta cells, as well as maintaining the β cell reserve through 
MSC inhibition of T cell-mediated immune responses against the newly formed β cells 
preventing further cell degeneration (Voltarelli, Couri et al. 2007; Couri and Voltarelli 2009; 
Ulicna, Danisovic et al. 2009; Sordi, Melzi et al. 2010). Hence, despite of the persisting hostile 
autoimmune response in the pancreas, when MSCs are applied at an early stage of the 
disease they potentially protect and allow the endogenous regeneration of the remaining 
intact β cell reserve.  
4.3 Solid organ transplantation  
In solid organ transplantation (e.g. liver transplant), rejection of a transplanted organ is 
typically caused by induction of T cell proliferation and presentation of allo-antigens to 
naive and memory T cells by antigen presenting cells (both host and donor) leading to 
activation and differentiation into effector T cells (Popp, Renner et al. 2009). Both the 
regenerative and immunomodulatory properties of MSCs are of medical importance in 
organ transplantation studies. MSCs have been shown to home to site of allograft and help 
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the body accommodate the new organ through immunosuppression or preventing rejection 
and acquisition of a state of tolerance (English, French et al. 2010). Furthermore, the 
regenerative properties of MSCs possibly maintain the organ to be transplanted stretching 
its lifespan in case of delayed transplantation (Hematti 2008; Hoogduijn, Popp et al. 2010). 
For MSCs to be used as a sole therapy or as a combination therapy replacing 
immunosuppressive drugs, reducing the burden on the patient and the risk for long term 
side effects, further investigation will be needed to fully explain the immunomodulatory 
properties of MSCs. However, MSCs were shown to increase immunosuppression when co-
administered complementing the therapy (Sundin, D'Arcy et al. 2011). In this regard, an  
interesting animal study of allogeneic heart graft transplantation that MSCs combined with 
the immunosuppressive drug mycophenolate mofetil (MMF) promoted the elimination of 
activated T cells in secondary lymphatic organs, delayed antigen presenting cells activation, 
and protected the graft from cellular infiltration by modulating the endothelium 
(Eggenhofer, Steinmann et al. 2011).  
5. Quality considerations and regulations in MSC based therapy 
Clinical use of MSCs for cellular therapeutic approaches will require that the bio-safety of 
these cells has to be adequately optimised. This requires the absence of chromosomal, 
functional, and phenotypical alterations in ex vitro expanded MSCs before considering their 
injection in patients. The safety of these cells has to be guaranteed upon their administration as 
immunocompromised patients might have an increased risk of tumour induction or the 
potential risk of stimulating the growth of a previously undetected cancer. The risk of 
tumorigenicity and genomic instability remains  an obstacle for any given stem-cell based 
therapy product and will have to be adequately assessed prior to approval for human use 
(Dittmar, Simann et al. 2010).  In this respect, the first clinical trials have been undertaken to 
assess the safety of MSC administration and potential treatment options for GvHD and it has 
been reported that autologous and allogeneic MSCs are safe to be injected in patients with life 
threatening acute GvHD not responding to conventional immunosuppressive therapy without 
acute toxicity and no signs of ectopic tissue formation (Lazarus, Koc et al. 2005).  
MSCs administered for therapy might carry viruses (e.g. herpes simplex virus, cytomegalo 
virus (CMV), Epstein-Barr Virus (EBV)) transmitted from the donor to the host tissue 
especially when the patient is immunocompromised. Interestingly, MSCs were shown to 
exert differential effects on alloantigen and virus-specific T cell responses (Karlsson, 
Samarasinghe et al. 2008). In this regard, it has been reported that despite MSC infusion as a 
cellular immunotherapy for GvHD, effector functions of virus specific T cells were retained 
with very little effect on T cell responses to pathogenic CMV and EBV contrasting the strong 
immunosuppressive effect on allo-reactive T cells suggesting that MSCs to be a promising 
cellular immunotherapy (Karlsson, Samarasinghe et al. 2008). This is an important 
advantageous aspect of MSCs therapy especially since after allogeneic organ transplantation; 
infections are a major cause of morbidity and mortality in immunocompromised patients. 
Therefore, MSCs can be safely administered without exacerbating their susceptibility to 
infectious pathogens.  
Currently large clinical trials are being carried out in using MSCs for the treatment of 
autoimmune diseases including diabetes as well as to treat or ameliorate symptoms of 
GvHD. Further, clinical trials are also testing the MSCs ability to facilitate the prevention of 
the rejection upon organ transplantation thereby reducing or completely eliminating the 
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MSCs co-transplantation with a solid organ most probably facilitates engraftment through 
the immunosuppressive action of MSCs and not by inducing specific tolerance to the 
transplant (Sundin, D'Arcy et al. 2011).  
4.1 Graft versus Host Disease 
GvHD occurs in donated organ recipients and patho-physiologically presents itself as 
damage in skin, mucosa, gastrointestinal tract, the liver, connective tissue and exocrine 
glands. It is considered chronic when it persists more than 100 days after transplantation 
and it is distinguished from acute GvHD which often cannot be ameliorated because of a 
coexistent immunosuppression.   It results from the attack of donor own T cells in the graft 
on recipient tissues after activation by recipient MHC molecules as well as activation of 
cytotoxic T cells, antigen presenting cells and NK cells. In GvHD the observation of an 
increased secretion of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-1, IL-2 and IL-
12 suggests that therapeutic approaches to inhibit these cytokines should lead to a decreased 
severity of GvHD (Aggarwal and Pittenger 2005).  
The immunosuppressive effects of MSCs have been evidenced in a successful clinical trial 
reported by Ringden et al (Ringden and Le Blanc 2011) in patients presented with acute 
GvHD after AHSCT and resistant to conventional immunosuppressive therapy. This study 
showed a dramatic improvement after MSCs infusion with acute GvHD disappearing 
completely in patients with steroid resistant GvHD suggesting that MSCs could be 
considered as a promising alternative immunosuppressive therapy with improved long 
term outcome for the treatment of GvHD (Le Blanc, Rasmusson et al. 2004; English, French 
et al. 2010; Ringden and Le Blanc 2011; Tolar, Villeneuve et al. 2011).  
4.2 Type 1 diabetes  
MSCs have been suggested as a prospective cell therapy of autoimmune type 1 diabetes 
known to be associated with an inflammation in the pancreas and degeneration of β cells. In 
a preclinical study, it has been shown that co-transplantation of bone marrow cells and 
syngeneic or allogeneic MSCs initiated endogenous pancreatic regeneration and improved 
blood glucose levels in streptozotocin induced diabetic mice (Ulicna, Danisovic et al. 2009). 
The success in the treatment was suggested to be due to MSCs aiding in the regeneration of 
recipient derived pancreatic beta cells, as well as maintaining the β cell reserve through 
MSC inhibition of T cell-mediated immune responses against the newly formed β cells 
preventing further cell degeneration (Voltarelli, Couri et al. 2007; Couri and Voltarelli 2009; 
Ulicna, Danisovic et al. 2009; Sordi, Melzi et al. 2010). Hence, despite of the persisting hostile 
autoimmune response in the pancreas, when MSCs are applied at an early stage of the 
disease they potentially protect and allow the endogenous regeneration of the remaining 
intact β cell reserve.  
4.3 Solid organ transplantation  
In solid organ transplantation (e.g. liver transplant), rejection of a transplanted organ is 
typically caused by induction of T cell proliferation and presentation of allo-antigens to 
naive and memory T cells by antigen presenting cells (both host and donor) leading to 
activation and differentiation into effector T cells (Popp, Renner et al. 2009). Both the 
regenerative and immunomodulatory properties of MSCs are of medical importance in 
organ transplantation studies. MSCs have been shown to home to site of allograft and help 
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the body accommodate the new organ through immunosuppression or preventing rejection 
and acquisition of a state of tolerance (English, French et al. 2010). Furthermore, the 
regenerative properties of MSCs possibly maintain the organ to be transplanted stretching 
its lifespan in case of delayed transplantation (Hematti 2008; Hoogduijn, Popp et al. 2010). 
For MSCs to be used as a sole therapy or as a combination therapy replacing 
immunosuppressive drugs, reducing the burden on the patient and the risk for long term 
side effects, further investigation will be needed to fully explain the immunomodulatory 
properties of MSCs. However, MSCs were shown to increase immunosuppression when co-
administered complementing the therapy (Sundin, D'Arcy et al. 2011). In this regard, an  
interesting animal study of allogeneic heart graft transplantation that MSCs combined with 
the immunosuppressive drug mycophenolate mofetil (MMF) promoted the elimination of 
activated T cells in secondary lymphatic organs, delayed antigen presenting cells activation, 
and protected the graft from cellular infiltration by modulating the endothelium 
(Eggenhofer, Steinmann et al. 2011).  
5. Quality considerations and regulations in MSC based therapy 
Clinical use of MSCs for cellular therapeutic approaches will require that the bio-safety of 
these cells has to be adequately optimised. This requires the absence of chromosomal, 
functional, and phenotypical alterations in ex vitro expanded MSCs before considering their 
injection in patients. The safety of these cells has to be guaranteed upon their administration as 
immunocompromised patients might have an increased risk of tumour induction or the 
potential risk of stimulating the growth of a previously undetected cancer. The risk of 
tumorigenicity and genomic instability remains  an obstacle for any given stem-cell based 
therapy product and will have to be adequately assessed prior to approval for human use 
(Dittmar, Simann et al. 2010).  In this respect, the first clinical trials have been undertaken to 
assess the safety of MSC administration and potential treatment options for GvHD and it has 
been reported that autologous and allogeneic MSCs are safe to be injected in patients with life 
threatening acute GvHD not responding to conventional immunosuppressive therapy without 
acute toxicity and no signs of ectopic tissue formation (Lazarus, Koc et al. 2005).  
MSCs administered for therapy might carry viruses (e.g. herpes simplex virus, cytomegalo 
virus (CMV), Epstein-Barr Virus (EBV)) transmitted from the donor to the host tissue 
especially when the patient is immunocompromised. Interestingly, MSCs were shown to 
exert differential effects on alloantigen and virus-specific T cell responses (Karlsson, 
Samarasinghe et al. 2008). In this regard, it has been reported that despite MSC infusion as a 
cellular immunotherapy for GvHD, effector functions of virus specific T cells were retained 
with very little effect on T cell responses to pathogenic CMV and EBV contrasting the strong 
immunosuppressive effect on allo-reactive T cells suggesting that MSCs to be a promising 
cellular immunotherapy (Karlsson, Samarasinghe et al. 2008). This is an important 
advantageous aspect of MSCs therapy especially since after allogeneic organ transplantation; 
infections are a major cause of morbidity and mortality in immunocompromised patients. 
Therefore, MSCs can be safely administered without exacerbating their susceptibility to 
infectious pathogens.  
Currently large clinical trials are being carried out in using MSCs for the treatment of 
autoimmune diseases including diabetes as well as to treat or ameliorate symptoms of 
GvHD. Further, clinical trials are also testing the MSCs ability to facilitate the prevention of 
the rejection upon organ transplantation thereby reducing or completely eliminating the 
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need for immunosuppressive therapies. Reviewing the clinical trials registered by the U.S. 
National Institutes of Health (NIH) in the United States and around the world (U.S. National 
Institutes of Health, http://clinicaltrials.gov/), 168 registered studies (with a start date 
between September 2004 and March 2011) were found upon entering the search criteria 
mesenchymal + stem + cells including clinical trials in regenerating organs (e.g. bone 
fractures, diabetic foot and foot ulcer), liver failure, the administration of MSCs for the 
treatment of type 1 Diabetes Mellitus as well as Type 2, acute GvHD including studies with 
patients who have failed to respond to steroid therapy (or with steroid resistance) and poor 
graft function. In addition to these trials, ongoing clinical studies investigating the safety 
and efficacy of MSCs promoting engraftment of allogeneic hematopoietic stem cells are in 
hand (Le Blanc, Rasmusson et al. 2004). 
The translation into cellular therapies satisfying safety and efficacy criteria by the regulatory 
authorities will have to ensure the identity, purity, potency, and lack of tumorigenicity. 
Questions regarding the expansion of MSCs in vitro and the passage at which they are used 
as well as the culture conditions containing foetal calf serum, optimal dosing, timing and 
HLA matching still remain to be answered (Le Blanc, Samuelsson et al. 2007; Sundin, 
Ringden et al. 2007). 
Scientists and clinicians should adhere to local, national and international guidelines and 
regulations that govern transfer of cells into patients. The clinical trial and the eventual cell 
therapeutic product is assessed and approved by a national regulatory agency, such as the 
European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).The 
International Society for Stem Cell Research (ISSCR) has published guidelines for the clinical 
translation of stem cells emphasising on the scientific, clinical and ethical issues that should 
be addressed for a responsible translation of basic stem cell research into suitable clinical 
applications. The guidelines give attention to the main areas of clinical translational stem 
cell research namely, cell processing and manufacture, the necessity of preclinical studies 
and clinical research promoting maximum safety and quality of the cells to be used (Hyun, 
Lindvall et al. 2008). 
6. Conclusion  
Understanding the immunomodulatory properties of MSCs and possibly identifying genes 
that regulate MSC inhibitory function, and genes regulating inflammation which play a 
major role in transplant rejection and inflammatory processes should help in developing 
applicable MSC based cellular therapies for solid organ transplantation, GvHD and 
autoimmune diseases.   
The currently available data, in vitro and in vivo, suggest that MSCs can be applied in a 
wide range of clinical approaches, ranging from tissue repair and regeneration, drug or gene 
delivery to injured tissue, treatment and prevention of GvHD and AHSCT engraftment 
offering a promising option for treating autoimmune mediated disorders as well as organ 
transplantation. Administration of MSCs provides novel modalities for the treatment of 
patients with allograft rejection with fewer side effects than existing immunosuppressive 
therapies following organ transplantation. 
There is an enormous amount of excitement and the scope of possible stem cell based 
therapies has expanded in the recent years due to rapid advances in stem cell research.  But 
today the range of diseases where stem cell treatments have been shown to be beneficial in 
responsibly conducted clinical trials is still extremely restricted.  
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The best defined and most extensively used is hematopoietic stem cell transplantation in 
blood malignancies and aplastic anaemia. To design safe and effective cellular therapies, the 
long term effects of MSCs injection will still need to be shown in relevant clinical trials and 
further studies are needed to optimize cell-dosing, time of injection and the combination 
with immunosuppressive drugs to confirm both efficacy and safety of this cell therapy, are 
still needed within the careful regulations of the EMA and FDA.  
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1. Introduction 
Results from cell transplantation research have received interest and attention both from a 
clinical, a scientific and a public point of view. This chapter discusses new endovascular 
transplantation methods for different cell systems. First different cell based therapies are 
presented, followed by an overview of pathological conditions wherein several cell based 
strategies are implemented. Thereafter the delivery of cells in broad terms, and then 
specifically by endovascular technique compared to surgical technique, is presented. A 
general description of the active process of diapedesis is provided, as it is understood for 
immunological cells, since this is most probably a fundamental process for endovascular 
transplantation of cells as well. 
1.1 Cell based therapies 
Cell based strategies are sought after as a way of repairing or facilitating self renewal in 
pathological organ systems that have little or no intrinsic regenerative capacity. The 
plethora of different diseases in organ systems that might have a regenerative capacity, but 
is limited through physiological processes, is almost boundless (Bajada et al. 2008). Cell 
based therapies have been successfully used in the clinical practice for distinct pathological 
conditions during a relatively long period of modern medicine. One of the broadest success 
stories are the transplantation of cells to patients suffering from hematological diseases 
(Buckner et al. 1974; Thomas et al. 1975; Thomas et al. 1975; Slavin et al. 1998). 
Hematological stem cell transplantation has also been expanded to comprise autologous 
transplantations following chemotherapy of solid tumor forms (Childs et al. 2000). 
Following the isolation of stem cell lines from human blastocysts (Thomson et al. 1998) and 
other adult sources such as the central nervous system (CNS) (Johansson et al. 1999), bone 
marrow (Bruder et al. 1997), multi-lineage mesenchymal (Pittenger et al. 1999), adipose 
tissue (Zuk et al. 2001) among others, new cell based approaches to disease treatment can be 
envisioned. The potential for in vivo expansion of these cells followed by transplantation, re-
implantation and/or tissue engineering becomes possible (Vacanti et al. 1999). These 
findings open up possibilities for strategies aimed at ameliorating disease burden, or in the 
long run, obtaining curative goals through cell therapies in a clinical setting. Proposed 
treatments can broadly be divided into stimulation of an endogenous population or 
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long run, obtaining curative goals through cell therapies in a clinical setting. Proposed 
treatments can broadly be divided into stimulation of an endogenous population or 
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transplantation of cells (Lindvall et al. 2006), be them homologous, from a donor or across 
the xeno-barrier. The wider implications of the prospect of cell based treatments are 
summarized in a review article where the coining of the effort and/or subject of 
Regenerative Medicine is presented (Daar et al. 2007). 
The CNS has attracted attention since the potential of restored function could be very 
valuable for patients. Particularly since pathological conditions in the CNS can be severely 
disabling. Cell based therapies are in clinical trials in e.g. Parkinsons Disease (Freed et al. 
2001; Gordon et al. 2004), ischemic stroke (Kondziolka et al. 2000; Bang et al. 2005) and 
spinal cord lesions (Sykova et al. 2006). Outside the CNS, other clinical trials with cell based 
therapies aimed at e.g. muscle dystrophy (Gussoni et al. 1997; Miller et al. 1997), ischemic 
heart disease (Stamm et al. 2003), graft versus host disease (Le Blanc et al. 2004; Ringden et 
al. 2006) and type I diabetes mellitus (Scharp et al. 1991; Shapiro et al. 2000; Korsgren et al. 
2008) have yielded promising results. So far, many of the cell therapies are still in trials since 
both safety and effects must be thoroughly evaluated. 
In many areas of pre-clinical, and to some extent clinical research, cell based therapies 
deliver positive results. However, as with the definition of stem cells/progenitor cells 
(Potten et al. 1990) the field of cell based therapies are a very heterogeneous one (Bajada et 
al. 2008). One feasible way of applying taxonomy to this field is by discussing different basic 
components in the treated diseases. The first example would be in pathological conditions 
with a definable population of cells being defect. Examples of diseases with certain cell 
types being depleted are Morbus Parkinson - dopamine producing cells, (Lindvall et al.), 
muscle dystrophy -satellite cells of the muscles (Gussoni et al. 1997) and type I diabetes - 
insulin producing cells (White et al. 2001). Such specialized cells might be easier to replace 
than the second general idea of cell transplantation wherein attempts of transplantation is 
aimed at more intricately functioning physiological systems. The complexity increases 
steeply when transplanted cells must differentiate into subpopulations of cell and/or 
interact within networks (e.g. the CNS). An example of that would be the transplantation of 
neural progenitor cells with the aim of full neural integration (Nikolic et al. 2009). A third 
strategy is to exert effects on existing cells/organs through transplantation but without 
functional integration. This strategy might explain some of the results from studies aimed at 
integration of cells, but without engraftment in the target organ, albeit with positive 
functional results observed (Borlongan et al. 2004). One explanation for that phenomenon is 
that in more complex situations, such as following CNS insults, some of the reported 
beneficial effects might be associated with immune modulation or local secretion of growth 
factors, thereby rescuing cells from apoptosis. Examples of immune modulation could be 
Fas-ligand expressing cells (Ghio et al. 1999; Nagata 1999; Lee et al. 2008) whereas secretion 
of growth factors could be exemplified by an over-expression of IGF-1 from transplanted 
mesenchymal cells (Haider et al. 2008). Modulation of the immunological response by cell 
transplantation has also been shown to favorably treat graft versus host reactions in clinical 
practice (Le Blanc et al. 2004; Ringden et al. 2006). The concept of transplantation of cells 
serving as self renewing, local, biologically active, pharmacological factories are attractive 
for many parts of regenerative medicine (Amar et al. 2003). Local, self-sustaining, treatments 
that are only affecting niche parts of organs have many benefits that might include, but are 
not limited to, higher local concentration, less risk of adverse events and customization to 
different pathological conditions. 
 
Endovascular Methods for Stem Cell Transplantation 161 
1.2 Delivery of cells 
For cell transplantation, different percutaneous techniques assisted by modern imaging are 
viable through minimal invasive methods (Bale et al. 2007) and most parts and locales of the 
human body can be reached with that approach. On the other hand, for organs with less 
accessible anatomical location, parenchymal access can be associated with significant 
surgical risks (Villiger et al. 2005; Ben-Haim et al. 2009). In situations where engraftment rate 
after intravenous or intra-arterial cell administration is low and when a high anatomical 
specificity is required, such as the scenario when replacing a distinct cell type, direct 
puncture of the parenchyma might be preferable. For CNS applications this can be done 
with stereotactic needle puncture or in a combination with open surgery (Hagell et al. 2002; 
Wennersten et al. 2004). 
Direct parenchymal access can also be achieved by endovascular technique. An example of 
this is a system that adds a possibility to, via large veins, administrate cells to the heart 
parenchyma (Thompson et al. 2003). The design of that system, requiring a large diameter 
catheter and without a closure device for the penetration site makes it usable only in large 
vessels on the venous side, more specifically, in the coronary sinus of the heart (Thompson 
et al. 2003; Siminiak et al. 2005). Other organs that might be difficult to reach, such as the 
CNS and the pancreas, are not reachable by the transvenous technique due to the design of 
that system requiring a large catheter diameter. Furthermore, venous navigation to most 
parts of the CNS and the pancreas, and to certain parts of the heart, is very difficult due to 
the more unpredictable venous anatomy and the venous valves. 
Insulin producing cells are today transplanted by a hybrid method with percutaneous 
access to the portal vein and then intra-luminal cell release in the bloodstream. The concept 
of the intra portal transplantation is considered superior to open surgical techniques, due to 
the un-acceptable risk of adverse events (Kandaswamy et al. 1999; Humar et al. 2000). The 
risk-analysis naturally differs substantially for different surgical procedures and 
transplantations, both with respect to organs and cells. Risks with portal vein 
transplantation include portal vein thrombosis, hemorrhages, and transient increase of 
transaminase values (Shapiro et al. 1995; Ryan et al. 2001). A continuous work of reaching a 
balance between the risk of bleeding after the procedure and portal vein thrombosis is of 
utmost importance for portal vein transplantations and results are improving steadily in 
clinical trials. Further adding to the risk side of the comparison is the need for 
immunosuppressant treatment after transplantation. The potential benefit of the procedure 
must also, as in the case with diabetes and insulin producing cells, be compared to the 
standard treatment of insulin injection and or pumps. Patients eligible  for portal vein 
transplantation of insulin producing cells are thus: patients already subject to 
immunosuppressive therapy due to previous transplantations, patients with unstable 
glycemia, unawareness hypoglycemia, or patients with progressive chronic complications 
despite intensive insulin treatment (Bertuzzi et al. 2006). It has been suggested that it would 
be of great benefit if insulin producing cells could be transplanted directly to the 
parenchyma of the pancreas. Advantages with pancreas as the target locale are e.g. the 
possibility of mimicking the physiological release of insulin and the more hospital micro-
environment for the insulin producing cells; the pancreas has a higher oxygen tension 
compared to the liver (Merani et al. 2008). 
Different strategies of cell based therapies are currently being evaluated in both pre-clinical 
and clinical trials but the cell delivery methods per se have received limited interest. One of 
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types being depleted are Morbus Parkinson - dopamine producing cells, (Lindvall et al.), 
muscle dystrophy -satellite cells of the muscles (Gussoni et al. 1997) and type I diabetes - 
insulin producing cells (White et al. 2001). Such specialized cells might be easier to replace 
than the second general idea of cell transplantation wherein attempts of transplantation is 
aimed at more intricately functioning physiological systems. The complexity increases 
steeply when transplanted cells must differentiate into subpopulations of cell and/or 
interact within networks (e.g. the CNS). An example of that would be the transplantation of 
neural progenitor cells with the aim of full neural integration (Nikolic et al. 2009). A third 
strategy is to exert effects on existing cells/organs through transplantation but without 
functional integration. This strategy might explain some of the results from studies aimed at 
integration of cells, but without engraftment in the target organ, albeit with positive 
functional results observed (Borlongan et al. 2004). One explanation for that phenomenon is 
that in more complex situations, such as following CNS insults, some of the reported 
beneficial effects might be associated with immune modulation or local secretion of growth 
factors, thereby rescuing cells from apoptosis. Examples of immune modulation could be 
Fas-ligand expressing cells (Ghio et al. 1999; Nagata 1999; Lee et al. 2008) whereas secretion 
of growth factors could be exemplified by an over-expression of IGF-1 from transplanted 
mesenchymal cells (Haider et al. 2008). Modulation of the immunological response by cell 
transplantation has also been shown to favorably treat graft versus host reactions in clinical 
practice (Le Blanc et al. 2004; Ringden et al. 2006). The concept of transplantation of cells 
serving as self renewing, local, biologically active, pharmacological factories are attractive 
for many parts of regenerative medicine (Amar et al. 2003). Local, self-sustaining, treatments 
that are only affecting niche parts of organs have many benefits that might include, but are 
not limited to, higher local concentration, less risk of adverse events and customization to 
different pathological conditions. 
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1.2 Delivery of cells 
For cell transplantation, different percutaneous techniques assisted by modern imaging are 
viable through minimal invasive methods (Bale et al. 2007) and most parts and locales of the 
human body can be reached with that approach. On the other hand, for organs with less 
accessible anatomical location, parenchymal access can be associated with significant 
surgical risks (Villiger et al. 2005; Ben-Haim et al. 2009). In situations where engraftment rate 
after intravenous or intra-arterial cell administration is low and when a high anatomical 
specificity is required, such as the scenario when replacing a distinct cell type, direct 
puncture of the parenchyma might be preferable. For CNS applications this can be done 
with stereotactic needle puncture or in a combination with open surgery (Hagell et al. 2002; 
Wennersten et al. 2004). 
Direct parenchymal access can also be achieved by endovascular technique. An example of 
this is a system that adds a possibility to, via large veins, administrate cells to the heart 
parenchyma (Thompson et al. 2003). The design of that system, requiring a large diameter 
catheter and without a closure device for the penetration site makes it usable only in large 
vessels on the venous side, more specifically, in the coronary sinus of the heart (Thompson 
et al. 2003; Siminiak et al. 2005). Other organs that might be difficult to reach, such as the 
CNS and the pancreas, are not reachable by the transvenous technique due to the design of 
that system requiring a large catheter diameter. Furthermore, venous navigation to most 
parts of the CNS and the pancreas, and to certain parts of the heart, is very difficult due to 
the more unpredictable venous anatomy and the venous valves. 
Insulin producing cells are today transplanted by a hybrid method with percutaneous 
access to the portal vein and then intra-luminal cell release in the bloodstream. The concept 
of the intra portal transplantation is considered superior to open surgical techniques, due to 
the un-acceptable risk of adverse events (Kandaswamy et al. 1999; Humar et al. 2000). The 
risk-analysis naturally differs substantially for different surgical procedures and 
transplantations, both with respect to organs and cells. Risks with portal vein 
transplantation include portal vein thrombosis, hemorrhages, and transient increase of 
transaminase values (Shapiro et al. 1995; Ryan et al. 2001). A continuous work of reaching a 
balance between the risk of bleeding after the procedure and portal vein thrombosis is of 
utmost importance for portal vein transplantations and results are improving steadily in 
clinical trials. Further adding to the risk side of the comparison is the need for 
immunosuppressant treatment after transplantation. The potential benefit of the procedure 
must also, as in the case with diabetes and insulin producing cells, be compared to the 
standard treatment of insulin injection and or pumps. Patients eligible  for portal vein 
transplantation of insulin producing cells are thus: patients already subject to 
immunosuppressive therapy due to previous transplantations, patients with unstable 
glycemia, unawareness hypoglycemia, or patients with progressive chronic complications 
despite intensive insulin treatment (Bertuzzi et al. 2006). It has been suggested that it would 
be of great benefit if insulin producing cells could be transplanted directly to the 
parenchyma of the pancreas. Advantages with pancreas as the target locale are e.g. the 
possibility of mimicking the physiological release of insulin and the more hospital micro-
environment for the insulin producing cells; the pancreas has a higher oxygen tension 
compared to the liver (Merani et al. 2008). 
Different strategies of cell based therapies are currently being evaluated in both pre-clinical 
and clinical trials but the cell delivery methods per se have received limited interest. One of 
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the larger obstacles that have been observed, is that the lung acts as a kind of clearance filter 
for the intravenous cell infusion, resulting in pulmonary trapping (Barbash et al. 2003; 
Fischer et al. 2009). An intra-arterial selective approach would possibly result in higher 
transplantation efficiency in certain conditions. The versatility of cell suspensions must not 
be underestimated and limit the way of thinking when considering treatments with cell 
based approaches (Nikolic et al. 2009). The cell suspensions can easily be handled and 
administrated through tubing and catheters, thus providing the possibility to by-pass the 
lung and selectively reach designated target vessels/parenchyma with a first passage effect. 
Those possibilities of cell handling forms the basis for catheter based strategies for cell 
transplantation. 
Endovascular treatments are continuously providing a third option to open surgical or 
percutaneous approaches. From the establishment of the Seldinger technique (Seldinger 
1953) and the first use of digital subtraction angiography (DSA) (Meaney et al. 1980) to the 
modern interventional lab with 3D road maps (Soderman et al. 2005) and CT like capacities 
of the C-arm (Soderman et al. 2008) the path has been long but rapidly progressing. The 
driving force up until today, that has made the leap ward style of improvements possible, is 
both rapid developments in computational power and material sciences. The arteries and 
veins can today be regarded as “internal routes” for navigation, diagnosis and intervention. 
The shift from open surgical options is for example illustrated by the patients that used to 
undergo thoracotomy and that now are being referred for percutaneous coronary 
intervention or the established coiling of intracranial aneurysms instead of open 
neurosurgical operation. 
1.3 Scaling from bench to bedside 
As this chapter hopes to illustrate; the rapid development of endovascular technique has 
implications on cell transplantation methods as well. To illustrate these implications as 
opposed to organ transplantation, one can visualize a liver transplantation. The wound in 
the abdominal wall must at least be big enough for the liver to go into the patient. This 
severely limits the possibility of minimal invasive transplantation of organs. On the other 
hand, the versatility of cell suspensions could make intra-luminal techniques the natural 
way of access. In experimental trials, open surgical options are used in e.g. rodent models 
for transplantation with positive results. This presents a limitation of scalability for 
clinical translation. For instance, when evaluating pre clinical CNS transplantation 
schemes in rodents one or two burr holes are established and cells are transplanted. One 
or two injections in the rat brain covers a relatively large volume but when scaling that to 
the human brain following e.g. a middle cerebral artery ischemic event, a large number of 
percutaneous trajectories would be required to cover a human brain volume 
corresponding to the experimental situation. The migratory capacity for transplanted 
mesenchymal cells after stereo-tactical transplantation has been shown to be around two 
millimeter over 14 days (Chen et al. 2001). Furthermore, the mechanical neuronal injury 
and the risk for intracerebral hemorrhage would increase with each injection trajectory. In 
brain stimulation procedures, the literature is somewhat divergent; the risk for 
hemorrhage could be as high as 5% per injection (Ben-Haim et al. 2009). The easier clinical 
scalability of endovascular access comes in the terms of cells delivered to a larger volume 
of tissue by taking advantage of the already existing vascular system. If an ischemic stroke 
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occurs due to a vessel occlusion at some point, it would be very tempting to 
intraluminally disperse cells from the same point via the vascular system in order to reach 
the affected parenchyma. A normal cell dose for a human adult would probably at least be 
hundredfold higher than in the rodent and needs to spread out over a vastly larger 
volume thus requiring many injection trajectories. The average human brain weight is 
quoted at around 1400 grams as opposed to the adult rat at 2 grams to give some sense to 
the scale proportions. 
Endovascular intervention is not without risks either, exemplified by the risk of adverse 
events reported at 0 to 4.0%, commonly reported at 0.5%, in different cerebral 
interventions (Raymond et al. 1997; Cognard et al. 1998; Ng et al. 2002; Murayama et al. 
2003; Gonzalez et al. 2004; Cronqvist et al. 2005). Added to the risk of the procedure per se 
is the risk of cell transplantations. The risk of intra-arterial transplantation has already 
been documented in humans for up to 24 months without severe complications, albeit in a 
small material (Sykova et al. 2006). Other pre-clinical studies with intra-arterial coronary 
injections performed in healthy dogs revealed micro-infarction of the heart parenchyma 
(Vulliet et al. 2004) whereas that has not been observed in clinical studies (Stamm et al. 
2003). Factors that might be limiting are the size of the cells injected versus the size of the 
capillary system, the proportion of shunts in the microcirculation, the stickyness of the 
cells and the amount of cells administrated. Many of the cells have a much larger 
diameter (10 up to 70 µm) as opposed to the capillaries 5 to 8 µm (Chien et al. 1975). The 
shunting zones in the microcirculation could potentially lead also large cells to the post-
capillary venules where diapedesis usually occurs (Tuma 2008). The main reason for 
leukocyte adhesion/diapedesis through venules is the usually restricted expression of 
adhesion molecules on venular but not arteriolar or capillary endothelium (Tuma 2008). 
In intravital microscopy studies, adipose mesenchymal cells have been shown to act as 
embolic material (Furlani et al. 2009). This risk could be speculated on to be lower than 
the comparable trauma of the surgical methods although a final risk assessment requires a 
randomized clinical trial. 
1.4 Leaving the bloodstream - diapedesis 
One limiting factor to specific intra-arterial and intravenous transplantations is that an intra-
parenchymal approach yields a higher efficacy. It has been shown that when performing 
transplantations to a rodent stroke model and comparing intravenous, intra-ventricular and 
intra-striatal injections, the highest efficacy in sheer number of cells were obtained with the 
intra-striatal route (Jin et al. 2005). Further limiting the selective intra-luminal approach is 
the speculation that some cell systems, such as insulin producing cells, appear incapable of 
leaving the bloodstream (Hirshberg et al. 2002). 
In all implementations aimed at intra-luminal administration (intra-luminal encompassing 
both intravenous and selective intra-arterial administration) the ability of the cells to leave 
the bloodstream, or perform diapedesis (Fulton et al. 1957) is fundamental. The diapedesis 
function has previously been studied predominantly in immunological cells (Fulton 1957), it 
is in fact the active process whereby cells leave the bloodstream. The diapedesis of 
immunologically active cells has been thoroughly studied since the discovery of the 
significant multistep, ordered, cross-talk procedure of leukocyte-endothelial cell interaction 
both in vitro and in vivo (Butcher 1991; Springer 1994). 
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the larger obstacles that have been observed, is that the lung acts as a kind of clearance filter 
for the intravenous cell infusion, resulting in pulmonary trapping (Barbash et al. 2003; 
Fischer et al. 2009). An intra-arterial selective approach would possibly result in higher 
transplantation efficiency in certain conditions. The versatility of cell suspensions must not 
be underestimated and limit the way of thinking when considering treatments with cell 
based approaches (Nikolic et al. 2009). The cell suspensions can easily be handled and 
administrated through tubing and catheters, thus providing the possibility to by-pass the 
lung and selectively reach designated target vessels/parenchyma with a first passage effect. 
Those possibilities of cell handling forms the basis for catheter based strategies for cell 
transplantation. 
Endovascular treatments are continuously providing a third option to open surgical or 
percutaneous approaches. From the establishment of the Seldinger technique (Seldinger 
1953) and the first use of digital subtraction angiography (DSA) (Meaney et al. 1980) to the 
modern interventional lab with 3D road maps (Soderman et al. 2005) and CT like capacities 
of the C-arm (Soderman et al. 2008) the path has been long but rapidly progressing. The 
driving force up until today, that has made the leap ward style of improvements possible, is 
both rapid developments in computational power and material sciences. The arteries and 
veins can today be regarded as “internal routes” for navigation, diagnosis and intervention. 
The shift from open surgical options is for example illustrated by the patients that used to 
undergo thoracotomy and that now are being referred for percutaneous coronary 
intervention or the established coiling of intracranial aneurysms instead of open 
neurosurgical operation. 
1.3 Scaling from bench to bedside 
As this chapter hopes to illustrate; the rapid development of endovascular technique has 
implications on cell transplantation methods as well. To illustrate these implications as 
opposed to organ transplantation, one can visualize a liver transplantation. The wound in 
the abdominal wall must at least be big enough for the liver to go into the patient. This 
severely limits the possibility of minimal invasive transplantation of organs. On the other 
hand, the versatility of cell suspensions could make intra-luminal techniques the natural 
way of access. In experimental trials, open surgical options are used in e.g. rodent models 
for transplantation with positive results. This presents a limitation of scalability for 
clinical translation. For instance, when evaluating pre clinical CNS transplantation 
schemes in rodents one or two burr holes are established and cells are transplanted. One 
or two injections in the rat brain covers a relatively large volume but when scaling that to 
the human brain following e.g. a middle cerebral artery ischemic event, a large number of 
percutaneous trajectories would be required to cover a human brain volume 
corresponding to the experimental situation. The migratory capacity for transplanted 
mesenchymal cells after stereo-tactical transplantation has been shown to be around two 
millimeter over 14 days (Chen et al. 2001). Furthermore, the mechanical neuronal injury 
and the risk for intracerebral hemorrhage would increase with each injection trajectory. In 
brain stimulation procedures, the literature is somewhat divergent; the risk for 
hemorrhage could be as high as 5% per injection (Ben-Haim et al. 2009). The easier clinical 
scalability of endovascular access comes in the terms of cells delivered to a larger volume 
of tissue by taking advantage of the already existing vascular system. If an ischemic stroke 
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occurs due to a vessel occlusion at some point, it would be very tempting to 
intraluminally disperse cells from the same point via the vascular system in order to reach 
the affected parenchyma. A normal cell dose for a human adult would probably at least be 
hundredfold higher than in the rodent and needs to spread out over a vastly larger 
volume thus requiring many injection trajectories. The average human brain weight is 
quoted at around 1400 grams as opposed to the adult rat at 2 grams to give some sense to 
the scale proportions. 
Endovascular intervention is not without risks either, exemplified by the risk of adverse 
events reported at 0 to 4.0%, commonly reported at 0.5%, in different cerebral 
interventions (Raymond et al. 1997; Cognard et al. 1998; Ng et al. 2002; Murayama et al. 
2003; Gonzalez et al. 2004; Cronqvist et al. 2005). Added to the risk of the procedure per se 
is the risk of cell transplantations. The risk of intra-arterial transplantation has already 
been documented in humans for up to 24 months without severe complications, albeit in a 
small material (Sykova et al. 2006). Other pre-clinical studies with intra-arterial coronary 
injections performed in healthy dogs revealed micro-infarction of the heart parenchyma 
(Vulliet et al. 2004) whereas that has not been observed in clinical studies (Stamm et al. 
2003). Factors that might be limiting are the size of the cells injected versus the size of the 
capillary system, the proportion of shunts in the microcirculation, the stickyness of the 
cells and the amount of cells administrated. Many of the cells have a much larger 
diameter (10 up to 70 µm) as opposed to the capillaries 5 to 8 µm (Chien et al. 1975). The 
shunting zones in the microcirculation could potentially lead also large cells to the post-
capillary venules where diapedesis usually occurs (Tuma 2008). The main reason for 
leukocyte adhesion/diapedesis through venules is the usually restricted expression of 
adhesion molecules on venular but not arteriolar or capillary endothelium (Tuma 2008). 
In intravital microscopy studies, adipose mesenchymal cells have been shown to act as 
embolic material (Furlani et al. 2009). This risk could be speculated on to be lower than 
the comparable trauma of the surgical methods although a final risk assessment requires a 
randomized clinical trial. 
1.4 Leaving the bloodstream - diapedesis 
One limiting factor to specific intra-arterial and intravenous transplantations is that an intra-
parenchymal approach yields a higher efficacy. It has been shown that when performing 
transplantations to a rodent stroke model and comparing intravenous, intra-ventricular and 
intra-striatal injections, the highest efficacy in sheer number of cells were obtained with the 
intra-striatal route (Jin et al. 2005). Further limiting the selective intra-luminal approach is 
the speculation that some cell systems, such as insulin producing cells, appear incapable of 
leaving the bloodstream (Hirshberg et al. 2002). 
In all implementations aimed at intra-luminal administration (intra-luminal encompassing 
both intravenous and selective intra-arterial administration) the ability of the cells to leave 
the bloodstream, or perform diapedesis (Fulton et al. 1957) is fundamental. The diapedesis 
function has previously been studied predominantly in immunological cells (Fulton 1957), it 
is in fact the active process whereby cells leave the bloodstream. The diapedesis of 
immunologically active cells has been thoroughly studied since the discovery of the 
significant multistep, ordered, cross-talk procedure of leukocyte-endothelial cell interaction 
both in vitro and in vivo (Butcher 1991; Springer 1994). 
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The barricades limiting the cells from haphazardly leaving the bloodstream are many. All 
blood vessels contain an endothelium and several organized barriers. In the CNS for 
instance, tight junctions are located between endothelial cells, predominantly to permit the 
conservation of the water fraction of the blood stream. The liquid pressure gradient 
composed of the blood pressure can be broken down to one force directed with the axis of 
the laminar flow of blood and one force aimed perpendicular to the flow on to the wall 
(Glagov et al. 1992; Fay 1994), thereby providing an evolutionary rationale for sealing the 
blood stream tightly. Situated underneath the endothelial cells and forming their structural 
base is the basal layer; a specific protein structure composed of extra cellular matrix (ECM) 
proteins abundant with expression of elastin, laminin and collagen type I, III and IV (Mayne 
1986). Collagen and elastin are the major structural components of blood vessels of all sizes 
throughout the mammalian body. The cross-banded fibrils in the tunica media and tunica 
adventitia, formed by type I and type III collagen, provide the tensile strength and comprise 
probably 80 to 90% of the total collagen present. The other major structural protein 
component in elastic arteries is elastin; the protein that provides the elastic component of the 
blood vessels (Mayne 1986). Around most capillaries, pericytes are situated which further 
seal the blood stream. The pericytes are less abundant in the post capillary venules where 
most of the diapedesis occurs. As a general note, the post capillary venules are the most 
“leaky” part of the vascular tree. It should be noted that blood vessels are not merely the 
plumbing in the mammal body, they are in all respects a vividly living part of the organism, 
reorganized as a response to stress and demand (Gibbons et al. 1994) and among other 
things have a self-generating electro potential towards the bloodstream that is important for 
the clotting cascade (Danon et al. 1976). 
As previously mentioned, in a diverging literature, it has been speculated that some cells 
totally lack the function of exiting the blood stream, thereby limiting intra-luminal based 
techniques. Even though insulin producing cells appears incapable of leaving the 
bloodstream, they are still transplanted through the portal vein (Hirshberg et al. 2002). The 
mechanism of action is believed to be microembolization of the cells to the liver parenchyma 
in the low pressure system that the portal vein constitutes (Lehmann et al. 2007). It has been 
speculated that arterial blood from the hepatic artery pushes back into the portal vein 
during the mixing of the two flows which would stop the cells and create advantageous 
conditions for engraftment. The cells found functioning in the livers of transplanted patients 
are, however, situated as plaques in the hepatic artery tree thus adding yet another hurdle 
to the understanding of portal vein transplantation. The hypothesis is that the cells cannot 
perform diapedesis but are instead primarily forming a mural thrombus after, with low 
probability, being displaced against the blood flow into the arterial tree and then 
encapsulated by endothelial cells. The plaque formation can thereby provide capillary 
ingrowth, an absolute requirement for endocrine function (Korsgren et al. 2008). Such a 
hypothesis would also shed further light on the low efficacy of portal transplantations 
methods. Nevertheless, the portal vein approach to transplantation is today the golden 
standard since the existing open surgical options of total pancreatic transplantation carries a 
mortality risk of 10% during the first year of follow-up (Kandaswamy et al. 1999; Humar et 
al. 2000). 
The process of diapedesis is basically divided into tethering, rolling and stopping of 
leukocytes prior to diapedesis into inflamed tissue. It is thought of as a multistep procedure 
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involving complex crosstalk between cells in the bloodstream and the endothelial cells. 
On the endothelial side intra-cellular adhesion molecule -1 (ICAM-1) (Dustin et al. 1986; 
Rothlein et al. 1986), vascular cell adhesion molecule -1 (VCAM-1) (Elices et al. 1990; 
Pulido et al. 1991) and junctional adhesion molecule –A (JAM-A) have all been implicated 
to play crucial roles. Interestingly, all of these receptors are part of the Ig-super family. 
Leukocytes capacity for homing and diapedesis is pivotal for the development of the 
inflammatory response to injury and starts as a tightly controlled up-regulation of 
endothelial E- and P-selectins that stimulate the leukocytes (Vestweber et al. 1999). These 
leukocytes then respond by activation of G protein-coupled receptors that increase the 
affinity for endothelial VCAM-1 and ICAM-1 (Muller 2003). Interaction with VCAM-1 is 
maintained through the heterodimer CD29 and CD49d forming the cell surface antigen 
Very Late Antigen – 4 (VLA-4) (Elices et al. 1990) and the CD11aCD18 heterodimer 
interacting with ICAM-1 (Meerschaert et al. 1995). VCAM-1 and ICAM-1 have previously 
been shown to be up-regulated on the endothelium as a response to inflammation (Dustin 
et al. 1986; Pulido et al. 1991). This interaction starts the diapedesis itself wherein the 
leukocytes “crawl” through, either a para-cellular or a trans-cellular pathway interacting 
with both PECAM-1 and/or CD99 or members of the JAM family of proteins (Petri et al. 
2006). Thus significant crosstalk is needed to initiate and execute the active process of 
diapedesis. 
VCAM-1 is also implicated both as a model of treatment for immunological modulation of 
the inflammatory responses following CNS insults and as surface antigen for cell 
treatment of CNS insults. In one study, fluorescence activated cell sorting (FACS) was 
performed for the expression of CD49d and identifying it as one of the important factors 
for directing diapedesis (Guzman et al. 2008). This finding has received a lot of interest 
from different fields, among other it has been shown that VCAM-1 expression has a 
critical role in transplantation of cells in dystrophic muscle (Gavina et al. 2006). Another 
utilization of VCAM-1 is the selective blocking by the monoclonal antibody drug 
Natalizumab used in multiple sclerosis, thereby inhibiting diapedesis for 
immunologically active cells (Stuve et al. 2008). VCAM-1 blockade has also been tested for 
neuroprotective effects following ischemic events in pre-clinical trials with disappointing 
results (Justicia et al. 2006). 
2. Results and discussion with emphasis on the central nervous system 
In this chapter three different types of endovascular methods of cell transplantation are 
discussed. The first two are the selective intra-arterial  and the intravenous methods, these 
are compared for efficacy. The third method is the trans-vessel wall technique by using the 
Extroducer; an endovascular catheter system developed within our group for penetrating 
the vessel wall from the inside to out, thereby creating a working channel to extravascular 
tissue. 
For certain cell types, the selective intra-arterial method is superior to the intravenous one 
after TBI in the rat. This was measured by the level of engraftment of hMSC at one and five 
days following TBI, without thrombo-embolic complications (Lundberg et al. 2009). 
Selective intra-arterial transplantation method for rNPC after TBI in the rat is also superior 
compared to intravenous method. We were, however, not able to engraft hNPC, ceteris 
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The barricades limiting the cells from haphazardly leaving the bloodstream are many. All 
blood vessels contain an endothelium and several organized barriers. In the CNS for 
instance, tight junctions are located between endothelial cells, predominantly to permit the 
conservation of the water fraction of the blood stream. The liquid pressure gradient 
composed of the blood pressure can be broken down to one force directed with the axis of 
the laminar flow of blood and one force aimed perpendicular to the flow on to the wall 
(Glagov et al. 1992; Fay 1994), thereby providing an evolutionary rationale for sealing the 
blood stream tightly. Situated underneath the endothelial cells and forming their structural 
base is the basal layer; a specific protein structure composed of extra cellular matrix (ECM) 
proteins abundant with expression of elastin, laminin and collagen type I, III and IV (Mayne 
1986). Collagen and elastin are the major structural components of blood vessels of all sizes 
throughout the mammalian body. The cross-banded fibrils in the tunica media and tunica 
adventitia, formed by type I and type III collagen, provide the tensile strength and comprise 
probably 80 to 90% of the total collagen present. The other major structural protein 
component in elastic arteries is elastin; the protein that provides the elastic component of the 
blood vessels (Mayne 1986). Around most capillaries, pericytes are situated which further 
seal the blood stream. The pericytes are less abundant in the post capillary venules where 
most of the diapedesis occurs. As a general note, the post capillary venules are the most 
“leaky” part of the vascular tree. It should be noted that blood vessels are not merely the 
plumbing in the mammal body, they are in all respects a vividly living part of the organism, 
reorganized as a response to stress and demand (Gibbons et al. 1994) and among other 
things have a self-generating electro potential towards the bloodstream that is important for 
the clotting cascade (Danon et al. 1976). 
As previously mentioned, in a diverging literature, it has been speculated that some cells 
totally lack the function of exiting the blood stream, thereby limiting intra-luminal based 
techniques. Even though insulin producing cells appears incapable of leaving the 
bloodstream, they are still transplanted through the portal vein (Hirshberg et al. 2002). The 
mechanism of action is believed to be microembolization of the cells to the liver parenchyma 
in the low pressure system that the portal vein constitutes (Lehmann et al. 2007). It has been 
speculated that arterial blood from the hepatic artery pushes back into the portal vein 
during the mixing of the two flows which would stop the cells and create advantageous 
conditions for engraftment. The cells found functioning in the livers of transplanted patients 
are, however, situated as plaques in the hepatic artery tree thus adding yet another hurdle 
to the understanding of portal vein transplantation. The hypothesis is that the cells cannot 
perform diapedesis but are instead primarily forming a mural thrombus after, with low 
probability, being displaced against the blood flow into the arterial tree and then 
encapsulated by endothelial cells. The plaque formation can thereby provide capillary 
ingrowth, an absolute requirement for endocrine function (Korsgren et al. 2008). Such a 
hypothesis would also shed further light on the low efficacy of portal transplantations 
methods. Nevertheless, the portal vein approach to transplantation is today the golden 
standard since the existing open surgical options of total pancreatic transplantation carries a 
mortality risk of 10% during the first year of follow-up (Kandaswamy et al. 1999; Humar et 
al. 2000). 
The process of diapedesis is basically divided into tethering, rolling and stopping of 
leukocytes prior to diapedesis into inflamed tissue. It is thought of as a multistep procedure 
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involving complex crosstalk between cells in the bloodstream and the endothelial cells. 
On the endothelial side intra-cellular adhesion molecule -1 (ICAM-1) (Dustin et al. 1986; 
Rothlein et al. 1986), vascular cell adhesion molecule -1 (VCAM-1) (Elices et al. 1990; 
Pulido et al. 1991) and junctional adhesion molecule –A (JAM-A) have all been implicated 
to play crucial roles. Interestingly, all of these receptors are part of the Ig-super family. 
Leukocytes capacity for homing and diapedesis is pivotal for the development of the 
inflammatory response to injury and starts as a tightly controlled up-regulation of 
endothelial E- and P-selectins that stimulate the leukocytes (Vestweber et al. 1999). These 
leukocytes then respond by activation of G protein-coupled receptors that increase the 
affinity for endothelial VCAM-1 and ICAM-1 (Muller 2003). Interaction with VCAM-1 is 
maintained through the heterodimer CD29 and CD49d forming the cell surface antigen 
Very Late Antigen – 4 (VLA-4) (Elices et al. 1990) and the CD11aCD18 heterodimer 
interacting with ICAM-1 (Meerschaert et al. 1995). VCAM-1 and ICAM-1 have previously 
been shown to be up-regulated on the endothelium as a response to inflammation (Dustin 
et al. 1986; Pulido et al. 1991). This interaction starts the diapedesis itself wherein the 
leukocytes “crawl” through, either a para-cellular or a trans-cellular pathway interacting 
with both PECAM-1 and/or CD99 or members of the JAM family of proteins (Petri et al. 
2006). Thus significant crosstalk is needed to initiate and execute the active process of 
diapedesis. 
VCAM-1 is also implicated both as a model of treatment for immunological modulation of 
the inflammatory responses following CNS insults and as surface antigen for cell 
treatment of CNS insults. In one study, fluorescence activated cell sorting (FACS) was 
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For certain cell types, the selective intra-arterial method is superior to the intravenous one 
after TBI in the rat. This was measured by the level of engraftment of hMSC at one and five 
days following TBI, without thrombo-embolic complications (Lundberg et al. 2009). 
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paribus, thus indicating that diapedesis and engraftment is an active process and that 
different cell systems have different capabilities to engraft following intraluminal delivery 
(Lundberg et al. 2011). We show, by indirect methods, that CD29CD49dVCAM-1 
interactions might be one of the factors with impact on engraftment in an intra-luminal 
transplantation setting (Lundberg et al. 2011). Further, we show that it is possible to perform 
minimally invasive parenchymal injections by trans-vessel wall technique by the 
development of the Extroducer (Lundberg et al. 2010). The Extroducer have no adverse long 
term effects on the blood vessels up to 3 months following interventions (Lundberg et al. 
2011) and it is feasible to use the system as a novel approach for transplantation of e.g. 
insulin producing cells to the CNS, to the pancreas or other cell types to organs that are 
difficult or risky to reach by traditional methods. The trans-vessel wall technique thereby 
adds a new possibility when transplanting cell populations without the necessary properties 
for performing diapedesis. The establishment of a working channel to the extravascular 
tissue, by endovascular method, also opens up several other possible applications, such as 
different methods for sampling. 
2.1 Selective intra-arterial method versus intravenous method 
We established a model for selective intra-arterial transplantation (Lundberg et al. 2009) that 
we applied to a model of TBI in the rat (Feeney et al. 1981). We compared the selective intra-
arterial method to intra-venous methods for different cell systems in the same TBI setting. 
Several different variables were tested such as cell concentration, days post injury for 
transplantation, time for infusion, level of immunosuppressant drugs etc. The majority of 
transplantation experiments were not successful from the start and many different variables 
were tested before robust engraftments could be reached. Too few cells had a dire impact on 
the success of transplantation; 200.000 (unpublished results) and 500.000 hMSCs did only 
result in very low engraftment. The failure of low cell numbers can obviously be interpreted 
as an indication that the efficacy of the intra arterial method in this setting is quite low 
although it is still superior to intravenous alternatives. 
Results of engraftment levels were obtained through IHC methods by counting engrafted 
cells in sectioned brains (Fig 1). We found that engraftment levels of rNPCs were more than 
five-fold higher than in the control group (p=0.034) and hMSC were more than fifteen-fold 
higher than the in control group in absolute values (p=0.007), with a large spread within the 
intra-arterial groups (Fig 2). Few studies compare selective intra-arterial and intravenous 
methods but recent clinical data suggest an advantage for the selective intra-arterial route 
(Sykova et al. 2006). A known problem with all intravenous methods is the fact that the lung 
acts as a kind of clearance filter during the first passage (Barbash et al. 2003; Fischer et al. 
2009). Following intravenous cell infusion, the blood transports the cells after venous 
passage to the right ventricle and then through the lung where up to 80% of cells are 
trapped during the first passage (Fischer et al. 2009). Thus as low as 20% of the cells 
transplanted might be ejected for the first total body distribution through the aorta. Of all 
the blood leaving the left ventricle of the heart, only somewhere between 1.8 to 8.5 percent 
of the blood actually reaches the brain of the rat (Pannier et al. 1973) leaving only 0.01 to 1.7 
percent of the initially transplanted cells to reach the brain in the first passage. All cells not 
distributed to the brain are then again re-transported for another passage through the lung, 
acting as a filter. This phenomenon has been studied e.g. by PET for mesenchymal stem cells   
 
Endovascular Methods for Stem Cell Transplantation 167 
 
Fig. 1. Representation of intra-arterial transplantation in the TBI model 
In the background is a reconstructed image showing a coronal section of the rat brain 2.5 
mm posterior to bregma stained with GFAP (red) and NeuN (Brown) five days after 
traumatic brain injury. In blow-up a. a low magnification single staining with HuN (human 
nuclear antigen, MAB 1281) without any counterstaining, along the peri-lesional zone is 
shown. Brown dots represent HuN positive, transplanted cells (arrow indicates an example 
of a positive cell). In blow-up b. the black area represents the contusion zone and the grey 
areas represent primary localization of engrafted mesenchymal stem cells. In blow-up c. a 
magnification of the injury area itself is presented. 
(Ma et al. 2005). This situation can readily be changed by placing a micro-catheter in the 
arteries supplying the organ of interest. An interesting finding in the present study is that 
our hMSCs predominantly were found in the spleen with few transplanted cells in the lung 
at 24 hours post injection, a bio-distribution phenomenon, from the lung to the spleen, 
previously described in rat following intravenous hMSC transplantation (Detante et al. 
2009). To increase the understanding of the role of cell line properties for engraftment, we 
conducted a study with transplantation of different cell lines through either intra-arterial or 
intravenous routes. This analysis showed that there were dramatic differences between the 
different cell lines; hNPCs did not engraft at all after intra-luminal delivery whereas there 
was a significant difference between the hMSCs and the rNPCs using the same 
transplantation method. Noteworthy is the large variability in the engraftment levels of the 
latter two cell lines. One important factor that might contribute to this is that neither hMSC 
nor rNPCs are defined homologous cell lines, succinctly there can be important variations 
within the cell systems transplanted. The remarkable finding that no engraftment was 
obtained following hNPC transplantations is even more noteworthy since the hNPCs have 
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previously been robustly transplanted by open surgical technique (Wennersten et al. 2004; 
Akesson et al. 2007). 
 
 
Fig. 2. Graph illustrating engraftment levels 
Engrafted cells were counted per section and is reported with median (marker), quartiles 
(box) and max – min (whiskers). In A a significant difference between engraftment levels 
per section following selective intra-arterial and intravenous transplantation in the 
ipsilateral hemisphere of the rNPC group. In B a significant difference between engraftment 
levels per section following selective intra-arterial and intravenous transplantation in the 
ipsilateral hemisphere of the hMSC group and finally in C a panel of all engraftment levels 
per section in the ipsilateral hemispheres of all groups. * marks p < 0.05 
2.2 Gene expression profiling of cell systems 
After discovering that there were differences in engraftment capability between the different 
cell lines, the opportunity to investigate the bio-molecular basis of said differences presented 
itself. We started with characterizing and confirming earlier results (Clausen et al. 2007) that 
our TBI model leads to up-regulation of VCAM-1 expression in the endothelium. That result 
may suggest that the injured CNS parenchyma could provide cues for diapedesis and 
migration of engrafted cells in similar ways as immunological cells respond to inflammatory 
cues (Butcher 1991; Springer 1994). As a screening method, we started by performing 
microarray on the human cells. rNPCs were not included in the microarray analysis due to 
problems with cross-species comparisons in the microarray chips used. hMSCs showed a 
broad expression of integrins, commonly expressed by immune  cells, that are important for 
diapedesis through the vessel endothelium and subsequent migration into the parenchyma. 
Specifically, analysis of the heterodimers forming receptors for ICAM-1 and VCAM-1 were 
 
Endovascular Methods for Stem Cell Transplantation 169 
analyzed, based on previous work indicating CD49d expression as important for successful 
intra-vasal transplantations (Guzman et al. 2008). Thus, probably the most interesting 
finding was the CD49d signal of 68 in hMSC as opposed to 0.4 in hNPC (p=0.0047). This was 
then confirmed with RT-qPCR data from all cell lines with average CD49d mRNA levels 
that were highest in the hMSC (0.98) followed by the rNPC (0.0057) and finally a dwindling 
finding in hNPC (0.0012). CD29 and CD49d forms a heterodimer named very late antigen -4 
(VLA-4) which was expressed in falling order in hMSC, rNPC and hNPC (Fig 3). The 
difference in mRNA levels between rNPC and hNPC is not large but might reflect larger 
differences in protein translation. Further studies at the protein and functional level are 
required to elucidate the importance of CD49d for diapedesis of these cell systems. CD11a 
mRNA was detected in hNPC (0.0029) albeit with low CD18 mRNA (0.00025), suggesting 
that CD11a-CD18-ICAM-1 interaction may be dispensable for engraftment. In contrast, 
hMSC displayed high CD18 mRNA levels (0.43) but no detectable CD11a expression, 
suggesting neglectable ICAM-1 dependent engraftment in the hMSCs. 
 
 
Fig. 3. RT-qPCR results from Cell systems 
Bars represent relative levels of integrin CD49d, CD29, CD11a and CD18 mRNA expression 
in rNPC, hNPC and hMSC compared to respective endogenous TBP mRNA levels. Error 
bars represent the distribution between the biological replicates. 
Finally, both our own findings regarding hNPCs and other previously known cells 
incapable of diapedesis, such as insulin producing cells (Hirshberg et al. 2002), shows the 
apparent need for surgical techniques. In some organs that are hard to reach and/or when 
surgical technique comes with a high risk of adverse events for the patients, the need for an 
alternative strategy becomes apparent. Thus, we also initiated the development of the trans-
vessel wall approach. 
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2.3 Trans-vessel wall transplantation 
An endovascularly based system that could penetrate the vessel wall would, in instances 
where the target parenchyma is either hard to reach or carries a significant surgical risk, be a 
method with both the merits of accurate placement and reduction of patient risk. Further, it 
would solve the problem for certain cells to leave the bloodstream. A proposed solution to 
this problem is a endovascular catheter system that we have named the Extroducer 
(Lundberg et al. 2010). 
2.3.1 Extroducer in vivo testing - small animals 
After extensive computer simulations and ex vivo testing, in vivo short term testing were 
performed in rat by creating arterial access from the medial tail artery and performing the 
Extroducer trans-vessel wall technique passage in either the subclavian or carotid artery. 
Two different stages of the procedure was tested; first the trans-vessel wall technique 
passage per se with surgical microscope monitoring of hemorrhage or other adverse events, 
and thereafter the deployment of the distal penetrating tip through the vascular wall and 
retracting the proximal part of the system. No cases of intra-operative hemorrhage or intra-
luminal thrombosis occurred. Thus, the vascular penetration procedure was uneventful and 
the vessel wall completely sealed around the Extroducer, thereby preventing leakage of 
blood. 
The second group with deposited Extroducer tips also showed absolute hemostasis during 
the primary intervention. Fourteen days post intervention, this group showed no signs of 
pain or discomfort. No signs of dissection of the vessels or impairment of blood-flow distal 
to intervention sites were observed and macroscopical analysis of the organ supplied by the 
vessel, showed no infarcts. 
With computer-based flow simulations, we found that there should be no blood-flow 
through the detached Extroducer interior lumen at physiological blood pressure. This was 
also tested in vivo by cannulating the deployed distal tip of the prototypes with a nitinol 
mandrel. This was done to reassure that even when removing possible clotting inside the 
prototype, it still prevented bleeding from inside the vessel to the extravascular space. 
Furthermore, no signs of delayed hemorrhage were detected. 
2.3.2 Extroducer in vivo testing - large animals 
After successful trials in small animals, the Extroducer system was tested in large animals. 
An adaptation towards clinical use was that these prototypes were manufactured from a 
longer nitinol tube, 1700 mm vis-à-vis 300 mm that was used in the rat. We evaluated the 
prototypes in the rabbit together with standard clinical catheters and angiographical 
equipment. 
The Extroducer prototypes within the microcatheters were visible at high magnification 
fluoroscopy and thereby maneuvered into the subclavian artery (SCA) (Fig 4). The rabbit 
SCA was chosen since it is close to the intended target vessel size of 0.5 to 3 millimeters, the 
SCA is fairly easy to access in order to perform simultaneous open surgical monitoring and 
it had been used in the rat. A slight amount of pressure was required on the protecting 
plastic catheter to advance the system through the microcatheter to the desired vessel wall, 
thereafter the Extroducer was gently advanced out through the vessel wall to the extra-
vascular space. Hemorrhages were neither observed by simultaneous direct observation 
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through a surgical microscope, nor by high resolution angiographical series (DSA), during 
and after the intervention (Fig 4). Further, no thromboembolic complications or vascular 
dissections were observed using high resolution DSA. No navigational problems were 
encountered with respect to Extroducer prototype integration with clinical catheters. 
 
 
Fig. 4. Trans-vessel wall interventions 
For full control over the procedure in the large animal trials, both a surgical microscope and 
high resolution angiographical series was used. In a. digital subtraction angiogram showing 
a detached Extroducer tip without hemorrhage, dissection or thromboembolic 
complications. In b. photograph showing the microsurgical view of the detached Extroducer 
tip. In c. x-ray image showing the detached Extroducer tip with guide catheter. In d. 
photograph from post-operative dissection showing the detached Extroducer tip with 
methylene blue injected in the surrounding tissue. In e. digital subtraction angiogram 
showing an extra vascular injection of 25 µl contrast agent through the Extroducer system. 
Finally, electrolysis detachment of the distal Extroducer distal tip was tested in rabbit. We 
chose electrolysis since it was the easiest way of performing detachment in our hands. Our 
design was  based on the work of the first detachable coils (Guglielmi et al. 1991). An 
important difference compared to the detachment zone in coils was, however, that we 
needed a hollow detachment zone which required additional development. After navigation 
to the designated intervention site and after methylene blue or contrast agent had been 
deposited in the extravascular space, a tension of 8V was applied and the distal tip was then 
detached after, on average, five minutes (range three to nine minutes). This was also un-
eventful without observation of hemorrhage from around the body of the distal tip or 
through the inner lumen. The procedure was successfully performed both with 
simultaneous microscopical monitoring via surgical access, and with 
fluoroscopical/angiographical guidance solely. In a previous work describing a method for 
penetrating large veins (Thompson et al. 2003), that system design required a much larger 
catheter and also lacked a method for sealing the vessel wall, thus making penetration 
through the arteries impossible. This severely limits the use of that system to their testing 
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vessel, i.e. the sinus coronarius of the heart, whereas the Extroducer is applicable in both 
arteries and veins of any sizes down to approximately 0.5 mm in diameter. Another system, 
in which vessel perforations are performed, is the trans-jugular intrahepatic portacaval stent 
shunt (TIPS) technique (Richter et al. 1990). That system also does not have the requirement 
of sealing the vessel wall when finishing the procedure, since a patent blood flow through 
the stent is the preferred result. On the contrary, thrombosis of the stent might be 
considered the main problem (Merli et al. 1998) which requires rigorous follow-up. 
Thus, the Extroducer system is unique in the ways that it permits safe exit of both arteries 
and veins and that it is usable in vessels with large dimensions as well as in the 
microvasculature with inner lumen diameters down to approximately 0.5 mm. 
2.2.3 Extroducer testing with long time follow up 
In a long term follow up, the end points five days, one month and three months after the 
deployment of the device was selected. No stenosis or late hemorrhagic complications were 
noted in any animals. No alterations in behavior or other measures of discomfort were 
noted either (Lundberg et al. 2011). 
The distribution of followed up animals were as follows; two at the five days end point , five 
at the 30 days end point and six at the 80 days end point with histological analysis of one 
resulting in a total number of 19 detached Extroducer tips. 
In the follow up DSA we also found that four of 19 (21 %) of the detached tips were no 
longer placed through the vessel wall but had instead been “pushed” or “migrated” through 
the endothelium to the extravascular space immediately adjacent to the penetration site. No 
vascular stenosis or other adverse reactions were observed around those tips. Also for the 
rest of the tips, that were located through the vessel wall, no adverse reactions were 
detected. An important endpoint was biocompatibility of the detached tips. The nitinol alloy 
used was selected for its many advantageous properties. Nitinol is a nickel/titanium alloy 
with both memory and super elastic properties (Adler et al. 1990). These special properties 
are the foundation for the use of nitinol in stent fabrication in clinical practice. Thus, the 
excellent biocompatibility of nitinol (Castleman et al. 1976) has been extensively studied, 
especially with respect to vessel wall interactions in the use of stents (Stoeckel et al. 2004). 
However, the compatibility of nitinol when placed through arterial walls has, to our 
knowledge, not been studied. The parylene, used as coating in our device, is also FDA 
approved and CE marked when used in pacemaker electrodes. To evaluate interaction 
between the deposited tips and the endothelium, we performed histological analysis with 
the prototypes in situ by a specialized grind-cutting technique and then consulted an 
external, independent, evaluator with expertise in the field of titanium implants. This 
evaluation showed full biocompatibility with a very small fibrotic capsule (< 1 µm) formed 
around the detached distal tips (fig 5). No ongoing inflammation was observable around 
any of the distal tips. Around one (of the total number 14 left in place) of the day five animal 
implants, three macrophages were indentified in the area of the detached distal tip. Apart 
from those three macrophages, no other signs of inflammation were observed. The 
endothelia showed no signs of alterations adjacent to the deposited tips. 
In conclusion, the biocompatibility of the distal tips was comparable to titanium implants. 
The interactions of nitinol with the interior of the vascular wall and the extra vascular space 
has not been as extensively studied since stents most often are positioned inside the vascular 
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lumen with direct contact only with the bloodstream and the endothelium. Therefore, the 
present histological analysis in this new application and new position of nitinol, adds 
important knowledge about biocompatibility for possible future applications. 
 
 
Fig. 5. Long term follow-up of the trans-vessel wall intervention 
In a. the initial follow up angiogram directly following detachment in the Superior 
Mesenteric Artery (SMA) is shown with a square marking the blow-up in b. Arrows indicate 
the detached distal tip. In c. an SMA angiogram, performed 80 days after the intervention in 
the same animal, is shown with a square indicating the blow-up in d. Arrows indicate the 
detached distal tip. In e. a microphotograph of a histological van Geeson and toulene blue 
staining prepared by grind-cutting with the detached tip in situ, is shown. Scale bar = 100 
µm. The blow-up in f shows the parylene coating surrounding the detached tip which is 
marked by an arrow. Note that no fibrous response or inflammation is observable. Scale bar 
= 4 µm. 
The prototypes excluded due to failed detachment were analyzed by sweep electron 
microscopy (SEM), since monitoring of electric current gave limited prognostic information 
about the failure to detach. We found that, in failed detachments, large amounts of chloride 
were observed by surface spectroscopy (6-10 wt %) indicating titanium chloride ion 
formations in a passive layer, thus providing current transmission without electrolysis. 
Titanium chloride molecules can provide a surface area that lets electron pass through but 
without formation of soluble titanium or nickel ions. This problem is probably due to the 
simple technique used for creating the insulation defect in our hands. However, numerous 
available solutions for detachment are available on the market that can easily be integrated 
with the trans-vessel wall technique in an industrialized manufacturing process. 
3. General discussion 
The rationale for our previous studies within the field of endovascular cell transplantation is 
the path to translating cell based regenerative medicine to patients. In a translational 
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perspective the actual route of transplantation will be important. For operative techniques 
there is a problem with scalability and for intravenous techniques there is a problem with 
efficacy. We show that by selective intra-arterial methods it is possible to increase the level 
of cerebral engraftment with certain cell types with six to fifteen fold yields. Further, not all 
cells are optimal for intra-luminal transplantation. It is, for example, known that insulin 
producing cells lack the capability to perform diapedesis (Hirshberg et al. 2002) and we 
show that hNPC, a cell system previously transplanted by open surgical means (Wennersten 
et al. 2004) also lacks the capability to perform diapedesis. For these cell systems, and other 
applications, we have developed the Extroducer as a tool to establish a direct, minimal 
invasive working channel with parenchymal access in organs that are difficult or risky to 
reach with traditional techniques. 
The first passage of cells delivered through selective intra-arterial approaches, compared to 
systemic intravenous delivery, results in a higher local concentration, shorter blood stream 
exposure and less mechanical stress factors before cells reach the target site. These factors 
could be of importance for successful engraftment. Supporting that hypothesis are the 
present results showing significantly higher total cerebral uptake of cells after intra-arterial 
compared to intra-venous administration. The next supporting fact is the higher uptake of 
cells in the ipsilateral hemisphere after intra-arterial administration and by the absence of 
difference between the hemispheres after intravenous transplantation. Future studies are 
needed for elucidating molecules responsible for diapedesis, e.g by direct methods such as 
knock-ins, of for example CD49d, in non-functioning cell systems and knock down or 
blocking in other cell systems. 
The absence of adverse effects in transplanted animals suggests that in the short term, the 
selective intra-arterial transplantation method is safe for delivering even high concentrations 
of cells. It has been reported ischemic events following intra-arterial approaches to the heart 
in dogs (Vulliet et al. 2004) thus indicating the need for thorough studies prior to translation 
into clinical practice. However, in clinical studies on intracoronary infusions (Stamm et al. 
2003) and in spinal cord artery infusions (Sykova et al. 2006) no embolic events have been 
recorded. Connected to the need for safety studies, it could be argued that the higher 
engraftment rates in our intra-arterial groups would be a consequence of microembolization 
of cells. In that scenario we would, however, have detected ischemic histological changes 
and localization of the transplanted cells within arterioles and capillaries, which we did not. 
For all intra-luminal approaches, this thesis shows that a thorough investigation must be 
performed to clarify if the cells actually can perform diapedesis prior to choosing 
transplantation strategy. hNPCs has previously been shown to have an impact on 
neurological outcome when transplanted with open surgical techniques, but in their present 
form they seem unsuitable for intra-luminal transplantation. Therefore, based on the 
findings in this thesis, considerations should be made that CD29CD49dVCAM-1 interaction 
is one of the best studied crosstalk mechanisms on how immunological cells leave the 
bloodstream to perform homing to disease ridden tissue where inflammation occurs (Elices 
et al. 1990). This line of reasoning is supported by other studies implicating VCAM-1 
interaction in both ischemic stroke and muscle dystrophy pre-clinical studies (Gavina et al. 
2006; Guzman et al. 2008). An interesting comparison can be made regarding diapedesis in 
cell systems aimed for transplantation compared to immunological cells. In such an exercise 
it could be considered blatantly ignorant to immediately dismiss the fylogenetically 
conserved mechanism of the immunological system and suggest a hitherto unknown 
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method of diapedesis for these cells. Applying Occam’s razor to the hypothesis of 
diapedesis for cell transplantation, two conclusions can potentially be made; i) the process of 
diapedesis is most probably an active process for cell systems transplanted, since there are 
no known inactive ways of diapedesis and ii) the most likely system for diapedesis crosstalk 
should be found within the same systems that are used by the immunological system, 
meaning that proteins are highly likely to come from the Ig-super family such as VCAM-1. 
The other, more complex, explanation would be that a hitherto unknown system for 
diapedesis exists. That it also unlikely since mutations in such a system would lead to 
genetical diseases that should be known, but without reasonable explanations. A research 
program dedicated on endovascular transplantation of different cell systems in different 
diseases should include a variety of diseases and cell systems to increase the understanding 
of both cell-endothelium interactions and the effects on target niches. 
When designing both pre-clinical and clinical cell transplantation studies, consideration 
should be taken to how the cells are hypothesized to reach their designated targets. The first 
option might be open surgical techniques for small niche locations in a target parenchyma. 
Downsides to open surgical/percutaneous techniques are e.g. impracticalities of accruing 
the desired extent of target tissue volume, especially if the volume is relatively large, such as 
following a major CNS insult. Further, the patient risk for adverse events might be 
unacceptable in relation to a potential benefit, in particular for “difficult to reach” organs 
such as the CNS, the pancreas and/or the heart. If the disadvantages of open 
surgical/percutaneous techniques are unacceptable, intra-luminal options could be 
explored. For intra-luminal approaches, the concept of how transplanted cells are presumed 
to leave the blood stream becomes an issue with several potential solutions. For a cell 
system without the necessary features for diapedesis, one could use knock-in methods to 
provide the necessary adhesion molecule set up, otherwise intra-parenchymal injections 
must be considered. For knock-in methods, an intra-arterial approach would probably still 
have benefits in efficacy over intravenous methods through the first passage effect and by 
avoiding pulmonary trapping. As previously discussed, an interesting purely academical 
calculation when performing intravenous cell transplantations could result in such a low 
cell dose to the brain as 0.01 to 1.7% after intravenous injection, assuming that 80% of cells 
are trapped in the first passage through the lung (Barbash et al. 2003; Fischer et al. 2009). 
This can readily be changed by placing a micro-catheter in vessels supplying the target 
parenchyma with blood thereby providing a chance for all cells to perfuse the target 
parenchyma. 
For more discrete functioning cells, an intra-parenchymal injection might be even more 
attractive for reasons such as shielding the cells from the exposure to the bloodstream and 
accurate anatomical placement. In difficult to reach organs, minimally invasive direct 
parenchymal transplantation could be performed by the trans-vessel wall technique 
described within this thesis. That technique might, however, not be suitable for treating a 
large ischemic lesion in humans. On the contrary, in discrete lesions where only a niche cell 
needs to be replaced, such as in type I diabetes, where the cells do not possess properties for 
diapedesis, the Extroducer could potentially really show its worth. The next natural step is 
transplantation of insulin producing cells to swine before planning for clinical trials.  
The Extroducer is not limited to cell transplantation. Its main design is to provide a working 
channel by endovascular technique to the parenchyma in various, otherwise, inaccessible 
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method of diapedesis for these cells. Applying Occam’s razor to the hypothesis of 
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no known inactive ways of diapedesis and ii) the most likely system for diapedesis crosstalk 
should be found within the same systems that are used by the immunological system, 
meaning that proteins are highly likely to come from the Ig-super family such as VCAM-1. 
The other, more complex, explanation would be that a hitherto unknown system for 
diapedesis exists. That it also unlikely since mutations in such a system would lead to 
genetical diseases that should be known, but without reasonable explanations. A research 
program dedicated on endovascular transplantation of different cell systems in different 
diseases should include a variety of diseases and cell systems to increase the understanding 
of both cell-endothelium interactions and the effects on target niches. 
When designing both pre-clinical and clinical cell transplantation studies, consideration 
should be taken to how the cells are hypothesized to reach their designated targets. The first 
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cell dose to the brain as 0.01 to 1.7% after intravenous injection, assuming that 80% of cells 
are trapped in the first passage through the lung (Barbash et al. 2003; Fischer et al. 2009). 
This can readily be changed by placing a micro-catheter in vessels supplying the target 
parenchyma with blood thereby providing a chance for all cells to perfuse the target 
parenchyma. 
For more discrete functioning cells, an intra-parenchymal injection might be even more 
attractive for reasons such as shielding the cells from the exposure to the bloodstream and 
accurate anatomical placement. In difficult to reach organs, minimally invasive direct 
parenchymal transplantation could be performed by the trans-vessel wall technique 
described within this thesis. That technique might, however, not be suitable for treating a 
large ischemic lesion in humans. On the contrary, in discrete lesions where only a niche cell 
needs to be replaced, such as in type I diabetes, where the cells do not possess properties for 
diapedesis, the Extroducer could potentially really show its worth. The next natural step is 
transplantation of insulin producing cells to swine before planning for clinical trials.  
The Extroducer is not limited to cell transplantation. Its main design is to provide a working 
channel by endovascular technique to the parenchyma in various, otherwise, inaccessible 
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organs. Through that working channel, other procedures such as local chemotherapy-, 
irradiation-, growth factor administration, tissue sampling, electrophysiological diagnostics 
and thermo-therapy becomes possible. Further, combined with optical spectroscopic 
analysis, it might even be possible to perform infra-light histological analysis of tissue via 
the Extroducer. 
3.1 Conclusions and future research 
We have discussed the rationale for using endovascular methods for cell transplantation 
and described findings from our group and other groups, showing that selective intra-
arterial administration is a safe way, with a short follow up time, to increase engraftment 
levels compared to intravenous delivery. However, not all cell systems are optimal for intra-
luminal transplantation. These factors might be dependent on integrin expression and 
endothelium interactions. For cells that lack the capacity to perform diapedesis, and 
especially for more specific niche cell systems in organ systems that are difficult to reach, we 
have also developed a system for trans-vessel wall parenchymal access. The Extroducer 
system has been evaluated both for long term effects and feasibility for pancreas access. 
Ergo, endovascular intervention should provide a number of methods for efficient and safe 
cell transplantation in current and future clinical practice. The transplantation method must 
be decided on a disease to disease, cell to cell and patient to patient manner. Future research 
should investigate the possibilities of providing cells meant for intravasal transplantation 
with the necessary properties for performing diapedesis. 
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organs. Through that working channel, other procedures such as local chemotherapy-, 
irradiation-, growth factor administration, tissue sampling, electrophysiological diagnostics 
and thermo-therapy becomes possible. Further, combined with optical spectroscopic 
analysis, it might even be possible to perform infra-light histological analysis of tissue via 
the Extroducer. 
3.1 Conclusions and future research 
We have discussed the rationale for using endovascular methods for cell transplantation 
and described findings from our group and other groups, showing that selective intra-
arterial administration is a safe way, with a short follow up time, to increase engraftment 
levels compared to intravenous delivery. However, not all cell systems are optimal for intra-
luminal transplantation. These factors might be dependent on integrin expression and 
endothelium interactions. For cells that lack the capacity to perform diapedesis, and 
especially for more specific niche cell systems in organ systems that are difficult to reach, we 
have also developed a system for trans-vessel wall parenchymal access. The Extroducer 
system has been evaluated both for long term effects and feasibility for pancreas access. 
Ergo, endovascular intervention should provide a number of methods for efficient and safe 
cell transplantation in current and future clinical practice. The transplantation method must 
be decided on a disease to disease, cell to cell and patient to patient manner. Future research 
should investigate the possibilities of providing cells meant for intravasal transplantation 
with the necessary properties for performing diapedesis. 
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1. Introduction 
Myocardial infarction (MI) results in necrosis, inflammation and scar formation in the 
myocardium. Such pathological insults place increasing mechanical demands on surviving 
cardiomyocytes (Boudoulas & Hatzopoulos, 2009). As cardiomyocytes have limited 
regenerative potential, loss of functional healthy tissue and subsequent left ventricular (LV) 
remodelling, eventually leads to pathological hypertrophic cardiomyopathy. Hypertrophy 
of the LV has been documented as a chronic response to MI and invariably progresses to 
heart failure (Hannigan et al., 2007). Chronic heart failure is a major health problem with 
patients experiencing a debilitating quality of life.  
Cardiac remodelling after MI is characterised by progressive and pathological interstitial 
fibrosis. During acute phase of cardiac repair, degradation of myocardial extracellular 
matrix (ECM) coupled with an influx of inflammatory cells and cytokines permits 
deposition of granulation tissue in the infarct region. At the site of tissue injury, 
granulation tissue composes of macrophages, myofibroblasts and neovascularisation. 
Activated myofibroblasts synthesise collagen and other ECM proteins to form dense scar 
tissue in the infarct in response to inflammatory mediators such as angiotensin II (Ang II) 
and transforming growth factor-1 (TGF-1). Macrophages drive the production of TGF-
1, an essential growth factor for fibroblast production, collagen synthesis and inhibition 
of collagen degradation (O'Kane & Ferguson, 1997; Sun & Weber, 2000). At the site of MI, 
increased expression of adhesion molecules (inter-cellular adhesion molecule-1, ICAM-1) 
and chemoattractant cytokines (monocyte chemotactic protein-1, MCP-1) facilitate 
migration of inflammatory cells (e.g. macrophages) enabling scavenging of necrotic 
tissues (Lu et al., 2004). This couples with elevated expression of matrix 
metalloproteinase-1 (MMP-1) results in remodelling of myocardial ECM by degradation 
of existing collagen I and III in the injured myocardium (Lu et al., 2004). Furthermore, 
MMP-9 has been implicated in tissue remodelling by cleaving collagen V at the amino-
terminus (Niyibizi et al., 1994). Consequently, this process compromises structural 
integrity of the ventricles, resulting in myocyte slippage, wall thinning and rupture 
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(Cleutjens et al., 1995b). Derangements in cardiomyocyte-ECM interactions cause the loss 
of cellular tensegrity and initiates anoikis in neighbouring healthy tissue (Michel, 2003). It 
is now well recognised that structural changes in the myocardial ECM can alter collagen-
integrin-cytoskeletal-myofibril relations, thus affecting overall geometry and function of 
the heart (Spinale, 2007).  
In non-cartilaginous tissues like the heart, collagen I, III and V are the predominant subtypes 
of the ECM (Breuls et al., 2009; Linehan et al., 2001). Collagen I is primarily a structural 
element of the myocardial ECM while collagen V represents a minor, but important 
component sequestered within collagen I fibres. However, collagen V levels increase in 
inflammation and scar tissue. The relative resistance of collagen V to mammalian 
collagenases makes it transiently available during tissue remodelling. The temporal 
availability of collagen V during active extracellular remodelling implies that it may play an 
important role in ECM remodelling and tissue stiffness (Breuls et al., 2009; Ruggiero et al., 
1994). In fact, collagen V plays a deterministic role in collagenous fibril structure, matrix 
organisation and stiffness (Fichard et al., 1995).  
Binding of ECM to integrins provides a linkage between the ECM and cellular 
cytoskeleton. Integrins are heterodimeric receptors composed of non-covalently bound  
and  subunits. (Brancaccio et al., 2006). Dynamic integrin-ECM interactions result in 
bidirectional signalling and determines cell morphology, gene expression, migration, 
proliferation, differentiation and death. Perkins et al. (2010) showed that integrin-
mediated adhesion is mandatory for maintenance of the sarcomeric architecture. They 
proposed that disintegration of the Z-line and progressive muscle degeneration can occur 
once the adhesion complex comprising of integrins, talin or integrin linked kinase (ILK) is 
not replenished. In the myocardium, integrins can function as mechanotransducers that 
transmit mechanical ECM cues to the myocyte, resulting in changes to myocyte biology 
and function (Ross & Borg, 2001). Integrins 21, 11, 31, v3, IIb3 are collagen 
binding heterodimers and adhesion to collagen V has been reported to be primarily 
mediated by integrin 21 and 11 (Ruggiero et al., 1994). Integrins 21 and 11 may 
play a significant role in remodelling of the heart where there is increased collagen 
synthesis and collagen V expression, although we have previously shown v3, but not 
21, in a collagen V associated cardiac differentiation of human mesenchymal stem cells 
(hMSCs) (Tan et al., 2010).  
Increased ejection fraction (EF) and fractional shortening (FS) parameters, coupled with a 
reduction in the amount of fibrotic scar tissue have been highlighted following cellular 
therapy (Chacko et al., 2009). Our previous study showed that cardiomyocyte-like cells 
(CLCs) that were differentiated from MSCs, improved systolic performance without 
compromising end-diastolic pressure of the infarcted myocardium when compared to 
MSCs. CLCs may facilitate hemodynamic recovery by preserving tissue elasticity in the 
collagen V-expressing peri-infarct borders. This unique cell/matrix relationship may be 
more conducive to a functionally adaptive remodelling response in maintaining contractile 
efficiency of post-infarcted myocardium (Tan et al., 2010).   
Experimental data show that MSC transplantation inhibits LV remodelling and improves 
heart function in animals with MI (Xu et al., 2005).  Despite the ability of angiogenic 
mechanisms to reduce infarct mass, only partial restoration of ventricular contraction occurs 
as myocytes are not regenerated (Gaudette & Cohen, 2006). In addition, cardiac 
differentiation and retention of surviving transplanted MSCs in-vivo is limited (Feygin et al., 
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2007). Influence of ECM proteins and integrin interactions on MSC differentiation have been 
widely investigated for chrondrogenic and osteogenic differentiation (Djouad et al., 2007; 
Gronthos et al., 2001). Conversely, studies investigating ECM role in cardiac differentiation 
of MSCs is limited. Unravelling of integrin roles in cardiac differentiation of MSCs would 
aid in understanding of mechanisms leading to retention and integration of stem cells in 
myocardium.  
We have previously reported in-vitro differentiation of human MSCs towards CLCs and 
shown that collagen V promoted adhesion and cardiac gene expression in CLCs (Shim et al., 
2004; Tan et al., 2010). In the present study, we further examine the role of individual 
integrins in cardiac differentiation of CLCs.  
2. Materials and methods 
2.1 Isolation and culture of bone marrow derived MSCs 
Bone marrow was isolated from the sternum of patients undergoing open-heart surgery. 
They were collected in 17 IU/ml heparin using a 23-gauge needle. Bone marrow aspirates 
were topped up to 15 ml with Dulbecco’s modified Eagle’s medium-low glucose (DMEM-
LG, GIBCO) supplemented with 10% fetal bovine serum (FBS, Hyclone) and 1% penicillin-
streptomycin (Gibco, Invitrogen). To deplete bone marrow asiprates of mature blood 
lineages, 15 ml of bone marrow blood mixture was overlaid onto 15 ml of Histopaque®-1077 
(Sigma-Aldrich) and centrifuged for 1500 rpm (Kubota Centrifuge) for 30 minutes at 4oC. 
The enriched cell fraction was collected from the interphase, washed once with 5 ml of 
media and centrifuged at 1200 rpm (Kubota Centrifuge) for 10 minutes. Resuspended cells 
were then transferred into tissue culture flasks with basal normal growth medium (NGM) 
comprising DMEM-LG supplemented with 10% FBS for 9 - 11 days to yield plastic adherent 
MSCs. Subconfluent cells were harvested using 1X Trypsin-EDTA solution for endothelial 
cell culture (Sigma-Aldrich), 14 – 21 days after initial plating and maintained as MSCs in 
basal NMG or differentiated towards CLCs in a myogenic differentiation medium (MDM) 
as previously described (Shim et al., 2004).  
Type V collagen (Sigma-Aldrich) and Type I collagen (BD™) were coated on 6-well 
plates or tissue culture flasks at 10g/cm2 for 3 hours at room temperature. Plates and 
flasks were washed twice with phosphate buffered saline (PBS) and kept at 4oC until 
required.  
2.2 Fluorescence microscopy 
Frozen tissue sections of the explanted ventricular rat hearts were fixed in 4% 
paraformaldehyde (PFA), permeabilised with 0.1% Triton X-100, and further blocked in 5% 
bovine serum albumin (BSA). This was followed by overnight incubation at 4oC with 
primary antibodies, including collagen I (Southern Biotech), collagen III (Affinity Bioregent) 
collagen V (Biotrend) and anti--sarcomeric actinin (Sigma-Aldrich) diluted in 1% BSA. 
Sections were incubated with Alexa Fluor® 488/555/660 - conjugated secondary antibodies 
(Molecular Probes) in 0.1% BSA at room temperature for 3 hours before staining the nuclei 
with DAPI. Immunofluorescence microscopy was performed with Zeiss Axiovert 200 M 
fluorescence microscope, using the Metamorph software (version 6.2, Molecular Devices) or 
Leica MZ 16 FA Fluorescence Steromicroscope, using the Leica Application Suite software 
(Version 3.3.0, Leica).  
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2.3 Flow cytometry  
Sternum-derived bone marrow MSCs were differentiated into CLCs and characterised by 
flow cytometry after 14 days in a MDM. CLCs cultured on uncoated, collagen I or V 
coated tissue culture flasks were stained with antibodies directed towards integrin 
subunits 1 (Abcam), 2 (Santa Cruz), v (Fitzgerald), 1 (Chemicon) and 3 (Cell 
Signaling). Cells were treated with Fix & Perm® Cell Permeabilisation Kit (Invitrogen) and 
subsequently blocked in PBS containing 5% BSA, 1% FBS and 5 mM 
ethylenediaminetetracetic acid (EDTA) for 30 minutes at 4oC on a roller. CLCs were then 
incubated with directly conjugated antibodies for 30 minutes at 4oC. Indirectly conjugated 
antibodies were incubated for 2 hours at 4oC and subsequently stained with their 
respective Alexa Fluor® 555 conjugated secondary antibodies (Invitrogen) for 2 hours at 
4oC. Isotype controls were stained in parallel with the test samples. Samples were washed 
in PBS containing 2% BSA, 2% FBS and 5 mM EDTA after each antibody staining and 
fixation step. All samples were fixed in PBS containing 4% PFA/PBS, washed and 
resuspended in PBS containing 2% FBS and 0.09% sodium azide (NaZ). Data analysis was 
performed using FACSDiva software (version 6.1.2, BDTM), FlowJo software (version 6.4, 
Tree Star, Inc.). Histogram overlays were performed and the change in median 
fluorescence intensity and overton subtraction percentages were computed. 
2.4 Integrin neutralisation assays 
Integrin neutralisation assays were performed on CLCs using neutralising antibodies 
against the integrin 1 (Millipore) subunit and v3 (Millipore) heterodimer, at 1g/ml 
and 10 g/ml respectively. CLCs treated with 1g/ml or 10 g/ml isotype IgG 
(Abcam/Dako) antibodies and untreated CLCs served as controls. After trypsin 
digestion, CLCs were incubated with neutralising and isotype control antibodies for 2 
hours at 4oC. 50,000 untreated and treated CLCs were seeded on collagen V pre-coated 6-
well plates. Plated CLCs were harvested after 72 hours of culture at 37oC, 5% CO2. Total 
RNA was extracted using the RNeasy Mini Kit (Qiagen) and treated with RNAse free 
DNase solution (Qiagen). DNAse treated RNA samples were stored at -80oC until 
required. 
2.5 Real-time reverse transcriptase polymerase chain reaction for quantitation of 
cardiac gene expression 
First strand cDNA was synthesised from total RNA using the SuperScript™ III First-
Strand Synthesis System (Invitrogen) and equal concentrations of cDNA were loaded into 
tubes containing QuantiFast SYBR Green PCR mastermix (Qiagen). Real-time reverse 
transcriptase polymerase chain reaction (RT-PCR) was performed on the Rotor-Gene Q 
thermocycler (Qiagen) using standard cycling parameters and relative gene expression of 
the following cardiac transcripts was quantitated using the CT method. These 
transcripts include  actin (BA), cardiac -actin (CAA), skeletal muscle -actin (SKAA), 
troponin T (Trop T), troponin C (Trop C), Nkx2.5 and GATA4 (Sigma-Aldrich). Target 
gene expression values were normalised relative to the untreated CLCs. BA served as a 
housekeeping gene for the real time RT-PCR experiments. No template controls were 
concurrently processed with test samples to rule out the presence of contaminated 
reagents and nucleic acids.  
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Table 1. Primer sequences for real time reverse transcriptase polymerase chain reaction (RT-
PCR). Transcripts obtained from RT-PCR assays were all less than 200 bp. CAA, cardiac -
actin; SKAA, skeletal muscle -actin; Trop T, troponin T; Trop C, troponin C; BA,  actin. 
2.6 Cell labelling 
CLCs were labelled with 1 mmol/L Vybrant CellTracker chloromethyldialkylcarbocyanie 
(CM-Dil; Molecular Probes) overnight at 37C and rinsed 3 times before trypsin disgestion 
and transplantation. MSCs were labelled with 10mmol/L Vybrant carboxy fluorescein 
diacetate succinimidyl ester (CFDA-SE; Molecular Probes). Cells were resuspended in a final 
concentration of 1 x 106/0.1 ml to 5 x 106/0.2 ml. 
2.7 Rat myocardial infarction model 
MI was created in n=20 female Wistar rats per group. Each rat weighed approximately 350 -
400g in body weight. The animals were subjected to left thoracotomy and the left anterior 
descending artery (LAD) was exposed and ligated. After which rats were allowed a week 
for recovery before given treatment of either injection with labelled cells or placebo to the 
area of infarction. Cyclosporin A was administered at a dose of 5mg/kg body weight at 3 
days before and daily following treatment for 6 weeks until end point.  
2.8 Echocardiography 
Baseline echocardiography was performed on each rat before MI and 6 weeks after 
treatment. Echocardiography images were acquired using Vivid 7 ultrasound machine 
(General Electric VingMed) equipped with i13L linear probe operated at 14MHz. Rats were 
anaesthetised using 1% - 2% isofluorane with 1L/hr oxygen and then fixed in the supine 
position on a heated platform. Rats were then shaved at the chest and abdominal areas 
before electrocardiography (ECG) electrodes were placed onto the left and right leg as well 
as the left upper extremity. All analysis was performed offline with EchoPAC workstation 
(General Electric Healthcare). 
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2.9 Statistical analysis 
One-way analysis of variance (ANOVA) was used to determine statistical significance 
between different treatment groups. Tukey Honestly Significant Difference (HSD) post-hoc 
analyses were used to determine statistical significance between treatment groups using 
SPSS 13 software (SPSS Inc.). p < 0.05 was considered statistically significant.  All data are 
presented as mean  standard deviation (SD).  
3. Results 
3.1 Integrin expression and cardiac differentiation 
Flow cytometric analysis showed that v and 1 were the predominant subunits of integrins 
in CLCs, independent of substrate surface (Table 2). In comparison to collagen V matrix, 
CLCs cultured on collagen I showed a higher expression of integrin 1 (59.4 ± 13.7% vs. 78.0 
± 0.9%) and 3 (44.7 ± 10.6% vs. 56.0 ± 21.8%) subunits. Furthermore, with the exception of 
1 subunit, 2, v, 1 and 3 integrins in CLCs cultured on either collagen matrices showed a 
reduction of expression in comparison to CLCs cultured on polystyrene tissue culture 
surface.    
 
 
Table 2. Flow cytometric analysis showed that integrin v and 1 were the predominant 
subunits in CLCs.  CLCs cultured on collagen I showed increased levels of 1 and 3. Data were 
derived from 3 independent experiments and the overton percentage positive results are 
expressed as mean ± SD. MSCs, Mesenchymal stem cells; CLCs, Cardiomyocyte-like cells.    
3.2 CLCs enhance cardiac gene expression via integrin 1 and v3 on collagen V 
matrices 
We previously reported that collagen V matrix enhanced cardiac gene expression when 
compared to CLCs seeded on collagen I matrix. Collagen V selectively upregulated 
expression of cardiac transcription factors (GATA4, Nkx2.5), calcium handling transporter 
(RyR2) and sarcomeric myofilament proteins (Trop T, Trop C, SKAA) in CLCs (Tan et al., 
2010). Neutralisation of v3 integrin or 1 subunit in this study did not affect CAA and 
SKAA gene expression in CLCs that were cultured on collagen V matrix. Furthermore, no 
significant changes in Nkx2.5 or GATA4 expression was observed in 1 subunit neutralised 
CLCs. However, Nkx2.5 down regulation was observed in CLCs neutralised with v3, 
although similar down regulation was also evident in the isotype control experiment. Gene 
expression of Trop C reduced significantly after v3 integrin neutralisation. In contrary, 1 
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subunit neutralisation upregulated Trop C expression. Furthermore, there was a 
concomitant upregulation of Trop T following 1 integrin neutralisation.  
 
 
Table 3. CLCs cultured on collagen V were treated with integrin 1 (1 g/ml) neutralising 
antibodies. Untreated and isotype IgG (1 g/ml) treated CLCs served as controls for this 
experiment. Optimal concentrations of test and control antibodies were predetermined in a 
series of titration experiments. CLCs cultured on collagen V were treated with integrin v3 
(10 g/ml) neutralising antibodies. Untreated and isotype IgG (10 g/ml) treated CLCs 
served as controls for this experiment. Results are expressed as mean ± SD. CAA, cardiac -
actin; SKAA, skeletal muscle -actin; Trop T, troponin T; Trop C, troponin C, N.D., not 
done; MSCs, Mesenchymal stem cells; CLCs, Cardiomyocyte-like cells. 
3.3 CLCs integrate into collagen V-rich cardiac syncytium 
Consistent with our previous report (Tan et al., 2010), collagen I as the main constituent of 
cardiac ECM in intact rat myocardium, was found to co-localise with collagen III matrix in  
the epicardium and perimysial space between major muscle bundles dispersed throughout 
the myocardium (Fig. 1A). On the other hand, collagen V was predominantly observed in 
the endomysial space surrounding healthy cardiomyocytes and in the perivascular 
structures within the myocardium. Following MI by ligating the LAD artery, significant wall 
thinning was observed in the anterior wall of the LV (Fig.1B). Accumulation of collagen 
matrices was evident in the infarcted and non-infarcted zones 7 weeks post infarction. 
Spatial remodelling and redistribution of collagen matrices were observed whereby 
perimysial collagen I diminished significantly and upregulation of collagen I and III were 
observed in the pericardium and epicardium of infarcted as well as non-infarcted zones. 
Furthermore, fibrosis consisted mainly of collagen I matrix was prominently found in the 
endocardium of infarcted zone while it co-localised with collagen III matrix in the 
pericardium/epicardium of the non-infarcted and infarcted zones (Fig. 1Bii & 1Biii). In 
contrast, collagen V fibrils were sparsely detected in the epicardium of infarct, but were 
prominently found in the peri-vascular structures within the infarct (Fig. 1Biii). In contrast 
to redistribution of collagen I matrix, collagen V remained in the endomysial matrix of 
individual muscle fibres in the non-infarcted borders (Fig.1Bii) and also surrounding 
isolated, but viable cardiac fibres in the infarct.  
Myocardial transplanted CLCs were closely associated with collagen V matrix in the 
endomysial space in the peri-infarct border of the myocardium (Fig. 2A). In contrast, 
similarly transplanted MSCs were only found in collagen I-rich infarct despite the presence 
of isolated, collagen V-expressing, myofibres at the infarct borders (Fig. 2B). Furthermore, 
CLCs were often intimately engrafted among -actinin stained native cardiomyocytes that 
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were surrounded by collagen V, but not collagen I, matrices (Fig. 2C and 2D). On the 
contrary, transplanted MSCs were sequestered in the infarct that was dominated with 
collagen I matrix and isolated from viable and -actinin stained myocardium that expressed 
collagen V matrix (Fig. 2E).  
 
 
Fig. 1. (A) Collagen distribution in an intact myocardium. (Ai) Higher magnification of the 
boxed area showing collagen I and III distribution in the perimysium while collagen V was 
expressed in the endomysial space. (B) Collagen distribution in an infarcted myocardium. 
(Bii) Higher magnification of the myocardium, epicardium and pericardium at the boxed 
area. Collagen V was predominantly expressed at the peri-infarct border surrounding viable 
myocytes and vasculature structures in the infarct region. Collagen I and III were positively 
stained in the infarcted epicardium and pericardium. (Biii) Higher magnification 
demonstrating severe thinning of the LV anterior wall. Co-localisation of collagen I and III 
extended from the pericardium into the infarcted myocardium whereas collagen I was 
primarily localised in the endocardium. Collagen V was expressed in the vessels and 
sparsely  in the infarct. Scale bar: 200µm.  
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Fig. 2. (A) Transplanted CLCs preferentially home to the collagen V-rich myocardial ECM. 
(B) Transplanted MSCs localised in the collagen I enriched infarct zone away from the 
collagen V peri-infarct region. (C) Engraftment of CLCs in the -actinin stained 
myocardium (D) showing an affinity towards collagen V matrix in the absence of collagen 
I staining. (E) MSCs were embedded in the collagen I-rich infarct zone and were isolated 
from -actinin expressing cardiomyocytes. (F) Collagen V was sparsely distributed in the 
infarcted region, but mainly surrounded viable myocytes at the peri-infarct border. Scale 
bar: 20µm. MSCs: Mesenchymal stem cells; CLCs: Cardiomyocyte-like cells; Col I: 
Collagen I; Col V: Collagen V. 
3.4 CLC therapy at high doses improve cardiac hemodynamics 
Consistent with their muscular engraftment, LV echocardiography confirmed a better 
cardiac performance of transplanted CLCs, 6 weeks post cell transplant (Table 4).  
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Transplanted CLCs (2.2  0.3 mm, p<0.05), but not MSCs (2.1  0.3 mm), improved LV 
anterior wall thickness as compared to control infarcted animal (1.8  0.4 mm). Nevertheless, 
other cardiac parameters indicated that CLCs and MSCs contributed comparably to 




Table 4. Ultrasound echocardiography assessment of post cellular therapy treated rats. 2D 
ultrasound echocardiography assessments showed significant improvements in cell 
transplanted animals. SF: Serum free control; CLC: Cardiomyocyte-like-cells; MSCs: 
Mesenchymal stem cells; LVIDed: Left ventricular internal dimension at end diastolic; LVID: 
Left ventricular internal dimension at end systolic; IVSed: Interventricular septum at end 
diastolic, IVSes: Interventricular septum at end systolic; AWT: Anterior wall thickening; FS: 
Fractional shortening; EF: Ejection fraction. 
4. Discussion  
Integrins and ECM are important modulators of stem cell behaviours. To date, cardiac cell 
therapy supported only modest benefits, likely due to low engraftment of transplanted cells 
in the infarcted myocardium. Exploration of specific integrin/ECM interaction may improve 
engraftment and survival of transplanted cells and ultimately, mechanical function of the 
heart. Our current study examines integrin/ECM interactions on cardiac gene expression of 
CLCs and distribution of transplanted CLCs in infarcted myocardium.  
The distribution and quantity of type I and III collagens in the heart play an important role 
in maintaining cardiac function. Alterations of collagen population and distribution in the 
myocardium affect size and shape of the heart chambers as well as myocardial diastolic and 
systolic function (Cleutjens et al., 1995a; Janicki & Brower, 2002). However, it is unclear if 
such alterations could affect stem cell migration and differentiation in the myocardium.  
We have previously demonstrated that CLCs showed preferential adhesion to collagen V 
over collagen I matrix by interacting with subsets of integrins (Shim et al., 2004; Tan et al., 
2010). van Laake et al. (2010) reported that pre and post transplanted human embryonic 
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cardiomyocytes (hESC-CM) express integrins matching ECM types they encountered in 
their environment. Therefore, the integrin modulating role of collagen V may aid in the 
observed retention of the myocardial transplanted CLCs. Furthermore, intimate engraftment 
of the transplanted CLCs with collagen V-expressing, -actinin positive, native 
cardiomyocytes supports an unique role of collagen V in the myocardium. Moreover, 
differential expression of 1 and 3 integrin between collagen I and V cultured CLCs coupled 
with the preferential homing demonstrated between transplanted MSCs and CLCs suggested 
a key role of collagen V matrix, not only in cellular retention, but cardiac differentiation of the 
transplanted stem cells. This is consistent with modulation of cardiac gene expression of CLCs 
demonstrated in relation to 1 and v3 neutralisation in vitro, although such relationship was 
not examined in vivo. Nevertheless, the comparable cardiac outcomes achieved in spite of 
selective homing of the transplanted cells, indicate that different reparative mechanisms may 
be initiated by MSCs and CLCs. Despite a positive trend of systolic improvement by CLCs, 
further mechanistic studies are warranted to discern their specific contribution to systolic and 
diastolic components of cardiac performance.  
Integrin 1 is known to transduce ECM signals to the cytoskeleton that activate downstream 
mitogen activated protein kinase (MAPK) and extracellular signal-regulated kinase 1 (ERK1) 
signalling pathways that phosphorylate and activate GATA4 (Akazawa & Komuro, 2003). 
However, GATA4 expression was unaffected by integrin 1 neutralisation despite the 
upregulated Trop C and Trop T belonging to downstream genes known to be activated by 
GATA4 (Liang et al., 2001; Tidyman et al., 2003). Similarly, neutralisation of v3 integrin 
attenuated Trop C expression despite GATA4 was previously shown to be unaffected by 
neutralisation of v3 (Tan et al., 2010). It is unclear if the modulation of myofilamental gene 
expression demonstrated was secondary to other nuclear transcription factors. However, 
integrins are known to mechanotransduce signals to activate Raf-MEK-ERK-1/2 cascade 
that has been shown to elicit cardiomyocyte growth, increased fetal-gene expression and 
cytoskeletal reorganisation in neonatal cardiomyocytes (Lorenz et al., 2009). Nevertheless, it 
is unclear if reduced expression of integrin demonstrated on either collagen surface as 
compared to CLCs cultured on uncoated polystrene surface was associated with enhanced 
proliferation of CLCs as previously reported (Tan et al 2010). However, contrary to our 
previous data, SKAA was not down regulated by integrin v3 neutralisation in the current 
study. This could be due to donor variations. Indeed, donor variation in integrin expression 
has been documented from different bone marrow isolates and passage numbers, resulting 
in different growth and proliferation potential (ter Brugge et al., 2002).  
Despite beneficial effects of collagen V on cardiac gene expression and stem cell 
distribution, it should be noted that collagen distribution in the infarcted rat hearts may 
be different from humans during MI. Furthermore, a 3D structure like the heart may 
transmit different environmental cues to integrins as compared to 2D environments 
provided in tissue culture experiments. It remains to be determined whether inhibitory 
antibodies may transactivate other integrin receptors during epitope occupancy. In 
addition, the promiscuity of integrins renders it technically challenging to identify 
whether a single integrin or interplay of synergistic interactions between a few integrins is 
required for regulation of cardiac gene expression. Future studies employing siRNA 
techniques that selectively silence 1 or v3 integrin may provide additional information 
regarding the regulation of cardiac gene expression of CLCs on collagen V matrix ex vivo 
or in the transplanted milieu of infarcted myocardium.  
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Mesenchymal stem cells; LVIDed: Left ventricular internal dimension at end diastolic; LVID: 
Left ventricular internal dimension at end systolic; IVSed: Interventricular septum at end 
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their environment. Therefore, the integrin modulating role of collagen V may aid in the 
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be initiated by MSCs and CLCs. Despite a positive trend of systolic improvement by CLCs, 
further mechanistic studies are warranted to discern their specific contribution to systolic and 
diastolic components of cardiac performance.  
Integrin 1 is known to transduce ECM signals to the cytoskeleton that activate downstream 
mitogen activated protein kinase (MAPK) and extracellular signal-regulated kinase 1 (ERK1) 
signalling pathways that phosphorylate and activate GATA4 (Akazawa & Komuro, 2003). 
However, GATA4 expression was unaffected by integrin 1 neutralisation despite the 
upregulated Trop C and Trop T belonging to downstream genes known to be activated by 
GATA4 (Liang et al., 2001; Tidyman et al., 2003). Similarly, neutralisation of v3 integrin 
attenuated Trop C expression despite GATA4 was previously shown to be unaffected by 
neutralisation of v3 (Tan et al., 2010). It is unclear if the modulation of myofilamental gene 
expression demonstrated was secondary to other nuclear transcription factors. However, 
integrins are known to mechanotransduce signals to activate Raf-MEK-ERK-1/2 cascade 
that has been shown to elicit cardiomyocyte growth, increased fetal-gene expression and 
cytoskeletal reorganisation in neonatal cardiomyocytes (Lorenz et al., 2009). Nevertheless, it 
is unclear if reduced expression of integrin demonstrated on either collagen surface as 
compared to CLCs cultured on uncoated polystrene surface was associated with enhanced 
proliferation of CLCs as previously reported (Tan et al 2010). However, contrary to our 
previous data, SKAA was not down regulated by integrin v3 neutralisation in the current 
study. This could be due to donor variations. Indeed, donor variation in integrin expression 
has been documented from different bone marrow isolates and passage numbers, resulting 
in different growth and proliferation potential (ter Brugge et al., 2002).  
Despite beneficial effects of collagen V on cardiac gene expression and stem cell 
distribution, it should be noted that collagen distribution in the infarcted rat hearts may 
be different from humans during MI. Furthermore, a 3D structure like the heart may 
transmit different environmental cues to integrins as compared to 2D environments 
provided in tissue culture experiments. It remains to be determined whether inhibitory 
antibodies may transactivate other integrin receptors during epitope occupancy. In 
addition, the promiscuity of integrins renders it technically challenging to identify 
whether a single integrin or interplay of synergistic interactions between a few integrins is 
required for regulation of cardiac gene expression. Future studies employing siRNA 
techniques that selectively silence 1 or v3 integrin may provide additional information 
regarding the regulation of cardiac gene expression of CLCs on collagen V matrix ex vivo 
or in the transplanted milieu of infarcted myocardium.  
 




In conclusion, our study indicates that 1 and v3 integrins drive cardiac gene expression of 
CLCs. Integrin families and ECM are important regulators of cardiac differentiation and 
myocardial distribution of adult MSCs and CLCs. Specific modulation of interaction 
between subclasses of collagen and integrin subunits in the post-infarct myocardial ECM 
could potentially offer a unique opportunity in cardiac regenerative medicine.    
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1. Introduction 
Hematopoietic stem cell transplantation (HSCT) has the potential to cure a variety of 
malignant and non- malignant diseases. Sources of hematopoietic stem cells for 
transplantation have expanded progressively since the beginning of the modern era of 
transplantation in the late 1960s. Although bone marrow was the main source of stem cells 
in the early years of transplantation, in the past 10 to 15 years peripheral blood has assumed 
increasing importance. The initial impetus for the use of PBSCs for transplantation was to be 
able to offer transplantation to patients who were not candidates for the use of bone marrow 
cells (tumor contamination of the marrow or those with hypocellular marrows). Subsequent 
studies demonstrated that PBSCs could be mobilized from the bone marrow with either 
hematopoietic growth factors (GM-CSF, G-CSF) or a combination of chemotherapy and 
growth factors, which increased the number of hematopoietic progenitors collected from the 
blood by 10- to 1000- fold compared with steady-state conditions. Umbilical cord blood 
represents the newest source of stem cells for transplantation. At now peripheral blood is 
the main source in the autologous setting. Within the allogeneic setting, multiple sources of 
stem cells are possible and include those derived from individuals related or unrelated to 
the patient. 
Hematopoietic progenitor cell (HPC) products contain hematopoietic stem and lineage-
committed progenitor cells capable of providing hematopoietic and immune reconstitution 
after myeloablative or reduced-intensity preparative regimens. HPCs administered 
intravenously migrate to the marrow, where they adhere, expand, selfrenew (stem cells 
only), and differentiate. The differentiated cells are released into the blood, restoring blood 
counts and immunity. The time from administration of HPCs to recovery of adequate or 
normal blood counts is variable. Recipients of peripheral blood stem cells recover counts 
faster than recipients of bone marrow. Cord blood tends to be the slowest to engraft.  
The minimum number of HPCs necessary for engraftment in a myeloablated recipient has 
not been established. Different products have widely different numbers of progenitors and 
stem cells. However, eligibility criteria for some protocols usually dictate a minimum 
number of cells to be collected and infused.  
Several methods are used to measure the number of cells in an HPC collection. Simple cell 
count may be adequate for many marrow collections. Most centers use flow cytometric 
enumeration of CD34+ cells for the majority of cellular products. The discovery of the CD34 
antigen in the early 1980s revolutionized our understanding of hematopoiesis. Cells 
expressing CD34 are capable of reconstituting hematopoiesis in lethally irradiated animals 
and humans, indicating that the putative hematopoietic stem cell expresses CD34.  
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Fig. 1. Sources of haematopoietic stem cells for different types of transplantation 
This type I transmembrane glycoprotein is expressed on: 
1- 3% of bone marrow mononuclear cells 
0,01- 0,1% of peripheral blood mononuclear cells 
0,1- 0,4% of umbilical cord blood cells 
2. Marrow as a source of stem cells 
Marrow is collected in the day surgery suite using either general or regional anesthesia. 
With proper fluid and blood replacement, overnight hospitalization should not be required. 
For the healthy donor, the risks of serious complications from either general or regional 
anesthesia are about the same. Spinal or epidural anesthesia avoid the nausea that may 
occur with general anesthesia, especially for young women, but hypotension from loss of 
vascular tone in the lower extremities often occurs as the volume of marrow is collected. 
General anesthesia is preferable for the donor with comorbid disorders such as 
cardiovascular or cerebral vascular disease because of the better control of donor airway and 
lower risk of hypotension during the harvest procedures. Local anesthesia is acceptable only 
if a very limited harvest is being performed, as large quantities of lidocaine are cardiotoxic 
and local anesthesia does not achieve anesthesia of the marrow space. The technique of bone 
marrow harvest is straightforward and involves repeated aspirations of small volumes 
(10ml) of marrow. The marrow is removed sterilely from both posterior iliac crests by two 
operators simultaneously to minimize anesthesia time. Occasionally marrow is obtained 
from the anterior iliac crest or sternum.Typically we do two puncture through the skin and 
multiple bone punctures. Do not take more than 25 ml of bone marrow per kilogram of 
donor -  this is the upper limit on the volume of collected bone marrow. The marrow is 
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The cell suspension is passed through sterile filters to remove fat, bone particles, and 
cellular debris [4,5]. For patients with a history of radiation or tumor involvement of one 
pelvic crest, adequate cells can be harvested from the anterior and posterior crests of the 
other side [6-8]. 
2.1 Toxicity and adverse events associated with bone marrow collection 
Anesthesia complications present the major health risk to the donor. Marrow aspiration is 
generally well tolerated. Major complications occur in approximately 0.27% of healthy 
allogeneic donors and up to 0.97% of autologous transplant patients [9-10]. Complications 
include hemorrhage and infections at skin puncture sites. Severe hematomas and neuralgias 
rarely occur, but attention to pelvic anatomy is required to decrease the risk of damage to 
vessels and nerves lying under or adjacent to the iliac crest harvest sites. Irritation of the 
sacral nerves may result from needle penetration through the pelvic bone or from blood 
tracking into the nerve roots and requires several months of convalescence. Localized pain is 
common, may last for several days, and may require a brief period of medication with 
opioid/acetaminophen combinations [4]. In a survey of almost 500 donors for unrelated 
marrow transplantation, the average time for recovery was 15.8 days, although 10% of 
donors required more than 30 days for self-reported complete recovery [11]. Most donors 
are able to return to routine activities 1 to 2 days after harvesting. In a study of related 
donors, an equivalent level of pain was reported by donors undergoing bone marrow 
harvesting and those receiving filgrastim for mobilization of PBSC [12]. Minor complications 
occur in 6-20% of marrow donations [11]. These include such events  as hypotension, 
syncope, severe post-spinal headache, excess pain, unexpected hospitalization and minor  
 
Symptom Women % Men % 
Tired 85 76 
Collection site pain 78 75 
Back pain 67 68 
Nausea 63 40 
Sore throat 62 57 
Pain sitting 62 57 
Lightheadedness 53 42 
Headache 40 32 
Vomiting 39 17 
Intravenous site pain 37 23 
Fever 22 22 
Bandage pain 19 26 
Bleeding at site 10 8 
Fainting 7 5 
Table 1. Symptoms reported by National Marrow Donor Program (NMDP) bone marrow 
donors, 1987-2000 (n=9601) [8]  
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Fig. 1. Sources of haematopoietic stem cells for different types of transplantation 
This type I transmembrane glycoprotein is expressed on: 
1- 3% of bone marrow mononuclear cells 
0,01- 0,1% of peripheral blood mononuclear cells 
0,1- 0,4% of umbilical cord blood cells 
2. Marrow as a source of stem cells 
Marrow is collected in the day surgery suite using either general or regional anesthesia. 
With proper fluid and blood replacement, overnight hospitalization should not be required. 
For the healthy donor, the risks of serious complications from either general or regional 
anesthesia are about the same. Spinal or epidural anesthesia avoid the nausea that may 
occur with general anesthesia, especially for young women, but hypotension from loss of 
vascular tone in the lower extremities often occurs as the volume of marrow is collected. 
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if a very limited harvest is being performed, as large quantities of lidocaine are cardiotoxic 
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marrow harvest is straightforward and involves repeated aspirations of small volumes 
(10ml) of marrow. The marrow is removed sterilely from both posterior iliac crests by two 
operators simultaneously to minimize anesthesia time. Occasionally marrow is obtained 
from the anterior iliac crest or sternum.Typically we do two puncture through the skin and 
multiple bone punctures. Do not take more than 25 ml of bone marrow per kilogram of 
donor -  this is the upper limit on the volume of collected bone marrow. The marrow is 
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infections. In National Marrow Donor Program (NMDP) observation the frequency of 
serious adverse events following marrow donation is estimated at 0,1-0,3%. Reactions to the 
anesthetic agents administrated may be adverse reactions, hypersesitivity or idiosyncratic 
reactions. One NMDP donor experienced laryngospasm following extubation. Additionally, 
several NMDP donors have experienced profound bradycardia during anesthesia, including 
regional anesthesia (spinal and epidural), that required emergency treatment. Death has 
occurred among normal marrow donors. A recent revive of 7857 marrow collections 
reported two deaths [13].  
2.2 Quantity of bone marrow cells for transplantation 
Generally, 10-20ml marrow/kg of donor weight is harvested to achieve a minimum 
mononuclear cell (MNC) count of 2 x 10 to 8 MNC/kg of recipient body weight, although 
ideally up to 4,0 x 10 to 8 MNC/kg is preferred to compensate for cell loss during processing 
and to ensure adequate engraftment. The only setting in which higher numbers of MNC/kg 
definitely have been shown to be of benefit is aplastic anemia, in which low cell counts have 
been associated with an increased risk of rejection. Marrow contains mature red cells, white 
cells, platelets, mast cells, fat cells, plasma cells, committed progenitors of all lineages and 
hematopoietic stem cells. The most common modifications of allogeneic marrow are to 
decrease the volume of ABO-incompatible red cells, remove ABO- incompatible plasma, 
isolate CD34+ cells and remove donor T lymphocytes. The most common modification of 
autologous marrow is to reduce the volume by removing plasma and red cells before 
cryopreservation [4]. 
2.3 “Rich” bone marrow 
Pretreatment of the marrow donor with filgrastim (granulocyte- colony-stimulating factor 
G-CSF) may increase the number of myeloid progenitor cells harvested and decrease the 
period of posttransplant aplasia to that achievable by PBSC transplantation [14]. 
Hematologic recovery in patients who are treated with autologous stem cells taken from 
bone marrow after G-CSF stimulation (rich bone marrow – RBM) is faster than in patients 
without G-CSF. In the Polish study [15] were estimated engraftment outcomes of patients 
who received bone marrow unstimulated or stimulated with G-CSF. The median and range 
for neutrophil engraftment times in this study when they used stimulated bone marrow 
were comparable with those published by Lemoli et al. [16]. It seems that a better method of 
obtaining stem cells from bone marrow is the RBM. Using of stimulated bone marrow can 
faster engraftment comparing to non-stimulated bone marrow and can help patients, who 
fail to collect adequate number of stem cells from their peripheral blood. It is generally 
accepted that RBM engraft more rapidly than unstimulated bone marrow and that RBM 
appear to have similar engraftment times to peripheral blood stem cell transplantations 
suggesting that it is prior G-CSF exposure, not the anatomic site, which influences 
engraftment [14,17,18]. CD34+ cell dose now is being correlated with transplant outcomes, 
with more rapid engraftment kinetics, possibly lower transplant-related mortality, and 
better overall survival, for example, in recipients of allogeneic products containing higher 
quantities of CD34+ cells. Otherwise patients receiving filgrastim- primed bone marrow had 
significantly less steroid-refractory acute graft-vs-host disease (GvHD), less chronic GvHD 
and fewer days of immunosuppressive therapy. Download stimulated bone marrow may 
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favor the acquisition of more hematopoietic cells and facilitate reconstitution after 
myeloablative therapy with no significant increase in risk of GvHD [19].  
 
 PLT> 20 ANC> 0.5 G/L Length of 
hospitalization 
Median time to recovery (RBM) 12,6 days 13,0 days 17,3 
Median time to recovery 
(bone marrow without stimulation  
of G-CSF) 
18,8 days 17,8 days 23,1 
Table 2. Time to recovery of platelets (PLT) and neutrophils (ANC) and length of 
hospitalization when we used bone marrow after stimulation G-CSF and without 
stimulation of G-CSF [15] 
3. Peripheral blood stem cells (PBSC) 
Stem cells were detected in the peripheral blood of mice in 1962 and in human in 1971 [20]. 
However, interest in peripheral blood stem cell transplantation did not develop until mid- 
1980s. During 1985-1986 several centers from different parts of the world reported 
encouraging results of the autologous transplants using hematopoietic progenitor cells 
collected from peripheral blood [21,22]. The first allogeneic transplant with peripheral blood 
progenitor cells was reported in 1989 [23]. Use of PBSC became more common after 1995 
with the publication reports of successful allogeneic transplants with PBSC [24-26]. By 
stimulating the donor with either hematopoietic growth factors, or chemotherapy and 
growth factors, a sufficient number of circulating stem cells for marrow rescue can be 
collected in one to three apheresis procedures. Mobilized PBSC products are routinely used 
as an alternative source of HSCs for transplantation [27,28]. A PBSC collection is performed 
with a cell separation device originally developed for therapeutic leukapheresis, 
plasmapheresis and platelet donation procedures. This apheresis device uses a centrifuge to 
separate and collect mononuclear cells, including HSCs, from the blood. In order to achieve 
an adequate HSCs for transplantation it is necessary to process 12 to 25 liters of blood or 2.5 
to 6.0 times the patient’s/ healthy donor’s calculated blood volume. Investigators have 
reported that the yield of CD34+ cells increases continuously as more blood volumes are 
processed. Although up to six times the donor’s blood volume can be safety processed, 
some donors are not able to tolerate 4 or 6 hours being connected to an apheresis machine. 
Therefore, these donors require repeated collections on sequential days once the peripheral 
CD34+ count has increased to acceptable levels (>10 CD34+ cells/µl) for collection. There 
are currently three different commercially available apheresis instruments. In each case, 
instrument settings such as inlet flow rate, centrifuge speed, collect pump flow rate and 
anticoagulant: whole blood ratio vary, depending on the target cell type to be collected. The 
three instruments operate differently. The Amicus (Baxter) and the COM.TEC (Fresenius) 
are more automated, computer-controlled instruments; however, the Spectra is more widely 
used [1,29]. Because an apheresis procedure is used to collect PBSC products, they contain 
very few erythrocytes or granulocytes, compared to marrow, and are primarily composed of 
mononuclear cells (MNCs). PBSC products also contain larger numbers of HPCs than either 
marrow or cord blood, and therefore facilitate faster engraftment and shorter hospital stays. 
 
New Advances in Stem Cell Transplantation 202 
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Patients who have been heavily pretreated with multiple rounds of chemotherapy or 
radiation therapy often mobilize poorly and require multiple collection episodes [30].  
Although the peripheral blood of healthy individuals contains fewer than 0,1% HSCs, this 
number increases dramatically during recovery from cytotoxic therapy and even more so 
more so then recombinant CSFs such as G-CSF are administered. Various mobilizing 
techniques are used by centers and generally consist of growth factor administration alone 
or in combination with various types of chemotherapy. G-CSF and high-dose 
cyclophosphamide (CY) are the most commonly used agents [28, 31-33]. Currently, almost 
all of autologous and a majority of allogeneic transplants are performed with PBSC. 
Advantages of PBSC over bone marrow include [21,34]: 
 Elimination of the need of general anesthesia, pain and other side effects of bone 
marrow aspiration. 
 Patients with bone marrow metastases could be transplanted with autologous PBSC as 
there is a potential for tumor cell free collection. 
 The hematological recovery with PBSC was faster than bone marrow significantly 
reducing the time to transfusion independence. 
PBSC products contain larger numbers of T cells than marrow collections, and thus present 
a greater risk of causing graft-versus-host disease (GvHD) in the allogeneic setting, although 
the rate of acute GvHD is less than originally feared [35-39]. In a prospective randomized 
study comparing PBSC donation with bone marrow, PBSC products contained double the 
number of CD34+ cells, eight fold more of T and NK cells than bone marrow collection. The 
advantages to the recipient were faster recovery of both neutrophil and platelets with PBSC 
compared to marrow without increasing risk of graft-vs-host disease. Another multi-center 
study also reported faster neutrophil and platelet recovery but significantly more frequent 
acute and chronic GvHD in PBSC recipients than recipients of bone marrow cells. There 
were no significant differences in transplant related mortality, relapse rate and overall 
survival were found [40-42].  
3.1 Mobilization regimens 
Recent advances in stem cell mobilization techniques have exploited the interactions 
between stem cells and the bone marrow microenvironment. Composed of stromal cells, 
endothelial cells, osteoblasts and other matrix components (collagens, fibronectins, 
proteoglycans), the bone marrow microenvironment anchors hematopoietic stem cells 
though a wide range of adhesive interactions [43]. Hematopoietic stem cells express a broad 
array of cell surface receptors, namely the adhesion molecules lymphocyte function-
associated Ag-1, very late Ag-4, and Mac-1; the chemokine receptors CXCR4 and CXCR2; 
the cell surface glycoproteins CD44 and CD62L; and the tyrosine kinase receptor c-kit [43-
45]. The bone marrow stroma contains stromal cell-derived factor-1 (SDF-1), CXC 
chemokine GRO-β, vascular cell adhesion molecule-1, kit-ligand, P-selectin glycoprotein 
ligand-1 and hyaluronic acid, all of which are cognate ligands for the stem cell adhesion 
molecules [43-45]. Data from a number of preclinical models showed that inhibition of these 
receptor-ligand interactions resulted in enhanced progenitor cell mobilization [46-48]. 
Several exogenous hematopoietic cytokines that can mobilize hematopoietic progenitor cells 
into circulation are now available. Granulocyte colony stimulating factor (G-CSF) 
(filgrastim, lenograstim, pegfilgrastim) and granulocyte macrophage colony stimulating 
factor (GM-CSF) (sargramostim) are most commonly used for mobilization. They are used  
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 G-CSF GM-CSF Erythropoietin Plerixafor 
Adhesion factors  
Additive effects 





additive when used 
in combination with 
G-CSF or GM-CSF 
 
CXCR4       or  
No effect  
or  
SDF-1   
MMPs   
Neutrophil elastase   
MMP- matrix metalloproteinase; SDF-1: stromal-derived factor 1α 
Table 3. Factors using for mobilization- mechanism of action [31] 
alone to mobilize hematopoietic stem cells into circulation in healthy donors for allogeneic 
transplantation and in patients who are in complete remission or in heavily pretreated ones 
for autologous transplantation. Approximately 4 days after the daily administration of G-
CSF at a dose of 8-20 mcg/kg body weight, there is an increase in the number of CD34+ cells 
in the blood of patients and healthy stem cell donors. With this method, the progenitor cell 
peak is reached between days 5 and 6 [49]. The extent of mobilization is determined by the 
age of the patient, the diagnosis, the earlier cytotoxic therapy, the dose of G-CSF and the 
sequence of G-CSF administration [50]. Kroger et al [51] showed that mobilization was more 
effective if the total dose of G-CSF was divided into two equal fractions and given in the 
morning and in the evening rather than as a single dose once daily. G-CSF administered 
every 12 h at doses of 5 µg/kg provides better CD34+ cell yield than 10 µg/kg once a day in 
normal donors which may translate into a decrease in the number of apheresis required to 
obtain enough numbers of CD34+ cells for allogeneic PBSC transplant.  
3.2 Which growth factor should we choose? 
Filgrastim is commonly used to mobilize peripheral blood stem cells. Pegylation of 
filgrastim (pegfilgrastim) leads to prolongation of its half- life without loss of activity. 
Attachment of the polyethylene glycol (PEG) moiety reduces renal excretion and masks 
proteolytic cleavage sites resulting in elevated G-CSF serum levels for up to 14 days after a 
single injection. While filgrastim is also cleared by the kidneys, pegfilgrastim is mainly 
eliminated via a neutrophil-mediated clearance mechanism [52-54]. The initial results of 
using pegfilgrastim obtained in limited numbers of patients with solid tumours showed that 
pegylated G-CSF was principally capable of mobilizing haematopoietic progenitor cells [54]. 
In 2001 and 2003, two studies were designed for the treatment of myeloma patients. The 
treatment regimens were comparable and employed DT-PACE [55,56] as mobilization 
chemotherapy. In the first study patients received twice a day filgrastim, until completion of 
stem cell collection; in the second study two doses of pegfilgrastim were administered after 
DT-PACE. After a cycle of DT-PACE, pegfilgrastim 6 mg was given subcutaneously on days 
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morning and in the evening rather than as a single dose once daily. G-CSF administered 
every 12 h at doses of 5 µg/kg provides better CD34+ cell yield than 10 µg/kg once a day in 
normal donors which may translate into a decrease in the number of apheresis required to 
obtain enough numbers of CD34+ cells for allogeneic PBSC transplant.  
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Attachment of the polyethylene glycol (PEG) moiety reduces renal excretion and masks 
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+6 and +13. If the WBC count > 100 G/l by day +13 the second dose of pegfilgrastim was 
not administered. Investigators found some advantages when pegfilgrastim was used: 
 A higher percentage of patients collected 15 x 10^6/kg in the first three days (p < 0.001) 
 The median number of CD34 cells/kg collected on day 1 was higher (p= 0.004) 
 The median number of growth factor injections was 2 versus 26 (p < 0.0001) 
 Post- transplantation neutrophil recovery was faster after first and second transplant (p 
< 0.001) 
 Platelet recovery was faster after first transplant (when less stem cells were infused) (p 
= 0.01) 
 Authors concluded, that pegfilgrastim may be considered the standard of care for stem 
cell mobilization. 
Kobbe et al. [54] found that in patients with multiple myeloma, a single dose of 6 mg 
pegfilgrastim after cyclophosphamide (4g/m^2) is equally effective in terms of the 
mobilization of haematopoietic progenitor cells as daily administration of conventional G-
CSF. There is no increase in this effect if the dose is doubled to 12 mg. This finding is 
consistent with the results of a recently published, blinded, placebo- controlled multicenter 
study conducted in patients with malignant lymphomas [57]. These results were also 
confirmed by other groups of investigators [58,59]. There are no studies on the use of 
pegfilgrastim to mobilize haematopoietic stem cells in patients with acute leukemia. 
Pegylated G-CSF has not also been studied in the so-called “poor mobilizers”.  
Two formulations of recombinant human (rh) G-CSF, one glycosylated form and one non-
glycosylated, are available. The glycosylated form, lenograstim, possesses at least 25% 
greater bioactivity in vitro. Some comparative studies into the preparation’s potential to 
mobilize haematopoietic stem cells were performed to assess the potential greater efficacy of 
lenograstim in vivo. Ataergin S et al. [60] investigated whether a 25% reduced dose of 
lenograstim at 7.5 µg/kg/day is equivalent  to 10 µg/kg/day filgrastim for autologous 
peripheral blood stem cell mobilization and transplantation. The two evaluated patients’ 
cohorts were similar in regard to disease, sex, body, weight, body surface area, conditioning 
regimens, previous chemotherapy cycles and radiotherapy. Each growth factor was 
administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In 
the posttransplant period, the same G-CSF was given at 5 µg/kg/day until leukocyte 
engraftment. No significant difference was seen in the median number of CD34+ cells 
mobilized, as well as the median number of apheresis, median volume of apheresis, 
percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, 
the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions 
were similar in both groups in the posttransplant period. In conclusion, lenograstim 7.5 
µg/kg/day is as efficious as filgrastim 10 µg/kg/day for autologous PBSC mobilization and 
transplantation. 
Another study [61] explored the efficacy of the IGEV regimen (ifosfamide, gemcytabine, 
vinorebline and prednisone) combined with a fixed dose of lenograstim (263 µg/day) to 
mobilize PBSCs in 90 Hodgkin’s lymphoma patients. An adequate number of CD34+ cells (> 
3 x 10^6/kg) were collected in 98,7% mobilized patients. Hematological and non-
hematological side effects were acceptable, and no toxic deaths occurred. These results 
confirm that the IGEV regimen with lenograstim support can be used successfully and 
safely to mobilize PBSCs.  
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Kopf B et al.[62], in 2006 conducted a prospective randomized clinical trial to assess the 
mobilizing efficacy of filgrastim, lenograstim and molgramostim (GM-CSF) following a 
disease-specific chemotherapy regimen. In conclusion, all three growth factors were 
efficacious in mobilizing peripheral blood progenitor cells with no statistically significant 
difference between CD34+ cell yield and the different regimens, and the time to apheresis is 
likely confounded by the different mobilization regimens. An advantage on platelet 
recovery with molgramostim, suggested by other authors [63,64] was not confirmed by 
results of this study. 
3.3 G-CSF in conjunction with chemotherapy 
Growth factor combined with chemotherapy are given for patients, who are candidates to 
autologous transplantation and need additional treatment as debulking therapy or to 
achieve complete/ partial remission before transplantation [65]. A variety of 
chemotherapeutic agents are used with G-CSF or GM-CSF to mobilize hematopoietic stem 
cells for autologous transplantation. Administration of CY with G-CSF is widespread, as this 
regimen mobilizes hematopoietic stem cells effectively and is highly active against tumor 
cells [65]. Successful chemomobilization regimens used in combination with G-CSF are often 
disease oriented. Some of the most frequently used chemotherapeutic regimens in 
lymphoma patients include IEV (ifosfamide, epirubicin and etoposide), DHAP and ESHAP 
(etoposide, Ara-C, methylprednisolone and cisplatin) [66,67]. Patients with other 
hematologic malignancies are frequently treated with ICE (ifosfamide, carboplatin and 
etoposide) plus G-CSF for mobilization [68].  
Chemomobilization is widely used in clinical practice because the addition of a 
myelosuppressive chemotherapy agent to a cytokine mobilization regimen results in higher 
CD34+ cell yields, which may promise better outcomes for patients. In particular, 
mobilization with CY and G-CSF rather than with G-CSF alone improves CD34+ cell 
collection significantly in patients with either MM [69,70]  or NHL [71,72]. However, it has 
been noted that the use of CY plus G-CSF severely depletes T cells and spares regulatory T 
cells, which could negatively affect immune reconstitution [73]. The benefits of adding 
chemotherapeutic agents to a G-CSF mobilization regimen may be offset by the increased 
risk of complications to the patients. Compared with mobilization regimens using G-CSF 
alone, chemomobilization is associated with increased morbidity, greater risk of infection, 
more hospital admissions, transfusions, antibiotic therapy and considerably greater cost 
overall. [28]. Although treatment-related mortality is rare, significant morbidity related to 
neutropenia that can often require hospitalization has been described, and many reports 
point to greater resource utilization with chemomobilization than with cytokine-alone 
mobilization [28]. 
Koumakis et al [74] compared various time schedules of granulocyte colony-stimulating 
factor (G-CSF) treatment in a clinical model of patients who received high-dose 
cyclophosphamide (4.5 g/m^2). They found, that: 
 G-CSF administration after high-dose cyclophosphamide has a similar effect upon the 
incidence and duration of severe leukopenia and thrombocytopenia 
 Severe leukopenia is shorter when G-CSF starts up to 72 hours after high-dose of 
cyclophosphamide 
 The length of G-CSF administration and its cost is also in favor of early initiation of 
treatment as well as the number of febrile days and antibiotic use 
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+6 and +13. If the WBC count > 100 G/l by day +13 the second dose of pegfilgrastim was 
not administered. Investigators found some advantages when pegfilgrastim was used: 
 A higher percentage of patients collected 15 x 10^6/kg in the first three days (p < 0.001) 
 The median number of CD34 cells/kg collected on day 1 was higher (p= 0.004) 
 The median number of growth factor injections was 2 versus 26 (p < 0.0001) 
 Post- transplantation neutrophil recovery was faster after first and second transplant (p 
< 0.001) 
 Platelet recovery was faster after first transplant (when less stem cells were infused) (p 
= 0.01) 
 Authors concluded, that pegfilgrastim may be considered the standard of care for stem 
cell mobilization. 
Kobbe et al. [54] found that in patients with multiple myeloma, a single dose of 6 mg 
pegfilgrastim after cyclophosphamide (4g/m^2) is equally effective in terms of the 
mobilization of haematopoietic progenitor cells as daily administration of conventional G-
CSF. There is no increase in this effect if the dose is doubled to 12 mg. This finding is 
consistent with the results of a recently published, blinded, placebo- controlled multicenter 
study conducted in patients with malignant lymphomas [57]. These results were also 
confirmed by other groups of investigators [58,59]. There are no studies on the use of 
pegfilgrastim to mobilize haematopoietic stem cells in patients with acute leukemia. 
Pegylated G-CSF has not also been studied in the so-called “poor mobilizers”.  
Two formulations of recombinant human (rh) G-CSF, one glycosylated form and one non-
glycosylated, are available. The glycosylated form, lenograstim, possesses at least 25% 
greater bioactivity in vitro. Some comparative studies into the preparation’s potential to 
mobilize haematopoietic stem cells were performed to assess the potential greater efficacy of 
lenograstim in vivo. Ataergin S et al. [60] investigated whether a 25% reduced dose of 
lenograstim at 7.5 µg/kg/day is equivalent  to 10 µg/kg/day filgrastim for autologous 
peripheral blood stem cell mobilization and transplantation. The two evaluated patients’ 
cohorts were similar in regard to disease, sex, body, weight, body surface area, conditioning 
regimens, previous chemotherapy cycles and radiotherapy. Each growth factor was 
administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In 
the posttransplant period, the same G-CSF was given at 5 µg/kg/day until leukocyte 
engraftment. No significant difference was seen in the median number of CD34+ cells 
mobilized, as well as the median number of apheresis, median volume of apheresis, 
percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, 
the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions 
were similar in both groups in the posttransplant period. In conclusion, lenograstim 7.5 
µg/kg/day is as efficious as filgrastim 10 µg/kg/day for autologous PBSC mobilization and 
transplantation. 
Another study [61] explored the efficacy of the IGEV regimen (ifosfamide, gemcytabine, 
vinorebline and prednisone) combined with a fixed dose of lenograstim (263 µg/day) to 
mobilize PBSCs in 90 Hodgkin’s lymphoma patients. An adequate number of CD34+ cells (> 
3 x 10^6/kg) were collected in 98,7% mobilized patients. Hematological and non-
hematological side effects were acceptable, and no toxic deaths occurred. These results 
confirm that the IGEV regimen with lenograstim support can be used successfully and 
safely to mobilize PBSCs.  
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efficacious in mobilizing peripheral blood progenitor cells with no statistically significant 
difference between CD34+ cell yield and the different regimens, and the time to apheresis is 
likely confounded by the different mobilization regimens. An advantage on platelet 
recovery with molgramostim, suggested by other authors [63,64] was not confirmed by 
results of this study. 
3.3 G-CSF in conjunction with chemotherapy 
Growth factor combined with chemotherapy are given for patients, who are candidates to 
autologous transplantation and need additional treatment as debulking therapy or to 
achieve complete/ partial remission before transplantation [65]. A variety of 
chemotherapeutic agents are used with G-CSF or GM-CSF to mobilize hematopoietic stem 
cells for autologous transplantation. Administration of CY with G-CSF is widespread, as this 
regimen mobilizes hematopoietic stem cells effectively and is highly active against tumor 
cells [65]. Successful chemomobilization regimens used in combination with G-CSF are often 
disease oriented. Some of the most frequently used chemotherapeutic regimens in 
lymphoma patients include IEV (ifosfamide, epirubicin and etoposide), DHAP and ESHAP 
(etoposide, Ara-C, methylprednisolone and cisplatin) [66,67]. Patients with other 
hematologic malignancies are frequently treated with ICE (ifosfamide, carboplatin and 
etoposide) plus G-CSF for mobilization [68].  
Chemomobilization is widely used in clinical practice because the addition of a 
myelosuppressive chemotherapy agent to a cytokine mobilization regimen results in higher 
CD34+ cell yields, which may promise better outcomes for patients. In particular, 
mobilization with CY and G-CSF rather than with G-CSF alone improves CD34+ cell 
collection significantly in patients with either MM [69,70]  or NHL [71,72]. However, it has 
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chemotherapeutic agents to a G-CSF mobilization regimen may be offset by the increased 
risk of complications to the patients. Compared with mobilization regimens using G-CSF 
alone, chemomobilization is associated with increased morbidity, greater risk of infection, 
more hospital admissions, transfusions, antibiotic therapy and considerably greater cost 
overall. [28]. Although treatment-related mortality is rare, significant morbidity related to 
neutropenia that can often require hospitalization has been described, and many reports 
point to greater resource utilization with chemomobilization than with cytokine-alone 
mobilization [28]. 
Koumakis et al [74] compared various time schedules of granulocyte colony-stimulating 
factor (G-CSF) treatment in a clinical model of patients who received high-dose 
cyclophosphamide (4.5 g/m^2). They found, that: 
 G-CSF administration after high-dose cyclophosphamide has a similar effect upon the 
incidence and duration of severe leukopenia and thrombocytopenia 
 Severe leukopenia is shorter when G-CSF starts up to 72 hours after high-dose of 
cyclophosphamide 
 The length of G-CSF administration and its cost is also in favor of early initiation of 
treatment as well as the number of febrile days and antibiotic use 
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 Delayed (> 72 hours) or supportive treatment indicate more febrile days, antibiotic use 
and higher cost when compared to the early groups 
For these reasons, preemptive rather than therapeutic administration of G-CSF is indicated 
in patients who receive high-dose cyclophosphamide as treatment for mobilization CD34+ 
cells into peripheral blood.  
3.4 Toxicity of growth factors 
Cytokine-mobilized PBSC collected from healthy sibling or unrelated donors are 
increasingly used as stem-cell source in the allogeneic setting. PBSCs have been shown to be 
superior to BM-derived stem cells during the early posttransplant course. The high CD34+ 
cell yield in PBSC grafts significantly shortens the posttransplant aplasia and the need for 
blood component support, especially platelets [40,41]. Both cytokine administration and 
harvest procedure cause unphysiological conditions in healthy individuals. The effects of 
rhG-CSF on peripheral blood count and leukocyte function, cytokine release and response, 
coagulation parameters and metabolic changes have been reviewed by Anderlini et al 
[75,76]. Limited data exist on the late effects of cytokine mobilization and PBSC collection. 
Until now, there is no convincing evidence that rhG-CSF administration leads to an 
increased risk to develop hematological malignancies in healthy individuals [77]. Leitner GC 
et al [78] investigated the actual quality of life (QoL) and health status of the donors as well 
as the need for medical treatment since PBSC donation by a questionnaire (151 donors were 
evaluated). The questionnaire was sent to donors at a median of 4 (range: 0.2-11) years after 
donation. rhG-CSF mobilization as well as subsequent PBSC collection is shown to be well 
tolerated in the short- and long-term profiles in these sibling donors. It had no negative 
influence on health status and QoL in the majority of them. Investigators observed no 
increased risk for hematological or oncological disorders. However, to acquire profound 
knowledge about rhG-CSF- and donation-related long term risks, consecutive monitoring of 
more donors for at least 10 years has to be performed. Hasenclever and Sextro [79] stated 
that to exclude or to show a 10-fold increase in the 10-year cancer incidence, a long-term 
prospective follow-up of several thousand donors for at least 10 years would be necessary. 
In 2009 the report from European Group for Blood and Marrow Transplantation Group was 
published [80]. Three hundred and thirty-eight allogeneic transplant teams from 35 
European countries were asked to report numbers of fatalities, severe adverse events and 
hematologic malignancies occurring among their hematopoietic stem cell donors. 51024 first 
allogeneic hematopoietic stem cell transplantations were evaluated, of which 27770 were 
bone marrow and 23254 peripheral blood. They observed five donor fatalities, one after a 
bone marrow donation and four after peripheral blood donation (incidence 0.98 per 10000 
donations; 95% CI 0.32-2.29), 37 severe adverse events (7.25/10000; 95% CI 5.11-9.99), of 
which 12 in bone marrow donors (4,32/10000; 95% CI 2.24-7.75) and 25 in peripheral blood 
donors (10.76/10000; 95% CI 6.97-15.85; p< 0.05) and 20 hematologic ,malignancies 
(3.92/10000; 95% CI 2.39-6.05), of which 8 after donating bone marrow and 12 after donating 
peripheral blood stem cells. The observed incidence rate of hematologic malignancies did 
not exceed the expected incidence in an age- and sex-adjusted general population. Authors 
concluded, that hematopoietic stem cell donation is associated with a small but define risk 
of fatalities and serious adverse events. True incidences might be higher, due to potential 
underreporting by study design. A continuous, standardized donor follow-up is needed to 
define donor risk groups and to monitor intermediate and long-term sequelae.  
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Healthy donors who were mobilized using lenograstim and who were undergoing 
peripheral hematopoietic cell collection with apheresis were enrolled in a surveillance 
protocol. The study was conducted by Martino et al [81]. The median dose of lenograstim 
was 10 µg/kg (range 5-15). 184 healthy donors have been assessed with a median follow-up 
of 62 months (range 2-155). The short-term adverse events: 
 Bone pain     71,2% 
 Headache    27,7% 
 Insomnia    22,3% 
 Fatigue    19,0% 
 Nausea    12,0% 
 Fever    5,4% 
 Increased spleen size   4,3% 
No vascular disorders, no cardiac disease 
Long-term follow-up included monitoring of adverse events, neoplastic disease or other 
pathologies: 
 
Type of adverse event Number of donors suffered 
from 
Time of occurrence after 
donation [months] 
Transit ischaemic attack 1 39 
Ankylosing spondylitis 1 28 
Secondary polyglobulia 1 50 
Lung cancer 1 19 
No haematological disease was observed 
 
During hematopoietic stem cell mobilization in healthy donors, slight thrombocytopenia is 
common and is attributed to the leukapheresis procedure or to splenomegaly. The platelet 
depletion is a recognized effect of continuous flow leukapheresis, particularly large-volume 
leukapheresis [75].  
About one-third of neutropenic patients chronically treated with rh-G-CSF develop 
palpable splenomegaly and there have been reports of spontaneous spleen rupture in 
rhG-CSF or cyclophosphamide plus rh G-CSF- mobilized individuals or even in patients 
treated with rhG-CSF  or rhGM-CSF after chemotherapy for acute leukemia or lymphoma. 
Few data are available on changes in spleen size as a result of a brief course of rhG-CSF 
[82]. Picardi et al. evaluated spleen size, comparing palpation with ultrasound (US)-
evaluated longitudinal diameter and volume, in 13 healthy donors and 22 patients with a 
hematological malignancy who were undergoing PBSC mobilization with rhG-CSF-
including regimens. When evaluated by sensitive methods, rhG-CSF caused spleen 
enlargement in almost all individuals treated. US-calculated volume proved to be an 
excellent method, much better than longitudinal diameter, for detecting non-palpable 
splenomegaly induced by rhG-CSF [83].  
G-CSF has been also discussed as the causative agent for the occurrence of [84-94]: 
 Sweet syndrome 
 Leukocytoclastic vasculitis 
 Interstitial pneumonitis 
 Adult respiratory distress syndrome (ARDS) 
 Pyoderma gangraenosum 
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 Delayed (> 72 hours) or supportive treatment indicate more febrile days, antibiotic use 
and higher cost when compared to the early groups 
For these reasons, preemptive rather than therapeutic administration of G-CSF is indicated 
in patients who receive high-dose cyclophosphamide as treatment for mobilization CD34+ 
cells into peripheral blood.  
3.4 Toxicity of growth factors 
Cytokine-mobilized PBSC collected from healthy sibling or unrelated donors are 
increasingly used as stem-cell source in the allogeneic setting. PBSCs have been shown to be 
superior to BM-derived stem cells during the early posttransplant course. The high CD34+ 
cell yield in PBSC grafts significantly shortens the posttransplant aplasia and the need for 
blood component support, especially platelets [40,41]. Both cytokine administration and 
harvest procedure cause unphysiological conditions in healthy individuals. The effects of 
rhG-CSF on peripheral blood count and leukocyte function, cytokine release and response, 
coagulation parameters and metabolic changes have been reviewed by Anderlini et al 
[75,76]. Limited data exist on the late effects of cytokine mobilization and PBSC collection. 
Until now, there is no convincing evidence that rhG-CSF administration leads to an 
increased risk to develop hematological malignancies in healthy individuals [77]. Leitner GC 
et al [78] investigated the actual quality of life (QoL) and health status of the donors as well 
as the need for medical treatment since PBSC donation by a questionnaire (151 donors were 
evaluated). The questionnaire was sent to donors at a median of 4 (range: 0.2-11) years after 
donation. rhG-CSF mobilization as well as subsequent PBSC collection is shown to be well 
tolerated in the short- and long-term profiles in these sibling donors. It had no negative 
influence on health status and QoL in the majority of them. Investigators observed no 
increased risk for hematological or oncological disorders. However, to acquire profound 
knowledge about rhG-CSF- and donation-related long term risks, consecutive monitoring of 
more donors for at least 10 years has to be performed. Hasenclever and Sextro [79] stated 
that to exclude or to show a 10-fold increase in the 10-year cancer incidence, a long-term 
prospective follow-up of several thousand donors for at least 10 years would be necessary. 
In 2009 the report from European Group for Blood and Marrow Transplantation Group was 
published [80]. Three hundred and thirty-eight allogeneic transplant teams from 35 
European countries were asked to report numbers of fatalities, severe adverse events and 
hematologic malignancies occurring among their hematopoietic stem cell donors. 51024 first 
allogeneic hematopoietic stem cell transplantations were evaluated, of which 27770 were 
bone marrow and 23254 peripheral blood. They observed five donor fatalities, one after a 
bone marrow donation and four after peripheral blood donation (incidence 0.98 per 10000 
donations; 95% CI 0.32-2.29), 37 severe adverse events (7.25/10000; 95% CI 5.11-9.99), of 
which 12 in bone marrow donors (4,32/10000; 95% CI 2.24-7.75) and 25 in peripheral blood 
donors (10.76/10000; 95% CI 6.97-15.85; p< 0.05) and 20 hematologic ,malignancies 
(3.92/10000; 95% CI 2.39-6.05), of which 8 after donating bone marrow and 12 after donating 
peripheral blood stem cells. The observed incidence rate of hematologic malignancies did 
not exceed the expected incidence in an age- and sex-adjusted general population. Authors 
concluded, that hematopoietic stem cell donation is associated with a small but define risk 
of fatalities and serious adverse events. True incidences might be higher, due to potential 
underreporting by study design. A continuous, standardized donor follow-up is needed to 
define donor risk groups and to monitor intermediate and long-term sequelae.  
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 Capillary leakage 
 Stroke 
 Acute gouty arthritis 
 Iritis 
 Severe anaphylactoid reactions 
 Non-traumatic rupture of the spleen 
 Severe pyogenic infection (painful perianal abscess and apical abscess) 
3.5 How can we predict the optimal time for adequate collection of peripheral blood 
progenitor cells after chemotherapy ? 
The absolute number of circulating Cd34+ cells was found to correlate closely with the 
CD34+ cell yield of the corresponding leucapheresis product. The number of CD34+ cells 
circulating in the peripheral blood reliably predicts both: 
 The number of CD34+ cells 
 The number of CFU-GM harvested 
By monitoring the level of circulating CD34+ cells during the mobilization period, generally 
starting at about day 9 or 10, the day to perform the leucapheresis can be planned. The 
optimal time for collecting PBSC is when a peripheral blood sample contains at least 20 x 
10^3 circulating CD34 cells/ml. This value provided at least 2 x 120^6 CD34+ cells/kg in a 
single leucapheresis, harvested the following day, in 94% of the collections regardless of the 
patient’s diagnosis or mobilization regimen [95]. In Hill’s study [96] a total of 168 adult 
patients with haematological malignancy were primed using low-moderate dose 
cyclophosphamide (1.5-3 g/m^2) with G-CSF 5-10 µg/kg per day. Harvesting was booked 
and peripheral blood counts first checked between 6 and 10 days post-priming. The 
peripheral blood CD34+ cell count correlated significantly with harvest yield (r= 0.8448, p< 
0.0001). A peripheral blood CD34+ count ≥ 10/ µl predicted  a collection of ≥ 2 x 10^6/kg 
(positive-predictive value of 61%, negative-predictive value 100%). There was no benefit to 
checking the peripheral blood CD34+ count or booking apheresis before day 9 post- 
cyclophosphamide. 
3.6 What is the minimal CD34+ cells threshold collected from peripheral blood for 
sufficient engraftment? 
What is the optimal CD34+ cells number for transplantation? 
Gandhi et al.[97] advocated a minimum CD34+ threshold of > 1.0 x 10^6/kg in patients 
without extensive prior chemoradiotherapy, and ≥ 2.0 x 10^6/kg in all other patients. In this 
study all patients infused with grafts containing CD34+ cell doses between 1.0 and 2.0  x 
10^6/kg engrafted by day 51. The only variable associated with slow platelet recovery was 
exposure to stem cell toxins (BCNU, melphalan, CCNU and mustine). The majority of 
patients with CD34+ > 1.0 x 10^6/kg achieved rapid and sustained engraftment and the 
only predictive factor of delayed recovery is prior exposure to stem cell toxins.  
Villalon et al. [98] analyzed the factors affecting mobilization and engraftment in autologous 
peripheral blood progenitor cell transplantation according to the number of CD34+ re-
infused ( < 2.0 x 10^6/kg CD34+ vs > 2.0 x 10^6/kg CD34+). They found that,: 
 Neutrophil and platelet engraftment was significantly longer with < 2.0 x 10^6/kg (12 
vs 10 days, p = 0.014 and 16 vs 13 days, p = 0.0001 respectively) 
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 Platelet recovery was affected by exposure to alkylating agents (p = 0.04), refractory 
disease (p= 0.02), and AML (p= 0.0001), but only the last two variables remained 
significant in Cox regression (p < 0.01) 
 Granulocyte engraftment was longer in CML (univariate, p = 0.04) and in refractory 
disease (multivariate, p= 0.02) 
 In patients re-infused with > 2.0 x 10^6/CD34+/kg, the Cox model did not identify 
prognostic factors for haematopoietic recovery 
They concluded, that although mobilization schedules and disease status influenced not 
only the yield of progenitor cells, but also the engraftment kinetics, the number of CD34+ re-
infused was the main predictor of hematopoietic recovery. While engraftment succeeded in 
most of the cases, the re-infusion of > 2.0 x 10^6/kg resulted in significantly shorter 
recovery times. Thus, for autologous stem cell transplantation, it is common practice to 
infuse at least 2.0 x 10^6/CD34+/kg to ensure rapid engraftment. But investigators [99-102] 
found, that when comparing patients receiving at least 5 x 10^6/kg and 2-5 x 10^6/kg 
CD34+ cells there are: 
 A significant reduction in the median number of days with fever 
 Incidence of fever 
 Duration of antibiotic treatment 
 Faster neutrophil recovery 
There was no significant difference in the number of platelet or red cell transfusions 
Thus, transplantations with stem cell dose of at least 5.0 x 10^6/kg reduce infectious 
complications and should thereby increase the safety of this type of therapy while reducing 
duration (and cost) of antibiotic therapy. 
In Bolwell study [103] investigators checked whether patients collecting high numbers of 
CD34+ cells (“super mobilizers”) have a better outcome than other patients. Super 
mobilizers were defined as collecting a minimum of 8.0 x 10^6/CD34+/kg. In this study 
super mobilizers were younger and more likely to have received two or fewer prior 
chemotherapy regimens. Median CD34+ cell dose for the super mobilizing group was 13.7 x 
10^6 CD34+/kg versus 4.4 x 10^6 CD34+/kg in the standard collecting group. The super 
mobilizer group had a superior overall survival (p = 0.006). In multivariable analysis, 
favorable disease status and younger age at transplant, and super mobilization were 
associated with improved survival. 
It is reasonable to believe that the CD34+ cell dose has a positive influence on engraftment 
and survival. But, when compared with BM, PBSC grafts contain significantly more 
nucleated cells, more CD34+ hematopoietic stem cells, and more CD3+ lymphocytes 
[104,105]. It has been shown that granulocyte colony-stimulating factor (G-CSF)-mobilized 
CD34+ hematopoietic stem cells not only participate in engraftment, but also have an 
immunogenic role [106-108]. In the setting of T-cell-depleted allogeneic transplants using 
CD34+ positive selection as T-cell-depletion method, Urbano- Ispizua et al [109] could show 
that a high CD34+ cell dose not only does not improve the clinical results, but also actually 
may be associated with a poorer outcome. There is the suggestion, that transplantation with 
a higher CD34+ cell dose was detrimental in terms of chronic GvHD in allogeneic CD34+ 
cell-selected peripheral blood stem cell transplantation. Moreover, this association may also 
exist in the context of allogeneic unmanipulated PBSCT where a higher T-cell content or 
extremely high dose of CD34+ cells can be involved. It should be noted that CD34+ cells not 
only participate in engraftment, but also have an immunogenic role. However, although 
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 Capillary leakage 
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cyclophosphamide. 
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 Platelet recovery was affected by exposure to alkylating agents (p = 0.04), refractory 
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cGvHD is a leading cause of late mortality in allogeneic settings, it also plays a positive role 
in preventing relapse, especially in advanced hematological malignancies with a high risk of 
relapse [110]. Sohn et al [111] investigated the impact of the CD34+ cell dose on chronic 
graft-versus-host disease and the clinical outcome in adult patients submitted to allogeneic 
peripheral blood stem cell transplantation from HLA-identical siblings. The patients were 
classified into “low” or “high” CD34+ cell dose groups based on whether they received less 
or more than a median CD34+ cell dose of 10.5 x 10^6/kg, respectively. There was a 
significant difference in the incidence of extensive cGvHD and relapse between the two 
groups. With a median follow up of 335 days, the 3-year survival estimate for whole 
population was 47.9%, while that for the low and high groups was 29.9 and 67.8% 
respectively (p = 0.0434). An inverse relation was noted between the relapse rate and the 
incidence of extensive cGvHD (p = 0.043). Authors concluded, that is would appear 
reasonable that the optimal dose of CD34+ cells should be determined based on the disease 
status or aggressiveness of the malignant cells in each patient. Thus, in the case of patients 
with a high risk of relapse, transplantation with a CD34+ cell dose > 10.5 x 10^6/kg would 
seem to be acceptable to minimize the risk of relapse. Mohty et al [110], Sohn et al [111] 
investigated whether there was a correlation between the composition of PBSC grafts 
(CD34+ and CD3+ cells) and hematological recovery, GvHD, relapse and relapse-free 
survival after myeloablative HLA-identical sibling PBSCT. Neither hematological recovery, 
acute or chronic GvHD, nor relapse, was significantly associated with CD3+ cell dose. 
Increasing CD34+ stem cells was associated with faster neutrophil and platelet recovery. 
The probability of extensive cGvHD at 4 years was 34% in patients receiving a “low” CD34+ 
cell dose (< 8.3 x 10^6/kg) as compared to 62% in patients receiving a “high” CD34+ cell 
dose (> 8.3 x 10^6/kg) (p = 0.01). At a median follow-up of 59 months, this has not 
translated into a difference in relapse. In patients evaluable for cGvHD relapse free survival 
was significantly higher in patients receiving “low” CD34+ cell dose as compared to those 
receiving a “high” CD34+ cell dose (p = 0.04). This difference was mainly because of a 
significantly higher cGvHD-associated mortality (p = 0.01). 
3.7 Factors to predict the efficiency of blood progenitor cell mobilization 
It is important to note that most patients mobilize adequate numbers of CD34+ cells using a 
regimen of G-CSF alone. Although the addition of chemotherapy improves CD34+ yield, 
this comes at the expense of increased short-term toxicity and, possibly, the increased risk of 
secondary myelodysplastic syndrome [112]. Even with chemotherapy-growth factor 
combination regimens, it may be difficult to achieve an adequate CD34+ cell yield in some 
patients. Several studies have identified  predictors of poor PBSC yield. 
 The most important factor is the amount of myelosuppressive therapy (chemotherapy 
+/- radiation therapy) received prior to mobilization 
 Using stem cell toxic agents prior to mobilization: nitrogen mustard, procarbazine, 
melphalan, carmustine and > 7.5 g of cyclophosphamide 
 The number of chemotherapeutic regimens > 6 and ≥ 11 
 Duration of exposure to chemotherapy (> 12 months) 
 Short time interval since last chemotherapy < 6 months and < 65 days 
 Previous radiation therapy 
 Hypocellular marrow 
 Refractory disease 
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A recent scoring system based on previous therapy may be useful in predicting CD34-
positive cell yield.  
Treatment score was built by Drake et al [113], and then improved by others [114,115]. 
Treatment score was evaluated (as given in detail by Drake et al ) [113] by Clark [114]. There 
was one except in Clark study, in addition, arbitrarily allocated a score of 2 for ifosfamide 
per treatment cycle.  
Briefly, chemotherapy drugs are assigned a toxicity factor as follows: 
0. prednisolone, dexamethasone; 
1. vincristine, vinblastine, bleomycin, alpha interferon; 
2. cyclophosphamide, anthracyclines, cisplatin, etoposide, ifosfamide; 
3. chlorambucil, procarbazine; 
4. melphalan, carmustine, mechlorethamine, lomustine. 
The number of courses of each drug received was multiplied by its toxicity factor, and the 
score for each drug administered was summed to yield an overall treatment score. An 
additional 2 points were added if mediastinal radiotherapy was administered. In this study 
was validated this scoring system on an independent group of 99 patients undergoing 103 
harvesting episodes. In 61 patients mobilized with cyclophosphamide 1.5 g/m2 and G-CSF, 
those with treatment scores less than 21 yielded significantly more CD34-positive cells than 
patients with scores greater than 63 (P = 0.0012). Previous treatment with melphalan or 
carmustine was associated with a significantly lower yield of CD34-positive cells (P = 
0.0001). No relationship was seen between the time from previous chemoradiotherapy and 
harvest outcome. Patients with treatment scores less than 21 required a shorter duration of 
G-CSF therapy (P = 0.05). Similar findings were seen in 42 further mobilization cycles 
undertaken with alternative mobilization schedules. The data suggest that a score 
summarizing previous treatment can be used to predict CD34 yields, and could be of clinical 
use to identify poor PBPC mobilisers in advance. The next improvement in scoring system 
was done by Jantunen et al. [115]. Results are shown in the table. 
 
0 Prednisolone, dexamethasone, METHYLPREDNISOLONE 
1 Vincristine, vinblastine, bleomycin, METHOTREXATE, alpha-interferon, CYTOSINE 
ARABINOSIDE 
2 MITOGUAZON, cyclophosphamide, IFOSFAMIDE, cisplatin, anthracyclines, 
MITOXANTRONE, etoposide 
3 Chlorambucila, procarbazine, FLUDARABINE, DACARBAZINE
4 Melphalan, carmustine, metchlorethamine, lomustine 
Changes to the original scoring system proposed by Drake et al [113] are shown in capital letters. 
aoral continuous treatment (4–6 mg/day) for a month=1 cycle. 
Table 4. An improved chemotherapy scoring system [115] 
3.8 Strategies of remobilization/ second-line stem cell harvest of patients who fail to 
achieve minimal progenitor thresholds at the first attempt 
After an initial mobilization attempt, if too few CD34+ cells are collected to ensure prompt 
engraftment, patients often undergo additional mobilization attempts, which increase the 
risks associated with treatment [116]. Several salvage regimens have been developed to 
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After an initial mobilization attempt, if too few CD34+ cells are collected to ensure prompt 
engraftment, patients often undergo additional mobilization attempts, which increase the 
risks associated with treatment [116]. Several salvage regimens have been developed to 
 
New Advances in Stem Cell Transplantation 214 
improve mobilization in patients in whom a first mobilization attempt with G-CSF alone 
fails to result in collection of an adequate cell dose. In recent years, several investigational 
agents have been developed that may prove useful for amplifying yields of CD34+ cells 
without introducing additional toxicity. As the understanding of stem cell interactions with 
the BM microenvironment grows, new mobilizing agents will emerge. 
 
STRATEGY 
second PBSC mobilization using the same regimen 
steady-state bone marrow 
stimulated BM-“rich bone marrow” 
Increase chemotherapy dose: 4-7 g/m^2 CTX apprears more effective than 2-4 g/m^2 
Prolong duration between last chemotherapy and planned collection 
Increase growth factor dose (up to 24 µg/kg G-CSF) and use twice daily schedule 
Use investigational agents  
Table 5. Strategies of remobilization/ second-line stem cell harvest of patients who fail to 
achieve minimal progenitor thresholds at the first attempt [27,28,117] 
 
Mobilization agent Mechanism
Cytokines approved for mobilization
GM-CSF Stimulates production of granulocytes and macrophages 
G-CSF Granulocyte expansion/activation, protease release and cleavage 
of adhesion molecules 
Chemotherapeutic agents commonly used for mobilization
CY Expansion and activation of granulocytes after bone marrow 
suppression Paclitaxel Etoposide 
Investigational mobilization agents
Pegylated G-CSF Granulocyte expansion/activation, protease release and cleavage 
of adhesion molecules 
EPO Stimulates erythropoiesis
Stem cell factor G-CSF potentiation
Plerixafor Disrupts CXCR4/SDF-1 α interactions
SB-251353 GRO- analog involved in directing the movement of stem cells 
and other leukocytes
TPO Regulates megakaryocyte development, G-CSF synergism 
Parathyroid hormone Activates osteoblasts, which produce HGFs in the stem cell niche 
Abbreviations: CXCR4=chemokine receptor 4; GRO- β=a human CXC chemokine; SDF-1=stromal cell-
derived-factor-1. TPO- thrombopoietin, HGFs- hematopoietic growth factors  
Table 6. Mobilization agents currently used in auto-HSCT [27,28,117] 
3.8.1 Erythropoietin- EPO 
EPO, which is commonly used to preserve blood hemoglobin concentrations in patients 
undergoing chemotherapy, has also been shown to potentiate the mobilization effect of G-
CSF or GM-CSF [118]. Although the mechanism of this cooperative effect is unknown, it is 
thought that expression of EPO receptors on CD34+ progenitor cells primed with G-CSF or 
GM-CSF may promote survival of these cells [119]. However, EPO use is generally regarded 
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as inefficient and, as such, has not become a standard of care. Studies evaluating the 
mobilization efficacy of EPO plus G-CSF or G-CSF alone in various doses have generated 
mixed results [120-122]. Further investigation is required to ascertain the clinical benefits of 
EPO combined with G-CSF [123].  
3.8.2 High-dose G-CSF 
High-dose G-CSF was investigated as a primary mobilization regimen throughout the 1990s. 
[49,124,125]. Although seldom used today for primary mobilization, high-dose G-CSF 
regimens are occasionally used for remobilization [126,127]. Although there is no standard 
protocol for high-dose G-CSF administration, doses ranging from 16 to 32 μg/kg s.c. daily to 
12–16 μg/kg s.c. twice daily have been considered high-dose regimens even though some of 
the available data apply to patients with aplastic anemia, solid tumors or hematological 
malignancies other than NHL [124,126,128]. 
3.8.3 GM-CSF plus G-CSF 
Significant synergism has been reported between GM-CSF and G-CSF in the formation of 
granulocytic colonies in vitro [129]. Mobilization regimens combining GM-CSF with G-CSF 
have consisted of sequential or concurrent administration of these agents at a range of doses 
(G-CSF, 5–10 μg/kg; GM-CSF, 5 μg/kg–250 μg/m2), with or without chemotherapeutic 
agents [130-133]. These combination regimens have not been shown to have substantial 
benefits over regimens that use G-CSF alone; therefore, GM-CSF and G-CSF are not 
commonly administered together for primary mobilization. However, the combination of G-
CSF and GM-CSF is used as a salvage mobilization regimen when mobilization with G-CSF 
alone has been unsuccessful [126,134,135].  
3.8.4 SCF 
The c-kit ligand SCF is produced in BM stromal cells and acts as a potent co-mitogen for 
many hematopoietic growth factors [32]. Recombinant methionyl human SCF (ancestim, 
Stemgen, Amgen Inc.) administered sc. in combination with G-CSF has been shown to 
enhance mobilization and may fasten recovery in transplant recipients [32, 136]. The 
combination of SCF and G-CSF exerts a sustained mobilization effect that persists longer 
than does the effect of G-CSF alone, which persists for up to 7 days, as shown by an increase 
in the numbers of circulating CD34+ cells for up to 13 days in patients with breast cancer 
(BC) who received the combination treatment [32]. Despite the efficacy of SCF, its use is 
hindered by the infrequent occurrence of severe anaphylactoid reactions and the resultant 
need to closely monitor patients after SCF administration [137]. Although approved for use 
in Canada and New Zealand, ancestim is not currently available in the United States, and it 
is seldom used in Europe because of the relatively high risk of side effects. 
3.8.5 Plerixafor 
Plerixafor is a reversible bicyclam inhibitor of hematopoietic stem cells (HSC) binding to 
SDF-1α on marrow stromal cells via the chemokine receptor 4 (CXCR4) on HSC [138-140]. 
Plerixafor used in conjunction with G-CSF has been shown in a phase 2 studies to quickly 
and predictably enhance the numbers of CD34+ cells circulating in the peripheral blood 
[141]. In patients in whom mobilization with G-CSF either alone or in combination with 
chemotherapy has previously failed, CD34+ cell yields have been noted to increase by 5- to 
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improve mobilization in patients in whom a first mobilization attempt with G-CSF alone 
fails to result in collection of an adequate cell dose. In recent years, several investigational 
agents have been developed that may prove useful for amplifying yields of CD34+ cells 
without introducing additional toxicity. As the understanding of stem cell interactions with 
the BM microenvironment grows, new mobilizing agents will emerge. 
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EPO, which is commonly used to preserve blood hemoglobin concentrations in patients 
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CSF or GM-CSF [118]. Although the mechanism of this cooperative effect is unknown, it is 
thought that expression of EPO receptors on CD34+ progenitor cells primed with G-CSF or 
GM-CSF may promote survival of these cells [119]. However, EPO use is generally regarded 
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as inefficient and, as such, has not become a standard of care. Studies evaluating the 
mobilization efficacy of EPO plus G-CSF or G-CSF alone in various doses have generated 
mixed results [120-122]. Further investigation is required to ascertain the clinical benefits of 
EPO combined with G-CSF [123].  
3.8.2 High-dose G-CSF 
High-dose G-CSF was investigated as a primary mobilization regimen throughout the 1990s. 
[49,124,125]. Although seldom used today for primary mobilization, high-dose G-CSF 
regimens are occasionally used for remobilization [126,127]. Although there is no standard 
protocol for high-dose G-CSF administration, doses ranging from 16 to 32 μg/kg s.c. daily to 
12–16 μg/kg s.c. twice daily have been considered high-dose regimens even though some of 
the available data apply to patients with aplastic anemia, solid tumors or hematological 
malignancies other than NHL [124,126,128]. 
3.8.3 GM-CSF plus G-CSF 
Significant synergism has been reported between GM-CSF and G-CSF in the formation of 
granulocytic colonies in vitro [129]. Mobilization regimens combining GM-CSF with G-CSF 
have consisted of sequential or concurrent administration of these agents at a range of doses 
(G-CSF, 5–10 μg/kg; GM-CSF, 5 μg/kg–250 μg/m2), with or without chemotherapeutic 
agents [130-133]. These combination regimens have not been shown to have substantial 
benefits over regimens that use G-CSF alone; therefore, GM-CSF and G-CSF are not 
commonly administered together for primary mobilization. However, the combination of G-
CSF and GM-CSF is used as a salvage mobilization regimen when mobilization with G-CSF 
alone has been unsuccessful [126,134,135].  
3.8.4 SCF 
The c-kit ligand SCF is produced in BM stromal cells and acts as a potent co-mitogen for 
many hematopoietic growth factors [32]. Recombinant methionyl human SCF (ancestim, 
Stemgen, Amgen Inc.) administered sc. in combination with G-CSF has been shown to 
enhance mobilization and may fasten recovery in transplant recipients [32, 136]. The 
combination of SCF and G-CSF exerts a sustained mobilization effect that persists longer 
than does the effect of G-CSF alone, which persists for up to 7 days, as shown by an increase 
in the numbers of circulating CD34+ cells for up to 13 days in patients with breast cancer 
(BC) who received the combination treatment [32]. Despite the efficacy of SCF, its use is 
hindered by the infrequent occurrence of severe anaphylactoid reactions and the resultant 
need to closely monitor patients after SCF administration [137]. Although approved for use 
in Canada and New Zealand, ancestim is not currently available in the United States, and it 
is seldom used in Europe because of the relatively high risk of side effects. 
3.8.5 Plerixafor 
Plerixafor is a reversible bicyclam inhibitor of hematopoietic stem cells (HSC) binding to 
SDF-1α on marrow stromal cells via the chemokine receptor 4 (CXCR4) on HSC [138-140]. 
Plerixafor used in conjunction with G-CSF has been shown in a phase 2 studies to quickly 
and predictably enhance the numbers of CD34+ cells circulating in the peripheral blood 
[141]. In patients in whom mobilization with G-CSF either alone or in combination with 
chemotherapy has previously failed, CD34+ cell yields have been noted to increase by 5- to 
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100-fold in response to administration of plerixafor plus G-CSF [141,142]. Preliminary 
results of two phase 3 multicenter randomized placebo-controlled studies indicated that the 
addition of plerixafor to a G-CSF regimen resulted in greater efficacy than was seen with a 
regimen of G-CSF alone [140, 143]. In general, treatment with plerixafor and G-CSF was 
associated with side effects similar to those seen with treatment with G-CSF alone. Most 
treatment-related AEs appeared to be mild and transient. The most common AEs were 
gastrointestinal tract effects, such as diarrhea, nausea and vomiting, and injection-site 
reactions, such as erythema or edema[140, 143].  
3.8.6 SB-251353 
SB-251353 is another investigational mobilization agent currently in preclinical studies 
[144,145]. SB-251353 is an analog of GRO-β, a human CXC chemokine involved in directing 
the movement of stem cells and leukocytes. Although human data are lacking, this agent, 
when combined with G-CSF in rhesus monkeys, was shown to greatly increase mobilization 
of stem cells and progenitor cells in comparison with G-CSF alone. Further research is 
necessary to determine the efficacy and potential toxicities of this treatment in humans. 
[144,145]. 
3.8.7 Thrombopoietin- TPO 
Endogenous TPO is the primary regulator of megakaryocyte development. Recombinant 
human TPO (rhTPO) has been shown to act synergistically with G-CSF to enhance stem cell 
mobilization [146]. This regimen has not been shown to be more efficacious or safer than 
existing mobilization regimens; however, a few studies document encouraging results [147]. 
AEs associated with the use of rhTPO plus G-CSF appear to be similar to those seen with the 
use of G-CSF alone [146,147], however, cytopenias owing to neutralizing antibodies to TPO 
have been reported in a small number of patients who were given rhTPO to treat 
chemotherapy-induced thrombocytopenia [148]. Currently, no TPOs have been approved by 
the FDA for mobilization [149].  
3.8.8 Parathyroid hormone 
Parathyroid hormone (PTH) activates osteoblasts, which produce hematopoietic growth 
factors in the stem cell niche, thereby increasing the numbers of circulating stem cells 
[150,151]. The efficacy and safety of PTH have yet to be established. In a recent phase 1 
study, 20 patients with MM, NHL, HD or AML, in whom one or two previous mobilization 
attempts had failed, received escalating doses of 40, 60, 80 and 100 μg of PTH (s.c.) for 14 
days; PTH doses were combined with G-CSF 10 μg/kg on the last 4 days of treatment [151]. 
Overall, 47% of patients in whom one previous mobilization attempt had failed reached the 
mobilization criterion of >5 CD34+ cells/μl in the peripheral blood, and 40% of patients who 
had previously experienced two failed mobilization attempts reached the mobilization 
criterion. No dose-limiting toxicity was evident, and PTH was well tolerated; AEs included 
headache, muscle pain, back pain, fatigue and hypothermia [151].  
3.9 BM vs. PBSC for whom? [152]  
BM for: 
a. Good risk younger patients 
 Children 
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 Aplastic anemia, CML in first chronic phase (CP1) 
b. PBSC for: 
 Advanced phase of diseases 
 If graft manipulation is needed 
 Reduced intensity transplants 
 Donor’s preference 
4. Umbilical cord blood 
The use of allogeneic blood and bone marrow stem cell transplantations are limited by the 
availability of suitably HLA- matched donors. Only 30% of patients have HLA-identical 
sibling donors and through the National Marrow Donors Program and other registries 
worldwide nearly 75% of Caucasians, but far fewer racial minorities find suitably HLA-
matched donors. In 1988 umbilical cord blood (UCB) hematopoietic stem cells from a related 
sibling were transplanted successfully into a 5-year-old child with Fanconi anemia. Fifteen 
years later, this patient is doing well with full donor hematopoietic and lymphoid 
reconstitution. UCB offers the advantages of easy procurement, no risk to donors, the 
reduced risk of transmitting infections, immediate availability of cryopreserved units and 
acceptable partial HLA mismatches. Nearly all patients can find at least one potential 4 of 6 
HLA-matched UCB units through either Netcord or other banks. Limited cell dose has been 
the major limitation to the wide use of UCB for allogeneic transplantation.  
The blood in the umbilical cord of newborn babies contains large numbers of stem cells, 
which have been shown to be capable of long-term engraftment in children and some 
adults after transplantation. Cord blood cells obtained from the umbilical cord at the time 
of delivery are used mainly for unrelated allogeneic stem cell transplantation. Patients 
without time to find an unrelated stem cell donor or who do not have a HLA 10/10 or 
9/10 unrelated bone marrow graft donor should be considered for cord blood cells 
transplantation (CBCT). The cord blood cells may also be used for family- member 
transplantation, particularly in children for both malignant or nonmalignant diseases 
[153-155].  
Advantages of CBCT compared with bone marrow or mobilized peripheral blood 
transplantations [156-161] : 
 significantly faster graft availability (patients receiving CBCT in a median of 3-5 weeks 
earlier than those receiving an unrelated bone marrow graft), 
 lack of risk to the donor,  
 higher frequency of rare haplotypes compared to bone marrow donor registries, 
 CD34+/CD38 cord blood cells proliferate more rapidly and generate large number of 
progenitor cells [162] 
 extension of the donor pool due to tolerance of 1-2 HLA mismatches out of 6,  
 lower incidence and severity of acute graft-versus-host disease, 
 lower risk of infections by latent viruses – such as Epstein-Barr virus or 
cytomegalovirus   
Disadvantages of CBCT compared with bone marrow or mobilized peripheral blood 
transplantations: 
 cell dose is based per kilogram of recipient weight, which can be limiting. Target is 1,7- 
3,5 x 10^7 total nucleated cells/kg, 
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100-fold in response to administration of plerixafor plus G-CSF [141,142]. Preliminary 
results of two phase 3 multicenter randomized placebo-controlled studies indicated that the 
addition of plerixafor to a G-CSF regimen resulted in greater efficacy than was seen with a 
regimen of G-CSF alone [140, 143]. In general, treatment with plerixafor and G-CSF was 
associated with side effects similar to those seen with treatment with G-CSF alone. Most 
treatment-related AEs appeared to be mild and transient. The most common AEs were 
gastrointestinal tract effects, such as diarrhea, nausea and vomiting, and injection-site 
reactions, such as erythema or edema[140, 143].  
3.8.6 SB-251353 
SB-251353 is another investigational mobilization agent currently in preclinical studies 
[144,145]. SB-251353 is an analog of GRO-β, a human CXC chemokine involved in directing 
the movement of stem cells and leukocytes. Although human data are lacking, this agent, 
when combined with G-CSF in rhesus monkeys, was shown to greatly increase mobilization 
of stem cells and progenitor cells in comparison with G-CSF alone. Further research is 
necessary to determine the efficacy and potential toxicities of this treatment in humans. 
[144,145]. 
3.8.7 Thrombopoietin- TPO 
Endogenous TPO is the primary regulator of megakaryocyte development. Recombinant 
human TPO (rhTPO) has been shown to act synergistically with G-CSF to enhance stem cell 
mobilization [146]. This regimen has not been shown to be more efficacious or safer than 
existing mobilization regimens; however, a few studies document encouraging results [147]. 
AEs associated with the use of rhTPO plus G-CSF appear to be similar to those seen with the 
use of G-CSF alone [146,147], however, cytopenias owing to neutralizing antibodies to TPO 
have been reported in a small number of patients who were given rhTPO to treat 
chemotherapy-induced thrombocytopenia [148]. Currently, no TPOs have been approved by 
the FDA for mobilization [149].  
3.8.8 Parathyroid hormone 
Parathyroid hormone (PTH) activates osteoblasts, which produce hematopoietic growth 
factors in the stem cell niche, thereby increasing the numbers of circulating stem cells 
[150,151]. The efficacy and safety of PTH have yet to be established. In a recent phase 1 
study, 20 patients with MM, NHL, HD or AML, in whom one or two previous mobilization 
attempts had failed, received escalating doses of 40, 60, 80 and 100 μg of PTH (s.c.) for 14 
days; PTH doses were combined with G-CSF 10 μg/kg on the last 4 days of treatment [151]. 
Overall, 47% of patients in whom one previous mobilization attempt had failed reached the 
mobilization criterion of >5 CD34+ cells/μl in the peripheral blood, and 40% of patients who 
had previously experienced two failed mobilization attempts reached the mobilization 
criterion. No dose-limiting toxicity was evident, and PTH was well tolerated; AEs included 
headache, muscle pain, back pain, fatigue and hypothermia [151].  
3.9 BM vs. PBSC for whom? [152]  
BM for: 
a. Good risk younger patients 
 Children 
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 Aplastic anemia, CML in first chronic phase (CP1) 
b. PBSC for: 
 Advanced phase of diseases 
 If graft manipulation is needed 
 Reduced intensity transplants 
 Donor’s preference 
4. Umbilical cord blood 
The use of allogeneic blood and bone marrow stem cell transplantations are limited by the 
availability of suitably HLA- matched donors. Only 30% of patients have HLA-identical 
sibling donors and through the National Marrow Donors Program and other registries 
worldwide nearly 75% of Caucasians, but far fewer racial minorities find suitably HLA-
matched donors. In 1988 umbilical cord blood (UCB) hematopoietic stem cells from a related 
sibling were transplanted successfully into a 5-year-old child with Fanconi anemia. Fifteen 
years later, this patient is doing well with full donor hematopoietic and lymphoid 
reconstitution. UCB offers the advantages of easy procurement, no risk to donors, the 
reduced risk of transmitting infections, immediate availability of cryopreserved units and 
acceptable partial HLA mismatches. Nearly all patients can find at least one potential 4 of 6 
HLA-matched UCB units through either Netcord or other banks. Limited cell dose has been 
the major limitation to the wide use of UCB for allogeneic transplantation.  
The blood in the umbilical cord of newborn babies contains large numbers of stem cells, 
which have been shown to be capable of long-term engraftment in children and some 
adults after transplantation. Cord blood cells obtained from the umbilical cord at the time 
of delivery are used mainly for unrelated allogeneic stem cell transplantation. Patients 
without time to find an unrelated stem cell donor or who do not have a HLA 10/10 or 
9/10 unrelated bone marrow graft donor should be considered for cord blood cells 
transplantation (CBCT). The cord blood cells may also be used for family- member 
transplantation, particularly in children for both malignant or nonmalignant diseases 
[153-155].  
Advantages of CBCT compared with bone marrow or mobilized peripheral blood 
transplantations [156-161] : 
 significantly faster graft availability (patients receiving CBCT in a median of 3-5 weeks 
earlier than those receiving an unrelated bone marrow graft), 
 lack of risk to the donor,  
 higher frequency of rare haplotypes compared to bone marrow donor registries, 
 CD34+/CD38 cord blood cells proliferate more rapidly and generate large number of 
progenitor cells [162] 
 extension of the donor pool due to tolerance of 1-2 HLA mismatches out of 6,  
 lower incidence and severity of acute graft-versus-host disease, 
 lower risk of infections by latent viruses – such as Epstein-Barr virus or 
cytomegalovirus   
Disadvantages of CBCT compared with bone marrow or mobilized peripheral blood 
transplantations: 
 cell dose is based per kilogram of recipient weight, which can be limiting. Target is 1,7- 
3,5 x 10^7 total nucleated cells/kg, 
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 low number of hematopoietic progenitor cells- single cord blood unit transplantation 
(100ml) contains 0,3x10^6 CD34+ cells/kg (small recipient, below 40kg), 
 in adults, single cord blood unit transplantation is associated with very delayed 
engraftment, combining two products seems to provide more rapid engraftment, albeit 
at the expense of higher rates of acute graft-versus-host disease, 
 donor cannot be used for donor lymphocyte infusion, 
 donor cannot be used for treatment of graft rejection or failure. 
The cell dose infused is consistently an important marker for improved engraftment and 
survival. The lower dose of CD34+ cells translate into increased risk of graft failure, delayed 
hematopoietic engraftment [160] and delayed immune reconstitution [162,163]. Because of 
the delayed  immune reconstitution infections are a serious problem in cord blood 
transplantation [164]. 
Many tests have been performed to enhance collection of hematopoietic stem cells in cord 
blood units. Examples include: in vivo or ex vivo expansion of cord blood cells [165,166], 
injecting cord blood cells directly into the bone marrow [167], use of double unit CBCT 
[168,169], use of reduced intensity conditioning  regimen [170,171], coinfusion with a 
haploidentical T cell depleted graft [172,173] or mesenchymal stem cells [174].  
5. Storage [1] 
Hematopoietic progenitor cell products are stored using various methods depending on the 
required duration of storage. Products used fresh can be refrigerated for at least 24 hours 
before infusion. If there is a > 48-hour delay before infusion, most products are frozen to 
maintain viability. Most frozen products are stored in the vapor phase of liquid nitrogen (< -
50 C). Products may be stored for up to 10 years although no longevity limit has yet been 
determined. Long-term storage is generally done in the liquid phase of liquid nitrogen. 
Hematopoietic progenitor cells have been frozen using cryoprotectant solutions. The most 
commonly used cryoprotectant is 10% DMSO and a protein additive such as human serum 
albumin. 
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1. Introduction  
The transplantation of stem cells can be performed in an autologous, where the recipient 
donates his own stem cells for later use, or in an allogeneic fashion, where the donor and the 
recipient are two different persons (Berz, McCormack, Winer, Colvin, & Peter J 
Quesenberry, 2007; A. Gratwohl et al., 2010). In some clinical settings, stem cells can be 
utilized within a 72 hour timeframe without the need for extensive storage (Fleming & A 
Hubel, 2006; Allison Hubel, Carlquist, Clay, & Jeff McCullough, 2004; Pettengell, Woll, 
O'Connor, Dexter, & Testa, 1994). The autologous transplantation of cellular products and 
the therapeutic use of umbilical cord stem cells rely heavily on the preservation of stem cells 
after initial collection to be utilized at a later point in time (Berz, McCormack, Winer, Colvin, 
& Peter J Quesenberry, 2007).  
Hematopoietic stem cell transplantation has been in clinical use for decades to treat benign 
and malignant hematologic and non-hematologic conditions (C. J. Hunt, 2011). The principal 
sources for those therapeutic strategies are bone marrow, peripheral blood hematopoietic 
progenitor cells and stem cells derived from umbilical cord blood. Although clinicians have 
decades of experience with the use of hematopoietic stem cells(HSC), the interest in the 
clinical use of non-hematopoietic stem cells, such as embryonic(C. J. Hunt, 2011; Leeb et al., 
2011), mesenchymal (Ding, Shyu, & Lin, 2011; Leclerc et al., 2011; Puglisi et al., 2011) and 
induced pluripotent stem cells (Leeb et al., 2011; Sohni & Verfaillie, 2011) is rapidly 
expanding. The therapeutic strategies utilizing such cellular products, depend heavily on 
the effective preservation of those cell products for clinical use at a later point in time. The 
need for ready availability of such products calls for storage procedures with favorable graft 
survival rates and a tolerable toxicity profile. While cryopreservation protocols for HSC are 
well developed, the field for non-hematopoietic stem cells still remains to be defined. 
The cryopreservation of all stem cells follows certain principal steps; First, Cytoreduction 
and prefreezing processing of the freshly collected graft. Second, the  cryopreservative 
medium is prepared and added. Third, the graft is assessed for viability and integrity. 
Microbial contamination is ruled out. Fourth, freezing of the stem cells is performed. Fifth, 
thawing of the cryopreserved graft is conducted. Last, the post thawing processing is 
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performed, including in certain situations washing of the stem cell concentrate. A standard 
algorithm for the preservation of HSC populations is depicted in figure 1 
No single, standardized cryopreservation protocol has been universally used and 
differences in techniques continue to exist in between different centers. 
We at our institution utilize a standardized NIH protocol. We collect Hematopoietic 
Progenitor Stem Cells in a minimally manipulated fashion as defined by the Foundation for 
the Accreditation of Hematopoietic Cell Therapy (FAHCT) with a minimal cell dose of at 
least 1.5-3.0 × 106–5.0 × 106 CD34(+) cells/kg body weight, depending on the clinical 
indication. The specimen is then centrifuged to develop the cell rich pellet. In autologous 
transplants donor plasma is used for re-suspension, if available. Human serum albumin 
solution is an alternative. Then, a solution of heparinized Plasmalyte  and 10% DMSO 
(Dimethylsulfoxide) is added. This usually eventuates into a cellular concentration of 200 × 
106 cells in the cryopreservate. We store the bone marrow or peripheral blood stem cell 
product at initially −4°C. Then the sample is frozen down to the target temperature of-135° 
to -156°Celsius to be placed into the vapor phase of the nitrogen tank. 
2. Types of stem cells 
a. Hematopoietic stem cells (HSC) are in therapeutic use for more than 50 years 
(THOMAS, LOCHTE, CANNON, SAHLER, & FERREBEE, 1959). In 2006 50,417 
hematopoietic stem cell transplants were performed globally, 21 516 allogeneic (43%) 
and 28 901 autologous (57%) (A. Gratwohl et al., 2010). The principal sources for HSCs 
are the bone marrow (BM), mobilized peripheral blood stem cells (PBSC) and umbilical 
cord stem cells (UCB)(Berz, McCormack, Winer, Colvin, & Peter J Quesenberry, 2007). 
Allogeneic grafts are often used shortly after collection, but autologous grafts and cord 
blood units are generally cryopreserved. The amount of cryopreserved cord blood units 
is rising and the storage time in cord blood banks often exceeds a decade (Valeri & 
Pivacek, 1996).  
b. Mesenchymal stem cells (MSC) were initially identified in 1976 as bone marrow stromal 
cells with the capability to form mesenchymal components such as fat, cartilage and 
bone(Friedenstein, Gorskaja, & Kulagina, 1976). Along with the large regenerative 
potential of damaged mesenchymal tissues, MSCs are powerful immune modulators 
with promising results in autoimmune diseases and GVHD(Dazzi & Krampera, 2011; 
McGuirk & Weiss, 2011).  
c. Human embryonic stem cells(hESC) are primitive precursor cells with an unlimited 
potential for self- renewal and the capability to differentiate into any cell type derived 
from all three germ cell layers(Murdoch et al., 2011). This pluripotent property makes 
hESCs powerful candidates for regenerative cellular therapies. 
d. Induced pluripotent stem cells (iPSC) are somatic cells which are transformed by 
genetic reprogramming into cells with pluripotent stem cell character. Initially 
described in 2007, such cells would be optimal candidates for autologous regenerative 
approaches without the ethical concerns about hESCs (Walia, Satija, Tripathi, & 
Gangenahalli, 2011). However, immunologic barriers have recently been identified even 
in autologous settings. Before a viable clinical use, such obstacles  have first to be 
overcome (Zhao, Z.-N. Zhang, Rong, & Y. Xu, 2011).  
Although most of our clinical expertise exists with HSC, efforts to develop appropriate 
cryopreservation protocols for non-hematopoietic stem cells are ongoing. This chapter will 
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primarily focus on the recent developments in the field of cryopreservation of hematopoietic 
stem cells, but also outline some of the similarities and differences between the 
cryopreservation of HSCs and non-hematopoietic stem cells. 
3. Processing prior to cryostorage 
3.1 Liquid phase storage 
Several centers, particularly in remote rural settings rely on the performance of autologous 
bone marrow transplantation without a local croypreservation expertise. Along with that, 
umbilical cord blood processing is only performed in highly specialized cell processing 
facilities, which are often geographically remote from the place of collection. In such clinical 
settings, the initial cell collections have to be transported to a center with the necessary 
expertise in a liquid form (Fleming & A Hubel, 2006; Rodrigues et al., 2008).  Liquid storage, 
either for transport purposes or to bridge a short time span prior to definitive clinical use 
has been successfully used for different clinical indications (Corato et al., 2000; Pettengell, 
Woll, O'Connor, Dexter, & Testa, 1994; Pettengell, Woll, Thatcher, Dexter, & Testa, 1995).  
Several studies have investigated the effects of temperature, total liquid phase duration and 
storage media with varying cell concentrations on functional outcomes. A short term storage 
temperature of 4° Celsius has been shown to be suitable for UB cord blood collections 
(Burger, A Hubel, & J McCullough, 1999; Allison Hubel, Carlquist, Clay, & Jeffrey 
McCullough, 2003) and  non cord blood hematopoietic progenitor cells (Burger et al., 1999; 
Allison Hubel, Carlquist, Clay, & Jeff McCullough, 2004; Allison Hubel et al., 2003). The 
major rationale for the choice of 4° Celsius was the concern about crystal formation and 
corresponding cell death at lower temperatures (Matsumoto et al., 2002). However, the 
actual freezing/crystallization point of human plasma has been shown to be at -0.8° Celsius 
(K. B. Storey & J. M. Storey, 1990).  Hence, different temperatures have been investigated for 
short term storage. A study from Japan established the feasibility of storage of HPC at -2 
Celsius in University of Wisconcin medium without cryopreservative additive (CPA) for up 
to 72 hours. In this short term storage conditions, appropriate for transport purposes, the 
post-thaw nucleated cell count recoveries and functional assay outcomes were both above 
90%. This was superior to a control, which was stored at -80° Celsius with DMSO for the 
same amount of time (Matsumoto et al., 2002).  The results of this and similar studies 
suggest that storage around the freezing point is more appropriate in short term storage for 
periods of less than 72 hours than the usual deep freezing temperatures.  
3.2 Centrifugation and resuspension 
The pre-cryostorage processing entails the actual collection procedure, the removal of cell 
bulk, volume reduction with concentration of the stem cells and addition of the cryo-
medium. The process is performed in a strictly sterile environment. It also includes the 
identification of the donor with labeling of the bag, general assessment of the collected 
specimen (such as weighing and cell enumeration) and ascertainment of a sterile specimen 
with microbiologic studies (S. M. Watt, Austin, & S. Armitage, 2007). 
Subsequently the specimen undergoes centrifugation and resuspension of the pellet in order 
to achieve volume reduction and concentration of the target cell population(Laroche et al., 
2005; Rebulla, 2002; Rowley, Bensinger, Gooley, & Buckner, 1994).  
The volume reduction process is well documented to be associated with loss of active cells 
(Koliakos et al., 2007). This is of particular relevance in UCB specimens, in which a paucity 
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in autologous settings. Before a viable clinical use, such obstacles  have first to be 
overcome (Zhao, Z.-N. Zhang, Rong, & Y. Xu, 2011).  
Although most of our clinical expertise exists with HSC, efforts to develop appropriate 
cryopreservation protocols for non-hematopoietic stem cells are ongoing. This chapter will 
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primarily focus on the recent developments in the field of cryopreservation of hematopoietic 
stem cells, but also outline some of the similarities and differences between the 
cryopreservation of HSCs and non-hematopoietic stem cells. 
3. Processing prior to cryostorage 
3.1 Liquid phase storage 
Several centers, particularly in remote rural settings rely on the performance of autologous 
bone marrow transplantation without a local croypreservation expertise. Along with that, 
umbilical cord blood processing is only performed in highly specialized cell processing 
facilities, which are often geographically remote from the place of collection. In such clinical 
settings, the initial cell collections have to be transported to a center with the necessary 
expertise in a liquid form (Fleming & A Hubel, 2006; Rodrigues et al., 2008).  Liquid storage, 
either for transport purposes or to bridge a short time span prior to definitive clinical use 
has been successfully used for different clinical indications (Corato et al., 2000; Pettengell, 
Woll, O'Connor, Dexter, & Testa, 1994; Pettengell, Woll, Thatcher, Dexter, & Testa, 1995).  
Several studies have investigated the effects of temperature, total liquid phase duration and 
storage media with varying cell concentrations on functional outcomes. A short term storage 
temperature of 4° Celsius has been shown to be suitable for UB cord blood collections 
(Burger, A Hubel, & J McCullough, 1999; Allison Hubel, Carlquist, Clay, & Jeffrey 
McCullough, 2003) and  non cord blood hematopoietic progenitor cells (Burger et al., 1999; 
Allison Hubel, Carlquist, Clay, & Jeff McCullough, 2004; Allison Hubel et al., 2003). The 
major rationale for the choice of 4° Celsius was the concern about crystal formation and 
corresponding cell death at lower temperatures (Matsumoto et al., 2002). However, the 
actual freezing/crystallization point of human plasma has been shown to be at -0.8° Celsius 
(K. B. Storey & J. M. Storey, 1990).  Hence, different temperatures have been investigated for 
short term storage. A study from Japan established the feasibility of storage of HPC at -2 
Celsius in University of Wisconcin medium without cryopreservative additive (CPA) for up 
to 72 hours. In this short term storage conditions, appropriate for transport purposes, the 
post-thaw nucleated cell count recoveries and functional assay outcomes were both above 
90%. This was superior to a control, which was stored at -80° Celsius with DMSO for the 
same amount of time (Matsumoto et al., 2002).  The results of this and similar studies 
suggest that storage around the freezing point is more appropriate in short term storage for 
periods of less than 72 hours than the usual deep freezing temperatures.  
3.2 Centrifugation and resuspension 
The pre-cryostorage processing entails the actual collection procedure, the removal of cell 
bulk, volume reduction with concentration of the stem cells and addition of the cryo-
medium. The process is performed in a strictly sterile environment. It also includes the 
identification of the donor with labeling of the bag, general assessment of the collected 
specimen (such as weighing and cell enumeration) and ascertainment of a sterile specimen 
with microbiologic studies (S. M. Watt, Austin, & S. Armitage, 2007). 
Subsequently the specimen undergoes centrifugation and resuspension of the pellet in order 
to achieve volume reduction and concentration of the target cell population(Laroche et al., 
2005; Rebulla, 2002; Rowley, Bensinger, Gooley, & Buckner, 1994).  
The volume reduction process is well documented to be associated with loss of active cells 
(Koliakos et al., 2007). This is of particular relevance in UCB specimens, in which a paucity 
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of donor cells is a concern (Koliakos et al., 2007; Laroche et al., 2005; J. C. Wang, Doedens, & 
Dick, 1997). 
Hence, volume reduction during pre-freezing processing remains a field of ongoing 
research to limit the cell loss. One example is a study, by Koliakos et al, which achieved 
limited cell loss by a careful double processing in the presence of 2% HES(Koliakos et al., 
2007). 
3.3 Cell concentration 
Triggered by concerns of toxicities of the cryopreservative additive to the cells, high stem 
cell concentrations in the cryopreserved unit were initially deemed to be detrimental. Also 
the osmotic shock during manipulation of the specimen could potentially be associated with 
untoward effects (Luciano et al., 2009). Hence the recommended cell concentrations in 
cryopreserved hematopoietic stem cells was suggested to be not above 2X107/mL (Aird, 
Labopin, Gorin, & Antin, 1992; Gorin, 1986; Rowley, 1992; Rowley, Bensinger, Gooley, & 
Buckner, 1994; Silberstein & Jefferies, 1996). This would lead to a total storage space of 7 
liters for every patient needing a routinely used cell dose (Rowley, Bensinger, Gooley, & 
Buckner, 1994). Early work by Law et al., established that stem cells have a high osmotic 
resistance (Law, Alsop, D C Dooley, & Meryman, 1983), what led to the investigation of 
higher cell concentrations with a smaller corresponding storage volumes. 
After initial preclinical experiments, several studies established that higher cell 
concentrations were compatible with good functional outcomes and engraftment kinetics 
(Cabezudo et al., 2000; Yoshifumi Kawano et al., 2004; Rowley, Bensinger, Gooley, & 
Buckner, 1994; Villalón et al., 2002). Cell counts between 1 and 2X108 were found to be safe 
and feasible (Alencar et al., 2010; Cabezudo et al., 2000; Yoshifumi Kawano et al., 2004; 
Rowley, Bensinger, Gooley, & Buckner, 1994; Villalón et al., 2002). A more recent study from 
Brazil (Alencar et al., 2010) compared the effect of PBSC concentrations on cell viability, 
functional assays and engraftment kinetics. No significant differences were observed 
between cell concentrations of 1X108/mL and 2X108mL. Today cell concentrations of 
2X108/mL and above are considered safe and are used in many cryopreservation centers. 
3.4 Creation and addition of the cryopreservation medium 
The cryopreseved unit for storage consists of the stem cell collection, the diluent medium 
and the cryopreservative additive(CPA). Often the cell concentrate is added to the 
cryopreservative medium (diluent medium+CPA) in a 1:1 volume ratio. The optimal 
consistency of the cryopreservation medium is still a matter of active research and is poorly 
standardized (S. M. Watt, Austin, & S. Armitage, 2007; Zeisberger et al., 2010). 
3.4.1 The diluent 
The diluent consists most frequently of cryoprecipitated autologous or allogeneic plasma. If 
unavailable human albumin solution is widely used (Berz, McCormack, Winer, Colvin, & 
Peter J Quesenberry, 2007; Rodrigues et al., 2008; S. M. Watt, Austin, & S. Armitage, 2007; 
Zeisberger et al., 2010). However, particularly in non-hematologic stem cell 
cryopreservation protocols, fetal bovine serum(FBS) is still used as a standard diluent 
(Ellerström et al., 2006; Holm et al., 2010; Unger, Skottman, Blomberg, Dilber, & Hovatta, 
2008; Zeisberger et al., 2010). The use of FBS, a xenobiotic mix with variable consistency, is 
associated with certain tangible risks. Immunologic responses to animal serum components 
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(Mackensen, Dräger, Schlesier, Mertelsmann, & Lindemann, 2000) or stimulated by hapten 
formation(Martin, Muotri, Gage, & Varki, 2005) and the transmission of known or unknown 
animal pathogens to the recipient(Elsaadany et al., 2011; Will et al., 1996) have been raised as 
concerns. Hence, current research focuses on the development of standardized, xeno-free 
cryopreservation practices for human stem cells (Ellerström et al., 2006; Holm et al., 2010; 
Zeisberger et al., 2010). Recently, Zeisberger et al. presented excellent viabilities with a xeno-
free, predefined cryomedium, suitable for hematopoietic and mesenchymal stem cells. 
3.4.2 The cryopreservative additive 
3.4.2.1 DMSO and its Toxicities 
Dimethylsulfoxide is the most widely used and was already described as cryoprotectant in 
1959(LOVELOCK & BISHOP, 1959). After having been initially synthesized by Alexander 
Mikhaylovich Zaitsev in 1867 (Lewis, 1994a; 1994b), DMSO has been used in the wood 
industry since the 19th century(Ruiz-Delgado et al., 2009). It also found medical application 
in a wide spectrum of musculoskeletal, autoimmune and metabolic diseases, including 
gonarthrosis, interstitial cystitis and amyloidosis (Albanell & Baselga, 2000; Eberhardt, 
Zwingers, & Hofmann, 1995; Iwasaki, Hamano, Aizawa, Kobayashi, & Kakishita, 1994; 
McCammon, Lentzner, Moriarty, & Schellhammer, 1998; Morassi, Massa, Mesesnel, Magris, 
& D'Agnolo, 1989). As a small amphiphatic molecule, DMSO penetrates also into stem cells 
and acts as a strong hydrogen bond disrupter and hence exerts colligative effects (Ruiz-
Delgado et al., 2009; N. C. Santos, Prieto, Morna-Gomes, Betbeder, & Castanho, 1997). 
The pulmonary excretion of DMSO accounts for the typical garlic like smell, noticed during 
stem cell infusion (Jacob & Herschler, 1983). Secondary to the wide pharmacokinetic 
distribution volume, including good blood brain barrier penetration, DMSO affects multiple 
organ systems with a wide spectrum of toxicities. Those adverse effects include CNS-, 
respiratory-, hemolytic-, gastrointestinal-, hepatic-, dermatologic-, cardiovascular- and renal 
toxicities. 
The overall most frequently reported side effects are of gastrointestinal and cardiovascular 
nature. Nausea and abdominal cramping are observed with incidences of up to 70%. Early 
studies by Davis et al. (J. M. Davis, Rowley, Braine, Piantadosi, & G. W. Santos, 1990; J. 
Davis, Rowley, & G. W. Santos, 1990) demonstrated that the incidence of side effects rose 
with the volume of DMSO and amount of cell lysis products infused.  
Vasovagal reactions with hypotension and bradycardia are observed with a high incidence. 
In a multinational survey study performed by Windrum et al., data from 97 EBMT 
transplant centers were included. DMSO related toxicities other than nausea and vomiting 
were observed in about one out of 50 transplants with a mean incidence of 2.2% in all 
administered units. Cardiovascular side effects were most frequently observed, witnessed in 
27% of the participating centers (Windrum, Morris, Drake, D Niederwieser, & Ruutu, 2005).  
The vagolytic effects of DMSO have been documented in physiologic experiments and the 
hypotension can be attributed to DMSO induced histamine release (J. M. Davis, Rowley, 
Braine, Piantadosi, & G. W. Santos, 1990; KLIGMAN, 1965). However, confounding is the 
fact, that stem cell concentrates are usually infused after thawing to a slushy state at a 
temperature of 4°-8°C. Hence, a substantial amount of the frequently observed bradycardia 
and hypotension could be calorically induced. Along with this, recipients of stem cell 
concentrates are usually premedicated with IV glucocorticosteroids, hydration, mannitol 
and anti-histamines (J. M. Davis, Rowley, Braine, Piantadosi, & G. W. Santos, 1990; J. Davis, 
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of donor cells is a concern (Koliakos et al., 2007; Laroche et al., 2005; J. C. Wang, Doedens, & 
Dick, 1997). 
Hence, volume reduction during pre-freezing processing remains a field of ongoing 
research to limit the cell loss. One example is a study, by Koliakos et al, which achieved 
limited cell loss by a careful double processing in the presence of 2% HES(Koliakos et al., 
2007). 
3.3 Cell concentration 
Triggered by concerns of toxicities of the cryopreservative additive to the cells, high stem 
cell concentrations in the cryopreserved unit were initially deemed to be detrimental. Also 
the osmotic shock during manipulation of the specimen could potentially be associated with 
untoward effects (Luciano et al., 2009). Hence the recommended cell concentrations in 
cryopreserved hematopoietic stem cells was suggested to be not above 2X107/mL (Aird, 
Labopin, Gorin, & Antin, 1992; Gorin, 1986; Rowley, 1992; Rowley, Bensinger, Gooley, & 
Buckner, 1994; Silberstein & Jefferies, 1996). This would lead to a total storage space of 7 
liters for every patient needing a routinely used cell dose (Rowley, Bensinger, Gooley, & 
Buckner, 1994). Early work by Law et al., established that stem cells have a high osmotic 
resistance (Law, Alsop, D C Dooley, & Meryman, 1983), what led to the investigation of 
higher cell concentrations with a smaller corresponding storage volumes. 
After initial preclinical experiments, several studies established that higher cell 
concentrations were compatible with good functional outcomes and engraftment kinetics 
(Cabezudo et al., 2000; Yoshifumi Kawano et al., 2004; Rowley, Bensinger, Gooley, & 
Buckner, 1994; Villalón et al., 2002). Cell counts between 1 and 2X108 were found to be safe 
and feasible (Alencar et al., 2010; Cabezudo et al., 2000; Yoshifumi Kawano et al., 2004; 
Rowley, Bensinger, Gooley, & Buckner, 1994; Villalón et al., 2002). A more recent study from 
Brazil (Alencar et al., 2010) compared the effect of PBSC concentrations on cell viability, 
functional assays and engraftment kinetics. No significant differences were observed 
between cell concentrations of 1X108/mL and 2X108mL. Today cell concentrations of 
2X108/mL and above are considered safe and are used in many cryopreservation centers. 
3.4 Creation and addition of the cryopreservation medium 
The cryopreseved unit for storage consists of the stem cell collection, the diluent medium 
and the cryopreservative additive(CPA). Often the cell concentrate is added to the 
cryopreservative medium (diluent medium+CPA) in a 1:1 volume ratio. The optimal 
consistency of the cryopreservation medium is still a matter of active research and is poorly 
standardized (S. M. Watt, Austin, & S. Armitage, 2007; Zeisberger et al., 2010). 
3.4.1 The diluent 
The diluent consists most frequently of cryoprecipitated autologous or allogeneic plasma. If 
unavailable human albumin solution is widely used (Berz, McCormack, Winer, Colvin, & 
Peter J Quesenberry, 2007; Rodrigues et al., 2008; S. M. Watt, Austin, & S. Armitage, 2007; 
Zeisberger et al., 2010). However, particularly in non-hematologic stem cell 
cryopreservation protocols, fetal bovine serum(FBS) is still used as a standard diluent 
(Ellerström et al., 2006; Holm et al., 2010; Unger, Skottman, Blomberg, Dilber, & Hovatta, 
2008; Zeisberger et al., 2010). The use of FBS, a xenobiotic mix with variable consistency, is 
associated with certain tangible risks. Immunologic responses to animal serum components 
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(Mackensen, Dräger, Schlesier, Mertelsmann, & Lindemann, 2000) or stimulated by hapten 
formation(Martin, Muotri, Gage, & Varki, 2005) and the transmission of known or unknown 
animal pathogens to the recipient(Elsaadany et al., 2011; Will et al., 1996) have been raised as 
concerns. Hence, current research focuses on the development of standardized, xeno-free 
cryopreservation practices for human stem cells (Ellerström et al., 2006; Holm et al., 2010; 
Zeisberger et al., 2010). Recently, Zeisberger et al. presented excellent viabilities with a xeno-
free, predefined cryomedium, suitable for hematopoietic and mesenchymal stem cells. 
3.4.2 The cryopreservative additive 
3.4.2.1 DMSO and its Toxicities 
Dimethylsulfoxide is the most widely used and was already described as cryoprotectant in 
1959(LOVELOCK & BISHOP, 1959). After having been initially synthesized by Alexander 
Mikhaylovich Zaitsev in 1867 (Lewis, 1994a; 1994b), DMSO has been used in the wood 
industry since the 19th century(Ruiz-Delgado et al., 2009). It also found medical application 
in a wide spectrum of musculoskeletal, autoimmune and metabolic diseases, including 
gonarthrosis, interstitial cystitis and amyloidosis (Albanell & Baselga, 2000; Eberhardt, 
Zwingers, & Hofmann, 1995; Iwasaki, Hamano, Aizawa, Kobayashi, & Kakishita, 1994; 
McCammon, Lentzner, Moriarty, & Schellhammer, 1998; Morassi, Massa, Mesesnel, Magris, 
& D'Agnolo, 1989). As a small amphiphatic molecule, DMSO penetrates also into stem cells 
and acts as a strong hydrogen bond disrupter and hence exerts colligative effects (Ruiz-
Delgado et al., 2009; N. C. Santos, Prieto, Morna-Gomes, Betbeder, & Castanho, 1997). 
The pulmonary excretion of DMSO accounts for the typical garlic like smell, noticed during 
stem cell infusion (Jacob & Herschler, 1983). Secondary to the wide pharmacokinetic 
distribution volume, including good blood brain barrier penetration, DMSO affects multiple 
organ systems with a wide spectrum of toxicities. Those adverse effects include CNS-, 
respiratory-, hemolytic-, gastrointestinal-, hepatic-, dermatologic-, cardiovascular- and renal 
toxicities. 
The overall most frequently reported side effects are of gastrointestinal and cardiovascular 
nature. Nausea and abdominal cramping are observed with incidences of up to 70%. Early 
studies by Davis et al. (J. M. Davis, Rowley, Braine, Piantadosi, & G. W. Santos, 1990; J. 
Davis, Rowley, & G. W. Santos, 1990) demonstrated that the incidence of side effects rose 
with the volume of DMSO and amount of cell lysis products infused.  
Vasovagal reactions with hypotension and bradycardia are observed with a high incidence. 
In a multinational survey study performed by Windrum et al., data from 97 EBMT 
transplant centers were included. DMSO related toxicities other than nausea and vomiting 
were observed in about one out of 50 transplants with a mean incidence of 2.2% in all 
administered units. Cardiovascular side effects were most frequently observed, witnessed in 
27% of the participating centers (Windrum, Morris, Drake, D Niederwieser, & Ruutu, 2005).  
The vagolytic effects of DMSO have been documented in physiologic experiments and the 
hypotension can be attributed to DMSO induced histamine release (J. M. Davis, Rowley, 
Braine, Piantadosi, & G. W. Santos, 1990; KLIGMAN, 1965). However, confounding is the 
fact, that stem cell concentrates are usually infused after thawing to a slushy state at a 
temperature of 4°-8°C. Hence, a substantial amount of the frequently observed bradycardia 
and hypotension could be calorically induced. Along with this, recipients of stem cell 
concentrates are usually premedicated with IV glucocorticosteroids, hydration, mannitol 
and anti-histamines (J. M. Davis, Rowley, Braine, Piantadosi, & G. W. Santos, 1990; J. Davis, 
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Rowley, & G. W. Santos, 1990).  Several of the cardiovascular side effects, including the 
frequently observed hypertensive episodes, could hence be multifactorial, like the small 
vessel smooth muscle constriction by DMSO, hydration in combination with mannitol and 
the influence of glucocorticosteroids in the presence of antihistamine premedication. 
Hypotensive attacks are more frequently observed in the absence of antihistamine 
premedication (English et al., 1989; O'Donnell, Burnett, Sheehan, Tansey, & G. A. 
McDonald, 1981). Other cardiovascular   toxicities, which are potentially related to DMSO 
are electrocardiographic abnormalities (J. M. Davis, Rowley, Braine, Piantadosi, & G. W. 
Santos, 1990), pulmonary edema and rarely observed case fatalities, such as cardiac 
arrest(Baum, Weissman, Tsukamoto, Buckle, & Peault, 1992; PEGG & KEMP, 1960; Ruiz-
Delgado et al., 2009). 
Respiratory side effects are also frequently observed with stem cell infusions and can often 
be attributed to DMSO toxicity. Mild bronchospasm and subclinical reductions of 
pulmonary capacity are frequently observed, but severe respiratory depressions with the 
need for pulmonary resuscitation have been reported (Benekli et al., 2000; Miniero, Vai, 
Giacchino, Giubellino, & Madon, n d). 
Other, less frequently observed toxicities are anaphylaxis, renal failure, seizures, acute 
hepatotoxicity and hemolysis. 
3.4.2.2 Alternatives to standard DMSO 
The above described toxicities led to efforts to reduce the patients’ exposure to DMSO. 
Principally five different approaches are possible. First, the reduction of DMSO 
concentration in the stem cell concentrate, second creating a stem cell product with a higher 
cell concentration and corresponding smaller volumes and a lower cumulative exposure to 
DMSO, third a prolonged infusion with a less intense exposure to DMSO, fourth DMSO 
depletion in post-thaw processing and last, using alternative CPAs, either alone or in 
combination with DMSO.  
A DMSO concentration of 10% in the stem cell concentrate is still considered standard in 
most centers around the world. However, several investigators examined the effects of 
lower DMSO concentrations on recovered cell counts, viability and colony forming capacity.  
DMSO concentration as low as 2% were used(Bakken, O Bruserud, & J F Abrahamsen, 2003; 
Balint et al., 1999; Galmés et al., 1999; Halle et al., 2001; Syme et al., 2004; Zeisberger et al., 
2010). Overall, 5% DMSO concentrations delivered comparable results to the standard 10% 
concentration, whilst DMSO concentrations of less or equal to 2% revealed inferior cell 
integrity, at least in some reports (Zeisberger et al., 2010).  In a recent retrospective report 
from Norway, 103 consecutive patients underwent autologous PBSC transplants after high 
dose chemotherapy for lymphoma or myeloma (Akkök et al., 2008).  The stem cell 
concentrates were preserved with 10% DMSO in the initial period and with 5% DMSO in the 
later period. Clinical outcomes, such as transfusion requirements and neutrophil/platelet 
recovery were essentially the same. 
In recent years, the disaccharides trehalose and sucrose have been evaluated as 
cryopreservative additives (Buchanan et al., 2004; Rodrigues et al., 2008; Scheinkönig, 
Kappicht, Kolb, & Schleuning, 2004; E J Woods et al., 2000; X. B. Zhang et al., 2003). The 
exact mode of action of those small molecules remains elusive, but it has been well 
demonstrated that the integrity of membrane layers and proteins during cryopreservation 
remains well preserved in the presence of those molecules (J H Crowe et al., 2001; John H 
Crowe, 2007).  Along with a favorable toxicity profile of those compounds, certain 
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pharmacokinetic properties may be of benefit. Trehalose is not able to permeate into the 
interior of the cells. This facilitates removal during post-thaw washing (Rodrigues et al., 
2008).  Sucrose/trehalose/DMSO combinations  with DMSO concentrations as low as 2.5% 
have been shown to be comparable with standard 10% DMSO as cryo-additive. Cell count 
recovery, viability and clonogenicity were similar in several studies (Rodrigues et al., 2008).  
Similarly encouraging results have been noticed in the presence of catalase type natural bio-
oxidants in the cryopreservation medium (Motta, Gomes, L F Bouzas, Paraguassú-Braga, & 
Porto, 2010; Sasnoor, Kale, & Limaye, 2003), although the exact role of the natural bio-
oxidant is still not known. 
Another group of substances which are excellent candidates as cryo-preservative additives 
are hydrophilic macromolecules. They also have the pharmacokinetic benefit of being 
restricted to the extracellular space and some follow a first order elimination kinetic. 
Albumin, modified gelatin, hydroxyethyl starch(HES), polyvinylpyrrolidone and 
polyethylene oxide  are members of this group of substances.  HES has been most widely 
studied, particularly to reduce the DMSO concentration (Clapisson et al., 2004; Jeffrey 
McCullough et al., 2010). A combination of 5% DMSO and 6%HES has been shown to be 
associated with successful long term storage of PBSC(Jeffrey McCullough et al., 2010).  In a 
blinded randomized phase III, patients underwent high dose chemotherapy with 
autologous PBSC support, either preserved with a standard solution containing 10% 
dimethylsulfoxide (DMSO, v/v) or 5% DMSO in combination with 6% hydroxyethylstarch 
(HES, w/v). One hundred and forty eight patients received PBSC frozen with 10% DMSO 
and 146 received cells frozen in 5% DMSO/6% HES. Whilst platelet recovery and the 
median amount of blood products transfused did not differ in between the two groups, the 
patients obtaining cell concentrates, cryopreserved with the DMSO/HES combination 
obtained neutrophil recovery in average one day earlier and needed one day less antibiotic 
administration(p=0.04)(Rowley et al., 2003). 
Unfortunately hematopoietic and other stem cells, particularly human embryonic stem cells, 
undergo apoptotic transformation during the cryopreservation process (Sangeetha, Kale, & 
Limaye, 2010; Stroh et al., 2002). This led to the study of caspase inhibitors as 
cryopreservatives. The initial encouraging results on cell cultures (Heng, Clement, & T. Cao, 
2007; Stroh et al., 2002), were recently supported by in vivo experiments(Sangeetha, Kale, & 
Limaye, 2010). 
Other cryo-preservative additives, such as α tocopherol(Neunert et al., 2009; E J Woods et 
al., 2000), are under investigation and may be of future interest. 
3.5 The freezing process 
3.5.1 Freezing rate 
The optimal method of freezing the cell concentrate to the target storage temperature still 
remains a matter of debate. Only few high quality studies are available to guide the clinician 
and laboratorian in the choice of the optimal technique. The controlled rate freezing(CRF)  
procedure still remains the defined standard in many countries (S. M. Watt, Austin, & S. 
Armitage, 2007).  The principal rationale for CRF as choice is the limited cell damage during 
the freezing process (Donaldson et al., 1996; Douay, 1985; Yang et al., 2001), particularly at 
the eutectic transition point. At the eutectic transition point the liquid phase transits into a 
solid phase and fusion heat is released. Prolonged cell exposure at this point is regarded 
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pulmonary capacity are frequently observed, but severe respiratory depressions with the 
need for pulmonary resuscitation have been reported (Benekli et al., 2000; Miniero, Vai, 
Giacchino, Giubellino, & Madon, n d). 
Other, less frequently observed toxicities are anaphylaxis, renal failure, seizures, acute 
hepatotoxicity and hemolysis. 
3.4.2.2 Alternatives to standard DMSO 
The above described toxicities led to efforts to reduce the patients’ exposure to DMSO. 
Principally five different approaches are possible. First, the reduction of DMSO 
concentration in the stem cell concentrate, second creating a stem cell product with a higher 
cell concentration and corresponding smaller volumes and a lower cumulative exposure to 
DMSO, third a prolonged infusion with a less intense exposure to DMSO, fourth DMSO 
depletion in post-thaw processing and last, using alternative CPAs, either alone or in 
combination with DMSO.  
A DMSO concentration of 10% in the stem cell concentrate is still considered standard in 
most centers around the world. However, several investigators examined the effects of 
lower DMSO concentrations on recovered cell counts, viability and colony forming capacity.  
DMSO concentration as low as 2% were used(Bakken, O Bruserud, & J F Abrahamsen, 2003; 
Balint et al., 1999; Galmés et al., 1999; Halle et al., 2001; Syme et al., 2004; Zeisberger et al., 
2010). Overall, 5% DMSO concentrations delivered comparable results to the standard 10% 
concentration, whilst DMSO concentrations of less or equal to 2% revealed inferior cell 
integrity, at least in some reports (Zeisberger et al., 2010).  In a recent retrospective report 
from Norway, 103 consecutive patients underwent autologous PBSC transplants after high 
dose chemotherapy for lymphoma or myeloma (Akkök et al., 2008).  The stem cell 
concentrates were preserved with 10% DMSO in the initial period and with 5% DMSO in the 
later period. Clinical outcomes, such as transfusion requirements and neutrophil/platelet 
recovery were essentially the same. 
In recent years, the disaccharides trehalose and sucrose have been evaluated as 
cryopreservative additives (Buchanan et al., 2004; Rodrigues et al., 2008; Scheinkönig, 
Kappicht, Kolb, & Schleuning, 2004; E J Woods et al., 2000; X. B. Zhang et al., 2003). The 
exact mode of action of those small molecules remains elusive, but it has been well 
demonstrated that the integrity of membrane layers and proteins during cryopreservation 
remains well preserved in the presence of those molecules (J H Crowe et al., 2001; John H 
Crowe, 2007).  Along with a favorable toxicity profile of those compounds, certain 
Cryopreservation of Hematopoietic and  
Non-Hematopoietic Stem Cells – A Review for the Clinician 
 
237 
pharmacokinetic properties may be of benefit. Trehalose is not able to permeate into the 
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and laboratorian in the choice of the optimal technique. The controlled rate freezing(CRF)  
procedure still remains the defined standard in many countries (S. M. Watt, Austin, & S. 
Armitage, 2007).  The principal rationale for CRF as choice is the limited cell damage during 
the freezing process (Donaldson et al., 1996; Douay, 1985; Yang et al., 2001), particularly at 
the eutectic transition point. At the eutectic transition point the liquid phase transits into a 
solid phase and fusion heat is released. Prolonged cell exposure at this point is regarded 
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detrimental to the survival of cells (Douay, 1985). The principal time trajectory during 
controlled rate freezing involves initially slow freezing, at a rate of -1° to -2° Celsius per 
minute, then very rapidly around the eutectic point, to be then further cooled at a steady, 
preset rate to a target temperature to be finally placed into nitrogen for durable storage. 
Several modifications of this technique have been described in the literature (Berz, 
McCormack, Winer, Colvin, & Peter J Quesenberry, 2007; Donaldson et al., 1996; Gorin, 
1986; Perez-Oteyza et al., 1998; Valeri & Pivacek, 1996; S. M. Watt, Austin, & S. Armitage, 
2007). Briefly, one typical algorithm for controlled rate freezing using the KRYO10 freezer 
encompasses, pre-cooling of the specimen to 6° Celsius and placement into a cryo-cassette. 
Then the cooling process proceeds at a rate of-1° to -2° Celsius/minute to a temperature of -
5° C, followed by rapid cooling around the eutectic point to avoid damage by fusion heat 
release. Then the cell concentrate continues to be cooled at a rate of -1 Celsius /minute to a 
temperature of -40 Celsius followed by a rate of -5 Celsius /minute to a target of -135 to -160 
Celsius. Finally, the product is placed into permanent nitrogen storage. 
Unfortunately, this technique requires sophisticated, costly equipment and a certain 
personal expertise, which are not available at every center (Almici et al., 2003; Perez-Oteyza 
et al., 1998).   
Several single armed studies have reported excellent viability and hematopoietic recovery 
rates with uncontrolled freezing procedures in bone marrow (Clark, Pati, & D. McCarthy, 
1991; Stiff, Murgo, Zaroulis, DeRisi, & Clarkson, 1983) and peripheral blood progenitor 
specimens (Almici et al., 2003; Cilloni et al., 1999; Halle et al., 2001).  
Few studies directly compared outcomes of controlled rate to  uncontrolled rate freezing 
processes.   
A preclinical study, using murine bone marrow samples compared two controlled rate 
freezing protocols with one uncontrolled rate protocol. Nuclear cell count, viability and 
several functional assays (MRA, CFU-S and CFU-GM) were assessed after thawing and 
washing. Although comparable cell counts and viability assays were achieved, superior 
functional assays (particularly CFU-S and CFU-GM) were achieved with the controlled rate 
freezing procedure (Balint et al., 1999). 
In a clinical study from Japan, two different freezing protocols were compared in the 
cryopreservation of peripheral blood stem cells (PBSC) (Y Takaue et al., 1994).  The PBSC 
were cryopreserved by either controlled rate or un-controlled rate freezing methods. No 
differences were observed in the granulocyte/platelet engraftment times and transfusion 
requirements were similar in both groups (Y Takaue et al., 1994).  
The interpretation of this study is somewhat complicated by the fact that the cells in the 
uncontrolled rate freezing arm also differed in the cryopreservative additive from the 
standard arm. In addition, only twelve patients obtained the cells, preserved by 
uncontrolled rate freezing and the study design was not randomized, using matched 
historical controls as reference.  
In a prospective, randomized controlled multicenter study from Spain, apheresis products 
from 105 patients, who obtained a peripheral stem cell transplant for various malignancies, 
were split into two bags. One was processed with controlled rate, the other one with 
uncontrolled rate freezing. Nucleated cell counts, viability and a committed functional assay 
(CFU-GM) were assessed after thawing. No difference in the loss of cell counts and viability 
were observed, but again the CFU-GM assay performed superior in the controlled rate 
freezing arm (Perez-Oteyza et al., 1998). Although the strength of the study was that each 
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sample functioned as its own control, i.e. all other the outcome influencing parameters were 
kept identical in both arms, the study was not powered to detect differences in the patients’ 
clinical outcomes, such as engraftment kinetics and survival. It remains hence unclear, if the 
differences in the functional assay outcome hold clinical relevance. 
In conclusion, we feel that the controlled rate and the uncontrolled rate freezing procedure 
are both viable techniques for the preservation of stem cells. At our institution, we perform 
controlled rate freezing only for bone marrow. Future studies, sufficiently powered to 
examine relevant clinical outcomes will be needed to determine if the more elaborate 
controlled rate approach is truly superior.  
3.5.2 Storage temperature 
The minimal requirements for a long term storage temperature are technical feasibility and a 
successful clinical outcome. The storage temperature for hematopoietic stem cells varies 
between different centers. Temperatures range from -196°C to -80°Celsius (Aird, Labopin, 
Gorin, & Antin, 1992; Cilloni et al., 1999; Galmés et al., 1999; Halle et al., 2001; Rubinstein et 
al., 1995; Son, Heo, Park, H. H. Kim, & K. S. Lee, 2010; Valeri & Pivacek, 1996). The initially 
used storage temperatures of -196°C, reflecting the liquid phase nitrogen storage, have 
largely been replaced by temperatures of  
-156°C to -135°C, reflecting the vapor phase storage (Berz, McCormack, Winer, Colvin, & 
Peter J Quesenberry, 2007) in BM-, PB- as well as umbilical cord derived stem cells(Aird, 
Labopin, Gorin, & Antin, 1992; Cilloni et al., 1999; Galmés et al., 1999; Halle et al., 2001; 
Rubinstein et al., 1995; Son, Heo, Park, H. H. Kim, & K. S. Lee, 2010; Valeri & Pivacek, 1996). 
This shift in culture was mainly induced by the observation that infectious pathogens can 
survive and be propagated in the liquid nitrogen phase (Bielanski & Vajta, 2009). This fact 
received a large deal of public attention, when in the mid-1990s six recipients of BM- and 
PBSC- transplants developed icteric hepatitis B. Follow up examinations revealed that 
leakage from one auto-donor’s stem cell product induced viral contamination of five 
patients’ units, which were stored in the same tank (Tedder et al., 1995). 
A recent study by McCullough et al. compared 5 different protocols for five year PBSC 
storage. Along with other variables, liquid phase nitrogen storage (-196°C) was also 
compared to a mechanical freezer temperature at -135°C. No significant outcome differences 
were observed between both temperatures (Jeffrey McCullough et al., 2010).  
For human embryonic stem cells, which are stored after vitrification, the storage 
temperature is a more crucial subject.  Even slight temperature variation can lead to de-
vitrification of the metastable cryopreservate with crystal formation and corresponding cell 
damage (Baicu, M. J. Taylor, Z. Chen, & Rabin, 2008; Wusteman, Robinson, & D. Pegg, 
2004). Techniques have been developed to minimize those potentially detrimental 
temperature fluctuations (C. J. Hunt, 2011; Rowley & Byrne, 1992). 
3.5.3 Infectious considerations 
The contamination of stem cell products with infectious pathogens can occur at several 
points during the stem cell processing-The marrow harvest, cord blood collection or 
apheresis, the transport of the product to the cryopreservation facility, the pre-thaw 
processing, the thawing and washing process as well as the infusion of the final product are 
all processing points with the potential for microbial contamination.  Infectious 
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contaminations during those processes are observed with varying degrees, generally 0-4.5% 
for PBSC and up to 26% for bone marrow, even if strictly aseptic protocols are 
followed(Attarian, Bensinger, Buckner, D. L. McDonald, & Rowley, 1996; Espinosa, Fox, 
Creger, & Lazarus, 1996; Jestice et al., 1996; Kamble et al., 2005; Larrea et al., 2004; Lowder & 
Whelton, 2003; Majado et al., 2007; D. J. Padley et al., 2003; D. Padley, Koontz, Trigg, 
Gingrich, & Strauss, 1996; Schwella et al., 1994; Webb et al., 1996). Along with this, bacteria, 
fungi and viruses are able to survive in the liquid nitrogen storage phase and cross-
contaminations between different units, stored in the same container have been observed 
(Bielanski, 2005; Bielanski, Bergeron, Lau, & Devenish, 2003; Bielanski & Vajta, 2009). 
If microbial contaminations in other blood products, such as red blood cells, platelet 
concentrates or plasma products are detected, they are usually discarded. However, in stem 
cell concentrates this decision is complicated by the fact, that the total amount of stem cells 
is limited. Several reports described case fatalities when stem cell recipients received 
microbially contaminated products(“Current good tissue practice for human cell, tissue, and 
cellular and tissue-based product establishments; inspection and enforcement. Final rule.,” 
2004; “Eligibility determination for donors of human cells, tissues, and cellular and tissue-
based products. Final rule.,” 2004; Kamble et al., 2005). The FDA recommends caution with 
the use of contaminated products and estimated that seven deaths per year could be 
prevented by the elimination of contaminated stem cell units. 
The predominant cultured bacterial subspecies are part of the skin flora and other 
commensal organisms, with the remainder being mainly enteric organisms. However, other 
opportunistic and non-opportunistic organisms like Stenotrophomonas maltophilia and 
MRSA have been identified (Kamble et al., 2005; Larrea et al., 2004; Patah et al., 2007; 
Vanneaux et al., 2007).  
The clinical relevance of microbial contamination of stem cell products has been questioned 
by several authors. Two recent studies examined cultures of stem cell collections at different 
time points of the cryopreservation process. All patients were routinely prophylaxed with 
fluoroquinolones, acyclovir and fluconazole. Further, organism specific antimicrobial 
therapy was added when positive cultures were detected prior to the infusion(Majado et al., 
2007; Patah et al., 2007). 
A study from the MD Anderson cancer center reported the experience with 3078 autologous 
or allogeneic hematopoietic stem cell infusions over a six year time span. Cultures were 
taken at apheresis or marrow harvest, infusion for fresh products (mainly allogeneic) and 
thawing/infusion of the cellular products.  The overall rate of positive cultures in this study 
was relative low at 1.2% and coagulase negative Staphylococci were the most frequently 
detected organisms. None of the 21.6% of the patients who died in the post-transplant 
period died from a cause, ascribed to the contaminated stem cell product (Patah et al., 2007).  
Another study from Spain summarized the experience with 152 patients receiving a total of 
617 bags of autologous, cryopreserved PBSC. Cultures were taken pre-freezing and at the 
end of the infusion from the post-thaw specimen. Overall, 31 were found to be contaminated 
(5%) and skin commensals were again the most frequently identified species. No increased 
mortality or other severe clinical sequelae were observed in the patients obtaining the 
contaminated stem cell infusions. The length of hospitalization in the acute transplant 
period was longer in this group of patients. However, this could not be attributed to 
infections with the contaminant, suggesting other patient specific factors in this patient 
group(Majado et al., 2007). 
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Other studies with a similar methodology were performed and confirmed all the following 
results(Kamble et al., 2005; Larrea et al., 2004; Vanneaux et al., 2007): First, skin commensals 
are the most prevalent cause of microbial contaminations; Second, the relatively increased 
incidence of positive cultures after bone marrow harvest when compared to peripheral 
blood apheresis products seems to be decreasing, possibly reflecting the implementation of 
recent asepsis guidelines. Third, the rate of  positive blood cultures is the highest directly after 
stem cell collection and lowest after cryopreservation. This eludes to a certain antimicrobial 
effect of the cryopreservation procedure and possibly the cryopreservative DMSO. 
 
Cultured organism Overall incidence of positive cultures[%] 
Fraction of positive 
cultures[%] 




Propionibacterium acni 0.6–2.2 0.1-27.2 
Staphylococcus aureus 0–1.6 0-2.3 
Bacillus cereus and other Bacillus 
spec. 0.06–0.35 0-0.8 
Pseudomonas spec.(aeruginosa, 
putida and fluoresces) 0–0.32 0–0.8 
Corynebacterium spec. 0–0.3 0-6.5 
Stenotrohomonas maltophilia 0-0.3 0-5.9 
Aspergillus fumigatus 0–0.3 0-7.6 
Mixed cultures 0.1–15.6 0-0.82 
Table 1. The table above describes the growth of different organisms when cultures were 
assessed in after thawing, before infusion of the unit. The studies, used to extract the table 
are referenced in the paragraph above. The middle column reflects the overall incidence of 
positive cultures by organisms over different studies, the right column lists the fraction 
those organisms represented. All values are expressed in percentages. 
However, bacteria and other organisms can survive cryopreservation and have to be 
considered when antibiotic coverage after infusion is administered. Fourth, the clinical 
impact of infusion with contaminated stem cell products seems to be managable, when 
handled by expert hands. Table 1 summarizes the results of the referenced studies. 
3.5.4 Durability 
The durability of a stem cell graft, is defined as the timespan a stem cell graft can be 
preserved and still exert the desired clinical effect when utilized. Although the time span 
between collection and infusion into the recipient for most allogeneic and autologous 
hematologic transplants is relatively short, for cord blood it can be much longer than a 
decade. The maximal possible cryopreservation time span is still unknown. 
Several of the above listed functional substitute assays have been used to determine the 
functional integrity of cryopreserved stem cell grafts. For bone marrow, peripheral blood as 
well as cord blood stem cells, it has been shown that clonogenic assays, such as the BFU-E 
and CFU-GM are compromised fairly early during the course of cryopreservation. In 
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between collection and infusion into the recipient for most allogeneic and autologous 
hematologic transplants is relatively short, for cord blood it can be much longer than a 
decade. The maximal possible cryopreservation time span is still unknown. 
Several of the above listed functional substitute assays have been used to determine the 
functional integrity of cryopreserved stem cell grafts. For bone marrow, peripheral blood as 
well as cord blood stem cells, it has been shown that clonogenic assays, such as the BFU-E 
and CFU-GM are compromised fairly early during the course of cryopreservation. In 
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contrast, the recovery of nucleated cells (NC) and CD34+ cells remains relatively well 
preserved(Attarian, Feng, Buckner, MacLeod, & Rowley, 1996; Hal E Broxmeyer et al., 2003; 
Buchanan et al., 2004; Cilloni et al., 1999; E J Woods et al., 2000; Xiao & Douglas C Dooley, 
2003; Yang et al., 2001; X. B. Zhang et al., 2003). In addition, the engraftment capacity in the 
immunodeficient NOD/SCID mice remains relatively well preserved for long periods of 
time (Bock, Orlic, Dunbar, H E Broxmeyer, & D M Bodine, 1995; Vormoor et al., 1994). The 
durability of cord blood stem cells beyond 15 years of cryopreservation has been shown by 
several authors with different functional substitute assays (Hal E Broxmeyer et al., 2003; 
Kobylka, Ivanyi, & Breur-Vriesendorp, 1998; Mugishima et al., 1999). Kobylka et al. and 
Mugishima et al. proved the durability after up to 15 years of storage with flow cytometric 
and clonogenic assays, whilst Broxmeier et al. also demonstrated hematopoietic 
reconstitution of sublethally irradiated NOD/SCID mice (Hal E Broxmeyer et al., 2003).  
The clinical experience with long term cryopreserved stem cell grafts remains somehow 
limited. Anecdotal reports confirmed successful trilineage engraftment with BM derived 
stem cell grafts, which were stored for 7 years (Walter et al., 1999). A systematic review 
evaluating the combined experience of the Brigham and Women’s Hospital and the EBMT 
Group(Aird, Labopin, Gorin, & Antin, 1992)  noticed that HSC can be effectively 
cryopreserved for up to 11 years. A retrospective study from Seattle revealed full trilineage 
recovery in patients receiving HSC, stored for up to 7.8 years without consistent detrimental 
effects (Attarian, Feng, Buckner, MacLeod, & Rowley, 1996). It also remains unclear if any of 
the currently used cryopreservation protocols reveals superior results when used for clinical 
applications in humans. A recent report by McCullough et al. compared four different 
protocols for cryopreservation of PBSC. After five years of storage the relative integrity of 
PBSCs was preserved, regardless which of the cryopreservation protocols was used (Jeffrey 
McCullough et al., 2010).  
3.5.5 Storage containers 
Containers for the long term storage of stem cell concentrates need to fulfill at least closure 
integrity, sample stability over long periods of time and easy accessibility as minimal 
requirements(Erik J Woods & Thirumala, 2011). With the increasing financial and 
environmental strain on health care systems, even in developed nations, and the increasing 
amount of umbilical cord stem cells banked, additional points of relevance are a low cost, 
potential for reuse, environmental sustainability and economic use of available long term 
storage space. Container devices prior to the actual long term cryopreservation need to 
allow for convenient collection of the stem cells and storage in the liquid phase at supra-
freezing temperatures for up to 72 hours. In addition, the processing of the stem cell 
collection often entails centrifugation and hence the requirement for the container to be 
resistant to significant gravitational forces. To date, most institutions use several containers 
or bags prior to the actual cryopreservation bag. In addition, to prevent spillage and cross 
contamination of concentrates stored in the same storage nitrogen tank, the ISCT 
recommends over-rap bags on their web site. Historically most stem cell storage institutions 
arose from blood banks with long standing expertise with bags as storage containers (Khuu 
et al., 2002; Thirumala, Goebel, & Erik J Woods, 2009; Erik J Woods & Thirumala, 2011). 
Hence, freezing bags are the most frequently used long term storage containers for stem 
cells and ethylene vinyl acetate(EVA) based products represent the majority in the 
market(Thirumala, Goebel, & Erik J Woods, 2009) .  
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A 2002 publication reported breakage of EVA based bags, storing PBSC and lymphocyte 
concentrates, with a microbial contamination rate of 42% (Khuu et al., 2002). Along with 
that, a recent publication described a breakage rate of 3.5% over a 6.5 year storage period on 
umbilical cord concentrates (Thyagarajan, Michael Berger, Sumstad, & McKenna, 2008). 
Similar concerns were raised in the past with different plastic materials (Valeri & Pivacek, 
1996). 
The historical experience with catastrophic viral cross infection (Tedder et al., 1995) as well 
as such recent reports triggered increasing concerns about EVA based products. EVA 
experiences a glass transition below   -15°C, what renders it brittle and potentially fragile 
below this temperature (Kempe MD, Jorgensen GJ, Terwilliger KM, McMahon TJ, Kennedy 
CE, n d). Those concerns, along with the desire to produce reusable materials, have 
prompted the exploration of other materials as base for cryocontainers (Eakins MN, n d).  
 
Trade name Material 
 Cryocyte/Baxter® 
 CellFlex/Maco Pharma® 
 Cell Freeze™ Charter Medical 
 Pall Medical® Freezing Bag 791-05 
 Cryostore EVA/Origen Biomedical Inc. 
 Thermogenesis® Corp./Freezing bag 80346-0 
 Origen Cryostore® 
 EVA CryoMACS® 
EVA* based 
 KryoSure®  
 American Fluoroseal® 
 Fresenius Hemocare/Hemofreeze® 





Table 2. The table above lists several commercially available bags for cryopreservation of 
stem cells. Please note, that some of them may not be currently available or FDA approved.  
A recent publication by Woods et al described a cyclic olefin co-polymer based container 
system with favorable cryo-physical properties. The small size of those containers at 2mL 
and 5mL would be prohibitive for large scale HSC storage but was successfully assessed for 
suitability of dental pulp derived MSC(Erik J Woods & Thirumala, 2011). 
Another report from the Czech republic demonstrated success cryopreservation in a 
reusable stainless steel container specifically designed for PBSC(Mĕricka et al., 1991). Table 2 
describes some of the products used for cryopreservation of stem cells around the world. 
3.6 Thawing and post-thaw processing 
At our institution the thawing of the cryopreserved unit is performed by the technician at 
the bedside. The unit is then handed over to the treating physician or nurse for infusion into 
the patient. Depending on the regulatory environment, in certain countries the unit is 
retrieved from the storage tank by the technician to be handed over for transport to the 
patient and thawing by the physician or supporting clinical staff. Regardless of the logistic 
specifics, the unit is thawed to a slushy state and then slowly infused into the recipient 
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contrast, the recovery of nucleated cells (NC) and CD34+ cells remains relatively well 
preserved(Attarian, Feng, Buckner, MacLeod, & Rowley, 1996; Hal E Broxmeyer et al., 2003; 
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and clonogenic assays, whilst Broxmeier et al. also demonstrated hematopoietic 
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The clinical experience with long term cryopreserved stem cell grafts remains somehow 
limited. Anecdotal reports confirmed successful trilineage engraftment with BM derived 
stem cell grafts, which were stored for 7 years (Walter et al., 1999). A systematic review 
evaluating the combined experience of the Brigham and Women’s Hospital and the EBMT 
Group(Aird, Labopin, Gorin, & Antin, 1992)  noticed that HSC can be effectively 
cryopreserved for up to 11 years. A retrospective study from Seattle revealed full trilineage 
recovery in patients receiving HSC, stored for up to 7.8 years without consistent detrimental 
effects (Attarian, Feng, Buckner, MacLeod, & Rowley, 1996). It also remains unclear if any of 
the currently used cryopreservation protocols reveals superior results when used for clinical 
applications in humans. A recent report by McCullough et al. compared four different 
protocols for cryopreservation of PBSC. After five years of storage the relative integrity of 
PBSCs was preserved, regardless which of the cryopreservation protocols was used (Jeffrey 
McCullough et al., 2010).  
3.5.5 Storage containers 
Containers for the long term storage of stem cell concentrates need to fulfill at least closure 
integrity, sample stability over long periods of time and easy accessibility as minimal 
requirements(Erik J Woods & Thirumala, 2011). With the increasing financial and 
environmental strain on health care systems, even in developed nations, and the increasing 
amount of umbilical cord stem cells banked, additional points of relevance are a low cost, 
potential for reuse, environmental sustainability and economic use of available long term 
storage space. Container devices prior to the actual long term cryopreservation need to 
allow for convenient collection of the stem cells and storage in the liquid phase at supra-
freezing temperatures for up to 72 hours. In addition, the processing of the stem cell 
collection often entails centrifugation and hence the requirement for the container to be 
resistant to significant gravitational forces. To date, most institutions use several containers 
or bags prior to the actual cryopreservation bag. In addition, to prevent spillage and cross 
contamination of concentrates stored in the same storage nitrogen tank, the ISCT 
recommends over-rap bags on their web site. Historically most stem cell storage institutions 
arose from blood banks with long standing expertise with bags as storage containers (Khuu 
et al., 2002; Thirumala, Goebel, & Erik J Woods, 2009; Erik J Woods & Thirumala, 2011). 
Hence, freezing bags are the most frequently used long term storage containers for stem 
cells and ethylene vinyl acetate(EVA) based products represent the majority in the 
market(Thirumala, Goebel, & Erik J Woods, 2009) .  
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A 2002 publication reported breakage of EVA based bags, storing PBSC and lymphocyte 
concentrates, with a microbial contamination rate of 42% (Khuu et al., 2002). Along with 
that, a recent publication described a breakage rate of 3.5% over a 6.5 year storage period on 
umbilical cord concentrates (Thyagarajan, Michael Berger, Sumstad, & McKenna, 2008). 
Similar concerns were raised in the past with different plastic materials (Valeri & Pivacek, 
1996). 
The historical experience with catastrophic viral cross infection (Tedder et al., 1995) as well 
as such recent reports triggered increasing concerns about EVA based products. EVA 
experiences a glass transition below   -15°C, what renders it brittle and potentially fragile 
below this temperature (Kempe MD, Jorgensen GJ, Terwilliger KM, McMahon TJ, Kennedy 
CE, n d). Those concerns, along with the desire to produce reusable materials, have 
prompted the exploration of other materials as base for cryocontainers (Eakins MN, n d).  
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Another report from the Czech republic demonstrated success cryopreservation in a 
reusable stainless steel container specifically designed for PBSC(Mĕricka et al., 1991). Table 2 
describes some of the products used for cryopreservation of stem cells around the world. 
3.6 Thawing and post-thaw processing 
At our institution the thawing of the cryopreserved unit is performed by the technician at 
the bedside. The unit is then handed over to the treating physician or nurse for infusion into 
the patient. Depending on the regulatory environment, in certain countries the unit is 
retrieved from the storage tank by the technician to be handed over for transport to the 
patient and thawing by the physician or supporting clinical staff. Regardless of the logistic 
specifics, the unit is thawed to a slushy state and then slowly infused into the recipient 
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under close clinical observation. Several elements of the post thaw process are still a matter 
of debate and we will here discuss relevant points on washing and the functional post-thaw 
assessment of stem cells. 
3.6.1 Washing of stem cells 
Since increased toxicities of DMSO have been observed with increasing amounts, attempts 
to develop protocols to deplete the DMSO content in the infused stem cell product have 
been undertaken. Several protocols to reduce the infused DMSO content have been 
published (Lemarie et al., 2005; Syme et al., 2004). Some of those procedures achieve 2 log 
reductions in the infused DMSO concentration. Theoretical concerns have been raised that 
extensive washing can negatively impact on engraftment kinetics. Unfortunately, only few 
prospective studies have examined the influence of post-thaw washing on toxicities and 
hematopoietic reconstitution (Akkök, Holte, Tangen, Ostenstad, & Oystein Bruserud, 2009; 
Lemarie et al., 2005; Syme et al., 2004).  
In a recent study by Akkök et al., 53 patients obtained high dose chemotherapy with PBSC 
transplant for multiple myeloma, non Hodgkins lymphoma, amyloidosis or POEMS 
syndrome. The maximal liquid storage time prior to cryopreservation was less than 24 
hours. The cryomedium contained AB allogeneic plasma and controlled rate freezing was 
routinely performed. The patients either received the graft either directly post-thaw (n=34) 
or cells, DMSO depleted cells by virtue of a one-step washing procedure(n=19). Only 
patients with a CD34+ count of at least 2.5X106 as backup were allowed for depletion. The 
washing solution consisted of an ACD-saline mixture. Directly after thawing, the graft was 
mixed with the washing solution and centrifuged at 850Xg for 6 minutes at 22°C. The 
supernatant was discarded and the pellet re-suspended with ACD-saline solution to a total 
volume of maximal 150mL. The total ex-vivo handling time after removal from liquid 
nitrogen storage was 50-60 minutes longer for the depleted grafts(Akkök et al., 2009). A 
statistically significant 23.1% loss of CD34+ cells was observed. However, the extracellular 
DMSO concentration and number of neutrophils were both reduced in the washed stem cell 
product. Overall less infusion related adverse events were observed in patients receiving the 
washed autografts (16% vs. 36%, p=0.024). The neutrophil recovery and length of 
neutropenic fever episodes were comparable in both arms, but the platelet recovery was 
delayed by two days (14 vs 12 days) in the group obtaining a washed graft. This was 
associated with a statistically not significant increase in clinically meaningful hemorrhage 
events. The authors concluded that in certain patient populations, a simple one-step 
washing procedure can reduce DMSO related adverse infusion reactions with a tolerable 
compromise of platelet engraftment kinetics. 
Although post-thaw washing is not a routinely performed technique at our center for PBSC 
and BM derived stem cell concentrates, it holds a higher relevance for UCB products.  
Umbilical cord blood transplantation is gaining increasing popularity for a variety of 
malignant and non-malignant diseases. To date, more than 20,000 UCB transplants have 
been performed on children and adults, and more than 400,000 UCB units are available in 
more than 50 public CB banks (Solves, Mirabet, & Roig, 2010). The way cord blood units are 
collected from the donor, renders them rich in hypertonic cryopreservative, red cells, 
plasma and cell debris. This demands additional processing, not routinely applied in PBSC 
and BM derived stem cells. This processing is partially performed before and partially after 
the cryopreservation. Initially, after collection, the collected unit contains a large amount of 
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red blood cell bulk and plasma. Volume reduction is essential to reduce the total amount of 
required storage space. The standard New York Blood Center protocol implies a two-step 
procedure. Here, 6% HES is added in a 1:5 volume ration to the collected, anticoagulated 
UCB. This increases the erythrocyte sedimentation rate. The mixture is then centrifuged at 
50Xg for 5 minutes at 10°C. The leukocyte rich supernatant is expressed and again 
centrifuged at 400Xg for 10 minutes. The pellet is resuspensed in supernatant plasma to a 
total volume of 20mL, which then is used to create the finally cryopreserved unit. The post-
thaw washing procedure entails the addition of an equal volume 2.5% albumin, 40 dextran 
solution and centrifugation at 400Xg for 10 minutes. The sedimented cells are then re-
dispensed in fresh albumin/dextran solution prior to infusion (Rubinstein et al., 1995). 
Although the washing UCB units has been shown to increase the viability of remaining 
cells(Rubinstein et al., 1995), concerns of cell loss in a product which intrinsically suffers 
from a paucity of cells have been raised(Laroche et al., 2005). Hence, alternative washing 
procedures, excluding the post-thaw centrifugation step have been proposed. Here, the 
deleterious osmotic shift is prevented by introduction of a dextran/albumin solution under 
laboratory conditions, but no centrifugation is subsequently performed. In a recent report 
from the Memorial Sloan Kettering Cancer Center (MSKCC), such a technique was applied 
in 54 consecutive patients, obtaining double cord blood transplants (Barker et al., 2009).  The 
sustained donor engraftment rate was excellent( 94%)and the amount of DMSO infused 
compared favorably with autologous transplants. The infusion reactions were manageable 
with the most prominent concern being the episodes of renal compromise, probably induced 
by residual cell debris.  
3.6.2 Functional substitute assays 
The ultimate functional stem cell assay is the engraftment with subsequent reconstitution of 
the desired physiologic function, such as cell count recovery in hematopoietic stem cells in 
the myeloablated human host. 
However, for obvious reasons we are relying on functional substitute assays to estimate the 
functional integrity of the stem cell graft. Such substitute assays consists of cell counting 
experiments enumerating cell populations with a high stem cell potential, viability tests, 
quantifying certain biologic functions, clonogenic assays, reflecting the potential of cell 
population to give rise to other subspecialized cell types and direct engraftment 
experiments in previously myelo-ablated or immune-deficient mammals (see table 3). 
The most frequently used cell counting assays are the total nucleated cell count and the 
count of CD34 positive cells (Kurtz, Seetharaman, N. Greco, & Moroff, 2007; Yang et al., 
2001). Increasing numbers of both have been shown to correlate positively with the 
hematopoietic recovery potential in HSC transplantation (Kurtz, Seetharaman, N. Greco, & 
Moroff, 2007; Yang et al., 2001). Another flow-cytometry marker, which has recently been 
found to correlate positively with the enumeration of viable stem cell populations is 
aldehyde dehydrogenase (ALDH+). The particular benefit of this maker is, that ALDH 
positive cells show a very low or absent apoptotic potential (D. A. Hess et al., 2004; Kurtz, 
Seetharaman, N. Greco, & Moroff, 2007). Trypan blue-, 7-aminoactinomycinD (7-AAD) and 
propidium iodide-exclusion have been shown to be particularly strongly expressed in 
immature, viable cell populations, such as stem cells  (Kurtz, Seetharaman, N. Greco, & 
Moroff, 2007; K. Liu et al., 2003; M. Solomon, Wofford, C. Johnson, Regan, & Creer, 2010; 
Ware, Nelson, & Blau, 2005; E J Woods et al., 2000; Xiao & Douglas C Dooley, 2003). They 
 
New Advances in Stem Cell Transplantation 
 
244 
under close clinical observation. Several elements of the post thaw process are still a matter 
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routinely performed. The patients either received the graft either directly post-thaw (n=34) 
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mixed with the washing solution and centrifuged at 850Xg for 6 minutes at 22°C. The 
supernatant was discarded and the pellet re-suspended with ACD-saline solution to a total 
volume of maximal 150mL. The total ex-vivo handling time after removal from liquid 
nitrogen storage was 50-60 minutes longer for the depleted grafts(Akkök et al., 2009). A 
statistically significant 23.1% loss of CD34+ cells was observed. However, the extracellular 
DMSO concentration and number of neutrophils were both reduced in the washed stem cell 
product. Overall less infusion related adverse events were observed in patients receiving the 
washed autografts (16% vs. 36%, p=0.024). The neutrophil recovery and length of 
neutropenic fever episodes were comparable in both arms, but the platelet recovery was 
delayed by two days (14 vs 12 days) in the group obtaining a washed graft. This was 
associated with a statistically not significant increase in clinically meaningful hemorrhage 
events. The authors concluded that in certain patient populations, a simple one-step 
washing procedure can reduce DMSO related adverse infusion reactions with a tolerable 
compromise of platelet engraftment kinetics. 
Although post-thaw washing is not a routinely performed technique at our center for PBSC 
and BM derived stem cell concentrates, it holds a higher relevance for UCB products.  
Umbilical cord blood transplantation is gaining increasing popularity for a variety of 
malignant and non-malignant diseases. To date, more than 20,000 UCB transplants have 
been performed on children and adults, and more than 400,000 UCB units are available in 
more than 50 public CB banks (Solves, Mirabet, & Roig, 2010). The way cord blood units are 
collected from the donor, renders them rich in hypertonic cryopreservative, red cells, 
plasma and cell debris. This demands additional processing, not routinely applied in PBSC 
and BM derived stem cells. This processing is partially performed before and partially after 
the cryopreservation. Initially, after collection, the collected unit contains a large amount of 
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red blood cell bulk and plasma. Volume reduction is essential to reduce the total amount of 
required storage space. The standard New York Blood Center protocol implies a two-step 
procedure. Here, 6% HES is added in a 1:5 volume ration to the collected, anticoagulated 
UCB. This increases the erythrocyte sedimentation rate. The mixture is then centrifuged at 
50Xg for 5 minutes at 10°C. The leukocyte rich supernatant is expressed and again 
centrifuged at 400Xg for 10 minutes. The pellet is resuspensed in supernatant plasma to a 
total volume of 20mL, which then is used to create the finally cryopreserved unit. The post-
thaw washing procedure entails the addition of an equal volume 2.5% albumin, 40 dextran 
solution and centrifugation at 400Xg for 10 minutes. The sedimented cells are then re-
dispensed in fresh albumin/dextran solution prior to infusion (Rubinstein et al., 1995). 
Although the washing UCB units has been shown to increase the viability of remaining 
cells(Rubinstein et al., 1995), concerns of cell loss in a product which intrinsically suffers 
from a paucity of cells have been raised(Laroche et al., 2005). Hence, alternative washing 
procedures, excluding the post-thaw centrifugation step have been proposed. Here, the 
deleterious osmotic shift is prevented by introduction of a dextran/albumin solution under 
laboratory conditions, but no centrifugation is subsequently performed. In a recent report 
from the Memorial Sloan Kettering Cancer Center (MSKCC), such a technique was applied 
in 54 consecutive patients, obtaining double cord blood transplants (Barker et al., 2009).  The 
sustained donor engraftment rate was excellent( 94%)and the amount of DMSO infused 
compared favorably with autologous transplants. The infusion reactions were manageable 
with the most prominent concern being the episodes of renal compromise, probably induced 
by residual cell debris.  
3.6.2 Functional substitute assays 
The ultimate functional stem cell assay is the engraftment with subsequent reconstitution of 
the desired physiologic function, such as cell count recovery in hematopoietic stem cells in 
the myeloablated human host. 
However, for obvious reasons we are relying on functional substitute assays to estimate the 
functional integrity of the stem cell graft. Such substitute assays consists of cell counting 
experiments enumerating cell populations with a high stem cell potential, viability tests, 
quantifying certain biologic functions, clonogenic assays, reflecting the potential of cell 
population to give rise to other subspecialized cell types and direct engraftment 
experiments in previously myelo-ablated or immune-deficient mammals (see table 3). 
The most frequently used cell counting assays are the total nucleated cell count and the 
count of CD34 positive cells (Kurtz, Seetharaman, N. Greco, & Moroff, 2007; Yang et al., 
2001). Increasing numbers of both have been shown to correlate positively with the 
hematopoietic recovery potential in HSC transplantation (Kurtz, Seetharaman, N. Greco, & 
Moroff, 2007; Yang et al., 2001). Another flow-cytometry marker, which has recently been 
found to correlate positively with the enumeration of viable stem cell populations is 
aldehyde dehydrogenase (ALDH+). The particular benefit of this maker is, that ALDH 
positive cells show a very low or absent apoptotic potential (D. A. Hess et al., 2004; Kurtz, 
Seetharaman, N. Greco, & Moroff, 2007). Trypan blue-, 7-aminoactinomycinD (7-AAD) and 
propidium iodide-exclusion have been shown to be particularly strongly expressed in 
immature, viable cell populations, such as stem cells  (Kurtz, Seetharaman, N. Greco, & 
Moroff, 2007; K. Liu et al., 2003; M. Solomon, Wofford, C. Johnson, Regan, & Creer, 2010; 
Ware, Nelson, & Blau, 2005; E J Woods et al., 2000; Xiao & Douglas C Dooley, 2003). They 
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function as true viability assays and are diminished or absent in apoptotic cell populations. 
The simple and fast feasibility of such tests qualifies them as excellent functional substitute 
assays, especially before freezing and after thawing of stem cell concentrates. 
Clonogenic assays such as the CFU-Sd12, CFU-GM, CFU-GEMM, BFU-E, LTC-IC and direct 
engraftment assays performed on NOD/SCID mice are more sophisticated functional 
substitute assays. Figure two displays images of clonogenic experiments. However, such 
assays are expensive, time intense, require specific personal expertise and laboratory 
equipment and are poorly standardized.  Hence, they are not routinely used in standard 
qualitative assessments of stem cell grafts.  
 
Biologic function Assay type Corresponding references 
Cell enumeration 
assays 
Nucleated Cell counts (Donnenberg et al., 2002; 
Shlebak et al., 1999; E J 
Woods et al., 2000) 
Flow cytometry for CD34+cells (Donnenberg et al., 2002; 
Sasnoor et al., 2003) 
Viability/apoptosis 
tests 
Trypan blue (K. Liu et al., 2003; Ware, 
Nelson, & Blau, 2005) 
7-AminoactinomycinD
 
(Xiao & Douglas C 
Dooley, 2003; Yang et al., 
2001)
Propidium Iodide (K. W. Johnson et al., 
2007)
SYTO16 assay (Sparrow & Tippett, 2005) 
Flow cytometry for ALDH+ 
reactivity 
(D. A. Hess et al., 2004; 
Kurtz, Seetharaman, N. 
Greco, & Moroff, 2007) 
Clonogenic assays CFU-sd12, CFU-GM, CFU-GEMM (Balint et al., 1999; 
Kobylka et al., 1998; 
Perseghin et al., 1997; 
Shlebak et al., 1999) 
BFU-E
 
(Balint et al., 1999; 
Kobylka et al., 1998; 
Perseghin et al., 1997) 
LTC-IC (Barker & Wagner, 2003; 
Ito et al., 2010) 
Direct engraftment 
experiments 
Engraftment in NOD/SCID mice (Halle et al., 2001; 
Matsumoto et al., 2002; 
Perez-Oteyza et al., 1998; 
Valeri & Pivacek, 1996) 
Table 3. The table above outlines different methods to assess a stem cell graft. The right 
column displays the biologic function assessed, the middle column the actually used assay 
and the right column references for review of the corresponding subject. long-term culture-
initiating cells (LTC-IC), CFU-GM-colony forming unit granulocyte/macrophage; -GEMM-
colony forming unit granulocyte/erythrocyte/macrophage/megakaryocyte; BFU-burst 
forming unit-erythrocyte, CFU-Sd12-colony forming unit spleen on day 12. 
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No final consensus is reached as to the optimal assessment of a donor graft. Cell counting 
assays, either with or without the enumeration of CD34 positive cells are still the most 
frequently used tests. Several problems have recently been outlined with the use of those 
assays. First, a substantial inter-laboratory variability in CD34 counts can be observed (Dzik, 
Sniecinski, & Fischer, 1999; Moroff et al., 2006). Second, although the total NC did not 
significantly change in several studies, the number of CD34+ cells can be significantly 
reduced after thawing (Kurtz, Seetharaman, N. Greco, & Moroff, 2007). Third, a significant 
number of CD34 bright cells are not functional when tested on viability assays. In a recent 
study by Pranke only about 1.8% of the bright CD34+ cells were alive, whereas a small part 
(19.0%) was actively undergoing apoptosis and most of them (79.2%) were dead, when 
judged by the 7-AAD exclusion assay (Pranke et al., 2006). Last, when novel enzymatic, such 
as the ALDH (N. J. Greco, W. R. Lee, Kurtz, Seetharaman, & Moroff, 2003), or apoptotic, 
such as SYTO16 (Sparrow & Tippett, 2005), markers are used, a more sophisticated 
assessment of the clonogenic/regenerative potential of the collected cell population may be 
possible. In a recent study by Kurtz et al., three different methods to enumerate CD34+ cells 
were assessed on pre-freeze and post-thaw samples, along with the viability marker 7-AAD 
and the apoptotic marker SYTO16. Although only minor changes in NC and CD34+ counts 
were observed, the functional assays were significantly impacted by the freezing/thawing 
process (Kurtz, Seetharaman, N. Greco, & Moroff, 2007).  
The above mentioned concerns notwithstanding, Yang et al demonstrated that viable CD34+ 
cell counts are reliable indictors for successful clinical hematopoietic recovery on pre-freeze 
and post-thaw samples (Yang et al., 2005).  This observation reflects most likely the dogma 
of stem cell biology, that principally only one cell with stem cell potential is necessary to 
regenerate the entire hematopoietic system of a myeloablated host. Although, the theoretical 
definition of a stem cell is relatively clear, it still remains unclear how to define its 
immunophenotype and although the CD34+ cell population certainly harbors cells with 
stem cell potential, those represent certainly only a small fraction (K. W. Johnson, M. 
Dooner, & P J Quesenberry, 2007; Peter J Quesenberry, M. S. Dooner, & Aliotta, 2010). Table 
3 depicts different methods to assess the functionality of a stem cell graft. At our center, we 
routinely perform NC-, CD34+- count as well as the trypan blue viability assay before freeze 
and after thaw with excellent observed engraftment correlations. 
3.7 Cryopreservation of Non-Hematologic Stem Cells 
The cryopreservation for the different hematologic stem cell populations are well defined 
with rather subtle evolving refinements. In contrast, the cryopreservative technology for 
non-hematologic stem cells is still evolving. The highest level of sophistication to date has 
been reached with the MSCs. A comprehensive discussion of cryopreservation for non-
hematopoietic stem cells would be beyond the scope of this chapter. Detailed reviews have 
been recently published  (Hanna & Allison Hubel, 2009; C. J. Hunt, 2011). We will briefly 
outline some of the parallels and differences between non-hematologic and hematologic 
stem cell cryopreservation in the following paragraph.  
a. Mesenchymal stem cells(MSC). No consensus has been reached as to the optimal 
cryopreservation protocol of MSC, but most of the published efforts were guided by 
cryopreservation approaches for HSCs (G. Liu et al., 2008; Thirumala, Gimble, & 
Devireddy, 2010; Thirumala, Goebel, & Erik J Woods, 2009; Erik J Woods et al., 2009). 
Several particular concerns were identified. First, MSCs seem to lose their viability very 
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initiating cells (LTC-IC), CFU-GM-colony forming unit granulocyte/macrophage; -GEMM-
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rapidly post-thaw, what can most likely be attributed to the rapid development of 
apoptotic processes. When Pal et al. investigated the behavior of MSC post thawing, a 
rapid decrease in viability from >80% at 2 hours to <40% at 8 hours was identified, even 
when the cells were maintained at 4°C (Pal, Hanwate, & Totey, 2008). Protocols utilizing 
anti-apoptotic agents, such as ROCK-inhibitors, have shown promise in preclinical 
experiments (Heng, 2009). Second, the reliability of standard viability assays for MSCs has 
been questioned. Trypan blue, which is still in wide application in the clinical use of HSCs 
in the US, may not as accurately as 7-AAD, the preferred HSC-viability-assay in Germany, 
reflect the viability of MSCs (D. E. Pegg, 1989). Third, MSCs may play a role in the 
treatment of acute and chronic processes of the heart muscle. DMSO as cryopreservative 
additive(CPA) with the associated cardio-toxicity may not be the best choice for these 
clinical scenarios (Zenhäusern, Tobler, Leoncini, O. M. Hess, & P. Ferrari, 2000). Fourth, 
the alternative CPAs for MSCs  are still poorly defined. Trehalose, glycerol and proline 
did have good efficacy in HSC but do not work in MSC (Grein et al., 2010; Y. Liu et al., n 
d). Last, most published protocols to date encompass the use of xenobiotic components, 
such as fetal calf serum(FCS). This is associated with the corresponding immunonologic 
as well as infectious concerns. Recent developments with xeno-free cryopreservation 
protocols seem to be viable options for MSCs (Zeisberger et al., 2010). 
b. Human embroynic stem cells(hESC). Initial attempts to preserve hESC with protocols 
analogous to the slow controlled rate freezing HSC protocols were associated with 
recovery rates below 30% and high post-thaw differentiation (Ha et al., 2005; Reubinoff, 
Pera, Vajta, & Trounson, 2001; C.-quan Zhou, Q.-yun Mai, T. Li, & Zhuang, 2004). 
Hence, alternative methods for crypreservation of hESC were explored. The vitrification 
technique is for long in use for cryopreservation of embryos and ooctyes in veterinary 
and human application (Yan et al., 2011). Vitrification represents the direct 
transformation of a substance into a glass like state without the formation of ice crystals 
(M. Ojovan, n d). This can be reached by very high cooling rates and high 
concentrations of cryopreservative. InReubinoff’s original open pulled straw (OPS) 
protocol 20% DMSO, 20% ethylene glycol and 0.5 mol/l sucrose were used as 
CPA(Reubinoff et al., 2001). The specimen consisting of a 20µL solution in an open 
straw, was then plunged directly into liquid nitrogen, achieving a cooling rate of 
approximately -75°C/second. This technique results in high post-thaw viabilities and 
low post-thaw differentiation rates. However, several practical problems exist with the 
OPS method. First, the volume preserved in one pulled open straw is with 20µL very 
small and hence logistically prohibitive for a large scale clinical use. Second, the open 
character of the system with storage in liquid nitrogen is associated with infectious 
concerns. Third, the glass like state achieved by this vitrification method is metastable 
and requires consistent temperatures below -135°Celsius, what is often a problem in 
conventional freezing tanks, which imply internal temperature gradients (C. J. Hunt, 
2011; Rowley & Byrne, 1992). Fourth, most formulations use animal proteins in the 
solution, what corresponds to infectious and allergic concerns. Fifth, substitute assays, 
to measure the functionaltiy of hESC for extended periods of time are still poorly 
defined (C. J. Hunt, 2011). Last, the method requires technical and personal 
sophistication, which is not necessarily everywhere available.  
Closed straw as well as potentially scalable techniques have been recently published(T. Li, 
Q. Mai, J. Gao, & C. Zhou, 2010; Richards, Fong, S. Tan, Chan, & Bongso, 2004). The reason 
for the difficulties with the preservation of hESC with traditional slow cooling protocols 
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may be the cooperative growth behavior and the inter-cellular interaction via gap junctions. 
Hence, ice crystal niduses formed within a hESC colony can easily cause mechanical 
damage throughout the entire cell cluster. The awareness of this idiosyncrasy in the growth 
behavior of hESC has led to a series of publications, trying to modify the different cryo-
biological parameters, such as cooling rate, ice nucleation, cryoprotectant concentration, 
osmotic effects associated with the introduction and removal of the cryoprotectant and 
matrix systems allowing for the seeding of cell clusters, maintaining continuous cell-to-cell 
contact in slow cooling protocols (Baran & Ware, 2007; J. Y. Lee et al., 2010; Yang Li, J.-C. 
Tan, & L.-S. Li, 2010; Valbuena et al., 2008).  The recovery success in those experiments was 
promising.  
c. Most of the principals applying to hESC also appear to apply to iPS and so far 
cryopreservation approaches similar to hESCs have been explored (C. J. Hunt, 2011; 
Nishigaki et al., 2011).  
4. Summary and conclusions 
4.1 Summary 
The cryopreservation of stem cells is a crucial component of their therapeutic use in 
hematologic disorders and regenerative medicine. Although protocols for the preservation 
of HSC are well defined, the standardization still remains poor. Protocols for the 
preservation of non-HSCs have been developed and will experience further clinical 
validation if hESC, MSC and iPSC will find wider clinical application in the future. Liquid 
phase storage is safe and effective for short term intervals. It is probably superior to 
cryopreservation at -80° to -156°C for period less than 72hrs, because it avoids the 
unnecessary physical and mechanical damage by more elaborate procedures. Volume and 
cell bulk reduction, although associated with a certain loss of cells, is necessary to 
accommodate the increasing logistical demands in the cellular therapy sector. Cell 
concentrations of 2X108/mL or even higher are safe, effective and necessary to limit the 
spatial needs, particularly considering the rising amount of cryopreserved UCB units.  
DMSO at concentrations of 5-10% is widely used and alternative cryoprevatives have been 
developed. Future studies are needed to define the optimal CPA with the most favorable 
side effect profile. For most stem cell products, controlled rate freezing is still considered 
standard in most countries, but uncontrolled rate freezing approaches are safe and 
associated with good clinical outcomes. The optimal long term storage temperature remains 
to be defined but the vapor phase of nitrogen tanks is suitable for most cellular products. In 
conclusion, future clinical and translational studies will be needed to define and standardize 
the optimal cryopreservation techniques with optimal clinical outcomes and minimal 
clinical, environmental and financial adverse effects. 
4.2 Future directives 
Efforts in the future should focus on clinical and basic science studies to further the 
understanding of the cryobiology of target cell population, to better explain the damage 
caused to the cells by the cryopreservation process. This will help with many issues, 
including the identification of optimal cryobiologic parameters, such as cell concentration, 
pre-freezing cell processing, freezing rate, storage temperature and others. In addition with 
a widening use of stem cells in regenerative medicine, less toxic cryopreservatives are in 
demand. Standardization and the implementation of good manufacturing practices remain a 
global issue. The existing and increasing financial strain on public health systems around 
 
New Advances in Stem Cell Transplantation 
 
248 
rapidly post-thaw, what can most likely be attributed to the rapid development of 
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anti-apoptotic agents, such as ROCK-inhibitors, have shown promise in preclinical 
experiments (Heng, 2009). Second, the reliability of standard viability assays for MSCs has 
been questioned. Trypan blue, which is still in wide application in the clinical use of HSCs 
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the world calls clearly for a global standardization with protocols, feasible also in less 
affluent parts of the world. Finally, an educational exchange across borders to ascertain 
optimal skill sets in laboratorians and clinicians, dealing with stem cell cryopreservation and 
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The most recent clinical trials on adult acute lymphoid leukaemia (ALL) have shown 
complete remission and disease-free survival (DFS) rates of 80-85% and 30-40%, respectively 
(Annino, et al, Durrant, et al, Kantarjian, et al, Larson, et al, Ribera, et al, Rowe). Intensified 
consolidation, particularly with high-dose methotrexate and high-dose cytarabine, may be 
one of the reasons for the improved outcome in recent series (Bassan and Hoelzer, Hoelzer 
and Gokbuget, Kebriaei and Larson). In addition, risk-adapted and subtype-oriented 
therapy may have contributed to this better outcome. However, the long term outcome of 
adult patients is still dismal, with approximately one third of the cases only being cured. At 
present, therapeutic options include conventional chemotherapy (CHT), high dose therapy 
with autologous and, especially, allogeneic stem cells transplantation (SCT) and, for certain 
subsets, such as BCR-ABL1+ ALL, specific targeted therapy (Piccaluga, et al). 
Although SCT has been used in adult ALL for more than 20 years, its role remains 
controversial as demonstrated by conflicting results in various studies. Previous case-
controlled studies did not show that allogeneic SCT (alloSCT) provided any advantage over 
CHT  (Horowitz, et al, Zhang, et al) while in some studies there was an advantage, but 
restricted to young adults (Oh, et al). The number of controlled published or ongoing trials is 
remarkably small and some of them did not include both standard-risk and high-risk 
patients. Thus, it is difficult to draw definitive conclusions from their results. In fact, while 
some authors did not report any differences between alloSCT and chemotherapy or 
autologous SCT (ASCT)(Gupta, et al, Labar, et al), others only found differences favouring 
allogeneic SCT in standard risk (Goldstone, et al) or high-risk ALL patients (Sebban, et al, 
Thiebaut, et al, Thomas, et al).  
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In this article, the Authors reviewed data concerning alloSCT in adult ALL and discuss 
current controversial and possible perspectives.  
2. Rationale for allogeneic SCT: the graft versus leukaemia effect in ALL 
Initial studies were conduced in patients with advanced stage disease, aiming to overcome 
drug resistance by intensifying the dose of CHT and rescuing patients with syngeneic or 
allogeneic haemopoietic stem cells (SC) (Fefer, et al, Thomas, et al). In the first study, 16 
patients with refractory ALL received high dose therapy followed by infusion of syngeneic 
bone marrow (Fefer, et al). Six out of these patients achieved a durable remission, 
demonstrating the efficacy and the potential curative effect of high dose therapy in ALL. On 
the other hand, the role of donor-derived immunologic anti-leukaemic effect - so called 
“graft versus leukaemia” (GVL) effect – was first established in animal models (Chester, et 
al). The first evidence of GVL effect in humans was actually demonstrated in ALL patients 
treated with alloSCT (Mathe, et al, Thomas, et al). In this series, patients who developed 
grade ≥2 graft versus host disease (GVHD) had a significantly lower relapse rate after 
transplant if compared with patients with grade 1 or no GVHD or with those who received 
syngeneic bone marrow (p<0.01). Subsequent studies further underlined this phenomenon 
(Doney, et al, Horowitz, et al, Lee, et al), although its relevance is less convincing than in 
myeloproliferative diseases such as chronic myeloid leukaemia, or chronic 
lymphoproliferative disease and possibly lymphomas.  
3. Designation of risk factors in ALL 
There is a considerable variation in the relapse risk which can be predicted by various risk 
factors (Table 1) (Hoelzer D 2002, Moorman, et al), including unfavourable cytogenetics,  
 
  Good Adverse
Age 15-35* >50-60
35-50
WBC at diagnosis <30x109/L (B-ALL) >30x109/L (B-ALL) 




hypodiploidy/almost triploidy  
complex karyotype 





MRD Negative Persistent ( ≥10-3) after induction   
Stable during follow up Increasing during treatment/follow up 
* Special benefit appear to be related in this group to the application of paediatric (i.e. intensified) regimens 
** intermediate prognosis 
WBC = white blood cells 
Table 1. Prognostic factors in adult ALL 
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poor/slow response to induction CHT, leukocyte count at diagnosis and phenotype. 
Accordingly, patients can be stratified as standard-risk (no risk factors) or high risk (one or 
more risk factors) with 45-60% vs less than 30% DFS, respectively (Hoelzer D). In particular, 
detection of minimal residual disease (MRD) after treatment was shown to be associated 
with impending relapse, independent of any other risk factor (Bassan, et al, Mortuza, et 
al)(Gazzola A et al, submitted). According to some investigators the status of MRD may be 
sufficient for stratification and the role conventional clinical risk factors appears 
questionable. 29  
4. Preparative regiments 
4.1 Ablative regimens 
Conditioning regimens used for alloSCT must ideally: 1) achieve adequate 
immunosuppression of the recipient to prevent rejection of the donor SC, and 2) destroy 
residual malignant cells while causing minimal toxicity. Most preparative regimens for ALL 
use total body irradiation (TBI) and cyclophosphamide (Cy) while some centres use 
etoposide and cytosine arabinoside (Ara-C) in addition to or instead of Cy. Busulphan-
cyclophosphamide (BU/Cy) has also been used to avoid radiation but an IBMTR study 
showed an inferior outcome with this regimen with a 3-year probability of DFS of 35% 
versus 50% when TBI and Cy were used (Davies, et al). Because most chemo-radiation 
regimens are at the limits of toxicity, any further dose escalation in an attempt to reduce the 
risk of relapse would probably increase the regimen-related toxicity to unacceptable levels, 
particularly in older or heavily pretreated patients. The addition of biological agents like 
monoclonal antibodies or radioconjugates to conventional conditioning regimens can 
potentially provide an augmented anti-leukaemic effect without increasing treatment 
related toxicity.  
4.2 Non-myeloablative regimens 
High-dose CHT and alloSCT carry substantial treatment related morbidity and mortality in 
older patients (>50 years), those with compromised organ function (e.g., congestive heart 
failure), coexisting infections, or those who were heavily pre-treated prior to SCT. In all of 
these patients, treatment-related mortality can exceed 50%, making them ineligible for SCT. 
More recently, new strategies for allografting have explored an approach of less intensive 
conditioning therapy with the aim of allowing partial engraftment of donor immune and 
haematopoietic systems with eventual replacement of the host’s own haematopoiesis and 
immunity. A variety of regimens based on low-dose TBI or fludarabine are increasingly 
used (Giralt, et al, Khouri, et al, Slavin, et al, Storb, et al). Such reduced intensity conditioning 
(RIC) regimens may be more suitable for patients with indolent malignancies where there is 
sufficient time for a graft versus malignancy effect to operate. Patient with acute leukaemia 
who have active disease transplanted with non-myeloablative regimens have a high relapse 
rate. Another major problem with submyeloablative regimens is an increased rate of graft 
failure ranging from 5% to 30% versus 1% to 5% in patients undergoing full myeloablation 
prior to alloSCT. The use of lymphodepleting antibodies or a combination of monoclonal 
antibodies in addition to cytotoxic or immunosuppressive drugs could potentially decrease 
rejection rates (Brenner, et al, Kottaridis, et al). 
Examples of preparative regimens used in ALL are summarized in Table 2. 
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Thomas et al 1982 
Vitale et al. 1983 
 
Tutschka et al. 1987 
Blume et al. 1993 
Rowe et al. 2001 
Bieri et al. 2001 
Cy 120 mg/Kg + TBI (SD 10 Gy) 
Cy 120 mg/Kg + fractioned TBI (2 Gy x6) 
 
BU 16 mg/Kg + Cy 120 mg/Kg 
Etoposide/TBI vs. BU/Cy 
Etoposide/TBI 
TBI at different doses* 
BU = busulfan; Cy = cyclophosphamide; SD = single dose 
* retrospective comparison 
Table 2. Examples of preparative regimens adopted in ALL 
5. Allogeneic stem cell transplantation for Ph-negative ALL 
Many factors need to be considered before recommending alloSCT including: 
1. Cure rate with conventional CHT; 
2. Transplant related mortality (TRM) and morbidity; 
3. Cure rate with alloSCT. 
As TRM and cure rates strongly depend on the disease phase at the time of transplant, 
different phases will be considered separately in our description. 
5.1 Acute lymphoid leukaemia (ALL) in first remission  
As the risk of transplant related mortality needs to be balanced against potential cure with 
standard CHT alone, alloSCT as post-consolidation therapy is favoured in patients who are 
at a high risk of relapse after standard CHT. While in children the likelihood of cure with 
modern intensive CHT range is 70–80% (Pui and Evans), in adults with ALL the cure rate 
with CHT is only 25–40% and, despite the intensification of CHT regimens, the majority of 
patients will relapse and die of their disease (Bassan and Hoelzer). In particular, the 
presence of any risk factor (Table 1) reduces the chance of long-term DFS with CHT to 
between 15% and 25%, making the patient a candidate for allografting in first remission 
(CR1). In fact, alloSCT in CR1 was suggested to provide a better anti-leukaemic effect and to 
improve patients’ outcome compared with a conventional post-remission CHT regimen.  
Retrospective studies evaluating the role of alloSCT in CR1 were encouraging with DFS 
ranging between 40 and 63% and relapse rates of 10-40% (Barrett, et al, Blume, et al, Blume, 
et al, Chao, et al, De Witte, et al, Thomas, et al, Vernant, et al, Vey, et al). However, most of the 
studies were small (with less than 50 patients each) and were limited by selection bias (see 
Table 3 for details). In addition, few studies retrospectively compared alloSCT vs. 
autologous SCT (ASCT) or CHT in ALL performed in CR1. None of these studies showed an 
improved survival in transplanted patients (Table 4). In particular, Horowitz and 
Colleagues, on behalf of the IBMTR, reported the outcome of adult ALL patients (aged 15-45 
years) treated with intensive CHT (IC, N=484) vs. allogeneic SCT (N=251) in CR1 (Horowitz, 
et al).  
Allografted patients had significantly reduced risk of relapse (26% vs. 59%). However, the 
DFS was not superior after SCT, reflecting the higher mortality rate observed after SCT (38% 
vs. 4%) (Horowitz, et al). 
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GVHD=graft versus host disease 
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Table 3. Retrospective non-comparative studies considering alloSCT in ALL 
Only few studies prospectively compared alloSCT to other post-remission strategies in ALL 
(Table 4) (Attal, et al, Fielding, et al, Fiere, et al, Goldstone, et al, Hunault, et al, Rowe, Sebban, 
et al, Thiebaut, et al), (Labar, et al). The BGMT group conduced a prospective trial evaluated 
alloSCT vs. ASCT in CR1. According to genetic randomization, patients with (n = 43) or 
without an HLA-identical sibling (n = 77) were assigned to receive allogeneic or autologous 
SCT, respectively. The 3-year post-CR probability of DFS was significantly higher in the 
HLA-identical sibling group than in the non-HLA-identical sibling group (68% v 26%; 
P<0.001) (Attal, et al). Recently, the 10-year follow-up results confirmed the marked 
superiority of alloSCT to CHT in terms of survival (44 vs 11%, P=0.009)(Marks, et al).   
The prospective randomized LALA87 trial compared alloSCT  vs. ASCT/CHT. Patients 
aged 15-40 years who achieved CR and had a matched related donor were assigned to 
allograft, whereas those without a donor were randomized to receive ASCT vs CHT. 
Seventy-six percent (436/572 evaluable patients) achieved CR. Intention to treat analysis, 
comparing patients assigned to alloSCT (N=116) vs. ASCT/CHT, showed increased survival 
in allografted patients (10 years overall survival – OS- 46% vs. 31%, p=0.04). In high risk 
patients, the advantage was more evident (44% vs. 115, p=0.009). On the contrary, standard 
risk patients did not significantly benefit from SCT (p=0.06) (Thiebaut, et al). 
The GOELAL02 trial evaluated the impact in high risk ALL patients of early alloSCT or 
delayed unpurged ASCT for patients who had no HLA–matched sibling donor or who were 
older than 50 years. Among 198 patients, the median age was 33 years. The CR rate was 80% 
with standard induction therapy. AlloSCT was performed after 2 consolidation courses 
while ASCT was delayed after 1 additional reinduction. Intensified conditioning regimen 
before transplantation included etoposide, cyclophosphamide, and total body irradiation 
(TBI). Median follow-up was 5.1 years. The median overall survival (OS) was 29 months, 
with a 6-year OS of 41%. On an intent-to-treat analysis for patients younger than 50 years, 
alloSCT significantly improved the 6-year OS (75% versus 40% after ASCT; P = .0027). On 
the other hand, randomized interferon-  maintenance had no effect on relapse or survival 
after ASCT (Hunault, et al).  
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with CHT is only 25–40% and, despite the intensification of CHT regimens, the majority of 
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improve patients’ outcome compared with a conventional post-remission CHT regimen.  
Retrospective studies evaluating the role of alloSCT in CR1 were encouraging with DFS 
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Table 3 for details). In addition, few studies retrospectively compared alloSCT vs. 
autologous SCT (ASCT) or CHT in ALL performed in CR1. None of these studies showed an 
improved survival in transplanted patients (Table 4). In particular, Horowitz and 
Colleagues, on behalf of the IBMTR, reported the outcome of adult ALL patients (aged 15-45 
years) treated with intensive CHT (IC, N=484) vs. allogeneic SCT (N=251) in CR1 (Horowitz, 
et al).  
Allografted patients had significantly reduced risk of relapse (26% vs. 59%). However, the 
DFS was not superior after SCT, reflecting the higher mortality rate observed after SCT (38% 
vs. 4%) (Horowitz, et al). 
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Only few studies prospectively compared alloSCT to other post-remission strategies in ALL 
(Table 4) (Attal, et al, Fielding, et al, Fiere, et al, Goldstone, et al, Hunault, et al, Rowe, Sebban, 
et al, Thiebaut, et al), (Labar, et al). The BGMT group conduced a prospective trial evaluated 
alloSCT vs. ASCT in CR1. According to genetic randomization, patients with (n = 43) or 
without an HLA-identical sibling (n = 77) were assigned to receive allogeneic or autologous 
SCT, respectively. The 3-year post-CR probability of DFS was significantly higher in the 
HLA-identical sibling group than in the non-HLA-identical sibling group (68% v 26%; 
P<0.001) (Attal, et al). Recently, the 10-year follow-up results confirmed the marked 
superiority of alloSCT to CHT in terms of survival (44 vs 11%, P=0.009)(Marks, et al).   
The prospective randomized LALA87 trial compared alloSCT  vs. ASCT/CHT. Patients 
aged 15-40 years who achieved CR and had a matched related donor were assigned to 
allograft, whereas those without a donor were randomized to receive ASCT vs CHT. 
Seventy-six percent (436/572 evaluable patients) achieved CR. Intention to treat analysis, 
comparing patients assigned to alloSCT (N=116) vs. ASCT/CHT, showed increased survival 
in allografted patients (10 years overall survival – OS- 46% vs. 31%, p=0.04). In high risk 
patients, the advantage was more evident (44% vs. 115, p=0.009). On the contrary, standard 
risk patients did not significantly benefit from SCT (p=0.06) (Thiebaut, et al). 
The GOELAL02 trial evaluated the impact in high risk ALL patients of early alloSCT or 
delayed unpurged ASCT for patients who had no HLA–matched sibling donor or who were 
older than 50 years. Among 198 patients, the median age was 33 years. The CR rate was 80% 
with standard induction therapy. AlloSCT was performed after 2 consolidation courses 
while ASCT was delayed after 1 additional reinduction. Intensified conditioning regimen 
before transplantation included etoposide, cyclophosphamide, and total body irradiation 
(TBI). Median follow-up was 5.1 years. The median overall survival (OS) was 29 months, 
with a 6-year OS of 41%. On an intent-to-treat analysis for patients younger than 50 years, 
alloSCT significantly improved the 6-year OS (75% versus 40% after ASCT; P = .0027). On 
the other hand, randomized interferon-  maintenance had no effect on relapse or survival 
after ASCT (Hunault, et al).  
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In the EORTC ALL-3 study, Labar and collegues evaluated the role of alloSCT based on a 
genetic randomization.(Labar, et al). Patients achieving CR and having an HLA-identical 
sibling were intended for alloSCT after completion of consolidation while the remaining 
ones were randomized to receive either ASCT or maintenance. Among 68 patients in the 
donor arm the transplantation was performed in 47 cases. According to the intention-to-
treat analysis the incidence of relapse at 6 years was decreased (38% vs. 56%) while the 
incidence non-relapse mortality increased (24% vs. 7%) in the “donor” compared with “no 
donor” arm. The probability of DFS was superimposable (38% vs. 37%, respectively). 
Among 116 patients lacking a donor only 45 were randomized making the  vs. maintenance 
comparison statistically underpowered. 
Recently, Ribera and Colleagues reported on 222 high risk ALL patients enrolled in the 
PETHEMA ALL-93 trial (Ribera, et al). All received a standard five-drug/five-week 
induction course. Patients in CR with an HLA identical family donor were assigned to 
alloSCT (n=84) and the remaining were randomized to ASCT (n=50) or to delayed 
intensification followed by maintenance CHT up to 2 years in complete remission (n=48). 
Overall, 183 patients achieved complete remission (82%). With a median follow-up of 70 
months, the median DFS and OS were 17 and 23 months, respectively. The 5-year DFS and 
OS were 35% (95% CI, 30%- 41%) and 34% (95% CI, 28%-39%), respectively. Patients 
allocated to the CHT, allogeneic and autologous SCT were comparable in the main pre-
treatment ALL characteristics and the rate of response to therapy. Intention-to-treat analysis 
showed no differences between patients according to whether they had or did not have a 
donor in DFS (39%, 95% CI 30-48% vs. 33%, 95% CI 23-41%) and OS (44%, 95% CI 35- 52% 
vs. 35%, 95% CI 25-44%), as well as for autologous SCT vs. CHT comparisons (DFS: 40%, 
95% CI 28-52% vs. 51%, 95% CI 37-67%; overall survival: 43%, 95% CI 29-58% vs. 52%, 95% 
CI 39-65%). No differences were observed when the analysis was made on the basis of the 
treatment actually performed (Ribera, et al). 
More recently, the final results of the MRC UKALL XII/ECOG 2993 protocol were available, 
regarding a large prospective randomized study aiming to establish the best post-remission 
therapy for adult ALL (Avivi and Goldstone, Rowe, et al, Rowe). In this study, patients 
(N=1,646) received 2 phases of induction and, if in remission, were assigned to allogeneic 
transplantation if they had a compatible sibling donor. Other patients were randomized to 
chemotherapy for 2.5 years versus an ASCT. A donor versus no-donor analysis showed that 
Ph- patients with a donor had a 5-year improved OS (53% versus 45%; p = .01), and the 
relapse rate was significantly lower (p ≤ .001). The survival difference was significant in 
standard-risk patients, but not in high-risk patients due to a high treatment related mortality 
(TRM) in the high-risk donor group. Interestingly, patients randomized to chemotherapy 
had a higher 5-year OS (46%) than those randomized to autologous transplantation (37%; p 
= .03) (Goldstone, et al). Importantly, a dedicated analysis was carried on Ph+ cases (N=267) 
(Fielding, et al). In this setting, in the comparison of the outcome after any alloSCT with the 
outcome after chemotherapy alone, OS (p = .001), EFS (p < .001), and RFS (P < .001) were all 
significantly superior for patients receiving any alloSCT over those receiving chemotherapy 
alone. Of note, there was a marked difference in the cause of death between alloSCT and 
chemotherapy recipients. Whereas the leading cause of death in chemotherapy treated 
patients was relapse, the leading cause of death after transplantation was TRM, which was 
27% after sibling-SCT and 39% after VUD-SCT (Fielding, et al). 
 







Age  TRM (%) RR (%) 5-y DFS 
Blaise et al. 
1990 
Allo vs. Auto 25 vs. 22 4-36 vs. 7-47 20 vs. 9 9 vs. 57 71 vs. 40 
Horowitz et al. 
1991 
Allo vs. CHT 234 vs. 484 15-45 vs. 15-
45 
39 vs. 4 26 vs. 59 44 vs. 38 
Attal et al. 
1995 
Allo vs. Auto 43 vs. 77 15-55 vs. 15-
55 
12 vs. 2 12 vs. 62 68 vs. 26 
(3-y) 
Oh et al. 1998 Allo vs. CHT 127 vs. 38 <30 32 vs. 3 22 vs. 69 30 vs. 30 
  Allo vs. CHT 87 vs. 38 >30 NA 37 vs. 70 30 vs. 26 
Fiere et al. 
1993 
Allo vs. Auto vs. 
CHT 




18 37 46 vs. 39 
vs. 32 
Fiere et al.1998 Allo vs. Auto vs. 
CHT 




NA NA 46 vs. 34 
vs. 30 




190 vs. 253 15-50 vs. 15-
50 
NA 24 vs. 60 52 vs. 36 
Hunault 2004 Allo vs. Auto* 41 vs. 115 15-52 vs. 15-
57 
15 vs. 3 10 vs. 49 75 vs. 38 
Labar et al. 
2004 
Allo vs. (Auto or 
CHT) 
68 vs. 116 <50 24 v.7 38 vs. 56 38 vs. 37 
Ribera et al. 
2006 
Allo vs. Auto vs. 
CHT 
84 vs. 50 vs. 
48 
16-49 vs. 15-
50 vs. 15-50 
8 vs. 3 vs. 
0 
62 vs. 57 
vs. 46 












* early alloSCT vs. delayed ASCT 
TRM=transplant related mortality 
RR=relapse risk 
5-y DFS=disease free survival at 5 years 
§ Overall survival 
Table 4. Studies comparing alloSCT vs. CHT/ASCT in ALL 
5.2 ALL in second remission  
More than 50% of adult ALL patients will relapse after initial CR. Half of these patients will 
actually obtain a second CR (CR2) following re-induction therapy. However, CR2 is not 
durable and only less of 10% of the patients will be cured with CHT or ASCT. By contrast, 
DFS after alloSCT performed in CR2 approaches 25-38% (Avivi and Goldstone, Herzig, et al, 
Thomas, et al). Indeed, alloSCT appears to be the best option for patients in CR2, 
irrespectively of the initial risk factors. However, unfortunately, no randomized trials 
compared alloSCT and CHT in this setting. Noteworthy, the outcome of alloSCT in CR2 is 
also affected by CR1 duration, being definitely better when CR1 was longer than 24 months 
(Forman, Kersey, et al, Thomas, et al). 
5.3 ALL after second relapse or primary induction failure  
Once patients are beyond second remission, the results of all allografting procedures worsen 
considerably, with only 10–15% of patients becoming long-term disease-free survivors 
(Goldman, et al, Storb, et al). Similarly, the outcome with transplant is poor with only 10–
 
New Advances in Stem Cell Transplantation 
 
272 
In the EORTC ALL-3 study, Labar and collegues evaluated the role of alloSCT based on a 
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5.2 ALL in second remission  
More than 50% of adult ALL patients will relapse after initial CR. Half of these patients will 
actually obtain a second CR (CR2) following re-induction therapy. However, CR2 is not 
durable and only less of 10% of the patients will be cured with CHT or ASCT. By contrast, 
DFS after alloSCT performed in CR2 approaches 25-38% (Avivi and Goldstone, Herzig, et al, 
Thomas, et al). Indeed, alloSCT appears to be the best option for patients in CR2, 
irrespectively of the initial risk factors. However, unfortunately, no randomized trials 
compared alloSCT and CHT in this setting. Noteworthy, the outcome of alloSCT in CR2 is 
also affected by CR1 duration, being definitely better when CR1 was longer than 24 months 
(Forman, Kersey, et al, Thomas, et al). 
5.3 ALL after second relapse or primary induction failure  
Once patients are beyond second remission, the results of all allografting procedures worsen 
considerably, with only 10–15% of patients becoming long-term disease-free survivors 
(Goldman, et al, Storb, et al). Similarly, the outcome with transplant is poor with only 10–
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15% DFS for patients who fail primary induction therapy. However, though  these results 
are not brilliant, SCT still offers the only prospect of cure (Biggs, et al). Biggs et al reported 
23% DFS in 38 ALL patients treated with alloSCT for primary induction failure disease; the 3 
years probability of persistent/recurrent disease was 59% (Biggs, et al). The result is, 
however, encouraging with almost one quarter of patients rescued after initial treatment 
failure. On the other hand, it should be considered that 26% of the cases in this study were 
aged under 19 years (and 8 less under 10) and 39% achieved a partial remission before 
transplant. TRM was significantly higher in patients older than 30 years or with poor 
performance status (PS). Thus, it appears that 10-20% of patients who fail to achieve CR after 
induction can benefit from alloSCT; however, patients to be referred to this procedure 
should be carefully selected basing on age and PS. 
6. Stem cell transplantation for Ph+ ALL 
The presence of Ph chromosome is one of the most relevant adverse prognostic factors in 
ALL. To date, alloSCT is the unique approach which can be considered as potentially 
curative, thus being the treatment of choice in adult Ph+ ALL (Avivi and Goldstone, Barrett, 
et al, Chao, et al, Dombret, et al, Fielding, et al, Ottmann and Pfeifer, Piccaluga, et al, 
Piccaluga, et al). Twenty-seven to 65% long-term survival has been reported for patients 
undergoing alloSCT in first complete remission (CR1), (Avivi and Goldstone, Fielding, et al). 
Unfortunately, relapse occurs in approximately 30% of patients, representing the primary 
cause of treatment failure together with treatment-related mortality, which increases with 
age and advanced disease (Avivi and Goldstone, Martin and Gajewski). Achievement and 
maintenance of a CR prior to SCT is an important prerequisite for a favourable outcome 
after SCT (Wassmann, et al). In fact, when performed further than first remission, only a 




N TRM REL Outcome








38% at 2 years (DFS) 
41%
Chao et al, 1995 38 NA NA 46% (CR1) at 2 years (DFS) 
28% (>CR1) 
Snyder et al, 
1999 
23 30% 12% 65% at 3 years (DFS) 
Goldstone et al, 
2001 
72 37% (Sib) vs 43% (VUD) 32% 42% at 5 years (DFS) 
Dombret et al,
2002 
56 25% 37% 37% at 3 years (OS) 
Fielding et al, 
2009 
267 27% (Sib.) vs. 39% (VUD) 32% 41%-36%* at 5 years (EFS) 
44%-36%* at 5 years (OS) 
N= number of patients 
TRM= transplant related mortality 
REL= relapse rate 
DFS= disease free survival 
CR1= first complete remission 
* Sibling donor vs. VUD 
Table 5. Results of allogeneic stem cells transplantation in adult Ph+ ALL 
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the probability of success is limited, alloSCT may be still curative in a subset of patients and 
it remains the treatment of choice (Garcia-Manero and Thomas). The probability of DFS 
(DFS) at 2 years after alloSCT in second or third remission or as salvage therapy for 
refractory disease has been reported to be 17% and 5%, respectively (Cornelissen, et al). In 
patients failing allogeneic SCT, further treatment is rarely successful. With this regard, the 
availability of novel tyrosine-kinase inhibitors (TKI), including imatinib, dasatinib and 
nilotinib, has became of great interest (Piccaluga, et al). In fact, TKI either can be added to 
CHT potentially increasing the number of patients to be referred to alloSCT in CR1 
(Wassmann, et al), and constitutes a possible salvage treatment in case of relapse after 
alloSCT (Olavarria, et al, Wassmann, et al). 
Results with allogeneic stem cells transplantation are summarized in Table 5 (Avivi and 
Goldstone, Barrett, et al, Chao, et al, Fielding, et al, Snyder, et al). 
7. Source of stem cell for allogeneic transplantation 
7.1 Bone marrow versus mobilized peripheral blood  
Cytokine-mobilized allogeneic peripheral blood stem cell (PBSC) harvest has become an 
alternative to bone marrow as a source of stem cells for matched-sibling transplants. Early 
phase II studies showed that this source of stem cells resulted in faster engraftment, no 
increase in acute GVHD (perhaps due to a G-CSF-mediated shift to Th2 helper cells) but an 
increased incidence of chronic GVHD (Bensinger, et al, Korbling, et al). A prospective 
randomized study of allogeneic PBSC compared to marrow showed a 2-year actuarial 
overall survival of 54% in patients receiving marrow compared with 66% in those receiving 
PBSCs (Bensinger, et al). Differences in survival were significant for patients with 
unfavourable-risk diseases but not for those with favourable-risk diseases (Bensinger, et al). 
Faster engraftment, similar GVHD and improvement in overall survival was also reported 
in a Canadian and New Zealand study (Couban, et al). In a retrospective multivariate 
analysis from the IBMTR comparing the results of 288 HLA-identical sibling blood stem cell 
transplants with the results of 536 HLA-identical sibling bone marrow transplants, the 
relapse incidence between the two transplant groups did not differ significantly (Champlin, 
et al). However, treatment-related mortality rates were lower and leukaemia-free survival 
rates were higher with use of blood stem cell transplants in patients with advanced versus 
early leukaemia  (Champlin, et al). While the results of more studies should become 
available over the next few years, the current experience suggests that peripheral blood 
should be the preferred source of stem cells for patients with high-risk disease and/or 
advanced phase. For patients with low-risk disease, the increased risk of chronic GVHD 
needs to be balanced against the risk of relapse. 
7.2 Alternative donor sources 
Most patients do not have a suitable histocompatible sibling donor for an allograft and the 
use of alternative donors such as voluntary unrelated donor (VUD),  haploidentical donor 
and umbilical cord blood (UCB) grafts. As regards VUD, the results are actually comparable 
to those obtained with matched sibling donors and many groups routinely refer to this 
source for patients in CR1. Conversely, to date, the other two options have been mainly 
reserved for patients in ≥CR2. Few large-scale studies compare these forms of alternative 
donor transplantation and the choice of stem cell source will also be influenced by clinical 
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15% DFS for patients who fail primary induction therapy. However, though  these results 
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N TRM REL Outcome








38% at 2 years (DFS) 
41%
Chao et al, 1995 38 NA NA 46% (CR1) at 2 years (DFS) 
28% (>CR1) 
Snyder et al, 
1999 
23 30% 12% 65% at 3 years (DFS) 
Goldstone et al, 
2001 
72 37% (Sib) vs 43% (VUD) 32% 42% at 5 years (DFS) 
Dombret et al,
2002 
56 25% 37% 37% at 3 years (OS) 
Fielding et al, 
2009 
267 27% (Sib.) vs. 39% (VUD) 32% 41%-36%* at 5 years (EFS) 
44%-36%* at 5 years (OS) 
N= number of patients 
TRM= transplant related mortality 
REL= relapse rate 
DFS= disease free survival 
CR1= first complete remission 
* Sibling donor vs. VUD 
Table 5. Results of allogeneic stem cells transplantation in adult Ph+ ALL 
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in a Canadian and New Zealand study (Couban, et al). In a retrospective multivariate 
analysis from the IBMTR comparing the results of 288 HLA-identical sibling blood stem cell 
transplants with the results of 536 HLA-identical sibling bone marrow transplants, the 
relapse incidence between the two transplant groups did not differ significantly (Champlin, 
et al). However, treatment-related mortality rates were lower and leukaemia-free survival 
rates were higher with use of blood stem cell transplants in patients with advanced versus 
early leukaemia  (Champlin, et al). While the results of more studies should become 
available over the next few years, the current experience suggests that peripheral blood 
should be the preferred source of stem cells for patients with high-risk disease and/or 
advanced phase. For patients with low-risk disease, the increased risk of chronic GVHD 
needs to be balanced against the risk of relapse. 
7.2 Alternative donor sources 
Most patients do not have a suitable histocompatible sibling donor for an allograft and the 
use of alternative donors such as voluntary unrelated donor (VUD),  haploidentical donor 
and umbilical cord blood (UCB) grafts. As regards VUD, the results are actually comparable 
to those obtained with matched sibling donors and many groups routinely refer to this 
source for patients in CR1. Conversely, to date, the other two options have been mainly 
reserved for patients in ≥CR2. Few large-scale studies compare these forms of alternative 
donor transplantation and the choice of stem cell source will also be influenced by clinical 
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urgency and the time taken to procure haematopoietic stem cells. Single centre results must 
be analysed carefully when deciding what plan to recommend in the individual patient.  
If a matched donor is not available, some data indicate that a single antigen mismatched 
family donor allograft may result in the same outcome as using a matched UD, but a 
perspective randomized comparison has never been performed. In general, if there is no 
molecularly matched UD, then a single allele mismatched UD, an UCB donor or a 
haploidentical stem cell donor could be considered as possible alternative (Marks, et al).  
In this regard, few small studies focused on the use of UCB in ALL, and basing on these data 
it is difficult to advise investigators how to approach potential patients. Small patient 
numbers, heterogeneity of remission status, variability of matching and incomplete 
information about UCB cell dose make data summary difficult. In general, these results are 
promising, but relapse remains a significant issue as well as does engraftment failure. 
Somewhere between 20 and 50% of patients in CR1 and an occasional CR2 patient can 
become long-term survivors. Double UCB transplants or intra-bone SC infusion (Castello, et 
al) may represent an advance, particularly addressing the issue of engraftment.  
Haploidentical transplant have the major advantage of donor availability and results have 
been possibly improved. In particular, the high rejection rate and incidence of severe GVHD 
are reduced by combining high-intensity conditioning and an infusion of a large dose of 
purified SC in adult ALL patients transplanted in CR1 or CR2. These data, however, have 
not been corroborated in multi-centre trials, and a variety of opportunistic infections 
continue to plague this approach that does not appear useful in the setting of advanced 
disease. Further avenues of improvement include the exploration of killer cell 
immunoglobulin-like receptor (KIR) mismatching between donor grafts and recipients. 
Data on alternative donor source in ALL have been recently reviewed by Marks et al 
(Marks, et al) and are summarized in Tables 6-7. 
8. Post transplant strategies to improve clinical outcome 
8.1 GVHD prophylaxis 
GVHD results from alloreactivity between donor and recipient. The two major prophylactic 
regimens employed to prevent this complication are pharmacological (administration of 
immunosuppressive drugs), and immunological (in vitro T-cell depletion). The standard 
pharmacologic prophylaxis has been cyclosporine (CsA) and short-course methotrexate, but 
recent studies suggest that the incidence of GVHD may be lower if FK506 is substituted for 
CsA (Nash, et al). MMF also shows promise in animal models, and its combination with CsA 
is being evaluated in clinical trials. Ex vivo T-cell depletion reduces the risk of both acute 
and chronic GVHD and may allow higher tolerance of mismatching but may also increase 
the risk of rejection and delay immune reconstitution. A confounding feature for 
interpreting the value of T-cell depletion is that a variety of methodologies are employed to 
remove T cells, including physical methods, poly- and mono-clonal antibodies. Some 
techniques produce a pan-T depletion, whereas others use antibodies with more restricted 
T-subset specificities. An IBMTR study showed a better outcome when antibodies with 
narrow specificities are used (Champlin, et al). 
8.2 Reducing the risk of relapse 
The major cause of failure after transplant for ALL is relapse. The outcome of patients who 
relapse after allogeneic SCT is very poor. Remissions are possible with standard CHT but 
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are not durable. Those who relapse more than 1-year post-transplant are more likely to 
achieve a further remission. Donor leukocyte infusions have been used but their success rate 
in patients with ALL is much lower than in patients with myeloid malignancies (Porter and 
Antin). Strategies to reduce the risk of relapse include intensifying conditioning regimens, 
altering the timing of transplant and augmenting the graft versus leukaemia effect. The risk 
of relapse may also be reduced by more precisely defining the biological risk factors that 
justify transplant in first remission, thus circumventing the possibility of selecting for 
leukaemia resistance during prolonged CHT. Patients who receive an alloSCT for ALL and 
develop graft versus host disease (GVHD) have a lower probability of relapse than patients 
who do not suffer this complication. A recent study showed that in patients with high levels 
of minimal residual disease (MRD) pre-transplant, the presence of acute or chronic GVHD 
may be needed to prevent relapse(Uzunel, et al). The likely explanation for this observations 
is that the alloreactive T cells in the donor graft are able to destroy residual host leukaemia 
cells. In support of this contention, administering lower doses of CsA reduces the relapse 
risk and improves DFS in children undergoing SCT for leukaemia (Locatelli, et al). Adoptive 
immunotherapy with donor mononuclear cells is less successful in ALL than in the myeloid 
leukaemias, although there is some evidence that use of immunostimulatory cytokines such 
as IL2 may amplify graft versus leukaemia mechanisms and induce remissions in patients 
who have failed to respond to donor lymphocyte infusions. Immune modulation post-
transplant may therefore be a therapeutic alternative to reduce the risk of relapse. One 
means of reducing the risk of GVHD is to administer antigen-specific cytotoxic T-cell lines 
(CTL) lines when a specific antigen is known. Potential targets include minor antigens 
differentially expressed on haemopoietic cells  (Mutis, et al) or lineage specific antigens, such 
as WTI or proteinase 3 (Ohminami, et al). Such lines could potentially mediate cytotoxic 
activity directed at recipient haemopoiesis (and leukaemia) but not donor haemopoiesis. An 
alternative approach when a tumour antigen is not defined is to increase the 
immunogenicity of the tumour and allow selection of the tumour antigen by responding 
immune system effector cells. This approach has shown efficacy in a number of animal 
models using molecules that modify antigen presentation such as Class I MHC molecules or 
GMCSF, co-stimulatory molecules such as B7 or T-cell activation factors such as IL2. For 
example pre B ALL cells lack B7-1(CD80) and induce allo-specific T-cell anergy. If ALL cells 
are transduced with B7, their antigen presentation capacity is improved and they are able to 
generate autologous leukaemia-specific CTL lines from marrow from the majority of 
patients (Cardoso, et al). Murine data also suggests that combination of molecules acting on 
different phases of the immune response may produce increased anti-tumour activity 
(Dilloo, et al) and this approach is currently being tested in a clinical trial in patients with 
ALL (Rousseau, et al). 
9. Autologous stem cell transplantation 
The role of  in adults with ALL has not been clearly defined. Prospective studies comparing  
with alloSCT in high-risk patients demonstrated increased risk of relapse and reduced 
probability of survival in the autologous setting (Attal, et al, Hunault, et al). Trials comparing  
with maintenance chemotherapy did not show survival benefit from high-dose treatment, 
however, a pooled analysis of three subsequent trials by the French group (LALA-85/87/94) 
suggested that ASCT may contribute to decreased risk of relapse (66% vs. 78%, p=0.05) 
(Dhedin, et al, Labar, et al, Ribera, et al, Thiebaut, et al). In the MRC UKALLXII/ECOG 2993 
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urgency and the time taken to procure haematopoietic stem cells. Single centre results must 
be analysed carefully when deciding what plan to recommend in the individual patient.  
If a matched donor is not available, some data indicate that a single antigen mismatched 
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perspective randomized comparison has never been performed. In general, if there is no 
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In this regard, few small studies focused on the use of UCB in ALL, and basing on these data 
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numbers, heterogeneity of remission status, variability of matching and incomplete 
information about UCB cell dose make data summary difficult. In general, these results are 
promising, but relapse remains a significant issue as well as does engraftment failure. 
Somewhere between 20 and 50% of patients in CR1 and an occasional CR2 patient can 
become long-term survivors. Double UCB transplants or intra-bone SC infusion (Castello, et 
al) may represent an advance, particularly addressing the issue of engraftment.  
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been possibly improved. In particular, the high rejection rate and incidence of severe GVHD 
are reduced by combining high-intensity conditioning and an infusion of a large dose of 
purified SC in adult ALL patients transplanted in CR1 or CR2. These data, however, have 
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continue to plague this approach that does not appear useful in the setting of advanced 
disease. Further avenues of improvement include the exploration of killer cell 
immunoglobulin-like receptor (KIR) mismatching between donor grafts and recipients. 
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(Marks, et al) and are summarized in Tables 6-7. 
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GVHD results from alloreactivity between donor and recipient. The two major prophylactic 
regimens employed to prevent this complication are pharmacological (administration of 
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pharmacologic prophylaxis has been cyclosporine (CsA) and short-course methotrexate, but 
recent studies suggest that the incidence of GVHD may be lower if FK506 is substituted for 
CsA (Nash, et al). MMF also shows promise in animal models, and its combination with CsA 
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and chronic GVHD and may allow higher tolerance of mismatching but may also increase 
the risk of rejection and delay immune reconstitution. A confounding feature for 
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techniques produce a pan-T depletion, whereas others use antibodies with more restricted 
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are not durable. Those who relapse more than 1-year post-transplant are more likely to 
achieve a further remission. Donor leukocyte infusions have been used but their success rate 
in patients with ALL is much lower than in patients with myeloid malignancies (Porter and 
Antin). Strategies to reduce the risk of relapse include intensifying conditioning regimens, 
altering the timing of transplant and augmenting the graft versus leukaemia effect. The risk 
of relapse may also be reduced by more precisely defining the biological risk factors that 
justify transplant in first remission, thus circumventing the possibility of selecting for 
leukaemia resistance during prolonged CHT. Patients who receive an alloSCT for ALL and 
develop graft versus host disease (GVHD) have a lower probability of relapse than patients 
who do not suffer this complication. A recent study showed that in patients with high levels 
of minimal residual disease (MRD) pre-transplant, the presence of acute or chronic GVHD 
may be needed to prevent relapse(Uzunel, et al). The likely explanation for this observations 
is that the alloreactive T cells in the donor graft are able to destroy residual host leukaemia 
cells. In support of this contention, administering lower doses of CsA reduces the relapse 
risk and improves DFS in children undergoing SCT for leukaemia (Locatelli, et al). Adoptive 
immunotherapy with donor mononuclear cells is less successful in ALL than in the myeloid 
leukaemias, although there is some evidence that use of immunostimulatory cytokines such 
as IL2 may amplify graft versus leukaemia mechanisms and induce remissions in patients 
who have failed to respond to donor lymphocyte infusions. Immune modulation post-
transplant may therefore be a therapeutic alternative to reduce the risk of relapse. One 
means of reducing the risk of GVHD is to administer antigen-specific cytotoxic T-cell lines 
(CTL) lines when a specific antigen is known. Potential targets include minor antigens 
differentially expressed on haemopoietic cells  (Mutis, et al) or lineage specific antigens, such 
as WTI or proteinase 3 (Ohminami, et al). Such lines could potentially mediate cytotoxic 
activity directed at recipient haemopoiesis (and leukaemia) but not donor haemopoiesis. An 
alternative approach when a tumour antigen is not defined is to increase the 
immunogenicity of the tumour and allow selection of the tumour antigen by responding 
immune system effector cells. This approach has shown efficacy in a number of animal 
models using molecules that modify antigen presentation such as Class I MHC molecules or 
GMCSF, co-stimulatory molecules such as B7 or T-cell activation factors such as IL2. For 
example pre B ALL cells lack B7-1(CD80) and induce allo-specific T-cell anergy. If ALL cells 
are transduced with B7, their antigen presentation capacity is improved and they are able to 
generate autologous leukaemia-specific CTL lines from marrow from the majority of 
patients (Cardoso, et al). Murine data also suggests that combination of molecules acting on 
different phases of the immune response may produce increased anti-tumour activity 
(Dilloo, et al) and this approach is currently being tested in a clinical trial in patients with 
ALL (Rousseau, et al). 
9. Autologous stem cell transplantation 
The role of  in adults with ALL has not been clearly defined. Prospective studies comparing  
with alloSCT in high-risk patients demonstrated increased risk of relapse and reduced 
probability of survival in the autologous setting (Attal, et al, Hunault, et al). Trials comparing  
with maintenance chemotherapy did not show survival benefit from high-dose treatment, 
however, a pooled analysis of three subsequent trials by the French group (LALA-85/87/94) 
suggested that ASCT may contribute to decreased risk of relapse (66% vs. 78%, p=0.05) 
(Dhedin, et al, Labar, et al, Ribera, et al, Thiebaut, et al). In the MRC UKALLXII/ECOG 2993 
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study investigators tested if ASCT may be administered instead of consolidation + 
maintenance for patients lacking an HLA-identical sibling, irrespective of the presence of 
risk factors. OS was significantly worse in the ASCT compared to chemotherapy arm (46% 
vs. 37% at 5 years, p=0.03) leading to conclusion that early ASCT cannot substitute 
consolidation. 
Disappointing results of prospective trials evaluating the role of ASCT led to a general 
tendency to abandon this treatment option in adults with ALL. It must be stressed, however, 
that in view of current knowledge design of the studies could have been suboptimal. First of 
all, the trials have been conducted before the era of routine MRD assessment. Low tumor 
burden is prerequisite of successful ASCT as in other conditions the transplant material may 
be contaminated by residual leukemic blasts leading to their re-transplantation and early 
relapse. Evaluation of MRD status in bone marrow reflecting the tumor load may therefore 
be crucial for selection of patients who could benefit from ASCT. Indeed, in a retrospective 
analysis by the European Working Group for Adult ALL, the MRD level was demonstrated 
the most important prognostic factor with DFS of 58% for patients with MRD<0.1% vs. 19% 
for those with MRD ≥0.1% in bone marrow (p=0.0002) (Giebel, et al). In a setting of 123 
ASCT recipients with HR ALL, the incidence of non-relapse mortality was 2.4%. In the 
analysis of a selected group of 50 patients in whom the MRD was evaluated with sufficient 
sensitivity to define the MRD status as negative at the level of 0.01%, the 5-years probability 
of DFS was 69%. 
In so far conducted prospective trials ASCT was administered instead of either maintenance 
or consolidation + maintenance and was considered the last stage of the treatment. There is, 
however, another option, which has not been prospectively tested i.e. incorporating ASCT in 
consolidation, followed by maintenance. Interim analysis of a retrospective study by the 
Central and Eastern Leukemia Group indicate significantly increased probability of the DFS 
if maintenance based on mercaptopurine + methotrexate was administered after ASCT (70% 
vs. 38% at 5 years, p=0.03). The effect was independent on the MRD status (HR=2.6, 
p=0.007) (unpublished data). 
Finally, ASCT followed by interferon alpha administration has been shown to be quite 
effective for Ph+ patients (Piccaluga, et al, Visani, et al). 
Taken together, ASCT is associated with low risk of transplant-related mortality and 
morbidity. Its efficacy should still be prospectively evaluated in patients with low MRD 
level, with post-transplant maintenance as an option. 
10. Conclusion 
Data from clinical trials trying to compare alloSCT and other post-remission therapies for 
ALL  patients in CR1 are sometimes difficult to interpret because of varying proportions of 
patients with different risk factors in each study (some of them are actually limited to high 
risk patients as many centres do not include alloSCT in the therapeutic program of standard 
risk patients in CR1). Prospective randomized studies have been carried out by various 
cooperative groups. These studies have compared patients with HLA identical siblings 
assigned to the allogeneic SCT group to those without HLA identical sibs assigned to either 
a standard chemotherapy or ASCT group. However, as up to 70% of adults with ALL 
cannot be allocated to SCT because of a lack of a matched related sibling, comorbidities, or 
severe infections, an objective and unbiased comparison among treatments is difficult (Avivi 
and Goldstone, Martin and Gajewski, Popat, et al). A major limitation of these studies is that 
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the proportion of patients in the allogeneic SCT group actually undergoing transplant varies 
from study to study. Despite this limitation, a donor versus no donor comparison is the best 
way to answer the question about role of allogeneic SCT in first remission, even though the 
so called “genetic randomization” (based on the availability of HLA-matched donor) is not a 
proper randomization. In addition, in some studies, patients receiving ASCT/CHT included 
cases over 50 years not suitable for alloSCT. Notable features of all these studies include a 
high treatment related mortality and a lower risk of relapse in allogeneic transplant arm. On 
the other hand, the most recent study from the MRC/ECOG group (MRC UKALL 
XII/ECOG E2993) (Fielding, et al, Goldstone, et al) represented the largest series in which the 
role of alloSCT in ALL was prospectively evaluated. Indeed, in this study alloSCT was 
shown to provide the best outcome specially in standard risk patients, thus offering a strong 
indication to this procedure in the majority of ALL cases. 
On the other hand, the randomized studies so far available did not compare alloSCT to the 
most recent risk-adapted, intensified consolidation schedules, which provided significant 
benefits in terms of both relapse free and overall survival in standard risk ALL cases (Bassan 
and Hoelzer). In addition, not all the patients can benefit from it, at present. Thus, 
optimizing SCT strategies (see above) as well as improving post SCT therapy are necessary. 
In this light, the possible interventions regards either cellular therapies and pharmacological 
approaches. For example, the development of grade ≥2 GVHD is correlated with reduced 
relapse rate but relevant morbidity and mortality are related to GVHD. Thus, future 
strategies should consider graft manipulation aiming to maintain GVL effect though 
reducing GVHD and TRM.  
Finally, the presence of minimal residual disease after SCT is associated with impending 
relapse. Thus, careful MRD monitoring after SCT should be performed  and treatment of 
molecular relapse should be considered. In this setting, targeted therapy, such as TKI and 
interferon alpha (Piccaluga, et al) or novel TKI for Ph+ ALL, FLT3 inhibitors for MLL+ cases, 
nelarabine/forodesine for T-ALL and, more in general, monoclonal antibodies (anti-CD19, 
anti-CD20, anti-CD22 and anti-CD33) surely warrants further evaluation in clinical trials. 
Accordingly, based on the currently available data, allogeneic SCT is a reasonable treatment 
option for adults with high-risk and possibly standard risk ALL in CR1. Patients in CR2 
with matched donor should be probably always referred to alloSCT unless major clinical 
contraindications are recorded. Finally, refractory patients as well as cases beyond CR2 
should be carefully evaluated and selected for alloSCT basing on age, PS and amount of 
previous CHT. 
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ASCT recipients with HR ALL, the incidence of non-relapse mortality was 2.4%. In the 
analysis of a selected group of 50 patients in whom the MRD was evaluated with sufficient 
sensitivity to define the MRD status as negative at the level of 0.01%, the 5-years probability 
of DFS was 69%. 
In so far conducted prospective trials ASCT was administered instead of either maintenance 
or consolidation + maintenance and was considered the last stage of the treatment. There is, 
however, another option, which has not been prospectively tested i.e. incorporating ASCT in 
consolidation, followed by maintenance. Interim analysis of a retrospective study by the 
Central and Eastern Leukemia Group indicate significantly increased probability of the DFS 
if maintenance based on mercaptopurine + methotrexate was administered after ASCT (70% 
vs. 38% at 5 years, p=0.03). The effect was independent on the MRD status (HR=2.6, 
p=0.007) (unpublished data). 
Finally, ASCT followed by interferon alpha administration has been shown to be quite 
effective for Ph+ patients (Piccaluga, et al, Visani, et al). 
Taken together, ASCT is associated with low risk of transplant-related mortality and 
morbidity. Its efficacy should still be prospectively evaluated in patients with low MRD 
level, with post-transplant maintenance as an option. 
10. Conclusion 
Data from clinical trials trying to compare alloSCT and other post-remission therapies for 
ALL  patients in CR1 are sometimes difficult to interpret because of varying proportions of 
patients with different risk factors in each study (some of them are actually limited to high 
risk patients as many centres do not include alloSCT in the therapeutic program of standard 
risk patients in CR1). Prospective randomized studies have been carried out by various 
cooperative groups. These studies have compared patients with HLA identical siblings 
assigned to the allogeneic SCT group to those without HLA identical sibs assigned to either 
a standard chemotherapy or ASCT group. However, as up to 70% of adults with ALL 
cannot be allocated to SCT because of a lack of a matched related sibling, comorbidities, or 
severe infections, an objective and unbiased comparison among treatments is difficult (Avivi 
and Goldstone, Martin and Gajewski, Popat, et al). A major limitation of these studies is that 
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the proportion of patients in the allogeneic SCT group actually undergoing transplant varies 
from study to study. Despite this limitation, a donor versus no donor comparison is the best 
way to answer the question about role of allogeneic SCT in first remission, even though the 
so called “genetic randomization” (based on the availability of HLA-matched donor) is not a 
proper randomization. In addition, in some studies, patients receiving ASCT/CHT included 
cases over 50 years not suitable for alloSCT. Notable features of all these studies include a 
high treatment related mortality and a lower risk of relapse in allogeneic transplant arm. On 
the other hand, the most recent study from the MRC/ECOG group (MRC UKALL 
XII/ECOG E2993) (Fielding, et al, Goldstone, et al) represented the largest series in which the 
role of alloSCT in ALL was prospectively evaluated. Indeed, in this study alloSCT was 
shown to provide the best outcome specially in standard risk patients, thus offering a strong 
indication to this procedure in the majority of ALL cases. 
On the other hand, the randomized studies so far available did not compare alloSCT to the 
most recent risk-adapted, intensified consolidation schedules, which provided significant 
benefits in terms of both relapse free and overall survival in standard risk ALL cases (Bassan 
and Hoelzer). In addition, not all the patients can benefit from it, at present. Thus, 
optimizing SCT strategies (see above) as well as improving post SCT therapy are necessary. 
In this light, the possible interventions regards either cellular therapies and pharmacological 
approaches. For example, the development of grade ≥2 GVHD is correlated with reduced 
relapse rate but relevant morbidity and mortality are related to GVHD. Thus, future 
strategies should consider graft manipulation aiming to maintain GVL effect though 
reducing GVHD and TRM.  
Finally, the presence of minimal residual disease after SCT is associated with impending 
relapse. Thus, careful MRD monitoring after SCT should be performed  and treatment of 
molecular relapse should be considered. In this setting, targeted therapy, such as TKI and 
interferon alpha (Piccaluga, et al) or novel TKI for Ph+ ALL, FLT3 inhibitors for MLL+ cases, 
nelarabine/forodesine for T-ALL and, more in general, monoclonal antibodies (anti-CD19, 
anti-CD20, anti-CD22 and anti-CD33) surely warrants further evaluation in clinical trials. 
Accordingly, based on the currently available data, allogeneic SCT is a reasonable treatment 
option for adults with high-risk and possibly standard risk ALL in CR1. Patients in CR2 
with matched donor should be probably always referred to alloSCT unless major clinical 
contraindications are recorded. Finally, refractory patients as well as cases beyond CR2 
should be carefully evaluated and selected for alloSCT basing on age, PS and amount of 
previous CHT. 
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1. Introduction 
Myelodysplastic syndromes are a heterogeneous group of clonal bone marrow disorders, 
which are considered to be cancers and have a tendency to transform into acute myeloid 
leukemia. MDS are characterised by the underproduction of normal blood cells. Disease-
induced cytopenias result infections and bleeding complications.  
The diverse pathobiology of the disease is manifested by a varied clinical course, with some 
patients having more indolent disease and longer life expectancy, and others presenting 
with aggressive variants that rapidly progress to AML. 
The frequency of the disease is the highest in the elderly. Number of diagnoses has 
increased in the past decade as a consequence of the increased recognition, and the aging of 
the population.  
Prognosis is influenced by the age and co-morbidities of the patient and also by the 
cytogenetic abnormalities. 
Risk stratification is based on the number of myeloblast in the bone marrow, the number of 
cytopenias and the cytogenetic abnormalities. The most widely used prognostic systems are 
the International Prognostic Scoring System (IPSS) and the WHO classification-based 
Prognostic Scoring System (WPSS). The latter system incorporates transfusion burden as 
well (Greenberg, 1998). 
From the standpoint of both disease biology and prognosis, it is important to distinguish 
primary MDS from therapy-related MDS; the latter is closely related to therapy-related 
AML and develops in the setting of prior exposure to chemotherapy (eg, alkylating agents, 
topoisomerase II inhibitors), radiotherapy, radiation accidents, benzene, or other toxins and 
is prognostically worse than primary MDS. Response to therapy is highly worse in this 
group of patients (Tefferi, 2010; Graubert, 2010). 
Treatment of MDS in the past was restricted to supplementation of the missing cell type 
thus relieving the patient’s symptoms. Advances over the last decade have given a 
multitude of treatment options. Therapeutic options now exist that not only reduce disease-
related symptoms, improve quality of life, but alter the natural history of the disease as well.  
2. Epidemiology 
The incidence of newly diagnosed MDS exceeds 10.000 cases in the US annually. MDS are 
the most common in older patients. At the time of diagnosis, 86 % of patients are 60 years or 
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1. Introduction 
Myelodysplastic syndromes are a heterogeneous group of clonal bone marrow disorders, 
which are considered to be cancers and have a tendency to transform into acute myeloid 
leukemia. MDS are characterised by the underproduction of normal blood cells. Disease-
induced cytopenias result infections and bleeding complications.  
The diverse pathobiology of the disease is manifested by a varied clinical course, with some 
patients having more indolent disease and longer life expectancy, and others presenting 
with aggressive variants that rapidly progress to AML. 
The frequency of the disease is the highest in the elderly. Number of diagnoses has 
increased in the past decade as a consequence of the increased recognition, and the aging of 
the population.  
Prognosis is influenced by the age and co-morbidities of the patient and also by the 
cytogenetic abnormalities. 
Risk stratification is based on the number of myeloblast in the bone marrow, the number of 
cytopenias and the cytogenetic abnormalities. The most widely used prognostic systems are 
the International Prognostic Scoring System (IPSS) and the WHO classification-based 
Prognostic Scoring System (WPSS). The latter system incorporates transfusion burden as 
well (Greenberg, 1998). 
From the standpoint of both disease biology and prognosis, it is important to distinguish 
primary MDS from therapy-related MDS; the latter is closely related to therapy-related 
AML and develops in the setting of prior exposure to chemotherapy (eg, alkylating agents, 
topoisomerase II inhibitors), radiotherapy, radiation accidents, benzene, or other toxins and 
is prognostically worse than primary MDS. Response to therapy is highly worse in this 
group of patients (Tefferi, 2010; Graubert, 2010). 
Treatment of MDS in the past was restricted to supplementation of the missing cell type 
thus relieving the patient’s symptoms. Advances over the last decade have given a 
multitude of treatment options. Therapeutic options now exist that not only reduce disease-
related symptoms, improve quality of life, but alter the natural history of the disease as well.  
2. Epidemiology 
The incidence of newly diagnosed MDS exceeds 10.000 cases in the US annually. MDS are 
the most common in older patients. At the time of diagnosis, 86 % of patients are 60 years or 
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older. The incidence of MDS rises from 3,4 cases per 100.000 in the general population to 15 
to 50 cases per 100.000 in people older than 75 years (Giralt et al., 2011).  
The incidence and prevalence of MDS has increased significantly over the past 20 years as a 
result of increasing longevity of the population and increasing physician awareness 
(Goldberg et al., 2010). 
Among patients diagnosed with MDS, 14% have been treated for other primary tumors 
prior to diagnosis (Ma et al., 2007; Sekeres, 2011a). 
3. Survival 
Patient outcomes vary depending on disease presentation. Among untreated patients with 
MDS, median survival varies from 5,7 years in low-risk patients to 0,4 years in patients with 
high risk disease. For patients with del(5q) as the only chromosomal aberration, medial 
survival is 73 months compared to 19,3 months for patients with more than one aberration. 
Transfusion need at diagnosis is the most independent parameter for survival, with 
transfusion-dependent patients having a median survival of 39 months versus 97 months for 
transfusion-independent patients. 
4. Staging system, risk stratification 
The IPSS was the first system to stratify patients according to their risk of death or evolution 
to AML. It is based on percentage of bone marrow blasts, cytogenetic abnormalities, and 
number of cytopenias. However, the IPSS does not consider the severity of anaemia and  
 
Factors for determining IPSS score 
 Score value 
Prognostic 
variable 




< 5 5-10 - 11-20 21-30 
Karyotype good Intermediate Poor - - 
Cytopenias 0/1 2/3 - - - 
Good = normal, -Y, del(5q), del(20q);  
poor = complex (3 abnormalities) or chromosome 7 anomalies;  
intermediate = other abnormalities. 
Risk of transformation and median survival 




Without therapy (years) 
Low 0 9.4 5.7 
Int-1 0.5-1.0 3.3 3.5 
Int-2 1.5-2.0 1.1 1.2 
High ≥ 2.5 0.2 0.4 
Int-1 = intermediate-1, Int-2 = intermediate-2 
Table 1. The International Prognostic Score System (IPSS) for MDS 
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transfusion requirement, which are definitely associated with reduced survival in MDS. The 
newer WPSS has five prognostic groups with distinct survival times and probabilities of 
progression to AML. While the IPSS is limited to newly diagnosed patients with MDS, the 
WPSS can be applied at any time during the disease course. It has been shown that the 
WPSS improves survival prediction and identifies patients with very low-risk disease who 
may achieve long-term survival. 
 
Variable 0 1 2 3  
WHO 
category 
RA, RARS, 5q- RCMD, 
RCMD-RS 
RAEB-1 RAEB-2  
Karyotype Good Intermediate Poor —  
Transfusion 
requirement 
No Regular — —  
Abbreviations: RA = refractory anaemia; RAEB-1 = refractory anaemia with excess blasts type 1; RAEB-
2 = refractory anaemia with excess blasts type 2; RARS = refractory anaemia with ringed sideroblasts; 
RCMD = refractory cytopenia with multilineage dysplasia; RCMD-RS = refractory cytopenia with 
multilineage dyslasia and ringed sideroblasts;  
Table 2. The WHO Classification-Based Prognostic Score System (WPSS) for MDS 
5. New prognostic factors 
Conventional metaphase cytogenetic analysis is limited by the sensitivity of the assay, and 
therefore new technologies are being applied in MDS to detect genomic alterations. One of 
these approaches has been the use of single-nucleotide polymorphism arrays (SNP-A). 
Using SNP-A, several candidate genes have been described recently, and include c-CBL 
(encodes an E3 ubiquitin ligase that inhibits tyrosine kinase signalling) (Sanada et al., 
2008), ASXL1, and TET-2 (which are significant because they may have a role in the 
control of epigenetic alterations in MDS.) (Boultwood et al., 2010; Jankowska et al., 2009; 
Garcia-Manero, 2010). 
6. Treatment goals and options 
The goals of treatment for patients with MDS are to prolong overall survival, reduce 
transfusion burden, and improve their quality of life (Scott, 2008). 
Treatment options for individual patients with MDS depend on the disease classification, 
prognostic stage and the age and health status of the patient. 
For patients with lower risk disease (IPSS: low- or intermediate-1-risk) options include 
lenalidomide, erythropoietin-stimulating agents and immunosuppressive therapy, as well 
as hypomethylating agents (azacitidine and decitabine). For patients with del(5q) 
syndrome lenalidomide is the treatment of choice. For patients with higher risk (IPSS: 
intermediate-2-, or high-risk), intensive therapy with allogeneic stem cell transplantation 
(alloSCT) remains the only potentially curative treatment option (Sekeres, 2009; Mufti & 
Chen, 2008).  
For the majority of patients who are not candidates for alloSCT, treatment options include 
azacitidine or decitabine, clinical trials, or supportive care. 
In addition, all patients receiving active therapy should receive continuous supportive care. 
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7. Considerations regarding to select the appropriate treatment options  
Treatment consideration must take into account many factors, including the pathologic 
diagnosis, the prognosis based on the IPSS or WPSS, the unique disease features in that 
particular patient, feasibility of performing a clinical trial, the appropriateness of a bone 
marrow transplantation, and the philosophy of the patient and the family concerning his or 
her care (Malcovati & Nimer, 2008; Barzi & Sekeres, 2010; Greenberg, 2010).  
In addition, if the patient has a secondary MDS, tolerability of therapy is probably worse 
because of previous exposure to DNA-damaging agents. 
Older age per se has a negative impact on survival of MDS patients, in particular of those 
with low-risk disease. However, age affects the survival of high-risk patients indirectly as 
well, by limiting their eligibility to intensive treatments. In addition, aging is associated with 
an increasingly high risk of developing co-morbidity. 
Co-morbidities have a significant impact on the outcome of patients with MDS. Risk 
stratification should also have to include the assessment of co-morbidities of the MDS 
patients.  
One of the most important areas of research is the identification of biomarkers of response to 
therapy (Garcia-Manero, 2010). A critical example is the discovery by List et al. of the 
relationship between the presence of a chromosome 5 alterations and response to 
lenalidomide (List et al., 2006), which resulted in the development of targeted approaches to 
these patients, as well as an entirely new field of research with the discovery of RPS14 as a 
critical gene in 5q31 (Ebert et al, 2008). Predictors of responsiveness to immunosuppressive 
therapy are younger age, HLA-DR15 type, the interval between first transfusion and starting 
of immunosuppressive treatment. (Sloand et al., 2008; Barrett et al., 2006). 
8. Patient selection 
The selection of an adequate treatment option has to be preceded by thorough 
consideration, that have to take account of several points of view. The proper patient 
selection is the key element of successful treatment. 
There is a significant role of the patient’s intent beyond the severity of the illness in the 
embracement of the most appropriate treatment option in case of a given patient. Patient has 
to be committed to the treatment as he or she takes the risk of the adverse effects of the 
treatment, and also he or she undertakes the inconveniences of a long-term treatment 
process.  
9. Treatment modalities in MDS 
Taking into account the above mentioned aspects, there are several possibilities to choose: 
observation, supportive care, iron chelation, erythropoiesis-stimulating agents (EPOs), 
immunosuppressive treatment, intensive chemotherapy, and also disease-altering options: 
hypomethylating agents, lenalidomide, alloSCT, as well as entrance in a clinical trial (Barzi 
& Sekeres, 2010).  
9.1 Observation 
Many patients, especially those who are older and frail, benefit from a period of observation 
before any discussion about the need for therapy is made. Treatment should be reserved 
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only if there are symptoms resulting from anaemia or other cytopenias or perhaps 
presymptomatic anaemia or severe thrombocytopenia. 
9.2 Supportive therapy 
Supportive care includes transfusion of red blood cells and platelets to minimize 
complication of cytopenias and to improve quality of life, as well as antibiotics to treat 
infections. 
Patients with symptomatic anaemia should receive transfusion to relieve their symptoms. 
Platelet transfusion must be given in case of severe thrombocytopenia which cause bleeding. 
9.3 Erythropoiesis-stimulating agents 
Once an MDS patient become transfusion-dependent, erythropoietin-stimulating agents 
(ESAs) can be considered. These include epoietin (Eprex) and darbopoietin alfa (Aranesp). 
The clinical practice guideline of the American Society of Haematology suggests to use 
epoietin and darbepoietin in adults with lower risk MDS without chemotherapy. 
Erythropoiesis stimulating agents are used by more than 50% of patients (Sekeres, 2011a,). 
Recently ESAs are increasingly used to treat anaemia of lower risk MDS, even before RBC 
transfusion requirement. Early introduction of ESA in lower risk MDS, may help to better 
avoid the consequences of anaemia and also to delay the need for RBC transfusions, 
hypothetically by slowing the disease course (Park et al., 2010). 
EPOs are recommended particularly for those with low serum EPO level. Serum 
erythropoietin (EPO) level  500 mU/ml may respond to EPO if relatively high doses are 
administered. The EPO dose required is 40.000-60.000 units 1-3 times a week 
subcutaneously. Erythroid response occur within 6 to 8 weeks of treatment (Hellström-
Lindberg E, 2003; Jädersten et al., 2008). 
In a phase 3 prospective randomized trial the efficacy and long-term safety of EPO with or 
without granulocyte colony-stimulating factor plus supportive care was evaluated versus 
supportive care alone for the treatment of anaemic patients with lower-risk MDS (Greenberg 
et al., 2009). In comparison with supportive care alone, patients receiving EPO with or 
without granulocyte colony-stimulating factor plus supportive care had improved erythroid 
responses, similar survival, and incidence of acute myeloid leukemia transformation. 
Responding patients had significantly lower serum EPO levels (45% vs 5% responses for 
levels < 200 mU/mL vs ≥ 200 mU/mL). (Rizzo et al., 2010).  
9.4 Iron chelation therapy 
Many MDS patients are dependent on red blood cell (RBC) transfusions for symptomatic 
management of refractory anaemia. Iron overload ensues when the iron acquired from 
transfused RBCs exceeds body storage capacity, thereby raising the risk for end organ 
damage (List, 2010).  
The use of iron chelation in myelodysplastic syndrome (MDS) has generated much 
controversy recently (Steensma, 2009a). Transfusion dependency is associated with 
shortened overall survival and leukemia-free survival in MDS. The major question is 
whether this effect is mediated by transfusional iron overload itself or if need for red cell 
transfusion is simply a marker of disease severity (Malcovati et al., 2005). 
Averting cardiac dysfunction in low-grade MDS patients who have sufficient longevity to 
experience deleterious cardiac effects of iron overload has been the major argument in favor 
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of iron chelation. However, the role of iron chelation therapy in MDS remains controversial. 
Although there is significant evidence showing the adverse impact of transfusion 
dependency on survival in MDS, direct evidence linking tissue iron overload to poor 
survival or in particular to cardiac dysfunction is lacking.  
Present evidence suggesting that the major benefit of iron chelation in MDS is not likely to 
come from reduction in cardiac and other end organ damage due to tissue iron overload, 
but from a potential favorable impact on 3 other outcomes namely: lowering infection risk, 
improving the outcome of allogeneic hematopoietic stem cell transplantation, and delaying 
leukemic transformation. These outcomes have particular relevance for patients with higher 
grades of MDS (Pullarkat, 2009).  
Application of recent advances in the treatment of MDS can reduce or eliminate the need for 
transfusions, thus minimizing the risk of iron overload.  
Iron chelation strategies include oral agents such as deferasirox (Exjade, Novartis), 
deferiprone (Ferriprox, Apotex Europe BV,) and parenteral administration of deferoxamine 
(Desferal, Novartis).  
Considering the short survival of patients with MDS, the benefit of iron chelation is 
debatable. This procedure is advised for those who have received more than 25 units of 
packed red blood cells. 
Unfortunately, iron chelation is expensive and, to date, has not shown a clear survival 
benefit in the MDS population. 
9.5 Hypomethylating agents 
MDS pathophysiology is complex, and still not completely understood. Structural 
alterations in DNA play a role in the pathogenesis of disease. Epigenetic changes in the form 
of modifications to the transcriptional capacity of the cell via processes, such as DNA 
methylation can also alter gene expression impacting disease biology. As such, 
hypermethylation of the promoters of certain tumor suppression genes is prevalent in MDS 
and secondary AML, and it is postulated that the DNA hypomethylation may result in the 
reactivation of silenced genes, restoring their cancer-suppressing functions, and inducing 
cellular differentiation providing a biologically rational therapeutic target for MDS.  
Currently, both FDA- (U.S. Food and Drug Administration) approved hypomethylating 
agents (azacitidine and decitabine) have shown good clinical responses in patients with 
MDS. In the last two decades the use of epigenetic therapy has gained popularity, given its 
favorable side effect profile and its potential to improve survival. 
9.5.1 Azacitidine (5-azacytidine; Vidaza) 
Azacitidine (5-azacytidine; Vidaza; Pharmion Corporation) for injectable suspension 
received regular approval by the FDA for the treatment of all subtypes of MDS in 2004. It 
was the first agent that has been reported to prolong survival in MDS patients. 
9.5.1.1 Mechanism of action 
Azacitidine is a nucleosid analog that incorporates into RNA and requires the activity of 
ribonucleotide reductase to be incorporated to DNA. The incorporation of azacitidine into 
DNA leads to inhibition of DNA methyltransferase (DNMT) which has been known to 
hypermethylate cytosine residues at cytosine-guanine repeat sequences. By reducing the 
quantity of hypermethylated DNA produced, azacitidine can serve to limit the proliferation 
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of malignant cells, while allowing an increased proportion of normal cells to differentiate. 
Although azacitidine falls into the category of hypomethylating agents, its mechanism of 
action is likely multifactorial (Yang et al, 2010).  
9.5.1.2 Identification patients for azacitidine treatment 
Azacitidine was approved by the US FDA on the basis of CALGB (Cancer and Leukemia 
Group B) 9221. This randomized trial compared azacitidine with best supportive care 
(BSC) targeting high-intermediate and high-risk disease and including low-intermediate 
risk patients with ongoing complications of cytopenias. The results demonstrated 
superiority of azacitidine over BSC in terms of quality of life, reduced transfusion needs, 
and delayed time to AML transformation or death for higher risk patients (Kurtin & 
Demakos. 2010,). 
It was the AZA-001 trial (the second randomized trial, which was conducted to define 
whether an endpoint not of response but overall survival (OS) could be met with 
hypomethylation therapy) which revealed that azacitidine significantly improved OS 
compared to that of the conventionally treated patients (either BSC, low-dose cytosine-
arabinoside, or intensive induction chemotherapy). There was no particular „winner” 
regarding the different subsets of patients treated. Response benefit was distributed fairly 
evenly across various subgroups of patients. This was true across younger and older 
patients, gender, performance status, FAB subtype, WPSS, IPSS score, cytogenetic risk 
category, and bone marrow blasts rate (Edlin et al., 2010). 
The rate of complete response (CR) was rather low in the AZA-001 trials (17 % in the 
azacitidine arm). The low CR rate provides compelling data against oncology dogma that 
achievement of CR is required for survival benefit. Indeed, a retrospective subset analysis 
examined the survival impact of azacitidine excluding patients who achieved CR. One-year 
survival rates were superior for azacitidine treatment versus conventional treatment (68% vs 
56 %, P= 0,015), thus achieving a CR is no longer a sufficient predictor for a therapy’s ability 
to extend survival and alter course of MDS. 
Critical to the success of azacitidine is the selection of appropriate patients. Higher risk MDS 
patients who are of reasonable performance status with adequate organ function are 
excellent candidates and also those lower risk patients who are transfusion dependent or 
have severe cytopenias. 
9.5.1.3 Side effects 
Adverse events are inevitably encountered. Haematological toxicities are common, 
particularly in the first one to two cycles. Infections have occured in 50 % of azacitidine-
treated patients in AZA-001 trial. 58 % of patients experienced thrombocytopenia and/or 
neutropenia.  
Common other adverse effects are gastrointestinal (vomiting, diarrhoea, anorexia), fevers, 
rigors, arthralgia, headache, and dizziness (San Miguel Amigo, 2011). 
9.5.1.4 Dosage and administration 
For azacitidine the most appropriate dosing schedule is 75 mg/m2 subcutaneously for 7 
days, every 4 weeks. It is also an important issue to keep on treatment for at least at six 
cycles. In case of the absence of unacceptable toxicity or the evidence of disease progression, 
therapy should be continued for the maintenance of the response. 
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of iron chelation. However, the role of iron chelation therapy in MDS remains controversial. 
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of malignant cells, while allowing an increased proportion of normal cells to differentiate. 
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The rate of complete response (CR) was rather low in the AZA-001 trials (17 % in the 
azacitidine arm). The low CR rate provides compelling data against oncology dogma that 
achievement of CR is required for survival benefit. Indeed, a retrospective subset analysis 
examined the survival impact of azacitidine excluding patients who achieved CR. One-year 
survival rates were superior for azacitidine treatment versus conventional treatment (68% vs 
56 %, P= 0,015), thus achieving a CR is no longer a sufficient predictor for a therapy’s ability 
to extend survival and alter course of MDS. 
Critical to the success of azacitidine is the selection of appropriate patients. Higher risk MDS 
patients who are of reasonable performance status with adequate organ function are 
excellent candidates and also those lower risk patients who are transfusion dependent or 
have severe cytopenias. 
9.5.1.3 Side effects 
Adverse events are inevitably encountered. Haematological toxicities are common, 
particularly in the first one to two cycles. Infections have occured in 50 % of azacitidine-
treated patients in AZA-001 trial. 58 % of patients experienced thrombocytopenia and/or 
neutropenia.  
Common other adverse effects are gastrointestinal (vomiting, diarrhoea, anorexia), fevers, 
rigors, arthralgia, headache, and dizziness (San Miguel Amigo, 2011). 
9.5.1.4 Dosage and administration 
For azacitidine the most appropriate dosing schedule is 75 mg/m2 subcutaneously for 7 
days, every 4 weeks. It is also an important issue to keep on treatment for at least at six 
cycles. In case of the absence of unacceptable toxicity or the evidence of disease progression, 
therapy should be continued for the maintenance of the response. 
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9.5.1.5 Azacitidine for maintenance of complete remission after chemotherapy 
A Phase II prospective study was performed to assess the feasibility and efficacy of 
maintenance azacitidine for older patients with high-risk MDS in CR after induction 
chemotherapy. Sixty patients were enrolled and treated by standard induction 
chemotherapy. Patients that reached CR started maintenance therapy with subcutaneous 
azacitidine, 5/28 days until relapse. Median overall survival was 20 months. A dose of 60 
mg/m(2) was well tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 
9.5 and 30% of the cycles, respectively, while haemoglobin levels increased during 
treatment. azacitidine treatment is safe, feasible and may be of benefit in a subset of patients 
(Grövdal et al., 2010). 
9.5.2 Decitabine (dezocitidine, Dacogen, SuperGen, Inc., Dublin) 
Decitabine is another hypomethylating agent approved by the US FDA in 2006 for the 
treatment of de novo and secondary MDS (for intermediate-1-, intermediate-2-, and high-risk 
MDS patients). It has been studied predominantly in higher-risk MDS patients. 
The FDA approval was based on the randomized phase III trial (EORTC 06011) versus BSC 
using the European administration schedule. Decitabine-treated patients had improved 
quality of life, and reduced transfusion needs. Although there was a delayed time to AML 
transformation or death, this trial failed to shown any survival benefit for decitabine arm. 
The relatively short duration of therapy administered was the main limitation of the study 
design which may negatively affected outcomes (Garcia et al., 2010,).  
Concerning studies with hypomethylating agents the best available evidence and consensus 
is that patients benefiting from therapy should continue treatment until progression or 
unacceptable toxicity. 
The toxicity profile of the two AZA nucleotides is similar.  
While the haematological response rates to both hypomethylating agents are similar, the 
survival advantage demonstrated by the FDA-approved dose schedule of azacitidine 
compared with conventional care, as well as the absence of such a survival advantage in 
response to the FDA-approved dose schedule of decitabine in two randomized studies, 
makes azacitidine the drug of choice for AZA nucleoside-naive, high-risk MDS patients. 
Perhaps the better-tolerated North American decitabine schedule would lead to similar 
survival advantage.  
A comparative trial of azacitidine versus decitabine recently opened to accrual (http:// 
www.ClinicalTrials.gov; identifier: CT01011283). Unfortunately, the trial is designed with a 
primary endpoint of early response at 6 months and is not powered to examine the more 
relevant question of OS. (Blum, 2010) 
9.5.2.1 Dosage and administration of decitabine 
European schedule is 15 mg/m2 intravenously over 3 hours, every 8 hours for 3 days, 
repeated every 6 weeks Kantarjian et al., 2006). In North America, the typical schedule is 20 
mg/m2 intravenously over 1 hour daily for 5 days, repeated every 4 weeks, based on 
promising high CR results of up to 39% in a single center (Kantarjian et al., 2007). A 
multicenter study of 99 patients with MDS using the same regimen, The Alternative Dosing 
for Outpatient Treatment (ADOPT) trial, showed a CR rate of 17%, with an overall response 
rate of 51% (Steensma et al., 2009b). The main point of administration is the number of 
cycles. The better OS results of azacitidine may be the consequence of the higher number of 
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cycles. In the EORTC 06011 study the median number of cycles per patient was four, and 
40% received two or fewer cycles. By comparison, the median number of cycles of AZA 
given in AZA-001 was nine. 
9.6 Lenalidomide 
Lenalidomide is an immunomodulatory drug that is FDA approved for lower risk patients 
with transfusion-dependent anaemia and an interstitial deletion of the long arm of 
chromosome 5 [del(5q)]. The approval was based on high rates of prolonged transfusion 
independence and complete cytogenetic response (Ximeri et al., 2010). 
Treatment with a 10 mg daily dose for 21 days in every 4 weeks results transfusion 
independence in 67 % of patients with del(5q). Lenalidomide treatment does not increase 
risk of AML progression according to the preliminary result of MDS-004 study. It was a 
significant concern in Europe, preventing approval of the drug. Despite the frequent need of 
dose reduction due to myelosuppression, the starting dose of lenalidomide is suggested to 
be 10 mg (Sekeres et al., 2008). 
Though lenalidomide is approved by FDA for del(5q) lower risk subset of MDS patients, it 
is reasonable to consider lenalidomide as frontline treatment in the few higher risk patients 
with MDS who have both isolated del(5q) and platelet count  100.000/µL (Kurtin & 
Demakos,  2010).  
In case of patients with lower risk and without del(5q) the ratio of patients reached 
transfusion independence was much lower and response duration was much shorter than 
that of patients with del(5q). Cytogenetic improvement was also inferior to that observed in 
the del(5q) patients. (Komrokji & List, 2010;, List et al., 2006). 
9.6.1 Mechanism of action 
The drug may have different mechanism of activity, depending on the disease type.  
In del(5q), lenalidomide suppresses the malignant clone, but in non-del(5q) it appears to 
promote erythropoiesis.  
There is now a better understanding of the mechanism of the karyotype-dependent drug 
action. In del(5q) patients, lenalidomide suppresses the clone by inhibiting the nuclear 
sequestration of the haplodeficient cell cycle regulatory protein cdc25c, thereby promoting 
selective G2 arrest and apoptosis (Wei et al., 2009). In non-del(5q) patients, lenalidomide 
enhances erythropoietin receptor signaling. 
9.6.2 Combination treatment 
The addition of lenalidomide to azacitidine may provide additional clinical benefit over e 
monotherapy. 
A recent Phase I trial testing the lenalidomide and azacitidine combination yielded 
encouraging results. In this study, 18 higher-risk MDS patients were treated with the 
combination for seven cycles, after which lenalidomide was discontinued in eight patients 
who achieved a complete response, with azacitidine monotherapy continuing until disease 
progression. Three patients who relapsed on monotherapy with excess blasts at 12, 19, and 
24 months, in whom lenalidomide was then resumed in combination with azacitidine. Each 
patient, one with normal cytogenetics at relapse; one with a 18 abnormality; and one with 
del(4q25), recaptured a complete response that was sustained for 5, 7, and 7+ months. 
The addition of lenalidomide to azacitidine provides additional clinical benefit over 
azacitidine monotherapy. (Sekeres et al., 2011b) 
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9.7 Immunosuppressive treatment 
An activated immune system has been observed in patients with myelodysplastic syndrome 
but its exact contribution to disease development and control is not fully clarified. On the 
one hand an activated and skewed T-cell repertoire has been reported, but on the other 
hand, decreased natural killer cell function has been found. Immune activation could reflect 
undesired autoimmune reactions against normal hematopoietic precursor cells as well as 
effective immune-surveillance against dysplastic clones (Chamuleau et al., 2009). 
Autoreactive T-cell clones have a role in the apoptosis in the bone marrow of MDS, mainly 
in patients with hypocellular bone marrow. Immunosuppressive agents such as 
cyclosporine A (CsA)and anti-thymocyte globulin (ATG), or combination of the two agents 
can improve cytopenia and can reduce transfusion need in a subset of MDS patients. The 
anti-TNF agent etanercept can also be applied in combination with ATG. (Deeg et al., 2004). 
Responses to immunosuppressive therapy in MDS remain among the most durable (and 
perplexing) of all available therapies in the disease. Typically, equine ATG is given at 40 
mg/kg intravenously for four consecutive days, in conjunction with methylprednisone and 
CsA. Initial reports of its use demonstrated achievement of transfusion independence in 21 
of 61 (34%) of patients. More importantly, the probability of continued transfusion 
independence after 5 years was 76%. However, the toxicity of the regimen has led to 
considerable apprehension in its use.  
Most ATG studies in MDS have been single center experiences, and several reports in 
unselected patients have demonstrated lower response rates and significant toxicity with the 
regimen. Clearly, judicious patient selection for the therapy is critical for its success and 
productive implementation. Helpful guidance for the use of ATG in MDS was recently 
published. Outcomes for patients with MDS who were given equine ATG (with or without 
CsA) in sequential protocols at the National Heart, Lung, and Blood Institute between 1971 
and 2003 were described. For 129 ATG-treated patients, 39 patients (30%) responded; 9% 
had CR. Serious infusion-related toxicities were infrequent, but meaningful because 9% of 
patients required temporary intensive care unit support. Responses included 18 of 74 (24%) 
treated with ATG alone, 20 of 42 (48%) treated with ATG_CsA, and 1 of 13 (8%) treated with 
CsA. Median response duration was 3 years (3 months to 10 years), and median survival in 
the cohort was 10,5 years. Notably, factors affecting response were younger age ( 60), HLA-
DR15 positivity, and use of combination ATG+CsA. There was no association of response 
with pretreatment marrow cellularity, paroxysmal nocturnal hemoglobinuria clone, or 
absolute neutrophil count. Furthermore, a multivariate analysis of the IST-treated group 
compared with results from a control group of 816 patients with MDS from the International 
Myelodysplasia Risk Analysis Workshop database showed that survival was improved in 
younger patients, those treated with IST, and those with low/intermediate IPSS risk scores. 
The role of IST in MDS treatment remains enigmatic, and the serious toxicities that can be 
encountered with its infusion and long-term immunosuppressive effects have properly led 
to hesitation to its use in community and academic practice. However, in a manner similar 
to the rigorous selection of patients for transplantation, appropriate selection of patients for 
IST affords some the opportunity for prolonged responses without the requirement for 
repeated maintenance chemotherapy (such as AZA or decitabine). IST should be considered 
instead of a hypomethylating agent for previously untreated, younger patients with MDS 
with low or Int-1 risk disease with HLADR15. 
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Predictors of responsiveness are younger age, HLA-DR15 type, the interval between first 
transfusion and starting of immunosuppressive treatment. (Sloand et al., 2008; Barrett et 
al., 2006). 
Passweg et al. reported open-label randomized phase III trial on patients with MDS 
randomly assigned to 15 mg/kg of horse ATG for 5 days and oral CSA for 180 days 
(ATG+CSA) (45 patients) or best supportive care (43 patients), stratified by treatment center 
and International Prognostic Scoring System (IPSS) risk score. Primary end point was best 
hematologic response at 6 months. This trial demonstrated that ATG+CSA treatment seems 
to be associated with hematologic response in a subset of patients without apparent impact 
on transformation free survival and OS (Passweg et al., 2011). 
Because of the toxicities associated with ATG/CsA, an alternative regimen with 
alemtuzumab in MDS was investigated (Sloand et al., 2010). It was a nonrandomized, off-
label, pilot, phase I/II study of alemtuzumab monotherapy in patients with MDS who were 
judged likely to respond to immunosuppressive treatment based on the following criteria: 
HLA-DR15-negative patients whose age plus the number of months of RBC transfusion 
dependence (RCTD) was less than 58; and HLA-DR15-positive patients whose age plus 
RCTD was less than 72. Thirty-two patients were enrolled they received alemtuzumab 10 
mg/d intravenously for 10 days. Primary end points were hematologic responses at 3, 6, 
and 12 months after alemtuzumab. Seventeen (77%) of 22 evaluable intermediate-1 patients 
and four (57%) of seven evaluable intermediate-2 patients responded to treatment with a 
median time to response of 3 months. Four of seven evaluable responders with cytogenetic 
abnormalities before treatment had normal cytogenetics by 1 year after treatment. Five 
(56%) of nine responding patients evaluable at 12 months had normal blood counts, and 
seven (78%) of nine patients were transfusion independent. Alemtuzumab seems to be safe 
and active in MDS and may be an attractive alternative to ATG in selected patients likely to 
respond to IST. 
9.8 Intensive chemotherapy 
About 25 % of patients with newly diagnosed MDS and 15-20 % of patients with established 
MDS have higher risk disease. These patients should be treated immediately, given the high 
likelihood of transformation to AML or death within 1.5 years. One of the treatment options 
is intensive chemotherapy (Bello et al., 2010; Gergis & Wissa, 2010). 
Intensive chemotherapy means some kind of acute leukemia protocol. One of them is the 
FLAG-Ida regimen. The combination of fludarabine, high dose cytarabine and granulocyte 
colony stimulating factor (FLAG) with idarubicin. According to a single centre experience 
treated a total of 105 patients over a 4-year period with 59% achieving a complete remission. 
For patients responding to FLAG - Ida, the median event-free survival was 11 months at 5 
years. Such patients proceeded either to further chemotherapy or a haematopoietic stem cell 
transplant (HSCT). The median EFS (13 months vs. 8 months) and projected 5-year survival 
(37% vs. 13%) of patients undergoing HSCT was significantly better than those who did not. 
The regimens were well tolerated, with the majority of patients experiencing grade 1 or less 
non-haematological toxicity (mainly nausea and vomiting). The median time to neutrophil 
and platelet recovery was 28 and 31 day, respectively. There was a 17% incidence of 
treatment-related deaths, of which 39% was caused by invasive aspergillus infection (Virchis 
et al., 2004). 
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Predictors of responsiveness are younger age, HLA-DR15 type, the interval between first 
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To date, no prospective randomized study has evaluated hypomethylating agents against 
intensive chemotherapy. Proponents of hypomethylating agents argue that they have a 
lower toxicity profile, allowing patients to receive therapy on an outpatient basis, and that 
the lower complete response rates do not necessarily translate into lower survival rates. This 
may be particularly relevant for older MDS patients, who are at higher risk of morbidity 
from intensive chemotherapy. (Scott & Estey, 2008). 
9.9 Autologous stem cell transplantation 
Intensive chemotherapy with AML-like schedules followed by autologous stem cell 
transplantation may provide an alternative option for patients lacking a suitable donor. 
Intensive chemotherapy results in complete remission rates of 15-65%. The median 
remission duration without stem cell transplantation is usually short due to a high incidence 
of early relapses. In view of the high relapse rate after chemotherapy alone transplantation 
with autologous stem cells after remission induction and consolidation chemotherapy has 
been applied in various clinical studies. 
Autologous SCT has been extremely investigated in MDS. It is limited to patients who have 
achieved a CR, can be harvested, and are candidates for the procedure. Autologous SCT 
after successful induction chemotherapy may increase the proportion of long-term 
survivors, thus improving CR duration in some patients with MDS, particularly in younger 
patients in remission. Results for older patients are unsatisfactory. The relapse rate is up to 
75%, with a 2-year probability of disease-free survival of only 25% for patients 40-60 years of 
age (Meletis & Terpos, 2009).  
Autologous peripheral stem cells (PB) result in faster hematopoietic recovery, but may be 
associated with a higher risk of relapse than bone marrow stem cells. In a study comparing 
336 patients transplanted with either bone marrow (BM) (n=104) or PB (n=232). In the 
multivariate Cox model, the event-free survival was not different after PB or BM HSCT. The 
relapse risk after transplantation with stem cells from either source was similar. A 
significant interaction between age and the source of stem cells indicated a more favorable 
potential of autologous PB HSCT in young age groups. As autologous PB and BM HSCT 
result in equivalent outcomes, given the more rapid hematopoietic recovery PB is the 
preferred source of stem cells (de Witte et al., 2006). 
According to the final results of a prospective randomized European Intergroup Trial 
(EORTC-06961) autologous stem cell transplantation does not provide longer survival than 
intensive chemotherapy (de Witte et al., 2010). Therefore, there is very limited enthusiasm 
for the future of autologous SCT in the management of MDS patients. 
Patients with therapy-related MDS/AML had a significantly better disease-free survival 
than did those with the other categories of disease, even after adjustment for confounding 
factors in the Cox model, including interval between diagnosis and transplantation. The 
explanation of this unexpected outcome is not straightforward, but the contribution of 
patients with favorable cytogenetic characteristics might be relevant. We identified eight 
patients with t(8;21) or inversion 16 in an incomplete and ongoing analysis. The 3-year 
disease-free survival of these patients was 57% (de Witte et al., 2007). 
9.10 Allogeneic stem cell transplantation  
Despite the approval of three novel agents for MDS, allogeneic stem cell transplantation 
(alloSCT) is the only curative treatment modality for MDS patients. Allogeneic SCT replaces 
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recipient dysplastic hemopoiesis with healthy donor haemopoiesis and immune system 
with an attendant graft-versus-leukemia (GvL) effect. Its applicability, however, is limited 
by the age of MDS patients, high rates of transplant-related mortality (TRM) and availability 
of a suitable HLA-matched donor. MDS is currently the third most common indication for 
alloSCT. As the disease is most frequent in the older population, the oftener use and 
acceptance of reduced-intensity conditioning (RIC) made the procedure more increased.  
There are several unresolved issues in connection with transplantation. These are the impact 
of pre-transplant tumor debulking, the optimal timing and the transplantation of older 
patients and of those with co-morbidities, and also the issue of post-transplant maintaining 
therapy. The main difficulty is whether can we identify a subset of patients that could 
benefit from early transplantation and also a subset that are anticipated not going to benefit 
from alloSCT. Recent efforts to optimize the curative potential of transplant have focused on 
pretransplant therapy options, the use of predictive models to improve patient selection, 
and transplant modifications using reduced conditioning intensity. 
Dependent upon disease status at the time of transplantation, 30% to 70% of patients can be 
expected to be cured of their disease and survive long term. However, posttransplant 
relapse and graft-versus-host disease (GvHD) remain problems (Bartenstein & Deeg, 2010). 
No prospective randomized controlled trials have directly compared non-transplant 
therapies with SCT for MDS. 
As more than 50% of the patients will fail to benefit from this treatment approach either due 
to TRM or to relapse after transplantation being mindful of patient selection is a main issue 
in decision making.  
9.10.1 Patient selection and decision making 
However, as the majority of patients with MDS are in the seventh or eighth decade of life 
careful consideration must be made to determine whether the patient is a candidate for 
alloSCT. Only approximately 5-10% of higher risk MDS patients are alloSCT candidates.  
Features to consider for alloSCT include the patient’s age and IPSS score (moreover WPSS), 
performance status, co-morbid conditions, availability of a suitable donor (Warlick, 2010; 
Malcovati et al., 2005; Cutler, 2010a,  2010b;).  
The proper assessment of co-morbidities becomes more important. A useful tool is 
hematopoietic cell transplantation co-morbidity index (HCTCI) developed by Sorror et a. 
(Sorror et al., 2005). It has been shown to have a predictive utility on survival also in MDS, 
even in case of patients getting only best supportive care (Zipperer et al., 2009). According to 
a study on 172 MDS patients assessing the impact of co-morbidities on survival and the 
prognostic utility of co-morbidity scores patients with an HCTCI of 0 had a median survival 
time of 68 months, those with an HCTCI of 1 or 2 lived for 34 months, and those with an 
HCTCI of ≥3 survived for 25 months. The HCTCI was able to further subdivide the IPSS 
intermediate-2 and high-risk groups. For patients in the IPSS intermediate-1 and low-risk 
groups, the HCTCI provided no additional prognostic information. The presence of 
pulmonary disease, gastrointestinal tract ulcers, cardiac disorders, and infection were 
independent prognostic factors for survival. HCTCI yielded prognostic information 
independent of the IPSS (Zipperer et al., 2009). 
It is also important to determine whether the patient’s marrow blast count is sufficiently 
low. Data suggest that patients with 5–20% marrow blasts have only 25-28% 5-year overall 
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survival whereas lower risk patients (based on WPSS risk score) do well with alloSCT, with 
a 5-year overall survival of 80% (Alessandrino et al., 2008). 
 








Group I (HCT-CI scores 0–2 and low-
risk diseases) 
Myeloablative 
(n=138) 11 14 78 75 
Nonmyeloablative 
(n=28) 4 33 70 63 
Group II (HCT-CI scores 0–2 and 
intermediate and high-risk diseases) 
Myeloablative 
(n=176) 24 34 51 43 
Nonmyeloablative 
(n=34) 3 42 57 56 
Group III (HCT-CI scores ≥ 3 and 
low-risk diseases) 
Myeloablative (n=52) 32 27 45 41 
Nonmyeloablative 
(n=19) 27 37 41 36 
Group IV (HCT-CI scores ≥ 3 and 
intermediate and high-risk diseases) 
Myeloablative (n=86) 46 34 24 20 
Nonmyeloablative 
(n=44) 29 49 29 23 
Table 3. Two-year NRM, relapse, OS, and RFS incidences among 4 risk groups of 
nonmyeloablative and myeloablative patients with AML or MDS. Donors were either 
related (n=301) or unrelated (n=276) (Sorror et al., 2005). 
9.10.2 Appropriate timing of alloSCT 
The timing of transplantation has always been the most controversial topic of discussion for 
both patients and physicians. The lack of prospective data adds to the doubtfulness in this 
topic. Faced with the uncertainty of transplantation outcomes but the certainty of eventual 
MDS disease progression, decisions are often made based on patient preference. It is clear 
that there is inherent bias in these types of analyses, because the patients included are often 
selected and represent the best transplant candidates.  
To address the shortcomings of these and other biased retrospective analyses, a Markov 
decision model was generated to best understand how treatment decisions would affect 
overall outcome in large cohorts of patients with newly diagnosed MDS (Cutler et al., 2004). 
The decision model was designed to determine if transplantation at the time of initial 
diagnosis, delayed a fixed number of years, or at the time of leukemic transformation was 
the optimal usage strategy for transplantation. Using data from several large, 
nonoverlapping databases, it was demonstrated that the optimal treatment strategy for 
patients with low- and intermediate-1-risk IPSS disease categories was to delay 
transplantation until the time of leukemic progression. Immediate transplantation was 
recommended for patients with high- and intermediate-2-risk IPSS scores (Cutler et al., 
2004). However, a major limitation of this study is that it excluded patients over the age of 
60 and focused solely on myeloablative conditioning.  
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According to the retrospective registry study of de Witte et al. low risk patients benefited by 
early transplantation (within one year after diagnosis) versus more than 12 months from 
diagnosis. Estimated four-year overall survival was 57 % versus 47% (de Witte et al., 2010).  
Beside the IPSS there are also important clinical events such as a new transfusion 
requirement, recurrent infection, or recurrent bleeding episodes that could be considered 
triggers to move on to transplantation. Transfusion requirement is a very strong predictor of 
the advantage of early transplantation. WPSS incorporates transfusion dependence into the 
score, and enables a dynamic assessment of prognosis during the time-course of the disease. 
WPSS appears more useful than IPSS particularly with respect to patients with low-risk 
disease (Malcovati et al., 2007). Presumably, identification of newer prognostic markers, 
using cytogenetic, immunophenotypic, and molecular techniques will enable further 
improvement in terms of risk stratification and help to clarify the optimal timing for 
transplantation, particularly for patients with low-risk disease. 
9.10.3 Conditioning regimen 
Standard myeloablative conditioning (SMC) results in high treatment-related mortality. 
While a high proportion of patients can achieve long-term disease control when undergoing 
transplantation in early phases of the disease using SMC, transplantation-related deaths 
account for 20% to 30% of treatment failures with such type of conditioning regimens 
(Bearman et al., 1988; de Lima et al., 2004). 
A combination of busulfan (Bu) and cyclophosphamide (Cy) has been used as a standard 
myeloablative regimen for alloSCT. Recent studies postulate that fludarabine (Flu) is a less 
toxic substitute for Cy. Lee et al. compared the two regimens (BuCy vs BuFlu) and showed 
that there was no significant intergroup difference in the time of engraftment, 
nausea/vomiting, acute/chronic graft-versus-host disease, hepatic veno-occlusive disease, 
or hemorrhagic cystitis. Moreover, the 2 groups showed no significant difference in the 
cumulative risk of relapse, event-free survival, or overall survival (Lee et al., 2010; Kindwall-
Keller & Isola, 2009). 
As the vast majority of MDS patients are over 60, using SMC is rarely an option. 
Conditioning regimens with less toxicity for alloSCT are being developed and should be 
available for a higher proportion of patients, particularly those who are elderly. 
It has been well established that for many malignancies the curative potential of allogeneic 
transplantation is, in large part, due to the graft versus malignancy (GVM) effect. This has 
led to the development of less toxic, nonmyeloablative, and reduced intensity 
transplantation regimens that would provide donor cell engraftment and generation of a 
GVM effect. This approach has allowed treatment of older and debilitated patients who 
have been considered ineligible for transplantation using myeloablative regimens (de Lima 
et al., 2004; Gale & Champlin, 1984). 
Reduced-intensity conditioning regimens (these regimens cannot be safely administered 
without stem cell support) usually involve a combination of a purine analog (primarily 
fludarabine) with an alkylating agent (usually melphalan or busulfan). These reduced-
intensity regimens are generally considered to include less than 16 mg/kg busulfan or less 
than 10 Gy total body irradiation (Giralt et al., 1999, 2001). They have been usually 
associated with prompt engraftment of donor cells procured from both HLA-matched 
related and unrelated donors, while the truly nonablative regimens (NMA; can be given 
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survival whereas lower risk patients (based on WPSS risk score) do well with alloSCT, with 
a 5-year overall survival of 80% (Alessandrino et al., 2008). 
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routinely without stem cell support, with neutrophil recovery within 28 days) have been 
associated with a varying degree of mixed chimerism and a higher risk of primary and 
secondary graft failures (de Lima et al., 2004).  
However, there are currently no completed prospective randomized controlled studies 
comparing outcomes of RIC to myeloablating conditioning. The best insight into differences 
in outcome comes from large registry-based retrospective studies. These studies 
demonstrate that the use of RIC is associated with a reduction in transplant-related 
mortality but an increased risk of disease relapse. (Horwitz, 2011). 
Based on recent relevant data regarding RIC for transplantation (Laport et al., 2008; 
McClune et al., 2010), patient age and disease status generally dictate the type of 
conditioning to be utilized. For example, those relatively older patients (i.e. >50 or 60 years) 
with <10% marrow blasts would generally be recommended to receive RIC, whereas 
younger patients with a higher marrow blast burden would generally be recommended to 
receive standard conditioning. Regimens assessing novel approaches to RIC for MDS are 
being evaluated (Pagel et al, 2009).  
At MD Anderson Cancer Center a retrospective analysis of transplantation outcomes was 
performed to determine whether in AML and MDS a reduced-intensity conditioning 
regimen would result in lower relapse rates than a truly nonablative regimen. Patients were 
included in this study if they had either AML or high-risk MDS and had undergone an 
alloSCT from an HLA-compatible donor with either a truly nonablative regimen of 
fludarabine, cytarabine (araC), and idarubicin (FAI) or with a RIC regimen with fludarabine 
in combination with melphalan 140 or 180 mg/m2 (FM140 or FM180). FAI was intended to 
be the treatment of choice for older patients (> 55 years) with early disease, having sibling 
donors and who were in remission, and with a high risk of relapse. The 2 doses of 
melphalan were investigated in an attempt to minimize toxicities observed with FM180. The 
lower age limit for participation in the FM studies was 55 years, but younger patients with 
organ dysfunction that made them ineligible for high-dose treatment protocols were also 
eligible. Both related and unrelated donors were allowed. Patients with more advanced 
disease were preferably treated with FM in order to provide higher dose intensity in the 
preparative regimen. The 3-year cumulative incidence of non–relapse-related mortality was 
significantly higher after conditioning with FM than with FAI. Conversely, the 3-year 
cumulative incidence of relapse-related mortality was higher after FAI than after FM. The 
analysis suggests that disease recurrence is more frequent in patients receiving the truly 
nonablative regimen as compared with those receiving the reduced-intensity regimen of 
fludarabine and melphalan. for AML and MDS both cytoreduction of the preparative 
regimen as well as GVM contribute to disease control after allografting with reduced-
intensity or nonablative conditioning regimens. The relative importance of these 
mechanisms, however, may differ with regimens other than those tested here. Truly 
nonablative regimens may be effective in minimal disease states or for diseases highly 
sensitive to GVM effects and may provide a platform for innovative cell therapy approaches 
that may obviate the need for direct cytoreduction of the malignancy (de Lima et al., 2004; 
Virchis et al., 2004). 
There are studies intented to compare outcomes with different conditioning approaches. 
The relative efficacy of 3731 SMC transplant were compared with 1448 RIC/NMA 
procedures performed at 217 centers between 1997 and 2004 on AML/MDS patients. NMA 
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conditioning resulted in inferior disease-free survival (DFS) and OS, but there was no 
difference in DFS and OS between RIC and SMC regimens. Late TRM negates early 
decreases in toxicity with RIC and NMA regimens. These data suggest that higher regimen 
intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles 
for both regimen intensity and graft vs leukemia in these diseases (Luger et al., 2011). 
The addition of alemtuzumab to a RIC regimen dramatically reduces the incidence of acute 
and chronic GVHD in patients with AML and MDS undergoing allogeneic transplantation, 
while TRM, relapse risk, OS and DFS are not affected (van Besien et al., 2009). In another 
study using alemtuzumab-based RIC alloSCT the 3-year non-relapse mortality (NRM) was 
31%, DFS was 41% and overall survival (OS) was 46%. Comorbidity scoring and 
performance status have been suggested as strategies to guide dose adjustment and to 
identify fit 65- to 70-year-old patients who can tolerate myeloablative conditioning while 
those with comorbidities receive less intense regimens. HCT-CI was found to be an 
independent variable affecting 3-year NRM, DFS and OS, indicating that the HCT-CI 
provides an important means of stratifying patients with a high risk of inferior transplant 
outcomes (Lim et al., 2010a; Artz et al., 2006). 
9.10.4 AlloSCT for the elderly 
The median age of diagnosis for patients with MDS is 76 years of age with 86% of patients 
older than 60 years. The NCCN Practice Guidelines, as well as recent expert reviews, 
recommend alloSCT for patients with high-risk MDS without making any age restrictions 
(Greenberg, 2010). However, registry analysis show that few patients older than 65 years are 
actually undergoing this procedure. 
There are no randomized controlled clinical trials evaluating the role of alloSCT for the 
treatment of elderly (> 60 years old) patients with intermediate- to high-risk MDS. The 
highest level of evidence is prospective cohort studies.  
Two studies address the question of age and outcomes after transplantation. 
Lim et al. recently published the results of their retrospective survey. Transplant outcomes 
of 1333 patients with MDS older than 50 years were reported to the European Group for 
Bone Marrow Transplant. The median age was 56 (range, 50 to 74) with 34% of patients 
being older than 60 years, 52% having advanced disease at the time of transplant and 62% 
receiving a RIC regimen. Overall survival for the whole group was 31% at 4 years, with 63% 
of patients dying of nonrelapse causes. The nonrelapse mortality rate was 36% at 4 years 
with no significant difference demonstrated in patients older or younger than 60 years. 
Patients receiving a myeloablative conditioning regimen had a higher risk of transplant-
related mortality than those receiving an RIC regimen (44% v 32%). Relapse rates were 
higher in patients receiving RIC regimens than those receiving myeloablative conditioning 
(41% v 33%). In their multivariate analysis, age was not a significant factor for clinical 
outcomes of relapse or survival. Significant factors associated with nonrelapse mortality 
included type of conditioning, advanced disease at transplantation, and donor type. The 4-
year overall survival estimate was not significantly different between those < 60 years old 
and those > 60 years old. However, relapse rate was increased in the > 60-year-old cohort 
(32% vs 41%). Finally, relapse rate and survival were significantly affected by poor-risk 
cytogenetics (Lim, et al., 2010b). 
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McClune et al. included 535 MDS patients and 545 AML patients in first complete remission  
registered with the Center for International Blood and Marrow Transplant Research from 
1995 to 2005. All transplants were (RIC or nonmyeloablative (NMA) conditioning, in 
contrast to the prior study. Thirty-four percent of MDS patients and 36% of AML patients 
were > 60 years old. In both the MDS and AML cohorts, age did not significantly affect 
nonrelapse mortality, disease-free survival, or overall survival. Long-term disease control 
was seen in about one-third of MDS patients independent of age, supporting the curative 
potential of SCT for patients with MDS over the age of 60 (McClune et al., 2010). 
Castagna et al. carried out a retrospective study of 63 patients >60 years with hematological 
malignancies and treated with RIC and alloSCT. Only the occurrence of aGVHD affected the 
TRM and OS. Acute GVHD is the main cause of TRM and more efforts should be made to 
reduce its incidence without sacrificing graft vs tumor effect (Castagna et al., 2010).  
Umbilical cord blood (UCB) is feasible as an alternative donor source for RIC alloSCT 
among older patients with MDS who do not have suitable HLA-matched sibling donors 
(MSD). Majhail et al. compared outcomes of allo-SCT, using MSD or UCB among older 
patients (age over 55 years) with AML or MDS. All patients received a RIC regimen 
consisting of cyclophosphamid, fludarabine and 200 cGy TBI. Median age at alloSCT was 63 
years for MSD and 61 years for UCB recipients. On multivariate analysis, donor source 
(MSD vs UCB) did not impact risks of OS, leukemia-free survival and relapse or treatment-
related mortality (Majhail et al., 2011). 
By means of the WPSS the impact of regular transfusion requirement (defined as requiring 
at least one transfusion every 8 weeks in a 4-month period) can be implicated into the risk 
stratification and those low-risk patients can be identified who can benefit of allo-SCT. 
Regular transfusion requirement is given the same regression weight as progressing to a 
higher cytogenetic risk group (Malcovati et al., 2007).  
Based on the available evidence, transplantation for MDS in patients aged 60 or older is the 
only available curative therapy, but its benefit in terms of OS has not been demonstrated in 
randomized controlled trials. Careful patient selection may improve the results (Giralt et al., 
2011; Ria et al,. 2009; Alatrash et al., 2011). 
9.10.5 The issue of the stem cell source and donor selection 
The patients with MDS who received peripheral blood stem cells (PBSC) had a faster 
engraftment and a lower relapse rate, resulting in improved DFS rates, than patients who 
received bone marrow stem cells (Guardiola et al., 2002). There is a shifting tendency 
towards to use PBSC rather than bone marrow stem cells. 
Umbilical cord blood has increased access to hematopoietic cell transplantation (HCT) for 
patients without HLA-matched sibling donors (MSD).  
A study was carried out through the Eurocord and European Group for Blood and 
Marrow Transplantation (EBMT) registries by Robin et al., aiming to evaluate the 
outcomes and risk factors in adult patients who underwent single or double unrelated 
cord blood transplantation (UCBT) for myelodysplastic syndrome (MDS) or secondary 
acute myeloblastic leukemia (sAML). A total of 180 adults with MDS (n=39) or sAML 
(n=69) were analyzed. Median age was 43 (18-72) years. In all, 77 patients (71%) received a 
single UCBT. Myeloablative conditioning regimen (MAC) was given to 57 (53%) patients. 
A 2-year non-relapse mortality (NRM) was significantly higher after MAC (62 vs 34). A 2-
year DFS and overall survival (OS) were 30 and 34%, respectively. In multivariate 
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analysis, patients with high-risk disease (blasts >5% and International Prognostic scoring 
system (IPSS) intermediate-2 or high in MDS) had significant poorer DFS. In spite of high 
NRM, these data indicate that UCBT is an acceptable alternative option to treat adults 
with high-risk MDS or sAML, without a suitable human leukocyte antigen (HLA)-
matched donor (Robin et al., 2011). 
The rate of related versus unrelated donor is also changing. The percentage of older patients 
who are receiving unrelated donor transplants is increasing (Karanes et al., 2008). 
A study compared allogeneic sibling-matched SCT data in MDS patients ≤60 years old to 
clinical outcomes of age-matched non-treated comparable stage MDS patients. Markov 
decision-making statistical analysis indicated that higher risk IPSS patients ≤60 years old 
should proceed to such human leucocyte antigen (HLA) identical sibling transplants at 
diagnosis, whereas for those lower risk MDS patients, delaying transplantation for several 
years and prior to disease progression would be beneficial (Cutler et al., 2004).  
According to newer studies minor HLA disparity in unrelated compared to related donors 
could have a significant impact on transplant outcomes. To assess whether use of unrelated 
donors (URD) engenders more potent graft versus leukaemia effect in RIC alloSCT 
compared to matched related donors (MRD), a retrospective study has been performed 
Dana-Farber Cancer Institute on patients with different haematological malignancies 
including 66 MDS patients (Ho et al., 2010). Patients received uniformly fludarabine and 
intravenous busulfan conditioning, and GVHD prophylaxis with tacrolimus/mini-
methroxate (mini-MTX) or tacrolimus/sirolimus ± mini-MTX. URD was associated with a 
lower risk of relapse (52% versus 65%). 
9.10.6 Reducing relapse rate 
The most important factors for TRM are age, co-morbidities, donor selection and intensity of 
the conditioning regimen. A careful donor selection and an appropriate choice of 
conditioning regimen will significantly reduce TRM. 
On the other hand preferring RIC as preparative regimen, the incidence of relapse will be 
higher. So effords are made to reduce relapse rate. Either improving of the pretransplant 
remission status or by using post-transplant strategies, such as maintenance or consolidation 
therapies can play a role in reducing the risk of relapse (Kröger, 2008). 
In addition to age, the cytogenetic risk score remained an independent prognostic factor for 
relapse. Lenalidomide has shown activity in terms of resolution of chromosomal 
abnormalities, especially in isolated 5q- but also in complex abnormalities involving 5q-. 
There are also some observations that MDS patients with poor cytogenetic abnormalities 
such as monosomy 7 may benefit from hypomethylating agents (Raj et al., 2007). 
Besides improving pretransplant status of patients with MDS by inducing clinical and 
cytogenetic remission, further approaches to reduce the risk of relapse after alloSCT involve 
post-transplant modifications. 
Donor lymphocyte infusion (DLI) can induce durable remission in relapsing patients with 
hematological malignancies after alloSCT. However, the experience of DLI in patients with 
MDS is limited. and the role of it is unclear. In Fred Hutchinson Cancer Research Center, 
Washington 16 patients treated with DLI for relapsed MDS after HCT between 1993 and 
2004. CR with resolution of cytopenias and prior disease markers occurred in 3 of 14 
patients who could be evaluated. Two patients survived without MDS for 68 and 65 months 
after DLI, respectively, but died with pneumonia. Grades II-IV acute GVHD and chronic 
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GVHD occurred after DLI in 6 (43%) and 5 (36%) patients, respectively. All three responders 
developed grades III-IV acute GVHD and extensive chronic GVHD after DLI. This result 
refers that DLI can result in CR in some patients with relapsed MDS after transplant, but 
long-term survival is infrequent (Campregher et al., 2007). Azacitidine combined with DLI 
for relapsed patients may also result remission (Czibere et al., 2010). 
Maintenance therapy with azacitidine is another option. Low dose azacitidine (at 32 mg/m2) 
given for 5 days is safe and can be administered after allogeneic transplant for at least 4 
cycles to heavily pretreated AML/MDS patients. The trial also suggested that this treatment 
may prolong event-free and overall survival, and that more cycles may be associated with 
greater benefit (de Lima et al., 2010). 
9.10.7 Treatment of relapse 
Standard induction chemotherapy may be used for re-induction. The tolerability and 
potential of low dose azacitidine for treatment of relapsed MDS is supported by a Phase I 
trial (de Lima et al., 2010). 
Immunotherapeutic strategies for example peptide vaccination targeting leukemia-
associated antigens, such as the Wilm’s Tumor protein (WT1) (Keilholz et al., 2009) and 
whole cell leukemia vaccination with CD80 and IL-2 genetically modified leukemic blasts 
are currently the subjects of Phase I clinical trial (Ingram et al., 2009). 
9.10.8 The effect of iron oveload on the post-tranplantation survival 
Pre-transplantation transfusion history and serum ferritin have significant prognostic value 
in patients with myelodysplastic syndrome undergoing myeloablative allogeneic stem cell 
transplantation, inducing a significant increase of non-relapse mortality. An elevated serum 
ferritin (1000 g/L) has been associated with reduced OS and increased risk of infection 
following HSCT. Given that ferritin is an acute phase reactant, the elevated ferritin serum 
level alone does not considered to be a satisfactory marker of iron overload. Other 
biomarkers of body iron load should be taken into account to estimate the effect of iron 
overload on the post-transplantation survival (Pullarkat, 2010). These results indicate that 
transfusion history should be considered in transplantation decision-making in patients 
with myelodysplastic syndrome. Outcome was significantly worse in subjects receiving 
more than 20 red cell units. 
Elevated pre-transplantation liver iron content estimated by magnetic resonance imaging 
(MRI) is significantly associated with inferior post-transplantation survival. There is a strong 
correlation between pre-transplantation serum ferritin level and liver iron content which 
was mostly dependent on prior transfusion history (Armand).  
9.11 New agents 
The past several years have brought exciting new treatments strategies for MDS. However, 
despite the huge progress, no curative therapy does exist exclusive of alloSCT nowadays. 
Furthermore, cure is not necessarily essential in the presence of drug therapy that can 
effectively control disease symptoms and prevent disease-related mortality (Tefferi, 2008; 
Rajkumar, 2008). Since the knowledge of molecular genetics in AML and MDS has 
expanded recently, targeted therapeutics should offer new possibilities for advancement 
(Bryan et al., 2010).  
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The nucleoside analog clofarabine, and the alkylating agent cloretazine are now being 
tested. There are several clinical trials using new agents that act at a number of different 
levels. There are new agents with new therapeutic targets, for example tyrosine kinase 
inhibitors (FLT3 inhibitors), farnesyl-transferase inhibitors (Braun & Fenaux, 2008), which 
are thought to target mutant ras activity, agents with c-jun modificating effect, MAP-kinase 
inhibitors, histone deacetylase inhibitors, which cause epigenetic alterations. 
Using combination of drugs with different and new mechanism of action may also be a 
novel approach. Azacitidine in combination with histone deacetylase inhibitors might offer 
better efficacy by modulating the methylation and acetylation states of silenced genes. 
Silverman, 2009, Leuk res 
Single-agent tipifarnib (a farnesyltransferase inhibitor) in high-risk MDS patients achieves 
responses comparable to those of standard epigenetic therapies, including hypomethylating 
agents, and for this reason, farnesyltransferase inhibitors deserve further in MDS. (Braun & 
Fenaux, 2008; Grant, 2009). 
10. Recommendations for treating lower risk (IPSS low, intermediate-1 or 
WPSS very low, low and Intermediate) MDS patients 
Patients with del(5q) chromosomal abnormalities and symptomatic anaemia should receive 
lenalidomide.  
Other patientswith symptomatic anaemia with EPO level  500 mU/ml, should be treated 
with recombinant human EPO or darbepoetin with or without granulocyte-colony 
stimulatin factor (G-CSF). Non-responders should be considered for treatment with 
azacitidine, decitabine or lenalidomide.  
Those anaemic patients with EPO levels  500 mU/ml should be evaluated to determine 
whether they have a good probability of responding to immunosuppressive therapy. For 
those with low probability treatment with azacitidine, decitabine or lenalidomide should be 
recommended. 
Non-responders and those with severe cytopenias participation in a clinical trial, or allo-SCT 
should be an option. 
11. Recommendations for treating higher risk (IPSS Intermediate-2, high-risk 
or WPSS high, very high) MDS patients 
Treatment recommendations for higher risk patients depend on whether they are candidate 
for intensive therapy. Decision should be made by considering the patient’s age, co-
morbidities, physiosocial status and also the patient’s preference and the availability of a 
suitable donor. 
For eligible patients the first choice regarding the donor source has remained an HLA-
matched sibling though results with HLA-matched unrelated donors have improved to a 
similar level. 
Patients older than 55-60 years, particularly those with less than 10 % marrow myeloblasts, 
would be conditioning with RIC. Patients with high blast count pretransplant debulking 
therapy is generally needed. Younger patients, regardless of marrow blast burden, will 
generally receive high dose conditioning.  
For patients eligible for intensive therapy lacking a suitable donor using an intensive 
induction chemotherapy should be recommended. 
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9.11 New agents 
The past several years have brought exciting new treatments strategies for MDS. However, 
despite the huge progress, no curative therapy does exist exclusive of alloSCT nowadays. 
Furthermore, cure is not necessarily essential in the presence of drug therapy that can 
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Using combination of drugs with different and new mechanism of action may also be a 
novel approach. Azacitidine in combination with histone deacetylase inhibitors might offer 
better efficacy by modulating the methylation and acetylation states of silenced genes. 
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agents, and for this reason, farnesyltransferase inhibitors deserve further in MDS. (Braun & 
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10. Recommendations for treating lower risk (IPSS low, intermediate-1 or 
WPSS very low, low and Intermediate) MDS patients 
Patients with del(5q) chromosomal abnormalities and symptomatic anaemia should receive 
lenalidomide.  
Other patientswith symptomatic anaemia with EPO level  500 mU/ml, should be treated 
with recombinant human EPO or darbepoetin with or without granulocyte-colony 
stimulatin factor (G-CSF). Non-responders should be considered for treatment with 
azacitidine, decitabine or lenalidomide.  
Those anaemic patients with EPO levels  500 mU/ml should be evaluated to determine 
whether they have a good probability of responding to immunosuppressive therapy. For 
those with low probability treatment with azacitidine, decitabine or lenalidomide should be 
recommended. 
Non-responders and those with severe cytopenias participation in a clinical trial, or allo-SCT 
should be an option. 
11. Recommendations for treating higher risk (IPSS Intermediate-2, high-risk 
or WPSS high, very high) MDS patients 
Treatment recommendations for higher risk patients depend on whether they are candidate 
for intensive therapy. Decision should be made by considering the patient’s age, co-
morbidities, physiosocial status and also the patient’s preference and the availability of a 
suitable donor. 
For eligible patients the first choice regarding the donor source has remained an HLA-
matched sibling though results with HLA-matched unrelated donors have improved to a 
similar level. 
Patients older than 55-60 years, particularly those with less than 10 % marrow myeloblasts, 
would be conditioning with RIC. Patients with high blast count pretransplant debulking 
therapy is generally needed. Younger patients, regardless of marrow blast burden, will 
generally receive high dose conditioning.  
For patients eligible for intensive therapy lacking a suitable donor using an intensive 
induction chemotherapy should be recommended. 
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For higher risk patients who are not candidate for intensive therapy the use of azacitidine, 
decitabine or a participation in a clinical trial should be considered. 
Good supportive care should be given to every MDS patients. This may be the only therapy 
for those with adverse clinical features or disease progression despite antitumor therapy. 
12. Conclusion 
Ten years ago, there was little to offer MDS patients other than transfusion support, but 
since then, the approach to treating patients with MDS has undergone a progress. New 
therapeutic options have added to the armamentarium of MDS treatments.  
Historically, treatment goals have varied based on patient risk category, with modification 
of disease reserved for patients in the higher-risk population and response rates being a 
primary endpoint. In the light of recent data the treatment paradigm should be reevaluated 
to focus on prolonging time to leukemic transformation and extending survival while 
improving quality of life. Lenalidomide can modify disease activity, the methyltransferase 
inhibitors have the ability to prolong survival. These are shifting the focus away from 
response rates alone. Azacitidine has demonstrated a sustained impact on overall survival. 
In addition, data suggest that treatment with these therapeutics in patients with lower-risk 
disease may further extend survival by altering the biology of MDS. The new treatment 
paradigm should aim for prolonging leukemic-free transformation and extending survival 
while optimizing quality of life and maintaining hematologic and cytogenetic response. 
The results of stem cell transplantation for MDS continue to improve together with the 
outlook of patients afflicted with myelodysplasia. 
The incidence of MDS is increasing parallely with the increase of the average age of the 
population. That gives a particular importance to the development of MDS therapy has 
taken place in the last decade. In the close future some more possible progress are expected. 
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1. Introduction 
1.1 Definition and clinical characteristics 
Mantle Cell Lymphoma (MCL) is a relatively rare type of mature B-cell lymphoma that 
comprises 5% of Non-Hodgkin’s Lymphomas(NHL)1-3. MCL was added to the Revised 
European–American Lymphoma classification in 1994. Having both indolent and incurable 
features associated with aggressive clinical course, MCL is most frequently seen in 6th 
decade of life, with male dominance 3 to 4:12. Malignant origin of MCL cells appear to 
derive from an antigen-naive pregerminal center cell4, 5. 
 
1. B-cell neoplasms 
1. Precursor B-cell 
2. Mature B-cell 
Chronic lymphocytic leukemia/small lymphocytic lymphoma 
Lymphoplasmacytic lymphoma 
Splenic marginal zone lymphoma 
Extranodal marginal zone B-cell lymphoma of MALT 
Nodal marginal zone B-cell lymphoma 
Follicular lymphoma 
Mantle cell lymphoma
Diffuse large B-cell lymphoma 
Mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
Primary effusion lymphoma 
Burkitt's lymphoma/leukemia 
3. B-cell proliferations of uncertain malignant potential 
2. T-Cell and NK-Cell neoplasms 
Table 1. World Health Organization Classification of Lymphomas1. 
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At the time of diagnosis, patients tend to have more extranodal disease and low serum 
albumin6. Although MCL has differential diagnosis with Chronic Lymphocytic Leukemia 
(CLL) and low-grade NHL, mimicking malignancies with indolent behavior, it follows an 
aggressive course with 10% to 15% long-term survivors7 despite administration of standard 
chemotherapy courses commonly used in NHLs8, corresponding to a median survival of 3 
to 5 years.  
2. Diagnosis 
Diagnosis of MCL can be made by lymph node or bone marrow biopsy, or analysis of 
malignant cells obtained from peripheral blood, if the disease is in the leukemic phase9, 10. 
Differential diagnosis with CLL is important since both MCL and CLL cell have co-
expression of CD5 and CD19/2011. Malignant cells are negative for CD10, CD23 and BCL6. 
Although absence of CD23 antigen expression on malignant cell population strongly favor a 
diagnosis of MCL12, 13, presence of cyclinD1 expression by immunohistochemical staining14 
or determination of t(11;14) translocation by molecular analysis15-18 is required to confirm 
the diagnosis19. Cyclin D1 is overexpressed in MCL as a result of the landmark 
t(11;14)(q13;q32) translocation20. Cyclin D1 complex with cyclin dependent kinases 4 and 6 
(Cdk4 and Cdk6) and cyclin E-Cdk2, leading to phosphorylation of retinoblastoma protein 
(Rb), irreversibly inducing progression of the cell from G1 to S phase, which is not the only 
biologic dysregulation on the way to malignant transformation21-24. 
 
Disease CD5 CD10 CD23 CD43 Cyclin D1 Ig class 
FL - + +/- - - IgM, IgG 
MCL + - - + + IgM/IgD 
CLL/SLL + - + + - IgM/IgD 
LPL - - - +/- - IgM (c) 
MALT - - - +/- - IgM (c, s) 
SMZL - - - - - IgM/IgD 
HCL - - - - -/+ IgG 
FL, follicular lymphoma; MCL, mantle cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small 
lymphocytic lymphoma; LPL, Lymphoplasmacytic lymphoma; MALT, marginal zone lymphoma of 
MALT type; SMZL, splenic marginal zone lymphoma; HCL, hairy cell leukemia; Ig class, most 
commonly expressed heavy chain classes; c, cytoplasmic Ig; s, surface Ig. 
Table 2. Differential Diagnosis of “Small” B-Cell Lymphomas25. 
3. Prognostic parameters 
Prognosis can be estimated by using MIPI (mantle cell lymphoma international prognostic 
index, Figure 1)26 which seems to be more efficient than international prognostic index 
(IPI)27 or follicular lymphoma international prognostic index (FLIPI)28, 29, which includes 
leukemic phase10, 30, 31, besides other clinical parameters used in the IPI.  
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Table 3. Simplified MIPI26. 
For each prognostic factor, 0 to 3 points were given to each patient and points were 
summed up to a maximum of 11. Patients with 0 to 3 points in summary were classified as 
low risk, patients with 4 to 5 points as intermediate risk, and patients with 6 to 11 points 
as high risk. 
 
 
Fig. 1. Overall survival according to the mantle cell lymphoma international prognostic 
index (MIPI). 
Although Ki-67 has previously been shown to predict prognosis (Figure 2)32-34, analysis of 
Ki-67 did not substantially change the regression coefficient of the MIPI score and served as 
an important biologic marker with strong additional prognostic relevance26.  
Recently, proliferation gene expression signature has been reported to be the best molecular 
predictor of survival in patients with MCL21, leading to a prognostic model defined as an 
optimized survival predictor composed of five genes: RAN, MYC, TNFRSF10B, POLE2, and 
SLC29A235. Furthermore, this model was validated for application in formalin-fixed 
paraffin-embedded tissue samples and appeared superior to the immunohistochemical 
marker Ki-6735.  
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Fig. 2. Overall survival of patients with MCL according to Ki-67 proliferation index33. 
4. Role of chemotherapy 
When it comes to assessment of long term overall survival, MCL has the worst prognosis 
among all lymphoma types36, a watch-and-wait strategy should be avoided. Retrospective 
analyses of administration of standard chemotherapy have not shown any improvement in 
overall survival in patients with MCL6, 37. Most regiments induce around 80% response rates 
with complete remissions up to 30% of cases6, 8. While more aggressive regimens were 
used38, reliable cure rates with conventional treatment has not been reported until now36.  
Compared to historical controls, median survival with conventional chemotherapy CVP and 
CHOP have not been improved37. In a randomized trial, these two regimens were associated 
with similar response rates (84% and 89%) and median overall survivals (32 and 37 
months)39. Only one third of patients with untreated40 or relapsed41 MCL will respond to 
rituximab as single agent.  Rituximab may also be used for purging tumor cells either with 
standard chemotherapy42 or prior to high dose therapy regimens with stem cell support43. 
But in a randomized trial, addition of rituximab to CHOP regimen failed to improve overall 
survival (Figure 3)44. Maintenance interferon-alfa therapy following induction regimen has 
not been proven to improve survival either45, 46. 
Fludarabine can also be used in patients with lymphoma with or without rituximab 
combination47. Fludarabine alone in previously treated MCL can induce temporary 
responses in a third of patients lasting between 4 to 8 months48. In newly diagnosed 
patients, fludarabine appears to be more active, inducing responses in 60% , half of  which is 
complete response49. Combining fludarabine with idarubicin or cyclophosphamide may 
improve induction of complete responses50, 51. Fludarabine and cyclophosphamide 
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combination(FC)  can induce a higher response rate of 63% in patients recurrent MCL51. 
Previously untreated patients have response rate up to 100% with a complete response rate 
of 70% and 28 months of progression free survival51.  
 
 
Fig. 3. Progression-free survival after cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) and rituximab and CHOP (R-CHOP)44. 
In a randomized study testing addition of rituximab to fludarabine, cyclophosphamide and 
mitoxantrone (FCM), patients in the rituximab arm were found to have significant 
improvement in disease free and overall survival52-54. Fludarabine combined with 
cyclophosphamide and rituximab is a highly effective regimen in patients relapsing from 
previously received CHOP regimen55.  Addition of rituximab to the chemotherapy regimens 
does not appear to increase toxicity56. 
Although tolerating patients treated with the hyper-CVAD regimen had excellent response 
and survival rates of greater than 90% at 3 years and 4.6 years of time to treatment failure 
(TTF at 8yr , 16% if age>65, 46% if age<65) following 10 year observation period7, 38, 57, 58, 
patients treated with conventional therapies have also reported to have similar 3 year 
survival rates59, 60. The hyper-CVAD regimen without stem cell transplantation was not 
associated with a plateau in the survival curves (Figure 4)57.  In this study, beta-2-
microglobulin levels and IPI/MIPI scores were found to predict survival57. Hyper-CVAD 
regimen data may suggest high efficacy of the high-dose Ara-C (HIDAC) regimen, which 
needs to be tested in further clinical trials. 
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Fig. 4. Overall survival and time to failure in 97 patients treated with R hyper-CVAD 
alternating with R M/A57. 
Due to advanced age at the time of presentation of MCL, there is a concern about intensive 
therapy regimens being associated with higher toxicity rates requiring patient selection and 
patients tolerating intensive therapies are being selected for high-dose therapies with stem 
cell support. 
5. New agents 
Recently, bortezomib61-63, lenalidomide64-66, bendamustine67-69, pixantrone70, azaepothilone 
ixabepilone71 and mTOR inhibitor temsirolimus72-74 has been shown to demonstrate activity 
alone and in combination with rituximab and mitoxantrone, and may induce complete 
responses in relapsed or refractory MCL61, 64, 69, 75, 76. Along with rituximab, these biotherapy 
agents can be used frontline or may also be introduced into post transplant maintenance to 
prevent or treat relapses61, 68, 77-81. There may be an advantage of combining rituximab with 
bendamustine compared to combining with the conventional CHOP regimen in terms of 
disease free survival82. Recently, it was reported that frontline use of cladribine and 
rituximab can induce an overall response rate of 87%, with 61% of patients achieving 
complete remission, suggesting use of this combination for the initial treatment of MCL83. 
Radioimmunotherapy with 90Y-labeled anti-CD20 monoclonal antibody (ibritumomab 
tiuxetan) or 131I-rituximab is now being tested in phase I-II trials, including stem cell 
transplant setting84-87.  
6. High dose chemotherapy with autologous stem cell support (ASCT) 
Since conventional and dose intense chemotherapy regimens have failed to induce cure or a 
plateau phase in time to treatment failure curves, high dose therapy with autologous stem 
cell support have been studied in the relapse setting88 as well as consolidating complete 
responses following frontline chemotherapy regimens88-94.  
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In a randomized trial testing ASCT versus IFN-alfa consolidation following response to 
CHOP or CHOP like regimens with or without rituximab, consolidation with BEAM/ASCT 
improved progression free survival (PFS) but has not been shown to improve overall 
survival (OS)(Figure 5)93. When patients responding to R-CHOP regimen received HIDAC 
therapy followed with autologous tranplantation with the BEAM regimen, also a plateau 
was not observed in time to treatment failure (TTF) and OS curves94. 
 
 
Fig. 5. Progression-free survival after high-dose radiochemotherapy followed by ASCT and 
IFN-alfa maintenance in MCL93. 
Autologous transplantation with conventional conditioning regimens without in vivo 
purging induced a median survival of 47 months88. Analysis of this patient group did not 
reveal a plateau in the survival curve88.  
Addition of rituximab to ASCT regimen leads to better event free survival (EFS) curves in 
patients with first remission, not affecting progression in patients with relapsed/refractory 
disease91. 
The R-HDS regimen consisting of high-dose sequential chemotherapy (including 
intravenous administration of high-dose cyclophosphamide, high-dose cytarabine, high-
dose melphalan, and high-dose mitoxantrone plus melphalan) and in vivo purging with 
rituximab resulted in OS and EFS rates at 54 months were 89% and 79%, respectively96. 
These results compare favorably with the 42% OS rate and the 18% EFS rate observed in 35 
age-matched historic controls treated with standard-dose chemotherapy at the participating 
centers (Figure 6)96. 
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Fig. 6. Overall survival for mantle cell lymphoma patients after autologous transplantation 
without in vivo purging88. 
 
 
Fig. 7. EFS following ASCT after myeloablative therapy with (broken line) or without 
peritransplant rituximab (solid line)95. 
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Fig. 8. PFS for patients receiving ASCT for relapsed/refractory disease91.  
 
 
Fig. 9. Overall survival and event-free survival of patients treated with R-HDS versus 
conventional chemotherapy96. 
Heavily treated patients with multiple recurrences may undergo an effective salvage with 
high-dose radioimmunotherapy (RIT) coupled with autologous stem cell support97. 
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Fig. 10. OS and PFS obtained in patients with relapsed MCL treated with 131I-tositumomab, 
etoposide, cyclophosphamide, and ASCT97. 
7. Allogeneic transplantation for achieving cure 
Myeloablative or non-myeloablative allo-HSCT is generally performed in patients with 
lymphoma relapsing following auto-HSCT, since patients need tumor-free grafts that can 
induce a graft-versus-lymphoma (GVL) effect. 
Physicians should consider the need for an allogeneic transplant when there is a need for a 
GVL effect (high risk of relapse) which can be predicted by the presence of; 
 A high MIPI score 
 Aggressive clinical behavior characterized by not achieving a satisfactory response to 
chemotherapy regimens 
 remaining PET positive following ASCT98 
 Multiple relapses 
and; 
 If the patient is young (<55 years) or, 
 Autologous stem cells cannot be mobilized 
in patients considered to be eligible following pretransplant screening tests.  
Evidence for presence of graft versus lymphoma (GVL) effect has been reported in patients 
with MCL who underwent allo-HSCT99. CVL effect may be observed as conversion to pcr 
negativity for t(11;14) or achieving CR in the presence of GVHD99, or observing lower 
relapse rates in allo-HSCT recipients compared to patients undergoing autologous 
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transplantation100-102. A healthy comparison of autologous and allogeneic transplants cannot 
be made at present, due to lack of randomized trials and the different prognostic groups 
undergoing  each transplant type. By using myeloablative regimens for relapsed patients, 
allogeneic transplants can induce three year event free survivals (EFS)around 50%99, 101-104. 
However, if performed in first CR or PR, EFS induced by allo transplants at three years can 











Fig. 11. Event-free survival according to type of BMT103. 
8. Reduced intensity allogeneic stem cell transplantation 
In the allogeneic transplant setting, benefit of cure over transplant related mortality can be 
positively affected by using reduced intensity (RIC) or non-myeloablative (NMA) 
conditioning regimens105-116. Using donor lymphocyte infusions for GVL effect in patients 
undergoing allogeneic transplantation with RIC or NMA regimens, low transplant 
mortality rates (<10%) and higher OS (73 to 85%)  and EFS rates (73 to 82%) can be 
achieved105, 117, 118. 
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Fig. 12. Kaplan-Meier overall survival (OS) and current progression-free survival (CPFS) 




Fig. 13. Favorable overall survival following reduced intensity allogeneneic  transplants by 
disease group117. 
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9. Decision making for transplant options 
While standard chemotherapy regimens do not offer long term progression free survival, 
intensive therapy followed by ASCT should be considered for each newly diagnosed 
patient92, especially if the MIPI score is translating into poor prognosis. 
Multiply relapsed patients will not do well after autologous transplants91, 103. Best time to 
perform an autologous transplant is following CR91, 92, 119, 120 obtained after high-dose 
therapy with hyperCVAD or HDS regimen, coupled with rituximab91, including in vivo 
purging prior to stem cell collection81, 92, 96. With this approach, patients eligible for these 
sequential intensive regimens may enjoy long term disease free survival, although cure 
cannot be achieved121. 
 
 
Fig. 14. Event-free survival according to remission status at BMT103. 
Newly diagnosed and relatively younger patients less than 60 years of age who are not 
eligible for ASCT or relapsing after ASCT, or patients with recurrence following 
chemotherapy, can still be cured by allogeneic SCT following an effective salvage regimen 
inducing CR or near CR121. 
As the outcome of transplantation is most promising in the newly diagnosed patients 
without chemorefractory disease, graft contamination and the lack of a survival plateau 
following autologous transplantation, allogeneic transplantation deserve investigation as 
the upfront therapy in the management of patients with MCL92. 
Patients over age 65, and individuals who are not eligible for ASCT with poor prognostic 
MIPI scores remain as a major challenge for the hematologist. In this group of patients, 
promising new drugs such as bendamustine, cladribine and bortezomib in combination 
with synergizing agents such as rituximab, may be offered to patients in the context of 
clinical trials. One should remember that ASCT with intermediate dose melphalan at doses 
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between 100 to 140 mg/m2 can still be utilized in patients over age 65, as well as non-
myeloablative allogeneic stem cell transplants, immediately after achieving a clinical 
complete response in experienced transplant centers. These approaches have to be tested in 
clinical trials in the near future. 
10. Rational approaches in managing patients with MCL 
Due to heterogeneity of disease, paucity of randomized trials, availability of a wide range of 
chemotherapy regimens including new agents, and altering prognostic factors among 
patients, an individualized treatment approach should be adapted for each patient 
diagnosed with MCL. As in therapy of patients with myeloma, long term survival may be 
achieved following sequential and risk-adapted use of available therapies such as intensive 
or nucleoside analogue based chemotherapy, followed by autologous and/or reduced 
intensity allogeneic transplantation, including radioimmunotherapy. 
Rational strategy at present can be outlined as; 
1. After assessing the MIPI score, low risk patients can be followed without 
transplantation strategy, because of late age of onset, which is over 60 in most patients. 
This group of patients will do well with standard chemotherapy regimens utilized in 
NHLs, such as R-CHOP or new generation combination regimens including a purine 
analogue and rituximab, such as R-FCM or FCR. 
2. Due to its poor prognosis and failure to achieve improved survival curves with 
conventional chemotherapy regimens, consideration should be given to upfront 
autologous transplantation in patients with high MIPI scores. To induce remission FCR, 
R-hyperCVAD and R-CHOP-14 regimens seem to be effective approaches. Inducing high 
quality complete responses -molecular remission for t(11;14) translocation-  prior to 
autologous transplantation may further improve disease free and overall survival curves. 
Success of this strategy has been shown in comparison to historical controls, and also has 
to be proven in randomized clinical trials. 
3. Young patients with intermediate MIPI scores may choose to continue with the same 
approach with the ones with high scores as described above. Elderly patients may 
receive R-CHOP, R-FCM or FCR as the initial therapy.   
4. Patients having recurrence following conventional chemotherapy or an autologous 
transplant and who are determined to be fit for an allogeneic transplant following a 
careful evaluation and screening tests should be given a chance to have this treatment 
option to achieve cure. 
5. Regardless of the MIPI score, patients who are not eligible for high dose therapy and 
autologous stem cell support and relapsing after conventional chemotherapy regimens 
and not a candidate for an allogeneic transplant may be treated with bendamustine and 
cladribine containing regimens in the context of clinical trials. 
Transplant strategy can be summarized as; 
Patients with predicted poor survival by MIPI score should undergo intensive induction 
regimens if eligible, to achieve CR, followed by ASCT preferably in first remission. If cure is 
targeted, especially in young patients, allogeneic SCT may be performed following an 
excellent cytoreduction with ASCT or intensive chemotherapy regimen including high dose 
Ara-C and rituximab, such as R-HDS or hyper-CVAD regimens. 
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11. Emerging new drugs to improve results in the near future 
New agents which may have potential to improve outcome of relapsed or refractory 
patients with MCL include chemicals targeting cyclin D1 and the cell cycle regulatory 
proteins (cdk), inhibitors of mammalian target of rapamycin, the proteasome, and 
proapoptotic family members122. 
Both histone deacetylase (HDAC) and mTOR inhibitors may downregulate cyclin D1 
reducing cell cycle drive, which is upregulated in patients with MCL. Cyclin D1 is the key 
factor for upregulating cellular proliferation rate22. HDAC inhibitor sueroylanilide 
hydroxamic acid (vorinostat) has ability to reduce intracellular cyclin D1 levels in MCL cells, 
leading to inhibition of progression to S-phase in the cell cycle, and may induce response in 
MCL patients, currently being tested in phase I clinical trials123. Cyclin D1 protein itself can 
be used as a target for sensitized T-cells, generating a potential treatment option by cellular 
therapy124. 
Other than overexpression of cyclin D1, activation of mammalian target of rapamycin 
(mTOR) also plays a major role in growth and proliferation in MCL cells125. Inhibitiors of 
mTOR (rapamycin, temsirolimus, everolimus) may increase apoptosis and decrease 
proliferation rate by causing G1 arrest in the cell cycle126. Single agent temsirolimus has been 
shown to have clinical activity in phase II trials, and a randomized phase III trial127-129. 
Alternative mTOR inhibitor everolimus is currently in phase II trials130, 131. 
Deficiencies  of Noxa and Bim proteins and aberrant expression of Bcl-2 may reduce 
apoptosis and lead to increased resistance to chemotherapeutic agents132. Proteasome 
inhibitors such as bortezomib and flavopiridol may function as accumulating cdk inhibitors 
(p21/p27), causing cell cycle arrest in malignant cells132-134. Accumulation of proapoptotic 
Noxa protein has been consistently shown in MCL cells treated with bortezomib135. 
There is a rationale combining bortezomib with HDAC inhibitor vorinostat.  Vorinostat may 
be able to turn off cyclin D1, whereas bortezomib turns on cdk inhibitors p27 and p21, 
targeting two complementary genetic lesions involved in the cell cycle aberration in MCL 
cells which may lead to induction of apoptosis136. Bortezomib may also be combined with 
cyproheptadine, recently identified inhibitor of cyclin D1, synergistic in inducing apoptosis 
in vitro137. 
Development of new drugs for MCL will further improve the recent achievements in the 
management options published in the last decade, in a disease currently not curable by 
medical therapy except allogeneic transplantation. 
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(mTOR) also plays a major role in growth and proliferation in MCL cells125. Inhibitiors of 
mTOR (rapamycin, temsirolimus, everolimus) may increase apoptosis and decrease 
proliferation rate by causing G1 arrest in the cell cycle126. Single agent temsirolimus has been 
shown to have clinical activity in phase II trials, and a randomized phase III trial127-129. 
Alternative mTOR inhibitor everolimus is currently in phase II trials130, 131. 
Deficiencies  of Noxa and Bim proteins and aberrant expression of Bcl-2 may reduce 
apoptosis and lead to increased resistance to chemotherapeutic agents132. Proteasome 
inhibitors such as bortezomib and flavopiridol may function as accumulating cdk inhibitors 
(p21/p27), causing cell cycle arrest in malignant cells132-134. Accumulation of proapoptotic 
Noxa protein has been consistently shown in MCL cells treated with bortezomib135. 
There is a rationale combining bortezomib with HDAC inhibitor vorinostat.  Vorinostat may 
be able to turn off cyclin D1, whereas bortezomib turns on cdk inhibitors p27 and p21, 
targeting two complementary genetic lesions involved in the cell cycle aberration in MCL 
cells which may lead to induction of apoptosis136. Bortezomib may also be combined with 
cyproheptadine, recently identified inhibitor of cyclin D1, synergistic in inducing apoptosis 
in vitro137. 
Development of new drugs for MCL will further improve the recent achievements in the 
management options published in the last decade, in a disease currently not curable by 
medical therapy except allogeneic transplantation. 
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1. Introduction 
"Lupus", from the Latin in the 19th century, had appeared in the West before and after the 
medical literature. In 1828, the French dermatologist Bette (Biett) firstly reported such a 
patient: facial skin has erythema the same as the the wolf bites. To the mid-19th century, 
there was a doctor named Carson Musharraf formally using the "lupus" (lupus 
erythematosus, LE) as the medical terminology, which only refered to skin lesions of discoid 
lupus erythematosus then. With the development of medical science and clinical practice, 
more and more doctors found that lupus is not only skin damage, but also associated with 
kidney, brain, heart, lungs, nerves, muscles and joints, blood and other systemic diseases. To 
the 1890s, American doctor Osler (Osler) proposed the disease as "systemic lupus 
erythematosus" (systemic lupus erythematosus, SLE) [1].  Systemic lupus erythematosus 
(SLE), a common autoimmune disease without explicit etiology, has a high incidence of 
secondary infection, treatment difficulties and high mortality, arousing the focus of 
domestic and foreign scholars. According to the prevalence rate from 70 to 100/10 million 
people [2], China has reached to 1.12 million patients which is constituted mainly by young 
women. In addition to involving the outer skin, the disease violates various body organs, 
including vital organs such as the nervous system, heart, kidney and so on, the central 
nervous system such as meningitis, encephalitis, acute cerebrovascular disease, spinal cord 
inflammation and subarachnoid hemorrhage, even to death. It is the most common when 
occurring cardiac involvement, such as pericarditis, pericardial effusion heart attack, and 
life-threatening acute cardiac tamponade, which affect the quality of life. Involving the 
kidneys, it may be kidney failure. Respiratory system involvement includes bronchial 
pneumonia, pleurisy, atelectasis and respiratory failure. Secondary infection is a common 
complication of SLE, causing death at worst.  
 SLE is considered a typical multi-organ involvement autoimmune disease, as a result of the 
disorder of immune system[3,4]. Before the 1960s, the 5-year survival rate was below 50%. 
With the progress of the treatment and the development of therapeutic drugs, especially 
corticosteroids and cytotoxic drugs for SLE, the survival rate has improved significantly, has 
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reached 93% to the 1990s, while 10 and 20 year survival rate has reached 92%, 68%, 
respectively[5,6].  
In treatment, we begin with corticosteroid and cytotoxic at large doses the most, in order to 
suppress the disease, in 1-2 weeks, if necessary, plus corticosteroid pulse therapy or 
immunosuppressive therapy. Glucocorticoid inhibits T lymphocytes mainly through the 
production of growth factors and Fc receptor expression [7,8]. However, the dosage of 
corticosteroids varies with the insensitivity of the patients. In addition, due to large amount 
of medication for a long time, it prones to side effects and complications, such as: infection 
(viruses, bacteria, fungi, etc.), induced diabetes, peptic ulcer, perforation or gastrointestinal 
bleeding, fractures and avascular necrosis, mental disorders, Cushing's syndrome, acne, 
hirsutism, etc. More than 60% of patients died of hormonal side effects, which has bad 
impact on life quality [7]. Therefore, it is still a medical problem without effective cure. The 
latest research reports, it is an effective and new treatment for SLE by hematopoietic stem 
cell transplantation [4], the evaluation of long-term efficacy of which remains to be seen.  
Since the pathological immune T, B lymphocytes from the common lymphoid stem / 
progenitor cells, it may be an effective way to cure the disease by the application of certain 
tools (such as chemotherapy or radiotherapy) to destroy pathological immune and re-
establish normal immune system by hematopoietic stem cell transplant[3,7]. In recent years, 
it gradually become a hot topic in international research for autologous peripheral blood 
stem cell transplantation for treatment of SLE and other autoimmune diseases,whose exact 
mechanism is not fully clear, only defined to the level of the original autoimmune cell clones 
completely destroyed, while normal one re-established [7 10]. Autoimmunity and self-
tolerance is a dynamic equilibrium between the process, in which, we use 
immunosuppressive agents to weaken the strength of their immune, while hematopoietic 
stem cell transplantation to support the power of self-tolerance and eventually make the 
body's immune system normal [11]. Theoretically, it is possible to cure SLE and other 
autoimmune disease, and may achieve the purpose of healing.  
2. Materials and methods 
2.1 Clinical data 
A total of 16 patients consistent with the diagnostic criteria for SLE by American College of 
Rheumatology in 1982 were recruited, for whom corticosteroids and immunosuppressive 
therapy ineffective. There are 4 males and 12 females, aging from 11-37 years old, and the 
type of renal pathology, II, III, IV, V were3, 3, 6, 4 cases, respectively. SLEDAI scores are 14-
35 points. 
2.2 Reagents 
CD34 + cell isolation kit, Germany Miltenyi Biotec Company; Lymphocyte separation 
medium, Beijing Ding Guo; Antibody (mouse IgG1-PE, mouse anti-human CD34-PE), 
American Gene Company; 3 - aminopropyl triethoxy silane solution, a company in Kyoto, 
Japan 
2.3 Main instruments 
Immunomagnetic separation system, company Miltenyi Biotec, Germany; Blood cell 
separator,U.S. BAXTER Company; BD's flow cytometry, U.S.; Low-speed desktop 
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centrifuge,Beijing Medical Centrifuge FactoryHettich, Germany's low-temperature high-
speed centrifuge 
2.4 Hematopoietic stem cell mobilization, collection, purification and cryopreservation   
Mobilization plan: cyclophosphamide + granulocyte colony stimulating factor. We use 
cyclophosphamide intravenous 4g/m2, divided into 2 to 3 days, and urine alkalization and 
hydration to protect the heart, liver and kidney. When WBC <1.0 × 109 / L, give 
Recombinant Human Granulocyte Colony-stimulating Factor Injection 5ug/kg, until WBC> 
5.58 × 109 / L and CD34 +> 2% we start collecting with CS3000Plus blood cell separator 
(BAXTER products). After dilution and volume adjustment, plus CD34 monoclonal 
antibody in cells in 19 ~ 25 ℃ for 30 minutes, then wash 2 times by PBS buffer to pre-sort on 
MiniMACS separator, at last cool and liquid nitrogen froze immediately. 
2.5 Pre-treatment    
Cyclophosphamide 50mg/kg daily, intravenous infusion, once every 4 days (-5 to -2 days); 
ATG 2.5mg/kg.d, intravenous infusion, once every 3 days, while urine alkalization and 
hydration to protect the heart, liver and kidney. 
2.6 Hematopoietic stem cell reinfusion    
Transplant day 0, recover the frozen stem cells in 37 ℃ ~ 40 ℃water bath, then rapid 
transfusion through subclavian vein cannulation. 
2.7 Follow-up indicators  
Dynamic monitoring hematopoietic and immune indicators of clinical manifestations of SLE 
patients after transplantation. 
2.8 Statistical analysis    
We use software package SPSS10.0 processing repeated measurements analysis of variance 
of autoantibodies, immune function monitoring indicators in patients with SLE who 
underwent autologous peripheral blood stem cell transplantation. 
3. Results 
3.1 Autologous peripheral blood stem cell mobilization 
The total number of collected CD34 + cells ranged from (2.06-9.9)  108, higher than  
the required 2  106/kg, is the success of hematopoietic stem cell collection for the 16 
patients. 
3.2 Mobilization-related complications 
The total of 16 patients have leukopenia and gastrointestinal adverse reactions, and all 
with varying degrees of fever, but blood cultures were negative. 1 case has severe edema, 
but alleviate after the supplement of albumin and furosemide. 1 case has atopic dermatitis 
(specific reasons unknown), the anti-histamine treatment effective. All the patients were 
in stable condition after mobilization without the original mobilization-related illness or 
death. 
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centrifuge,Beijing Medical Centrifuge FactoryHettich, Germany's low-temperature high-
speed centrifuge 
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Recombinant Human Granulocyte Colony-stimulating Factor Injection 5ug/kg, until WBC> 
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(specific reasons unknown), the anti-histamine treatment effective. All the patients were 
in stable condition after mobilization without the original mobilization-related illness or 
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3.3 Changes in clinical transplantation 
Within 1 month after transplantation, the facial rash, joint pain and other symptoms 
disappeared completely in all patients. 13 patients with proteinuria disappeared completely 
in three months, 3 cases of the four V-type, still urinary protein in a year, but the 24-hour 
urine protein continued to decline. One patient, 1 year after transplantation, had the 
recurrence of oral ulcers, arthralgia, leukopenia and elevated titers of autoantibodies. The 
other patient, 2 and a half years after transplantation, had facial erythema, leukopenia and 
elevated titers of autoantibodies. 
3.4 Hematopoietic reconstitution after transplantation 
The number of peripheral blood leukocytes is > 1.0×109 / L  after 7 to 15 days, platelets is > 
20×109 / L 0 to 21 days. 
3.5 Transplant-related complications 
All patients suffered from uneven serum sickness-like reactions, 1 case severe renal failure 
and heart failure, 3 cases hemorrhagic cystitis, 1 case psychogenic mental disorders, 1 case 
perineal candidiasis, 1 case acute pulmonary edema, 1 case septic shock, but all recovered 
after active treatment. 2 patients had fever after transplantation because of tuberculosis 
infection (see Chapter VII). One case with fever in October after transplantation, had chest 
CT showing: 1, multiple new lung nodules; 2, left lung consolidation; 3, pericardial 
thickening, small left pleural effusion. According to CT, it was much as the invasive nature 
of purulent bacterial or fungal infection, in combination with other manifestations, at last 
diagnosed as fungal infections, alleviated after itraconazole injection . 12 cases of 
cytomegalovirus infection became negative after ganciclovir treatment (see Chapter VI). 3 
cases of herpes zoster, 1 case of generalized herpes zoster, were recovered after treatment by 
ganciclovir. 1 case in the purification of autologous peripheral blood stem cell 
transplantation in August, appeared Evans syndrome (also known as idiopathic 
thrombocytopenic purpura with autoimmune hemolytic anemia). Check ENA polypeptide: 
ANA 70.50u/ml, ds-DNA 18.65u/ml, RNP 49.90u/ml, Sm 15.44u/ml, Coomb’s test showed: 
more than a single specific anti-human globulin (++), specific anti-C3 (+), monospecific anti-
IgG (+). Bone marrow pathology: bone marrow dysfunction, three lines of hematopoietic 
cells can be seen, the proportion of red tablets was normal, megakaryocyte number and 
morphology were without exception. Be double filtration plasmapheresis and 
methylprednisolone injection pulse therapy, Coomb’s test showed: more specific anti-
human globulin (+), single-specific anti-C3 (+), I (-). Plus immunosuppressive agents 
cyclosporine and vincristine, while reducing the hormone dosage, it is stable in clinical and 
laboratory condition. 
3.6 Post-transplant changes in autoantibody 
After transplantation ANA, anti Ds-DNA antibodies, anti-Sm antibodies, anti-RNP antibody 
titers decreased than those before transplantation, but among the different phases  they 
showed no significant ( P> 0.05), while ANA, anti-RNP antibody titers were significantly 
lower than before transplantation (P <0.05), specifically in chapter IV. 
3.7 Post-transplant immune reconstitution 
It is different for CD3 +, CD45RA + CD4 +, CD45RA + CD8 +, CD45RO + CD4 + expression 
when 3 months,6 months and 1 year after transplantation (P <0.05). (1) 3,6 month after 
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treatment, CD3 + expression levels were significantly lower than that before transplantation 
(P <0.05); (2) 6,12months after transplantation, CD45RA + CD4 + expression levels were 
significantly higher than that 3 months after transplantation (P <0.05), but no significant 
difference than before treatment (P> 0.05); (3) 3,6 months after transplantation when 
CD45RA + CD8 + expression levels were significantly lower than before transplantation ( P 
<0.05). (4) 3,6, 12 months after transplantation,  the CD45RO + CD4 + expression levels were 
significantly lower than that before transplantation (P <0.05). Detailed in Table 1. and 
Chapter. 
 
time CD3+ CD45RA+CD4+ CD45RA+CD8+ CD45RO+CD4+ 
Before 
transplantion 
74.49±9.79 5.80±3.96 28.95±11.28 16.66±5.60 
3 months later 58.04±20.61* 3.41±4.46 20.29±11.11* 8.43±3.32* 
6 months later 62.75±17.09* 6.33±4.87∆ 18.89±8.18* 10.26±4.84* 
12 months 
later 
67.28±14.16 7.84±3.63∆ 23.14±10.15 11.55±5.25* 
F  3.727 4.457 4.539 8.325 
Mauchly test of sphericity, P> 0.05, the spherical assumption is not rejected, without correction with 
correction factor ε freedom. 
* Compared with the pre-transplant, P <0.05; Δ compared with 3 months after transplant, P <0.05 
Table 1. Alternation of immune function in patients with SLE before and after AHSCT 
4. Discussion 
Systemic lupus erythematosus is an autoimmune disease, without clear cause and difficult 
to cure. In recent years, with the increasing levels of health care, new drugs and treatments 
are emerging for treatment. Particularly glucocorticoids and cytotoxic drugs for SLE, the 
survival rate has improved significantly. To the 1990s, 5,10,20-year survival rate has reached 
93%, 1 92%, 68%,respectively [5,6]. 
Though corticosteroid treatment with cytotoxic drugs is still the preferred solution, 
However, due to the large amount of medication for a long time, prone to side effects and 
complications and make 60% of patients eventually die from side effects o [7]. Therefore, it 
is still medical problem at home and abroad. 
In 1985, Ikehara confirmed Allo-BMT to treat mice autoimmune disease. In 1991 Knaan-
Shanzer confirmed their bone marrow transplant for adjuvant arthritis in rats. At the 
same time,it was discovered that receiving Allo-BMT or autologous bone marrow 
transplantation can achieve remission for autoimmune disease such as the blood system 
or other malignancies [12]. Karussis et al [13] firstly used cyclophosphamide and 
granulocyte colony-stimulating factor to stimulate the bone marrow to release 
hematopoietic stem cells into the blood, and isolated, purified and separate mouse 
hematopoietic stem cells in vitro. After sorting the total number of CD34+ cells greater 
than 2.0 × 106/kg, use large doses of immunosuppressive agents in the second step for 
abnormal immune cells elimination, then reinfuse the CD34+ cells into mice. After the 
reconstruction of immune system, and long term follow up, it was found that it has 
achieved remarkable results in animal models. 
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In recent years, it is effective that autologous peripheral blood stem cell transplantation for 
autoimmune diseases and becoming a hot topic in international research. Firstly, we use 
doses of immunosuppressive agents or radiation in patients to finish a strong immune 
suppression, and then rebuild the patient's immune system by autologous hematopoietic 
stem cell transplantation. The use of peripheral blood transplantation, hematopoietic stem 
cells has no anesthesia, trauma and has an earlier immune reconstitution compared to bone 
marrow transplantation. The patient's immune regulation in the reconstruction process can 
reach a new equilibrium and (or) immune tolerance, may complete remission or even 
completely cured[7 ~ 11]. 
Hematopoietic stem cell transplantation (HSCT) for the treatment of SLE has opened up a 
new way, however, there is a certain risk, which confined its use. Combined with existing 
research and the experience, the performance of at least one of the following may be 
considered for HCST treatment;  epileptic seizures or psychiatric symptoms;  lung 
involvement at one of the following: pulmonary hemorrhage, infiltration and no infection is 
present, within the last 6 months is greater than 15% lower forced vital capacity, pulmonary 
hypertension;  refractory hemolytic anemia, reticulocyte count is greater than 3%, 
hemoglobin less than 100g / L; or the decreaseing of other fatal blood cells;  SLE disease 
activity index greater than 16 points;  serious anti-cardiolipin antibody syndrome. 
Nephritis and has one of the following persons: proteinuria greater than 1g / d and albumin 
less than 30 g / L, serum creatinine greater than 15mg / L, and hematuria, cellular casts, 
renal biopsy with acute proliferative damage. Patients also need the following therapy: oral 
prednisone 0.5mg/kg at least 2 months, last 6 months or intravenous methyl poured nylon 
1g, 3 times; application CTX 500 mg/m2, 3 times/month [3,7]. 
Stem cells can self-renew,replicate to mature blood cells, has CD34 antigen expressed, 
including hematopoietic progenitor / unique cell populations. The cceptable number of 
CD34+ cell transplantation cellsis in the range (2 ~ 5) × 106/kg, but the number of peripheral 
blood stem cells often less than 0.1%. Therefore, we need a way to increase the concentration 
of peripheral blood stem cells, which is called stem cell mobilization. The key method is 
chemotherapy + granulocyte colony-stimulating factor or single granulocyte colony-
stimulating factor. The former may alleviate the disease, while the later may deteriorate it. 
Joint mobilization is better than single granulocyte-colony stimulating factor, 
cyclophosphamide 4g/m2 than 2g/m2 [3,14,15]. The group of 16 patients were treated  with 
cyclophosphamide 4g/m2 combined granulocyte colony-stimulating factor 5ug/kg to make 
a success rate of 100%. But in the process of collecting peripheral blood stem cells, there are 
two important problems to be solved, that is, when to start and when to end. We need to 
keep abreast of peripheral blood mononuclear cells and stem cells numbers timely for 
clinical decisions.CD34+ cell count is the most widely used in the determination of graft 
stem / progenitor cells of the indicators. The absolute count of which is closely related to 
content, to predict the effect of acquisition. The peripheral blood WBC, MNC count and the 
number of harvested CD34+ cells were not significantly correlated, indicating which does 
not accurately reflect the level of peripheral blood stem cells, so it became the key that the 
absolute count of CD34+ collection . In general, the best collection time should be when the 
peripheral blood CD34+ cells is from 20 to 85 / uL, according to its cell surface antigen and 
labeled antibody to the tiny beads binded specifically. Some scholars [16] reported that 
CD34+ cell graft up to a median of 49% by positive selection, compared with pre-separation 
concentration as 33 times. The main purpose is to remove the graft in the immune cells to 
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reduce the chance of a relapse transplant. We used the German company Miltenyi Biotec 
MACS immunomagnetic system in CD34+ sorting [17]. 
Mobilization of patients with SLE-related complications included fever, hypotension, 
abdominal pain, joint pain, seizures, myocardial infarction, pulmonary edema [17]. The total 
of 16 patients mobilized had both leukopenia and gastrointestinal adverse reactions, with 
varying degrees of fever, while blood cultures negative, after CD34+ cells collected the 
temperature returned to normal but its mechanism remains unclear, needing further study. 
Pretreatment is one of the important part of autologous hematopoietic stem cell 
transplantation. Its main purpose is to destroy the abnormal cells in vivo in patients, 
minimize recurrence, and provided the necessary space to implant. Regimen should also 
have the function to suppress hematopoietic and immune, which often require multiple 
medications and / or radiotherapy combined. 
Currently, there are no uniform for conditioning regimen for SLE. In general, the efficacy of 
pre-clinical and pre-treatment intensity have some relevance, for example, by 
cyclophosphamide / busulfan, cyclophosphamide or other drugs combined with systemic 
lymph node irradiation, the disease recurrence rate is low, but transplant-related mortality 
also increased. Because of the transplanted organ damage associated with SLE patients, 
most scholars do not advocate the use of intense myeloablative program, but the lymphatic 
clearance program. The current use of cyclophosphamide (200mg/kg) + anti-thymocyte 
globulin (ATG, 90mg/kg) is more common, while some individual case reports 
cyclophosphamide (120 ~ 150mg/kg) + systemic lymph node irradiation (400 ~ 600cGy, 
lung shielding to 400cGy) or cyclophosphamide (120mg/kg) + busulfan (16 mg / kg) and 
the BEAM program (BCNU 300mg / m2, VP16 400 ~ 800mg / m2, cytarabine 800 ~ 1600mg 
/ m2, melphalan 140mg / m2) [10,15,18]. The whole body and lymph node irradiation can 
induce more tumor-related complications, should be taken seriously enough [15]. 
Conditioning regimen containing cyclophosphamide, 5% patients emerged life-threatening 
cardiac toxicity and severe cardiac toxicity, mainly showing low-voltage ECG, progressive 
heart failure or pericarditis with the drug doses. One case in our group occurred serious 
heart failure in use of drugs to support and pericardiocentesis when necessary. 
Over 90% patients had the incidence of oral mucositis after hematopoietic stem cell 
transplantation, approximately the date of reinfusion, continuing until blood implanted. 
Some patients have severe pain and require total parenteral parenteral nutrition support 
and make fungal, bacterial, viral and other infections common. 
Almost all patients have varying degrees of gastrointestinal reactions, mainly nausea, 
vomiting, or diarrhea. We can use 5 - hydroxy tryptophan-blockers to control 
gastrointestinal adverse reactions before chemotherapy. 
Renal dysfunction is a common complication with amounts of pathogenic factors, such as 
direct drug toxicity, hypovolemia and use of nephrotoxic drugs. By disabling nephrotoxic 
drugs, paying attention to water and electrolyte balance, most patients can return to 
normal. 
Another prominent side effect caused by cyclophosphamide is hemorrhagic cystitis, 
mainly due to as cyclophosphamide metabolites acrolein from urine, causing extensive 
mucosal ulceration, necrosis and bleeding. The effective prevention measures include 
alkaline urine and application Gomez sodium, which can be combined with acrolein to 
reduce the cell toxicity in a total dose of 1.6 times of that of cyclophosphamide  and 
divided in 4 times. 
 
New Advances in Stem Cell Transplantation 
 
350 
In recent years, it is effective that autologous peripheral blood stem cell transplantation for 
autoimmune diseases and becoming a hot topic in international research. Firstly, we use 
doses of immunosuppressive agents or radiation in patients to finish a strong immune 
suppression, and then rebuild the patient's immune system by autologous hematopoietic 
stem cell transplantation. The use of peripheral blood transplantation, hematopoietic stem 
cells has no anesthesia, trauma and has an earlier immune reconstitution compared to bone 
marrow transplantation. The patient's immune regulation in the reconstruction process can 
reach a new equilibrium and (or) immune tolerance, may complete remission or even 
completely cured[7 ~ 11]. 
Hematopoietic stem cell transplantation (HSCT) for the treatment of SLE has opened up a 
new way, however, there is a certain risk, which confined its use. Combined with existing 
research and the experience, the performance of at least one of the following may be 
considered for HCST treatment;  epileptic seizures or psychiatric symptoms;  lung 
involvement at one of the following: pulmonary hemorrhage, infiltration and no infection is 
present, within the last 6 months is greater than 15% lower forced vital capacity, pulmonary 
hypertension;  refractory hemolytic anemia, reticulocyte count is greater than 3%, 
hemoglobin less than 100g / L; or the decreaseing of other fatal blood cells;  SLE disease 
activity index greater than 16 points;  serious anti-cardiolipin antibody syndrome. 
Nephritis and has one of the following persons: proteinuria greater than 1g / d and albumin 
less than 30 g / L, serum creatinine greater than 15mg / L, and hematuria, cellular casts, 
renal biopsy with acute proliferative damage. Patients also need the following therapy: oral 
prednisone 0.5mg/kg at least 2 months, last 6 months or intravenous methyl poured nylon 
1g, 3 times; application CTX 500 mg/m2, 3 times/month [3,7]. 
Stem cells can self-renew,replicate to mature blood cells, has CD34 antigen expressed, 
including hematopoietic progenitor / unique cell populations. The cceptable number of 
CD34+ cell transplantation cellsis in the range (2 ~ 5) × 106/kg, but the number of peripheral 
blood stem cells often less than 0.1%. Therefore, we need a way to increase the concentration 
of peripheral blood stem cells, which is called stem cell mobilization. The key method is 
chemotherapy + granulocyte colony-stimulating factor or single granulocyte colony-
stimulating factor. The former may alleviate the disease, while the later may deteriorate it. 
Joint mobilization is better than single granulocyte-colony stimulating factor, 
cyclophosphamide 4g/m2 than 2g/m2 [3,14,15]. The group of 16 patients were treated  with 
cyclophosphamide 4g/m2 combined granulocyte colony-stimulating factor 5ug/kg to make 
a success rate of 100%. But in the process of collecting peripheral blood stem cells, there are 
two important problems to be solved, that is, when to start and when to end. We need to 
keep abreast of peripheral blood mononuclear cells and stem cells numbers timely for 
clinical decisions.CD34+ cell count is the most widely used in the determination of graft 
stem / progenitor cells of the indicators. The absolute count of which is closely related to 
content, to predict the effect of acquisition. The peripheral blood WBC, MNC count and the 
number of harvested CD34+ cells were not significantly correlated, indicating which does 
not accurately reflect the level of peripheral blood stem cells, so it became the key that the 
absolute count of CD34+ collection . In general, the best collection time should be when the 
peripheral blood CD34+ cells is from 20 to 85 / uL, according to its cell surface antigen and 
labeled antibody to the tiny beads binded specifically. Some scholars [16] reported that 
CD34+ cell graft up to a median of 49% by positive selection, compared with pre-separation 
concentration as 33 times. The main purpose is to remove the graft in the immune cells to 
Autologous Peripheral Blood Purified Stem Cells  
Transplantation for Treatment of Systemic Lupus Erythematosus 
 
351 
reduce the chance of a relapse transplant. We used the German company Miltenyi Biotec 
MACS immunomagnetic system in CD34+ sorting [17]. 
Mobilization of patients with SLE-related complications included fever, hypotension, 
abdominal pain, joint pain, seizures, myocardial infarction, pulmonary edema [17]. The total 
of 16 patients mobilized had both leukopenia and gastrointestinal adverse reactions, with 
varying degrees of fever, while blood cultures negative, after CD34+ cells collected the 
temperature returned to normal but its mechanism remains unclear, needing further study. 
Pretreatment is one of the important part of autologous hematopoietic stem cell 
transplantation. Its main purpose is to destroy the abnormal cells in vivo in patients, 
minimize recurrence, and provided the necessary space to implant. Regimen should also 
have the function to suppress hematopoietic and immune, which often require multiple 
medications and / or radiotherapy combined. 
Currently, there are no uniform for conditioning regimen for SLE. In general, the efficacy of 
pre-clinical and pre-treatment intensity have some relevance, for example, by 
cyclophosphamide / busulfan, cyclophosphamide or other drugs combined with systemic 
lymph node irradiation, the disease recurrence rate is low, but transplant-related mortality 
also increased. Because of the transplanted organ damage associated with SLE patients, 
most scholars do not advocate the use of intense myeloablative program, but the lymphatic 
clearance program. The current use of cyclophosphamide (200mg/kg) + anti-thymocyte 
globulin (ATG, 90mg/kg) is more common, while some individual case reports 
cyclophosphamide (120 ~ 150mg/kg) + systemic lymph node irradiation (400 ~ 600cGy, 
lung shielding to 400cGy) or cyclophosphamide (120mg/kg) + busulfan (16 mg / kg) and 
the BEAM program (BCNU 300mg / m2, VP16 400 ~ 800mg / m2, cytarabine 800 ~ 1600mg 
/ m2, melphalan 140mg / m2) [10,15,18]. The whole body and lymph node irradiation can 
induce more tumor-related complications, should be taken seriously enough [15]. 
Conditioning regimen containing cyclophosphamide, 5% patients emerged life-threatening 
cardiac toxicity and severe cardiac toxicity, mainly showing low-voltage ECG, progressive 
heart failure or pericarditis with the drug doses. One case in our group occurred serious 
heart failure in use of drugs to support and pericardiocentesis when necessary. 
Over 90% patients had the incidence of oral mucositis after hematopoietic stem cell 
transplantation, approximately the date of reinfusion, continuing until blood implanted. 
Some patients have severe pain and require total parenteral parenteral nutrition support 
and make fungal, bacterial, viral and other infections common. 
Almost all patients have varying degrees of gastrointestinal reactions, mainly nausea, 
vomiting, or diarrhea. We can use 5 - hydroxy tryptophan-blockers to control 
gastrointestinal adverse reactions before chemotherapy. 
Renal dysfunction is a common complication with amounts of pathogenic factors, such as 
direct drug toxicity, hypovolemia and use of nephrotoxic drugs. By disabling nephrotoxic 
drugs, paying attention to water and electrolyte balance, most patients can return to 
normal. 
Another prominent side effect caused by cyclophosphamide is hemorrhagic cystitis, 
mainly due to as cyclophosphamide metabolites acrolein from urine, causing extensive 
mucosal ulceration, necrosis and bleeding. The effective prevention measures include 
alkaline urine and application Gomez sodium, which can be combined with acrolein to 
reduce the cell toxicity in a total dose of 1.6 times of that of cyclophosphamide  and 
divided in 4 times. 
 
New Advances in Stem Cell Transplantation 
 
352 
Animal experiments confirmed that the graft of T lymphocytes related to disease recurrence 
after transplantation [3,7,11]. At present, most foreign scholars are using cell sorting system 
to remove T-cell line in vitro, only can remove about 3 logarithmic T cells, which can be re-
entered to arouse the body's own response to the disease clone. ATG is a kind of polyclonal 
immunoglobulin antibodies using the human thymus cells immunized animals to collect the 
serum extract, selective against human T lymphocytes. Anti-thymocyte globulin in the body 
can bind to T cells, swallowed by circulating monocytes, and fixed macrophages 
components, through the activation of complement to remove T cells [19]. We applied 
plenty of ATG in vivo to remove the residual T lymphocytes and memory cells to enhance 
the success rate and reduce the relapse rate. 
The exact mechanism of autologous peripheral blood stem cell transplantation for 
autoimmune diseases is not fully clear, what can be certain is that the original autoimmune 
cell clones were completely destroyed while re-established a normal immune system [7-10]. 
By high dose systemic immunosuppressants or radiation, we eliminate its own mature 
immune cells, while stem cells, due to a large quantity of aldehyde dehydrogenase, can 
resist to cyclophosphamide. Pretreatment process can avoid the impact of memory T cell so 
that the new stem cells can develop into non-anti-self lymphocytes, inducing tolerance to 
the autoantigen. In addition, the mobilization and pre-processing stage eliminate 
autoimmune lymphocytes, reduce antibodies and immune complexes to allow healing of 
damaged tissue and normal immune. 
Autoimmunity and self-tolerance is a dynamic equilibrium between the process. By using 
immunosuppressive agents and hematopoietic stem cell transplantation can eventually 
balance the body's immune system back to normal [11]. Theoretically, it is possible to cure 
autoimmune disease.  
Since 1997, Marmont using autologous bone marrow stem cell transplantation for treatment 
of SLE has been successful, there have been a lot of research on bone marrow and peripheral 
blood stem cell transplantation for treatment of SLE at home and abroad, and have achieved 
encouraging clinical results. In 2003, ASH meeting reported the U.S. total number of cases is 
681, of which 127 cases were systemic lupus erythematosus, mainly in remission. Van lear 
have found that 45 SLE patients undergoing transplantation, 27 of which have significantly 
improved, 14 recurred after the initial alleviation, 7 deaths, for 5 have relation with the 
transplantation and the overall transplant-related mortality rate  is 11% [20]. Traynor et al 
from North America [10] found 15 patients with SLE completing the study of autologous 
transplantation were alive, but 2 died after mobilization. In more than 1 year’s follow-up, 12 
patients, 8 cases completely withdrawaled, 2 have small doses of hormones to maintain, 2 
had disease activity requiring the addition of immunosuppressive agents. Our studies show 
that it has an ideal short-term effect about autologous peripheral blood purified CD34 + cell 
transplantation for SLE, for all patients had hematopoietic reconstitution well, most of the 
clinical manifestations and related immunological parameters disappeared and were 
markedly improved in survival quality. But there are still many issues worth further 
reflection and research [3], such as: SLE multiple genetic abnormalities exist in the stem cell 
gene level, the transplanted stem cells will differentiate into the same self-reactive immune 
cells; whether disease recurrence are related to stem cells derived from the input; if the new 
input stem cells in the relatively normal environment can develop into self-tolerance T, B 
lymphocytes, and so on. 
Autologous Peripheral Blood Purified Stem Cells  
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1. Introduction  
Paroxysmal nocturnal hemoglobinuria /PNH/ is an acquired, clonal disorder of 
hematopoietic stem cell, characterized by intravascular hemolysis and manifested by 
episodes of hemoglobinuria, life-threatening venous thromboses, bone marrow failure and 
smooth muscle dystonias. The triad of hemolytic anemia, pancytopenia and thrombosis 
makes PNH a truly unique clinical syndrome. The disease can arise de novo or in the setting 
of acquired aplastic anemia (Robert A. Brodsky, 2008). The name of the disease refers to the 
occurrence of hemoglobinuria responsible for red or dark brown urine. Hemoglobinuria in 
patients with PNH very often appears after awakening and is due to intravascular lysis of 
red blood cells that are abnormally sensitive to the complement attack (Bessler and Hiken, 
2008). PNH is unique as it is an acquired hemolytic disorder resulting from abnormality of  
the red cell. Almost all other acquired hemolytic conditions are due to an extrinsic attack on 
the red cells, eg. antibody- mediated or mechanical hemolysis (Hillmen, 2008). So it is not 
surprising that this rare disease (the estimated incidence of 2 to 5 new cases per million 
inhabitants (Brodsky, 2008) has been fascinating scientists for almost 150 years. The first 
clear and detailed clinical description of “intermittent haematuria” in an anemic patient 
was given by Wiliam Gull in 1866. Dr. Paul Strubling recognized the urinary pigment as 
haemoglobin and called this sign “paroxysmal haemoglobinuria” in 1882. He has 
developed the hypothesis that the erythrocytes of PNH are abnormally sensitive to 
hemolysis when the plasma is acidified during sleep because of carbon dioxide and lactic 
acid accumulation as a result of slower circulation (Parker, 2008). His work was largely 
ignored until Marchiafava reported a case in Italy 29 years later. In 1931 Michelli 
published further observations and used the term “ splenomegalic hemolytic anemia with 
hemoglobinuria and hemosiderinuria Marchiafava-Michelli type”- hence the name 
Marchiafava-Michelli disease. Early in the 20th century Van der Bergh showed that 
erythrocytes from PNH patients underwent lysis in acidified serum and he suspected that 
complement played a role in this abnormality. In 1944, Dacie noted a possible association 
with aplasia and suggested that PNH is an acquired clonal dysfunction affecting 
hematopoietic stem cells  occurring due to their somatic mutation (Johnson RJ et al, 2002). 
The mechanism of clonal dominance in PNH remains unknown.  
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2. Pathogenesis and classification 
PNH is not only interesting for hematologists, but it is also very important problem for 
neurologists, nephrologists, gastroenterologists, pediatricians (about 10% of patients are 
younger than 21 years)  and gynecologists (25% of the cases are diagnosed during 
pregnancy (Parker et al. 2005). 
PNH is caused by an acquired somatic mutation of the PIG-A gene located on the short arm of 
the X chromosome in multipotent hematopoietic stem cell. Most PIG-A mutations are small 
insertions or deletions that result in a frame-shift in the coding region and consequently a 
shortened non-functional GPI product (Brodsky, 2008). Due to its localization on the X 
chromosome and due to X inactivation in the female somatic cells, only one mutation is 
required in either males or females to abolish the expression GPI-linked proteins. To date over 
180 mutations have been identified in the PIG-A gene in blood cells from patients with PNH 
(Hillmen, 2008). Small to moderate PNH clones are found in up to 70% of patients with 
acquired aplastic anemia, demonstrating a patho-physiological link between these disorders 
(Schrezenmeier et al. 1995; Dunn DE et al. 1999; Mukhima GL et al. 2001; Wang H et al, 2002). 
What is more, many of aplastic anemia patients exhibit expansion of the PIG-A mutant clone 
and progress to clinical PNH (Brodsky, 2008). GPI- anchored proteins deficient cells have also 
been reported in patients with myelodysplastic syndrome (MDS) (Dunn DE et al. 1999; 
Mukhina Gl et al. 2001; Wang H et al. 2002). Patients with MDS possessing small PNH 
populations tend to be classified as having refractory anemia and often have a hypocellular 
marrow with HLA-DR15 positivity, normal cytogenetics, moderate to severe 
thrombocytopenia and high likelihood of response to immunosuppressive therapy (Wang H et 
al. 2002; Nagarajan S et al. 1995; Sugimori C et al. 2006). 
PIG-A gene encodes complement-protecting surface proteins which are normally tethered to 
the cell membrane of erythrocytes, neutrophils and platelets by the GPI anchor (Rosse WF et 
al. 2004). Two proteins play particularly important role: 
- CD55 (DAF- Decay Accelerating Factor) which controls the first steps of the 
complement cascade by regulating the activity of C3 and C5 convertases (Rosse WF et 
al. 2004; Johnson RJ et al. 2002; Parker C et al. 2005). 
- CD59 (MIRL-Membrane Inhibitor of Reactive Lysis) which inhibits the formation of the 
Terminal Complement Complex by preventing the incorporation of C9 in the C5b-8 
complex, thereby preventing the formation of Membrane Attack Complex (MAC or 
C5b-9) (Rosse WF et al. 2004; Johnson RJ et al. 2002; Parker C et al. 2005). 
Defect in PIG-A gene leads to partial or complete deficiency of these protective factors 
(CD55 and CD59) on the cell surface responsible for susceptibility to the lytic effects of 
activated complement and intravascular lysis of erythrocytes. 
Flow cytometry  analysis reveals that all hematopoietic lineages: myeloid, erythroid and 
lymphoid are involved (Brodsky, 2008). 
Glycosylphosphatidyloinositol (GPI) protein deficiency on PNH red cells can be complete 
(PNH type III cels) or partial (PNH type II cells). Cells with normal levels of GPI proteins on 
their surface are referred to as type I cells (Fujioka & Yamada, 1994). The analysis of GPI-
anchored proteins on the surface of the hematopoietic cells, particularly red cells in PNH 
reveals that approximately 40% of patients have a combination of types I, II, III PNH cells 
(Hill et al. 2007). 
Current classification system has recently been proposed, which divides patients with PNH 
clones into the following subgroups (Parker C et al. 2005): 
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- Classic PNH- patients have clinical evidence of intravascular hemolysis: signs of 
marrow stimulation- reticulocytosis, high levels of LDH and direct or indirect bilirubin, 
low concentration of serum haptoglobin, without evidence of another defined bone 
marrow abnormality. 
- PNH in the setting of another bone marrow disorder- patients in this subcategory have 
clinical and laboratory evidence of hemolysis, but also have or have had a history of a 
defined underlying marrow abnormality (eg. PNH/ aplastic anemia, PNH/ refractory 
anemia-MDS). 
- Subclinical PNH- patients have no clinical or laboratory evidence of hemolysis. PNH-sc 
is observed in association with bone marrow failure syndromes, particularly aplastic 
anemia and refractory anemia-MDS. 
The course of the disease is marked by exacerbations of hemolysis of varying severity on top 
of the chronic hemolysis which exists in these patients. Repeated paroxysmal episodes often 
necessitate a transfusion. The paroxysms may be triggered by infections, stress, trauma, 
surgery, pregnancy and drugs.  
Intravascular hemolysis is responsible for most symptoms observed in PNH patients. Free 
hemoglobin released from PNH red cells during intravascular hemolysis can completely 
deplete haptoglobin and then overflow into the urine resulting in hemoglobinuria (Tabbara, 
1992). Once the capacity of this hemoglobin scavenging protein is exceeded, (Parker et al. 
2005) consumption of endogenous nitric oxide (NO) ensues. This reduced bioavailability of 
NO could also promote platelet and endothelial activation, leading to intravascular 
thrombosis (Rosse WF et al. 2004; Parker C et al. 1996; Rother RP et al. 2005). The occurrence 
of thrombotic events can sometimes lead to the diagnosis. Venous thrombosis may be 
recurrent  and often occur in uncommon sites  (Gralnick HR et al. 1995) such as pre-hepatic 
veins (Budd-Chiari syndrome), splenic, portal, renal, cerebral or mesenteric veins or inferior 
vena cava. An increased incidence of arterial thrombosis has also been reported. 
Nitric oxide depletion also causes disturbances in the regulation of smooth muscle tone 
(especially during PNH exacerbations), resulting in abdominal pain, dysphagia and erectile 
dysfunction- it has been well established that local NO deficiency is one of the major factors 
responsible for erectile dysfunction (Corbin et al. 2002). Moreover, about 50% of patients 
with hemolytic PNH have elevated pulmonary artery systolic pressure (Hill et al 2006). 
About 35% of PNH patients are presenting symptoms of anemia. It should be distinguished 
how much of the anemia is a consequence of hemolysis and how much is due to impaired 
erythropoiesis. Review of the complete blood count is informative, because evidence of 
thrombocytopenia, leucopenia or both suggests stem cell dysfunction. Marrow failure is 
likely to be a contributing factor in a patient with PNH who has anemia with an 
inappropriately low reticulocyte count. 
3. Diagnostics 
As PNH is a very rare disease, appropriate choice of patients for PNH screening is a very 
important issue.  It should include patients with hemoglobinuria, Coombs negative 
intravascular hemolysis (based on abnormally high serum LDH, especially with iron 
deficiency), venous thrombosis involving unusual sites, aplastic anemia and refractory anemia. 
In 1939 Ham and Dingle’s historic paper described the first diagnostic test for PNH utilizing 
the finding that PNH red cells were exquisitely sensitive to hemolysis in the setting of 
acidified serum, now known as the Ham’s test. It has been used to diagnose PNH for 
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- Classic PNH- patients have clinical evidence of intravascular hemolysis: signs of 
marrow stimulation- reticulocytosis, high levels of LDH and direct or indirect bilirubin, 
low concentration of serum haptoglobin, without evidence of another defined bone 
marrow abnormality. 
- PNH in the setting of another bone marrow disorder- patients in this subcategory have 
clinical and laboratory evidence of hemolysis, but also have or have had a history of a 
defined underlying marrow abnormality (eg. PNH/ aplastic anemia, PNH/ refractory 
anemia-MDS). 
- Subclinical PNH- patients have no clinical or laboratory evidence of hemolysis. PNH-sc 
is observed in association with bone marrow failure syndromes, particularly aplastic 
anemia and refractory anemia-MDS. 
The course of the disease is marked by exacerbations of hemolysis of varying severity on top 
of the chronic hemolysis which exists in these patients. Repeated paroxysmal episodes often 
necessitate a transfusion. The paroxysms may be triggered by infections, stress, trauma, 
surgery, pregnancy and drugs.  
Intravascular hemolysis is responsible for most symptoms observed in PNH patients. Free 
hemoglobin released from PNH red cells during intravascular hemolysis can completely 
deplete haptoglobin and then overflow into the urine resulting in hemoglobinuria (Tabbara, 
1992). Once the capacity of this hemoglobin scavenging protein is exceeded, (Parker et al. 
2005) consumption of endogenous nitric oxide (NO) ensues. This reduced bioavailability of 
NO could also promote platelet and endothelial activation, leading to intravascular 
thrombosis (Rosse WF et al. 2004; Parker C et al. 1996; Rother RP et al. 2005). The occurrence 
of thrombotic events can sometimes lead to the diagnosis. Venous thrombosis may be 
recurrent  and often occur in uncommon sites  (Gralnick HR et al. 1995) such as pre-hepatic 
veins (Budd-Chiari syndrome), splenic, portal, renal, cerebral or mesenteric veins or inferior 
vena cava. An increased incidence of arterial thrombosis has also been reported. 
Nitric oxide depletion also causes disturbances in the regulation of smooth muscle tone 
(especially during PNH exacerbations), resulting in abdominal pain, dysphagia and erectile 
dysfunction- it has been well established that local NO deficiency is one of the major factors 
responsible for erectile dysfunction (Corbin et al. 2002). Moreover, about 50% of patients 
with hemolytic PNH have elevated pulmonary artery systolic pressure (Hill et al 2006). 
About 35% of PNH patients are presenting symptoms of anemia. It should be distinguished 
how much of the anemia is a consequence of hemolysis and how much is due to impaired 
erythropoiesis. Review of the complete blood count is informative, because evidence of 
thrombocytopenia, leucopenia or both suggests stem cell dysfunction. Marrow failure is 
likely to be a contributing factor in a patient with PNH who has anemia with an 
inappropriately low reticulocyte count. 
3. Diagnostics 
As PNH is a very rare disease, appropriate choice of patients for PNH screening is a very 
important issue.  It should include patients with hemoglobinuria, Coombs negative 
intravascular hemolysis (based on abnormally high serum LDH, especially with iron 
deficiency), venous thrombosis involving unusual sites, aplastic anemia and refractory anemia. 
In 1939 Ham and Dingle’s historic paper described the first diagnostic test for PNH utilizing 
the finding that PNH red cells were exquisitely sensitive to hemolysis in the setting of 
acidified serum, now known as the Ham’s test. It has been used to diagnose PNH for 
 
New Advances in Stem Cell Transplantation 
 
358 
decades. Other traditional diagnostic tests were sucrose and thrombin lysis tests, cheap and 
simple to perform, but with decreased sensitivity due to the short half-life of circulating 
PNH red blood cells (Bessler and Hiken, 2008). 
Nowadays flow cytometry  is the gold standard method as it is the most sensitive and  
yields the most quantitative and qualitative information (Parker C et al. 2005). This 
technique uses specific antibodies directed against antigens normally tethered by GPI to the 
surface of hematopoietic cells (erythrocytes, granulocytes and  monocytes). Analysis of 
erythrocytes should either precede transfusions or be performed during a period of 
transfusion abstinence. The results of the analysis for erythrocytes should include the 
percentage of type I,  type II, and type III PNH cells (Parker C et al. 2005). Analysis of 
granulocytes provides the best estimate of the size of the PNH clone and it is unaffected by 
red cells transfusion (Bessler and Hiken 2008). Another method used for PNH diagnosis is 
lack of FLAER (fluorescently labeled inactive toxin aerolysin) binding to GPI anchor on 
peripheral blood granulocytes. The method cannot be used for the analysis of red blood cells 
or platelets, thus it might be difficult to perform in severe aplastic anemia due to very low 
number of circulating granulocytes. PIGA gene mutation analysis, although very specific, is 
not used for diagnosing PNH. Supportive laboratory tests confirming presence of 
intravascular hemolysis are helpful, although not diagnostic: increased lactate 
dehydrogenase (LDH), low haptoglobin, increased unconjugated bilirubin, hemoglobinuria, 
hemosiderinuria, reticulocytosis and erythroid hyperplasia in the bone marrow. 
Median survival in PNH is 10 to 15 years after diagnosis, with a wide range (Brodsky, 2009). 
Men and women are affected equally and there is no familial tendency. Thrombophilia is a 
major cause of morbidity and mortality in PNH (Hillmen et al. 1995; Socie G et al. 1996). 
About 40% of patients with PNH experience a thrombotic event during the course of disease 
(Hillmen et al. 1995; Socie G et al. 1996; Ware RE et al. 1992). Risk of developing thrombosis 
is proportional to the size of the PNH clone (Hillmen P et al. 2007; Hall C et al. 2003; Moyo V 
et al. 2004; Nishimura J 2004). Population of PNH granulocytes >50% predicts an increased 
risk of thrombosis (Hall C et al. 2003). The cause of thrombotic tendency in PNH is multi-
factorial. Free plasma hemoglobin may contribute to platelets activation and thrombosis. 
The effect of free hemoglobin on platelet function is probably through the scavenging of 
nitric oxide (NO). Reduction of NO generation leeds to increased platelet aggregation 
(Broekman et al. 1991,  Schafer et al. 2004). 
Another complication in PNH is bone marrow insufficiency (Hillmen et al. 1995). It has long 
been known that there is a close correlation between PNH and aplastic anemia.  
Renal failure has been recognized as a complication of PNH for many years. Between 8% and 
18 % of deaths in PNH have been reported to have renal failure as at least a contributing factor 
(Nishimura JI et al. 2004; Clark DA et al. 1981). The cause of renal failure is probably damage 
of proximal renal tubules by iron released during intravascular hemolysis (Hillmen 2008).  
PNH is only rarely associated with acute myeloid leukemia. It occurs in approximately 5% 
of patients with aplastic anemia. Marrow aplasia predisposes to PNH and to the leukemic 
transformation into acute leukemia. In most leukemia patients with PNH who have been 
studied the leukemic clone has been derived from the PNH clone (Hillmen P et al. 1995). A 
significant proportion of patients survive for prolonged  periods (approximately 25% 
surviving over 25 years with blood transfusion support only) and about 10% to 15% 
experiences a spontaneous recovery from PNH with no sequelae attributable to the disease . 
A possible hypothesis to explain occasional spontaneous recovery is that intensity of  
aplastic process that is positively selecting PNH clones reduces with time. Recovery would 
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depend on the presence of normal stem cells capable of regenerating the bone marrow  
(Hillmen P et al. 1995) 
Before initiating treatment of PNH, it is useful to stratify patients into classical or 
hypoplastic PNH. This can usually be accomplished by obtaining a complete blood and 
reticulocyte count, LDH determination, peripheral blood flow cytometry and bone marrow 
examination. Regardless of how patients with small PNH clones are classified (eg. 
AA/PNH, MDS/PNH or subclinical PNH), they do not have to and should not be treated, 
unless symptoms appear. Patients with PNH clones less than 10% rarely require clinical 
intervention, nevertheless they should be monitored closely because expansion of the clone 
may occur. Monitoring of granulocyte and erythrocyte clone size is sometimes performed 
every 6 to 12 months.  Patients with PNH have an impaired quality of life in comparison 
with the general population. They suffer from chronic fatique, which seriously compromises 
their professional and personal lives (Moyo VM et al. 2004). Patients with chronic hemolysis 
complain of lethargy, malaise, myalgia (Clark DA et al. 1981). The dysphagia and male 
impotence of PNH appear related to hemolysis (Rosse WF 2000).  
4. Treatment 
PNH patients with either chronic hemolysis or with acute hemolytic exacerbations may be 
treated with corticosteroids (Rosse WF 1982; Zhao M et al. 2002; Bourants K 1994; Issaragrisil 
S et al. 1987). Some patients respond rapidly and dramatically to prednisone given in the 
dose range of 0,25-1,0 mg/kg per day, but chronic use of corticosteroids may cause adverse 
effects such as immunosuppression, osteopenia, myopathy, iatrogenic Cushing syndrome, 
hypertension or in diabetes (Rosse WF 1982). Androgen therapy either alone or combination 
with steroids has been used successfully to treat anemia in PNH (Rosse WF 1982; Hartman 
RC 1966), especially caused by the underlying bone marrow failure. Although starting dose 
of 400 mg twice a day is recommended, a lower dose (200-400mg/24h) may be adequate to 
control chronic hemolysis. Potential complications of androgen treatment include liver 
toxicy (cholestatic jaundice, peliosis hepatic) prostatic hypertrophy and virilizing effects.  
Transfusion therapy, despite improvement of blood hemoglobin, reduces hemolysis by 
suppressing erythropoiesis. The iron overload that follows repeated transfusion is prevented 
by the urinary loss of iron due to the hemoglobinuria and hemosiderinuria connected with 
intravascular hemolysis (Parker C et al. 2005). To prevent transfusion reaction arising from the 
interaction between donor leukocytes and recipient’s antibodies hemofiltration is 
recommended. Folates supplementation (5 mg/24h) is recommended to compensate for their 
utilization associated with increased erythropoiesis consequencing from hemolysis (Parker et 
al. 2005).  Chronic hemosiderinuria and hemoglobinuria may lead to severe iron deficiency 
despite repeated transfusions, thus PNH patients often require iron supplementation. PNH 
patients with cytopenias often respond to immunosuppressive therapy with anti-lymphocyte 
globulin and/or ciclosporin, because of associated aplastic anemia. 
As the hemolysis of PNH is a consequence of complement- mediated cytolysis, inhibition of 
complement is a logical approach to therapy (Parker CJ 2003).  Eculizumab is a humanized 
monoclonal antibody that targets complement protein C5, thereby preventing assembly of 
the terminal complement complex (also called the Membrane Attack Complex or MAC) 
during complement activation. Eculizumab is an IgG kappa immunoglobulin with 
engineered Fc portion that is a hybrid of IgG2 and IgG4 designed to have no downstream 
activity- thus eculizumab is a purely “blocking” antibody that prevents the cleavage and 
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decades. Other traditional diagnostic tests were sucrose and thrombin lysis tests, cheap and 
simple to perform, but with decreased sensitivity due to the short half-life of circulating 
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red cells transfusion (Bessler and Hiken 2008). Another method used for PNH diagnosis is 
lack of FLAER (fluorescently labeled inactive toxin aerolysin) binding to GPI anchor on 
peripheral blood granulocytes. The method cannot be used for the analysis of red blood cells 
or platelets, thus it might be difficult to perform in severe aplastic anemia due to very low 
number of circulating granulocytes. PIGA gene mutation analysis, although very specific, is 
not used for diagnosing PNH. Supportive laboratory tests confirming presence of 
intravascular hemolysis are helpful, although not diagnostic: increased lactate 
dehydrogenase (LDH), low haptoglobin, increased unconjugated bilirubin, hemoglobinuria, 
hemosiderinuria, reticulocytosis and erythroid hyperplasia in the bone marrow. 
Median survival in PNH is 10 to 15 years after diagnosis, with a wide range (Brodsky, 2009). 
Men and women are affected equally and there is no familial tendency. Thrombophilia is a 
major cause of morbidity and mortality in PNH (Hillmen et al. 1995; Socie G et al. 1996). 
About 40% of patients with PNH experience a thrombotic event during the course of disease 
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depend on the presence of normal stem cells capable of regenerating the bone marrow  
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every 6 to 12 months.  Patients with PNH have an impaired quality of life in comparison 
with the general population. They suffer from chronic fatique, which seriously compromises 
their professional and personal lives (Moyo VM et al. 2004). Patients with chronic hemolysis 
complain of lethargy, malaise, myalgia (Clark DA et al. 1981). The dysphagia and male 
impotence of PNH appear related to hemolysis (Rosse WF 2000).  
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engineered Fc portion that is a hybrid of IgG2 and IgG4 designed to have no downstream 
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thus activation of C5 (Hillmen, 2008). Eculizumab is highly effective in reducing 
intravascular hemolysis in PNH, but it does not stop extravascular hemolysis, and it does 
not treat the bone marrow failure. Thus treatment with eculizumab is most effective in 
patients with classic PNH- it decreases or eliminates the need of blood transfusion, reduces 
the risk of thrombosis and improves quality of life (Hillmen et al. 2007; Hillmen et al. 2006; 
Brodsky RA 2008). Eculizumab has been approvated by FDA for PNH treatment in 2007. 
Thrombosis is an absolute indication for initiating treatment with eculizumab (Brodsky 
2009). Some authors recommend eculizumab for patients with disabling fatigue, transfusion 
dependency, frequent painful paroxysms, renal insufficiency. Watchful waiting is 
appropriate for asymptomatic patients or those with mild symptoms (Brodsky and Jones, 
2005; Young 2002). Eculizumab therapy shouldn’t be initiated in patients with unresolved 
serious Neisseria menigitidis infection and who are not currently vaccinated against it. 
Eculizumab is administered intravenously at a dose of 600mg weekly for first 4 weeks, then 
900mg biweekly starting on week 5 (Brodsky 2009). Eculizumab is generally well tolerated, 
but the most frequent adverse events observed in clinical studies were: headache, 
nasopharyngitis, back pain, nausea and fatique. Eculizumab increases risk of meningococcal 
infections, so ideally patients should be vaccinated 2 weeks before commencing eculizumab 
and re-vaccinated every 2 to 3 years. Patients also need to be instructed to contact doctor 
immediately if they develop any symptoms suggesting meningococcal infection, such as 
very high temperatures, a hemorrhagic rash or neck stiffness (Hillmen 2008).  Most patients 
with PNH who are treated with eculizumab will cease to require transfusions. This leads to 
an increase in the proportion of PNH red cells as they are not destroyed by complement nor 
diluted by transfusions (Socie G et al. 2007). In some patients the proportion of PNH red 
cells may exceed 90% so if eculizumab is stopped for any reason, it may be followed by a 
sudden fall in hemoglobin and brisk hemoglobinuria. Patients who receive eculizumab must 
be educated that they cannot simply miss a scheduled dose of therapy (Hillmen, 2008). 
Prophylaxis against thromboembolic events in patients with PNH is an issue of debate 
among members of the International PNH Interests Group (Moyo VM et al. 2004; Nishimura 
et al. 2004; Clark DA et al 1981;  Sloand EM, 2000). The relatively high risk of a 
thromboembolic complications justifies prophylaxis with warfarin in PNH when over 50% 
granulocytes are GPI-AP deficient and there are no contraindications to anticoagulation 
(Nishimura et al. 2004). Patients with PNH who experience a thromboembolic event should 
receive high-intensity warfarin therapy (International Normalized Ratio INR 3.0-4.0) or 
subcutaneous low molecular weight heparin (Parker et al. 2005). Prophylactic 
anticoagulation with low molecular weight heparin should be initiated in PNH patients 
with elevated D-dimer levels, during pregnancy and puerperal period  and in the 
perioperative period (Brodsky, 2009) . Patients with acute thrombotic events require 
anticoagulation with heparin. Thrombolytic therapy (McMullin et al. 1994; Sholar et al. 1985) 
or radiologic intervention (Griffith et al. 1996) should be strongly considered in patients 
with acute onset of Budd-Chiari syndrome.  
5. Hematopoietic cell transplantation 
Nowadays, the availability of option to prevent complement-dependent hemolysis by use of 
eculizumab has decreased use of allogeneic hematopoietic cell transplantation (allo-HCT) in 
PNH. Allo-HCT is the only curative and durable therapy for PNH which is still 
recommended for PNH patients with life-threatening cytopenias, hemolysis or thrombosis, 
that is not controlled with eculizumab therapy. The decision to perform allo-HCT should 
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weigh disease prognosis by incorporating known adverse prognostic factors such as 
previous history of thrombosis and/or evolution to pancytopenia, against the risk of 
transplant-related complications. Multiple transplant-related risk factors for hemolysis can 
be managed without exacerbation of hemolysis during the  procedure (Markiewicz et al. 
2006). Selection of the appropriate candidate and, equally important, the right time to 
perform allo-HCT are important questions that need to be answered (Matozs-Fernandez et 
al. 2009). The fact that the majority of patients undergoing allo-HCT usually already had an 
extensive transfusion history is an important issue. PNH patients with peripheral cytopenias 
meeting criteria for severe aplastic anemia are considered good candidates for allo-HCT. 
Allo-HCT should not be offered as initial therapy for most patients with classical PNH. 
Exceptions are patients with PNH in countries where eculizumab therapy is not available, 
primarily due to considerable cost of treatment. Although allogeneic hematopoietic cell 
transplantation (allo-HCT) offers complete cure of PNH with complete eradication of the 
PNH clone, outcomes presented in the past were controversial. Thus it is important to re-
evaluate results of allo-HCT in PNH. There are few reports on the use of allo-HCT for PNH 
and nearly all of them include small numbers of patients. Small series and reporting biases 
make assessment of transplant outcomes difficult. There are few risk factors associated with 
worse survival: occurrence of thrombosis, progression to pancytopenia, transformation to 
myelodysplastic syndrome or acute leukemia and thrombocytopenia at diagnosis. 
Transplants from siblings and especially from unrelated donors performed in the past, 
before implementation of complete allelic HLA-typing, were based on suboptimal donor-
recipient matching. Moreover, improvements of HLA typing, growing experience of 
transplant teams and better either myeloablative or reduced intensity conditioning and 
concomitant therapy with introduction of novel antimicrobial agents enabled achieving 
better outcomes of allo-HCT in PNH. Similar to other allo-HCT transplantation patients, 
younger age and the availability of a fully HLA-matched sibling donor are favorable 
prognostic factors.  
Proper choice of conditioning regimen is a very important component of treatment with 
allo-HCT. Eradication of the PNH clone has been achieved with both myeloablative and 
reduced-intensity conditioning regimens (Matozs-Fernandez et al. 2009; Suenaga et al. 2001). 
Myeloablative regimens used in PNH consisted of busulfan and cyclophosphamide or 
fludarabine, high-dose cyclophosphamide alone or together with total body irradiation (TBI) 
(Raiola et al. 2000; Woodard et al. 2001). This type of conditioning has been associated with 
high treatment-related mortality, high-dose cyclophosphamide used alone did not exert a 
significant effect on PNH clone in the long term (Cho SG et al. 2003). In reduced-intensity 
conditioning fludarabine has been used with or without TBI or cyclophosphamide, and less 
often with cladribine, thiotepa, busulfan or  melphalan in various combinations 
(Grosskreutz C et al. 2003). In addition to conditioning anti-thymocyte globulin (ATG, 
Thymoglobuline) and alemtuzumab (Campath) are used in unrelated allo-HCT setting.  
High-dose myeloablative conditioning regimen is not required. Non-myeloablative 
regimens, capable to completely eradicate the PNH clone and thus cure PNH, may be 
preferable in younger patients seeking to maintain fertility or in patients with moderate 
organ dysfunction who may not tolerate myeloablative doses of chemotherapy. Non-
myeloablative syngeneic bone marrow transplantation did not cure the disease, suggesting 
that there is an important “graft versus PNH” effect of transplantation. The conditioning 
regimen of cyclophosphamide/ATG is recommended for patients with PNH/aplastic 
anemia. For patients with classic PNH a more myeloablative regimen is indicated, eg. 
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weigh disease prognosis by incorporating known adverse prognostic factors such as 
previous history of thrombosis and/or evolution to pancytopenia, against the risk of 
transplant-related complications. Multiple transplant-related risk factors for hemolysis can 
be managed without exacerbation of hemolysis during the  procedure (Markiewicz et al. 
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Transplants from siblings and especially from unrelated donors performed in the past, 
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Myeloablative regimens used in PNH consisted of busulfan and cyclophosphamide or 
fludarabine, high-dose cyclophosphamide alone or together with total body irradiation (TBI) 
(Raiola et al. 2000; Woodard et al. 2001). This type of conditioning has been associated with 
high treatment-related mortality, high-dose cyclophosphamide used alone did not exert a 
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regimen of cyclophosphamide/ATG is recommended for patients with PNH/aplastic 
anemia. For patients with classic PNH a more myeloablative regimen is indicated, eg. 
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radiation- or busulfan- based (Parker C et al. 2005). The rationale for use of treosulfan-
based conditioning has been its favorably low non-hematological toxicity profile and 
myeloablative efficiency demonstrated earlier in a dose-finding study (Casper J et al. 
2010). It has been reported to be safe and efficient conditioning treatment for PNH 
(Markiewicz et al. 2005). 
The primary objective of the reduced intensity conditioning (RIC) is to achieve stable 
engraftment of donor cells rather than bone marrow ablation. It provides the potentially 
curative option for patients with advanced PNH (Hegenbart U et al. 2003). The non-
myeloablative conditioning regimens consisting of fludarabine with either TBI (Grosskreutz 
C et al. 2003; Hegenbart U et al. 2003), or cyclophosphamide (Takahashi Y et al. 2004) were 
reported to have adequate potential to eliminate the PNH clone and to allow engraftment. 
Fludarabine seems to be a highly immunosuppressive nucleoside analogue that has been 
used in several reduced-intensity conditioning regimens, yielding high engraftment rates 
with minimal conditioning-related morbidity (Sirinivasan R et al. 2006). Numerous 
evidence suggests that donor alloimmune effects play a critical role in the eradication of 
PNH cells following reduced-intensity conditioning with fludarabine. Importantly, in 
vitro and in vivo data from patients undergoing fludarabine-based reduced-intensity 
conditioning have shown that allo-reactive donor T-cells recognizing minor 
histocompatibility antigens expressed on both normal and GPI-anchored protein negative 
recipient cells can eradicate PNH (Takahashi Y et al. 2004). At first PNH cells persist 
following conditioning chemotherapy, then gradual decline of GPI-negative cells takes 
place followed by conversion to full donor T-cell chimerism and disappearance of 
residual PNH cells after CsA withdrawal. Minor histocompatibility antigen-specific donor 
T-cells can be expanded from patients post-transplant with in vitro cytotoxicity against 
GPI-negative cells of recipient origin. Addition of fludarabine to cyclophosphamide and 
ATG provides additional host immunosuppression that helps to achieve engraftment in 
patients at high risk for rejection. It also enables to reduce the traditional dose of 
cyclophosphamide (200mg/kg) without compromising engraftment. Excellent 
engraftment and long-term survival has been reported in patients with PNH undergoing 
this reduced-intensity transplant approach (Sirinivasan R, 2006), especially suitable for 
heavily transfused and/or alloimmunized PNH patients. 
Overall survival for unselected PNH patients who undergo transplantation using a HLA-
matched sibling donor is in the range of 50 to 60% (Parker C et al. 2005). Acute GVHD and 
extensive chronic GVHD are reported as a major complications that may increase treatment-
related mortality after alloHCT in PNH. Chronic graft-versus host disease (GVHD) is a 
major complication of patients after allo-HCT. Acute and chronic GVHD after RIC are also 
seen and may not differ substantially from those occurring after fully ablative 
transplantation (Grosskreutz C et al. 2003). The combination of methotrexate and 
cyclosporine A appears to be superior to either agent alone in preventing acute GVHD 
(Strob R et al. 1986).  
6. Transplant centers’ experience 
There are few reports about survival after allogenic transplantation in PNH.  
The International Bone Marrow Transplantation Registry reported 2-year survival in 
recipients of HLA-identical sibling transplantation in years 1978-1995 (median age of 
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recipients was 28 years) (Saso R, 1999).  Saso et al. described 57 patients who underwent 
transplantation with myeloablative conditioning from related (n=50) und unrelated (n=7) 
donors. 19 (33,3%) died within the first 4 months from graft failure (35%), infection (15%), 
GvHD (15%), bleeding (5%) and interstitial pneumonitis or acute respiratory distress 
syndrome (30%). The majority of the deaths in this study occurred within one year of 
transplantation. Long-term survival was 56% after related and 14% after unrelated 
transplantation.  
The EBMT (European group for Blood and Marrow Transplantation) has reported 70% 
survival after allo-HCT for PNH, but only 54% met the criteria of classical PNH (Latour RP 
et al. 2008). Graft failure occurred in 6% of patients. Acute and chronic GVHD occurred in 
15% and 20% of patients, respectively. Uni-variant analysis showed better outcome in 
younger patients (less than 30 years of age) and in patients transplanted less than 2 years 
from the date of diagnosis (Piccin A et al. 2009).  
The GITMO (Gruppo Italiano Trapianto Midollo Osseo) has reported a retrospective study 
of 26 patients (median age 32 years) with PNH who received allo-HCT between 1988 and 
2006 (Santaronr et al. 2010). Median time from diagnosis to transplant was 33 months 
(range: 3-208 months). HLA-matched sibling donor were used for 22 patients, HLA-matched 
unrelated donor for 1 patient and 3 patients received cells from HLA-mismatched donors (2 
related and 1 unrelated). Myeloablative conditioning regimen (busulfan and 
cyclophosphamide) has been used in 15 patients and non-myeloablative regimen (treosulfan 
and cyclophosphamide) in 11 patients. The 10-year probability of survival was 57% for all 
patients with a median follow-up of 131 months. There has been one primary graft failure 
after myeloablative conditioning regimen and one secondary graft failure in a patient who 
received RIC allo-HCT. Both died from complications of a second transplant. Acute GVHD 
greater than stage 2 occurred in 2 of the 26 patients. The cumulative incidence of chronic 
GVHD in 20 evaluable patients was 50%, in 4 of them chronic GVHD was extensive. 
Transplant related mortality at one year was 25% in patients after myeloablative 
conditioning and 63% in patients after RIC. Three patients died of multiorgan failure after 
RIC allo-HCT from non-identical donor. 15 patients are alive with complete hematologic 
recovery and no evidence of PNH.  
21 patients with PNH or AA/PNH have received allo-HCT after treosulfan-based 
conditioning in Department of Hematology and BMT of Medical University of Silesia in 
Katowice, Poland, in years 2004-2011 (see Table 1).  
19 allo-HCTs were from 10/10 (15 pts) or 9/10 (4 pts) HLA-matched unrelated donors and 2 
from HLA-matched siblings. Median age of recipients was 28 (range 20-51) years and 
donors 33 (19-53) years, median time from diagnosis to allo-HCT was 16 (2-97) months. 
Median size of PNH clone was 90% (4%-98%) granulocytes. Indication for allo-HCT was 
aplastic/hypoplastic bone marrow (11 pts),  MDS (1 pt), severe course of PNH with 
hemolytic crises (5 pts) and transfusion-dependency (in remaining 4 pts). Additional risk 
factors were Budd-Chiari syndrome and hepatosplenomegaly (1 pt), history of renal 
insufficiency requiring hemodialyses (2 pts) and chronic hepatitis B (1 pt). The preparative 
regimen consisted of treosulfan 3x14 g/m2 plus fludarabine 5x30 mg/m2 (19 pts) or 
treosulfan 2x10 g/m2 plus cyclophosphamide 4x40 mg/kg (2 pts). Standard GVHD 
prophylaxis consisted of  cyclosporine-A, methotrexate and pre-transplant ATG or 
thymoglobulin in MUD-HCT. Source of cells was bone marrow (9 pts) or peripheral blood 
(12 pts) with median 2.9 or 11.0 x10(8)NC/kg, 2.4 or 6.2 x10(6)CD34+cells/kg, 26.2 or 266.9 
x10(6)CD3+cells/kg, respectively. Results of alloHCT are presented in Table 2. 
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Patient characteristics Mean (range)
 
Age (years) 
  Patients 




Time from diagnosis to allo-HCT (months) 16 (2-97)
 
Number of transplanted cells /kg
  Bone marrow 
      x10(8) NC 2.9 (0.5-3.9)
      x10(6) CD34+cells 2.4 (1.2-6.3)
      x10(6) CD3+cells 26.2 (1.6-266.2)
  Peripheral blood
      x10(8) NC 11.0 (4.3-16.5)
      x10(6) CD34+cells 6.2 (4.1-14.8)
      x10(6) CD3+cells
 
266.9 (21.9-712.0)
 Number of pts
Sex 
  Patients 
     Men 15 
     Women  6 
  Donors 
     Men 12
     Women  9
 
Primary indication for allo-HCT
  Aplastic/hypoplastic bone marrow  11
  Myelodysplasia  1
  Severe course of PNH with hemolytic crises  5
  Transfusion-dependency  4
 
Source of transplant
  Sibling  2
  Unrelated donor 19
 
Source of cells 
  Bone marrow 9
  Peripheral blood 12
 
Regimen 
  treosulfan 3x14 g/m2, fludarabine 5x30 mg/m2  19
  treosulfan 2x10 g/m2, cyclophosphamide 4x40 mg/kg  2
Table 1. Characteristics of donor/recipient pairs and  allo-HCT procedures for PNH in 
Department of Hematology and BMT of Silesian Medical University in Katowice, Poland, 
experience in years 2004 to 2011. 
 





Absolute agranulocytosis <0.1 G/l  (days)
 
Number of transfusions (units) 





  Platelets  6 (3-15)
 
Regeneration of hematopoiesis (days) 
  Granulocytes 1.0 G/l
 
17 (13-39)
  Platelets 50 G/l 17 (9-39)
  Hb 10 g/dl 30 (16-50)
 
LDH decrease at 30 days post-transplant 80% (5%-91%)
 
 Number of pts
 
Survival at 26 months (2-82) post-transplant
  Alive 20 (95.2%)
  Died 1 (previously hemodialysed pt) 
 
GVHD  
  Acute grade I 8
            grade II  5
            grade III 1
  Chronic, limited 7
 
Other complications
  FUO 5
  CMV reactivation 3
  Mucositis 3
  VOD 1
  Neurotoxicity 1
  Venal thrombosis 1
  Hemorrhagic cystitis 1
 
Achieving 100% donor chimerism 21 (100%)
PNH clone disappearance 21 (100%)
 
Table 2. Results of allo-HCT for PNH in Department of Hematology and BMT of Silesian 
Medical University in Katowice, Poland, experience in years 2004 to 2011. 
Myeloablation was complete in all pts with median 9 (6-13) days of absolute agranulocytosis 
<0.1 G/l. Median number of transfused RBC and platelets units was 7(0-12) and 6(3-15). All 
pts engrafted, median counts of  granulocytes 1.0 G/l, platelets 50 G/l and Hb 10 g/dl were 
achieved on days 17(13-39), 16(9-39) and 30(16-50). Acute GVHD grade I,II and III was 
present in 8, 5 and 1 pt, limited chronic GVHD in 7 pts. LDH decreased by 80%(5%-91%) in 
first 30 days indicating disappearance of hemolysis. 100% donor chimerism was achieved in 
all pts. 1 previously hemodialysed pt died on day +102 in a consequence of nephrotoxicity 
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complicating adenoviral/CMV hemorrhagic cystitis. Complications in survivors were FUO 
(5 pts), CMV reactivation (3), VOD (1), neurotoxicity (1), venal thrombosis (1), hemorrhagic 
cystitis (1) and mucositis (3). 20 pts (95.2%) are alive 16 months (2-61) post-transplant and 
are doing well without treatment. Complete disappearance of PNH clone was confirmed by 
flow cytometry in all surviving patients. We concluded that allo-HCT with treosulfan-based 
conditioning is effective and well tolerated curative therapy in PNH. 
Another novel theoretically interesting approach is related to selection of normal 
circulating CD34+/CD59+ cells with flow cytometry from PNH patients who have a 
mixed population of normal and abnormal cells for the purpose of performing autologous 
hematopoietic cell transplantation (AHCT). As yet, no case of AHCT for PNH has been 
reported (Xiao et al. 2010). 
7. Conclusion 
In conclusion, allo-HCT can be offered as an effective treatment option for PNH patients. 
Transplant-related risk factors for hemolysis can be managed without exacerbation of 
hemolysis during the procedure. Treosulfan, fludarabine and antithymocyte globulin 
treatment can be safely and effectively used for conditioning in PNH. 
Since the first report of allo-HCT performed in PNH from sibling in 1973, several questions 
related to PNH and transplantation remain unresolved.  What is the optimal time for 
alloHCT in PNH? What type of the conditioning therapy– conventional or reduced- enables 
to achieve durable cure without exacerbation of possible complications? And for what 
extend benefit of cure offered by alloHCT will defend recommendations for this method in 
the era of lifelong treatment of the disease with complement inhibitors? We are still looking 
for answers to these questions. 
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complicating adenoviral/CMV hemorrhagic cystitis. Complications in survivors were FUO 
(5 pts), CMV reactivation (3), VOD (1), neurotoxicity (1), venal thrombosis (1), hemorrhagic 
cystitis (1) and mucositis (3). 20 pts (95.2%) are alive 16 months (2-61) post-transplant and 
are doing well without treatment. Complete disappearance of PNH clone was confirmed by 
flow cytometry in all surviving patients. We concluded that allo-HCT with treosulfan-based 
conditioning is effective and well tolerated curative therapy in PNH. 
Another novel theoretically interesting approach is related to selection of normal 
circulating CD34+/CD59+ cells with flow cytometry from PNH patients who have a 
mixed population of normal and abnormal cells for the purpose of performing autologous 
hematopoietic cell transplantation (AHCT). As yet, no case of AHCT for PNH has been 
reported (Xiao et al. 2010). 
7. Conclusion 
In conclusion, allo-HCT can be offered as an effective treatment option for PNH patients. 
Transplant-related risk factors for hemolysis can be managed without exacerbation of 
hemolysis during the procedure. Treosulfan, fludarabine and antithymocyte globulin 
treatment can be safely and effectively used for conditioning in PNH. 
Since the first report of allo-HCT performed in PNH from sibling in 1973, several questions 
related to PNH and transplantation remain unresolved.  What is the optimal time for 
alloHCT in PNH? What type of the conditioning therapy– conventional or reduced- enables 
to achieve durable cure without exacerbation of possible complications? And for what 
extend benefit of cure offered by alloHCT will defend recommendations for this method in 
the era of lifelong treatment of the disease with complement inhibitors? We are still looking 
for answers to these questions. 
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High-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation 
(AHSCT) was first introduced as an experimental treatment for solid tumours in the late 
seventies (1). The basic line for such treatment was extremely simple: can grams work where 
milligrams fail? Initial data were from pediatric tumors, but soon after an incredible amount 
of data came from germ cell tumor (GCT), breast carcinoma (BC), small cell lung cancer 
(SCLC), ovarian cancer and nearly all tumor types have been treated, many of them 
reported as anecdotal.  
After more than thirty years of investigations we are now in the position of giving a lookout 
of what happened and why some questions received an answer and why others did not. The 
“rush to transplantation” in the early times led to thousands of patients (pts) treated with 
such modality, BC being the most preferred indication with nearly 2,000 pts per year in the 
late nineties only in Europe (2). Unfortunately, the vast majority of those pts have been 
treated outside clinical trials, so the level of evidence for years remained at the lowest level. 
Nevertheless some important studies have been conducted and at least for some tumor 
types some robust data have been provided.  
This article will try to clarify what happened and where we are now in this still fascinating 
and probably not exhausted field. We will first consider BC due to the huge amount of data 
available, and then other tumors for which HDC has been widely utilized. 
2. Breast cancer 
Several nonrandomized studies conducted in the eighties and early nineties demonstrated 
considerable improvements for pts with BC receiving HDC (3-5). This led to the premature 
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acceptance of HDC as a treatment option for high risk adjuvant and metastatic BC, and the 
number of transplants performed worldwide consistently increased during the nineties (2). 
By the mid-1990s, BC had become the most common indication for AHSCT in North 
America and Europe. There followed a phase of disillusion after premature reports of some 
randomized studies not showing significant overall survival (OS) benefit of HDC and after a 
case of scientific misconduct (6). The scene was set for the demise of HDC in BC, and in 
more recent years the number of procedures has diminished and in fact abandoned by the 
vast majority of Centers (7). In more recent years, new information provided from mature 
phase III trials and a metaanalysis (8-10) suggest that HDC may still have a role in 
subgroups of pts with BC. 
2.1 Adjuvant setting 
The body of evidence consists of 15 randomized studies including more than 6,200 pts 
(10,11)  Three of those have to be considered pilot or feasibility studies with less than 100 pts 
each (12-14). The Scandinavian Study by Bergh et al (15) is the only one with a poorer 
survival of the HDC arm. However, because of the unusual design of the study 
(chemotherapy (CT) in the control arm tailored to individual tolerance), pts in the control 
arm received a significantly higher total dose of CT and had a higher incidence of treatment-
related leukemia and myelodysplastic syndromes.  
Three important trials conducted in the era of peripheral blood stem cells, and comparing 
HDC with appropriate control have been recently published. The transplant-related 
mortality (TRM) in these studies ranged from 0 to 1%. The IBCSG reported a PFS advantage 
of intensified doxorubicin-cyclophosphamide regimen over conventional antracyclin-based 
CT pts with high risk of relapse harboring ER+ tumors (16). The largest study of HDC in BC, 
recently updated with a follow up of 7 years (8), has shown a clear advantage in favour of 
HDC in RFS in women with > 9 positive nodes and in OS in pts with > 3 positive nodes and 
Her2 negative tumors. Finally, Nitz et al (9) demonstrated a significant RFS and OS 
improvement in pts with high-risk BC (>9 positive nodes) with a tandem high-dose regimen 
with no treatment-related mortality.  
Some have argued that HDC have been so far compared with “old fashion” conventional 
treatments. Among new antineoplastic agents introduced in the last two decades, taxanes, 
the only ones to show additional benefit to conventional antracycline-based combinations, 
produce limited survival advantage, if any, in the higher risk population for nodal status, 
i.e. > 3 LN (17,18). Moreover, taxanes are more effective in the HER2 positive pts (17), which 
is the population not likely to benefit from HDC alkylating agents. The only targeted 
therapy currently utilized in the adjuvant setting of BC (trastuzumab) is effective (and 
approved) in HER2+ disease. It is true that taxanes and targeted therapies were not included 
in the control arms. But they were not included in the HDC arms as well 
In summary, the following considerations in the adjuvant setting can be drawn: 
1. Most of the studies of HDC show an advantage in RFS, regarded as the primary end-
point in the adjuvant setting by oncologists, while an OS benefit was observed in two 
modern trials comparing HDC with appropriate control and utilizing blood stem cells. 
2. The Dutch study (8) and the recent metaanalysis by Berry at al. (10) provide evidence 
that only pts with Her2 negative tumors do benefit from HDC. This observation 
confirms the conclusion of several retrospective analyses that Her2 positive tumors 
should probably not receive HD alkylating CT. Moreover, if one assumes that 25-30% of 
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pts in randomized studies have HER2 positive disease, these pts will not benefit from 
HDC and will in fact do worse if effective antracycline-based CT is withheld, then any 
benefit from HDC for the HER2 negative tumors will be invisible in the final outcome.  
3. While difficult to perform due to the limited interest of the pharmaceutical companies, 
future studies on HDC should concentrate on populations likely to benefit most from 
this form of therapy and on regimens with low mortality rate. 
2.2 Metastatic BC 
Individual studies have suggested that age/menopausal status, hormone-receptor status or 
HER-2/neu expression, tumor load, and chemosensitivity  may be predictive of the benefits 
of HDC (19-22).  
When looking at prospective randomized studies An equivalent or better EFS has been 
shown in all trials but, only one published as full report could demonstrate an OS advantage 
(11). A recent metaanalysis of phase III studies failed to demonstrate a survival advantage of 
HDC in MBC (23). Also for MBC it would be important to identify pts, if any, that are likely 
to benefit most from HDC. In particular, HDC appears to be effective in stage IV pts who 
were rendered free of macroscopic disease by previous therapy or in patients with 
oligometastatic disease (19,22). It clearly comes out from two large retrospective analysis 
(2,24) that a significant proportion of patients undergoing HDC after achieving response 
from conventional treatments are long term (>5 years) disease free survivors. Such results 
suggest that HDC with AHSCT can cure a subset of patients with MBC. 
Finally, as observed in the adjuvant setting, also stage IV pts with HER2 positive tumors 
derive no benefit from high-dose alkylating agents (19). It requires to be demonstrated 
whether the use of non-alkylating drugs, including taxanes, antracycline and mitoxantrone 
(24, 32), in HDC regimens might prove effective in subset of pts with HER2 positive or with 
other biological tumor characteristics (29). 
Also in the setting of metastatic disease, randomized studies in selected patient populations 
are necessary to define the exact role of HDC. 
2.3 Small cell lung carcinoma (SCLC) 
Probably due to its high chemosensitivity and its poor prognosis, SCLC has been the first 
adult tumor to be tested with HDC in a relative large number of pts. The first attempts have 
been very pioneristic, with pts usually grafted after first or subsequent lines with poor 
performance status and in a chemorefractory phase of their diseases. 
After several small studies conducted in the eighties and early nineties showing that HDC 
might have a role in selected patients (25), The EBMT launched the first and so far only 
randomized study where pts with limited and extensive disease ≤ 2 metastatic sites were 
given either conventional CT or a multiple transplant program, i.e. three high-dose ICE 
(ifosfamide, carboplatin and etoposide) shots (26). This international study, enrolling 145 pts 
(half of the planned number), showed no significantly improved 3-year PFS or OS benefit of 
increasing the dose–intensity, the peak-dose or the total dose of ICE. It is important to note 
that 9% of pts in the HDC arm died of therapy-related toxicity, a data that other than being 
unacceptable today, can per se explain the lack of favourable results of this study. 
At present the number of pts receiving HDC worldwide is anecdotal. The role of dose 
intensification in the treatment of SCLC would deserve further evaluation, taking into 
consideration also the very poor progress obtained in such tumor in the last decades and the 
so far pessimistic scenario of target therapy in this disease (27). 
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2.4 Germ cell tumors (GCT) 
Because of the extremely high chemosensitivity of GCTs, the concept of HDC in this disease 
has been rapidly developed worldwide and intensively investigated. Clinical trials have 
been performed in a variety of settings, ranging from resistant or absolute refractory disease 
to chemosensitive relapse. The role of dose-intensification with stem cell support has also 
been explored as a part of first-line strategy for patients at higher risk of recurrence. This 
issue has  been recently comprehensively reviewed by Simonelli et al (28) who suggest that 
the role of HDC in GCTs remains controversial mainly due to the heterogeneity of patient 
population and treatment approaches, the lack of well-defined prognostic variables and the 
limited number of randomized trials conducted.  
HDC with stem cell rescue cannot be proposed for poor risk patients, neither as front-line 
therapy nor as consolidation, in patients achieving response by conventional CT. The two 
randomized studies conducted in this patient population (29,30) failed to demonstrate an OS 
benefit. Albeit supported by limited data, first line “consolidation” HDCT may be 
considered in selected patients with chemosensitive primary mediastinal disase (31,32). 
Intensified treatments has been more widely investigated as a salvage therapy for patients 
with an incomplete response to initial CT and for those with relapsed GCTs. Despite the 
robust data from the Indiana group (33) and from other retrospective/phase II studies (28), 
the role of HDCT as second line treatment for relapsed GCTs, remains today uncertain. Also 
in view of the very recent data produced by Lorch et al (34), the most pressing issues in GCT 
treatment are defining standards of HDC and optimizing outcomes of salvage treatment. 
The recently proposed TIGER study, comparing four cycles of conventional dose TIP versus 
paclitaxel/ifosfamide followed by multiple HD-CE as first line salvage treatment in 
refractory/relapsed GCT patients, goes in this direction (35). HDC should be considered  a 
treatment option for patients that are (primary) refractory to platinum-based CT or for those 
with a first or further relapse (33,36,37). Multiple intensified cycles with 
carboplatin/etoposide (33,38) is recommended as the standard HD treatment also due to 
concern that using a three-drug regimen would require dose reductions of the two most 
active drugs in this setting. 
2.5 Ovarian carcinoma  
Early reports of HDC for ovarian carcinoma dealt with pts with resistant or refractory 
disease. Several small phase II studies have shown activity of HDC, but responses were 
generally short lasting (39). These early studies were extremely heterogeneous in terms of 
pts’ selection, use of chemotherapeutic agents and schedule of administration.  
Stiff et al reported a single centre experience in 100 pts with relapsed or persistent disease 
treated with various HDC regimens (40). The median OS were 9,6 and 23.1 months for pts 
with platinum-resistant and platinum-sensitive disease, respectively, leading to the 
conclusion that platinum sensitivity and tumor bulk are the two most important predictors 
of survival following HDC. Two large retrospective analyses including data from the 
European and American registries database (251 and 421 patients, respectively) suggested  a 
survival benefit in  pts receiving HDC as consolidation following conventional first line CT 
(41) or being in remission at transplant (42).  
In late 1998 the EBMT launched an international randomised trial of multi-cycle HDC in 
optimally debulked pts. Control arm consisted of 6 courses of standard dose carboplatin-
paclitaxel. Later on this study merged with a similar German trial. The final analysis of this 
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combined study included 149 patients, half of the planned population providing evidence of 
no benefit of HDC on survival (43).  Two other randomised trials, conducted by the 
Gynaecological Oncology Group and by a Finnish group closed early due to poor 
recruitment. At present no HDC studies are ongoing in ovarian cancer. 
2.6 Sarcoma 
In soft tissue sarcoma (STS) several phase I and II studies have been conducted (39, 44) but, 
because of the heterogeneity of study population and histology, no evidence-based 
conclusions could be extrapolate. Recently, the only randomized study to date has been 
published by the French sarcoma group. This trial failed to show an OS advantage for 
advanced STS patients treated with dose-intensified chemotherapy with stem cell support (45). 
In the highly chemosensitive Ewing family of tumors (EFT), a rare disease in adults, data are 
far more convincing both in locally advanced and metastatic disease (46-48). First line EFT 
pts with good responding disease, i.e. complete-partial response, as well as patients with 
sensitive relapse are good candidates to be considered for HDC, whenever possible within 
controlled studies.  
Finally, evidence of HDC role in rhabdomyosarcomas and osteosarcomas is still missing (49,50).  
3. Conclusion 
What we can take from the bulk of clinical studies performed over the last 30 years, which 
unfortunately include a limited number of randomized studies, is that greatly increasing the 
total dose of CT may prove effective in subgroup of pts with defined clinical and biological 
characteristics, as suggested for BC. Many oncologists believe that is not quite enough and 
suggest that this approach should cease while we entered the era of targeted therapies (51). 
However, such a conclusion could be just as premature and thoughtless as the uncritical use 
of HDC that was so common 15 years ago.  
HDC with AHSCT has become a safe and reasonably well-tolerated treatment modality (52) 
that can even be administered in the outpatient setting. Moreover, the prognosis of solid 
tumors discussed in this article has changed very little in the past decades, as novel targeted 
therapies had a clear impact only in the subset of pts with BC overexpressing HER2 (53,54).  
We believe that, instead of simply giving up on a potential treatment modality, it is more 
logical and practical to refine and improve this existing therapy in addition to developing 
new approaches in the clinical trial setting (55). Improvement of treatment of solid tumor 
may well come, in the future, by integrating intensified CT, being per-se capable of 
remarkable and rapid tumor regression, with novel treatment strategies (i.e. 
immunotherapy or target-specific therapy) for their potential to eliminate residual disease 
(56,57) 
In conclusion, data available to date do not support, outside controlled trials, the use of 
HDC with AHSCT for solid tumors in adults, with the possible exception of highly selected, 
well informed pts with GCTs, BC and EFT.  
4. References 
[1] Skipper HE. Dose intensity versus total dose of chemotherapy: An experimental basis. 
In: De Vita VT, Hellman S, Rosenberg SA eds. Important Advances in Oncology. 
Philadelphia Lippincott, 1990, pp 43-64. 
 
New Advances in Stem Cell Transplantation 
 
374 
2.4 Germ cell tumors (GCT) 
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limited number of randomized trials conducted.  
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benefit. Albeit supported by limited data, first line “consolidation” HDCT may be 
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of survival following HDC. Two large retrospective analyses including data from the 
European and American registries database (251 and 421 patients, respectively) suggested  a 
survival benefit in  pts receiving HDC as consolidation following conventional first line CT 
(41) or being in remission at transplant (42).  
In late 1998 the EBMT launched an international randomised trial of multi-cycle HDC in 
optimally debulked pts. Control arm consisted of 6 courses of standard dose carboplatin-
paclitaxel. Later on this study merged with a similar German trial. The final analysis of this 
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combined study included 149 patients, half of the planned population providing evidence of 
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remarkable and rapid tumor regression, with novel treatment strategies (i.e. 
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1. Introduction 
The prognosis of malignant solid tumors in children has been improved by 
multidisciplinary therapy involving surgery, radiotherapy and chemotherapy. High-dose 
chemotherapy (HDC) followed by autologous (Auto) or allogeneic (Allo) hematopoietic 
stem cell transplantation (HSCT) has contributed significantly to improvements in the 
prognosis of high-risk chemosensitive tumors. It has been utilized in many kinds of 
pediatric malignancies, not only hematopoietic tumors but also solid tumors such as 
neuroblastoma, brain tumors, Ewing’s sarcoma, osteosarcoma, Wilms’ tumor, 
rhabdomyosarcoma, hepatoblastoma, and retinoblastoma.  Fig, 1 shows the numbers of 
cases in which HSCT was used for pediatric solid tumors in Japan. When HSCT is utilized in 
patients with malignant solid tumors, there are several treatment objectives. First, it can be 
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Fig. 1. The number of hematopoietic stem cell transplants for pediatric solid tumors in Japan. 
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conventional therapies. Second, it can be used in refractory or relapsed disease when 
conventional doses of anti-tumor drugs may have not reached or killed tumor cells. Third, it 
can be used for the immunological effect of Allo HSCT. Allo HSCT grafts sometimes have 
immunological anti-tumor effects called graft versus tumor (GVT) effects. Non-
myeloablative conditioning regimens with Allo HSCT for solid tumors are one such 
example. Furthermore, tandem HSCT to increase dose intensity and HSCT with targeted 
radionuclide therapy have been studied clinically. In this chapter, I review the literature on 
HSCT for malignant solid tumors, especially non-hematopoietic tumors in children 
according to tumor type and consider future therapy. 
Fig. 1. The Japan Society for Hematopoietic Cell Transplantation Office of Nationwide 
Survey, (March 2011), The Japan Society for Hematopoietic Cell Transplantation Annual Report of 
Nationwide Survey 2010, p. 60  
2. Neuroblastoma 
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. The 
prognostic indicators of NB are age at diagnosis, tumor stage as classified by the 
International NB Staging System (INSS) (Brodeur et al., 1993), amplification of the MYCN 
oncogene (Brodeur et al., 1984), and histological findings (Shimada et al., 1999). HSCT has 
been performed for high-risk NB, characterized as stage IV by INSS, stage III with other 
negative prognostic factors e.g. unfavorable histology (Shimada system), or any stage with 
amplification of the MYCN oncogene (Matthay et al., 1999; Weinstein et al., 2003). 
2.1 Stem cell sources for HSCT in NB 
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) 
following mobilization by granulocyte colony-stimulating factor (G-CSF) are available for 
Auto HSCT in patients with NB (Fish & Grupp, 2008). Since NB cells infiltrate the bone 
marrow (BM) more frequently than peripheral blood (Cohn et al., 1997; Trager et al., 2003), 
and PB stem cells provide faster hematopoietic recovery, PB stem cells are used more often 
than BM cells in Auto HSCT (Fish & Grupp, 2008). Allo umbilical cord blood transplantation 
(CBT) from an unrelated donor, as well as Allo BMT or PBSCT, have also been performed in 
NB patients (Vanlemmens et al., 1992; Wagner, 1993). 
2.2 CD34+ positive selection of HSCT for NB 
Since minimal residual disease (MRD) in PBSC, as evaluated by anti-GD2 
immunofluorescence or tyrosine hydroxylase reverse transcriptase-polymerase chain 
reaction (RT-PCR), is one of the prognostic factors of NB, the positive selection of CD34+ 
Auto PB stem cells has been studied in NB (Marabelle et al., 2011). MRD has been shown to 
exist in the CD34 negative fraction with most NB cells removed by the selection. CD34+ 
positive selection does not affect long-term hematopoiesis although immune recovery is 
delayed. Treatment with 13-cis-retinoic acid therapy after HSCT is thought to be effective for 
MRD (Marabelle et al., 2011). 
2.3 Conditioning regimens of HSCT for NB 
As a preparative regimen prior to Auto or Allo HSCT for patients with NB, fractionated 
total body irradiation (TBI) or local irradiation is often utilized (Kushner et al., 1991). TBI-
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containing regimens to treat NB have acceptable toxicity and are as effective as non-TBI 
preparative regimens (Kamani et al., 1996; McCowage et al., 1995). Patients who receive TBI 
have long-term adverse effects such as growth failure (Hovi et al., 1999) and severe 
disturbances of dental development (Holtta et al., 2002) more often than patients who 
receive non-TBI-containing regimens. Many kinds of regimens, especially melphalan-based 
regimens with or without TBI, have been studied as conditioning regimens for Auto HSCT 
in high-risk NB patients (Yalcin et al., 2011). Recently, a study of 36 patients with high-risk 
NB (median age at transplantation: 3 years, range: 0.7–14 years) who received high-dose 
busulfan and melphalan as the conditioning regimen for Auto HSCT was reported. No toxic 
deaths were observed. With a median follow-up of 55 months, progression-free survival 
(PFS) was 57 ± 9% for the whole group and patients who achieved early complete remission 
(CR) following transplantation (3 months post-transplantation) had a better outcome than 
those who did not (PFS: 91 ± 6% vs. 9 ± 8%). They also showed younger patients with no 1p 
deletions had better outcomes (Molina et al., 2011). 
2.4 Randomized studies of HSCT for NB 
The Children’s Cancer Group (CCG) in the US first reported a randomized trial involving 
Auto HSCT.  High-risk NB patients between 1 to 18 years of age who received five cycles of 
initial chemotherapy (doxorubicin 30 mg/m2, etoposide 100 mg/m2 daily for 2 days, and 
cyclophosphamide 1000 mg/m2 daily for 2 days) who showed no disease progression were 
randomized to myeloablative therapy (carboplatin 1000 mg/m2, etoposide 640 mg/m2, 
melphalan 140 mg/m2), TBI (333 cGy daily for 3 days), or to three cycles of continuation 
chemotherapy (cisplatin 160 mg/m2, etoposide 500 mg/m2 and doxorubicin 40 mg/m2). The 
mean event-free survival (Fangusaro et al.) rate three years after randomization was 
significantly better among the 189 patients who were assigned to undergo transplantation 
than among the 190 patients assigned to receive conventional chemotherapy (34 ± 4% vs. 22 
± 4%, p = 0.034) (Matthay et al., 1999) . 
There are two reported randomized trials from Europe. The European NB Study Group 
(ENSG) demonstrated the value of melphalan myeloablative therapy. In their study, 167 
children with stage III or IV (44 stage III and stage IV from 6 to 12 month old at diagnosis, 
123 stage IV > 1 years old) were treated by initial induction chemotherapy consisting of 
vincristine, cisplatin, epipodophyllotoxin, and cyclophosphamide and surgical excision of 
the primary tumor. Ninety patients were achieved complete or good partial responses, and 
then 65 (72%) children were actually randomized either to high-dose melphalan (180 
mg/m2) with Auto bone marrow support or to no further treatment. The 5-year EFS with 
median follow-up from randomization of 14.3 years was 38% (95% confidence interval (CI): 
24–54%) in the melphalan-treated group and 27% (95% CI: 12–42%) in the group who did 
not receive melphalan. Although this difference was not statistically significant, the outcome 
of 48 randomized stage IV patients >1 year at diagnosis was significantly better in the 
melphalan-treated group (5-year EFS 33% vs. 17%, p = 0.01) (Pritchard et al., 2005). 
In Germany, a randomized study involving myeloablative HDC with Auto HSCT versus 
oral maintenance chemotherapy was conducted. Two hundred and ninety-five patients with 
high-risk NB (i.e. stage IV or MYCN amplified tumors) were randomly assigned to 
myeloablative HDC (melphalan, etoposide, and carboplatin) with Auto HSCT (n = 149) or 
oral maintenance chemotherapy with cyclophosphamide (n = 146). The 3-year EFS in the 
HDC group (47%, 95% CI: 38–55%) was better than that (30%, 95% CI: 45–62%) in the oral 
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maintenance therapy group (p = 0.0221), but there was no difference in overall survival (OS) 
(62%; 95% CI: 54–70% vs. 53%; 95% CI: 45–62%; p = 0.0875). In the HDC group, five patients 
died from acute complications related to HDC, but no patients on oral maintenance therapy 
died from acute treatment-related toxic effects (Berthold et al., 2005). 
2.5 MYCN Amplification in NB and HSCT 
In patients with stage II or III neuroblastoma with MYCN amplification, the prognosis of 
patients who received high-dose busulfan (600 mg/m2) and melphalan (140 mg/m2) (n = 12) 
is better than that of patients who received conventional chemotherapy (carboplatin, 
etoposide, vincristine, cyclophosphamide, and doxorubicin), radiotherapy, or both (n = 20). 
The 6-year OS was significantly different (25 ± 10% vs. 83 ± 11%; p = 0.004) (Laprie et al., 
2004). 
2.6 Tandem HSCT for NB 
Scheduled multiple cycles of (tandem) Auto HSCT for high-risk NB were reported first by 
Philip et al. They used two different regimens for advanced NB and harvested bone marrow 
twice before and after first BMT. The harvested bone marrow cells were purged in vitro by 
an immunomagnetic technique. The first regimen was a combination of tenoposid, 
carmustine, and cisplatinium (or carboplatin). The second regimen consisted of vincristine, 
melphalan, and TBI. This double HSCT achieved a prolonged relapse free survival (Philip et 
al., 1993). There are several reports of double Auto HSCT with one course of TBI (George et 
al., 2006; Sung et al., 2007) or without TBI (Grupp et al., 2000). Central nervous system 
relapse and secondary malignancies are rare in patients who receive tandem HSCT (George 
et al., 2006), although there is an increase in treatment-related deaths after the second HSCT 
(Grupp et al., 2000; Sung et al., 2007) and a higher rate of late adverse effects including 
growth hormone deficiency, dental problems, osteochondromas, and hearing deficiencies 
(Hobbie et al., 2008). Children’s Healthcare of Atlanta performed a study comparing single 
versus tandem HSCT for high-risk NB. There were 28 patients who received a single HSCT 
and 56 who received tandem HSCT. Tandem HSCT had a significantly improved 4-year EFS 
(59.3 ± 6.7% vs. 26.8 ± 9.2%, p = 0.01) and OS (70.6 ± 9.2% vs. 44.7 ± 11.2%, p = 0.06) when 
compared with single HSCT (Qayed et al., 2011). 
Triple-tandem HDC with PBSCT for high-risk NB was reported by two different groups. 
The conditioning regimens of the first first consisted of two courses of carboplatin (667 
mg/m2 daily for 2 days) and etoposide (1000 mg/m2 daily for 2 days) following one course 
of thiotepa (300 mg/m2 daily for 3 days) and cyclophosphamide (60 mg/kg daily for 3 
days). Seventeen patients were able to complete all three cycle of HSCT. The 3-year EFS and 
survival were 57 ± 11% and 79 ± 10%, respectively (Kletzel et al., 2002). The study by the 
Children’s Oncology Group in the US involved patients with stage IV NB receiving three 
cycles of interpatient dose escalating carboplatin (800 to 1000 mg/m2), cyclophosphamide (4 
g/m2) and etoposide (600 mg/m2). The overall 3-year EFS and OS rates were 20 ± 10% and 
26 ± 11%, respectively (Bensimhon et al., 2010). 
2.7 Allo HSCT for NB 
Allo HSCT with TBI for NB has been attempted more than a quarter century ago (August et 
al., 1984). Although the graft contains no contamination of tumor cells, initial studies of 
conventional Allo HSCT failed to show a clear clinical benefit with a high ratio of treatment-
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related mortality (TRM) and graft versus host diseases (GVHD) (Evans et al., 1994; 
Ladenstein et al., 1994; Matthay et al., 1994). However, the development of supportive care 
and the establishment of Allo HSCT for leukemia had renewed interest in Allo immunity for 
various malignant cells that is described as a graft versus tumor effect (GVT) (Pedrazzoli et 
al., 2002). Cytotoxic T-lymphocytes can target antigens found on malignant cells. These 
antigens include linage-restricted antigens found on tumors of similar origin and on related 
normal cells (e.g., GD2 ganglioside expressed in NB), antigens found on tumors of different 
origins but not on normal tissue, and tumor-specific antigens produced by mutant genes 
within the tumor (Navid et al., 2009).  
Clinical GVT was first described in a patient with NB who received HSCT from a HLA 
haplo-identical donor. Although the patient received further chemotherapy after the Allo 
HSCT and the response was not correlated to GVHD, the patient entered and sustained 
complete remission for 4 years (Inoue et al., 2003). A more recent report shows clinical GVT 
for NB is correlated with GVHD in a patient who underwent a reduced intensity Allo HSCT 
(Marabelle et al., 2007). In mice, efficient GVT for NB could be induced by donor 
lymphocyte infusion or immunomodulation with dendritic cells after Allo HSCT in the 
absence of GVHD (Ash et al., 2009; Ash et al., 2010). Allo CBT for NB was also performed 
since the early 1990s in three patients with advanced NB with highly amplified MYCN 
(Vanlemmens et al., 1992; Wagner, 1993). After receiving Auto HSCT followed by Allo CBT, 
they have maintained disease-free survival (DFS) for 37 to 60 months without severe acute 
complications (Goi et al., 2011). Recently, a reduced-intensity conditioning regimen 
(cyclophosphamide 50 mg/kg, fludarabine 40 mg/m2 daily for two days, TBI 200 cGy, and 
rabbit anti-thymocyte globulin 2.5 mg/kg daily for two days) followed by unrelated CBT 
was studied for patients with relapsed NB. Although all patients progressed after transplant 
(median: 55 days, range: 26 to 180 days), natural killer (NK) cell counts were normal within 
2 months with no evidence of GVHD, whereas the T-cell recovery was slower. These results 
show the possibility of treating patients with MRD after transplant with less intensive 
immunosuppression and adding NK-cell based post-transplant immunotherapy (Jubert et 
al., 2011). 
2.8 Radioactive Iodine therapy with HSCT for NB 
The norepinephrine analog metaiodobenzylguanidine (MIBG) is selectively accumulated in 
sympathetic nervous tissue, and several clinical studies of high dose iodine-131-labeled 
MIBG (131I-MIBG) in combination with myeloablative chemotherapy and Auto HSCT for the 
treatment of NB were performed. Although this regimen has acceptable toxicity (Yanik et 
al., 2002), six of 22 assessable patients had complete or partial remission and the 3-year EFS 
and survival rates were 31% ± 10% and 58% ± 10% (Yanik et al., 2002).  A case of 131I-MIBG 
therapy with reduced intensity Allo HSCT in recurrent extensive neuroblastoma was also 
reported. This patient achieved remission which was maintained for 3 months after 
transplantation (Takahashi et al., 2008). A study of high-dose 131I-MIBG with T cell-depleted 
haplo-identical HSCT and post-transplant immunotherapy in children with relapsed or 
refractory NB shows durable remission. All five patients in this study had no acute GVHD 
and four patients who received additional treatment with donor lymphocyte infusion (DLI) 
developed controllable chronic GVHD after DLI. Analysis of immunologic recovery showed 
a fast reappearance of NK- and T-cells. Two patients are alive with no evidence of disease 40 
and 42 months after transplantation (Toporski et al., 2009). A phase I trial in which patients 
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maintenance therapy group (p = 0.0221), but there was no difference in overall survival (OS) 
(62%; 95% CI: 54–70% vs. 53%; 95% CI: 45–62%; p = 0.0875). In the HDC group, five patients 
died from acute complications related to HDC, but no patients on oral maintenance therapy 
died from acute treatment-related toxic effects (Berthold et al., 2005). 
2.5 MYCN Amplification in NB and HSCT 
In patients with stage II or III neuroblastoma with MYCN amplification, the prognosis of 
patients who received high-dose busulfan (600 mg/m2) and melphalan (140 mg/m2) (n = 12) 
is better than that of patients who received conventional chemotherapy (carboplatin, 
etoposide, vincristine, cyclophosphamide, and doxorubicin), radiotherapy, or both (n = 20). 
The 6-year OS was significantly different (25 ± 10% vs. 83 ± 11%; p = 0.004) (Laprie et al., 
2004). 
2.6 Tandem HSCT for NB 
Scheduled multiple cycles of (tandem) Auto HSCT for high-risk NB were reported first by 
Philip et al. They used two different regimens for advanced NB and harvested bone marrow 
twice before and after first BMT. The harvested bone marrow cells were purged in vitro by 
an immunomagnetic technique. The first regimen was a combination of tenoposid, 
carmustine, and cisplatinium (or carboplatin). The second regimen consisted of vincristine, 
melphalan, and TBI. This double HSCT achieved a prolonged relapse free survival (Philip et 
al., 1993). There are several reports of double Auto HSCT with one course of TBI (George et 
al., 2006; Sung et al., 2007) or without TBI (Grupp et al., 2000). Central nervous system 
relapse and secondary malignancies are rare in patients who receive tandem HSCT (George 
et al., 2006), although there is an increase in treatment-related deaths after the second HSCT 
(Grupp et al., 2000; Sung et al., 2007) and a higher rate of late adverse effects including 
growth hormone deficiency, dental problems, osteochondromas, and hearing deficiencies 
(Hobbie et al., 2008). Children’s Healthcare of Atlanta performed a study comparing single 
versus tandem HSCT for high-risk NB. There were 28 patients who received a single HSCT 
and 56 who received tandem HSCT. Tandem HSCT had a significantly improved 4-year EFS 
(59.3 ± 6.7% vs. 26.8 ± 9.2%, p = 0.01) and OS (70.6 ± 9.2% vs. 44.7 ± 11.2%, p = 0.06) when 
compared with single HSCT (Qayed et al., 2011). 
Triple-tandem HDC with PBSCT for high-risk NB was reported by two different groups. 
The conditioning regimens of the first first consisted of two courses of carboplatin (667 
mg/m2 daily for 2 days) and etoposide (1000 mg/m2 daily for 2 days) following one course 
of thiotepa (300 mg/m2 daily for 3 days) and cyclophosphamide (60 mg/kg daily for 3 
days). Seventeen patients were able to complete all three cycle of HSCT. The 3-year EFS and 
survival were 57 ± 11% and 79 ± 10%, respectively (Kletzel et al., 2002). The study by the 
Children’s Oncology Group in the US involved patients with stage IV NB receiving three 
cycles of interpatient dose escalating carboplatin (800 to 1000 mg/m2), cyclophosphamide (4 
g/m2) and etoposide (600 mg/m2). The overall 3-year EFS and OS rates were 20 ± 10% and 
26 ± 11%, respectively (Bensimhon et al., 2010). 
2.7 Allo HSCT for NB 
Allo HSCT with TBI for NB has been attempted more than a quarter century ago (August et 
al., 1984). Although the graft contains no contamination of tumor cells, initial studies of 
conventional Allo HSCT failed to show a clear clinical benefit with a high ratio of treatment-
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related mortality (TRM) and graft versus host diseases (GVHD) (Evans et al., 1994; 
Ladenstein et al., 1994; Matthay et al., 1994). However, the development of supportive care 
and the establishment of Allo HSCT for leukemia had renewed interest in Allo immunity for 
various malignant cells that is described as a graft versus tumor effect (GVT) (Pedrazzoli et 
al., 2002). Cytotoxic T-lymphocytes can target antigens found on malignant cells. These 
antigens include linage-restricted antigens found on tumors of similar origin and on related 
normal cells (e.g., GD2 ganglioside expressed in NB), antigens found on tumors of different 
origins but not on normal tissue, and tumor-specific antigens produced by mutant genes 
within the tumor (Navid et al., 2009).  
Clinical GVT was first described in a patient with NB who received HSCT from a HLA 
haplo-identical donor. Although the patient received further chemotherapy after the Allo 
HSCT and the response was not correlated to GVHD, the patient entered and sustained 
complete remission for 4 years (Inoue et al., 2003). A more recent report shows clinical GVT 
for NB is correlated with GVHD in a patient who underwent a reduced intensity Allo HSCT 
(Marabelle et al., 2007). In mice, efficient GVT for NB could be induced by donor 
lymphocyte infusion or immunomodulation with dendritic cells after Allo HSCT in the 
absence of GVHD (Ash et al., 2009; Ash et al., 2010). Allo CBT for NB was also performed 
since the early 1990s in three patients with advanced NB with highly amplified MYCN 
(Vanlemmens et al., 1992; Wagner, 1993). After receiving Auto HSCT followed by Allo CBT, 
they have maintained disease-free survival (DFS) for 37 to 60 months without severe acute 
complications (Goi et al., 2011). Recently, a reduced-intensity conditioning regimen 
(cyclophosphamide 50 mg/kg, fludarabine 40 mg/m2 daily for two days, TBI 200 cGy, and 
rabbit anti-thymocyte globulin 2.5 mg/kg daily for two days) followed by unrelated CBT 
was studied for patients with relapsed NB. Although all patients progressed after transplant 
(median: 55 days, range: 26 to 180 days), natural killer (NK) cell counts were normal within 
2 months with no evidence of GVHD, whereas the T-cell recovery was slower. These results 
show the possibility of treating patients with MRD after transplant with less intensive 
immunosuppression and adding NK-cell based post-transplant immunotherapy (Jubert et 
al., 2011). 
2.8 Radioactive Iodine therapy with HSCT for NB 
The norepinephrine analog metaiodobenzylguanidine (MIBG) is selectively accumulated in 
sympathetic nervous tissue, and several clinical studies of high dose iodine-131-labeled 
MIBG (131I-MIBG) in combination with myeloablative chemotherapy and Auto HSCT for the 
treatment of NB were performed. Although this regimen has acceptable toxicity (Yanik et 
al., 2002), six of 22 assessable patients had complete or partial remission and the 3-year EFS 
and survival rates were 31% ± 10% and 58% ± 10% (Yanik et al., 2002).  A case of 131I-MIBG 
therapy with reduced intensity Allo HSCT in recurrent extensive neuroblastoma was also 
reported. This patient achieved remission which was maintained for 3 months after 
transplantation (Takahashi et al., 2008). A study of high-dose 131I-MIBG with T cell-depleted 
haplo-identical HSCT and post-transplant immunotherapy in children with relapsed or 
refractory NB shows durable remission. All five patients in this study had no acute GVHD 
and four patients who received additional treatment with donor lymphocyte infusion (DLI) 
developed controllable chronic GVHD after DLI. Analysis of immunologic recovery showed 
a fast reappearance of NK- and T-cells. Two patients are alive with no evidence of disease 40 
and 42 months after transplantation (Toporski et al., 2009). A phase I trial in which patients 
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with refractory or relapsed NB received double 131I-MIBG infusions (target red marrow 
radiation index ranged from 22 to 50 mCi/kg) at 2-week intervals with Auto HSCT 2 weeks 
after the second dose was reported. This regimen had no dose-limiting toxicities and dose 
intensification of 131I-MIBG. The PFS at 6 and 12 months was 57 ± 11% and 33 ± 11%, 
respectively (Matthay et al., 2009).  
3. Brain tumors 
Brain tumors are the most common pediatric malignant tumors with various types and 
various grades of malignancy. Recent advances in multidisciplinary treatment have 
improved the OS of pediatric brain tumors, especially chemotherapy-sensitive high-grade 
malignant tumors such as medulloblastoma (MB) or primitive neuroectodermal tumors 
(PNET). Many studies of HSCT were undertaken for high-grade pediatric brain tumors that 
are both chemotherapy-sensitive and resistant. Initial HSCT studies for high-grade glioma 
and ependymoma, which are relatively chemotherapy-resistant, failed to show an efficient 
clinical effect (Grill et al., 1996; Kalifa et al., 1992), although HSCT for patients with high-risk 
MB played an important role in improving survival (Gajjar & Pizer, 2010). Recently, 
molecular targeted therapies for adult high-grade gliomas and various grades of pediatric 
glioma or ependymoma are being studied (Tsuruta et al., 2011a). The combination of 
molecular therapy and HSCT may be of special interest in such chemotherapy-resistant 
cases. 
3.1 Conditioning regimens & stem cell sources of HSCT for brain tumors 
Until the early 1990's, high-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) based 
regimens followed by Auto BMT were utilized for high-risk brain tumors, especially for 
high-grade glioma in adults. In 1979, the first use of intensive BCNU and Auto BMT for 
brain tumors was reported with doses of 900 mg/m2 and 1500 mg/m2 (Phillips et al., 1979). 
Subsequent reports of single treatment BCNU showed the limiting dose of BCNU ranges 
from 600 to 1,200 mg/m2 (Hochberg et al., 1981; Phillips et al., 1983). Although several 
studies of high-dose BCNU treatment for high-grade glioma showed responses (Hochberg 
et al., 1981) or prolonged survival when compared with historical control groups (Johnson et 
al., 1987), the effects were thought to be limited by late toxicity (Phillips et al., 1986).  In 
France, an analysis of high-dose BCNU (800 mg/m2) single treatment followed by Auto 
HSCT (BMT = 84, PBSCT = 30) and local irradiation (60 Gy) for patients (median age, 44 
years) with supratentorial high-grade glioma (glioblastoma (GB) = 78, anaplastic 
astrocytoma (AA) = 24, anaplastic oligodendroglioma (OD) = 12) was performed. With 89 
months of median follow-up, the OS was 12 months for GB, 37 months for OD, and 81 
months for AA. There were some long-term survivors, although OS was comparable to that 
described for other treatments (Durando et al., 2003). A BCNU combination regimen (BCNU 
600 mg/m2, thiotepa 900 mg/m2, and etoposide 1,500 or 750 mg/m2) followed by BMT and 
local irradiation was studied in 42 relatively young patients (median age, 12.2 years) with 
high-risk brain tumors at 10 academic oncology centers in the US, UK, and Australia. Of 25 
(GB = 20) evaluable newly diagnosed patients, 20% achieved CR and 4% partial remission 
(PR), while 28% remained in continuing complete remission (CCR) and 44% remained with 
stable disease prior to radiation therapy Of eight (GB = 3) evaluable patients with recurrent 
disease, one (GB = 1) achieved CR and two (GB = 1) PR, while one (GB = 1) remained in 
CCR and four with stable disease for 1 to 110.2 months (Papadakis et al., 2000).  
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A Phase II study of high-dose busulfan (150 mg/m2 daily for 4 days) and thiotepa (350 
mg/m2 daily for 3 days) followed by BMT in children with recurrent brain tumors was 
designed in France.  In 20 children (median age, 6 years), five partial responses (3/6 MB, 1/5 
ependymoma, 1/2 PNET), three objective responses, ten cases of stable disease, and one 
case of progressive disease were observed, although one patient died due to toxicity. There 
were high levels of toxicity in terms of aphasia and cutaneous, hepatic, and neurological 
complications (Kalifa et al., 1992). Subsequent studies of regimens of thiotepa + etoposide, 
cyclophosphamide + melphalan, busulfan + melphalan, carboplatin + etoposide, and 
thiotepa + melphalan followed by BMT (or PBSCT) in patients with high-risk brain tumors 
reported some long-term survivors, including some patients with recurrent tumors (Finlay 
et al., 1996; Graham et al., 1997; Hara et al., 1998; Mahoney et al., 1996). In patients with 
recurrent tumors, long-term survivors usually have local recurrence, and patients with 
disseminated tumors have very poor prognosis (Graham et al., 1997)  
Recently, a study of low-dose continuous intravenous etoposide (day −22 to day −2) along 
with high-dose carboplatin (667 mg/m2 daily or area under the curve (AUC) = 9 
mg/ml/min for 3 days) and thiotepa (300 mg/m2 daily for 3 days) followed by HSCT 
conducted in patients with recurrent malignant brain tumors reported that some patients 
had long-term survival (Grodman et al., 2009). 
3.2 HSCT & type of brain tumors 
HSCT was often considered in patients with high-risk (e.g. metastatic or disseminated) or 
recurrent MB. The Children’s Cancer Group in the US reported 23 patients with recurrent 
MB who were treated with Auto HSCT and a conditioning regimen consisting of 
carboplatin, thiotepa, and etoposide. This resulted in long-term survivors; the EFS and OS 
were 34 ± 10% and 46 ± 11%, respectively, at 36 months post-HSCT (Dunkel et al., 1998). In 
Spain, 19 patients with high-risk (n = 13) and recurrent (n = 6) MB and supratentorial PNET 
were treated with high-dose busulfan and melphalan followed by Auto HSCT. The 2-year 
EFS was 38 ± 14% in all patients and 57 ± 15% for the high-risk group (Perez-Martinez et al., 
2005).  In France, high-dose busulfan and thiotepa with HSCT followed by posterior fossa 
irradiation for local MB recurrence or progression after conventional chemotherapy was 
studied in 39 children (median age at diagnosis, 31 months) and was showed to yield a high 
OS rate (68.8% at 5 years; 95% CI: 53.0–81.2%) (Ridola et al., 2007).  A risk-adapted 
craniospinal radiotherapy (23.4–39.6 Gy) followed by high-dose HSCT (St Jude 
Medulloblastoma-96) performed at St. Jude Children’s Research Hospital also showed an 
improved outcome (Gajjar et al., 2006). Patients aged < 3 years at diagnosis had a better 
outcome (Shih et al., 2008). Pre-relapse definitive radiation therapy is thought to be one of 
the prognostic factors for recurrent MB. HDC is not effective in patients with recurrent MB 
who received cranial radiation therapy prior to recurrence (Gururangan et al., 2008; 
Massimino et al., 2009). 
In the 1990s, two studies of HDC (thiotepa, busulfan, etoposide, and carboplatin) followed 
by HSCT for patients with recurrent ependymoma failed to show clinical efficacy (Grill et 
al., 1996; Mason et al., 1998). On the other hand, for patients with relapsed or progressive 
central nervous system germ cell tumors, thiotepa-based HDC regimens followed by HSCT 
were studied. Patients with germinomas have better outcomes than patients with 
nongerminomatous germ cell tumors (Modak et al., 2004).  
Central nervous system atypical teratoid/rhabdoid tumors (CNS AT/RT) are rare tumors of 
childhood with a very poor prognosis. Median survival of CNS AT/RT is less than 1 year 
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with refractory or relapsed NB received double 131I-MIBG infusions (target red marrow 
radiation index ranged from 22 to 50 mCi/kg) at 2-week intervals with Auto HSCT 2 weeks 
after the second dose was reported. This regimen had no dose-limiting toxicities and dose 
intensification of 131I-MIBG. The PFS at 6 and 12 months was 57 ± 11% and 33 ± 11%, 
respectively (Matthay et al., 2009).  
3. Brain tumors 
Brain tumors are the most common pediatric malignant tumors with various types and 
various grades of malignancy. Recent advances in multidisciplinary treatment have 
improved the OS of pediatric brain tumors, especially chemotherapy-sensitive high-grade 
malignant tumors such as medulloblastoma (MB) or primitive neuroectodermal tumors 
(PNET). Many studies of HSCT were undertaken for high-grade pediatric brain tumors that 
are both chemotherapy-sensitive and resistant. Initial HSCT studies for high-grade glioma 
and ependymoma, which are relatively chemotherapy-resistant, failed to show an efficient 
clinical effect (Grill et al., 1996; Kalifa et al., 1992), although HSCT for patients with high-risk 
MB played an important role in improving survival (Gajjar & Pizer, 2010). Recently, 
molecular targeted therapies for adult high-grade gliomas and various grades of pediatric 
glioma or ependymoma are being studied (Tsuruta et al., 2011a). The combination of 
molecular therapy and HSCT may be of special interest in such chemotherapy-resistant 
cases. 
3.1 Conditioning regimens & stem cell sources of HSCT for brain tumors 
Until the early 1990's, high-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) based 
regimens followed by Auto BMT were utilized for high-risk brain tumors, especially for 
high-grade glioma in adults. In 1979, the first use of intensive BCNU and Auto BMT for 
brain tumors was reported with doses of 900 mg/m2 and 1500 mg/m2 (Phillips et al., 1979). 
Subsequent reports of single treatment BCNU showed the limiting dose of BCNU ranges 
from 600 to 1,200 mg/m2 (Hochberg et al., 1981; Phillips et al., 1983). Although several 
studies of high-dose BCNU treatment for high-grade glioma showed responses (Hochberg 
et al., 1981) or prolonged survival when compared with historical control groups (Johnson et 
al., 1987), the effects were thought to be limited by late toxicity (Phillips et al., 1986).  In 
France, an analysis of high-dose BCNU (800 mg/m2) single treatment followed by Auto 
HSCT (BMT = 84, PBSCT = 30) and local irradiation (60 Gy) for patients (median age, 44 
years) with supratentorial high-grade glioma (glioblastoma (GB) = 78, anaplastic 
astrocytoma (AA) = 24, anaplastic oligodendroglioma (OD) = 12) was performed. With 89 
months of median follow-up, the OS was 12 months for GB, 37 months for OD, and 81 
months for AA. There were some long-term survivors, although OS was comparable to that 
described for other treatments (Durando et al., 2003). A BCNU combination regimen (BCNU 
600 mg/m2, thiotepa 900 mg/m2, and etoposide 1,500 or 750 mg/m2) followed by BMT and 
local irradiation was studied in 42 relatively young patients (median age, 12.2 years) with 
high-risk brain tumors at 10 academic oncology centers in the US, UK, and Australia. Of 25 
(GB = 20) evaluable newly diagnosed patients, 20% achieved CR and 4% partial remission 
(PR), while 28% remained in continuing complete remission (CCR) and 44% remained with 
stable disease prior to radiation therapy Of eight (GB = 3) evaluable patients with recurrent 
disease, one (GB = 1) achieved CR and two (GB = 1) PR, while one (GB = 1) remained in 
CCR and four with stable disease for 1 to 110.2 months (Papadakis et al., 2000).  
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A Phase II study of high-dose busulfan (150 mg/m2 daily for 4 days) and thiotepa (350 
mg/m2 daily for 3 days) followed by BMT in children with recurrent brain tumors was 
designed in France.  In 20 children (median age, 6 years), five partial responses (3/6 MB, 1/5 
ependymoma, 1/2 PNET), three objective responses, ten cases of stable disease, and one 
case of progressive disease were observed, although one patient died due to toxicity. There 
were high levels of toxicity in terms of aphasia and cutaneous, hepatic, and neurological 
complications (Kalifa et al., 1992). Subsequent studies of regimens of thiotepa + etoposide, 
cyclophosphamide + melphalan, busulfan + melphalan, carboplatin + etoposide, and 
thiotepa + melphalan followed by BMT (or PBSCT) in patients with high-risk brain tumors 
reported some long-term survivors, including some patients with recurrent tumors (Finlay 
et al., 1996; Graham et al., 1997; Hara et al., 1998; Mahoney et al., 1996). In patients with 
recurrent tumors, long-term survivors usually have local recurrence, and patients with 
disseminated tumors have very poor prognosis (Graham et al., 1997)  
Recently, a study of low-dose continuous intravenous etoposide (day −22 to day −2) along 
with high-dose carboplatin (667 mg/m2 daily or area under the curve (AUC) = 9 
mg/ml/min for 3 days) and thiotepa (300 mg/m2 daily for 3 days) followed by HSCT 
conducted in patients with recurrent malignant brain tumors reported that some patients 
had long-term survival (Grodman et al., 2009). 
3.2 HSCT & type of brain tumors 
HSCT was often considered in patients with high-risk (e.g. metastatic or disseminated) or 
recurrent MB. The Children’s Cancer Group in the US reported 23 patients with recurrent 
MB who were treated with Auto HSCT and a conditioning regimen consisting of 
carboplatin, thiotepa, and etoposide. This resulted in long-term survivors; the EFS and OS 
were 34 ± 10% and 46 ± 11%, respectively, at 36 months post-HSCT (Dunkel et al., 1998). In 
Spain, 19 patients with high-risk (n = 13) and recurrent (n = 6) MB and supratentorial PNET 
were treated with high-dose busulfan and melphalan followed by Auto HSCT. The 2-year 
EFS was 38 ± 14% in all patients and 57 ± 15% for the high-risk group (Perez-Martinez et al., 
2005).  In France, high-dose busulfan and thiotepa with HSCT followed by posterior fossa 
irradiation for local MB recurrence or progression after conventional chemotherapy was 
studied in 39 children (median age at diagnosis, 31 months) and was showed to yield a high 
OS rate (68.8% at 5 years; 95% CI: 53.0–81.2%) (Ridola et al., 2007).  A risk-adapted 
craniospinal radiotherapy (23.4–39.6 Gy) followed by high-dose HSCT (St Jude 
Medulloblastoma-96) performed at St. Jude Children’s Research Hospital also showed an 
improved outcome (Gajjar et al., 2006). Patients aged < 3 years at diagnosis had a better 
outcome (Shih et al., 2008). Pre-relapse definitive radiation therapy is thought to be one of 
the prognostic factors for recurrent MB. HDC is not effective in patients with recurrent MB 
who received cranial radiation therapy prior to recurrence (Gururangan et al., 2008; 
Massimino et al., 2009). 
In the 1990s, two studies of HDC (thiotepa, busulfan, etoposide, and carboplatin) followed 
by HSCT for patients with recurrent ependymoma failed to show clinical efficacy (Grill et 
al., 1996; Mason et al., 1998). On the other hand, for patients with relapsed or progressive 
central nervous system germ cell tumors, thiotepa-based HDC regimens followed by HSCT 
were studied. Patients with germinomas have better outcomes than patients with 
nongerminomatous germ cell tumors (Modak et al., 2004).  
Central nervous system atypical teratoid/rhabdoid tumors (CNS AT/RT) are rare tumors of 
childhood with a very poor prognosis. Median survival of CNS AT/RT is less than 1 year 
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with conventional therapy. One study involving high-dose carboplatin, thiotepa, and 
etoposide followed by HSCT was performed in 13 patients with CNS AT/RT after tumor 
resection and conventional chemotherapy consisting of cisplatin, vincristine, 
cyclophosphamide, and etoposide with or without high-dose methotrexate. Three of seven 
patients who received the high-dose methotrexate combined HSCT regimen had long-term 
remission (42+, 54+, and 67+ months), although they received no radiation therapy (Gardner 
et al., 2008). Trilateral retinoblastoma is also a rare brain tumor in the pineal region with 
very poor prognosis. HDC for trilateral retinoblastoma has some effect (De Ioris et al., 2010; 
Dunkel et al., 2010b), even if the tumor has relapsed (Tsuruta et al., 2011b). 
3.3 HSCT for young children with brain tumors 
HSCT is often considered for young children with newly diagnosed MB instead of radiation 
therapy because cranial irradiation in young children is thought to incur late complications 
(Kim et al., 2010).  In the US, the Memorial Sloan-Kettering Cancer Center study of HDC 
followed by Auto BMT for young children with newly diagnosed malignant brain tumors 
shortened the period of maintenance chemotherapy and reduced the risk of radiation 
therapy and had some long survivors (Mason et al., 1998). The neuropsychological findings 
of patients who received BMT revealed within low average range of intelligence (Sands et 
al., 1998). They also studied Auto BMT for young children with recurrent malignant tumors 
and showed that HDC with BMT followed by additional external-beam irradiation is 
effective for some young children with recurrent malignant tumors (Guruangan et al., 1998).  
Patients with supratentorial PNET have poor outcomes when compared to MB. HDC 
followed by HSCT in young patients with newly diagnosed supratentorial PNET provides 
improved EFS and OS and radiation therapy for these patients can sometimes be deferred or 
eliminated (Fangusaro et al., 2008). 
3.4 Tandem & allo HSCT for brain tumors 
Tandem HSCT is performed for brain tumors as well as neuroblastoma.  Two courses of 
high-dose melphalan (100 mg/m2) with PBSCT in 16 patients with cerebral PNET safely 
resulted in a high response rate, i.e. 11 PR in 14 patients with measurable disease (Vassal et 
al., 2001). A study of children with newly diagnosed MB and supratentorial PNET who were 
treated with four cycles of high-dose cyclophosphamide (4,000 mg/m2), cisplatin (75 
mg/m2), and vincristine (1.5 mg/m2 x 2) with 49 of 53 patients completing all four cycles 
and HSCT showed a 2-year PFS rate of 73.7 ± 10.5% for high-risk patients (residual tumor ≥ 
1.5 cm2 after conventional therapy) and 93.6 ± 4.7% for average-risk patients (Strother et al., 
2001). In Korea, 18 patients with high-risk solid tumors including brain tumors received two 
courses of HDC (cyclophosphamide, melphalan, thiotepa, carboplatin, etoposide, etc.) with 
HSCT. In this study, all patients with MB were alive and disease-free, although patients 
with other types of brain tumors died (Sung et al., 2003). Our case report series showed that 
double HDC consisting of melphalan and thiotepa may cure patients with primary 
disseminated MB; however, a patient with high expression of erythroblastic leukemia viral 
oncogene homolog 2 (ERBB2) relapsed (Aihara et al., 2010).  Recently, there is a report that 
single HSCT regimens have greater toxicity than ≥ 3 tandem HSCT which use milder HDC 
per HSCT cycle (Panosyan et al., 2011). 
Allo HSCT for brain tumors is still experimental, although there are case reports from 1992 
(Lundberg et al., 1992; Tsuruta et al., 2011b). An antitumor GVT effect associated with 
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chronic GVHD was observed in a patient with metastatic MB after Allo HSCT, (Secondino et 
al., 2008). 
4. Ewing’s sarcoma 
Studies of Auto BMT for patients with Ewing’s sarcoma (ES) were reported in both adults 
and children since the early 1980s. In initial studies of Auto BMT for ESwing, melphalan-
based conditioning regimens were used for disseminated or relapsed patients, with some 
achieving remission (Cornbleet et al., 1981; Graham-Pole et al., 1984). Subsequent studies of 
Auto HSCT for ES involved regimens combined with TBI or busulfan. 
4.1 TBI combined regimens for ES 
Until the 1990s, TBI-combined regimens were often utilized.  Regimens consisting of TBI (12 
Gy), melphalan, and etoposide with or without carboplatin for multi-focal or relapsed ES 
showed better outcomes (relapse-free survival 45 ± 12% at 6 years) when compared with 
historical controls (Burdach et al., 1993). For patients with high-risk ES in first CR, HSCT 
with or without TBI was associated with a DFS of 62.7 ± 11% overall and 40 ± 21.9% for 
those with metastatic disease (Madero et al., 1998).  One study of HSCT with versus without 
TBI for patients with primary metastatic (stage IV) ES (n = 171) showed improved prognosis 
(overall EFS 40% vs. 19%), although patients with pulmonary or skeletal metastases had 
especially poor outcome (EFS 27% vs. 0%) (Paulussen et al., 1998). HSCT with TBI for 
patients with ES did not improve the prognosis of patients with metastases to bone or bone 
marrow; the majority experienced relapse and died with progressive disease (Kushner & 
Meyers, 2001; Meyers et al., 2001). Recurrent ES also has a poor prognosis. However, in 
secondary remission HSCT can improve the prognosis of recurrent ES (Barker et al., 2005). 
4.2 Busulfan & melphalan regimens for ES 
Since the late 1990s busulfan has been often utilized instead of TBI. Studies of melphalan-
based conditioning regimens including busulfan were reported from several groups. In 21 
children with high-risk ES resistant to conventional therapy and recurrent disease, PBSCT 
with melphalan-based regimens did not show any benefit (Drabko et al., 2005). In a study of 
33 recurrent or progressive ES patients treated with regimens of high-dose busulfan or 
melphalan with or without TBI, some patients achieved long-term survival although the 
treatment was associated severe toxicity (McTiernan et al., 2006). In 2006, in Europe the 
benefits of high-dose busulfan (600 mg/m2) and melphalan (140 mg/m2) for ES with 
metastasis to lung or bone without bone marrow involvement were shown (Oberlin et al., 
2006). The subsequent Euro-EWING-99 trial reported an estimated 3-year EFS of 45% in 46 
children younger than 14 years with primary disseminated multifocal ES (Ladenstein et al., 
2010). Recently, an Italian and Scandinavian group showed the effectiveness of HSCT with 
busulfan and melphalan for patients with non-metastatic, poor-response ES (5-year EFS of 
HSCT and non-HSCT group was 72% and 33%) (Ferrari et al., 2011). 
4.3 Tandem HSCT for ES 
The European Intergroup Cooperative Ewing Sarcoma Study (EICESS) compared the 
regimen of HyperME (TBI 12 Gy,  melphalan 120 to 180 mg/m2, etoposide 40 to 60 mg/kg, 
and carboplatin maximum dose 1,800mg) to TandemME (two cycles of melphalan 120 to 
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with conventional therapy. One study involving high-dose carboplatin, thiotepa, and 
etoposide followed by HSCT was performed in 13 patients with CNS AT/RT after tumor 
resection and conventional chemotherapy consisting of cisplatin, vincristine, 
cyclophosphamide, and etoposide with or without high-dose methotrexate. Three of seven 
patients who received the high-dose methotrexate combined HSCT regimen had long-term 
remission (42+, 54+, and 67+ months), although they received no radiation therapy (Gardner 
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therapy because cranial irradiation in young children is thought to incur late complications 
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mg/m2), and vincristine (1.5 mg/m2 x 2) with 49 of 53 patients completing all four cycles 
and HSCT showed a 2-year PFS rate of 73.7 ± 10.5% for high-risk patients (residual tumor ≥ 
1.5 cm2 after conventional therapy) and 93.6 ± 4.7% for average-risk patients (Strother et al., 
2001). In Korea, 18 patients with high-risk solid tumors including brain tumors received two 
courses of HDC (cyclophosphamide, melphalan, thiotepa, carboplatin, etoposide, etc.) with 
HSCT. In this study, all patients with MB were alive and disease-free, although patients 
with other types of brain tumors died (Sung et al., 2003). Our case report series showed that 
double HDC consisting of melphalan and thiotepa may cure patients with primary 
disseminated MB; however, a patient with high expression of erythroblastic leukemia viral 
oncogene homolog 2 (ERBB2) relapsed (Aihara et al., 2010).  Recently, there is a report that 
single HSCT regimens have greater toxicity than ≥ 3 tandem HSCT which use milder HDC 
per HSCT cycle (Panosyan et al., 2011). 
Allo HSCT for brain tumors is still experimental, although there are case reports from 1992 
(Lundberg et al., 1992; Tsuruta et al., 2011b). An antitumor GVT effect associated with 
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chronic GVHD was observed in a patient with metastatic MB after Allo HSCT, (Secondino et 
al., 2008). 
4. Ewing’s sarcoma 
Studies of Auto BMT for patients with Ewing’s sarcoma (ES) were reported in both adults 
and children since the early 1980s. In initial studies of Auto BMT for ESwing, melphalan-
based conditioning regimens were used for disseminated or relapsed patients, with some 
achieving remission (Cornbleet et al., 1981; Graham-Pole et al., 1984). Subsequent studies of 
Auto HSCT for ES involved regimens combined with TBI or busulfan. 
4.1 TBI combined regimens for ES 
Until the 1990s, TBI-combined regimens were often utilized.  Regimens consisting of TBI (12 
Gy), melphalan, and etoposide with or without carboplatin for multi-focal or relapsed ES 
showed better outcomes (relapse-free survival 45 ± 12% at 6 years) when compared with 
historical controls (Burdach et al., 1993). For patients with high-risk ES in first CR, HSCT 
with or without TBI was associated with a DFS of 62.7 ± 11% overall and 40 ± 21.9% for 
those with metastatic disease (Madero et al., 1998).  One study of HSCT with versus without 
TBI for patients with primary metastatic (stage IV) ES (n = 171) showed improved prognosis 
(overall EFS 40% vs. 19%), although patients with pulmonary or skeletal metastases had 
especially poor outcome (EFS 27% vs. 0%) (Paulussen et al., 1998). HSCT with TBI for 
patients with ES did not improve the prognosis of patients with metastases to bone or bone 
marrow; the majority experienced relapse and died with progressive disease (Kushner & 
Meyers, 2001; Meyers et al., 2001). Recurrent ES also has a poor prognosis. However, in 
secondary remission HSCT can improve the prognosis of recurrent ES (Barker et al., 2005). 
4.2 Busulfan & melphalan regimens for ES 
Since the late 1990s busulfan has been often utilized instead of TBI. Studies of melphalan-
based conditioning regimens including busulfan were reported from several groups. In 21 
children with high-risk ES resistant to conventional therapy and recurrent disease, PBSCT 
with melphalan-based regimens did not show any benefit (Drabko et al., 2005). In a study of 
33 recurrent or progressive ES patients treated with regimens of high-dose busulfan or 
melphalan with or without TBI, some patients achieved long-term survival although the 
treatment was associated severe toxicity (McTiernan et al., 2006). In 2006, in Europe the 
benefits of high-dose busulfan (600 mg/m2) and melphalan (140 mg/m2) for ES with 
metastasis to lung or bone without bone marrow involvement were shown (Oberlin et al., 
2006). The subsequent Euro-EWING-99 trial reported an estimated 3-year EFS of 45% in 46 
children younger than 14 years with primary disseminated multifocal ES (Ladenstein et al., 
2010). Recently, an Italian and Scandinavian group showed the effectiveness of HSCT with 
busulfan and melphalan for patients with non-metastatic, poor-response ES (5-year EFS of 
HSCT and non-HSCT group was 72% and 33%) (Ferrari et al., 2011). 
4.3 Tandem HSCT for ES 
The European Intergroup Cooperative Ewing Sarcoma Study (EICESS) compared the 
regimen of HyperME (TBI 12 Gy,  melphalan 120 to 180 mg/m2, etoposide 40 to 60 mg/kg, 
and carboplatin maximum dose 1,800mg) to TandemME (two cycles of melphalan 120 to 
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140mg/m2 and etoposide 60mg/kg).  The 5-year EFS of Hyper ME and TandemME were 22 
± 8% and 29 ± 9%, respectively, while the lethal complication rate was 23% in HyperME and 
4% in TandemME (Burdach et al., 2003). A study using two cycles of alkylating agent-based 
HDC for primary metastatic bulky disease or recurrent ES showed acceptable toxicities and 
OS of 45% and EFS of 47% at 3 years, although only 65% of patients were able to proceed to 
the second cycle (Rosenthal et al., 2008).  
4.4 Allo HSCT for ES 
From EICESS, 26 cases of Auto HSCT and 10 cases of Allo HSCT for multifocal or recurrent 
advanced ES were reported. Although patients who received Allo HSCT failed to show 
allogeneic immunological effects e.g. GVT, eight of 26 cases with Auto HSCT received 
systemic interleukin-2 (IL-2) therapy after HSCT. The IL-2 group had a better EFS rate (60 ± 
18%) compared to the groups that received Allo HSCT (20 ± 13%) alone or Auto HSCT alone 
(22 ± 13%) (Burdach et al., 2000).  A case report of a 6 year-old girl with multifocal ES who 
received Allo HSCT from her HLA-matched mother showed a shrinkage of her pulmonary 
tumors and grade 1 GVHD during a taper of the immunosuppression (Lucas et al., 2008). 
Recently, reduced- versus high-intensity conditioning for Allo HSCT was compared. There 
was no improvement in survival with reduced intensity conditioning due to an increased 
rate of death caused by  disease and relapse (Thiel et al., 2011). 
5. Osteosarcoma 
The prognosis of metastatic or relapsed osteosarcoma is very poor. High-dose methotrexate 
has been used since the 1970s, but HSCT for osteosarcoma remains experimental. There are 
fewer reports of HSCT for osteosarcoma than for ES since patients with metastatic or 
recurrent disease have < 20% chance of long-term survival despite aggressive treatment 
(Chou et al., 2008). However, many kinds of new agents including antifolate compounds 
and muramyl tripeptide phosphatidylethanolamine are under investigation (Jaffe, 2009). 
The initial study of HSCT in two cases of advanced osteosarcoma failed to reveal a clinical 
effect. In 2001, the Cooperative German-Austrian-Swiss Osteosarcoma Study Group 
reported the results of HSCT in 15 patients with relapsed osteosarcoma. Three of the 15 
patients died of toxic complications and the treatment outcome was not better than with 
conventional therapy (Sauerbrey et al., 2001). A study using tandem HSCT for relapsed 
osteosarcoma by the Italian Sarcoma Group Study showed two points: only patients who are 
chemosensitive to induction treatment can obtain complete remission after HSCT, and the 
length of remission is short (Fagioli et al., 2002).  From Japan, two case reports of Allo HSCT 
for osteosarcoma were presented.  In the first case, non-myeloablative chemotherapy 
followed by PBSCT for a third CR showed a GVT effect in reduction of the metastatic lung 
lesion with GVHD (Kounami et al., 2005). In the second report, a patient with progressive 
osteosarcoma and multiple lung and bone metastases received TBI combined with 
myeloablative HCT (thiotepa 600 mg/m2 and etoposide 1,000mg/m2) followed by Allo 
BMT. The metastatic lesions successfully disappeared (Goi et al., 2006). 
6. Wilms’ tumor 
Although multidisciplinary therapies including chemotherapy improved the cure rate of 
Wilms’ tumor (WT) to approximately 80–85%, the EFS in recurrent disease was less than 
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15% before HDC with HSCT was developed (Grundy et al., 1989). Furthermore, a number of 
adverse prognostic factors related to poor outcomes during relapse have been identified and 
are used as inclusion criteria for studies involving HSCT (Dallorso et al., 2008) e.g. loss of 
heterozygosity in chromosomes 1p and 16q (Grundy et al., 2005). 
The European Bone Marrow Transplantation for Solid Tumor Registry reported a study of 
25 children with WT (12 stage IV, 5 stage III, 3 stage II, and 1 stage I) who were treated with 
Auto BMT and melphalan-based or other regimens. Of 21 recurrent cases, 13 achieved 
second or subsequent CR after Auto BMT and eight patients were event-free at 14–90 
months (Garaventa et al., 1994). High-dose melphalan, etoposide, and carboplatin (MEC) 
followed by Auto HSCT in high-risk recurrent WT patients with chemotherapy-responsive 
disease was evaluated prospectively by the French Society of Pediatric Oncology. The  DFS 
and OS at 3 years were 50 ± 17% and 60 ± 18%, respectively (Pein et al., 1998). A report of 23 
patients with high-risk WT, including 20 recurrent cases, treated with HDC including MEC 
followed by Auto HSCT in the German Cooperative Wilms Tumor Studies showed an 
estimated survival and EFS are 60.9% and 48.2% (Kremens et al., 2002).  At the Children’s 
Memorial Hospital in Chicago, one or two cycles of HSCT were tried in patients with 
relapsed WT. The EFS and OS of this study at 4 years were 60% and 73%, respectively 
(Campbell et al., 2004). A study in Italy also showed the benefit of Auto HSCT for high-risk 
relapsed WT with a 3-year DFS approaching 50% (Spreafico et al., 2008).  A meta-analysis of 
6 studies with or without HDC followed by Auto HSCT revealed that patients who only 
relapsed in the lung have a higher survival rate than those who relapsed in other locations. 
The 4-year survival rate among stage I or II patients was about 30% higher in the no HSCT 
group than the HSCT group, but the 4-year survival rate was similar in HSCT vs. no-HSCT 
in stage III and IV patients. These findings suggest that salvage chemotherapy is typically 
the better choice for relapsed WT patients, and that HSCT could be considered for stage III 
or IV patients with relapse only in the lungs (Presson et al., 2010). There is a case report 
describing a refractory case of WT with lung metastasis being cured by CBT (Massimino et 
al., 2010). There are rare case reports of WT successfully treated by HSCT, e.g. a case of third 
remission (Brown et al., 2010), a bilateral Wilms’ tumor treated without any irradiation 
(Saarinen-Pihkala et al., 1998), and an anephric pediatric case with multiple recurrent WT 
treated in conjunction with hemodialysis (Dagher et al., 1998). 
7. Rhabdomyosarcoma 
Since the end of 1990s, the prognosis of patients with localized rhabdomyosarcoma (RS) has 
improved with an EFS rate of approximately 70%. Although HDC with or without TBI 
followed by Auto or Allo HSCT has been performed for patients with metastatic or 
recurrent diseases by several groups, a retrospective multi-center analysis with 36 patients 
by the German and Austrian Pediatric Bone Marrow Transplantation Group in 1997 showed 
that the effect of HSCT was uncertain. In this study, the EFS rate at 2 years after HDC in 26 
patients who were treated with MEC with or without TBI regimen was 36 ± 7%, and none of 
the 5 patients who received Allo BMT alive (Koscielniak et al., 1997). The European 
Intergroup MMT4-89 (including 4 cycles of standard chemotherapy) and MMT4-91 
(melphalan-based HDC followed by HSCT after three courses of standard chemotherapy) 
studies on childhood metastatic RS suggested that there was prolonged survival with the 
MMT4-91 regimen (EFS and OS at 3 years were 29.7% and 40%, respectively) when 
compared with the MMT4-89 regimen (EFS and OS at 3 year were 19.2% and 27.7%, 
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140mg/m2 and etoposide 60mg/kg).  The 5-year EFS of Hyper ME and TandemME were 22 
± 8% and 29 ± 9%, respectively, while the lethal complication rate was 23% in HyperME and 
4% in TandemME (Burdach et al., 2003). A study using two cycles of alkylating agent-based 
HDC for primary metastatic bulky disease or recurrent ES showed acceptable toxicities and 
OS of 45% and EFS of 47% at 3 years, although only 65% of patients were able to proceed to 
the second cycle (Rosenthal et al., 2008).  
4.4 Allo HSCT for ES 
From EICESS, 26 cases of Auto HSCT and 10 cases of Allo HSCT for multifocal or recurrent 
advanced ES were reported. Although patients who received Allo HSCT failed to show 
allogeneic immunological effects e.g. GVT, eight of 26 cases with Auto HSCT received 
systemic interleukin-2 (IL-2) therapy after HSCT. The IL-2 group had a better EFS rate (60 ± 
18%) compared to the groups that received Allo HSCT (20 ± 13%) alone or Auto HSCT alone 
(22 ± 13%) (Burdach et al., 2000).  A case report of a 6 year-old girl with multifocal ES who 
received Allo HSCT from her HLA-matched mother showed a shrinkage of her pulmonary 
tumors and grade 1 GVHD during a taper of the immunosuppression (Lucas et al., 2008). 
Recently, reduced- versus high-intensity conditioning for Allo HSCT was compared. There 
was no improvement in survival with reduced intensity conditioning due to an increased 
rate of death caused by  disease and relapse (Thiel et al., 2011). 
5. Osteosarcoma 
The prognosis of metastatic or relapsed osteosarcoma is very poor. High-dose methotrexate 
has been used since the 1970s, but HSCT for osteosarcoma remains experimental. There are 
fewer reports of HSCT for osteosarcoma than for ES since patients with metastatic or 
recurrent disease have < 20% chance of long-term survival despite aggressive treatment 
(Chou et al., 2008). However, many kinds of new agents including antifolate compounds 
and muramyl tripeptide phosphatidylethanolamine are under investigation (Jaffe, 2009). 
The initial study of HSCT in two cases of advanced osteosarcoma failed to reveal a clinical 
effect. In 2001, the Cooperative German-Austrian-Swiss Osteosarcoma Study Group 
reported the results of HSCT in 15 patients with relapsed osteosarcoma. Three of the 15 
patients died of toxic complications and the treatment outcome was not better than with 
conventional therapy (Sauerbrey et al., 2001). A study using tandem HSCT for relapsed 
osteosarcoma by the Italian Sarcoma Group Study showed two points: only patients who are 
chemosensitive to induction treatment can obtain complete remission after HSCT, and the 
length of remission is short (Fagioli et al., 2002).  From Japan, two case reports of Allo HSCT 
for osteosarcoma were presented.  In the first case, non-myeloablative chemotherapy 
followed by PBSCT for a third CR showed a GVT effect in reduction of the metastatic lung 
lesion with GVHD (Kounami et al., 2005). In the second report, a patient with progressive 
osteosarcoma and multiple lung and bone metastases received TBI combined with 
myeloablative HCT (thiotepa 600 mg/m2 and etoposide 1,000mg/m2) followed by Allo 
BMT. The metastatic lesions successfully disappeared (Goi et al., 2006). 
6. Wilms’ tumor 
Although multidisciplinary therapies including chemotherapy improved the cure rate of 
Wilms’ tumor (WT) to approximately 80–85%, the EFS in recurrent disease was less than 
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15% before HDC with HSCT was developed (Grundy et al., 1989). Furthermore, a number of 
adverse prognostic factors related to poor outcomes during relapse have been identified and 
are used as inclusion criteria for studies involving HSCT (Dallorso et al., 2008) e.g. loss of 
heterozygosity in chromosomes 1p and 16q (Grundy et al., 2005). 
The European Bone Marrow Transplantation for Solid Tumor Registry reported a study of 
25 children with WT (12 stage IV, 5 stage III, 3 stage II, and 1 stage I) who were treated with 
Auto BMT and melphalan-based or other regimens. Of 21 recurrent cases, 13 achieved 
second or subsequent CR after Auto BMT and eight patients were event-free at 14–90 
months (Garaventa et al., 1994). High-dose melphalan, etoposide, and carboplatin (MEC) 
followed by Auto HSCT in high-risk recurrent WT patients with chemotherapy-responsive 
disease was evaluated prospectively by the French Society of Pediatric Oncology. The  DFS 
and OS at 3 years were 50 ± 17% and 60 ± 18%, respectively (Pein et al., 1998). A report of 23 
patients with high-risk WT, including 20 recurrent cases, treated with HDC including MEC 
followed by Auto HSCT in the German Cooperative Wilms Tumor Studies showed an 
estimated survival and EFS are 60.9% and 48.2% (Kremens et al., 2002).  At the Children’s 
Memorial Hospital in Chicago, one or two cycles of HSCT were tried in patients with 
relapsed WT. The EFS and OS of this study at 4 years were 60% and 73%, respectively 
(Campbell et al., 2004). A study in Italy also showed the benefit of Auto HSCT for high-risk 
relapsed WT with a 3-year DFS approaching 50% (Spreafico et al., 2008).  A meta-analysis of 
6 studies with or without HDC followed by Auto HSCT revealed that patients who only 
relapsed in the lung have a higher survival rate than those who relapsed in other locations. 
The 4-year survival rate among stage I or II patients was about 30% higher in the no HSCT 
group than the HSCT group, but the 4-year survival rate was similar in HSCT vs. no-HSCT 
in stage III and IV patients. These findings suggest that salvage chemotherapy is typically 
the better choice for relapsed WT patients, and that HSCT could be considered for stage III 
or IV patients with relapse only in the lungs (Presson et al., 2010). There is a case report 
describing a refractory case of WT with lung metastasis being cured by CBT (Massimino et 
al., 2010). There are rare case reports of WT successfully treated by HSCT, e.g. a case of third 
remission (Brown et al., 2010), a bilateral Wilms’ tumor treated without any irradiation 
(Saarinen-Pihkala et al., 1998), and an anephric pediatric case with multiple recurrent WT 
treated in conjunction with hemodialysis (Dagher et al., 1998). 
7. Rhabdomyosarcoma 
Since the end of 1990s, the prognosis of patients with localized rhabdomyosarcoma (RS) has 
improved with an EFS rate of approximately 70%. Although HDC with or without TBI 
followed by Auto or Allo HSCT has been performed for patients with metastatic or 
recurrent diseases by several groups, a retrospective multi-center analysis with 36 patients 
by the German and Austrian Pediatric Bone Marrow Transplantation Group in 1997 showed 
that the effect of HSCT was uncertain. In this study, the EFS rate at 2 years after HDC in 26 
patients who were treated with MEC with or without TBI regimen was 36 ± 7%, and none of 
the 5 patients who received Allo BMT alive (Koscielniak et al., 1997). The European 
Intergroup MMT4-89 (including 4 cycles of standard chemotherapy) and MMT4-91 
(melphalan-based HDC followed by HSCT after three courses of standard chemotherapy) 
studies on childhood metastatic RS suggested that there was prolonged survival with the 
MMT4-91 regimen (EFS and OS at 3 years were 29.7% and 40%, respectively) when 
compared with the MMT4-89 regimen (EFS and OS at 3 year were 19.2% and 27.7%, 
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respectively) (Carli et al., 1999).  However, their final report concluded there is no evidence 
that consolidation HDC improves outcomes (Carli et al., 2004).  The analysis of 177 patients 
with stage IV RS from 22 studies who received HSCT also concluded that HSCT for patients 
with relapsed or refractory high-risk RS does not provide a significant advantage (Weigel et 
al., 2001). A recent meta-analysis of three non-randomized controlled studies on survival 
showed 3-year OS ranged from 22% to 55% in the HSCT group versus 18% to 55% in the 
control group, and also showed no differences between treatments (Peinemann et al., 2011). 
On the other hand, an analysis of HSCT for high-risk RS according to histological type 
suggested that for unfavorable histologies (alveolar or undifferentiated subtypes) HSCT 
after relapse may have some benefit because long-term survivors were sometimes seen (Stiff 
et al., 2010). 
8. Hepatoblastoma 
HCT followed by Auto or Allo HSCT for patients with high-risk hepatoblastoma (HB) was 
tried by several groups. The initial report described three patients with stage II or III HB 
who achieved CR after receiving Auto HSCT, and one patient with a third relapse showed 
PR (Hara et al., 1998). HSCT for MRD may improve survival (Yoshinari et al., 1998).  
Subsequent reports of tandem HSCT for three high-risk patients (metastatic or recurrent 
disease) showed that they failed to remain in remission (Katzenstein et al., 2002). Recent 
reports by the Japanese Study Group for Pediatric Liver Tumors also showed that the 
prognosis of HDC with HSCT for metastatic HB was poor (5-year OS of 43.9%) (Hishiki et 
al., 2011). On the other hand, a report of a patient with recurrent metastatic HB who 
received non-myeloablative HSCT from a HLA-matched unrelated donor showed a 
probable GVT effect with GVHD (Inaba et al., 2006). 
9. Retinoblastoma 
The prognosis of retinoblastoma improved to a 5-year survival rate of approximately 90% 
through early diagnosis and proper treatment, including enucleation, chemotherapy, or 
radiation therapy.  However, the outcome of progressive disease, i.e. optic nerve invasion, 
extra-ocular extension, or metastatic disease, especially into central nervous system (CNS), 
remains poor (Ali et al., 2011; Chantada et al., 2007; Cozza et al., 2009).  Since the 1980s, 
HDC with HSCT with or without TBI has been performed with immunomagnetic purging 
(Saleh et al., 1988), or monitoring of MRD in the BM or PB by monoclonal antibody of 3A7 
(Saarinen et al., 1991) or protein gene product 9.5 gene expression (Yamane et al., 1999) 
because retinoblastoma frequently infiltrates into these sites  (Karcioglu et al., 1997). Several 
trials of Auto HSCT for metastatic retinoblastoma with or without CNS involvement were 
reported.  Patients without CNS involvement were successfully treated by HDC followed by 
HSCT with or without local irradiation (Dunkel et al., 2000; Kremens et al., 2003; Matsubara 
et al., 2005). A patient with recurrent disseminated retinoblastoma in the lymph nodes, 
bone, and BM was successfully treated by HDC with CD34-selected Auto HSCT (Hertzberg 
et al., 2001). High-dose carboplatin (250 or 350 mg/m2 daily for 5 days), etoposide (350 
mg/m2 daily for 5 days), and cyclophosphamide (1.6 g/m2 daily for 4 days), followed by 
HSCT, can improve survival in retinoblastoma involving bone or BM but not the CNS 
(Namouni et al., 1997). A patient with cerebrospinal fluid metastasis who received HSCT 
with high-dose/short-infusion cyclosporine to inhibit P-glycoprotein, which is expressed by 
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most metastatic retinoblastomas, achieved long-term remission (Dimaras et al., 2009). A 
recent study of HDC with Auto HSCT for stage 4b (CNS involvement) retinoblastoma 
showed some benefit for some patients with CNS metastasis (Dunkel et al., 2010a).  
Furthermore, a study of HDCT in South America for metastatic retinoblastoma with CNS 
involvement also showed that 2 of 4 patients with CNS involvement were alive and disease 
free at 39 and 27 months (Dunkel et al., 2010a). Tandem HSCT was attempted to treat 
advanced bilateral retinoblastoma. Nine patients with bilateral retinoblastoma received two 
cycles of HDC with regimens of MEC + BM (busulfan and melphalan) or CTE (carboplatin, 
thiotepa, and etoposide) + CM (cyclophosphamide and melphalan) followed by Auto HSCT 
in order to avoid external-beam radiation therapy. All patients had at least one functional 
eye and in two patients both eyes were preserved (Lee et al., 2008).  
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respectively) (Carli et al., 1999).  However, their final report concluded there is no evidence 
that consolidation HDC improves outcomes (Carli et al., 2004).  The analysis of 177 patients 
with stage IV RS from 22 studies who received HSCT also concluded that HSCT for patients 
with relapsed or refractory high-risk RS does not provide a significant advantage (Weigel et 
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showed 3-year OS ranged from 22% to 55% in the HSCT group versus 18% to 55% in the 
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et al., 2010). 
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bone, and BM was successfully treated by HDC with CD34-selected Auto HSCT (Hertzberg 
et al., 2001). High-dose carboplatin (250 or 350 mg/m2 daily for 5 days), etoposide (350 
mg/m2 daily for 5 days), and cyclophosphamide (1.6 g/m2 daily for 4 days), followed by 
HSCT, can improve survival in retinoblastoma involving bone or BM but not the CNS 
(Namouni et al., 1997). A patient with cerebrospinal fluid metastasis who received HSCT 
with high-dose/short-infusion cyclosporine to inhibit P-glycoprotein, which is expressed by 
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most metastatic retinoblastomas, achieved long-term remission (Dimaras et al., 2009). A 
recent study of HDC with Auto HSCT for stage 4b (CNS involvement) retinoblastoma 
showed some benefit for some patients with CNS metastasis (Dunkel et al., 2010a).  
Furthermore, a study of HDCT in South America for metastatic retinoblastoma with CNS 
involvement also showed that 2 of 4 patients with CNS involvement were alive and disease 
free at 39 and 27 months (Dunkel et al., 2010a). Tandem HSCT was attempted to treat 
advanced bilateral retinoblastoma. Nine patients with bilateral retinoblastoma received two 
cycles of HDC with regimens of MEC + BM (busulfan and melphalan) or CTE (carboplatin, 
thiotepa, and etoposide) + CM (cyclophosphamide and melphalan) followed by Auto HSCT 
in order to avoid external-beam radiation therapy. All patients had at least one functional 
eye and in two patients both eyes were preserved (Lee et al., 2008).  
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unrestricted proliferation potential and (b) cells that are multipotent and able to give rise to 
all cell lineages in a particular tissue. Stem cells repopulate damaged or lost tissue either 
through differentiation into tissue appropriate cells and or by releasing paracrine signaling 
molecules to recruit inflammatory cells and other tissue progenitor cells. As such, these cells 
have a key role in therapeutic tissue regeneration (Lau, 2009). From the establishment of the 
location of corneal epithelial stems cells to promising developments in diagnosis and 
treatment of ophthalmic diseases, an enhanced understanding of stem cells in 
ophthalmology offers promising diagnostic and therapeutic advances.  
The purpose of this chapter is to outline our current knowledge and recent advances in stem 
cell research in ophthalmology. We will focus on the potential clinical applications of stem 
cell research in six main areas: Cornea, Conjunctiva, Orbit, Eyelid, Trabecular Meshwork 
and Retina.  
2. Cornea 
2.1 Background 
The human cornea is highly specialized. The refractive index of a normal cornea is 1.376 and 
is essential to maintaining clarity of visual images on the retina. The cornea receives 
nutrition via glucose from the aqueous humour and oxygen through the tear film, although 
the peripheral cornea gets oxygen from the corneoscleral limbus. The cornea is composed of 
five layers: the epithelium, Bowman’s layer, the stroma, Descemet’s membrane and the 
endothelium (see Figure 2). The epithelium is composed of stratified squamous epithelial 
cells. These cells make up about 5% of corneal thickness. Perilimbal basal epithelial cells give  
 
 
Fig. 2. Anatomy of the Cornea (Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye 
Institute, University of Miami Miller School of Medicine) 
 
Stem Cells in Ophthalmology 407 
rise to superficial cells which then desquamate into the tear film over a period of one to 
two weeks. Constant renewal of the epithelial cells is essential to the cornea’s visually 
essential role of light transmittance and refraction. With each blink, superficial epithelial 
cells may be shed into the tear pool, and these cells must be constantly repopulated from 
epithelial stem cells. 
The stroma is also essential to the maintenance of clear vision. It is composed of keratocytes 
in a lattice arrangement, which reduces light scattering by destructive interference. The 
lattice is smaller than the wavelength of visible light, an essential characteristic to 
maintaining corneal clarity. Corneal transparency also depends on corneal hydration which 
depends on the endothelial pump. The endothelium is especially susceptible to damage as 
endothelial cells do not proliferate and cell loss leads to enlargement and spread of 
neighboring cells to cover the defect.  
Thus, each layer of the cornea is essential to maintaining clarity of visual images. The 
discovery of the location of corneal epithelial stems cells at the limbus (the junctional zone 
between the cornea and conjunctiva) was one of the first major stem cell advances in the 
field of ophthalmology, and was proposed in the early 1970s (Davanger and Evenson, 1971).  
2.2 Stem cell localization  
An extensive review of corneal stem cells will be documented in the chapter Limbal Stem Cell 
Transplantation and Corneal Neovascularization by Katikireddy and Ula. The purpose of this 
section of the chapter is to provide a brief overview of corneal stem cells in the context of other 
stem cell research in ophthalmology, such as in extensive ocular surface disease.  
The corneal limbus was first proposed in 1971 as the site of corneal stem cells based on the 
observation that pigment migrated from the limbus to the central cornea in healing corneal 
defects (Davanger & Evenson, 1971). Subsequent studies demonstrated that slow-cycling 
limbal epithelial basal cells retained tritiated thymidine (Cotsarelis et al, 1989), supporting 
the notion that this was the location of stem cells. In addition, keratinocyte growth factor 
(KGF) is known to stimulate limbal epithelial precursor cells to grow (Wilson et al, 1994), 
and limbal epithelial cells exhibit higher levels of KGF compared to similar corneal 
epithelial cells (Li & Tseng, 1997). Interestingly, corneal epithelial cells grown on limbal 
stroma also revert to a more proliferative cell type (Espana et al, 1987). In addition, stem cell 
markers such as p63 (Pelligrini et al, 2001) and transporter ABCG2 (Watanabe et al, 2004) 
have been identified in the limbal cell population. Even studies on the distribution of stem 
cells in the human corneal stroma and endothelium which found precursor cells distributed 
throughout the cornea show that the peripheral cornea has the large majority of the stem cell 
population (Yamagami et al, 2007).  
How does this translate into the clinical setting? In culture, limbal basal cells have the 
highest proliferative capacity, diseases affecting the limbus result in delayed healing and 
conjunctival overgrowth, and limbal transplants can regenerate corneal-like epithelium. 
These findings all support the premise that the corneal surface is renewed by limbal stem 
cells in both normal physiological conditions and after injury.  
What are the key characteristics of corneal stem cells?  Corneal stem cells are characterized 
by small size, low rate of replication, and expression of a side population (SP) phenotype 
(Watanabe et al, 2004), a common feature of stem cells in other organ systems. These cells 
represent only a minor fraction of the cell population in the cornea. In the mouse model, 
these limbal stem cells only represent from <1% (Budak et al, 2005) to 3.8% (Krulova et al, 
2008) of the limbal cell population. In rat and human cornea, flow cytometry and analysis of 
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certain stem cell markers (such as ABCG2 expression) has shown that these cells range from 
0.20% (Watanabe et al, 2004) to 10% (Umemoto et al, 2005) of the total limbal epithelial cell 
population. The small fraction they represent is important in understanding techniques for 
extraction and cultivation of stem cells.  
What about the stem cell niche?  Even in tissues with a high turnover rate, such as the 
cornea, there are a proportion of stem cells among this population that are quiescent and 
reactivate only in specific situations such as injury or trauma (Wang et al, 2010). This stem 
cell “niche” hypothesis maintains that upon stem cell division one cell remains a stem cell 
and returns to replenish the stem cell supply while the other becomes differentiated to 
repair and resupply lost cells (Schofield, 1983). In addition, the niche in which stem cells 
reside provides ongoing nutritional support and protection. For example, in the cornea the 
stem cells at the limbus are close to blood vessels which can provide essential nutrients and 
allow for ongoing proliferation. The properties and environment which lead to support and 
proliferation of stem cells as well as maintenance of supply are key factors to the successful 
treatment of diseases with limbal stem cell deficiency.  
2.3 Pathology 
The protective microenvironment which maintains the stem cell population and allows for 
self-renewal is extremely important. Any disruption in this environment can damage the 
stem cells and cause pathologic changes with significant consequences, such as occurs in 
limbal stem cell deficiency. There are congenital and acquired forms of limbal stem cell 
deficiency. For example, aniridia is a congenital ocular disease associated with limbal stem 
cell deficiency. More commonly, limbal stem cell deficiency develops due to local tissue 
injury. Stevens Johnson syndrome (see Figure 3), ocular cicatricial pemphigoid, chemical or 
thermal burns, severe contact lens keratopathy, surgical damage to the limbus and other 
cicatrizing disease can all lead to a deficiency in these important cells.  
 
 
Fig. 3. Corneal scarring from Stevens Johnson Syndrome (Courtesy of Miami VA Hospital 
Photography Department) 
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Typically, when limbal stem cell deficiency occurs, the neighboring conjunctival cells 
(normally hindered by limbal cells) migrate over the cornea and cause conjunctivalization 
(corneal neovascularization, appearance of goblet cells and an irregular epithelium) (Daniels 
et al, 2001). The result of this overgrowth is poor vision, corneal opacity, surface irregularity 
and patient discomfort. In the cornea, the identification of limbal stem cells has enabled 
advances in not only the diagnosis of corneal disease but also in treatment options for 
patients with severe limbal stem cell deficiency.  
2.4 Treatment 
In certain severe ocular diseases with corneal compromise, treatment of limbal stem cell 
deficiency was initially demonstrated to be effective via transplantation of limbal allografts, 
autografts or keratoepithelioplasty (Frucht-Pery et al, 1998) (Kenyon & Tseng, 1989). Limbal 
allografts, however, carry a high risk of rejection because of the presence of specific antigens 
which are more likely to stimulate an immune response (Pels & van der Gaag, 1984). As a 
result, they require long term immunosuppression. In addition, cadaver grafting, which in 
cases of severe bilateral disease is sometimes the only option, has a high failure rate 
compared to living related donor in the treatment of total limbal stem cell deficiency (Miri, 
Al-Deiri et al, 2010). This form of grafting has been associated with poor clinical outcomes.  
Prolonged inflammation due to the ongoing disease process can also destroy corneal stem 
cells and substantially increases the risk of any surgical intervention in these cases. As such, 
limbal transplantation is contraindicated in patients with severe dry eye given the low 
chance of survival of the graft (Dua et al, 2010). Given these factors, it is important that an 
extensive ocular evaluation is performed including eyelid position and function, ocular 
surface lubrication and presence or absence of dry eye syndrome, visual potential of the eye, 
condition of the fellow eye and systemic health of the patient (especially when allografts are 
planned and immunosuppression is required). Treatment of ocular or systemic co-
morbidities is essential to the long-term success of stem cell transplantation in the eye, just 
as in other organ systems. 
The following general algorithm for surgical intervention in cases of stem cell deficiency 
was proposed (Dua et al, 2010): 
1. Partial stem cell deficiency with no involvement of the visual axis, aggressive 
lubrication 
2. Partial stem cell deficiency with visual involvement, sequential sector conjunctival 
epitheliectomy (SSCE) 
3. Partial stem cell deficiency with pannus, SSCE with a sector limbal transplant 
4. Total unilateral stem cell deficiency, autolimbal transplantation  
5. Total bilateral stem cell deficiency use of allografts from a living related or cadaver donor  
For partial stem cell deficiency, amniotic membrane transplantation with superficial 
keratectomy is also a viable treatment option (Anderson et al, 2001). The details of the 
surgical procedures are beyond the scope of this chapter, but the extensive algorithm 
summarizes the significant advances that have taken place in terms of our understanding of 
the anatomy, pathology and treatment options for stem cell deficiency in the cornea.  
2.5 Further stem cell applications and new advances 
Limitations of the aforementioned treatment modalities have led to treatment of unilateral 
or bilateral total stem cell deficiency with ex vivo expansion of limbal derived cells with or 
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without a substrate (Dua et al, 2010). Ex vivo transplantation uses cells from a small biopsy 
sample which are cultured to generate cohesive sheets of corneal epithelium. This 
epithelium can then be transplanted (Pelligrini et al, 1997). Several techniques are used for 
producing ex vivo cultured limbal epithelial cells for transplantation. The explants culture 
system and the suspension culture system have been shown to have similar success rates 
(Shortt et al, 2007). Ex vivo cultured oral mucosal epithelium has also been used to treat 
limbal stem cell deficiency (Inatomi et al, 2006). While ex vivo expansion has the advantage 
of limited donor site morbidity because it only requires a small biopsy, it necessitates 
specialized techniques, takes time to generate the limbal stem cells and is very costly.  
What about the niche environment?  The success of limbal stem cell transplantation, 
whether ex-vivo or in-vivo, is also not surprisingly dependent on the limbal stem cell niche 
environment. Processing of cultured limbal stem cells may become more efficient and 
treatments more efficacious as these factors are elucidated. In fibroblast cultures from the 
cornea, limbus and sclera of donor ocular tissue, only corneal and limbal fibroblasts 
supported limbal epithelial precursor culture establishment; limbal fibroblasts also had 
significantly better growth (Ainscough et al, 2011). Scleral fibroblasts had increased 
myofibroblast formation, which inhibited limbal epithelial stem cell growth, possibly 
preventing proliferation of limbal epithelial stem cells towards the sclera (Ainscough et al, 
2011). These surrounding fibroblasts thus regulate the stem cell enrivonment. In addition, in 
the rabbit model, corneal stromal inflammation was associated with poor graft outcome 
(Tsai, & Tseng 1995). The environment in which the cultured epithelial graft cells are placed 
is therefore important for the long term therapeutic effect.  
How does this translate into clinical applications? Improved success of cultured limbal 
epithelial grafts may be obtained by “debriding” the wound of myofibroblasts. Stromal 
tissue substitutes that provide a good scaffold and hinder growth of myofibroblasts may 
lead to improved clinical outcomes (Ainscough et al, 2011). Transplantation with 
surrounding conjunctival tissue may lead to improved clinical results even in cadaver grafts 
(Dua et al, 2010). It is possible this frill of conjunctiva possesses factors which enhance 
clinical outcomes of transplantation. Co-transfer of limbal stem cells with other stem cells, 
such as mesenchymal cells, may also lead to improved outcomes by inhibiting local 
inflammation and improving healing through immunosuppressive properties of these cells 
(Zajicova et al, 2010). Furthermore, human amniotic membrane may serve as a niche for 
limbal stem cells, possibly through the suppression of apoptosis and expression of certain 
growth factors (Tseng et al, 1998). As such, amniotic membrane may contribute to the long 
term survival of cultured limbal stem cell transplantation (Tsai RJ & Tsai RY, 2010). 
Understanding the milieu into which stems cells are to be transplanted for maximal success 
is essential to the advancement of these treatment options. 
Therapy focused on reconstruction of the ocular surface in disease such as severe ocular 
burns, ocular cicatricial pemphigoid, Stevens Johnson Syndrome and others has thus been 
dramatically improved with limbal stem cell and amniotic membrane transplantation, with 
improved corneal clarity and clinical outcomes. As new growth factors are elucidated and 
stem cell culture techniques are developed, the treatment of corneal disease with stem cells 
will continue to advance. Further analysis of the location and level of markers such as CK3, 
CK19, p63, ABCG2, and vimentin (Ghoubay-Benallaoua et al, 2011) will enhance 
understanding of stem cell deficiency as well as stem cell treatment in the cornea and other 
organ systems. In addition, emerging advances in nanotechnology for stem cell application 
 
Stem Cells in Ophthalmology 411 
in the eye have shown that electrospun nanofibers can serve as a scaffold to grow and 
transfer limbal stem cells in the treatment of limbal stem cell deficiency (Zajicova et al, 2010). 
As biological discoveries identify key factors to stem cell survival and technological 
advances provide new biomaterials, the potential for improved treatment is dramatic.  
3. Conjunctiva  
3.1 Background  
The conjunctiva is essential to ocular health as it contains essential support cells, provides 
for passage of fluids and nutrients and is a barrier to pathogen entrance and fluid loss. It 
functions to provide mucin for the tear film, immune defense (via production of 
antimicrobial peptides such as defensins as well as the conjunctiva associated lymphoid 
tissue – CALT), and a mechanical barrier. It is a thin transparent mucous membrane that is 
made up of a non-keratinized epithelium and a vascularized stroma. The epithelium varies 
from stratified cuboidal cells over the tarsus to columnar in the fornices to squamous on the 
globe. The basal cell layer contains goblet cells, which secrete mucin. The membrane covers 
the posterior surface of the eyelids and the anterior surface of the globe and is made up of 
the tarsal conjunctiva, forniceal conjunctiva, bulbar conjunctiva and the semilunar fold. The 
tarsal conjunctiva adheres firmly to the underlying tarsus. In contrast, the bulbar 
conjunctiva is loosely adherent to Tenon’s capsule and has multiple folds, allowing for 
unrestricted ocular movement.  
Therefore, the conjunctiva is essential to ocular health, providing a mechanical and 
immunological barrier to injury and infection, as well as contributing to the production and 
stability of the tear film through goblet cell secretion of mucin (Qi et al, 2010). Diseases of 
the conjunctiva can therefore have significant ocular morbidity.  
Interestingly, there has been considerable debate regarding the role of the conjunctiva in 
corneal regeneration, and some have proposed that corneal and conjunctival epithelia are 
equipotent (Majo et al, 2010). Despite these findings and its essential role in ocular health, 
conjunctival stem cell biology has not been as well investigated as that of corneal stem cells 
(Ang & Tan, 2004). 
3.2 Stem cell localization 
The location of conjunctival stem cells has been proposed to include the fornix (Wei, 1995), 
palpebral and bulbar conjunctiva (Pelligrini et al, 1999), bulbar conjunctiva (Qi et al, 2010; 
Chen et al, 2003), and mucocutaneous junction (Wirstschafter et al, 1999). Human bulbar 
and forniceal conjunctival cells have been found to have equivalent proliferative capacity, 
suggesting that conjunctival epithelial stem cells may be evenly distributed between the 
bulbar and forniceal conjunctiva  (Pelligrini et al, 1999). Various keratins and molecules 
associated with stem cells were found in undifferentiated basal cells in the human bulbar 
conjunctival epithelium, supporting the localization of progenitor cells in this region (Qi et 
al, 2010). Research has focused on not only the location of these progenitor cells but also 
their differentiation potential. Interestingly, both conjunctival non-goblet and goblet cells 
are thought to be derived from a common progenitor (Pelligrini et al, 1999). This suggests 
that differentiation into goblet cells may occur late and these cells may be generated from 
transient amplifying cells (Schrader et al, 2010).  
In pathological processes, a decrease in the conjunctival stem cell population has been 
demonstrated through staining for stem cell markers such as p63 in humans, rats and mice, 
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without a substrate (Dua et al, 2010). Ex vivo transplantation uses cells from a small biopsy 
sample which are cultured to generate cohesive sheets of corneal epithelium. This 
epithelium can then be transplanted (Pelligrini et al, 1997). Several techniques are used for 
producing ex vivo cultured limbal epithelial cells for transplantation. The explants culture 
system and the suspension culture system have been shown to have similar success rates 
(Shortt et al, 2007). Ex vivo cultured oral mucosal epithelium has also been used to treat 
limbal stem cell deficiency (Inatomi et al, 2006). While ex vivo expansion has the advantage 
of limited donor site morbidity because it only requires a small biopsy, it necessitates 
specialized techniques, takes time to generate the limbal stem cells and is very costly.  
What about the niche environment?  The success of limbal stem cell transplantation, 
whether ex-vivo or in-vivo, is also not surprisingly dependent on the limbal stem cell niche 
environment. Processing of cultured limbal stem cells may become more efficient and 
treatments more efficacious as these factors are elucidated. In fibroblast cultures from the 
cornea, limbus and sclera of donor ocular tissue, only corneal and limbal fibroblasts 
supported limbal epithelial precursor culture establishment; limbal fibroblasts also had 
significantly better growth (Ainscough et al, 2011). Scleral fibroblasts had increased 
myofibroblast formation, which inhibited limbal epithelial stem cell growth, possibly 
preventing proliferation of limbal epithelial stem cells towards the sclera (Ainscough et al, 
2011). These surrounding fibroblasts thus regulate the stem cell enrivonment. In addition, in 
the rabbit model, corneal stromal inflammation was associated with poor graft outcome 
(Tsai, & Tseng 1995). The environment in which the cultured epithelial graft cells are placed 
is therefore important for the long term therapeutic effect.  
How does this translate into clinical applications? Improved success of cultured limbal 
epithelial grafts may be obtained by “debriding” the wound of myofibroblasts. Stromal 
tissue substitutes that provide a good scaffold and hinder growth of myofibroblasts may 
lead to improved clinical outcomes (Ainscough et al, 2011). Transplantation with 
surrounding conjunctival tissue may lead to improved clinical results even in cadaver grafts 
(Dua et al, 2010). It is possible this frill of conjunctiva possesses factors which enhance 
clinical outcomes of transplantation. Co-transfer of limbal stem cells with other stem cells, 
such as mesenchymal cells, may also lead to improved outcomes by inhibiting local 
inflammation and improving healing through immunosuppressive properties of these cells 
(Zajicova et al, 2010). Furthermore, human amniotic membrane may serve as a niche for 
limbal stem cells, possibly through the suppression of apoptosis and expression of certain 
growth factors (Tseng et al, 1998). As such, amniotic membrane may contribute to the long 
term survival of cultured limbal stem cell transplantation (Tsai RJ & Tsai RY, 2010). 
Understanding the milieu into which stems cells are to be transplanted for maximal success 
is essential to the advancement of these treatment options. 
Therapy focused on reconstruction of the ocular surface in disease such as severe ocular 
burns, ocular cicatricial pemphigoid, Stevens Johnson Syndrome and others has thus been 
dramatically improved with limbal stem cell and amniotic membrane transplantation, with 
improved corneal clarity and clinical outcomes. As new growth factors are elucidated and 
stem cell culture techniques are developed, the treatment of corneal disease with stem cells 
will continue to advance. Further analysis of the location and level of markers such as CK3, 
CK19, p63, ABCG2, and vimentin (Ghoubay-Benallaoua et al, 2011) will enhance 
understanding of stem cell deficiency as well as stem cell treatment in the cornea and other 
organ systems. In addition, emerging advances in nanotechnology for stem cell application 
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in the eye have shown that electrospun nanofibers can serve as a scaffold to grow and 
transfer limbal stem cells in the treatment of limbal stem cell deficiency (Zajicova et al, 2010). 
As biological discoveries identify key factors to stem cell survival and technological 
advances provide new biomaterials, the potential for improved treatment is dramatic.  
3. Conjunctiva  
3.1 Background  
The conjunctiva is essential to ocular health as it contains essential support cells, provides 
for passage of fluids and nutrients and is a barrier to pathogen entrance and fluid loss. It 
functions to provide mucin for the tear film, immune defense (via production of 
antimicrobial peptides such as defensins as well as the conjunctiva associated lymphoid 
tissue – CALT), and a mechanical barrier. It is a thin transparent mucous membrane that is 
made up of a non-keratinized epithelium and a vascularized stroma. The epithelium varies 
from stratified cuboidal cells over the tarsus to columnar in the fornices to squamous on the 
globe. The basal cell layer contains goblet cells, which secrete mucin. The membrane covers 
the posterior surface of the eyelids and the anterior surface of the globe and is made up of 
the tarsal conjunctiva, forniceal conjunctiva, bulbar conjunctiva and the semilunar fold. The 
tarsal conjunctiva adheres firmly to the underlying tarsus. In contrast, the bulbar 
conjunctiva is loosely adherent to Tenon’s capsule and has multiple folds, allowing for 
unrestricted ocular movement.  
Therefore, the conjunctiva is essential to ocular health, providing a mechanical and 
immunological barrier to injury and infection, as well as contributing to the production and 
stability of the tear film through goblet cell secretion of mucin (Qi et al, 2010). Diseases of 
the conjunctiva can therefore have significant ocular morbidity.  
Interestingly, there has been considerable debate regarding the role of the conjunctiva in 
corneal regeneration, and some have proposed that corneal and conjunctival epithelia are 
equipotent (Majo et al, 2010). Despite these findings and its essential role in ocular health, 
conjunctival stem cell biology has not been as well investigated as that of corneal stem cells 
(Ang & Tan, 2004). 
3.2 Stem cell localization 
The location of conjunctival stem cells has been proposed to include the fornix (Wei, 1995), 
palpebral and bulbar conjunctiva (Pelligrini et al, 1999), bulbar conjunctiva (Qi et al, 2010; 
Chen et al, 2003), and mucocutaneous junction (Wirstschafter et al, 1999). Human bulbar 
and forniceal conjunctival cells have been found to have equivalent proliferative capacity, 
suggesting that conjunctival epithelial stem cells may be evenly distributed between the 
bulbar and forniceal conjunctiva  (Pelligrini et al, 1999). Various keratins and molecules 
associated with stem cells were found in undifferentiated basal cells in the human bulbar 
conjunctival epithelium, supporting the localization of progenitor cells in this region (Qi et 
al, 2010). Research has focused on not only the location of these progenitor cells but also 
their differentiation potential. Interestingly, both conjunctival non-goblet and goblet cells 
are thought to be derived from a common progenitor (Pelligrini et al, 1999). This suggests 
that differentiation into goblet cells may occur late and these cells may be generated from 
transient amplifying cells (Schrader et al, 2010).  
In pathological processes, a decrease in the conjunctival stem cell population has been 
demonstrated through staining for stem cell markers such as p63 in humans, rats and mice, 
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which had reduced expression in damaged conjunctiva and conjunctivalized cornea (Moore 
et al, 2002). These discoveries and others have enhanced our understanding of conjunctival 
epithelial stem cells, which enables more appropriate surgical and medical treatment of 
conjunctival disease through advances such as tissue engineering.  
3.3 Pathology 
Cicatrizing ocular processes that affect the cornea can also affect the conjunctiva, such as 
ocular cicatricial pemphigoid, Stevens Johnson syndrome, graft versus host disease, 
autoimmune disease, post surgical changes and myriad other causes. Conjunctival disease 
and inflammation can lead to conjunctival thickening, forniceal foreshortening, 
symblepharon, severe dry eye due to poor blink dynamic, and subsequent keratinization of 
the ocular surface epithelia. In addition, damage to the goblet cells, ineffective blink and 
keratinization of the ocular surface epithelium can lead to disruption of the tear film and dry 
eye syndrome. Forniceal cicatrization can lead to cicatricial entropion and secondary 
trichiasis which damages the already susceptible corneal surface epithelium and makes the 
eye more prone to recurrent erosions, with the risk of secondary bacterial infection.  
3.4 Treatment 
Prolonged conjunctival inflammation can also deplete the limbal epithelial stem cell 
population, causing decreased vision through the mechanisms highlighted above. Given the 
interposition of conjunctival disease on corneal dysfunction, treatment of severe scarring, or 
cicatrizing disease, is fraught with associated complications, as discussed previously. 
Traditional treatment regimens have been staged, multi-specialty approaches. Prior to any 
corneal reconstruction, the ocular surface must be optimized so as to reduce the risk of 
subsequent failure (Gomes et al, 2003). Surgical reconstruction of the fornix can improve 
conjunctival function and lead to better long term success, with improved vision and 
comfort for the patient. The frequent ongoing inflammatory disease, however, can hinder 
long-term benefits.  
Treatment modalities are all aimed at excision of scar tissue with placement of a tissue 
substitute to recreate the fornices and ocular epithelial surface. This can be achieved through 
mucous membrane grafting, conjunctival autografts, and amniotic membrane. Amniotic 
membrane transplantation has been used for severe cicatrizing conjunctival diseases, such 
as ocular cicatricial pemphigoid (Barabino et al, 2003). Inflammation at the time of grafting 
can have deleterious effects on outcomes (Tsai & Tseng, 1995). Thus, transplantation is often 
performed in a staged surgical process whereby amniotic membrane transplantation is 
performed first to be followed by limbal transplantation in order to achieve the optimal 
result (Barabino et al, 2003). In cases of chemical burns with partial and total limbal stem cell 
deficiency, amniotic membrane transplantation has been shown to be an effective 
component of ocular surface reconstruction (Gomes et al, 2003). As previously highlighted, 
amniotic membrane may hinder apoptosis of essential cells and promote growth of stem 
cells essential to graft success (Tseng et al, 1998). When performed in conjunction with 
limbal stem cell transplantation, it is effective at improving the ocular surface in cases of 
limbal stem cell deficiency (Barabino et al, 2003).  
Other bioengineered synthetic material also has the potential to help in cases of severe 
ocular surface disease. Acellular polymer (such as porous collagen-glycosaminoglycan 
copolymer matrix) grafting can minimize fornix contracture after injury by inhibiting early 
scar formation (Schrader et al, 2009). Engineered tissue substitutes are limited, however, 
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because they do not have a donor epithelium and are often not elastic enough for forniceal 
placement. As with any surgical intervention in these cases, outcomes may be dependent on 
the level of inflammation. Features of the ideal transplant material include: low 
immunogenicity, high tolerance, easy surgical manipulation and elasticity, with an 
associated layer of donor epithelium available in cases of conjunctival stem cell deficiency 
(Schrader, 2009). 
3.5 Further stem cell applications and new advances 
While current transplantation techniques such as conjunctival autografts, oral mucous 
membrane grafts, nasal turbinate mucosa grafts and amniotic membrane are often used 
with benefit in patients with conjunctival stem cell deficiency and scarring, they are 
limited by complications secondary to the underlying stem cell deficiency and ongoing 
inflammatory disease. Long term success in patients with diffuse loss of conjunctival 
epithelial stem cells may require that the transplanted tissue contains epithelial stem cells 
(Pelligrini et al, 1999).  
How are conjunctival epithelial stem cells transplanted? Conjunctival epithelial cells have 
been cultured in serum-free media. These cells have been shown to have a similar in vivo 
proliferative capability as those cultured in serum with 3T3 feeder cells, mitigating the need 
for use of animal serum (Ang, Tan, Beuerman et al, 2004). A conjunctival epithelial 
equivalent has been developed using this serum-free culture system (Ang, 2004). 
Subsequently, autologous cultivated conjunctival cells grown in this manner on amniotic 
membrane have been successfully transplanted in primary pterygium (Ang et al, 2005). As 
in the cornea, conjunctival epithelial cell differentiation and growth on amniotic membrane 
in vitro has been demonstrated (Meller et al, 1999). Other synthetic materials, such as 
ultrathin poly(epsilon-caprolactone) membrane substrate, have been studied for possible 
transplantation and found to be biocompatible and able to support conjunctival epithelial 
cell proliferation (Ang et al, 2006).  
What about the surrounding environment?  Understanding the matrix and appropriate 
substrates for growth of these cells is an integral component of tissue transplantation 
success. The goal of treatment should be not only tissue replacement but also stimulation of 
new growth and proliferation of healthy tissue. Both the extracellular matrix and the co-
culture environment are essential to the proliferation and differentiation of conjunctival 
epithelial cells (Tsai & Tseng, 1988; Tsai et al, 1994). Certain growth factors can also 
modulate the outcomes of stem cells. For example, when placed in the appropriate 
environment and with associated factors such as nerve growth factor (Li W et al, 2010), 
progenitor cells can differentiate into goblet cells (Ang, Tan, Phan et al, 2004). This is not 
surprising given the previous suggestion of the common origin of these cells (Pelligrini et al, 
1999). Due to the essential role of goblet cells in the stability of the tear film, this is an 
integral part of restoring the ocular surface. Similar to limbal stem cells, support is also 
required in the stroma for conjunctival cell growth. Serum free co-culture of conjunctival 
epithelial cells with mitotically active subconjunctival fibroblasts stimulates the maintenance 
of conjunctival cells with stem cell characteristics (Ainscough et al, 2011). Thus, the 
conjunctival stromal scaffold and surrounding growth factors may also need manipulation 
in order to best support epithelial grafts.  
All of these advances will continue to be translated into clinical application, allowing for 
improved treatment of severe conjunctival disease and it’s potentially blinding sequelae. 
Cultivated conjunctival cells on amniotic membrane or biocompatible membranes can help 
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which had reduced expression in damaged conjunctiva and conjunctivalized cornea (Moore 
et al, 2002). These discoveries and others have enhanced our understanding of conjunctival 
epithelial stem cells, which enables more appropriate surgical and medical treatment of 
conjunctival disease through advances such as tissue engineering.  
3.3 Pathology 
Cicatrizing ocular processes that affect the cornea can also affect the conjunctiva, such as 
ocular cicatricial pemphigoid, Stevens Johnson syndrome, graft versus host disease, 
autoimmune disease, post surgical changes and myriad other causes. Conjunctival disease 
and inflammation can lead to conjunctival thickening, forniceal foreshortening, 
symblepharon, severe dry eye due to poor blink dynamic, and subsequent keratinization of 
the ocular surface epithelia. In addition, damage to the goblet cells, ineffective blink and 
keratinization of the ocular surface epithelium can lead to disruption of the tear film and dry 
eye syndrome. Forniceal cicatrization can lead to cicatricial entropion and secondary 
trichiasis which damages the already susceptible corneal surface epithelium and makes the 
eye more prone to recurrent erosions, with the risk of secondary bacterial infection.  
3.4 Treatment 
Prolonged conjunctival inflammation can also deplete the limbal epithelial stem cell 
population, causing decreased vision through the mechanisms highlighted above. Given the 
interposition of conjunctival disease on corneal dysfunction, treatment of severe scarring, or 
cicatrizing disease, is fraught with associated complications, as discussed previously. 
Traditional treatment regimens have been staged, multi-specialty approaches. Prior to any 
corneal reconstruction, the ocular surface must be optimized so as to reduce the risk of 
subsequent failure (Gomes et al, 2003). Surgical reconstruction of the fornix can improve 
conjunctival function and lead to better long term success, with improved vision and 
comfort for the patient. The frequent ongoing inflammatory disease, however, can hinder 
long-term benefits.  
Treatment modalities are all aimed at excision of scar tissue with placement of a tissue 
substitute to recreate the fornices and ocular epithelial surface. This can be achieved through 
mucous membrane grafting, conjunctival autografts, and amniotic membrane. Amniotic 
membrane transplantation has been used for severe cicatrizing conjunctival diseases, such 
as ocular cicatricial pemphigoid (Barabino et al, 2003). Inflammation at the time of grafting 
can have deleterious effects on outcomes (Tsai & Tseng, 1995). Thus, transplantation is often 
performed in a staged surgical process whereby amniotic membrane transplantation is 
performed first to be followed by limbal transplantation in order to achieve the optimal 
result (Barabino et al, 2003). In cases of chemical burns with partial and total limbal stem cell 
deficiency, amniotic membrane transplantation has been shown to be an effective 
component of ocular surface reconstruction (Gomes et al, 2003). As previously highlighted, 
amniotic membrane may hinder apoptosis of essential cells and promote growth of stem 
cells essential to graft success (Tseng et al, 1998). When performed in conjunction with 
limbal stem cell transplantation, it is effective at improving the ocular surface in cases of 
limbal stem cell deficiency (Barabino et al, 2003).  
Other bioengineered synthetic material also has the potential to help in cases of severe 
ocular surface disease. Acellular polymer (such as porous collagen-glycosaminoglycan 
copolymer matrix) grafting can minimize fornix contracture after injury by inhibiting early 
scar formation (Schrader et al, 2009). Engineered tissue substitutes are limited, however, 
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because they do not have a donor epithelium and are often not elastic enough for forniceal 
placement. As with any surgical intervention in these cases, outcomes may be dependent on 
the level of inflammation. Features of the ideal transplant material include: low 
immunogenicity, high tolerance, easy surgical manipulation and elasticity, with an 
associated layer of donor epithelium available in cases of conjunctival stem cell deficiency 
(Schrader, 2009). 
3.5 Further stem cell applications and new advances 
While current transplantation techniques such as conjunctival autografts, oral mucous 
membrane grafts, nasal turbinate mucosa grafts and amniotic membrane are often used 
with benefit in patients with conjunctival stem cell deficiency and scarring, they are 
limited by complications secondary to the underlying stem cell deficiency and ongoing 
inflammatory disease. Long term success in patients with diffuse loss of conjunctival 
epithelial stem cells may require that the transplanted tissue contains epithelial stem cells 
(Pelligrini et al, 1999).  
How are conjunctival epithelial stem cells transplanted? Conjunctival epithelial cells have 
been cultured in serum-free media. These cells have been shown to have a similar in vivo 
proliferative capability as those cultured in serum with 3T3 feeder cells, mitigating the need 
for use of animal serum (Ang, Tan, Beuerman et al, 2004). A conjunctival epithelial 
equivalent has been developed using this serum-free culture system (Ang, 2004). 
Subsequently, autologous cultivated conjunctival cells grown in this manner on amniotic 
membrane have been successfully transplanted in primary pterygium (Ang et al, 2005). As 
in the cornea, conjunctival epithelial cell differentiation and growth on amniotic membrane 
in vitro has been demonstrated (Meller et al, 1999). Other synthetic materials, such as 
ultrathin poly(epsilon-caprolactone) membrane substrate, have been studied for possible 
transplantation and found to be biocompatible and able to support conjunctival epithelial 
cell proliferation (Ang et al, 2006).  
What about the surrounding environment?  Understanding the matrix and appropriate 
substrates for growth of these cells is an integral component of tissue transplantation 
success. The goal of treatment should be not only tissue replacement but also stimulation of 
new growth and proliferation of healthy tissue. Both the extracellular matrix and the co-
culture environment are essential to the proliferation and differentiation of conjunctival 
epithelial cells (Tsai & Tseng, 1988; Tsai et al, 1994). Certain growth factors can also 
modulate the outcomes of stem cells. For example, when placed in the appropriate 
environment and with associated factors such as nerve growth factor (Li W et al, 2010), 
progenitor cells can differentiate into goblet cells (Ang, Tan, Phan et al, 2004). This is not 
surprising given the previous suggestion of the common origin of these cells (Pelligrini et al, 
1999). Due to the essential role of goblet cells in the stability of the tear film, this is an 
integral part of restoring the ocular surface. Similar to limbal stem cells, support is also 
required in the stroma for conjunctival cell growth. Serum free co-culture of conjunctival 
epithelial cells with mitotically active subconjunctival fibroblasts stimulates the maintenance 
of conjunctival cells with stem cell characteristics (Ainscough et al, 2011). Thus, the 
conjunctival stromal scaffold and surrounding growth factors may also need manipulation 
in order to best support epithelial grafts.  
All of these advances will continue to be translated into clinical application, allowing for 
improved treatment of severe conjunctival disease and it’s potentially blinding sequelae. 
Cultivated conjunctival cells on amniotic membrane or biocompatible membranes can help 
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improve the long term outcomes of surgical interventions in these difficult cases by 
stimulating new growth and creation of a new niche environment for stem cell proliferation.  
4. Orbit 
4.1 Background  
The orbit provides the support framework for the eye. Each orbit is a bony cavity that 
contains the eye, optic nerve, extraocular muscles, nerves, fat, lacrimal gland, and blood 
vessels. Orbital anatomy is intricate and any disruption to the orbital tissue via 
inflammation, infection, trauma, scarring or neoplasm can cause significant visual 
consequences. In addition, multiple apertures and fossa connect the orbit to the surrounding 
structures of the cranium and sinus cavities. The proximity of the orbit to the cranial vault 
and nasal cavity can lead to neurological or nasal sequelae from orbital disease. In cases of 
more aggressive malignant tumors, tumor spread into the brain can lead to devastating 
neurological consequences. In addition, infectious processes, such as sinusitis, can spread 
from the sinuses into the orbital cavity and cause blindness. These infections can also spread 
into the brain and become life threatening.  
Processes within the orbit are further complicated by the confined bony walls of the orbital 
cavity. For example, in cases of benign orbital tumors in the intraconal space such as 
cavernous hemangiomas, as the tumors grow they can sometimes compress the optic nerve 
and cause visual loss. In addition, all of the rectus muscles in the orbit originate from the 
annulus of zinn, a fibrous ring formed by their origin which encircles the optic foramen and 
the central portion of the superior orbital fissure. Diseases such as thyroid eye disease (TED) 
can lead to blindness by enlargement of these extraocular muscles causing compression of 
the optic nerve. For purposes of brevity, this chapter will focus on orbital adipose tissue and 
fibroblasts and one of the most common diseases affecting the orbit, thyroid eye disease 
(TED).  
4.2 Stem cell localization 
As stem cell research elsewhere has discovered, the human adipose tissue is a source of 
multipotent stem cells. Processed lipoaspirate cells can differentiate into osteogenic, 
adipogenic, myogenic, neurogenic and chondrogenic lineages and have many similar 
features to mesenchymal stem cells (Zuk et al, 2002). While adipose stem cells have been 
studied extensively throughout the body, research on the orbital adipose stem cell 
population is limited.  
Interestingly, orbital adipocytes (which are continuous with the nasal fat pad) are derived 
from neural crest cells, versus adipose tissue throughout the body which is generally 
mesodermal in origin (Johnston et al, 1979). The central preaponeurotic fat has been 
presumed to be more similar to systemic adipose tissue and derived from mesoderm. The 
eyelid, therefore, provides a unique place to compare orbital stem cells (nasal fat pad) with 
fat more similar to systemic adipose tissue (central fat pads) (Korn et al, 2009). Both nasal 
and central adipose depots have been found to have the potential to differentiate into 
adipocytes, smooth muscle and neuronal/glial lineages (Korn et al, 2009). Interestingly, the 
nasal adipose stem cells expressed a higher level of antigens such as CD34 correlated with 
neurogenic differentiation potential. Conversely, central cells expressed more 
neuronal/glial associated antigens under the neurogenic environment used, suggesting that 
the pathway for differentiation is modulated at several levels (Korn et al, 2009).  
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Further study of orbital adipose tissue is needed to understand the factors which lead to 
differentiation of this tissue and the neurogenic potential. Orbital adipose stem cell ability to 
differentiate into smooth muscle, neuronal lineages and adipocytes may also provide novel 
therapeutic treatments in disease affecting nerves, soft tissue, and muscles in the orbit. In 
addition, understanding the factors necessary for adipogenesis and expansion of the orbital 
adipose compartment in diseases such as TED has significant clinical applications. The ease 
of access to orbital adipose tissue makes it an interesting new target for stem cell research.  
4.3 Pathology 
Thyroid eye disease is an autoimmune inflammatory disease that has significant orbital 
consequences. Clinical signs of thyroid eye disease can vary from mild to severe and include 
proptosis (bulging of the eye), strabismus (double vision), bulging eyelids, exposure 
keratopathy, eyelid retraction and optic neuropathy. Enlargement of the extraocular muscles 
and expansion of the orbital fat from stimulation of orbital fibroblasts and adipogenesis in 
the fixed volume of the bony orbit can lead to these symptoms. Increased volume of the 
retroocular tissue and fibrotic changes can compress the optic nerve, cause extraocular 
muscle or eyelid dysfunction, or push the eye forward leading to corneal compromise.  
The pathology of thyroid eye disease involves an autoantibody cross-reaction from the 
thyroid-stimulating hormone (TSH) receptor with orbital fibroblasts. This leads to orbital 
fibroblast stimulation of lymphocytes, release of various cytokines and stimulation of orbital 
fibroblast production of glycosaminoglycans that increase volume by osmotic edema. In 
addition, preadipocyte fibroblasts in this environment can differentiate into adipocytes, 
leading to expansion of the orbital fat cavity. De novo adipogenesis within orbital tissues is 
an important factor in the pathology of TED (Kumar et al, 2003). Proliferation of fibroblasts 
and adipocytes and secondary hyaluronan accumulation (among other aminoglycosides) 
causes tissue volume expansion, orbital congestion, exophthalmos, and compressive optic 
neuropathy (Kahaly et al, 1998). Differentiation of fibroblasts to adipocytes and proliferation 
of orbital fibroblasts are thus critical steps in the development of TED.  
 
 
Fig. 4. Orbital Congestion from extraocular muscle enlargement in TED Note: arrows 
pointing to enlarged extraocular muscles 
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improve the long term outcomes of surgical interventions in these difficult cases by 
stimulating new growth and creation of a new niche environment for stem cell proliferation.  
4. Orbit 
4.1 Background  
The orbit provides the support framework for the eye. Each orbit is a bony cavity that 
contains the eye, optic nerve, extraocular muscles, nerves, fat, lacrimal gland, and blood 
vessels. Orbital anatomy is intricate and any disruption to the orbital tissue via 
inflammation, infection, trauma, scarring or neoplasm can cause significant visual 
consequences. In addition, multiple apertures and fossa connect the orbit to the surrounding 
structures of the cranium and sinus cavities. The proximity of the orbit to the cranial vault 
and nasal cavity can lead to neurological or nasal sequelae from orbital disease. In cases of 
more aggressive malignant tumors, tumor spread into the brain can lead to devastating 
neurological consequences. In addition, infectious processes, such as sinusitis, can spread 
from the sinuses into the orbital cavity and cause blindness. These infections can also spread 
into the brain and become life threatening.  
Processes within the orbit are further complicated by the confined bony walls of the orbital 
cavity. For example, in cases of benign orbital tumors in the intraconal space such as 
cavernous hemangiomas, as the tumors grow they can sometimes compress the optic nerve 
and cause visual loss. In addition, all of the rectus muscles in the orbit originate from the 
annulus of zinn, a fibrous ring formed by their origin which encircles the optic foramen and 
the central portion of the superior orbital fissure. Diseases such as thyroid eye disease (TED) 
can lead to blindness by enlargement of these extraocular muscles causing compression of 
the optic nerve. For purposes of brevity, this chapter will focus on orbital adipose tissue and 
fibroblasts and one of the most common diseases affecting the orbit, thyroid eye disease 
(TED).  
4.2 Stem cell localization 
As stem cell research elsewhere has discovered, the human adipose tissue is a source of 
multipotent stem cells. Processed lipoaspirate cells can differentiate into osteogenic, 
adipogenic, myogenic, neurogenic and chondrogenic lineages and have many similar 
features to mesenchymal stem cells (Zuk et al, 2002). While adipose stem cells have been 
studied extensively throughout the body, research on the orbital adipose stem cell 
population is limited.  
Interestingly, orbital adipocytes (which are continuous with the nasal fat pad) are derived 
from neural crest cells, versus adipose tissue throughout the body which is generally 
mesodermal in origin (Johnston et al, 1979). The central preaponeurotic fat has been 
presumed to be more similar to systemic adipose tissue and derived from mesoderm. The 
eyelid, therefore, provides a unique place to compare orbital stem cells (nasal fat pad) with 
fat more similar to systemic adipose tissue (central fat pads) (Korn et al, 2009). Both nasal 
and central adipose depots have been found to have the potential to differentiate into 
adipocytes, smooth muscle and neuronal/glial lineages (Korn et al, 2009). Interestingly, the 
nasal adipose stem cells expressed a higher level of antigens such as CD34 correlated with 
neurogenic differentiation potential. Conversely, central cells expressed more 
neuronal/glial associated antigens under the neurogenic environment used, suggesting that 
the pathway for differentiation is modulated at several levels (Korn et al, 2009).  
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Further study of orbital adipose tissue is needed to understand the factors which lead to 
differentiation of this tissue and the neurogenic potential. Orbital adipose stem cell ability to 
differentiate into smooth muscle, neuronal lineages and adipocytes may also provide novel 
therapeutic treatments in disease affecting nerves, soft tissue, and muscles in the orbit. In 
addition, understanding the factors necessary for adipogenesis and expansion of the orbital 
adipose compartment in diseases such as TED has significant clinical applications. The ease 
of access to orbital adipose tissue makes it an interesting new target for stem cell research.  
4.3 Pathology 
Thyroid eye disease is an autoimmune inflammatory disease that has significant orbital 
consequences. Clinical signs of thyroid eye disease can vary from mild to severe and include 
proptosis (bulging of the eye), strabismus (double vision), bulging eyelids, exposure 
keratopathy, eyelid retraction and optic neuropathy. Enlargement of the extraocular muscles 
and expansion of the orbital fat from stimulation of orbital fibroblasts and adipogenesis in 
the fixed volume of the bony orbit can lead to these symptoms. Increased volume of the 
retroocular tissue and fibrotic changes can compress the optic nerve, cause extraocular 
muscle or eyelid dysfunction, or push the eye forward leading to corneal compromise.  
The pathology of thyroid eye disease involves an autoantibody cross-reaction from the 
thyroid-stimulating hormone (TSH) receptor with orbital fibroblasts. This leads to orbital 
fibroblast stimulation of lymphocytes, release of various cytokines and stimulation of orbital 
fibroblast production of glycosaminoglycans that increase volume by osmotic edema. In 
addition, preadipocyte fibroblasts in this environment can differentiate into adipocytes, 
leading to expansion of the orbital fat cavity. De novo adipogenesis within orbital tissues is 
an important factor in the pathology of TED (Kumar et al, 2003). Proliferation of fibroblasts 
and adipocytes and secondary hyaluronan accumulation (among other aminoglycosides) 
causes tissue volume expansion, orbital congestion, exophthalmos, and compressive optic 
neuropathy (Kahaly et al, 1998). Differentiation of fibroblasts to adipocytes and proliferation 
of orbital fibroblasts are thus critical steps in the development of TED.  
 
 
Fig. 4. Orbital Congestion from extraocular muscle enlargement in TED Note: arrows 
pointing to enlarged extraocular muscles 
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Fibroblast proliferation and infiltration into muscle fibers leads to extraocular muscle 
fibrosis and disabling diplopia, which some classify as the first subtype of TRO, 
characterized by prominent extraocular muscle enlargement (see Figure 4) and diplopia 
(Hiromatsu et al, 2000). Fibroblast differentiation into adipocytes leads to accumulation of 
fatty tissue in the orbit, which has been classified by some as type two TED, associated with 
expansion of the orbital fat compartment and proptosis (Hiromatsu et al, 2000). Thus, a key 
aspect of the clinical progression of TED is the ability of these fibroblasts to differentiate into 
adipocytes and propagate at a pathological level.  
4.4 Treatment 
Traditional treatment of TED focuses on the ocular sequelae. Proptosis or eyelid retraction 
can lead to corneal exposure. Mild cases may be treated with medical management, such as 
aggressive lubrication, elevation of the head while sleeping, patching at night, and the use of 
eye shields. Patients with persistent symptoms despite these treatments may necessitate 
tarsorrhaphy (surgical closure of part of the eyelid) to help protect the cornea. In severe 
cases, orbital decompression (removing some of the bones of the orbit cavity to expand 
orbital volume) is sometimes indicated. Lid retraction and resultant exposure keratopathy 
are treated with aggressive lubrication, patching, botulinum toxin to the Müllers muscle, 
and sometimes a tarsorrhaphy in the near term; levator recession and lower lid retraction 
repair via a number of different techniques is used for permanent treatment of lid retraction. 
In cases of optic neuropathy from compression at the apex, steroids and surgical treatment 
with orbital decompression may be used. For disabling diplopia, radiation therapy and 
steroids may be of benefit. Surgical intervention is indicated once disease stability has been 
documented (with prisms and patching often recommended in the interim if the above 
treatment modalities are not sufficient). The order of any possible surgical intervention is 
important, with decompression prior to strabismus surgery followed by eyelid surgery, in 
order to achieve the best long-term outcome.  
Despite various treatment options available, the ophthalmopathy may be progressive 
during times of thyroid dysfunction making surgical intervention more risky. In addition, 
some patients are not good candidates for surgery. Steroids are used as treatment in many 
cases, but the side effect profile of steroids is significant. As such, treatment advances have 
more recently been focused on alternative forms of immunomodulation (Salvi et al, 2006).  
4.5 Further stem cell applications and new advances 
Localization of orbital stem cells may help provide important therapeutic targets for TED. 
Preadipocyte fibroblasts in the adipose tissues are the precursor cells that differentiate into 
adipocytes in a process controlled by multiple regulatory genes and transcription factors 
(Sorisky, 1999). Preadipocyte fibroblast differentiation is associated with an increase in TSH 
receptor mRNA expression in patients with TED (Feliciello et al, 1993). Studies have also 
shown that cultured orbital preadipocytes can be induced in vitro to differentiate into 
adipocytes with functional TSH receptors (Valyasevi, 1992). Significant progress has been 
made into understanding the interactions between autologous T-lymphocytes and 
proliferation of fibroblasts (Feldon et al, 2005; Valyasevi et al, 1992). Understanding the 
factors that lead to differentiation of these fibroblasts into adipocytes as well as their 
proliferation in the orbit may help provide interventions to prevent this cell differentiation 
and stimulation. In addition, if orbital adipose stem cells are able to differentiate into 
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neuronal, adipose and smooth muscle lineages, they may offer treatment options for myriad 
ocular conditions.  
Orbital stem cells have been studied much less extensively than those in other areas of 
ophthalmology. The potential clinical applications for research in this area are broad. Orbital 
adipose tissue and the reservoirs of stem cells within are routinely excised during 
blepharoplasty surgery. As such, further research into these progenitor cells may provide 
insight on pathological processes affecting the orbit, such as TED. In addition, treatment 
modalities may be advanced through harvesting and differentiation of these stem cells.  
5. Eyelid 
5.1 Background 
The eyelid is made up of an anterior and posterior lamella, both of which are essential to 
maintaining appropriate lid height, eyelid closure, blink dynamic, functioning of the 
nasolacrimal drainage system and protection of the globe. The skin of the eyelid is the 
thinnest in the body, with no underlying subcutaneous fat layer. Underlying the skin are the 
muscles of protraction, the orbicularis oculi, whose function can become altered by diseases 
such as seventh nerve palsies or benign essential blepharospasm. The orbital septum is the 
next layer which is a thin, multilayered sheet of fibrous tissue that separates preseptal from 
postseptal or orbital tissue planes. The fat lies posterior to the septum and anterior to the 
muscles of retraction, the levator palpebrae and the müllers muscle. Inferior to the müllers  
 
 
Fig. 5. Anatomy of the eyelid (Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye 
Institute, University of Miami Miller School of Medicine) 
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Fibroblast proliferation and infiltration into muscle fibers leads to extraocular muscle 
fibrosis and disabling diplopia, which some classify as the first subtype of TRO, 
characterized by prominent extraocular muscle enlargement (see Figure 4) and diplopia 
(Hiromatsu et al, 2000). Fibroblast differentiation into adipocytes leads to accumulation of 
fatty tissue in the orbit, which has been classified by some as type two TED, associated with 
expansion of the orbital fat compartment and proptosis (Hiromatsu et al, 2000). Thus, a key 
aspect of the clinical progression of TED is the ability of these fibroblasts to differentiate into 
adipocytes and propagate at a pathological level.  
4.4 Treatment 
Traditional treatment of TED focuses on the ocular sequelae. Proptosis or eyelid retraction 
can lead to corneal exposure. Mild cases may be treated with medical management, such as 
aggressive lubrication, elevation of the head while sleeping, patching at night, and the use of 
eye shields. Patients with persistent symptoms despite these treatments may necessitate 
tarsorrhaphy (surgical closure of part of the eyelid) to help protect the cornea. In severe 
cases, orbital decompression (removing some of the bones of the orbit cavity to expand 
orbital volume) is sometimes indicated. Lid retraction and resultant exposure keratopathy 
are treated with aggressive lubrication, patching, botulinum toxin to the Müllers muscle, 
and sometimes a tarsorrhaphy in the near term; levator recession and lower lid retraction 
repair via a number of different techniques is used for permanent treatment of lid retraction. 
In cases of optic neuropathy from compression at the apex, steroids and surgical treatment 
with orbital decompression may be used. For disabling diplopia, radiation therapy and 
steroids may be of benefit. Surgical intervention is indicated once disease stability has been 
documented (with prisms and patching often recommended in the interim if the above 
treatment modalities are not sufficient). The order of any possible surgical intervention is 
important, with decompression prior to strabismus surgery followed by eyelid surgery, in 
order to achieve the best long-term outcome.  
Despite various treatment options available, the ophthalmopathy may be progressive 
during times of thyroid dysfunction making surgical intervention more risky. In addition, 
some patients are not good candidates for surgery. Steroids are used as treatment in many 
cases, but the side effect profile of steroids is significant. As such, treatment advances have 
more recently been focused on alternative forms of immunomodulation (Salvi et al, 2006).  
4.5 Further stem cell applications and new advances 
Localization of orbital stem cells may help provide important therapeutic targets for TED. 
Preadipocyte fibroblasts in the adipose tissues are the precursor cells that differentiate into 
adipocytes in a process controlled by multiple regulatory genes and transcription factors 
(Sorisky, 1999). Preadipocyte fibroblast differentiation is associated with an increase in TSH 
receptor mRNA expression in patients with TED (Feliciello et al, 1993). Studies have also 
shown that cultured orbital preadipocytes can be induced in vitro to differentiate into 
adipocytes with functional TSH receptors (Valyasevi, 1992). Significant progress has been 
made into understanding the interactions between autologous T-lymphocytes and 
proliferation of fibroblasts (Feldon et al, 2005; Valyasevi et al, 1992). Understanding the 
factors that lead to differentiation of these fibroblasts into adipocytes as well as their 
proliferation in the orbit may help provide interventions to prevent this cell differentiation 
and stimulation. In addition, if orbital adipose stem cells are able to differentiate into 
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neuronal, adipose and smooth muscle lineages, they may offer treatment options for myriad 
ocular conditions.  
Orbital stem cells have been studied much less extensively than those in other areas of 
ophthalmology. The potential clinical applications for research in this area are broad. Orbital 
adipose tissue and the reservoirs of stem cells within are routinely excised during 
blepharoplasty surgery. As such, further research into these progenitor cells may provide 
insight on pathological processes affecting the orbit, such as TED. In addition, treatment 
modalities may be advanced through harvesting and differentiation of these stem cells.  
5. Eyelid 
5.1 Background 
The eyelid is made up of an anterior and posterior lamella, both of which are essential to 
maintaining appropriate lid height, eyelid closure, blink dynamic, functioning of the 
nasolacrimal drainage system and protection of the globe. The skin of the eyelid is the 
thinnest in the body, with no underlying subcutaneous fat layer. Underlying the skin are the 
muscles of protraction, the orbicularis oculi, whose function can become altered by diseases 
such as seventh nerve palsies or benign essential blepharospasm. The orbital septum is the 
next layer which is a thin, multilayered sheet of fibrous tissue that separates preseptal from 
postseptal or orbital tissue planes. The fat lies posterior to the septum and anterior to the 
muscles of retraction, the levator palpebrae and the müllers muscle. Inferior to the müllers  
 
 
Fig. 5. Anatomy of the eyelid (Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye 
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muscle is the tarsus, a firm, dense plate of connective tissue that serves as the “backbone” of 
the eyelid. The most posterior layer is the conjunctiva which extends from the 
mucocutaneous junction to the fornix (see Figure 5). 
The purpose of this section is to discuss potential stem cell applications in cutaneous wound 
repair in the eyelid as well as neurogenic causes of poor orbicularis tone, namely facial 
nerve palsy. While stem cell applications may also extend to the muscles of retraction, the 
tarsus and posterior lamellar reconstruction, the chapter will focus on these two principal 
areas.  
5.2 Pathology 
Pathologic processes affecting the cutaneous layer of the eyelid are extensive. The primary 
relevance of stem cell research to the eyelid skin relate to tissue reengineering in the cases of 
loss of tissue that most often arise from cutaneous malignancy, orbital malignancy, or 
trauma. While only 15-20% of eyelid neoplasms are malignant, malignancy is becoming an 
increasingly common cause for severe loss of eyelid tissue. Basal cell carcinoma, squamous 
cell carcinoma, melanoma, sebaceous cell carcinoma as well as other much less frequent 
malignancies can invade locally, necessitating extensive resection. In cases of recurrent 
malignancies in patients who have undergone previous radiation, tissue shortage and poor 
vascular supply compound this issue. 
In addition, traumatic and post-surgical cases of anterior lamellar deficiency can have 
significant potential ocular repercussions. Restoration of eyelid function is essential to the 
eye, as the eyelid functions to lubricate and protect the globe and eyelid opening is 
necessary for vision. Improper repair of eyelid defects or chronic wound healing problems 
can lead to loss of the vision and even loss of the eye.  
5.3 Stem cell localization 
Cutaneous wound repair in the eyelid, as in other places of the body, has been researched 
extensively. Wound healing and subsequent scar formation occurs through a cascade of 
events, including inflammatory, proliferative (granulation tissue deposition) and tissue 
remodeling phases. The details of these processes are beyond the scope of this chapter (see 
Lau et al, 2009 for a good review), but stem cells are integral to each of the phases. In the 
process of wound healing, several factors lead to a relatively hypoxic environment, in which 
bone marrow-derived mesenchymal stem cells thrive (Ren, 2006). Hypertrophic scars or 
keloids can develop from dysregulation of some of the processes involved in wound repair. 
Conversely, inadequate healing after radiation, infection, or in cases of poor vascular status 
often seen in diabetics or smokers can lead to insufficient wound repair.  
Where are the stem cells? The major components of the epidermis with the potential for self-
renewal are the interfollicular epidermis, sebaceous gland and hair follicle. These are all 
repopulated by the differentiation of their own stem cells in physiologic conditions (Ko et al, 
2011). In cases of skin injury, the stem cells become more pluripotent and are able to 
repopulate one another. For example, keratinocytes that reepithelialize a wound are derived 
from both the interfollicular epithelial stem cells and the hair follicle bulge stem cells (Lau et 
al, 2009). The interfollicular epithelial stem cells reside in the basal layer of the interfollicular 
epidermis. The hair follicle bulge epidermal stem cells are located in the outer root sheath of 
the hair follicle and play an essential role in epidermal healing in the early phases of wound 
repair (Nowak et al, 2008). In addition, the bulge epidermal stem cells retain a larger 
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reservoir with age as opposed to the interfollicular stem cells which decline with age 
(Nowak et al, 2008). This tissue is easily isolated, allowing for easier procurement of these 
stem cells.  
What about the surrounding environment? Angiogenesis plays a key role in wound healing, 
and is likewise dependent on surrounding stem cells. Precursor cells such as the “tissue-
resident endothelial precursors” and “pluripotent nestin expressing cells” (Lau et al, 2009) 
are important components to this process. In addition, as previously highlighted, adipose 
stem cells may also play a role in wound healing through promotion of angiogenesis. As 
with mesenchymal stem cells, adipose-derived stromal cells proliferate and support 
angiogenesis under the hypoxic conditions of wound healing (Lee et al, 2009). Chemokines 
also play an integral role as they induce wound repair via the accumulation of mesenchymal 
derived stem cells both in vitro and in vivo in the mouse model (Sasaki et al, 2008). It is 
thought that this process is modulated through paracrine signaling and the release of 
growth factors such as fibroblast growth factor and endothelial growth factors. Stem cells 
therefore contribute to wound healing both through repopulation of the cells that are 
essential for wound repair (i.e. keratinocytes) as well as modulating the wound repair 
process.  
5.4 Treatment 
Treatment of eyelid pathology is dependent on the underlying etiology and subsequent 
defect. Eyelid defects are repaired by sub-specialty trained Oculoplastic surgeons to 
reconstruct an anterior and posterior lamella best able to simulate normal anatomy. The 
myriad techniques for repair are beyond the scope of this chapter, but each is aimed at 
achieving the optimal functional and cosmetic result. In cases of severe trauma or tumor 
resection, the absence of an adequate amount of tissue for anterior lamellar reconstruction 
can be a complicating factor. Tissue expanders and other advances are helpful techniques in 
these types of patients, but tissue engineering with viable stem cell transplantation has 
potential significant applications.  
5.5 Further stem cell applications and new advances 
In patients with large eyelid defects from cutaneous malignancy requiring reconstruction, 
stem cells may help augment wound repair. In many patients with recurrent malignancy 
that have previously undergone radiation therapy, the risk of tissue necrosis is increased 
and stem cell promotion of angiogenesis may have an integral role. Patients with radiation 
damage may also have decreased functionality of their own stem cells. Certain factors 
integral to attracting stem cells to the wound, thus essential to the wound healing process, 
can also become deficient with age and diabetes (Ko et Al, 2010).  
Because of the deficiency in stem cell functionality in cases of radiation, diabetes and age, 
stem cell application to these wounds may accelerate healing. Stem cell application to 
wounds using artificial dermis in patients with radiation injuries was shown to improve fat 
angiogenesis and dermal reconstitution, and minimize inflammatory epidermal damage 
(Akita et al, 2010). In addition, mesenchymal stem cells applied to wounds were found to 
accelerate wound closure and increase proangiogenic factors in both normal and diabetic 
mice (Wu et al, 2007). Translating these findings into clinical application, bone marrow-
derived stem cells were applied topically to non-healing wounds and led to clinical closure 
of the wound and histological evidence of reduced scarring (Badiavas & Falanga, 2003). 
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muscle is the tarsus, a firm, dense plate of connective tissue that serves as the “backbone” of 
the eyelid. The most posterior layer is the conjunctiva which extends from the 
mucocutaneous junction to the fornix (see Figure 5). 
The purpose of this section is to discuss potential stem cell applications in cutaneous wound 
repair in the eyelid as well as neurogenic causes of poor orbicularis tone, namely facial 
nerve palsy. While stem cell applications may also extend to the muscles of retraction, the 
tarsus and posterior lamellar reconstruction, the chapter will focus on these two principal 
areas.  
5.2 Pathology 
Pathologic processes affecting the cutaneous layer of the eyelid are extensive. The primary 
relevance of stem cell research to the eyelid skin relate to tissue reengineering in the cases of 
loss of tissue that most often arise from cutaneous malignancy, orbital malignancy, or 
trauma. While only 15-20% of eyelid neoplasms are malignant, malignancy is becoming an 
increasingly common cause for severe loss of eyelid tissue. Basal cell carcinoma, squamous 
cell carcinoma, melanoma, sebaceous cell carcinoma as well as other much less frequent 
malignancies can invade locally, necessitating extensive resection. In cases of recurrent 
malignancies in patients who have undergone previous radiation, tissue shortage and poor 
vascular supply compound this issue. 
In addition, traumatic and post-surgical cases of anterior lamellar deficiency can have 
significant potential ocular repercussions. Restoration of eyelid function is essential to the 
eye, as the eyelid functions to lubricate and protect the globe and eyelid opening is 
necessary for vision. Improper repair of eyelid defects or chronic wound healing problems 
can lead to loss of the vision and even loss of the eye.  
5.3 Stem cell localization 
Cutaneous wound repair in the eyelid, as in other places of the body, has been researched 
extensively. Wound healing and subsequent scar formation occurs through a cascade of 
events, including inflammatory, proliferative (granulation tissue deposition) and tissue 
remodeling phases. The details of these processes are beyond the scope of this chapter (see 
Lau et al, 2009 for a good review), but stem cells are integral to each of the phases. In the 
process of wound healing, several factors lead to a relatively hypoxic environment, in which 
bone marrow-derived mesenchymal stem cells thrive (Ren, 2006). Hypertrophic scars or 
keloids can develop from dysregulation of some of the processes involved in wound repair. 
Conversely, inadequate healing after radiation, infection, or in cases of poor vascular status 
often seen in diabetics or smokers can lead to insufficient wound repair.  
Where are the stem cells? The major components of the epidermis with the potential for self-
renewal are the interfollicular epidermis, sebaceous gland and hair follicle. These are all 
repopulated by the differentiation of their own stem cells in physiologic conditions (Ko et al, 
2011). In cases of skin injury, the stem cells become more pluripotent and are able to 
repopulate one another. For example, keratinocytes that reepithelialize a wound are derived 
from both the interfollicular epithelial stem cells and the hair follicle bulge stem cells (Lau et 
al, 2009). The interfollicular epithelial stem cells reside in the basal layer of the interfollicular 
epidermis. The hair follicle bulge epidermal stem cells are located in the outer root sheath of 
the hair follicle and play an essential role in epidermal healing in the early phases of wound 
repair (Nowak et al, 2008). In addition, the bulge epidermal stem cells retain a larger 
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reservoir with age as opposed to the interfollicular stem cells which decline with age 
(Nowak et al, 2008). This tissue is easily isolated, allowing for easier procurement of these 
stem cells.  
What about the surrounding environment? Angiogenesis plays a key role in wound healing, 
and is likewise dependent on surrounding stem cells. Precursor cells such as the “tissue-
resident endothelial precursors” and “pluripotent nestin expressing cells” (Lau et al, 2009) 
are important components to this process. In addition, as previously highlighted, adipose 
stem cells may also play a role in wound healing through promotion of angiogenesis. As 
with mesenchymal stem cells, adipose-derived stromal cells proliferate and support 
angiogenesis under the hypoxic conditions of wound healing (Lee et al, 2009). Chemokines 
also play an integral role as they induce wound repair via the accumulation of mesenchymal 
derived stem cells both in vitro and in vivo in the mouse model (Sasaki et al, 2008). It is 
thought that this process is modulated through paracrine signaling and the release of 
growth factors such as fibroblast growth factor and endothelial growth factors. Stem cells 
therefore contribute to wound healing both through repopulation of the cells that are 
essential for wound repair (i.e. keratinocytes) as well as modulating the wound repair 
process.  
5.4 Treatment 
Treatment of eyelid pathology is dependent on the underlying etiology and subsequent 
defect. Eyelid defects are repaired by sub-specialty trained Oculoplastic surgeons to 
reconstruct an anterior and posterior lamella best able to simulate normal anatomy. The 
myriad techniques for repair are beyond the scope of this chapter, but each is aimed at 
achieving the optimal functional and cosmetic result. In cases of severe trauma or tumor 
resection, the absence of an adequate amount of tissue for anterior lamellar reconstruction 
can be a complicating factor. Tissue expanders and other advances are helpful techniques in 
these types of patients, but tissue engineering with viable stem cell transplantation has 
potential significant applications.  
5.5 Further stem cell applications and new advances 
In patients with large eyelid defects from cutaneous malignancy requiring reconstruction, 
stem cells may help augment wound repair. In many patients with recurrent malignancy 
that have previously undergone radiation therapy, the risk of tissue necrosis is increased 
and stem cell promotion of angiogenesis may have an integral role. Patients with radiation 
damage may also have decreased functionality of their own stem cells. Certain factors 
integral to attracting stem cells to the wound, thus essential to the wound healing process, 
can also become deficient with age and diabetes (Ko et Al, 2010).  
Because of the deficiency in stem cell functionality in cases of radiation, diabetes and age, 
stem cell application to these wounds may accelerate healing. Stem cell application to 
wounds using artificial dermis in patients with radiation injuries was shown to improve fat 
angiogenesis and dermal reconstitution, and minimize inflammatory epidermal damage 
(Akita et al, 2010). In addition, mesenchymal stem cells applied to wounds were found to 
accelerate wound closure and increase proangiogenic factors in both normal and diabetic 
mice (Wu et al, 2007). Translating these findings into clinical application, bone marrow-
derived stem cells were applied topically to non-healing wounds and led to clinical closure 
of the wound and histological evidence of reduced scarring (Badiavas & Falanga, 2003). 
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Accelerated closure of wounds was also demonstrated by topical application of autologous 
bone marrow-derived mesenchymal stem cells in culture via a fibrin spray system (Falanga 
et al, 2007). Biological skin substitutes with stem cells have also been found to be suitable for 
wound bed repair for future autografting in cases of full-thickness skin defects caused by 
burn or trauma in a Phase I/II study (Schurr et al, 2009). Such advances and the application 
of other technologies and biomaterials for the application of cells and growth factors to the 
wound all have potential clinical application in repairing severe eyelid defects.  
In addition, as hair growth stimulation has been supported elsewhere by adipose stem cells, it 
is possible that these stem cells could also play a role in treatment of hypotrichosis and/or 
eyelash loss after eyelid reconstruction. Bimatoprost (LatisseTM) has been shown to promote 
hair growth in several studies (Wester et al, 2010) and has been found to be beneficial in cases 
of hypotrichosis, but it requires ongoing application of the solution. In cases of severe 
hypotrichosis, it is possible that stem cells applied topically may have a benefit as well. Won et 
al studied hair growth from topical application and injection of adipose stem cells and suggest 
that these cells may promote hair growth by increasing the proliferation of dermal papilla cells 
through cell cycle modulation and activation of the anagen phase (Won, 2010). This may be 
important in hair loss surrounding surgical wounds and in treatment of hypotrichosis.  
Stem cell research in the eyelid is in its nascency, but findings in other organ systems can be 
translated into wound repair. Future research may focus on application of cutaneous stem 
cell treatments to periocular regions. Research in this area may provide key therapeutic 
options for patients with significant soft tissue defects which can lead to inadequate ocular 
lubrication and blindness if not treated appropriately.  
6. Facial nerve  
6.1 Background 
A number of peripheral nerves greatly impact ocular function. For example, the facial nerve, 
cranial nerve seven, arises in the pons and enters the petrous temporal bone into the internal 
auditory meatus (in close proximity to the inner ear), then runs a tortuous course through 
the facial canal. It travels the longest distance through a bony canal of any nerve in the body. 
After passing through the facial canal it emerges from the stylomastoid foramen and passes 
through the parotid gland, where it divides into five major branches (see Figure 6). The five 
major branches that exit the parotid gland include the temporal, zygomatic, buccal, 
marginal mandibular and cervical branch, all of which are essential to facial movement. The 
facial nerve also functions as the efferent limb of the corneal reflex and the blink reflex.  
6.2 Stem cell localization  
Stem cells in the area of denervated axons have been found to have an essential role in the 
attachment and growth of the regenerating axons. These cells contribute to the up-
regulation of multiple genes and downstream release of cytokines and growth factors 
which provides a stimulatory environment for nerve repair (Walsh 2009). Schwann cells 
also initially up-regulate multiple factors used for the attachment and growth of 
regenerating axons.  
Over time, however, in the absence of axonal contact these cells slowly lose their capacity to 
proliferate and lose the ability to support axonal regeneration (Chen, 2010). Chronic 
denervation leads to a decrease in this capacity and a decline in the Schwann cell 
population, hindering further axonal regeneration (De Medinaceli & Rawlings, 1987). The 
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clinical implication is that axonal regeneration must occur during a “critical window” to 
maximize success of reinnervation.  
 
 
Fig. 6. Facial Nerve Anatomy (Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye 
Institute, University of Miami Miller School of Medicine) 
6.3 Pathology 
Seventh nerve injury can affect the periocular tissue and eye and lead to chronic irritation, 
corneal infection, and even blindness. Seventh nerve palsy is a cause of paralytic ectropion that 
causes neurogenic orbicularis dysfunction and chronic ocular symptoms. Upper eyelid 
lagophthalmos from orbicularis dysfunction and poor blinking and eyelid closure causes 
chronic ocular irritation and potential infection. Chronic stimulation of reflex secretors causes 
secondary tearing, but poor blink dynamic and lid closure can lead to severe exposure 
keratopathy and infection. The etiology ranges from viral or other infectious causes to 
congenital or neoplastic causes, and trauma, toxic exposures, or iatrogenic causes. In addition, 
because of the long course and narrow caliber of the canal, inflammatory processes involving 
the central nervous system and facial nerve, and traumatic or other injuries to the temporal 
bone and surrounding structures can affect the function of the nerve.  
The most common cause of unilateral facial paralysis is Bell’s palsy, idiopathic facial 
paralysis, which accounts for the majority of cases of acute unilateral facial paralysis. The 
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wound bed repair for future autografting in cases of full-thickness skin defects caused by 
burn or trauma in a Phase I/II study (Schurr et al, 2009). Such advances and the application 
of other technologies and biomaterials for the application of cells and growth factors to the 
wound all have potential clinical application in repairing severe eyelid defects.  
In addition, as hair growth stimulation has been supported elsewhere by adipose stem cells, it 
is possible that these stem cells could also play a role in treatment of hypotrichosis and/or 
eyelash loss after eyelid reconstruction. Bimatoprost (LatisseTM) has been shown to promote 
hair growth in several studies (Wester et al, 2010) and has been found to be beneficial in cases 
of hypotrichosis, but it requires ongoing application of the solution. In cases of severe 
hypotrichosis, it is possible that stem cells applied topically may have a benefit as well. Won et 
al studied hair growth from topical application and injection of adipose stem cells and suggest 
that these cells may promote hair growth by increasing the proliferation of dermal papilla cells 
through cell cycle modulation and activation of the anagen phase (Won, 2010). This may be 
important in hair loss surrounding surgical wounds and in treatment of hypotrichosis.  
Stem cell research in the eyelid is in its nascency, but findings in other organ systems can be 
translated into wound repair. Future research may focus on application of cutaneous stem 
cell treatments to periocular regions. Research in this area may provide key therapeutic 
options for patients with significant soft tissue defects which can lead to inadequate ocular 
lubrication and blindness if not treated appropriately.  
6. Facial nerve  
6.1 Background 
A number of peripheral nerves greatly impact ocular function. For example, the facial nerve, 
cranial nerve seven, arises in the pons and enters the petrous temporal bone into the internal 
auditory meatus (in close proximity to the inner ear), then runs a tortuous course through 
the facial canal. It travels the longest distance through a bony canal of any nerve in the body. 
After passing through the facial canal it emerges from the stylomastoid foramen and passes 
through the parotid gland, where it divides into five major branches (see Figure 6). The five 
major branches that exit the parotid gland include the temporal, zygomatic, buccal, 
marginal mandibular and cervical branch, all of which are essential to facial movement. The 
facial nerve also functions as the efferent limb of the corneal reflex and the blink reflex.  
6.2 Stem cell localization  
Stem cells in the area of denervated axons have been found to have an essential role in the 
attachment and growth of the regenerating axons. These cells contribute to the up-
regulation of multiple genes and downstream release of cytokines and growth factors 
which provides a stimulatory environment for nerve repair (Walsh 2009). Schwann cells 
also initially up-regulate multiple factors used for the attachment and growth of 
regenerating axons.  
Over time, however, in the absence of axonal contact these cells slowly lose their capacity to 
proliferate and lose the ability to support axonal regeneration (Chen, 2010). Chronic 
denervation leads to a decrease in this capacity and a decline in the Schwann cell 
population, hindering further axonal regeneration (De Medinaceli & Rawlings, 1987). The 
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clinical implication is that axonal regeneration must occur during a “critical window” to 
maximize success of reinnervation.  
 
 
Fig. 6. Facial Nerve Anatomy (Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye 
Institute, University of Miami Miller School of Medicine) 
6.3 Pathology 
Seventh nerve injury can affect the periocular tissue and eye and lead to chronic irritation, 
corneal infection, and even blindness. Seventh nerve palsy is a cause of paralytic ectropion that 
causes neurogenic orbicularis dysfunction and chronic ocular symptoms. Upper eyelid 
lagophthalmos from orbicularis dysfunction and poor blinking and eyelid closure causes 
chronic ocular irritation and potential infection. Chronic stimulation of reflex secretors causes 
secondary tearing, but poor blink dynamic and lid closure can lead to severe exposure 
keratopathy and infection. The etiology ranges from viral or other infectious causes to 
congenital or neoplastic causes, and trauma, toxic exposures, or iatrogenic causes. In addition, 
because of the long course and narrow caliber of the canal, inflammatory processes involving 
the central nervous system and facial nerve, and traumatic or other injuries to the temporal 
bone and surrounding structures can affect the function of the nerve.  
The most common cause of unilateral facial paralysis is Bell’s palsy, idiopathic facial 
paralysis, which accounts for the majority of cases of acute unilateral facial paralysis. The 
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etiology has been attributed to several possible causes including viral (such as HSV), 
inflammatory, autoimmune, and ischemic etiologies. In the large majority of cases, Bell’s 
palsy resolves spontaneously within the first few months (Ropper & Samuels, 2009), but 
others may persist longer and have more significant consequences.  
6.4 Treatment  
Even the non-ophthalmic literature highlights that the most important primary 
consideration in the treatment of facial paralysis is protection of the eye and vision (Meltzer 
& Alam, 2010). Temporary treatment includes artificial tears, ointment, eyelid taping, and 
moisture chambers. In cases without resolution, or other etiologies of seventh nerve 
dysfunction which are less likely to have spontaneous improvement, long-term treatment 
includes tarsorrhaphy, canthoplasty, gold weight placement, horizontal eyelid tightening, 
fascia lata or silicone suspension sling of the lower lid and full thickness hard palate 
mucosal grafting to the lower eyelid.  
In cases of damage to a nerve via transection or other trauma, surgical repair is often 
indicated. Gaps or scars are particularly complicated to repair as the regenerating axons face 
a gap between the injury and the target (which becomes more difficult to overcome the 
longer the distance). Interpositional nerve grafts are often used as a treatment for longer 
gaps or scar segments to provide a pathway for regenerating axons, while direct repair can 
be used for shorter areas of denervation (Millesi et al, 1972). Current strategies use cable 
grafting in most cases of facial paralysis when primary repair is not possible, using greater 
auricular, sural or medial and lateral antebrachial cutaneous nerves (Humphrey & Kreit, 
2008). Importantly, these grafts are only recommended if they are performed within the time 
period during which reinnervation is possible.  
Despite these treatments, however, recovery of nerve function is often suboptimal in cases 
of seventh nerve palsy. Prolonged degeneration in the distal denervated nerve leads to 
changes that render the Schwann cells less able to promote axon regeneration, thus limiting 
the success of these procedures over time (Meltzer et al, 2010). In addition, while peripheral 
nerves do regenerate better than the central nervous system, recovery can be incomplete or 
misdirected, even when surgical treatment is attempted. In the cases of facial nerve palsy, 
synkinesis (miswiring of nerves after injury) can lead to post paretic sequelae such as Marin 
Amat syndrome and crocodile tears. Chronic facial spasm can also develop after resolution 
of the facial nerve palsy. Surgical procedures in cases of chronic paralysis are often focused 
on static suspension procedures, regional myofascial procedures and free tissue transfer 
with the goal of achieving maximal symmetry. Ipsilateral and contralateral nerve transfers, 
static slings (such as used in the brow), dynamic muscle transfers, and gracilis 
microneurovascular free tissue transfer are all also used in the treatment of facial palsy, but 
have associated morbidities (Meltzer et al, 2010).  
6.5 Further stem cell applications and new advances 
Adipose and skin derived precursor cells have been shown to have the potential to 
differentiate and proliferate into Schwann and glial-like cells when treated with the 
appropriate medium (Zavan et al, 2010). While autologous nerve grafts remain the gold 
standard, harvesting of autologous stem cells and differentiation into neurogenic lineages 
has tremendous clinical potential in peripheral nerve injuries. The accessibility of skin and 
adipose derived stem cells may “bridge” the gap and allow translation of this into clinical 
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applications in such areas as facial nerve palsies. Hair follicle bulge cells used to repair a 
peripheral nerve gap contributed to recovery of function by differentiating into glial cells 
(Amoh, 2005). Skin-derived stem cells injected into a nerve distal to a crush injury were 
found to associate with axons, express stem cell markers, and eventually express a 
myelinating phenotype (Walsh, 2009). Nerve repair in patients may be improved in the 
future by the use of autologous, cultured stem cells to help promote nerve regeneration. 
Skin and adipose derived stem cells have the added benefit that they can be easily harvested 
and have been shown to have neurogenic potential, as previously outlined.  
7. Retina 
The retina is developmentally an outgrowth from the forebrain, and like the rest of the 
central nervous system, exhibits neurodegenerative diseases that prove devastating to 
affected patients. Retinal degenerations often end with the death of retinal neurons, such as 
rod and cone photoreceptors in age-related macular degeneration and retinitis pigmentosa 
(discussed in section 7.1 below) and retinal ganglion cells in optic neuropathies such as 
glaucoma (discussed in section 7.2 below). Although it may be possible to salvage these cells 
before they die, for example, using neurotrophic factors or stem cells or gene therapy, for 
the many patients who have lost these cells, the challenge remains to figure out a way to 
replace them and thereby restore vision.  
7.1 Outer retina: Photoreceptors and retinal pigment epithelium 
7.1.1 Background 
Photoreceptors are the retinal cells that initiate vision by converting photons of light into 
chemical signals. In humans, photoreceptors are divided into rods and cones, which are 
responsible for dim, achromatic and brighter color vision, respectively. The center of the 
retina is more cone-dominant and the periphery more rod-dominant. Throughout the retina, 
photoreceptors are in close, critical contact with an adjacent layer of supportive cells, the 
retinal pigment epithelium (RPE). The RPE is responsible for phagocytosis of photoreceptor 
outer segments, critical to the constant replenishment of the membranous discs that house 
the photoreceptors’ photon-conversion machinery. The RPE is also responsible for the 
replenishment of critical photopigments in the photoreceptor outer segments.  
7.1.2 Pathology 
Primary degeneration of either the photoreceptors or RPE leads to eventual degeneration of 
the other, and in either case degenerative loss of vision. Such pathologies are observed in a 
number of diseases, including common diseases like macular degeneration, and less 
common diseases such as retinitis pigmentosa.  
Age-related macular degeneration (ARMD) is one of the most common causes of blindness 
worldwide (Klein et al., 2011). ARMD usually affects older adults and occurs in “dry” and 
“wet” forms. In dry ARMD, deposits called drusen accumulate between the retina and the 
choroid, and slow degeneration of RPE and later photoreceptors leads to localized 
“geographic” atrophy and central vision loss. In wet ARMD, new, leaky blood vessels grow 
up from the choroid behind the retina, leading to acute vision loss (Wong et al., 2008).  
Retinitis pigmentosa is a collection of genetic diseases that generally start with night 
blindness and then continues on to tunnel vision, reflecting a pathology that affects rod 
photoreceptors in the peripheral retina earlier in the disease (Sahel et al.). Hundreds of 
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etiology has been attributed to several possible causes including viral (such as HSV), 
inflammatory, autoimmune, and ischemic etiologies. In the large majority of cases, Bell’s 
palsy resolves spontaneously within the first few months (Ropper & Samuels, 2009), but 
others may persist longer and have more significant consequences.  
6.4 Treatment  
Even the non-ophthalmic literature highlights that the most important primary 
consideration in the treatment of facial paralysis is protection of the eye and vision (Meltzer 
& Alam, 2010). Temporary treatment includes artificial tears, ointment, eyelid taping, and 
moisture chambers. In cases without resolution, or other etiologies of seventh nerve 
dysfunction which are less likely to have spontaneous improvement, long-term treatment 
includes tarsorrhaphy, canthoplasty, gold weight placement, horizontal eyelid tightening, 
fascia lata or silicone suspension sling of the lower lid and full thickness hard palate 
mucosal grafting to the lower eyelid.  
In cases of damage to a nerve via transection or other trauma, surgical repair is often 
indicated. Gaps or scars are particularly complicated to repair as the regenerating axons face 
a gap between the injury and the target (which becomes more difficult to overcome the 
longer the distance). Interpositional nerve grafts are often used as a treatment for longer 
gaps or scar segments to provide a pathway for regenerating axons, while direct repair can 
be used for shorter areas of denervation (Millesi et al, 1972). Current strategies use cable 
grafting in most cases of facial paralysis when primary repair is not possible, using greater 
auricular, sural or medial and lateral antebrachial cutaneous nerves (Humphrey & Kreit, 
2008). Importantly, these grafts are only recommended if they are performed within the time 
period during which reinnervation is possible.  
Despite these treatments, however, recovery of nerve function is often suboptimal in cases 
of seventh nerve palsy. Prolonged degeneration in the distal denervated nerve leads to 
changes that render the Schwann cells less able to promote axon regeneration, thus limiting 
the success of these procedures over time (Meltzer et al, 2010). In addition, while peripheral 
nerves do regenerate better than the central nervous system, recovery can be incomplete or 
misdirected, even when surgical treatment is attempted. In the cases of facial nerve palsy, 
synkinesis (miswiring of nerves after injury) can lead to post paretic sequelae such as Marin 
Amat syndrome and crocodile tears. Chronic facial spasm can also develop after resolution 
of the facial nerve palsy. Surgical procedures in cases of chronic paralysis are often focused 
on static suspension procedures, regional myofascial procedures and free tissue transfer 
with the goal of achieving maximal symmetry. Ipsilateral and contralateral nerve transfers, 
static slings (such as used in the brow), dynamic muscle transfers, and gracilis 
microneurovascular free tissue transfer are all also used in the treatment of facial palsy, but 
have associated morbidities (Meltzer et al, 2010).  
6.5 Further stem cell applications and new advances 
Adipose and skin derived precursor cells have been shown to have the potential to 
differentiate and proliferate into Schwann and glial-like cells when treated with the 
appropriate medium (Zavan et al, 2010). While autologous nerve grafts remain the gold 
standard, harvesting of autologous stem cells and differentiation into neurogenic lineages 
has tremendous clinical potential in peripheral nerve injuries. The accessibility of skin and 
adipose derived stem cells may “bridge” the gap and allow translation of this into clinical 
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applications in such areas as facial nerve palsies. Hair follicle bulge cells used to repair a 
peripheral nerve gap contributed to recovery of function by differentiating into glial cells 
(Amoh, 2005). Skin-derived stem cells injected into a nerve distal to a crush injury were 
found to associate with axons, express stem cell markers, and eventually express a 
myelinating phenotype (Walsh, 2009). Nerve repair in patients may be improved in the 
future by the use of autologous, cultured stem cells to help promote nerve regeneration. 
Skin and adipose derived stem cells have the added benefit that they can be easily harvested 
and have been shown to have neurogenic potential, as previously outlined.  
7. Retina 
The retina is developmentally an outgrowth from the forebrain, and like the rest of the 
central nervous system, exhibits neurodegenerative diseases that prove devastating to 
affected patients. Retinal degenerations often end with the death of retinal neurons, such as 
rod and cone photoreceptors in age-related macular degeneration and retinitis pigmentosa 
(discussed in section 7.1 below) and retinal ganglion cells in optic neuropathies such as 
glaucoma (discussed in section 7.2 below). Although it may be possible to salvage these cells 
before they die, for example, using neurotrophic factors or stem cells or gene therapy, for 
the many patients who have lost these cells, the challenge remains to figure out a way to 
replace them and thereby restore vision.  
7.1 Outer retina: Photoreceptors and retinal pigment epithelium 
7.1.1 Background 
Photoreceptors are the retinal cells that initiate vision by converting photons of light into 
chemical signals. In humans, photoreceptors are divided into rods and cones, which are 
responsible for dim, achromatic and brighter color vision, respectively. The center of the 
retina is more cone-dominant and the periphery more rod-dominant. Throughout the retina, 
photoreceptors are in close, critical contact with an adjacent layer of supportive cells, the 
retinal pigment epithelium (RPE). The RPE is responsible for phagocytosis of photoreceptor 
outer segments, critical to the constant replenishment of the membranous discs that house 
the photoreceptors’ photon-conversion machinery. The RPE is also responsible for the 
replenishment of critical photopigments in the photoreceptor outer segments.  
7.1.2 Pathology 
Primary degeneration of either the photoreceptors or RPE leads to eventual degeneration of 
the other, and in either case degenerative loss of vision. Such pathologies are observed in a 
number of diseases, including common diseases like macular degeneration, and less 
common diseases such as retinitis pigmentosa.  
Age-related macular degeneration (ARMD) is one of the most common causes of blindness 
worldwide (Klein et al., 2011). ARMD usually affects older adults and occurs in “dry” and 
“wet” forms. In dry ARMD, deposits called drusen accumulate between the retina and the 
choroid, and slow degeneration of RPE and later photoreceptors leads to localized 
“geographic” atrophy and central vision loss. In wet ARMD, new, leaky blood vessels grow 
up from the choroid behind the retina, leading to acute vision loss (Wong et al., 2008).  
Retinitis pigmentosa is a collection of genetic diseases that generally start with night 
blindness and then continues on to tunnel vision, reflecting a pathology that affects rod 
photoreceptors in the peripheral retina earlier in the disease (Sahel et al.). Hundreds of 
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different mutations in dozens of different primary genes lead to similar pathologies, 
including RPE hypertrophy, migration and proliferation and photoreceptor death (Daiger et 
al., 2007). Interestingly, these mutations may be found in either the photoreceptor or RPE 
cells, reinforcing the mutual interdependence of these two cell types. 
7.1.3 Current treatment 
Wet ARMD is currently treated with success using anti-VEGF antibodies (Mitchell, 2011); 
dry ARMD is slowed slightly by nutritional supplementation, at least in the later stages. 
Both of these sets of degenerative processes have in recent years become the target of a 
number of newer therapeutic approaches designed to slow, halt, or even reverse the disease 
process. Neurotrophic factors such as ciliary neurotrophic factor (CNTF) may provide 
neuroprotection (Sieving et al., 2006; Tao et al., 2002; Zhang et al., 2011). Gene therapy 
delivered with viral vectors may replace the defective gene (Ashtari et al., 2011; Cideciyan, 
2010; Simonelli et al., 2009). However, both forms of the disease eventually lead to loss of 
photoreceptors and RPE cells, and these are not replaced through endogenous reparative 
mechanisms once lost. Thus there is considerable motivation to bring stem cell therapies to 
treat these diseases.  
7.1.4 Stem cell research and opportunities 
Significant steps forward have been made in using stem cells to replace photoreceptors and 
retinal pigment epithelium to address these diseases. Stem cells may prove therapeutic in 
two regards. As more commonly conceived, they may differentiate into the cell type lost in 
the disease, take up that cell’s connections, and thereby replace that cell’s function. 
However, it turns out stem cells also have remarkable properties of neuroprotection. 
How do stem cells protect other cells from degenerating? One key way likely involves their 
expression and secretion of neurotrophic factors (Crigler et al., 2006) and immune system 
modulators that deter invading immune cells from creating neuronal death (Pluchino et al., 
2005). Their neuroprotective activity can be further enhanced by transducing them with 
vectors that further increase their expression of specific neurotrophic survival factors (see 
section 7.2.4). An attraction to harnessing the neuroprotective effects of stem cell 
transplantation is that it does not require any specific differentiation and integration: the 
transplanted cells need only persist locally, for example in the vitreous or subretinal space. 
Success with such approaches has been demonstrated in rat and mouse models of retinitis 
pigmentosa (Arnhold et al., 2007; Inoue et al., 2007).  
A major advantage in thinking about cell replacement therapy approaches for these diseases 
is that photoreceptors and RPE cells only have to interact with local, neighboring cells to 
carry out their full roles in retinal physiology (Lamba et al., 2009b). A number of stem cell 
therapies are approaching human clinical investigation now, including trials in the United 
Kingdom, Israel and the United States. All three of these are directed at the use of stem cell-
derived RPE cells implanted subretinally to resume the function of lost RPE and thereby 
protect photoreceptors from further degeneration (Lu et al., 2009; Lund et al., 2006). Similar 
approaches for photoreceptor replacement have demonstrated some success (Lamba et al., 
2009a) and may be aided by treatments that manipulate the host retinal environment to 
encourage grafting and integration, for example through steroid treatment (Singhal et al.), 
matrix metalloproteinase manipulation (Zhang et al., 2007), or disruption of the outer 
limiting membrane of the retina (West et al., 2008).  
 
Stem Cells in Ophthalmology 425 
A number of cell sources may prove valuable for replacing photoreceptors, although direct 
comparison of different cell sources has not yet been performed. One study recently 
examined retinal progenitors isolated from different developmental stages, and found that 
donor cells from retinas at an age close to photoreceptors’ peak birthdate in vivo 
demonstrated the greatest integration after transplantation (Hernit-Grant & Macklis; 
MacLaren et al.). , and postmitotic rod precursors reintegrated synaptically in the 
photoreceptor layer better than multipotent progenitor cells. Transplantation of immature 
rods improved visually evoked potentials in mouse models of retinitis pigmentosa, either by 
direct synaptic input or by improving the function of the residual photoreceptors (MacLaren 
et al.). 
Can we harvest retinal stem cells from patients? Recently, it was demonstrated that in adult 
humans, a small population of stem cells reside at the edge of the retina, called the ciliary 
marginal zone (Coles et al., 2004; Tropepe et al., 2000). It is unclear where these cells come 
from during development, or whether they have any normal role to play in the retina. 
Importantly, however, if you remove them from the eye into cell cultures, they can 
proliferate and be induced to differentiate into all the cell types in the retina, including rods 
and cones (Coles et al., 2004; Tropepe et al., 2000). Such a technique could benefit patients by 
offering a source of retinal progenitor cells that are autologous (from the patient 
themselves), or allogeneic (from a matched donor), for example. However, many questions 
remain, including how to optimally support these progenitor cells’ proliferative capacity, 
and how to guide their differentiation into specific retinal neurons such as photoreceptors or 
retinal ganglion cells. 
7.2 Inner retina and optic nerve 
7.2.1 Background 
Retinal ganglion cell axons originate at the retinal ganglion cell bodies in the inner layer of 
the retina. Retinal ganglion cells receive synaptic signals from inner retinal bipolar and 
amacrine cells, and project this visual information down their axon in the nerve fiber layer. 
The optic nerve begins at the optic nerve head or optic disk, and from there through the 
orbit (Wolff, 1948) and optic canal (Maniscalco & Habal, 1978) to the chiasm, optic tract and 
into the brain.  
7.2.2 Pathology 
The inner retina and optic nerve are commonly involved in disease, resulting in retinopathy 
and optic neuropathy, and thus visual loss. Vein occlusions, in which the inner retinal 
circulation is compromised, are the most common cause of inner retinal injury, damaging 
retinal ganglion cells as well as amacrine cells but sparing the outer retina including 
photoreceptors (Laouri et al., 2011). Less common, retinal artery occlusions have the same 
effects (Mangat, 1995). More specific damage to retinal ganglion cells occurs when the 
ischemic insult is observed at the optic nerve in arteritic and non-arteritic anterior ischemic 
optic neuropathies. This is generally accompanied by a pale disk and loss of optic nerve 
axons. Ischemia in either location may result from hypotension or from occlusive or embolic 
disease (Connolly et al., 1994; Johnson et al., 1987). 
Glaucoma is the most common optic neuropathy and the most common cause of irreversible 
blindness worldwide (Quigley & Broman, 2006). Glaucomatous optic neuropathy is 
distinguished by a distinct morphology of progressive excavation of the nerve head without 
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different mutations in dozens of different primary genes lead to similar pathologies, 
including RPE hypertrophy, migration and proliferation and photoreceptor death (Daiger et 
al., 2007). Interestingly, these mutations may be found in either the photoreceptor or RPE 
cells, reinforcing the mutual interdependence of these two cell types. 
7.1.3 Current treatment 
Wet ARMD is currently treated with success using anti-VEGF antibodies (Mitchell, 2011); 
dry ARMD is slowed slightly by nutritional supplementation, at least in the later stages. 
Both of these sets of degenerative processes have in recent years become the target of a 
number of newer therapeutic approaches designed to slow, halt, or even reverse the disease 
process. Neurotrophic factors such as ciliary neurotrophic factor (CNTF) may provide 
neuroprotection (Sieving et al., 2006; Tao et al., 2002; Zhang et al., 2011). Gene therapy 
delivered with viral vectors may replace the defective gene (Ashtari et al., 2011; Cideciyan, 
2010; Simonelli et al., 2009). However, both forms of the disease eventually lead to loss of 
photoreceptors and RPE cells, and these are not replaced through endogenous reparative 
mechanisms once lost. Thus there is considerable motivation to bring stem cell therapies to 
treat these diseases.  
7.1.4 Stem cell research and opportunities 
Significant steps forward have been made in using stem cells to replace photoreceptors and 
retinal pigment epithelium to address these diseases. Stem cells may prove therapeutic in 
two regards. As more commonly conceived, they may differentiate into the cell type lost in 
the disease, take up that cell’s connections, and thereby replace that cell’s function. 
However, it turns out stem cells also have remarkable properties of neuroprotection. 
How do stem cells protect other cells from degenerating? One key way likely involves their 
expression and secretion of neurotrophic factors (Crigler et al., 2006) and immune system 
modulators that deter invading immune cells from creating neuronal death (Pluchino et al., 
2005). Their neuroprotective activity can be further enhanced by transducing them with 
vectors that further increase their expression of specific neurotrophic survival factors (see 
section 7.2.4). An attraction to harnessing the neuroprotective effects of stem cell 
transplantation is that it does not require any specific differentiation and integration: the 
transplanted cells need only persist locally, for example in the vitreous or subretinal space. 
Success with such approaches has been demonstrated in rat and mouse models of retinitis 
pigmentosa (Arnhold et al., 2007; Inoue et al., 2007).  
A major advantage in thinking about cell replacement therapy approaches for these diseases 
is that photoreceptors and RPE cells only have to interact with local, neighboring cells to 
carry out their full roles in retinal physiology (Lamba et al., 2009b). A number of stem cell 
therapies are approaching human clinical investigation now, including trials in the United 
Kingdom, Israel and the United States. All three of these are directed at the use of stem cell-
derived RPE cells implanted subretinally to resume the function of lost RPE and thereby 
protect photoreceptors from further degeneration (Lu et al., 2009; Lund et al., 2006). Similar 
approaches for photoreceptor replacement have demonstrated some success (Lamba et al., 
2009a) and may be aided by treatments that manipulate the host retinal environment to 
encourage grafting and integration, for example through steroid treatment (Singhal et al.), 
matrix metalloproteinase manipulation (Zhang et al., 2007), or disruption of the outer 
limiting membrane of the retina (West et al., 2008).  
 
Stem Cells in Ophthalmology 425 
A number of cell sources may prove valuable for replacing photoreceptors, although direct 
comparison of different cell sources has not yet been performed. One study recently 
examined retinal progenitors isolated from different developmental stages, and found that 
donor cells from retinas at an age close to photoreceptors’ peak birthdate in vivo 
demonstrated the greatest integration after transplantation (Hernit-Grant & Macklis; 
MacLaren et al.). , and postmitotic rod precursors reintegrated synaptically in the 
photoreceptor layer better than multipotent progenitor cells. Transplantation of immature 
rods improved visually evoked potentials in mouse models of retinitis pigmentosa, either by 
direct synaptic input or by improving the function of the residual photoreceptors (MacLaren 
et al.). 
Can we harvest retinal stem cells from patients? Recently, it was demonstrated that in adult 
humans, a small population of stem cells reside at the edge of the retina, called the ciliary 
marginal zone (Coles et al., 2004; Tropepe et al., 2000). It is unclear where these cells come 
from during development, or whether they have any normal role to play in the retina. 
Importantly, however, if you remove them from the eye into cell cultures, they can 
proliferate and be induced to differentiate into all the cell types in the retina, including rods 
and cones (Coles et al., 2004; Tropepe et al., 2000). Such a technique could benefit patients by 
offering a source of retinal progenitor cells that are autologous (from the patient 
themselves), or allogeneic (from a matched donor), for example. However, many questions 
remain, including how to optimally support these progenitor cells’ proliferative capacity, 
and how to guide their differentiation into specific retinal neurons such as photoreceptors or 
retinal ganglion cells. 
7.2 Inner retina and optic nerve 
7.2.1 Background 
Retinal ganglion cell axons originate at the retinal ganglion cell bodies in the inner layer of 
the retina. Retinal ganglion cells receive synaptic signals from inner retinal bipolar and 
amacrine cells, and project this visual information down their axon in the nerve fiber layer. 
The optic nerve begins at the optic nerve head or optic disk, and from there through the 
orbit (Wolff, 1948) and optic canal (Maniscalco & Habal, 1978) to the chiasm, optic tract and 
into the brain.  
7.2.2 Pathology 
The inner retina and optic nerve are commonly involved in disease, resulting in retinopathy 
and optic neuropathy, and thus visual loss. Vein occlusions, in which the inner retinal 
circulation is compromised, are the most common cause of inner retinal injury, damaging 
retinal ganglion cells as well as amacrine cells but sparing the outer retina including 
photoreceptors (Laouri et al., 2011). Less common, retinal artery occlusions have the same 
effects (Mangat, 1995). More specific damage to retinal ganglion cells occurs when the 
ischemic insult is observed at the optic nerve in arteritic and non-arteritic anterior ischemic 
optic neuropathies. This is generally accompanied by a pale disk and loss of optic nerve 
axons. Ischemia in either location may result from hypotension or from occlusive or embolic 
disease (Connolly et al., 1994; Johnson et al., 1987). 
Glaucoma is the most common optic neuropathy and the most common cause of irreversible 
blindness worldwide (Quigley & Broman, 2006). Glaucomatous optic neuropathy is 
distinguished by a distinct morphology of progressive excavation of the nerve head without 
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significant pallor of the remaining neuroretinal rim. Within the retina, there are decreased 
numbers of retinal ganglion cell bodies in glaucoma (Giles & Soble, 1971; Minckler, 1989; 
Quigley, 1995), and this likely reflects death by apoptosis (Dkhissi et al., 1999; Kerrigan et 
al., 1997; Okisaka et al., 1997; Quigley et al., 1995). The number of retinal ganglion cells lost 
correlates with the visual field deficit (Quigley et al., 1989). In addition to the retinal 
ganglion cell body loss, there is loss of the ganglion cell axons, manifested by segmental loss 
of the nerve fiber layer (Airaksinen et al., 1984; Drance, 1985; Hoyt et al., 1973; Iwata et al., 
1985; Quigley et al., 1980), increased cup-to-disk ratio, thinning of the optic nerve (Stroman 
et al., 1995) and chiasm (Iwata et al., 1997), changes in post-synaptic cell counts within the 
lateral geniculate nucleus (Chaturvedi et al., 1993; Vickers et al., 1997; Weber et al., 2000; 
Yücel et al., 2000) (the main target of retinal ganglion cell axons in higher animals), and even 
the cerebral cortex (Crawford et al., 2001; Crawford et al., 2000).  
Other optic neuropathies include optic neuritis, ischemic optic neuropathy and compressive 
optic neuropathy, commonly associated with a tumor or aneurysm. Examples of these 
tumors include cavernous hemangioma, hemangiopericytoma, fibrous histiocytoma, 
lymphoma, and schwannoma. In addition, enlargement of the orbital extraocular muscles 
themselves, as in Grave’s ophthalmopathy, may compress the optic nerve and lead to death 
of retinal ganglion cells (see Section 5). Traumatic optic neuropathy and optic nerve 
transection are less commonly observed in humans but have been the best studied causes of 
retinal ganglion cell death in animal models. In humans, direct transection or even 
concussive injury to the optic nerve injures axons and leads to retinal ganglion cell death 
back in the retina. Optic neuritis is the most common inflammatory optic neuropathy in 
young adults (1997; Rizzo & Lessell, 1988). Demyelination itself does not immediately cause 
loss of retinal ganglion cells; many rounds of inflammation and demylination eventually 
lead to axon loss (Evangelou et al., 2000; Perry & Anthony, 1999; Trapp et al., 1998), which 
again clinically appears as optic atrophy and loss of the nerve fiber layer (MacFadyen et al., 
1988).  
What mechanisms induce retinal ganglion cell death in glaucoma and other optic 
neuropathies? Glaucoma, for example, has been extensively modeled in animals (reviewed 
in (Morrison et al., 2005; Whitmore et al., 2005). Studies of tissue from human patients with 
glaucoma and non-human primates and other mammals with experimental glaucoma 
confirm changes at the optic nerve head, such as with respect to bowing out of the lamina 
cribrosa, intra-axonal accumulation of organelles (consistent with blocked axonal transport), 
and Wallerian degeneration distal to the lamina cribrosa (Fontana et al., 1998; Quigley & 
Addicks, 1980; Quigley et al., 1981). Whether due to mechanical trauma of axons (Allcutt et 
al., 1984a; Allcutt et al., 1984b; Barron et al., 1986; Berkelaar et al., 1994), ischemia (Cioffi & 
Sullivan, 1999), generation of nitric oxide (Neufeld, 1999; Neufeld et al., 1997), or other 
causes, axonal injury causes changes in retinal ganglion cells, eventually resulting in death. 
Increased intraocular pressure perturbs rapid anterograde and retrograde axonal transport 
at the lamina cribrosa (Anderson & Hendrickson, 1974; Minckler et al., 1977; Quigley et al., 
1979; Radius, 1983). This may cause retinal ganglion cells to be deprived of neurotrophic 
factors or other survival signals produced by brain targets. Studies in experimental animals 
have shown that injury to the optic nerve, for example from increased intraocular pressure 
in experimental glaucoma, blocks the retrograde transport of the neurotrophic factor brain-
derived neurotrophic factor (BDNF) along with its associated receptor, TrkB (Johnson et al., 
2000; Pease et al., 2000; Quigley et al., 2000). Interestingly, one of the genes associated with a 
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hereditary form of glaucoma, optineurin (Rezaie et al., 2002), may in its mutated form 
contribute to retinal ganglion cell sensitivity to optic nerve insults by failing to adequately 
participate in retrograde transport of neurotrophin signaling complexes, or by redox 
dysregulation (Anborgh et al., 2005; Chalasani et al., 2007; De Marco et al., 2006; Park et al., 
2006). 
7.2.3 Current treatment 
Current treatment for optic neuropathies and optic nerve and retinal ischemias is directed 
almost exclusively at reducing risk factors for disease progression. For example, primary 
open-angle glaucoma therapy is focused on reducing the only known modifiable risk factor, 
intraocular pressure (discussed in section 8, below). Retinal and optic nerve ischemia 
treatment is directed at reducing identifiable risk factors such as uncontrolled diabetes or 
hypertension. All of these treatments, however, are directed at reducing disease progression 
or preventing recurrence. There are no current treatments able to restore function already 
lost once retinal ganglion cells die or their axons are severed in the optic nerve. Thus, there 
is considerable clinical need for novel therapeutics directed at enhancing function through 
restoration of lost cells and connectivity, as well as improved approaches to 
neuroprotection, similar to that discussed for the photoreceptor/RPE complex above. 
7.2.4 Stem cell research and opportunities 
There is considerable promise regarding the use of stem cells for glaucoma and other optic 
neuropathies, although most of this work has focused on the use of stem cells as 
neuroprotection delivery agents. Mesenchymal stem cells transplanted into the vitreous 
body in a rodent model of glaucoma showed considerable capacity to protect retinal 
ganglion cell degeneration (Johnson et al., 2010; Yu et al., 2006). This did not require any 
differentiation or integration of the transplanted stem cells. Similar results including RGC 
neuroprotection have been demonstrated in models of retinal ischemia (Li et al., 2009). 
As a cell replacement therapy for glaucoma, stem cells face a much tougher set of hurdles. 
Transplanted stem cells thus far have shown limited success at integrating into and 
restoring function elsewhere in the central nervous system in preclinical models (Calford et 
al., 2005; Sohur et al., 2006). Optimal cellular integration may be limited by immune 
reactivity, response to injury, or factors found in development but missing in the adult 
microenvironment. For replacing retinal ganglion cells, stem cells would have to properly 
differentiate into retinal ganglion cells, integrate with their presynaptic partners in the retina 
to receive visual information, and project their axons down the optic nerve and properly 
wire up with their targets in the lateral geniculate nucleus of the thalamus and other regions 
of the brain (Goldberg, 2003b).  
Considerable progress on understanding how retinal ganglion cells differentiate from their 
precursors has been made. For example, two well-studied transcription factors, Math5 and 
Brn3, are required for initial and terminal differentiation, respectively. In the absence of 
Math5 expression, retinal ganglion cells fail to differentiate from retinal progenitors during 
development (Brown et al., 2001; Wang et al., 2001). Math5 normally activates the expression 
of Brn3 genes (Mu et al., 2005), but in the absence of Brn3 expression, retinal ganglion cells 
die shortly after their generation in the retina (Badea et al., 2009; Wang et al., 2002). Despite 
these and other steps forward in our understanding of retinal ganglion cell differentiation, 
we know little about how to force stem cells to differentiate into retinal ganglion cells with 
high efficiency. 
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Considerable recent progress has been made in our understanding of how to encourage 
retinal ganglion cells to regenerate their axons through the optic nerve towards the brain 
(Moore & Goldberg, 2011). A combination of inhibitory molecules in the optic nerve (Berry 
et al., 2008), insufficient neurotrophic factors available to promote axon growth (Aguayo et 
al., 1996), and a decreased intrinsic regenerative capacity of retinal ganglion cells after an 
early period of developmental growth (Liu et al., 2011) all contribute to regenerative failure, 
but overcoming these alone or in combination enhances regenerative ability (Benowitz & 
Yin, 2007). A major question remains as to whether retinal ganglion cells derived from stem 
cells will also need to be treated to overcome these barriers to optic nerve axon growth and 
reconnection to the brain. 
8. Trabecular meshwork 
8.1 Background 
The trabecular meshwork is a tissue in the angle between the cornea and iris in the anterior 
segment of the eye that is responsible for drainage of aqueous fluid. The ciliary body 
secretes aqueous fluid into the anterior chamber of the eye, which bathes and feeds the lens 
and cornea with critical nutrients (See Fig. 7). The balance between aqueous secretion and 
outflow is a major determinant of intraocular pressure (IOP), which is a major risk factor for 
the development of glaucoma (Goldberg, 2003a). 
 
 
Fig. 7. Anterior chamber of the eye, with arrow demonstrating flow of aqueous humour 
(Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye Institute, University of Miami 
Miller School of Medicine) 
The trabecular meshwork is comprised of endothelial cells and extracellular matrix that 
separate the anterior chamber from an outflow track called Schlemm’s canal. These 
trabecular meshwork cells may be divided into endothelial cells, juxtacanalicular cells, and 
Schlemm’s canal cells, although the relationships between these anatomical distinctions is 
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not well understood. The interaction between trabecular meshwork cells and the 
extracellular matrix, including the ability of the cells to phagocytose debris and thereby 
prevent clogging (Buller et al., 1990), is thought to create the mechanical relationships that 
determine outflow (WuDunn, 2009). 
8.2 Pathology 
In glaucoma, RGCs and their axons in the optic nerve demonstrate a typical pattern of 
damage and degeneration associated with permanent loss of vision, as discussed above. IOP 
is a major risk factor for glaucoma, although most people with IOP above population 
averages never develop glaucoma, and many people with “normal” IOP but particularly 
susceptible RGCs develop glaucoma. Randomized clinical trials have demonstrated that 
glaucoma patients with either “high” or “normal” starting IOPs can slow the progression of 
their disease by lowering IOP (reviewed elsewhere). Thus there is strong motivation to 
understand the dynamics of aqueous fluid production and outflow in the determining IOP 
and devising treatment strategies to lower IOP. 
In glaucoma, changes in the cellular and molecular milieu of the trabecular meshwork have 
been observed. There is an age-dependent (Grierson & Howes, 1987) and glaucoma-
dependent (Alvarado et al., 1984; Alvarado et al., 1981) loss of trabecular meshwork cells. 
Cultured trabecular meshwork cells (Gasiorowski & Russell, 2009) have provided a rich 
source of experimental evidence that their biology likely plays a role in determining outflow 
and thus IOP-associated glaucoma risk . 
8.3 Current treatment 
Current treatment for glaucoma is focused on lowering IOP, the only modifiable risk factor 
for primary open-angle glaucoma. Topical and oral medications designed to decrease 
aqueous production or increase outflow are typically first-line treatments, followed by laser 
trabeculoplasty and a number of incisional surgical approaches . Interestingly, laser 
trabeculoplasty may work by stimulating local cell replacement in the trabecular meshwork. 
Explanted human donor eyes treated with laser trabeculoplasty demonstrated increased cell 
division in the trabecular meshwork and in a line of cells located just anterior to the 
trabecular meshwork called insert cells (Acott et al., 1989; Alexander & Grierson, 1989; 
Alexander et al., 1989; Dueker et al., 1990). Cells from this anterior zone were observed to 
migrate into the trabecular meshwork, raising the hypothesis that these were stem cells or 
progenitor cells for this tissue. 
8.4 Stem cell research and opportunities 
Human trabecular meshwork cells can now be isolated and cultured, and a subset of these 
cells in culture appear to behave like stem cells (or, trabecular meshwork progenitor cells) . 
Whether this proliferative population is derived from insert cells or a subpopulation of 
trabecular meshwork cells remains to be determined. trabecular meshwork progenitor cells 
can be expanded in three-dimensional sphere-like cultures (Gonzalez et al., 2006). Cells from 
these cultures express markers and gene expression profiles associated with monolayer 
cultures of TM stem cells (Gonzalez et al., 2006).  
This raises the question, would transplanting trabecular meshwork cells or trabecular 
meshwork progenitor cells back to the trabecular meshwork enhance outflow, thereby 
lowering IOP and protecting RGCs from damage in glaucoma? There is little data yet 
 
New Advances in Stem Cell Transplantation 428 
Considerable recent progress has been made in our understanding of how to encourage 
retinal ganglion cells to regenerate their axons through the optic nerve towards the brain 
(Moore & Goldberg, 2011). A combination of inhibitory molecules in the optic nerve (Berry 
et al., 2008), insufficient neurotrophic factors available to promote axon growth (Aguayo et 
al., 1996), and a decreased intrinsic regenerative capacity of retinal ganglion cells after an 
early period of developmental growth (Liu et al., 2011) all contribute to regenerative failure, 
but overcoming these alone or in combination enhances regenerative ability (Benowitz & 
Yin, 2007). A major question remains as to whether retinal ganglion cells derived from stem 
cells will also need to be treated to overcome these barriers to optic nerve axon growth and 
reconnection to the brain. 
8. Trabecular meshwork 
8.1 Background 
The trabecular meshwork is a tissue in the angle between the cornea and iris in the anterior 
segment of the eye that is responsible for drainage of aqueous fluid. The ciliary body 
secretes aqueous fluid into the anterior chamber of the eye, which bathes and feeds the lens 
and cornea with critical nutrients (See Fig. 7). The balance between aqueous secretion and 
outflow is a major determinant of intraocular pressure (IOP), which is a major risk factor for 
the development of glaucoma (Goldberg, 2003a). 
 
 
Fig. 7. Anterior chamber of the eye, with arrow demonstrating flow of aqueous humour 
(Illustration by Jennifer Thomson Ph D., Bascom Palmer Eye Institute, University of Miami 
Miller School of Medicine) 
The trabecular meshwork is comprised of endothelial cells and extracellular matrix that 
separate the anterior chamber from an outflow track called Schlemm’s canal. These 
trabecular meshwork cells may be divided into endothelial cells, juxtacanalicular cells, and 
Schlemm’s canal cells, although the relationships between these anatomical distinctions is 
 
Stem Cells in Ophthalmology 429 
not well understood. The interaction between trabecular meshwork cells and the 
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exploring this question, but the observation that laser trabeculoplasty enhances both 
cellularity and trabecular meshwork outflow suggests that additional cells, if added in the 
right fashion, may remodel the trabecular meshwork to similarly reduce IOP. A number of 
groups are working on this hypothesis, and the relatively easy accessibility of the anterior 
segment makes this an attractive approach to consider cell therapies in the eye (Kelley et al., 
2009).  
9. Conclusion 
In summary, there is considerable interest in and scientific basis for pursuing stem cell 
therapies in ophthalmology. From epithelial to mesenchymal and even endothelial cell-
based approaches, the eye and periocular tissues present a range of diseases with immense 
clinical need for novel therapeutics. We look forward to the advances in both pre-clinical 
and translational research into cell therapies for ophthalmology, and predict a rapid and 
encouraging step into a new generation of stem cell-based therapeutics throughout the field.  
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1. Introduction 
The human ocular surface spans from the conjunctiva to the cornea and plays a critical role 
in visual perception. Cornea, the anterior portion of the eye, is transparent and provides the 
eye with two-thirds of its focusing power and protection of ocular integrity. The cornea 
consists of five main layers, namely, corneal epithelium, Bowman’s layer, corneal stroma, 
Descemet’s membrane and corneal endothelium. 
The outermost layer of the cornea, which is exposed to the external environment, is the 
corneal epithelium. Corneal epithelial integrity and transparency are maintained by somatic 
stem cells (SC) that reside in the limbus. The limbus, an anatomical structure 1-2 mm wide, 
circumscribes the peripheral cornea and separates it from the conjunctiva (Cotsarelis et al., 
1989, Davanger and Evensen, 1971) (Figure 1). Any damage to the ocular surface by burns, 
or various infections, can threaten vision. The most insidious of such damaging conditions is 
limbal stem cell deficiency (LSCD). Clinical signs of LSCD include corneal vascularization, 
chronic stromal inflammation, ingrowth of conjunctival epithelium onto the corneal surface 
and persistent epithelial defects (Lavker et al., 2004). Primary limbal stem cell deficiency is 
associated with aniridia and ectodermal dysplasia. Acquired limbal stem cell deficiency has 
been associated with inflammatory conditions (Stevens–Johnson syndrome (SJS), ocular 
cicatricial pemphigoid), ocular trauma (chemical and thermal burns), contact lens wear, 
corneal infection, neoplasia, peripheral ulcerative corneal disease and neurotrophic 
keratopathy (Dua et al., 2000, Jeng et al., 2011). Corneal stem cells and/or their niche are 
known to play important anti-angiogenic and anti-inflamatory roles in maintaining a 
normal corneal microenvironment, the destruction of which in LSCD, tips the balance 
toward pro-angiogenic conditions (Lim et al., 2009). 
For a long time, the primary treatment for LSCD has been transplantation of healthy - 
keratolimbal tissue from autologous, allogenic, or cadaveric sources. In the late 1990s, 
cultured, autologous, limbal epithelial cell implants were used successfully to improve 
vision in two patients with chemical injury-induced LSCD (Pellegrini et al., 1997). Since then, 
transplantation of cultivated epithelial (stem) cells has become a treatment of choice for 
numerous LSCD patients worldwide. While the outcomes are promising, the variability of 
methodologies used to expand the cells, points to an underlying need for better 
standardization of ex vivo cultivation-based therapies and their outcome measures (Sangwan 
et al., 2005, Ti et al., 2004, Grueterich et al., 2002b, Kolli et al., 2010). 
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Fig. 1. (A) Photograph of the front of the human eye. The cornea, which is clear, can be seen 
at the front of the eye highlighted by the light reflections. The cornea is continuous with the 
limbus, the narrow band of tissue found encircling the cornea. The limbus is continuous 
with the conjunctiva and its underlying sclera, together forming the anterior portion of the 
eye. (B) Cross section of human limbal palisades of Vogt. 
This chapter provides a general update on LSCD pathogenesis, the key role of stem cells and 
their niche in maintaining corneal homeostasis and avascularity and a general update on 
LSCD pathogenesis. An overview of different methodologies used for ex vivo stem cell 
expansion will shed some light on the future of cell-based therapy for LSCD patients.  
2. What defines limbal stem cell niche 
The ocular surface is anatomically composed of the entire epithelial surface of the cornea, 
limbus and conjunctiva, and is physically continuous with the eyelids and adenexa. The 
limbal epithelium, which separates the corneal epithelium from the conjunctival epithelium, 
is made up of a nonkeratinizing, stratified squamous epithelium, which is much thicker, up 
to 10 cell layers, than the central corneal epithelium. Moreover, limbal epithelium is thought 
to contain the source of the stem cells (SC) that serve as the source of corneal epithelial cell 
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renewal and provide a barrier between conjunctival and corneal epithelia. These cells are 
known as corneal epithelial SCs or limbal stem cells (LSCs). In addition to intrinsic factors 
(i.e., characteristics inherent to the stem cells), extrinsic influences from the 
microenvironment surrounding the stem cells may also play a role in corneal cell renewal 
(Barros et al., 1995, Morrison et al., 1997, Tseng, 1996), as discussed below. 
2.1 Limbal microenvironment and stem cell properties 
Within the limbus, LSCs are thought to reside in a stem cell niche, which maintains them in 
their undifferentiated state. This stem cell niche is anatomically denoted as the palisades of 
Vogt. The palisades of Vogt are radial infoldings (Figure 1 B) located at the limbo-corneal 
junction, extending outwards of 1–2 mm from that junction (Goldberg and Bron, 1982); a 
anatomical feature unique to the human eye that can be used as a clinical marker indicating 
the presence of corneal epithelial stem cells. Davenger and Evensen  (1971) and Bron (1973) 
reported the  significant characterizations of the palisades of Vogt in 1971 (Davanger and 
Evensen, 1971, Bron, 1973). The authors observed heavily pigmented epithelium migrating 
in lines from the limbus to the central cornea in response to corneal epithelial defects.  
2.1.1 Characterization and microenvironment of the palisades of Vogt 
The limbal basement membrane differs from that of the cornea that undulates, with pegs of 
stroma extending upward and interconnecting with anchoring fibrils that link to the 
basement membrane (Gipson, 1989). This structure could provide resident stem cells with 
an adherent niche, protecting them from injury and movement within their 
microenvironment. Differences in the composition of the limbal and central corneal 
basement membranes have been observed, and these are thought to play a role in the 
maintenance of their respective populations of epithelial cells. Moreover the LSC niche lies 
beneath a number of cell layers where oxygen tension is likely to be lower. Limbal cells are 
in close proximity to a blood supply and have access to survival factors such as keratinocyte 
growth factor (KGF), IL-6 and components of basement membrane unavailable to cells of 
the central cornea. Interestingly, hypoxic ex vivo conditions have been found to produce 
larger, less differentiated limbal epithelial cell colonies, suggesting that low oxygen levels 
may induce selective proliferation of undifferentiated cells (Miyashita et al., 2007). 
Photomicrographic, angiographic and histological studies have demonstrated the 
fibrovascular nature of the palisades and the presence of “ridges of thickened epithelium” in 
the interpalisade zone (Goldberg and Bron, 1982, Townsend, 1991). Confocal microscopy 
along with scanning electron microscopy (SEM) provides the opportunity to optically 
section the corneal limbus and create 3D reconstructions of the tissue (Romano et al., 2003, 
Shortt et al., 2007). This approach allows identification of previously unrecognized 
candidates for the LSC niche, limbal crypts (LCs) and focal stromal projections (FSPs), and 
has significantly advanced understanding of the structure of this adult stem cell niche. 
2.1.2 Asymmetric cell division 
Adult SCs exist in an optimal microenvironment or ‘niche’ that promotes their maintenance 
in an undifferentiated state (Fuchs et al., 2004). When SCs undergo asymmetric division, 
only one of the daughter cells can re-enter the niche to replenish the SC population (Figure 
2). The other cell loses the protection of the niche and is destined to differentiate and become 
a transient amplifying cell (TAC). The role of the TAC is to divide at an exponential rate in 
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section the corneal limbus and create 3D reconstructions of the tissue (Romano et al., 2003, 
Shortt et al., 2007). This approach allows identification of previously unrecognized 
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2). The other cell loses the protection of the niche and is destined to differentiate and become 
a transient amplifying cell (TAC). The role of the TAC is to divide at an exponential rate in 
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order to provide increased cell numbers. The ability of the TAC to multiply is limited and 
will eventually differentiate into a post-mitotic cell that can no longer multiply (Cotsarelis et 
al., 1989). The PMCs are committed to cellular differentiation and mature to form terminally 
differentiated cells that represent the final phenotypic expression of the tissue type. These 
mechanisms are essential for the understanding of normal stem cell function and 
homeostasis. Moreover the LSC population is positioned to be influenced by a wide variety 
of cells. These influences include cell-to-cell contact, cell–extracellular matrix contact, and 
paracrine signalling factors and their receptors, and they from adjacent conjunctival 
epithelial cells and fibroblasts, corneal epithelium and fibroblasts, limbal blood vessels, 
limbal melanocytes, corneal nerves and Langerhans cells. The limbal fibroblasts in the 
underlying stroma are heterogeneous and express secreted protein acidic and rich in 
cysteine (SPARC), which may contribute to LSC adhesion (Shimmura et al., 2006). 
2.1.3 Cell signalling  
Cytokine of the cornea and limbus implied specific differences in their microenvironments, 
suggesting fibroblast-mediated paracrine regulation of LSCs. For example, corneal 
fibroblasts release hepatocyte growth factor (HGF), whereas limbal fibroblasts secrete 
keratinocyte growth factor (KGF) (Sotozono et al., 1994). Most importantly, epithelial cells at 
the basal layer of the limbus express high levels of the KGF-R, in contrast to central corneal 
epithelium, which expresses fewer of this receptor. KGF is a potent stimulator of 
proliferation in epithelial cells, and its presence in the limbus results in the proliferation of 
LSCs and TACs (Sotozono et al., 1994). HGF is known to stimulate the migration of epithelial 
cells, and it has been proposed that HGF aids the migration of new TACs produced at the 
limbus through the action of KGF (Wilson et al., 1994). The basement membrane separates 
the LSC from stroma and, thus modulates growth factors and cytokines involved in LSC 
regulation and function (Klenkler and Sheardown, 2004). 
Sonic hedgehog, Wnt/β-catenin, TGF-β and Notch signalling pathways have all been 
implicated in niche control of stem cells; however, little is known of their potential roles in 
the LSC niche. Lack of Dkk2, leads to increased Wnt/β-catenin signalling in limbal stroma. 
This demonstrates the importance of limbal niche control over LSC differentiation during 
development. PAX6 expression is also lost in the corneal epithelial cells of mutant mice, 
suggesting the control downstream of Dkk2 (Mukhopadhyay et al., 2006).  PAX6 deficiency 
leads to aniridia, resulting in turn to impaired corneal epithelial function and eventual LSC 
failure, which may be due to altered niche development. A more recent study by Schlotzer-
Schrehardt et al. found patchy immunolocalization of the laminin γ3 chain, BM40/SPARC 
and tenancin C, which were also found to colocalize with ABCG2/p63/K19-positive cell 
clusters. These factors may be involved in retaining cell stemness (Schlotzer-Schrehardt et 
al., 2007). 
3. Insult to the niche and corneal limbal stem cell deficiency 
Corneal blindness is a condition currently affecting about 10 million people worldwide 
(Klenkler et al., 2005). Corneal damage and disease can be a result of LSC deficiency, which 
can be heritable or acquired. Limbal stem cell deficiency (LSCD) results from the loss or 
dysfunction of LSC, most often because of injury or inflammation (Dua et al., 2000). When 
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order to provide increased cell numbers. The ability of the TAC to multiply is limited and 
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differentiated cells that represent the final phenotypic expression of the tissue type. These 
mechanisms are essential for the understanding of normal stem cell function and 
homeostasis. Moreover the LSC population is positioned to be influenced by a wide variety 
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cysteine (SPARC), which may contribute to LSC adhesion (Shimmura et al., 2006). 
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suggesting fibroblast-mediated paracrine regulation of LSCs. For example, corneal 
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the basal layer of the limbus express high levels of the KGF-R, in contrast to central corneal 
epithelium, which expresses fewer of this receptor. KGF is a potent stimulator of 
proliferation in epithelial cells, and its presence in the limbus results in the proliferation of 
LSCs and TACs (Sotozono et al., 1994). HGF is known to stimulate the migration of epithelial 
cells, and it has been proposed that HGF aids the migration of new TACs produced at the 
limbus through the action of KGF (Wilson et al., 1994). The basement membrane separates 
the LSC from stroma and, thus modulates growth factors and cytokines involved in LSC 
regulation and function (Klenkler and Sheardown, 2004). 
Sonic hedgehog, Wnt/β-catenin, TGF-β and Notch signalling pathways have all been 
implicated in niche control of stem cells; however, little is known of their potential roles in 
the LSC niche. Lack of Dkk2, leads to increased Wnt/β-catenin signalling in limbal stroma. 
This demonstrates the importance of limbal niche control over LSC differentiation during 
development. PAX6 expression is also lost in the corneal epithelial cells of mutant mice, 
suggesting the control downstream of Dkk2 (Mukhopadhyay et al., 2006).  PAX6 deficiency 
leads to aniridia, resulting in turn to impaired corneal epithelial function and eventual LSC 
failure, which may be due to altered niche development. A more recent study by Schlotzer-
Schrehardt et al. found patchy immunolocalization of the laminin γ3 chain, BM40/SPARC 
and tenancin C, which were also found to colocalize with ABCG2/p63/K19-positive cell 
clusters. These factors may be involved in retaining cell stemness (Schlotzer-Schrehardt et 
al., 2007). 
3. Insult to the niche and corneal limbal stem cell deficiency 
Corneal blindness is a condition currently affecting about 10 million people worldwide 
(Klenkler et al., 2005). Corneal damage and disease can be a result of LSC deficiency, which 
can be heritable or acquired. Limbal stem cell deficiency (LSCD) results from the loss or 
dysfunction of LSC, most often because of injury or inflammation (Dua et al., 2000). When 
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the corneal limbal stem cells are depleted below a certain threshold, the cornea becomes 
covered by an abnormal conjunctiva-like epithelium, a process termed “conjunctivalization.” 
As a result of LSC deficiency, neovascularization, chronic inflammation, recurrent erosions, 
ulceration and stromal scarring can occur, causing painful vision loss (Holland and 
Schwartz, 1996, Kenyon and Tseng, 1989). 
LSCD is classified as either primary or secondary. Primary LSCD is characterized by the 
absence of identifiable external factors and an insufficient microenvironment to support the 
LSCs. Primary LCSD is seen in hereditary aniridia, congenital erythrokeratoderma, keratitis 
with multiple endocrine deficiencies and inadequate nutrition or cytokine supply, 
neurotrophic keratopathy, peripheral inflammation, and sclerocornea (Puangsricharern and 
Tseng, 1995). Dysfunction/poor regulation of stromal microenvironment of limbal epithelial 
SCs results in gradual loss of the SC population or TAC generation and amplification. 
Secondary LSCD occurs following the destruction of LSCs by external factors such as 
trauma, chemical–acid or alkali or thermal injuries (Tseng, 1985), or ultraviolet and ionizing 
radiation (Fujishima et al., 1996); systemic conditions such as Stevens-Johnson Syndrome 
(SJS), or ocular cicatricial pemphigoid (OCP) (Pfister, 1994). 
3.1 Clinical conditions 
The corneal epithelium cannot be maintained or renewed in eyes with LSCD, and leads to 
chronic epithelial defects. As the condition progresses, punctate epithelial keratopathy may 
develop and lead to severe epithelial defect. Due to decreased healing ability, corneal 
epithelial defects may become persistent, which can lead to stromal scarring, ulceration, and 
perforation (Puangsricharern and Tseng, 1995). Conjunctivalization of the cornea may occur, 
where the corneal epithelium is replaced with a conjunctival epithelial phenotype (Huang 
and Tseng, 1991). Loose intercellular connections result in stippled or late staining with 
fluorescein, and a lack of normal hemidesmosomal attachments at the base of corneal 
epithelial cells (Dua and Forrester, 1990). The cause of the LSCD often dictates whether the 
disease is unilateral or bilateral (i.e., affecting one eye or both). 
3.1.1 Pathology of limbal stem cell deficiency and histologic, ultrastructural studies 
Currently, diagnosis of LSCD is based on clinical evaluation, although clinical signs and 
symptoms of LSCD are nonspecific and common to several ocular surface diseases. The 
disease manifests as epithelial defects, chronic inflammation, keratitis, vascularization, and 
fibrosis, ultimately resulting in corneal blindness. In the absence of specific markers for 
limbal stem cells, identification of conjunctival goblet cells on the corneal surface is used to 
demonstrate conjunctival epithelial ingrowth or growth of epithelia on the corneal surface 
and to confirm the diagnosis of LSCD (Tseng, 1989, Dua and Forrester, 1990, Pfister, 1994).  
Normal limbal architecture, with rows of palisades and a perilimbal vascular arcade, is 
usually best defined at the superior and inferior limbus. Definition of the palisades is less 
distinct nasally and temporally. Delicate changes such as staining of conjunctiva-derived 
cells on and across the limbus, which may be associated with a persistent epithelial defect, 
and other changes such as scarring, vascularization, or limbal hyperaemia, indicating 
chronic inflammation, can be seen in the early stages. SC deficiency following mild injury, a 
superficial or a disease process is slowly progressive, and loss of a segment of limbal 
epithelium may occur without significant damage to the substratum. A sheet of 
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conjunctival/metaplastic epithelium without any notable vascularization consequently 
covers the cornea (Dua, 1998). Other pathological conditions resulting from LSCD are 
abnormal conjunctival/metaplastic epithelium; tags of loose epithelium filaments with 
mucus, and recurrent erosions, with unstable tear film that readily takes up fluorescein dye 
(Huang and Tseng, 1991). 
In moderate to severe cases of SC deficiency, superficial and/or deep vascularization of the 
cornea occurs. Initially it is restricted to the segment with SC deficiency, but in later stages, 
the entire circumference may become involved. However, in moderate to severe cases of SC 
deficiency, epithelial cover of the denuded cornea is associated with encroachment of 
fibrovascular tissue of varying thicknesses (Kenyon and Tseng, 1989). In human eyes, ocular 
surface insult from chemical burns may go beyond damage to the limbal tissue, leading to 
long-term ocular surface damage. This damage may include distortion and dysfunction of 
proximal or distal bulbar conjunctiva, tarsal conjunctiva, and anterior orbital tissues, 
resulting in abnormalities in surface mucous secretion and wetting, cicatrizing of 
conjunctiva, symblepharon, and entropion (McCulley, 1990, McCulley et al., 1983, Grant and 
Kern, 1955).  
In summary, alkali burns are the commonest cause of severe LSCD, producing long-
standing and persistent changes, like epithelial hyperplasia, fibrosis, and inflammation of 
the ocular surface. Presence of goblet cells on the cornea confirms the diagnosis of LSCD, 
but their absence does not rule it out, and correlates presence or absence with prolonged 
interval and squamous metaplasia of the entire surface in such cases (Fatima et al., 2008).  
3.1.2 Accompanying neovascularization 
The cornea is avascular, but a wide variety of insults can cause capillary invasion from the 
limbal vascular plexus. This process of new blood vessel formation is termed as corneal 
neovascularization (NV) (Chang et al., 2001, Takahashi et al., 1999). The three major 
categories of corneal NV are superficial vascularization, fibrovascular pannus, and deep 
stromal vascularization. Superficial vascularization rarely causes a decrease in vision; 
however, the latter two types of corneal NV can lead to significant loss of vision if they 
involve the visual axis. The most frequent causes of corneal angiogenesis are injury and 
defective limbal stem cells. 
4. Putative mechanisms of LSCD and corneal neovascularization 
There is a delicate balance between angiogenic and anti-angiogenic factors in the cornea, 
which determines its vascularity or lack thereof. The normal cornea is avascular, and corneal 
epithelial stem cells may play a significant role in maintaining the angiogenic balance in 
favour of avascularity. Nevertheless, there are numerous pro-angiogenic factors that play 
key roles in pathologic corneal NV. A comprehensive review of all the factors was described 
by Lim  et.al, and included key factors and their possible mechanisms of action (Lim et al., 
2009). 
4.1 Angiogenic factors and anti-angiogenic factors  
Vascular endothelial growth factor (VEGF) is a protein that acts as a mitogen for vascular 
endothelial cells, stimulating these cells to divide and multiply. The most important member 
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ulceration and stromal scarring can occur, causing painful vision loss (Holland and 
Schwartz, 1996, Kenyon and Tseng, 1989). 
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neurotrophic keratopathy, peripheral inflammation, and sclerocornea (Puangsricharern and 
Tseng, 1995). Dysfunction/poor regulation of stromal microenvironment of limbal epithelial 
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(SJS), or ocular cicatricial pemphigoid (OCP) (Pfister, 1994). 
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The corneal epithelium cannot be maintained or renewed in eyes with LSCD, and leads to 
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develop and lead to severe epithelial defect. Due to decreased healing ability, corneal 
epithelial defects may become persistent, which can lead to stromal scarring, ulceration, and 
perforation (Puangsricharern and Tseng, 1995). Conjunctivalization of the cornea may occur, 
where the corneal epithelium is replaced with a conjunctival epithelial phenotype (Huang 
and Tseng, 1991). Loose intercellular connections result in stippled or late staining with 
fluorescein, and a lack of normal hemidesmosomal attachments at the base of corneal 
epithelial cells (Dua and Forrester, 1990). The cause of the LSCD often dictates whether the 
disease is unilateral or bilateral (i.e., affecting one eye or both). 
3.1.1 Pathology of limbal stem cell deficiency and histologic, ultrastructural studies 
Currently, diagnosis of LSCD is based on clinical evaluation, although clinical signs and 
symptoms of LSCD are nonspecific and common to several ocular surface diseases. The 
disease manifests as epithelial defects, chronic inflammation, keratitis, vascularization, and 
fibrosis, ultimately resulting in corneal blindness. In the absence of specific markers for 
limbal stem cells, identification of conjunctival goblet cells on the corneal surface is used to 
demonstrate conjunctival epithelial ingrowth or growth of epithelia on the corneal surface 
and to confirm the diagnosis of LSCD (Tseng, 1989, Dua and Forrester, 1990, Pfister, 1994).  
Normal limbal architecture, with rows of palisades and a perilimbal vascular arcade, is 
usually best defined at the superior and inferior limbus. Definition of the palisades is less 
distinct nasally and temporally. Delicate changes such as staining of conjunctiva-derived 
cells on and across the limbus, which may be associated with a persistent epithelial defect, 
and other changes such as scarring, vascularization, or limbal hyperaemia, indicating 
chronic inflammation, can be seen in the early stages. SC deficiency following mild injury, a 
superficial or a disease process is slowly progressive, and loss of a segment of limbal 
epithelium may occur without significant damage to the substratum. A sheet of 
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conjunctival/metaplastic epithelium without any notable vascularization consequently 
covers the cornea (Dua, 1998). Other pathological conditions resulting from LSCD are 
abnormal conjunctival/metaplastic epithelium; tags of loose epithelium filaments with 
mucus, and recurrent erosions, with unstable tear film that readily takes up fluorescein dye 
(Huang and Tseng, 1991). 
In moderate to severe cases of SC deficiency, superficial and/or deep vascularization of the 
cornea occurs. Initially it is restricted to the segment with SC deficiency, but in later stages, 
the entire circumference may become involved. However, in moderate to severe cases of SC 
deficiency, epithelial cover of the denuded cornea is associated with encroachment of 
fibrovascular tissue of varying thicknesses (Kenyon and Tseng, 1989). In human eyes, ocular 
surface insult from chemical burns may go beyond damage to the limbal tissue, leading to 
long-term ocular surface damage. This damage may include distortion and dysfunction of 
proximal or distal bulbar conjunctiva, tarsal conjunctiva, and anterior orbital tissues, 
resulting in abnormalities in surface mucous secretion and wetting, cicatrizing of 
conjunctiva, symblepharon, and entropion (McCulley, 1990, McCulley et al., 1983, Grant and 
Kern, 1955).  
In summary, alkali burns are the commonest cause of severe LSCD, producing long-
standing and persistent changes, like epithelial hyperplasia, fibrosis, and inflammation of 
the ocular surface. Presence of goblet cells on the cornea confirms the diagnosis of LSCD, 
but their absence does not rule it out, and correlates presence or absence with prolonged 
interval and squamous metaplasia of the entire surface in such cases (Fatima et al., 2008).  
3.1.2 Accompanying neovascularization 
The cornea is avascular, but a wide variety of insults can cause capillary invasion from the 
limbal vascular plexus. This process of new blood vessel formation is termed as corneal 
neovascularization (NV) (Chang et al., 2001, Takahashi et al., 1999). The three major 
categories of corneal NV are superficial vascularization, fibrovascular pannus, and deep 
stromal vascularization. Superficial vascularization rarely causes a decrease in vision; 
however, the latter two types of corneal NV can lead to significant loss of vision if they 
involve the visual axis. The most frequent causes of corneal angiogenesis are injury and 
defective limbal stem cells. 
4. Putative mechanisms of LSCD and corneal neovascularization 
There is a delicate balance between angiogenic and anti-angiogenic factors in the cornea, 
which determines its vascularity or lack thereof. The normal cornea is avascular, and corneal 
epithelial stem cells may play a significant role in maintaining the angiogenic balance in 
favour of avascularity. Nevertheless, there are numerous pro-angiogenic factors that play 
key roles in pathologic corneal NV. A comprehensive review of all the factors was described 
by Lim  et.al, and included key factors and their possible mechanisms of action (Lim et al., 
2009). 
4.1 Angiogenic factors and anti-angiogenic factors  
Vascular endothelial growth factor (VEGF) is a protein that acts as a mitogen for vascular 
endothelial cells, stimulating these cells to divide and multiply. The most important member 
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of this group is VEGF-A, which has been shown to stimulate endothelial cell proliferation 
and migration. It also increases microvascular permeability. In rats with surgically induced 
LSCD, high levels of VEGF correlated with inflammation and corneal NV. The corneal NV 
was suppressed with the addition of anti-VEGF antibody (Amano et al., 1998). Other 
members of this family include VEGF-B, VEGF-C, VEGF-D, and placenta growth factor. 
Inflammatory cytokines, chemokines, and cell adhesion molecules (CAMs) play a significant 
role in inflammatory cell infiltration and angiogenesis. The inflammatory cytokine 
interleukin-1 (IL-1) interacts directly with endothelial cells to stimulate migration and 
proliferation. IL-6 can stimulate corneal and inflammatory cells, in a paracrine manner, to 
secrete VEGF (Biswas et al., 2006). Tumor necrosis factor- (TNF-) enhances leukocyte 
infiltration (Yoshida et al., 1997). Chemokines are a family of secreted proteins that act as 
chemoattractants for inflammatory cells through activation of chemokine receptors. They 
may also enhance endothelial cell chemotaxis and proliferation (Berger et al., 1999). The 
chemokines IL-8 (Strieter et al., 1992, Koch et al., 1992) and monocyte chemoattractant-1 
(MCP-1) (Goede et al., 1999) have been shown to induce corneal NV in rabbit corneas. Cell 
adhesion molecules (CAMs) are proteins located on the cell surface involved in binding with 
other cells or with the extracellular matrix. They facilitate inflammatory cell infiltration into 
the corneal stroma by mediating the rolling, adhesion, or trans-endothelial migration of 
leukocytes (Vaporciyan et al., 1993). Fibroblast growth factors (FGF) are a family of heparin-
binding peptides that are expressed in tissues during angiogenesis, cellular differentiation, 
mitogenesis, and wound repair. Basic fibroblast growth factor (bFGF) is an angiogenic factor 
that exhibits differential binding of vascular basement membranes in newly formed corneal 
vessels, based on degree of maturation of the vessels (Soubrane et al., 1990). 
Several anti-angiogenic factors are produced by corneal epithelial cells, and a variety of 
vascular endothelial cell inhibitors including angiostatin, endostatin, restin, neostatin, and 
thrombospondins. Several of these endogenous anti-angiogenic factors are derived from the 
proteolysis of larger extracellular matrix proteins that have no intrinsic anti-angiogenic 
activity. Angiostatin, for example, is derived from the proteolysis of plasminogen.  
Endostatin is another example, produced by the cleavage of collagen XVIII. It inhibits 
proliferation (Hanai et al., 2002) and migration (Dhanabal et al., 1999) of endothelial cells 
(EC), and induces EC apoptosis. It may block the activation and catalytic activity of matrix 
metalloproteinases (MMPs) (Kim et al., 2000) and interfere with the binding of VEGF to its 
receptors. Arrestin, canstatin, and tumstatin, derived from collagen IV, also inhibit the 
proliferation and migration of ECs and induce EC apoptosis. Restin, which is related to 
endostatin, is produced by the proteolytic cleavage of collagen XV and is believed to inhibit 
EC migration (Ramchandran et al., 1999).  Neostatin, derived from collagen XVIII, and 
thrombospondin are other inhibitors of EC proliferation. 
Avascular tissue-derived factors, such as pigment epithelium-derived factor (PEDF), and 
angiogenic factor antagonists, such as angiopoetin-2, have been found in the cornea 
(Karakousis et al., 2001). PEDF and angiopoetin-2 inhibit angiogenesis by inhibiting 
endothelial cell migration and inducing EC apoptosis. 
4.1.1 Role of matrix metalloproteinases (MMPs) 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases. They are 
commonly categorized as collagenases, gelatinases, matrilysins, or membrane-type MMPs, 
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and they play a role in the proteolytic processes involved in angiogenesis (Chang et al., 
2001). Their action is inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs). 
Some are involved in the cleavage process that generates the anti-angiogenic factors 
angiostatin and endostatin. Plasminogen activator inhibitors inhibit tissue plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA), the activators of plasminogen, 
thereby preventing fibrinolysis and the physiologic breakdown of blood clots. 
In response to corneal injury, lipid mediators are released from cell membranes. Platelet 
activating factor (PAF) is a lipid mediator that facilitates endothelial cell migration through 
the cornea via increased expression of VEGF (Tao et al., 1996), MMP-9 (Tao et al., 1995), and 
uPA (Tao et al., 1996). Another important lipid mediator is 12(R)-HETrE, an arachidonic acid 
metabolite that binds to limbal endothelial cells and causes endothelial mitogenesis and 
neovascularization (Stoltz and Schwartzman, 1997). 
4.1.2 Animal disease models 
Development of experimental animal models to study ocular NV have been useful in 
understanding its mechanisms and pathogenesis, as well as to developing potential 
therapeutic modalities. For example, this basic research led to the discovery of new 
therapeutic targets for pathologic ocular NV (Barouch and Miller, 2006).  In the field of 
neovascular research, the testing of angiogenic and anti-angiogenic substances relies heavily 
on the sensitivity and specificity of in vivo and ex vivo bioassays.  
Several corneal angiogenesis models in the rabbit have been described, including direct 
intrastromal injections of substances like heparin-copper complex (Alessandri et al., 1983), 
induced chemical or thermal injury (Deutsch and Hughes, 1979, Korey et al., 1977), and 
intrastromal tumor implantation (Gimbrone et al., 1974). The cornea suture model created in 
mice and rabbits simulate a clinical scenario and are not expensive. However, models 
inducing an inflammatory component have disadvantages that are surgery dependent and 
yield highly variable responses. Recently developed micropocket assay models are not 
expensive, less time consuming; however, they are surgery dependent and yield highly 
variable responses (Rogers et al., 2007, Loughman et al., 1996). 
A conjunctivalized corneal epithelium lacks the smoothness and cohesion of normal corneal 
epithelium, making it optically inferior and prone to erosions. It is also heavily vascularized. 
To study inflammatory response, an important component of NV, Moromizato et al. 
produced burn and chemical cornea model lesions by corneal cauterization or local injection 
into the cornea of small amounts of acid (hydrochloric acid, 0.1 N) or alkali (sodium 
hydroxide, 0.1 N) (Moromizato et al., 2000). Complex pathophysiology is a disadvantage of 
this model. 
Animal models will continue to be needed for evaluation of safety and efficacy of 
combination therapies (Kim et al., 2006). Each model has strengths and weaknesses; thus, in 
order to gain the most useful information about the disease process and responses to 
therapy, the best approach may be combination of different models. Therefore, search for 
better, more reliable and reproducible animal models should continue. 
5. Treatment modalities 
A number of therapeutic strategies have been adopted to treat LCSD. In patients with partial 
limbal stem cell deficiency, mechanical debridement of the conjunctivalized epithelium can 
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of this group is VEGF-A, which has been shown to stimulate endothelial cell proliferation 
and migration. It also increases microvascular permeability. In rats with surgically induced 
LSCD, high levels of VEGF correlated with inflammation and corneal NV. The corneal NV 
was suppressed with the addition of anti-VEGF antibody (Amano et al., 1998). Other 
members of this family include VEGF-B, VEGF-C, VEGF-D, and placenta growth factor. 
Inflammatory cytokines, chemokines, and cell adhesion molecules (CAMs) play a significant 
role in inflammatory cell infiltration and angiogenesis. The inflammatory cytokine 
interleukin-1 (IL-1) interacts directly with endothelial cells to stimulate migration and 
proliferation. IL-6 can stimulate corneal and inflammatory cells, in a paracrine manner, to 
secrete VEGF (Biswas et al., 2006). Tumor necrosis factor- (TNF-) enhances leukocyte 
infiltration (Yoshida et al., 1997). Chemokines are a family of secreted proteins that act as 
chemoattractants for inflammatory cells through activation of chemokine receptors. They 
may also enhance endothelial cell chemotaxis and proliferation (Berger et al., 1999). The 
chemokines IL-8 (Strieter et al., 1992, Koch et al., 1992) and monocyte chemoattractant-1 
(MCP-1) (Goede et al., 1999) have been shown to induce corneal NV in rabbit corneas. Cell 
adhesion molecules (CAMs) are proteins located on the cell surface involved in binding with 
other cells or with the extracellular matrix. They facilitate inflammatory cell infiltration into 
the corneal stroma by mediating the rolling, adhesion, or trans-endothelial migration of 
leukocytes (Vaporciyan et al., 1993). Fibroblast growth factors (FGF) are a family of heparin-
binding peptides that are expressed in tissues during angiogenesis, cellular differentiation, 
mitogenesis, and wound repair. Basic fibroblast growth factor (bFGF) is an angiogenic factor 
that exhibits differential binding of vascular basement membranes in newly formed corneal 
vessels, based on degree of maturation of the vessels (Soubrane et al., 1990). 
Several anti-angiogenic factors are produced by corneal epithelial cells, and a variety of 
vascular endothelial cell inhibitors including angiostatin, endostatin, restin, neostatin, and 
thrombospondins. Several of these endogenous anti-angiogenic factors are derived from the 
proteolysis of larger extracellular matrix proteins that have no intrinsic anti-angiogenic 
activity. Angiostatin, for example, is derived from the proteolysis of plasminogen.  
Endostatin is another example, produced by the cleavage of collagen XVIII. It inhibits 
proliferation (Hanai et al., 2002) and migration (Dhanabal et al., 1999) of endothelial cells 
(EC), and induces EC apoptosis. It may block the activation and catalytic activity of matrix 
metalloproteinases (MMPs) (Kim et al., 2000) and interfere with the binding of VEGF to its 
receptors. Arrestin, canstatin, and tumstatin, derived from collagen IV, also inhibit the 
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and they play a role in the proteolytic processes involved in angiogenesis (Chang et al., 
2001). Their action is inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs). 
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be performed. This prevents conjunctival epithelium from crossing the limbus and allows 
the corneal epithelium to heal the defect. A groundbreaking report by Kenyon and Tseng, 
describes case studies where autologous limbal stem cell transplantation proved to be a 
powerful and effective surgical procedure to restore severely damaged ocular surfaces 
(Kenyon and Tseng, 1989). However, in later studies, where donor tissue was harvested in a 
“blinded” fashion, two surgical risks were identified. First, if the donor limbal grafts do not 
contain adequate numbers of stem cells, the surgery will either fail immediately or lack 
longevity. Second, if too many stem cells are removed, the donor eye will develop problems 
associated with LSCD (Copeland and Char, 1990, Holland and Schwartz, 1996, Holland, 
1996, Frucht-Pery et al., 1998). 
5.1 Amniotic membrane transplantation 
Human amniotic membrane (HAM) has several properties that render it extremely useful as 
a biomaterial for surgical purposes and it promotes epithelialization, inhibits fibrosis, has 
anti-inflammatory, anti-angiogenic, antimicrobial and antiviral properties, and has a high 
hydraulic conductivity (van Herendael et al., 1978, Gomes et al., 2005, Fernandes et al., 2005) 
Moreover, HAM shows low or no immunogenicity (Akle et al., 1985, Akle et al., 1981). Over 
the past decade, HAM’s abilities to reduce scarring and inflammation, and enhance wound 
healing, as well as its epithelialization properties, has led to an increase in its use as a 
biomaterial in ophthalmic surgery, particularly for ocular surface reconstruction. HAM has 
also been used to promote healing in corneal diseases such as chemical and thermal burns, 
neurotrophic ulcers, persistent epithelial defects, shield ulcers, microbial keratitis, band 
keratopathy and bullous keratopathy (Dua et al., 2004, Tosi et al., 2005a, Tosi et al., 2005b). 
Furthermore, the use of HAM as a biomaterial has not been confined to ophthalmologyit 
is also widely used in general surgery and wound treatment, e.g., for burned skin, bedsores, 
ulcers (Faulk et al., 1980), and in head and neck surgery (Zohar et al., 1987). More recently, 
HAM has been used as a culture substrate for ex vivo cultured LSC transplantation. 
5.1.1 Corneal limbal autografts and allografts 
The current treatment for LSCD is limbal transplantation using auto- or allograft limbal 
tissues, each of which have their associated risks and benefits. In 1989, Kenyon and Tseng, 
treated LSCD by transplanting healthy limbal tissue on diseased limbus, procedure termed 
as conjunctival limbal autograft (CLAU) and living-related conjunctival limbal autograft (lr-
CLAL) (Kenyon and Tseng, 1989). The main disadvantage of taking limbal tissue from the 
patient’s own contralateral healthy eye or from that of a living related donor is the risk of 
inducing LSCD in the donor eye, if a large amount of tissue is required (Jenkins et al., 1993). 
In bilateral cases with total LSCD, or in a one-eyed patient who develops total LSCD in the 
seeing eye, an allograft limbal transplant utilizing donor tissue from a cadaver or a living 
relative is the only option. A high risk of immune rejection is associated with such 
transplantation because of the vascularity of the limbus, the high immunogenic stimulus of 
the limbal transplant relative to the abundance of Langerhan’s cells and HLA-DR antigens. 
Hence, an effective immunosuppressant is essential indefinitely or until the graft is viable. 
Moreover, the dosage of immunosuppression can be increased or decreased if it proves 
ineffective or causes adverse effects, respectively (Tseng et al., 1998, Coster et al., 1995, Santos 
et al., 2005). For this reason, transplantation of auto-or allograft limbal tissues is not often a 
viable treatment option. 
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5.1.2 Ex vivo expansion of corneal limbal stem cells  
A novel method of transplanting limbal stem cells is ex vivo expansion of LSCs. This 
technique is based on Rheinwald and Green’s pioneering work in skin (Green et al., 1977). 
Skin epithelial cells have been grown successfully on a feeder layer of 3T3 fibroblasts that 
have been rendered mitotically inactive by irradiation or treatment with mitomycin C 
(Rheinwald, 1980). In the late 1990s, cultured autologous limbal epithelial cells were 
successfully used to improve vision in two patients with chemical injury-induced LSCD. 
From 1–2 mm2 limbal tissue, epithelial cells were isolated and expanded in the laboratory on 
tissue culture plastic, in the presence of growth-arrested 3T3 mouse fibroblast feeders, 
before transfer to the eye on a petrolatum gauze or a soft contact lens  (Pellegrini et al., 1997). 
This technique has theoretical advantages over conventional treatments. Its proposed 
advantage over CLAU and lr-CLAL is that the required size of the limbal biopsy is 
substantially smaller. This minimizes the risk of precipitating stem cell failure in the donor 
eye and provides the option of taking a further biopsy if required.  
Since 1997’s landmark report, a variety of culture techniques have been developed to 
produce contiguous epithelial cell sheets for transplantation. These techniques can be 
broadly defined as either explant culture in which cells migrate out from limbal tissue 
attached to a surface (Grueterich et al., 2002b, Koizumi et al., 2001a, Koizumi et al., 2001b, 
Sangwan et al., 2006) or suspension culture in which cells are released from enzymatically 
digested extracellular matrix before culture (Daya et al., 2005, Nakamura et al., 2006, 
Pellegrini et al., 1997). The aforementioned methods have been used in studies to culture 
limbal epithelial cells successfully, on either a growth-arrested 3T3 fibroblast feeder layer or 
an amniotic membrane (AM), with varying results (Kim et al., 2004, Zito-Abbad et al., 2006). 
5.1.3 Explant culture method 
The explant culture method involves plating a whole piece of limbal tissue or limbal 
explant, sized approximately 1 mm by 1 mm. One variation of the explant culture system 
uses AM, which acts as both a substrate and a carrier for the cultured cells. To attain growth 
from limbal explants the limbal biopsy is placed on the basement membrane surface of the 
amniotic membrane and allowed to adhere to it. Once attached, the biopsy and amniotic 
membrane are submerged in culture medium (Figure 3). This contains nutrients and 
mitogens that stimulate LSCs to proliferate and migrate out of the biopsy and cover the 
surface of the AM, which occurs over a period of 14 to 28 days.  
Recently, exciting discussions have led to the question of whether or not AM epithelial cells 
are necessary to cultivate limbal epithelial cells. Several groups have cultured limbal 
epithelial cells on intact AM (AM with amniotic epithelium) and have reported that these 
limbal epithelial cells contained slow-cycling and label-retaining characteristic cells, which 
did not express corneal epithelial differentiation proteins cytokeratin 3 (CK3) or  cytokeratin 
12 (CK12) and connexin 43. The amniotic epithelial cells were killed by cryopreservation and 
then removed by enzymatic digestion, chemical treatment, or physical scraping of the 
membrane prior to use (Koizumi et al., 2001a, Koizumi et al., 2001b, Nakamura et al., 2004b, 
Sangwan et al., 2005). Grueterich et al. demonstrated that culturing LSC on amnion with 
intact amniotic epithelium may result in a more stem cell-like phenotype than with de-
epithelialized amnion (Grueterich et al., 2002b). Their study showed that, while cells on both 
the substrates were well attached to the AM stroma, morphologically superior, better 
stratified and/or differentiated limbal cells could be cultured on denuded AM compared to 
those cells cultured on intact AM. As a result, these studies hypothesized that denuded AM 
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Fig. 3. The explant culture system. This method employs amniotic membrane as the carrier 
for cultured cells (A, Left); or cell culture insert (A-Right) as a substrate.  Phase contrast 
micrograph reveals LSC (black arrow) migrating out of the explants (red arrow) and 
covering the surface of the cell culture insert over the course of 14 to 28 days (B). 
is probably a more practical carrier for human limbal epithelial cell cultures in a cell-
suspension culture system. Kolli et al. analyzed the outgrowths from human cadaveric 
limbal explants cultured on AM by dividing the explant outgrowths into three zones—
inner, middle, and outer, depending on proximity to the explant. This yielded a successive 
decline in colony-forming efficiency (CFE), and ΔNp63α and ABCG2 expression, and an 
increase in expression of CK3 in zones further away from the explants. These Results 
support the importance of putative niche environment in maintaining the undifferentiated 
state of the limbal stem cells during explant outgrowth  (Kolli et al., 2008). 
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5.1.4 Suspension culture system 
The cell suspension culture system employs the enzymes dispase, which digests basement 
membrane collagen and separates epithelial cells from the stroma, and trypsin, which 
separates clumps of limbal epithelial cells into a suspension of single cells (Figure 4). The 
single cells are then seeded either onto AM or onto a plastic tissue culture dish containing a 
feeder layer of growth-arrested 3T3 fibroblasts. Culture medium is then added, and the cells 
are incubated for 14 to 21 days. When confluent, the epithelial sheet is transferred to the 






Fig. 4. The suspension culture system. This method employs the enzymes dispase and 
trypsin. This suspension is seeded onto either amniotic membrane (A, Left) or a plastic 
tissue culture dish that contains a feeder layer of growth-arrested 3T3 fibroblasts (A, Right). 
Phase contrast micrograph of limbal epithelial colonies on 3T3 cells (B).  
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1999). Recently, Di Girolamo et al. cultured limbal epithelial cells in autologous serum, on 
lotrafilcon A and balafilcon A contact lenses. The cells cultured on the lotrafilcon A contact 
lenses proliferated, migrated, showed a corneal phenotype and microvillae on the apical 
surface; whereas cells cultured on balafilcon A contact lenses showed no growth (Di 
Girolamo et al., 2007).  
Various substrates have been used in suspension culture systems for proliferation of limbal 
epithelial cells, for example, reconstituted collagen substrate membrane from HAM (Merrett 
et al., 2008), a chitosan cross-linked collagen membrane (Auxenfans et al., 2009), which has 
good adherence, retains epithelial morphology and supports the nontoxic nature of the 
membrane. Reconstituted human amniotic collagen membrane has been used to act as 
collagen scaffolding for the culture of limbal epithelial cells (Doillon et al., 2003, Griffith et 
al., 1999, Li et al., 2005). Rama et al. have provided data demonstratng that the use of fibrin as 
a carrier supports stem cell maintenance (Rama et al., 2001). 
5.1.5 Variations in explant and suspension cultures 
The variations in explant and cell suspension culture systems are airlifting and/or (with or 
without the addition) of 3T3 feeder cells. In airlifting cultures, the level of culture medium in 
the dish is lowered to the surface level of the epithelium, promoting stratification and 
differentiation of the epithelium (Ban et al., 2003, Cooper et al., 2004, Koizumi et al., 2001a, 
Nakamura et al., 2003b). This method can, therefore, be used for investigating the 
stratification and differentiation potential of cultured limbal epithelial cells with high 
expression of CK3 and CK12. The latter culture method, adding 3T3 feeder cells as an 
additional feeder layer of growth-arrested 3T3 fibroblasts in the bottom of the cell culture 
well is a duplex system (Miyashita et al., 2008). 3T3 fibroblasts are primitive cells isolated 
from embryonic mice. They have a high proliferative capacity and have been used 
extensively in the culture of epithelial stem cells especially in skin and cornea. Both amniotic 
membrane and growth-arrested 3T3 fibroblasts inhibit the differentiation of corneal 
epithelial cells ex vivo, which allows the expansion of the population of LSCs (Grueterich et 
al., 2003, Pellegrini et al., 1999). Denuded AM is thought to be an excellent substrate for the 
corneal limbal cell culture used for ocular surface reconstruction, even though AM epithelial 
cells contain various growth factors with 3T3 feeder cells. This theory, however, remains to 
be fully investigated. 
The variation in suspension culture techniques are use of novel temperature-responsive 
culture surfaces. Temperature-responsive polymers chemically immobilized to thin films on 
cell-culture surfaces facilitate cell adhesion and growth of cells in normal culture conditions, 
at 37°C. Temperatures below 30°C can reversibly alter cell hydration properties with respect 
to temperature, hydration and swellingprompting complete detachment of adherent cells 
without the use of proteolytic enzymes or treatment with EDTA (Nishida et al., 2004b, 
Nishida et al., 2004a). The advantage of this system is that no enzymes are needed to free the 
epithelial sheet from the culture membrane; however, application of temperature-responsive 
polymers in a clinical setting remains questionable for safety and efficacy. 
6. Ex vivo expansion of alternative sources of epithelium 
Although adult stem cells hold considerable promise for the treatment of a number of 
diseases in regenerative medicine, the second major obstacle has been to obtain sufficient 
number of autologous or allogeneic stem cells.  
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6.1 Oral mucosal cells 
In an attempt to overcome the problems inherent in the transplantation of allogeneic tissue, 
there has been recent interest in the possibility of using alternative autologous epithelial 
cells. There are several potential sources of non-keratinizing, stratified squamous epithelium 
in the adult human, including oral mucosal, conjunctival, nasal, esophageal, vaginal and 
rectal epithelia. The main concept is to use the smooth surface of the oral mucosa, with its 
stem cell properties, to reconstruct the ocular surface. Oral mucosae are thought to be at a 
lower stage of differentiation than epidermal keratinocytes (Collin et al., 1992, Schermer et 
al., 1986) because they divide rapidly and can be maintained in culture for prolonged 
periods without keratinization (Hata et al., 1995). Various antimicrobial peptides (AMPs) are 
known to be present on the epithelial cells of ocular and oral surfaces (Haynes et al., 1999). 
Moreover, keratin 3 is expressed by both corneal epithelium (Sangwan et al., 2003b) and oral 
mucosa (Collin et al., 1992, Juhl et al., 1989), suggesting that gene expression in oral and 
corneal epithelium may be similar. Wet-surfaced epithelia, produce a group of highly 
glycosylated, protective membrane glycoproteins termed mucins (Gipson, 2007). Although 
the function of these mucins in the oral cavity remains to be elucidated, it is possible that 
they contribute to the epithelial protective mucin layer and act as receptors initiating one or 
more intracellular signal transduction pathways (Argueso et al., 2003). At the ocular surface, 
at least three membrane-associated mucins (MUC1, -4, and -16) and two secreted mucins 
(MUC5 and -7) are expressed (Hori et al., 2007).  
More extensive studies have been performed to check the feasibility of using cultivated oral 
mucosal epithelium (COME) for this purpose, as it is readily available and could be 
harvested without invasive surgery. A small biopsy of the patient’s oral mucosa is 
harvested, connective tissue is dissected and, after enzymatic digestion, an epithelial cell 
suspension is prepared. The oral epithelial cells are cultivated on the substrate with a feeder 
layer. The sheet of cultivated cells is then transplanted onto the diseased ocular surface 
(Figure 5). These studies suggest that oral mucosal epithelium is a feasible alternative for  
 
 
Fig. 5. Systematic representation of cultivated oral mucosal epithelium transplantation. 
Adopted from (Lim et al., 2009). 
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membrane and growth-arrested 3T3 fibroblasts inhibit the differentiation of corneal 
epithelial cells ex vivo, which allows the expansion of the population of LSCs (Grueterich et 
al., 2003, Pellegrini et al., 1999). Denuded AM is thought to be an excellent substrate for the 
corneal limbal cell culture used for ocular surface reconstruction, even though AM epithelial 
cells contain various growth factors with 3T3 feeder cells. This theory, however, remains to 
be fully investigated. 
The variation in suspension culture techniques are use of novel temperature-responsive 
culture surfaces. Temperature-responsive polymers chemically immobilized to thin films on 
cell-culture surfaces facilitate cell adhesion and growth of cells in normal culture conditions, 
at 37°C. Temperatures below 30°C can reversibly alter cell hydration properties with respect 
to temperature, hydration and swellingprompting complete detachment of adherent cells 
without the use of proteolytic enzymes or treatment with EDTA (Nishida et al., 2004b, 
Nishida et al., 2004a). The advantage of this system is that no enzymes are needed to free the 
epithelial sheet from the culture membrane; however, application of temperature-responsive 
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Although adult stem cells hold considerable promise for the treatment of a number of 
diseases in regenerative medicine, the second major obstacle has been to obtain sufficient 
number of autologous or allogeneic stem cells.  
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6.1 Oral mucosal cells 
In an attempt to overcome the problems inherent in the transplantation of allogeneic tissue, 
there has been recent interest in the possibility of using alternative autologous epithelial 
cells. There are several potential sources of non-keratinizing, stratified squamous epithelium 
in the adult human, including oral mucosal, conjunctival, nasal, esophageal, vaginal and 
rectal epithelia. The main concept is to use the smooth surface of the oral mucosa, with its 
stem cell properties, to reconstruct the ocular surface. Oral mucosae are thought to be at a 
lower stage of differentiation than epidermal keratinocytes (Collin et al., 1992, Schermer et 
al., 1986) because they divide rapidly and can be maintained in culture for prolonged 
periods without keratinization (Hata et al., 1995). Various antimicrobial peptides (AMPs) are 
known to be present on the epithelial cells of ocular and oral surfaces (Haynes et al., 1999). 
Moreover, keratin 3 is expressed by both corneal epithelium (Sangwan et al., 2003b) and oral 
mucosa (Collin et al., 1992, Juhl et al., 1989), suggesting that gene expression in oral and 
corneal epithelium may be similar. Wet-surfaced epithelia, produce a group of highly 
glycosylated, protective membrane glycoproteins termed mucins (Gipson, 2007). Although 
the function of these mucins in the oral cavity remains to be elucidated, it is possible that 
they contribute to the epithelial protective mucin layer and act as receptors initiating one or 
more intracellular signal transduction pathways (Argueso et al., 2003). At the ocular surface, 
at least three membrane-associated mucins (MUC1, -4, and -16) and two secreted mucins 
(MUC5 and -7) are expressed (Hori et al., 2007).  
More extensive studies have been performed to check the feasibility of using cultivated oral 
mucosal epithelium (COME) for this purpose, as it is readily available and could be 
harvested without invasive surgery. A small biopsy of the patient’s oral mucosa is 
harvested, connective tissue is dissected and, after enzymatic digestion, an epithelial cell 
suspension is prepared. The oral epithelial cells are cultivated on the substrate with a feeder 
layer. The sheet of cultivated cells is then transplanted onto the diseased ocular surface 
(Figure 5). These studies suggest that oral mucosal epithelium is a feasible alternative for  
 
 
Fig. 5. Systematic representation of cultivated oral mucosal epithelium transplantation. 
Adopted from (Lim et al., 2009). 
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allogenous limbal transplants (Nakamura et al., 2003b, Nakamura et al., 2004a, Inatomi et al., 
2006, Nishida et al., 2004b, Hayashida et al., 2005). Oral mucosal epithelium cultured on 
human amniotic membrane with the help of feeder cells has been characterized extensively, 
and has been used to reconstruct the ocular surface in rabbits (Nakamura et al., 2003a) as 
well as humans with chemical injury and SJS (Nakamura et al., 2004a). In the lengthiest 
study reported so far, cultured oral mucosal epithelial cells were transplanted into patients 
with LSCD and followed up with for up to 34 months (Inatomi et al., 2006) where the 
followups continued until tissue became viable. 
The main advantages of using oral mucosa are the absence of tissue rejection and, therefore, 
avoidance of immunosuppression; easy access to the oral cavity; inconspicuous location of 
the resultant small scar, and repeatability. This treatment method has not, however, 
provided satisfactory long-term results. The oral mucosal epithelial cell grafts seldom 
transdifferentiate to a corneal epithelium phenotype, e.g., expression of keratin 12 (Krt12) 
(Inatomi et al., 2006). This new approach, however, provides an exciting possibility for 
treatment of this difficult group of patients with blindness from bilateral total LSCD and 
warrants further study. 
6.1.2 Dental pulp stem cells 
In an attempt to prevent rejection, isolated human immature dental pulp stem cells 
(hIDPSC) from deciduous teeth have been used as an autologous alternative epithelium 
source for LSCD treatment or corneal reconstruction. hIDPSCs are known to express both 
mesenchymal stem cell markers (SH2, SH3 and SH4) and human embryonic stem cell 
markers (OCT 4, NANOG, SSEA-3 and SSEA-4) (Gomes et al., 2010). Furthermore, hIDPSCs 
have a normal karyotype and show the capacity for multilineage differentiation into 
neurons, smooth and skeletal muscle, cartilage, bone, and other cell types ex vivo and in vivo 
(Kerkis et al., 2006, Lavagnolli et al., 2009). Limited studies have been performed to test 
dental pulp stem cells as potential treatment for LSCD. Monteiro et al. demonstrated, using 
immunohistochemistry and reverse transcription polymerase chain reaction, that hIDPSCs 
express markers in common with LSCs, such as ABCG2, integrin β1, vimentin, p63, 
connexin 43 and cytokeratins 3/12. These have been shown to be capable of reconstructing 
the eye surface after induction of unilateral total LSCD in rabbits (Monteiro et al., 2009). 
Further studies are required to understand the long-term outcome of LSCD treated using 
hIDPSCs. 
6.1.3 Hair follicle stem cells 
Hair has the potential to regenerate from stem cells located at the lower part of the follicle 
called the bulge (Oshima et al., 2001). Additionally, hair follicle stem cells (HFSCs) can give 
rise to epidermis and sebaceous gland tissues. Recently, Blazejewska et al. demonstrated that 
murine HFSCs can transform into epithelia-like cells when cultured in limbal fibroblast-
derived medium (Blazejewska et al., 2009). Although, these findings need further 
substantiation using in vivo functional studies in animal models, they provide the first step 
towards the design of protocols that could use human autologous hair follicle stem cells  
to replace corneal epithelium in therapeutic applications. Due to their multipotency,  
easy accessibility, and high proliferation rate ex vivo, hair follicles are an attractive source  
of autologous adult stem cells and a promising therapeutic tool for ocular surface 
reconstruction. 
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6.1.4 Embryonic stem cells 
Embryonic stem cells (ESCs) are pluripotent (i.e., they can give rise to any cell type in the 
body) and are derived from the inner cell mass of a blastocyst. Differentiation of ESCs to a 
corneal epithelial lineage could be achieved by replication of the LSC niche environment. 
Transplantation of epithelial cells derived from mouse ESCs have been used to reconstruct 
chemically injured mouse corneas (Homma et al., 2004). Moreover, human ESCs express 
cornea-like epithelial markers such as CK3 and CK12 when cultured in conditions similar to 
those of the limbal stem cell niche. Ex vivo replication of the LSC niche environment has been 
achieved by culturing hESCs on an extracellular matrix of collagen IV and fed with medium 
conditioned with limbal fibroblasts (Ahmad et al., 2007). The differentiated human ESCs 
demonstrate phenotypic differences to cultured human limbal epithelial cells, such as 
differences in size and cilia length, which are characteristically much longer than those of 
limbal epithelial cells. These data suggest that some differences exist between LSCs and hESC-
derived corneal progenitors (Ahmad et al., 2007). The translation of this approach to human 
therapeutic use requires further work to overcome problems associated with functionality, 
complete hESC differentiation and immune rejection as well as ethical concerns. 
7. Future considerations for cultivated epithelial transplants 
Ex vivo expansion of limbal epithelium has been performed by several unrelated groups in a 
number of countries and used to treat a variety of ocular surface disorders that are thought 
to be the result of limbal stem cell failure. Despite a substantial number of experimental 
models of this technique and an ever-growing body of laboratory data on limbal epithelial 
stem cell biology, scientific basis for this procedure is poorly understood. Future 
considerations in the field of limbal epithelial cell culture and transplantation methods are 
discussed below. 
7.1 Culture methodologies 
The culture of limbal epithelium is essential for furthering our understanding of limbal stem 
cell biology. Ex vivo expansion of LSCs for the treatment of LSCD is one of the more recent 
stem cell treatments available in the field of regenerative medicine. Although the technique 
of ex vivo expansion of LSCs is still in its infancy, it is starting to be used by several groups 
for clinical purposes, and different approaches have been attempted. There are many 
varying techniques for culturing limbal epithelial cells, such as different media and sera; 
culture with 3T3 fibroblasts or amniotic membrane, or both; removal of amniotic membrane 
epithelial cells from the membrane, or not; use of explant or suspension methods; and 
airlifting of the culture, or not (Shortt et al., 2007, Grueterich et al., 2003). Whichever culture 
method is used, the end result, often after a period of weeks, is a cultivated epithelial sheet 
composed of LSCs. The ease of explanting culture technique could be adapted without 
initial dispase treatment for transplantation studies. However, further studies on the 
interaction between epithelial progenitor and autologous stromal cells ex vivo, and complete 
characterization of limbal cells in this culture system, including cell junction proteins, are 
required. 
7.1.2 Autologous sources and xenobiotic-free conditions 
With growing concerns regarding the potential transmission of opportunistic agents such as 
prions and animal viruses, it would be preferable to culture cells for human transplantation 
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allogenous limbal transplants (Nakamura et al., 2003b, Nakamura et al., 2004a, Inatomi et al., 
2006, Nishida et al., 2004b, Hayashida et al., 2005). Oral mucosal epithelium cultured on 
human amniotic membrane with the help of feeder cells has been characterized extensively, 
and has been used to reconstruct the ocular surface in rabbits (Nakamura et al., 2003a) as 
well as humans with chemical injury and SJS (Nakamura et al., 2004a). In the lengthiest 
study reported so far, cultured oral mucosal epithelial cells were transplanted into patients 
with LSCD and followed up with for up to 34 months (Inatomi et al., 2006) where the 
followups continued until tissue became viable. 
The main advantages of using oral mucosa are the absence of tissue rejection and, therefore, 
avoidance of immunosuppression; easy access to the oral cavity; inconspicuous location of 
the resultant small scar, and repeatability. This treatment method has not, however, 
provided satisfactory long-term results. The oral mucosal epithelial cell grafts seldom 
transdifferentiate to a corneal epithelium phenotype, e.g., expression of keratin 12 (Krt12) 
(Inatomi et al., 2006). This new approach, however, provides an exciting possibility for 
treatment of this difficult group of patients with blindness from bilateral total LSCD and 
warrants further study. 
6.1.2 Dental pulp stem cells 
In an attempt to prevent rejection, isolated human immature dental pulp stem cells 
(hIDPSC) from deciduous teeth have been used as an autologous alternative epithelium 
source for LSCD treatment or corneal reconstruction. hIDPSCs are known to express both 
mesenchymal stem cell markers (SH2, SH3 and SH4) and human embryonic stem cell 
markers (OCT 4, NANOG, SSEA-3 and SSEA-4) (Gomes et al., 2010). Furthermore, hIDPSCs 
have a normal karyotype and show the capacity for multilineage differentiation into 
neurons, smooth and skeletal muscle, cartilage, bone, and other cell types ex vivo and in vivo 
(Kerkis et al., 2006, Lavagnolli et al., 2009). Limited studies have been performed to test 
dental pulp stem cells as potential treatment for LSCD. Monteiro et al. demonstrated, using 
immunohistochemistry and reverse transcription polymerase chain reaction, that hIDPSCs 
express markers in common with LSCs, such as ABCG2, integrin β1, vimentin, p63, 
connexin 43 and cytokeratins 3/12. These have been shown to be capable of reconstructing 
the eye surface after induction of unilateral total LSCD in rabbits (Monteiro et al., 2009). 
Further studies are required to understand the long-term outcome of LSCD treated using 
hIDPSCs. 
6.1.3 Hair follicle stem cells 
Hair has the potential to regenerate from stem cells located at the lower part of the follicle 
called the bulge (Oshima et al., 2001). Additionally, hair follicle stem cells (HFSCs) can give 
rise to epidermis and sebaceous gland tissues. Recently, Blazejewska et al. demonstrated that 
murine HFSCs can transform into epithelia-like cells when cultured in limbal fibroblast-
derived medium (Blazejewska et al., 2009). Although, these findings need further 
substantiation using in vivo functional studies in animal models, they provide the first step 
towards the design of protocols that could use human autologous hair follicle stem cells  
to replace corneal epithelium in therapeutic applications. Due to their multipotency,  
easy accessibility, and high proliferation rate ex vivo, hair follicles are an attractive source  
of autologous adult stem cells and a promising therapeutic tool for ocular surface 
reconstruction. 
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6.1.4 Embryonic stem cells 
Embryonic stem cells (ESCs) are pluripotent (i.e., they can give rise to any cell type in the 
body) and are derived from the inner cell mass of a blastocyst. Differentiation of ESCs to a 
corneal epithelial lineage could be achieved by replication of the LSC niche environment. 
Transplantation of epithelial cells derived from mouse ESCs have been used to reconstruct 
chemically injured mouse corneas (Homma et al., 2004). Moreover, human ESCs express 
cornea-like epithelial markers such as CK3 and CK12 when cultured in conditions similar to 
those of the limbal stem cell niche. Ex vivo replication of the LSC niche environment has been 
achieved by culturing hESCs on an extracellular matrix of collagen IV and fed with medium 
conditioned with limbal fibroblasts (Ahmad et al., 2007). The differentiated human ESCs 
demonstrate phenotypic differences to cultured human limbal epithelial cells, such as 
differences in size and cilia length, which are characteristically much longer than those of 
limbal epithelial cells. These data suggest that some differences exist between LSCs and hESC-
derived corneal progenitors (Ahmad et al., 2007). The translation of this approach to human 
therapeutic use requires further work to overcome problems associated with functionality, 
complete hESC differentiation and immune rejection as well as ethical concerns. 
7. Future considerations for cultivated epithelial transplants 
Ex vivo expansion of limbal epithelium has been performed by several unrelated groups in a 
number of countries and used to treat a variety of ocular surface disorders that are thought 
to be the result of limbal stem cell failure. Despite a substantial number of experimental 
models of this technique and an ever-growing body of laboratory data on limbal epithelial 
stem cell biology, scientific basis for this procedure is poorly understood. Future 
considerations in the field of limbal epithelial cell culture and transplantation methods are 
discussed below. 
7.1 Culture methodologies 
The culture of limbal epithelium is essential for furthering our understanding of limbal stem 
cell biology. Ex vivo expansion of LSCs for the treatment of LSCD is one of the more recent 
stem cell treatments available in the field of regenerative medicine. Although the technique 
of ex vivo expansion of LSCs is still in its infancy, it is starting to be used by several groups 
for clinical purposes, and different approaches have been attempted. There are many 
varying techniques for culturing limbal epithelial cells, such as different media and sera; 
culture with 3T3 fibroblasts or amniotic membrane, or both; removal of amniotic membrane 
epithelial cells from the membrane, or not; use of explant or suspension methods; and 
airlifting of the culture, or not (Shortt et al., 2007, Grueterich et al., 2003). Whichever culture 
method is used, the end result, often after a period of weeks, is a cultivated epithelial sheet 
composed of LSCs. The ease of explanting culture technique could be adapted without 
initial dispase treatment for transplantation studies. However, further studies on the 
interaction between epithelial progenitor and autologous stromal cells ex vivo, and complete 
characterization of limbal cells in this culture system, including cell junction proteins, are 
required. 
7.1.2 Autologous sources and xenobiotic-free conditions 
With growing concerns regarding the potential transmission of opportunistic agents such as 
prions and animal viruses, it would be preferable to culture cells for human transplantation 
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under xenobiotic-free conditions. In limbal corneal epithelial cultures, the use of autologous 
human serum in the medium and/or human amniotic membrane would be appropriate as it 
would reduce the need for animal cells or products in the culture (Kolli et al., 2010, 
Nakamura et al., 2004a, Nakamura et al., 2006). To avoid contamination from xeno-feeder 
layers, different human feeder layers have also been developed and analyzed (Chen et al., 
2007). Moreover, cells have been cultured on feeder layers during the proliferative phase 
and further separated using robotic technology (Schneider et al., 2008). Limbal epithelial 
cells grown with MRC–5 human embryonic fibroblasts can sustain the stem cell phenotype 
(Notara et al., 2007). The successful use of autologous serum–derived oral epithelial 
equivalent to treat severe ocular surface disease was reported in 2006 (Ang et al., 2006, 
Nakamura et al., 2006). This represents an important advance in the pursuit of completely 
autologous xenobiotic-free bioengineered ocular equivalents for clinical transplantation.  
In conclusion, a specific culture system that mimics natural tissue architecture and its niche 
closely by enabling formation of an autofeeder layer, thereby eliminating the need for xeno-
feeder layers for ex vivo expansion of epithelial progenitor cells is important.  
7.1.3 Combination techniques with anti-angiogenic treatments 
Angiogenic and anti-angiogenic cytokines are involved in cell migration and differentiation 
in wound healing and tumor progression (even in the absence of angiogenesis). The ever-
increasing use of anti-angiogenic therapy for corneal neovascularization brings great 
promise for the treatment of a wide variety of corneal conditions, including LSCD. TGF-β, 
IL-1, and VEGF are the key pro-angiogenic factors involved in the process of angiogenesis; 
and are targets for anti-angiogenic therapies. The ultimate goal for research on corneal 
angiogenesis is to discover effective treatment for pathological corneal neovascularization; 
however, to date, most anti-angiogenic therapies remain experimental. 
Angiostatin, a 38 kDa proteolytic fragment of plasminogen, is a potent anti-angiogenic 
factor. Recombinant angiostatin has been used successfully to suppress tumor growth and 
metastasis in animal model systems (Shin et al., 2000, Ambati et al., 2002). Gabison and 
associates have demonstrated the involvement of angiostatin in corneal avascularity after 
wounding. They confirmed that angiostatin-like molecules are expressed in the corneal 
epithelium and in cultured corneal epithelial cells (Gabison et al., 2004). Corneal 
neovascularization was observed after excimer laser keratectomy when anti-angiostatin 
antibodies were injected into the cornea; this was significantly higher than when plasmin B 
chain antibodies were injected. These studies suggest that angiostatin may contribute to the 
maintenance of corneal avascularity after excimer laser keratectomy.  
The corneal epithelium may be the source of anti-angiogenic molecules. It has long been 
demonstrated that corneal epithelium inhibits angiogenesis (Kaminski and Kaminska, 1978). 
Ferreras and associates demonstrated the generation of endostatin-like fragments by 
cleaving collagen XVIII with MMP-2, -3, -9, -12, -13, or -14 (Ferreras et al., 2000). 
Upregulation of matrix-derived anti-angiogenic factors such as endostatin (Kato et al., 2003) 
and restin (Saika et al., 2004), along with increased anti-inflammatory factor IL-1ra may play 
an important role in LSC and AM transplantation-mediated anti-angiogenic effect. Recently, 
Cursiefen et al. demonstrated a critical mechanism that contributed to corneal avascularity 
by VEGF receptor 3, which is normally present on lymphatic and proliferating blood 
vascular endothelium, is strongly constitutively expressed by corneal epithelium and is 
mechanistically responsible for suppressing inflammatory corneal angiogenesis (Cursiefen 
et al., 2006). Knowledge gained from using epithelia–matrix interaction to regulate corneal 
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angiogenesis will enable us to optimize the anti-angiogenic effect of the cultivated cells like 
oral mucosal epithelial cells or mesehchymal stem cells for future ocular surface 
reconstruction. 
8. Clinical trials and outcomes: present and future  
LSCD by any cause may result in poor corneal epithelialization, persistent epithelial defects, 
corneal vascularization, corneal scarring, and so-called conjunctivalization of the cornea. 
These problems may in turn lead to decreased vision, ocular discomfort and pain, as well as 
an unstable ocular surface. Limbal stem cells may be partially or totally depleted, resulting 
in varying degrees of stem cell deficiency and resulting abnormalities on the corneal surface.  
The first use of ex vivo expanded LSCs for the treatment of LSCD in human subjects was 
described by Pellegrini and co-workers, who used a culture system of LSCs grown on mouse 
J2-3T3 fibroblasts with fetal calf serum (FCS) supplemented media (Pellegrini et al., 1997). Since 
then, several studies have been reported on the transplantation of ex vivo cultured LSCs to treat 
LSCD (Schwab et al., 2000, Tsai et al., 2000, Koizumi et al., 2001b, Grueterich et al., 2002a). 
Schwab et al. reported the results of treating 19 eyes of 18 patients (Schwab, 1999). In 2003, 
Sangwan et al. reported the largest study to date, which enrolled 125 patients (Sangwan et al., 
2003b). In this study ex vivo cultured limbal and conjunctival epithelial cells were grown on 
AM. In 2006, Sangwan et al. published a more detailed report on clinical outcomes for 88 eyes 
of 86 patients (Sangwan et al., 2006). In 2001, Rama et al. reported treatment outcomes for 18 
eyes of 18 patients (Rama et al., 2001). The same group recently reported a 10 year follow-up 
with permanent restoration of transparent corneal epithelium in 76.6% of eyes, with few 63 
instances of inflammation out of 113 eyes treated (Rama et al., 2010). The outcome of cultured 
limbal stem cells transplants differed significantly depending on whether the transplanted 
cultures contained more than 3% p63-bright holoclone-forming stem cells or 3% or less — the 
success rates were 78% with the larger number of stem cells and 11% increase with the smaller 
number of p63 cells (Rama et al., 2001, Rama et al., 2010), suggesting the importance of a high 
percentage of p63 in cultured limbal stem cells. The remaining studies each treated between 2 
and 14 patients (Kolli et al., 2010, Grueterich et al., 2002b, Nakamura et al., 2004a, Sangwan et 
al., 2003a).  
In total, current  studies reported data to enable analysis of outcomes in 506 eyes (Baylis et 
al., 2011) treated using ex vivo, cultured LSC transplants and 27 eyes treated with ex vivo 
cultured oral mucosal epithelium. To date, the limited periods (mean follow-up was 16.74 
months, median 14 months, range 6 to 29.5 months), the use of subjective outcome 
measures, and the absence of a reliable method for detecting transplanted (stem) cells shows 
that a long term success rate has yet to be established. 
Ex vivo expansion and transplantation of limbal epithelium have been performed by several 
unrelated groups in a number of countries, with uncertainty in the limbal stem cell 
cultivation, with different variables, including source of donor limbal tissue, culture method 
(e.g., suspension versus explant culture), culture composition (e.g., 3T3 fibroblasts, amniotic 
membrane and fibrin), and variation in culture time. Overall the success rate for cultured 
limbal epithelial transplantation is 76%. This is based on clinical restoration of the corneal 
epithelium. It is interesting that, despite the different methodologies employed, the success 
rates and number of significant clinical outcomes are remarkably high. It would, therefore, 
appear that, as long as viable limbal epithelial stem cells are transferred, the method used to 
achieve this is relatively unimportant. 
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under xenobiotic-free conditions. In limbal corneal epithelial cultures, the use of autologous 
human serum in the medium and/or human amniotic membrane would be appropriate as it 
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and are targets for anti-angiogenic therapies. The ultimate goal for research on corneal 
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factor. Recombinant angiostatin has been used successfully to suppress tumor growth and 
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epithelium and in cultured corneal epithelial cells (Gabison et al., 2004). Corneal 
neovascularization was observed after excimer laser keratectomy when anti-angiostatin 
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chain antibodies were injected. These studies suggest that angiostatin may contribute to the 
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and restin (Saika et al., 2004), along with increased anti-inflammatory factor IL-1ra may play 
an important role in LSC and AM transplantation-mediated anti-angiogenic effect. Recently, 
Cursiefen et al. demonstrated a critical mechanism that contributed to corneal avascularity 
by VEGF receptor 3, which is normally present on lymphatic and proliferating blood 
vascular endothelium, is strongly constitutively expressed by corneal epithelium and is 
mechanistically responsible for suppressing inflammatory corneal angiogenesis (Cursiefen 
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angiogenesis will enable us to optimize the anti-angiogenic effect of the cultivated cells like 
oral mucosal epithelial cells or mesehchymal stem cells for future ocular surface 
reconstruction. 
8. Clinical trials and outcomes: present and future  
LSCD by any cause may result in poor corneal epithelialization, persistent epithelial defects, 
corneal vascularization, corneal scarring, and so-called conjunctivalization of the cornea. 
These problems may in turn lead to decreased vision, ocular discomfort and pain, as well as 
an unstable ocular surface. Limbal stem cells may be partially or totally depleted, resulting 
in varying degrees of stem cell deficiency and resulting abnormalities on the corneal surface.  
The first use of ex vivo expanded LSCs for the treatment of LSCD in human subjects was 
described by Pellegrini and co-workers, who used a culture system of LSCs grown on mouse 
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2003b). In this study ex vivo cultured limbal and conjunctival epithelial cells were grown on 
AM. In 2006, Sangwan et al. published a more detailed report on clinical outcomes for 88 eyes 
of 86 patients (Sangwan et al., 2006). In 2001, Rama et al. reported treatment outcomes for 18 
eyes of 18 patients (Rama et al., 2001). The same group recently reported a 10 year follow-up 
with permanent restoration of transparent corneal epithelium in 76.6% of eyes, with few 63 
instances of inflammation out of 113 eyes treated (Rama et al., 2010). The outcome of cultured 
limbal stem cells transplants differed significantly depending on whether the transplanted 
cultures contained more than 3% p63-bright holoclone-forming stem cells or 3% or less — the 
success rates were 78% with the larger number of stem cells and 11% increase with the smaller 
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percentage of p63 in cultured limbal stem cells. The remaining studies each treated between 2 
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al., 2011) treated using ex vivo, cultured LSC transplants and 27 eyes treated with ex vivo 
cultured oral mucosal epithelium. To date, the limited periods (mean follow-up was 16.74 
months, median 14 months, range 6 to 29.5 months), the use of subjective outcome 
measures, and the absence of a reliable method for detecting transplanted (stem) cells shows 
that a long term success rate has yet to be established. 
Ex vivo expansion and transplantation of limbal epithelium have been performed by several 
unrelated groups in a number of countries, with uncertainty in the limbal stem cell 
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appear that, as long as viable limbal epithelial stem cells are transferred, the method used to 
achieve this is relatively unimportant. 
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The future directions in LSC transplantation involve modifications of existing technologies 
to allow improved safety and efficacy of techniques at hand.  The studies on the molecular 
mechanism of limbal stem cells and their niche will enhance our knowledge of how cell 
therapy can be further modified to closely mimic in vivo conditions. Identification of key 
niche factors controlling limbal stem cell behaviour would allow these conditions to 
replicate ex vivo and, thus, make the process of culturing limbal stem cells safer and more 
efficient. Newly developed transplantation techniques using tissue-engineered epidermal 
adult stem cells, immature dental pulp stem cells (Gomes et al., 2010), and hair follicle bulge-
derived stem cells (Blazejewska et al., 2009) were reportedly successful for the reconstruction 
of corneal epithelium in an animal model of severe LSCD. The recombinant human cross-
linked collagen scaffold and a Food and Drug Administration-approved contact lens are 
also promising new techniques for successfully achieving ocular surface reconstruction (Di 
Girolamo et al., 2007). There are main challenges in improving the established techniques, in 
elimination of animal-derived products and minimization of allogeneic human tissue use.  
Since cell-based therapies are being scrutinized by ever-increasing regulatory requirements, 
many investigators that have been successfully performing ex vivo cultivation in the past 
are reformulating their methodologies to conform to these guidelines (Daniels et al., 2006, 
Kolli et al., 2010). The future of this methodology lies in the standardization of the stem cell 
preparation and cultivation techniques with clearly defined endpoints and outcome 
measures of treatment success.  
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In 1927 Harvey Cushing described the outcome for soldiers with spinal cord injury (SCI) 
sustained during World War I: "Fully 80 percent died in the first few weeks in consequence 
of infection from bedsores and catheterization. Only those cases survived in which the spinal 
cord lesion was a partial one" (Cushing 1927). Nowadays, this has been reversed. In well-
organized systems of care for trauma and SCI and due to improved critical-care medicine 
most patients survive the initial hospitalization. At present, there is no treatment available 
that effectively re-establishes disrupted axonal circuitries that are necessary to restore 
injury-induced functional deficits. Due to the lack of a cure and the improved health care, 
the number of wheelchair bound people increases steadily each year. Currently, in the 
United States there are an estimated 400,000 people with SCI, with an annual incidence of 
11,000 (The National Spinal Cord Injury Statistical Center, Birmingham, AL). In Western 
European countries similar leading causes of SCI are obtained as in the United States, with 
vehicular crashes and falls as leading causes of SCI and predominantly young males are 
affected (Ditunno & Formal, 1994; Ackery et al., 2004). In contrast to the developed 
countries, in the less developed countries a shift of etiology can be observed towards falls 
(Hoque et al., 1999) and violence (Da Paz 1992, Dincer 1992, Hart 1994). 
Following the first medical care in a hospital, continuing medical care is necessary to 
maintain the SCI patient’s health and quality of life. This does not lead to functional repair. 
Repair-promoting pharmaceutical and/or surgical interventions will be necessary to 
significantly change the functional outcome after SCI. Transplantation of repair-supporting 
cells is considered a candidate repair approach. A bone marrow stromal cell (BMSC) 
transplant has shown great promise for spinal cord repair. This chapter will give an 
overview of clinical consequences, assessments, and treatments of SCI and will then focus 
on stem cells and in particular BMSC as a therapy for SCI. 
2. Clinical consequences of SCI 
A direct force to the vertebral column can cause damage to bony and soft tissue structures. 
Torn ligaments or fractures can cause instability of the vertebral column with potential risk 
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of additional damage. Fracture dislocation and hematomas can directly compress the spinal 
cord and cause immediate neural cell death, axon damage and demyelination, resulting in 
instant loss of motor and sensory function. After the first destructive events, a sequence of 
molecular and cellular pathophysiological events, including an aggressive inflammatory 
response within the damaged tissue leads to additional tissue loss at the injury epicenter 
and at distant sites (secondary injury; Blight 1992; Hagg & Oudega, 2006). The functional 
consequences of SCI are highly variable and depend on the degree of tissue damage, which 
in turn depends on the impact severity. In patients with SCI with a relatively small amount 
of tissue damage, some endogenous recovery of function can be observed, which is most 
likely resulting from plasticity of the spinal nervous tissue (Dietz & Harkema, 2004; Dobkin 
et al, 2007). In people with SCI with extensive tissue damage the neurological deficits are 
generally major and permanent. There are very few reports of people with a large injury 
that regain motor function to a degree that independence can be achieved.  
Over 95% of SCI patients survive their initial hospitalization. The relatively young age when 
SCI occurs, improved medical care, and lack of effective therapies are responsible for the 
continually increasing number of paralyzed people with SCI. This puts a high financial 
burden on the patient, his/her family, and society (Fiefler et al., 1999; Ackery et al, 2004). 
The psychological consequences of SCI should not be underestimated and appropriate 
guidance of patient and family should have an important place in the management of SCI 
(Boekamp et al., 1996; Widerström-Noga et al., 1999/2007). Patients need time to accept their 
deficits. One can expect an initial period of denial and/or inability to fully comprehend the 
consequences of the paralysis caused by the injury. After the patient realizes his/her fate to 
the fullest extent, a period of acceptance will have to run its course (Boekamp et al., 1996). 
After that, the patient needs to learn to live with his/her disabilities, and this may be 
accompanied by bouts of depression. The mental state of the patient can have its effect on 
his/her medical treatments (Widerström-Noga et al., 1999).  
SCI is the second most expensive condition to treat in the United States after respiratory 
distress syndrome in infants and is ranked third in medical conditions requiring the longest 
stay in hospitals (Winslow et al., 2002). The costs of lifetime care for a SCI patient varies 
between 1 and 3 million dollars. The Center for Disease Control in the United States 
estimated that about 10 billion dollars are spent yearly on SCI treatment excluding the 
management of pressure ulcers, a common adverse effect of SCI, which adds another billion 
dollars per year (McKinley et al., 1999).  
2.1 Clinical assessment of SCI 
The American Spinal cord Injury Association (ASIA) impairment scale is widely used and 
provides clinicians with a standard way of grading the functional severity of a spinal cord 
injury. The scale has one grade for complete injuries (ASIA A), three other grades for 
incomplete injuries (ASIA B-D), and another for no impairment from the injury (ASIA E). To 
categorize the grades for incomplete injuries, clinicians determine the degree of muscle 
strength, being active movement against full resistance, of the key muscles below the 
neurological level of the injury. The assignment is based on the extent to which more than 
half of the key muscles have a muscle strength grade of 3 or higher. Classifications of SCI 
can also be achieved by implementing tests that measure functional ability (Ditunno et al., 
2005). A widely used scale for such measurements is the Functional Independence Measure 
(FIM), which uses a 7-point scale to measure 18 items concerning mobility, locomotion, self-
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care, bowel and/or bladder function, communication, and social cognition (McKinley et al., 
2004; Ditunno et al., 2007). Other functional assessment scales are the Quadriplegic Index of 
Function (QIF), Modified Barthel Index (MBI), Walking Index for SCI (WISCI), Capabilities 
of Upper Extremity Instrument (CUE), Spinal Cord Independence Measure (SCIM), and the 
Canadian Occupational Performance Measure (COPM). These functional tests become more 
important in the rehabilitation phase of the patient when it is important to analyze the 
limitations in daily life. 
2.2 Treatment of SCI 
An acute and a chronic phase can be distinguished after SCI. Since SCI is often a 
consequence of severe accidents, initial treatment is generally focused on stabilization of the 
patient. There is insufficient evidence that would support standards of care during the acute 
phase of SCI. It is advised to maintain patients in an intensive care unit for close monitoring 
of respiratory and hemodynamic complications. For adequate spinal perfusion, which can 
be at risk due to injury-induced edema, a mean arterial pressure of 85-90 mmHg should be 
maintained (Botel et al., 1997). Depending on the type of injury, surgical interventions 
should be considered to decompress the spinal cord and or stabilize the spinal column 
(Brodkey et al., 1980; Fehlings & Perrin, 2006). Decompression surgeries may accelerate 
functional improvements and result in shorter hospitalization and rehabilitation periods 
(Papadopoulos et al., 2002; McKinley et al., 2004). However, it does not result in an 
improved functional outcome (Chen et al., 1998). A lack of consensus of care during the 
acute phase of SCI is in part due to the large variability among injuries and makes its early 
management complicated. If bone fragments continue to compress the spinal cord, early 
surgery may be vital to prevent exacerbation of spinal cord tissue destruction. However, in 
cases without a clear sign of such urgency there is no consensus on whether and what type 
of early surgical/clinical interventions must be implemented (Fehlings & Perrin, 2006). The 
type of surgical intervention should be considered on a case-to-case basis, which makes it 
complicated to study the efficacy of intervention in the acute phase after SCI in randomized 
and controlled clinical trials.  
Besides surgical interventions, pharmacological treatments to limit the secondary injury 
after SCI are often considered. The best-known treatment is a high dose of the 
glucocorticosteroid, methylprednisolone sodium succinate (MPSS) within 8 hours after the 
injury (Bracken et al., 1990/ 1997/ 2002). Experimentally it was demonstrated that a high 
dose of MPSS reduces the inflammatory response and limit tissue loss after damage to the 
spinal cord. The effects of MPSS in patients with SCI were investigated in 3 consecutive 
National Acute Spinal Cord Injury Studies (NASCIS; Bracken et al., 1990/ 1997/ 2002). The 
results demonstrated that MPSS treatment in the acute phase of SCI resulted in neurological 
improvements up to 6 months after injury. After a thorough review of the results from the 
NASCIS studies and a more comprehensive assessment of the benefits and risks involved in 
high dose MPSS treatment, the therapeutic benefits are now disputed (Nesutherai, 1998/ 
2001; Lee et al., 2007). Especially in patients with complete SCI high dose steroid treatment 
can lead to adverse effects such as myopathy and wound infection that may negatively 
influence functional outcome and in some cases may be life-threatening (Qian et al., 2005; 
Lee et al., 2007). Currently, many SCI clinics worldwide have discontinued the ‘standard’ 
acute administration of MPSS after SCI.  
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Treatment paradigms in the chronic stage after SCI are multidisciplinary and intensive. 
Different complications may occur that each demands specific interventions. For instance, 
SCI can lead to pain (Widerstrom et al., 1999/ 2004), decreased fertility (Patki et al., 2007), 
and autonomic dysreflexia with loss of bladder and bowel control (Weaver et al., 2006). It 
has to be taken into consideration that many SCI patients get accustomed to the specific 
injury-related pain they experience and as a result reveal their distress to their physician 
often at a late stage (Mariano, 1992; Sawatzky et al., 2008). For some SCI-related conditions, 
such as decreased fertility, it is the patient’s personal desire that should guide the 
physician’s actions. Other common problems that arise after SCI are septicemia, respiratory 
insufficiency, and pneumonia due to muscle atrophy. These complications may cause 
clinical deterioration and could eventually result in death. They often occur without typical 
symptoms. It is imperative that SCI patients receive annual screenings and long-term 
follow-ups to prevent these secondary complications. It is advised to treat patients on a 
regular basis with pneumococcal and influenza vaccine to prevent opportunistic infections. 
Monitoring the skin and urinary tract and implementing aggressive treatments against 
pressure ulcers and urinary tract infections is needed to reduce the risk of septicemia. 
Appropriate nutrition and exercise should also be incorporated in the (new) lifestyle. 
Rehabilitation programs should be implemented to reduce the risk of cardiovascular disease 
(Kennedy  et al., 2003; Strauss et al., 2006). 
3. A stem cell; the origin of life? 
Stem cells are defined by their capacity to divide in one cell that remains the stem cell 
without signs of ageing (self-renewal), and another cell that begins the process of 
differentiation, thus providing an unlimited source for implantation. Moreover, a stem cell 
is able to differentiate into different lineages (pluripotency). It may also be possible for a 
stem cell to cease proliferation, entering a quiescent phase, in which it is not an actual stem 
cell, but still has the potential since it can re-enter the cycle of self-renewal (Potten et al., 
1990).  
3.1 The origin of life  
Aristotle (384-322 BC) developed the concept of spontaneous generation, which was first 
mentioned during ancient Roman times, and described that earth, air, fire, and water (the 
four elements) mixed with an essence known as "quintessence" or "ether" would give ‘life’ 
after it was brought in contact with ’pneuma’ (or `soul`). In the middle ages it became 
generally believed that the concept of living was based on “spontaneous generation”, 
hypothesizing that the embryo was derived from the mother’s menstrual blood, based on 
the concept that living animals arose from slime or decaying matter. It was not until 1855 
that zoologist and comparative anatomist, Leydig pronounced that life could only arise from 
preexisting life (omne vivum ex vivo). Virchow extended this and postulated that all cells in 
an organism are derived from preexisting cells (omnis cellula e cellula); all cells of the human 
body arise from the fertilized egg. The theoretical proof for his hypothesis was provided by 
the French chemist and biologist, Louis Pasteur (1822-1895) in his essay "Mémoire sur les 
corpuscules organisés qui existent dans l'atmosphère" of 1861 in which he described a series 
of experiments showing that germs do not form spontaneously in sterilized flasks. 
Nineteenth century pathologists first hypothesized the presence of stem cells in the adult as 
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“embryonal rests” to try to explain the cellular origin of cancer cells. Cancer results from an 
imbalance between the rate at which cells are produced and the rate of their apoptosis. 
Nowadays, it is generally agreed that stem cells reside in the adult body as well, possibly in 
a quiescent state. Certain cues can cause them to re-enter the cycle of cell proliferation and 
differentiation (Sell, 2004). 
3.2 Determination 
The ultimate stem cell is the fertilized egg, a totipotent cell, which can differentiate in each 
cell type. After a few divisions, when the dividing cells are called blastomeres (32 to 64 
cells), the cells are determined to become specific for one of the three germ layers; the 
ectodermal layer, which will give rise to skin and neural tissue, the mesodermal layer, 
which will give rise to connective tissue, muscle, bone and blood cells, and the endodermal 
layer, which will give rise to gastrointestinal tract and internal glandular organ cells. In 
classic embryology, this ‘determination’ of stem cells is thought to be an irreversible process. 
As the cell mass develops, the daughter cells begin to acquire properties different from one 
another, so that different regions destined to become different components of the embryo 
are formed. Recently, it has been suggested that the determined stem cell is in fact 
phenotypically plastic and is able to give rise to cells from different germ layers, a process 
known as transdifferentiation (Morrison et al., 1997; Johansson et al., 2003). The process of 
transdifferentiation can also result in the formation of abnormal phenotypes having no 
counterpart in the normal body (dysplasia). These dysplastic cells may be the first step in 
carcinogenesis (Slack, 2007). The possibility of transdifferentiation has raised the interest in 
using of easy to harvest (adult) stem cells and try to transdifferentiate them into a more 
desirable cell type. 
3.3 Embryonic versus adult 
Embryonic stem (ES) cells are obtained from the undifferentiated inner cell mass of the 
blastocyst, which in humans forms 4 to 5 days after fertilization. At this stage the inner cell 
mass consists of around 50-150 cells. ES cells are pluripotent cells and can develop into more 
than 200 cell types of the adult body when given the appropriate stimuli for differentiation 
(Morrison et al., 1997). They are known to proliferate rapidly in culture. Because of this 
plasticity some people prefer to use embryonic stem cells for research purposes. On the 
other hand, it recently has been shown that the ES cells need to be genetically modified and 
extensively manipulated in vitro before they can be transplanted safely. Direct transplant of 
ES cells are known to give rise to teratomas and uncontrollable cell proliferation (Slack, 
2007). To avoid immune rejection a life-long use of immunosuppressive drugs after 
transplantation is necessary or the ES cells have to be tissue-matched from a bank of stem 
cells created from ‘spare’ human embryos; a procedure prone to failure and morally 
objectionable to many, including scientists. 
By contrast, adult stem cells can be transplanted directly without genetic modification or 
pre-treatments. There is no problem with immune rejection because the cells can readily be 
isolated from the patient’s bone marrow, skin, fat, umbilical cord blood and other sources 
(autografting). Although the adult stem cells show less plasticity in vitro, they do show high 
degrees of genomic stability during culture. They have the potential to differentiate in 
response to cues from the surrounding tissues and do not show uncontrollable proliferation 
resulting in tumors. Finally, since it is not necessary to take cells from embryos there are less 
ethical concerns for the use of this kind of stem cell.  
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3.4 Ethical and social perspectives 
The involvement of human cells gives rise to ethical and social concerns, mostly concerning 
the status of the human embryo. Although there is a general consensus that the early human 
embryo is worthy of some measure of respect as an organized assembly of human cells, 
opinions vary as to the measure of respect deserved. The Roman Catholic Church teaches 
that “from its conception, the child has a right to life” and “it must be treated from 
conception as a person” (Roman Catholic Church, 1994). On the other hand, there are those 
that consider the early human embryo as merely an assembly of human cells and not a 
human individual at all at this stage. The embryo should be considered an individual once it 
becomes viable. Over the last few decades this viability of the embryo has shifted as a result 
of advanced medical techniques to the 20th week of gestation (Goldenring, 1985; Peterfy, 
1995). The use of human embryo’s for research or therapeutic purposes is still the subject of 
controversy. 
The conversion of stem cells into gametes (sperm or egg cells) in itself presents, if any, few 
ethical hurdles (Testa & Harris, 2005). On the positive side, stem cells as a potential source of 
oocytes for clinical applications, such as in vitro fertilization to induce pregnancy in 
childless couples, have proven successful. Many of the ethical concerns arise from the 
potential for misuse rather than the use of such gametes (Westpal, 2003). The ability to 
derive oocytes from stem cells of male origin, inducing X and Y chromosomes and fertilized 
oocytes would raise the possibility of in vitro fertilization of such oocytes and the 
production of a child with two male biological parents (Hubner et al., 2003; Geijsen et al., 
2004; Azim, 2004). Most extreme, the possibility of producing oocytes from the male stem 
cells and fertilizing these oocytes with his own sperm would open the avenue for single-
parent families and in theory would be the most incestuous relationship. Obviously, there 
still has to be a female surrogate mother to bring any offspring to term. The offspring can be 
expected, if it survived, to exhibit many developmental defects resulting from acquisition of 
pairs of (recessive) genes for anomalies (Hubner et al., 2003, Whittaker, 2007).  
Therapeutic cloning and genetic manipulation of stem cells have ethical and social concerns. 
Cloning of cells, genetically matched for the host can contribute to the field of organ 
transplantation, where a shortage of donor organs and rejection of not perfectly matched 
grafted organs by the host are major  concerns. However, the destruction of human embryos 
for this application opposes obvious problems in itself and is in general considered 
unethical. Genetic manipulation may perhaps be one of the most significant applications of 
converting embryonic stem cells into gametes, opening the possibility for germ line gene 
therapy (GLGT) (Newson & Smajdor, 2005). GLGT offers the possibility for eliminating the 
transfer of a gene mutation from a parent to their children and their children's children, and 
as a result eliminating the aberrations in the gene pattern. Genetic manipulation could, even 
more controversially, open the possibilities for inserting 'desirable' genes into the germ line, 
resulting in the so-called “designer babies”.  
Stem cell-based therapies are still at a very early stage and the associated risks are still 
unclear. On the other hand, when a patient is suffering from a disabling and sometimes life-
threatening disease, a case might be made for lowering the ethical barriers to enable 
treatment. As with any medical interventions, the questions to be asked are whether this 
approach is the most likely to achieve success and whether the potential benefits outweight 
the potential risks. 
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4. Stem cells for central nervous system repair 
The promise of neural stem/progenitor cells (NSC) for repair of traumatic injuries of central 
nervous tissue lies in their ability to differentiate into the three neural cell types; neurons, 
astrocytes, and oligodendrocytes (Fig. 1). Besides NSC, other types of stem cells may also be 
beneficial for replacement-based repair approaches if they can be successfully manipulated 
into the neural lineage (i.e., transdifferentiation). 
Although, following an injury to the central nervous system, endogenous NSC are typically 
recruited, they generally do not lead to significant repair. A potential approach to benefit 
more from NSC for neural repair is to isolate the cells from donor tissue and prepare them 
ex vivo for transplantation. The advantages of ex vivo isolation of cells are the large 
numbers of cells that can be cultured, and the opportunity of committing the cells towards a 
certain cell type. Experimental evidence has demonstrated that neural stem cells after 
transplantation into damaged nervous tissue are more likely to differentiate into astrocytes 
than into neurons or oligodendrocytes. In some cases this may be the objective, but most 
likely there is a larger need for neurons or oligodendrocytes. Therefore, it is more effective 
to transplant cells already committed to become a certain neural cell type such as 
oligodendrocyte-precursor cells (OPCs) and glial-restricted precursor cells (GRPCs).   
  
 
Fig. 1. Neural lineage differentiation: Neural stem cells differentiate into neuroblasts, which 
give rise to neurons, and in glioblasts, which give rise to astrocytes and oligodendrocytes. 
Replacement of lost neurons with NSC-derived neurons may provide the cellular 
foundation for restoring axonal connections between affected regions in the nervous system 
(Fig. 2). The prerequisite for such repair is that the transplanted neurons grow their axon 
towards the original (or new) target cells and form functional synaptic connections. 
Replacing lost oligodendrocytes by ones generated from stem/progenitor cells may benefit 
remyelination of axons that have survived the initial and secondary damage but have lost 
their insulating myelin sheaths due to oligodendrocyte death (Fig. 2). In addition, 
oligodendrocyte replacement may help myelination of newly generated axons from the 
transplanted neurons as well as regenerated axons from original neurons. Research has 
demonstrated that oligodendrocyte replacement using OPCs is a powerful tool to elicit 
(re)myelination and as a result improve functional recovery. Currently, OPCs are being 
tested in a clinical trial for their potential to repair the spinal cord. Replacement of lost 
astrocytes can also be of great value. Astrocytes play a crucial role in a number of events 
such as neuronal functioning, blood-spinal cord-barrier maintenance, and more. Astrocyte 
 
New Advances in Stem Cell Transplantation 
 
476 
3.4 Ethical and social perspectives 
The involvement of human cells gives rise to ethical and social concerns, mostly concerning 
the status of the human embryo. Although there is a general consensus that the early human 
embryo is worthy of some measure of respect as an organized assembly of human cells, 
opinions vary as to the measure of respect deserved. The Roman Catholic Church teaches 
that “from its conception, the child has a right to life” and “it must be treated from 
conception as a person” (Roman Catholic Church, 1994). On the other hand, there are those 
that consider the early human embryo as merely an assembly of human cells and not a 
human individual at all at this stage. The embryo should be considered an individual once it 
becomes viable. Over the last few decades this viability of the embryo has shifted as a result 
of advanced medical techniques to the 20th week of gestation (Goldenring, 1985; Peterfy, 
1995). The use of human embryo’s for research or therapeutic purposes is still the subject of 
controversy. 
The conversion of stem cells into gametes (sperm or egg cells) in itself presents, if any, few 
ethical hurdles (Testa & Harris, 2005). On the positive side, stem cells as a potential source of 
oocytes for clinical applications, such as in vitro fertilization to induce pregnancy in 
childless couples, have proven successful. Many of the ethical concerns arise from the 
potential for misuse rather than the use of such gametes (Westpal, 2003). The ability to 
derive oocytes from stem cells of male origin, inducing X and Y chromosomes and fertilized 
oocytes would raise the possibility of in vitro fertilization of such oocytes and the 
production of a child with two male biological parents (Hubner et al., 2003; Geijsen et al., 
2004; Azim, 2004). Most extreme, the possibility of producing oocytes from the male stem 
cells and fertilizing these oocytes with his own sperm would open the avenue for single-
parent families and in theory would be the most incestuous relationship. Obviously, there 
still has to be a female surrogate mother to bring any offspring to term. The offspring can be 
expected, if it survived, to exhibit many developmental defects resulting from acquisition of 
pairs of (recessive) genes for anomalies (Hubner et al., 2003, Whittaker, 2007).  
Therapeutic cloning and genetic manipulation of stem cells have ethical and social concerns. 
Cloning of cells, genetically matched for the host can contribute to the field of organ 
transplantation, where a shortage of donor organs and rejection of not perfectly matched 
grafted organs by the host are major  concerns. However, the destruction of human embryos 
for this application opposes obvious problems in itself and is in general considered 
unethical. Genetic manipulation may perhaps be one of the most significant applications of 
converting embryonic stem cells into gametes, opening the possibility for germ line gene 
therapy (GLGT) (Newson & Smajdor, 2005). GLGT offers the possibility for eliminating the 
transfer of a gene mutation from a parent to their children and their children's children, and 
as a result eliminating the aberrations in the gene pattern. Genetic manipulation could, even 
more controversially, open the possibilities for inserting 'desirable' genes into the germ line, 
resulting in the so-called “designer babies”.  
Stem cell-based therapies are still at a very early stage and the associated risks are still 
unclear. On the other hand, when a patient is suffering from a disabling and sometimes life-
threatening disease, a case might be made for lowering the ethical barriers to enable 
treatment. As with any medical interventions, the questions to be asked are whether this 
approach is the most likely to achieve success and whether the potential benefits outweight 
the potential risks. 
 
Bone Marrow Stromal Cells for Repair of the Injured Spinal Cord 
 
477 
4. Stem cells for central nervous system repair 
The promise of neural stem/progenitor cells (NSC) for repair of traumatic injuries of central 
nervous tissue lies in their ability to differentiate into the three neural cell types; neurons, 
astrocytes, and oligodendrocytes (Fig. 1). Besides NSC, other types of stem cells may also be 
beneficial for replacement-based repair approaches if they can be successfully manipulated 
into the neural lineage (i.e., transdifferentiation). 
Although, following an injury to the central nervous system, endogenous NSC are typically 
recruited, they generally do not lead to significant repair. A potential approach to benefit 
more from NSC for neural repair is to isolate the cells from donor tissue and prepare them 
ex vivo for transplantation. The advantages of ex vivo isolation of cells are the large 
numbers of cells that can be cultured, and the opportunity of committing the cells towards a 
certain cell type. Experimental evidence has demonstrated that neural stem cells after 
transplantation into damaged nervous tissue are more likely to differentiate into astrocytes 
than into neurons or oligodendrocytes. In some cases this may be the objective, but most 
likely there is a larger need for neurons or oligodendrocytes. Therefore, it is more effective 
to transplant cells already committed to become a certain neural cell type such as 
oligodendrocyte-precursor cells (OPCs) and glial-restricted precursor cells (GRPCs).   
  
 
Fig. 1. Neural lineage differentiation: Neural stem cells differentiate into neuroblasts, which 
give rise to neurons, and in glioblasts, which give rise to astrocytes and oligodendrocytes. 
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(Fig. 2). The prerequisite for such repair is that the transplanted neurons grow their axon 
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replacement is often undervalued mainly because astrocytes are known to be an integral 
component of the glial scar that forms at an injury site. This glial scar presents a molecular 
and cellular barrier for axon growth and thus for functional restoration.  
 
 
Fig. 2. Replacement strategies for nervous tissue repair. Neural progenitor cells could be 
employed to replace lost cells. This may result in formation of new neurons, 
oligodendrocytes or astrocytes.  
The cellular consequences after SCI in time can generally be characterized in 5 stages, 
starting with 1) immediate neural cell death and axonal damage accompanied by motor and 
sensory function loss due to the trauma; 2) progressive loss of tissue resulting in the 
development of cystic cavities; 3) infiltration of macrophages to remove cellular debris; 4) 
formation of a glial scar surrounding the injury epicenter limiting and/or preventing 
endogenous axonal sprouting; 5) dieback of damaged axon stumps away from the injury.  
In general, there are three therapeutic platforms for spinal cord repair (Fig. 3); 
neuroprotection (i.e., limiting additional loss of nervous tissue; rescue tissue), regeneration 
(i.e., promoting axonal growth and/or myelination, nervous tissue formation/modeling; 
restore tissue), and plasticity (i.e., exploiting axonal circuits that were left intact; reuse tissue).  
 
 
Fig. 3. Repair platforms for the injured spinal cord. Spinal cord repair may be achieved 
through a variety of opportunities that involve tissue rescue (neuroprotection), tissue 
restoration (axonal regeneration/myelination), and tissue reuse (plasticity). Stem cells may 
influence all of these platforms as well as replace lost cells, which has its own repair effects. 
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The consensus in the field of spinal cord injury/repair is that different interventions 
addressing the different repair platforms need to be combined in an approach to obtain 
significant functional restoration. The components of such combination strategies will need 
to be applied simultaneously and/or successively depending on each individual purpose 
thereby creating optimal conditions for histological and functional repair. Intensive 
rehabilitation to develop and stabilize new axonal circuits will be necessary either as one of 
the components in the repair strategy or as an ‘anchoring’-mechanism of the outcomes 
obtained by neuroprotection- and regeneration-based interventions. 
5. Bone marrow stromal cells 
Mesenchymal stem cells from bone marrow (BMSC) have therapeutic potential for the 
injured spinal cord (Nandoe Tewarie et al., 2006). BMSC were shown to differentiate into 
bone, fat, tendon and cartilage cells (Pittenger et al., 1999). Although still debated, it has 
been reported that BMSC can transdifferentiate in vitro into liver cells (Petersen et al., 1999), 
skeletal cells (Wakitani et al., 1995), cardiac muscle cells (Orlic et al., 2001), and neural cells 
(Petersen et al., 1999, Mezey et al., 2000). Besides this ability, BMSC are also known to 
produce different types of growth factors that could potentially influence nervous tissue 
repair positively. Together, these abilities make BMSC interesting for repair strategies for 
the injured spinal cord.   
Several other aspects make BMSC interesting candidates for cell-based approaches for 
central nervous system repair. Firstly, BMSC are relatively easy to obtain from a fairly 
routine bone marrow extraction followed by a quick centrifuge and culture procedure to 
remove the hematopoietic cells. Secondly, BMSC are easy to culture as they do not need 
complicated growth media or special culture circumstances. Basic cell culture equipment is 
sufficient to successfully culture millions of BMSC.  Thirdly, BMSC are easy to transduce 
with viral vectors which, if necessary, may be helpful to boost the overall reparative abilities 
of the cells. The use of viral vectors to genetically modify cells prior to transplantation has 
not yet become mainstream as there are some biological and ethical issues that need to be 
resolved. Finally, BMSC do not have the ethical concerns that embryonic or fetal stem cells 
have, and therefore circumvent public rejection as a possible treatment for neural and non-
neural trauma and disorders.    
At this time, there is no irrefutable evidence that BMSC transplanted into the damaged 
nervous tissue differentiate into neural cells that successfully replace lost cells. Also, there is 
no convincing evidence that neural cells derived from grafted BMSC contributed to 
functional improvements after transplantation. As long as the potential of BMSC for 
differentiation into neural cells is in debate, the ability to produce and secrete different types 
of growth-promoting molecules, which include several neurotrophins and cytokines, is the 
more interesting and more likely characteristic of BMSC that makes these cells important 
candidates for spinal cord repair approaches. By releasing these molecules, BMSC can 
positively influence all consequences of spinal cord injury and support anatomical and 
functional repair. 
6. Rodent models of SCI 
Promising therapies for spinal cord injury are typically tested in rodent models, and mostly 
in rats. Similar as in humans, a SCI in the rat results in progressive loss of the grey and 
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replacement is often undervalued mainly because astrocytes are known to be an integral 
component of the glial scar that forms at an injury site. This glial scar presents a molecular 
and cellular barrier for axon growth and thus for functional restoration.  
 
 
Fig. 2. Replacement strategies for nervous tissue repair. Neural progenitor cells could be 
employed to replace lost cells. This may result in formation of new neurons, 
oligodendrocytes or astrocytes.  
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The consensus in the field of spinal cord injury/repair is that different interventions 
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white matter creating large fluid filled cysts. Proliferation and activation of astrocytes result 
in formation of scar tissue, which acts as a barrier for axonal regeneration.  Importantly, as 
in humans, there is no spontaneous regeneration in the injured spinal cord in rodents. The 
histological similarity between human and rat spinal cord injury has made the rat an 
extensively studied model for experimental therapeutic strategies, including BMSC 
transplantation.  
The most widely used model of spinal cord injury involves a spinal cord contusion inflicted 
by an impactor device. A contusion is clinically the most frequently occurring type of spinal 
cord injury; approximately 75% of all human injuries are contusions. The consequences of a 
contusive injury in rats are similar as the known consequences in the contused human 
spinal cord. Figure 4 shows the rat model system for spinal cord contusive injury.  
 
 
Fig. 4. Rat spinal cord contusion model. A. A laminectomy is performed exposing the 
underlying spinal cord. B.  Enlarged view of the exposed spinal cord segment. C. A 
computerized impactor is used to contuse the spinal cord. The piston is attached to a sensor 
to record velocity, force and displacement to ensure consistency. D. A moderate contusion 
results in loss of function at and below the level of injury and loss of bladder function.  
An alternative model for a contusion-like spinal cord injury is the clip compression model. 
The main difference between the impactor-inflicted contusion and the clip-inflicted 
compression is time. With an impactor the spinal cord is compressed for a brief moment of 
time while with a clip the spinal cord is compressed for a longer, regulatable, time. The clip 
model is clinically more relevant as most spinal cord injuries are inflicted by a lasting 
compression rather than a brief one.   
There are a number of other, non-contusive, spinal cord injury models employed in 
laboratories around the world to test treatment paradigms. These are valuable in their own 
right to investigate the underlying mechanisms and/or validity of certain approaches. 
Partial transections of specific regions in the spinal cord are used especially to study the 
effects of treatments that aim to promote axonal regeneration; specific descending or 
ascending pathways can be damaged with relatively small local knife cuts and the 
regeneration response quantified at later time points. The involvement of specific axonal 
pathways in locomotor function can also be investigated using partial transections. The 
main disadvantages of partial transections are the low clinical relevance and the possible 
misinterpretation of results due to compensatory sprouting, i.e., other previously non-
involved axonal pathways become involved in particular functions.   
Another model that has been used is the complete transection of the spinal cord. Although 
this is not often seen in the clinic, complete transections are particularly advantageous to 
study cell types for their ability to promote regeneration of damaged axons without 
contaminating sprouting of undamaged pathways and to serve as bridging material 
between spinal cord stumps. This model is also suitable to study the efficacy of synthetic or 
natural biomaterials for their efficacy to serve as carrier of cells or drugs.  A disadvantage 
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besides the low clinical relevance is that rats with a completely transected spinal cord are 
more laborious to maintain.  
7. BMSC preparation and injection 
It is difficult to provide standard guidelines for cell preparation because every cell type 
requires special conditions and circumstances for optimal isolation and culturing. Cell 
injection procedures may vary but are essentially similar. The standard procedures to 
harvest, culture and genetically modify BMSC with lentiviral vectors encoding for green 
fluorescent protein (GFP) to enable easy identification in vivo, as well as to inject BMSC as 
used in our laboratory are depicted in Figure 5. The length of the culture (preparation) time 
for BMSC depends on how many cells are needed to fill the damaged area. Thus, the 
number of BMSC necessary depends on the overall loss of tissue which, in turn, depends on 
the severity of the initial insult and on the time between insult and transplantation. Imaging 
techniques may provide the necessary information to guide the decisions on damaged tissue 
volumes and number of cells. 
There are a number of studies that have explored injection paradigms other than straight 
acute injections into the injury site. BMSC have been infused systemically or into the 4th 
ventricle (Ohta et al, 2004), or transplanted acutely into the cervical (Lu et al, 2004) or 
thoracic spinal cord (Hofstetter et al, 2002; Ankeny et al, 2004) or into the chronically injured 
cord (Zurita and Vaquero, 2004).  
 
 
Fig. 5. Transplantation of BMSC. A. BMSC are isolated from femurs of rats by cutting off the 
epiphyses and flushing out the bone marrow. Cells are plated onto plastic culture dishes. 
Non-adherent hematopoietic stem cells are removed and the plastic-adherent BMSC are 
infected with LV-GFP. B. Cells are injected into the spinal cord contusion epicenter using a 
Hamilton syringe with a pulled glass needle attached, held within a micromanipulator.  C. 
Appearance of transplanted BMSC (green) in the contused rat spinal cord seven days post 
transplantation (20 μm thick section at 2.5 x magnification). The red color represents 
immunohistochemically stained glial fibrillary acidic protein (GFAP), a commonly used 
marker for astrocytes.  
8. BMSC transplantation improves function after spinal cord contusion 
BMSC have been transplanted into rodent models of spinal cord injury by various research 
groups and with generally promising results. Considerable variation exists between injury 
models, treatments paradigms, and analytical methods used by the various investigators, 
and consequently, different results have been found by different groups. The injection 
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besides the low clinical relevance is that rats with a completely transected spinal cord are 
more laborious to maintain.  
7. BMSC preparation and injection 
It is difficult to provide standard guidelines for cell preparation because every cell type 
requires special conditions and circumstances for optimal isolation and culturing. Cell 
injection procedures may vary but are essentially similar. The standard procedures to 
harvest, culture and genetically modify BMSC with lentiviral vectors encoding for green 
fluorescent protein (GFP) to enable easy identification in vivo, as well as to inject BMSC as 
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paradigms vary considerably in time, number, location, survival times, etc. Given these 
differences between the approaches, it is difficult to compare the respective results and thus 
to properly value the regeneration-promoting abilities of BMSCs. 
However, it was observed by most groups and it is clear that some histological and/or 
functional beneficial effects can be expected after transplantation of BMSC into the injured 
spinal cord. These effects include improvements in locomotion, sensorimotor function, 
sensory function, promotion of axonal regeneration, and preservation of neural tissue 
(reviewed by Nandoe Tewarie et al., 2006).  
Improvements in hind limb locomotor recovery have been reported after BMSC 
transplantation in the acutely, subacutely, and chronically injured spinal cord. Hind limb 
function is typically evaluated using the open field BBB-test, which scores for joint 
movements, paw placement, weight support, and coordination between fore limbs and hind 
limbs. Although a valid way to test hind limb function, the BBB test has limitations; the 
scoring is subjective and difficult for observation of coordination. This may affect the 
assessment of hind limb motor performance. Other sensorimotor tests such as foot print, 
grid and beam walking, and analysis of gait using the CatWalk® provide a more complete 
measurement of hind limb function (Figure 6). Recently, Ritfeld et al. (2011) performed an 
extensive battery of functional tests after BMSC transplantation into a spinal cord contusion 
injury rat model, including BBB open field testing, performance on horizontal ladder, 
footprint analysis, mechanical allodynia and thermal hyperalgesia. Improvements were 
found in the BBB-subscore, horizontal ladder performance, base of support, angle of paw 
rotation, and mechanical and thermal hypersensitivity. No improvements were found in 
BBB open field locomotion, illustrating the importance of using multiple functional outcome 
assays to detect treatment-mediated effects on functional recovery. 
 
 
Fig. 6. A. Performance on a horizontal ladder is used as an indicator of sensorimotor 
function. The number of slips made on the rungs is counted by playing the videotaped runs 
back in slow motion.  B. Testing of BBB open field locomotion includes scoring for joint 
movements, paw placement, weight support, and fore/hind limb coordination. C. In 
footprint analysis stride length, base of support and angle of paw rotation are determined.  
The finding that BMSC transplantation into the contused spinal cord leads to improvements 
in functional restoration holds promise for future BMSC-based repair strategies for the 
injured spinal cord. However, knowledge of the underlying mechanisms is essential to 
increase the overall outcomes. Which repair-mechanisms are positively influenced by the 
BMSC transplant? Which molecules and receptors are involved? How do BMSC transplant-
mediated events elicit functional recovery? Initial reports on BMSC-initiated functional 
improvements suggested that beneficial effects could be due to replacement of lost cells by 
BMSC. The first study that provided evidence that BMSC can differentiate into neural-like 
cells in vivo was from Mezey and colleagues (2000). Using a mouse model they transplanted 
male BMSC into the peritoneal cavity of female recipients. The grafted BMSC preparation 
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did not contain neuron- or glia-like cells at the time of transplantation, although it should be 
noted that about 18% of the cells expressed the neural precursor cell marker nestin, when 
cultured for several weeks. Using in situ hybridization techniques, Y chromosome-
containing neurons were located in the brain of the host, suggesting that the grafted BMSC 
had crossed the blood-brain barrier and formed neurons within the CNS.  
Interestingly, Cogle and colleagues (2004) also demonstrated Y chromosome-containing 
neurons that were nicely integrated in the hippocampus of three female humans that had 
received transplants of male BMSC up to six years earlier. It should be mentioned that a 
fusion between a grafted BMSC and a host cell could provide false-positive results. In 
several studies it has been reported that BMSC can spontaneously fuse with other cells in 
vitro. Whereas this is a real possibility, Cogle and coworkers (2004) used fluorescence in situ 
hybridization techniques to reveal the presence of only one X chromosome, concluding that 
the neurons found in their study had not fused with BMSC. The Y chromosome containing, 
transgender cells accounted for approximately 1 % of all neurons and 1 -2 % of all astrocytes 
and microglial cells in the hippocampus. These studies have provided exciting data 
suggesting that BMSC can differentiate into neural cells in the mature CNS. However, to 
date this possible transdifferentiation of BMSC is intensely debated and conclusive evidence 
of this possibility is lacking. The data showing functional and histological improvements 
after BMSC transplantation into spinal cord contusion injury models point to repair 
mechanisms other than cell replacement of lost cells by BMSC. Within spinal cord injury 
models, few investigators have shown expression of neural markers by BMSC transplanted 
in the spinal cord. Functionality of BMSC-derived neurons (e.g. synapse formation, firing of 
action potentials, release of neurotransmitters, myelination) and astrocytes has not been 
demonstrated. Thus whether transplanted BMSC can transdifferentiate into neural cells in 
the damaged spinal cord is highly questionable. Whether BMSC-derived neural cells are 
involved in the observed functional improvements after BMSC transplantation in the 
injured spinal cord is even more improbable. This raises the question in what manner 
transplanted BMSC contribute to the functional improvements.   
9. BMSC and neuroprotection 
One possible repair mechanism that could be influenced by a BMSC transplant is 
neuroprotection. Neuroprotection aims to protect neural cells from loss due to 
pathophysiological events secondary to the initial injury resulting in more spinal cord 
nervous tissue which may lead to functional gains. Neuroprotective approaches are 
considered the first line of defense against the devastating life-debilitating consequences of 
spinal cord injury. The sooner neuroprotective strategies are implemented after injury the 
more effective they will be. If functional recovery is not achieved with neuroprotective 
strategies there may still be important benefits because a larger volume of nervous tissue is 
present to serve as a substrate for regenerative or plasticity-promoting interventions. In 
general, stem/progenitor cell transplants may elicit neuroprotection through different direct 
and indirect mechanism. After transplantation the cells may secrete molecules that 
prevent/limit the loss of neural cells due to apoptosis (direct mechanism), decrease the 
invasion of macrophages and thus macrophage-mediated cell death (indirect mechanism), 
or prevent the breakdown of blood vessels leading to blood-spinal cord-barrier permeability 
(indirect mechanism).   
Our current understanding of BMSC-mediated repair points towards a mechanism that 
involves secretion of trophic factors by BMSC resulting in decreased loss of neural tissue 
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paradigms vary considerably in time, number, location, survival times, etc. Given these 
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rotation, and mechanical and thermal hypersensitivity. No improvements were found in 
BBB open field locomotion, illustrating the importance of using multiple functional outcome 
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(i.e., neuroprotection). Ritfeld and colleagues (2011) demonstrated a strong correlation 
between improved function and volumes of spared tissue in rats with BMSC transplanted in 
their contused spinal cord at three days post-injury. The mechanisms underlying BMSC-
mediated tissue sparing in the injured spinal cord are still under investigation. A possible 
mechanism is that BMSC transplants positively influence blood vessel presence in the injury 
site either by blood vessel stabilization/rescuing or formation which results in tissue 
sparing. This in turn may involve sparing of descending and ascending axons mediating 
those functions that were improved (Ritfeld et al., 2011). 
BMSC have been shown to secrete various growth factors, including brain-derived 
neurotrophic factors (BDNF), glial-derived neurotrophic factor (GDNF), vascular 
endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), nerve growth factor 
(NGF) and neurotrophin-3.  NGF and BDNF increase survival and decrease apoptotic death 
of neurons and oligodendrocytes. BDNF also increases oligodendrocyte proliferation. GDNF 
has been implicated in the rescue of motor neurons, possibly by activating MAP kinase and 
Bcl-2, an anti-apoptotic regulator. FGF-2 is known to positively affect tissue sparing and 
promote neuronal survival and angiogenesis following spinal cord injury. VEGF is a potent 
angiogenic factor and as such could positively affect tissue preservation. Thus, based on the 
secretion profile, BMSC may contribute to neuroprotection in a direct manner (rescuing 
neural cells) and/or in an indirect manner (promoting angiogenesis).   
The secretion of these molecules is thought to be the main factor behind the observed 
functional improvements after BMSC transplantation in spinal cord injury models (Figure 
7). However, which factors or combinations of factors are specifically necessary and the 
precise mechanisms by which these factors elicit their effect remain to be elucidated in 
future investigations. Such mechanistic information is imperative as it can provide us with 
valuable insights on how to increase the overall reparative effects of BMSC transplants. For  
 
 
Fig. 7. BMSC secrete various growth factors, including BDNF, VEGF, NGF and NT-3. These 
factors are thought to limit the loss of tissue in the injured spinal cord, contributing to the 
increased functional outcomes after BMSC transplantation. 
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example, increasing the production and secretion of certain growth factors by viral 
transduction of the cells before transplantation is currently used to gain mechanistic insights 
and to optimize the therapeutic effect of BMSC. 
10. BMSC and axonal regeneration 
BMSC transplantation may also lead to improved functional outcomes by promoting axonal 
regeneration. Spinal cord injury leaves axons cut and/or demyelinated which prevents or 
limits the conduction of information to their target cells, including signals essential for the 
generation and control of motor behaviors. Eliciting axonal growth after injury may lead to 
the reestablishment of previously existing axonal circuits that were involved in motor 
function or in the formation of new axonal circuits that could be recruited for motor 
functions.  Remyelination is an integral part of axonal regeneration and crucial for proper 
functioning of axons. A major obstacle in axonal regeneration after spinal cord injury is the 
distance between injury, where the proximal end of the cut axon is located, and the target 
area, where synaptic connections need to be established. Many axonal regeneration 
therapies have shown to promote axonal regeneration but fail to elicit lengthy regeneration. 
The relative short regenerated sprouts may in the best scenario form synaptic connections 
with neurons close to the injury site, but not with original target neurons or with neurons 
nearby or in the target area. As a result, the resulting behavioral effects may be limited or 
absent, despite the axonal regeneration response.  
In general, stem/progenitor cell transplants could promote axonal regeneration (i.e., growth 
and/or (re-)myelination) by producing and secreting molecules that initiate the growth-
process in damaged neurons and promote oligodendrocytes to form myelin sheaths around 
new or existing undamaged but demyelinated axons. Secreted molecules that promote the 
differentiation of local oligodendrocyte progenitor cells into mature oligodendrocytes could 
also contribute effectively to the axonal regeneration process. Alternatively, 
stem/progenitor cells may elicit an axonal growth response by diminishing the growth-
inhibitory nature of the injury environment especially that of the glial scar. This latter effect 
could set the stage for successful axon growth initiated by the stem/progenitor cells and/or 
endogenous axon sprouting. 
There are few studies that have focused on the axonal regeneration promoting abilities of 
BMSC. Lu and co-workers (2004) demonstrated that transplantation of native BMSCs into 
the contused spinal cord promoted modest sensory and motor axon regeneration. In another 
study from Lu and colleagues (2005) it was shown that BMSC modified to produce and 
secrete higher levels of BDNF also promoted axonal regeneration. BMSCs produce and 
secrete several growth factors including GDNF, NGF, and BDNF that could positively affect 
axonal growth and/or myelination. To date, most studies that investigated the effects of 
BMSC transplants in the injured spinal cord have limited focus on axonal regeneration. In 
those studies that did focus on axonal regeneration lengthy regeneration was not 
demonstrated and the involvement of the responding axons in behavioral recovery not 
proven. Clearly, further investigations are necessary to establish the axonal regeneration-
promoting abilities of BMSC transplants in the injured spinal cord. Especially effective in 
such studies could be techniques that silence the production of particular molecules in 
BMSC, for instance approaches based on small interfering RNA molecules, to elucidate 
which of the molecules if any are in fact needed for BMSC to elicit an axonal growth 
response.  
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Fig. 7. BMSC secrete various growth factors, including BDNF, VEGF, NGF and NT-3. These 
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example, increasing the production and secretion of certain growth factors by viral 
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11. BMSC and plasticity 
BMSC transplants may lead to functional recovery after spinal cord injury by promoting 
plasticity within circuits that have been spared. Most spinal cord injuries in humans are 
anatomically incomplete; connections between brain and below-level spinal cord segments 
exist but are ineffective. Locomotor patterns can be generated by a complex network of 
axonal circuits which is present in the lumbar spinal cord segments and known as the 
central pattern generator (CPG). The existence of ineffective axonal connections and the 
CPG offers the possibility to elicit plasticity within these circuitries after spinal cord after 
injury possibly resulting in motor activities. Plasticity may occur at the molecular level 
resulting in changes in neuronal properties (e.g., excitability), or at the structural level 
resulting in new synaptic connections. Eliciting plasticity has gained much attention in the 
last decade as an interventional goal with the potential to elicit functional recovery after 
spinal cord injury. 
Intraspinal stem/progenitor cell transplants may evoke plasticity via secreting molecules 
that could elicit changes in the functioning of neurons or modulations in synaptic 
organization. Although plasticity within the damaged spinal cord has been in the spotlight 
for some time, studies that involve stem/progenitor cells in general or BMSC in particular 
and address plasticity in the injured spinal cord are sparse. There are, however, many BMSC 
studies that have demonstrated some degree of functional restoration without clear 
evidence for underlying mechanisms. Possibly, plasticity was among the BMSC-mediated 
effects in the damaged spinal cord resulting in improved functional outcomes.   
12. BMSC survival in damaged nervous tissue  
Although functional and histological improvements are observed after BMSC 
transplantation in the injured rodent spinal cord, BMSC survival is typically poor, with the 
majority of cells dying within the first week after transplantation (Nandoe Tewarie et al., 
2009). Possible cytotoxic factors include an extensive inflammatory response, free radical 
accumulation due to initial cell loss, lack of oxygen and nutrients due to the loss of blood 
vessels, and lack of a survival-promoting substrate. The question arises how BMSC 
transplant exert their repair effects if their survival is poor. To date, the answer to this 
question is not known but the most likely answer is that their relative short presence in the 
injury site is sufficient to bring about repair-supporting processes. This would point at 
neuroprotection as the main mechanism underlying BMSC-mediated repair because axonal 
regeneration and plasticity may require their presence in later stages after injury. Evidence 
that supports this idea is that BMSC transplantation at seven days post-injury or later does 
not lead to tissue sparing whereas transplantation immediately or three days after injury 
does (Nandoe Tewarie et al., 2009). An interesting associated question is whether BMSC are 
in fact necessary during later stages after injury. Future investigations will need to be 
conducted to obtain the right answers to these questions which will have major impact on 
BMSC-based spinal cord repair approaches.  
The growth factors secreted by BMSCs may affect BMSC survival and/or proliferation in 
vivo through autocrine actions. Poor survival then may reflect inadequate amounts of these 
factors to positively affect their own survival within an extremely harsh injury milieu with 
many cells and factors that negatively influence survival. Timing of BMSC transplantation, 
combination with anti-inflammatory and/or immune-modulatory drugs, and 
 
Bone Marrow Stromal Cells for Repair of the Injured Spinal Cord 
 
487 
transplantation within a surviving –promoting scaffold have been studied for their effects 
on BMSC survival.  
13. Timing of transplantation  
In an experiment by Nandoe Tewarie and colleagues (2006), BMSC were transplanted into a 
moderately contused adult rat spinal cord at 15 min, and at 3, 7, and 21 day post-injury and 
BMSC survival was closely assessed both during the transplantation procedure and up to 
four weeks after transplantation. In addition, the effect of the timing of BMSC 
transplantation on tissue sparing was determined. BMSC were collected from culture dishes, 
kept on ice, and passed through a glass pulled needle for injection into the contusion site. 
This procedure resulted in a majority (67 %) of the BMSC intended to be transplanted being 
present in the contusion at 15 min after transplantation. Thereafter, BMSC numbers rapidly 
decreased. The rate at which cell death occurs is different when transplanting acutely or 
delayed. In an acute transplantation paradigm (15 min post-contusion) and sub-acute 
transplantation paradigm (3 days post-injury) BMSC survival is better than in a delayed 
transplantation paradigm (7 days or 21 days post-injury). The percentages of BMSC in the 
contusion at seven days after transplantation are 32% and 52% for acute and sub-acute 
transplantation, respectively, and 9% for delayed transplantation. Four weeks after 
transplantation, almost no BMSC can be found in either paradigm (see figure 8). 
Interestingly, the presence of BMSC for this short period of time is sufficient to elicit tissue 
sparing. Acute and subacute transplantation, but not delayed transplantation results in 
neuroprotection, and tissue volumes in these paradigms are strongly correlated with the 
number of BMSC present (Nandoe Tewarie et al., 2009). These results indicate that timing of 
BMSC transplantation is important for optimal survival and neuroprotective effect, with 
acute and subacute transplantation being superior to delayed transplantation. However, 
 
 
Fig. 8. A. BMSC numbers within a moderate contusion in the adult rat thoracic spinal cord 
decrease during 28 days post-injection. The rate at which cell death occurs is higher when 
BMSC are transplanted 7 or 21 days post-contusion, compared to BMSC transplantation 15 
min or 3 days after contusion. B. The decreasing transplant is shown at 15 min (A–C), 7 days 
(D–F), and 28 days (G–I) after an injection at 15 min (acute), 7 days, and 21 days, 
respectively, post-injury. All microphotographs are from horizontal cryostat sections. (A) 
Scale bar, 600 mm in A–I. 
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because of the clinical relevance of delayed treatment, it seems imperative to find strategies 
to improve BMSC survival in delayed paradigms. 
Previously, using a rat contusion injury model, Hofstetter and colleagues (2002) showed that 
more BMSCs survived when transplanted one week after injury compared to immediately 
after injury. The surviving cells were located within trabeculae that span the injury site. 
These data are in disagreement with those from the Nandoe Tewarie study (2009) although 
long-term results were in agreement with only 1% of the cells (about 3000 total) surviving at 
4 weeks after grafting.. The difference in early survival between the two studies may be that 
Hofstetter and co-workers (2002) injected the BMSC not only into the contusion but also 
rostral and caudal thereof into the spinal cord nervous tissue. Possibly, the surviving cells 
were located nearby but not in the contusion epicenter. Most studies have reported a poor 
survival of BMSC. Nandoe Tewarie and colleagues (2009) demonstrated that the contusion 
milieu is less detrimental during the first week after injury than the second and fourth week 
after injury. What factors are important for BMSC survival in vivo? BMSCs are cultured in 
medium containing 10-20% serum. Factors other than present in serum are not essential for 
their survival and proliferation within the culture dish. In fact, addition of growth factors 
such as BDNF, FGF-2, or NT-3 instigates differentiation of the BMSCs into neural-like cells 
rather than affect survival. To date, the factors that may promote BMSC survival in vivo are 
unknown and further investigations are necessary to reveal them.  
14. Anti-inflammatory drugs  
It has been proposed that one of the mechanisms underlying death of cells transplanted into 
the spinal cord is injury-induced inflammation. The cellular and molecular components of the 
inflammatory response could initiate cell death, which would also explain improved survival 
with delayed grafting paradigms. Application of immune-modulatory molecules could 
possibly support better transplanted cell survival. A role of macrophages in death of 
transplanted cells has been suggested for a number of cell types and anti-inflammatory drugs 
often improve the outcome. A direct relationship between number of macrophages and 
transplanted cell survival is less clear in case of BMSC. For instance, if macrophage number 
plays a role in survival of BMSC then delayed transplantation paradigms at time points when 
macrophage numbers are lower would lead to better survival. This was not demonstrated by 
Nandoe Tewarie and colleagues (2009). On the contrary, delayed grafting into the adult rat 
contused spinal cord resulted in decreased survival rates of transplanted BMSC.  
Ritfeld and colleagues (2010) studied the effect of pharmacologically decreasing the number 
of macrophages in the contused rat spinal cord on transplanted BMSC survival. Systemic 
treatment with the anti-inflammatory agents methylprednisolone, minocycline, or 
cyclosporine, all showed an effective decrease in macrophage presence in the contused 
spinal cord at three days post-contusion, the time point of BMSC transplantation. However, 
the decreased number of macrophages did not significantly improve BMSC survival. A 
trend towards improved survival was seen, however, for cyclosporine, and accordingly, 
other studies have reported beneficial effects of cyclosporine on BMSC survival. 
Conflictingly, BMSC have been reported to have the ability to evade immune responses due 
to low expression of MHC I and no expression of MHC II molecules. As such, BMSC are 
being explored for their potential use as immune suppressing agents in combination with 
other cell transplants. At present, no consensus exists on the necessity, type or dose of 
immune-suppressing agents for BMSC transplantation. 
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15. Survival promoting scaffolds  
Another means of improving BMSC survival in the injured spinal cord is the use of 
biomaterials as scaffolds for BMSC transplants. Hydrogels, extracellular matrix-based 
materials (e.g.fibronectin), agarose scaffolds and fibrin scaffold are among the materials 
being used as scaffolds for BMSC transplantation. Typically, BMSC survival can be 
improved by use of such materials, either by providing the cells with a substrate for 
survival/growth and/or by protecting the cells from detrimental immune responses. 
16. Clinical application of BMSC 
BMSC have several features that make them appealing candidates for transplantation after 
spinal cord injury in the human. BMSC can be easily isolated under local anesthetics, 
rapidly and extensively expanded in cell culture and there is no evidence of tumorigenicity 
in vivo, even after immortalization to ensure an unlimited source of self-renewal ex vivo. In 
addition, these cells have demonstrated capacity for tissue repair, and secrete growth factors 
that enhance histological and functional repair. Clearly, BSMC are a promising candidate for 
transplantation into the injured spinal cord. However, since considerable variation consists 
among donors regarding gender, genetics, and general health, specific parameters need to 
be found that allow rapid and reliable selection of BMSC with therapeutic potential. In 
addition, it is also clear that our current understanding of BSMC function is not yet 
sufficient to provide us with the so-called “silver-bullet”, the one therapy that will promote 
regeneration and restore function in the injured spinal cord. In fact, it is generally accepted 
in the field of spinal cord injury research that such a therapy does not exist. Spinal cord 
injury results in a particularly complex cascade of histopathological events and a treatment 
aimed at functional repair requires that these events are dealt with in a timely, most likely 
sequential, fashion. Despite our incomplete knowledge, several clinical trials are being 
conducted in Korea, Mexico, Columbia, Brazil, and India. In a Korean study, 35 complete 
spinal cord injured patients received a BMSC transplant, combined with granulocyte 
macrophage-colony stimulating factor (GM-CSF) administration within 2 weeks, between 2 
weeks and 8 weeks or after 8 weeks of spinal cord injury. Patients were assessed using the 
American Spinal Injury Association Impairment Scale (ASIA), electrophysiology, and 
magnetic resonance imaging (MRI). No adverse histological were observed on MRI at four 
months and no serious clinical adverse effects were reported. In 30.4 % of the acute and 
subacute treated group ASIA score increased to ASIA B or ASIA C after a median follow-up 
period of 10.4 months after injury. The chronic treatments group showed no improvements. 
Although these results are promising, neuropathic pain and tumor formation remain to be 
evaluated and a long-term and large scale multicenter clinical study is required for more 
accurate assessment of efficacy. Other studies have reported no adverse effects of BMSC 
transplants, but efficacy remains to be revealed. 
17. Conclusion 
Stem cells have gained attraction over the last years in the field of neuroscience. In vitro it 
has been shown, although still disputed, that BMSC can transdifferentiate into cells of 
neural lineage. This has made this adult stem cell type interesting for neural transplantation 
paradigms. We have shown that after transplantation of BMSC in the injured spinal cord 
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accurate assessment of efficacy. Other studies have reported no adverse effects of BMSC 
transplants, but efficacy remains to be revealed. 
17. Conclusion 
Stem cells have gained attraction over the last years in the field of neuroscience. In vitro it 
has been shown, although still disputed, that BMSC can transdifferentiate into cells of 
neural lineage. This has made this adult stem cell type interesting for neural transplantation 
paradigms. We have shown that after transplantation of BMSC in the injured spinal cord 
 
New Advances in Stem Cell Transplantation 
 
490 
most cells die. Nevertheless, especially in early transplantation, cells have a neuroprotective 
effect on the host tissue. This effect may well be the result of secretion of growth factors. 
Further studies are needed to investigate the true potential of BMSC.  
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1. Introduction 
Transplantation of stem cells may provide cures for the damaged Central nervous system 
(CNS). They hold an enormous potential in cell replacement therapy following traumatic 
brain injury (TBI) and received a great scientific and public interest in recent years. TBI 
remains the leading cause of long-term neurological disabilities, including cognitive, 
sensory, motor and emotional impairments among children and young adults. It has been 
suggested that stem cells hold great potential for the repair of the damaged nervous system. 
The therapeutic potential of stem cells has been examined in experimental brain injury using 
a variety of approaches. Although these results emphasized their potential therapeutic role 
in traumatic brain injury, crucial mechanism on how stem cells take effect, e.g. timing of 
stem cell implanation, stem cell survival and integration, effect of brain microenvironment 
and local trophic support, will be explained in this Overview of Different In-vivo/In-vitro 
Experimental Settings. 
TBI is the leading cause of death and disability worldwide (Bruns 2003). Thus, TBI is a 
highly relevant medical and socio-economic problem of modern society. During the last two 
decades, improvements in acute pre- and inhospital care, time management, diagnostic 
procedures, and rehabilitation strategies have substantially improved the level of care and 
outcome following TBI (Maegele 2007). But still, to date, no therapeutic approach has been 
proven effective in reversing the pathologic cellular sequelae underlying the progression of 
cell loss and in improving neurobehavioral outcome. As the brain has limited capacity for 
self-repair, restorative approaches with focus on replacement and repair of dysfunctional 
and dead cells by transplantation of cells (eg stem cells) into the traumatically injured brain 
have been studied. In the last 15 years various types of cells have been tested for their 
potential to restore the function in animal models after TBI. These cells include fetal cells, 
adult stem cells isolated from bone marrow as well as pluripotent stem cells (see review 
Schouten 2004). 
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In the traumatically injured brain, several experimental studies have been performed using 
engrafted hNT cells. These are post-mitotic human neurons (NT2N cells, commercially 
known as hNT cells, or LBS-neurons; Layton Bioscience Inc., Palo Alto, CA), derived from a 
human embryonal teratocarcinoma line (NT2 cell line) and differentiated into an exclusively 
neuronal phenotype by retinoic acid treatment in vitro (Trojanowski 1993). These cells 
appear to possess many of the key features of normal developing and mature human 
neurons, and survive up to 1 year in the brain after transplantation in immunodeficient 
neonatal or adult mice (Trojanowski et al., 1997). Muir (1999) first transplanted hNT cells 
into the injured cortex at 24 h after lateral Fluid Percussion (FP) brain injury in adult rats. 
The hNT transplant remained viable for up to 2 weeks, although no significant effect on 
acute posttraumatic neurologic motor function was observed. A follow-up study reported 
long-term (4-week) survival of hNT cells transplanted into the injured cortex 24 h following 
lateral FP brain injury in non-immunosuppressed adult rats. Integration of the graft in the 
peri-injured cortex was noted, again without significant improvement in motor or cognitive 
function (Philips 1999). More recently, hNT cells genetically engineered ex vivo to express 
NGF, transplanted into the medial septum at 24 h following Controlled Cortical Impact 
(CCI) brain injury in mice, attenuated cognitive dysfunction for up to 4 weeks post-
transplant (Watson 2003; Longhi 2005).  
Bone marrow stromal cells (BMSCs) have been evaluated in the CCI model of TBI in adult 
rats, administered by intra-arterial or intravenous injection at 24 h post-injury were 
subsequently found in multiple organs, including the brain. In these studies, 
improvement of neurological outcome and cellular expression of both the neuronal 
marker NeuN and the astrocytic marker GFAP in the engrafted cells were observed at 1 
and 2 weeks post-administration (Lu 2001; Mahmood 2001). Intraparenchymal 
transplantation of whole bone marrow into the pericontusional tissue at 24 h after CCI 
brain injury in rats also resulted in improved functional outcome and differentiation of 
transplanted cells into populations of cells expressing neuronal and glial markers up to 4 
weeks post-transplantation (Mahmood 2001).The mechanism by which BMSCs limit 
damage or promote repair has been suggested to be either via cell replacement by 
proliferation and differentiation of transplanted BMSCs into the phenotype of the 
damaged and/or lost cells, via trophic support, or via manipulation of the environment to 
stimulate endogenous regeneration (Hofstetter 2002). However, Breitbach showed, that 
the developmental fate of BM-derived cells is not restricted by the surrounding tissue and 
that the MSC fraction may underlie extended bone formation. These findings seriously 
question the biologic basis and clinical safety of using BM and in particular MSCs to treat 
nonhematopoietic disorders (Breitbach 2007). 
Immortalized cells, eg HiB5 cells, derived from the embryonic rat hippocampus and 
conditionally immortalized, were first transplanted into the neonatal brain, where they 
acquired neuronal and glial morphologies appropriate to the site of transplantation. Stable 
transduction of HiB5 cells to secrete (Nerve Growth Factor) NGF in vivo have been 
observed up to 9 months following transplantation into the medial septum, resulting in a 
prevention or reversal of cholinergic neuronal atrophy and related behavioral impairments 
normally occurring with age (Martinez-Serrano 1996, 1998). In non-immunosuppressed rats 
subjected to lateral FP brain injury, HiB5-NGF cells were transplanted in the injured cortex, 
24 h after injury (Philips 2001). Thereby brain-injured animals receiving either the HiB5-
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NGF cells or untransduced HiB5 cells showed significant improvements in neuromotor 
function and spatial learning, but hippocampal cell death was significantly reduced only in 
the HiB5-NGF cell transplant group, indicating that the transplantation of HiB5 cells 
genetically engineered to secrete trophic factors may have behavioral and neuroprotective 
effects after brain injury (Philips 2001). 
The C17.2 cell is a clonal multipotent progenitor cell derived from the external germinal 
layer of the neonatal murine cerebellum, immortalized by retroviral transduction of the 
avian gene myc (Ryder 1990). The cells were also marked with a second retrovirus for 
expression of bacterial X-galactosidase. A recent study form our working group has 
evaluated the behavioral effects of engrafted C17.2 cells following experimental TBI. In 
adult mice subjected to CCI brain injury, transplantation of C17.2 cells into the cortex 
(either ipsilateral or contralateral to the injury) at 3 days after injury significantly 
improved motor function but not cognitive function over a 12-week post-transplantation 
period (Riess 2002). Following engraftment, the C17.2 cells expressed either neuronal or 
astrocytic markers when transplanted ipsilateral to the lesion, while after contralateral 
transplantation only neuronal differentiation was observed.  
Pluripotent murine embryonic stem cells (ESC) have been shown to survive in the 
implanted healthy and hypoxic injured brain. Furthermore they differentiate into neural cell 
types following transplantation into rat brains in an experimental stroke model. 
Additionally it was shown, that they migrate along the corpus callosum to the ventricular 
walls and they populate the border zone of the damaged brain tissue on the hemisphere 
opposite to the implantation site, indicating that ES cells have high migrational dynamics 
(Hoehn 2002, Erdoe 2003). Based on these results, our working group has implanted these 
undifferentiated, eGFP-expressing ES-D3 cells into the ipsi- or contra-lateral cortex of rat 
brains following the induction of a moderate lateral fluid-percussion (FP) brain injury (Riess 
2007, Molcanyi 2007).  
As one result we were able to show, that the differentiation and integration of 
transplanted ES-D3 cells was barely observed at any time point. But sporadic tumor 
formation was observed. However, ES-D3 cell grafted animals demonstrated a significant 
improvement in functional outcome on a range of behavioral tasks. Motor function 
improvements were observed as early as one week following implantation. Other 
observers are reporting that transplantation of pre-differentiated ES cells improved 
behavioural outcome on sensorimotor and locomotor tests but failed to improve cognitive 
function during memory tasks assessed by Morris water maze (Hoane 2004). An 
improvement of motor function was also demonstrated when motoneuron enriched 
neural cells derived from mouse embryonic stem cells were transplanted after cryogenic 
brain injury (Chiba 2003). 
However, the success of TX depends not only on cell type and their differentiation state, but 
also on several other important parameters, such as inflammatory response after injury, 
microenvironment of the host tissue, time window for TX, immune response to cell TX, 
immunosuppression, site of TX.  
2. Location for TX 
Miyazono (Miyazono 1995) demonstrated that the proliferation, differentiation and 
survival of implanted cells were modulated by the anatomical target site into which the 
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grafts were placed. The implantation of undifferentiated Ntera-derived cells into rat 
cortex resulted into formation of lethal tumors within 70 days posttransplantation. In 
contrast, the same cells implanted into caudoputamen ceased to proliferate and 
progressively differentiated into postmitotic neuron-like cells. Following transplantation 
of C17.2 NSCs following CCI brain injury, our working group was able to show, that cell 
differentiation depends on the location of the implantation site. Thirteen weeks after the 
transplantation under the contusion cavity, NSCs were found in the ipsilateral 
hippocampus and in the cortical parenchyma adjacent to the injury cavity. NSCs 
transplanted into the contralateral hemisphere were also detected in the contralateral 
hippocampus and the contralateral cortex. The NSCs in the injured cortex were found to 
express neuronal and astrocytic markers, implicating differentiation into neurons and 
glia, whereas the NSCs transplanted into the uninjured contralateral cortex showed an 
almost exclusively neuronal phenotype. The reasons underlying these apparent variations 
in differentiation remain unclear, although the demand for both neurons and glial cell 
replacement may be far greater in the areas of the injured hemisphere that have sustained 
significant tissue loss. 
3. Timepoint for TX 
Beyond cell specific effects on functional improvement following TX Soares and 
coworkers suggested that an optimal time window for TX may exist (Soares 1991). 
However, studies evaluating optimal time for transplantation in models of experimental 
TBI are still pending. In most studies cells were implanted between 24 and 72 hours 
following TBI. However this relatively early time point for transplantation may be 
appropriate for avoiding the peak of any inflammatory reaction and may allow the 
integration, migration and differentiation of cells prior to formation of the astroglial scar 
that may counteract these processes. Glial scar formed by CNS injury is considerd as the 
main inhibitory barrier of nerve regeneration. Many efforts have been made to prevent 
scarring and to pomote axonal regeneration after injury (see review: Sofroniew 2010). In 
their experiment, Soares and coworkers demonstrated that there is a temporal window in 
which fetal cortical transplants can attenuate glial scarring as well as be successfully 
incorporated into host brains following FP injury. They showed that cells transplanted 
two days, one week and two weeks after injury survived and were incorporated into the 
host tissue whereby the cells transplanted at later time points (4 weeks) failed to 
incorporate. This phenomenon was explained by the fact that there was a little evidence of 
a glial scar formation at day two and one week time points, whereas the scarring raised 
significantly thereafter (Soares 1991). More evidence for a optimal time window for TX is 
shown by comparing the following experiments in experimental Spinal Cord Injury. Han 
(Han 2002) reported that immediately TX of neuronal restricted progenitors (NRPs) after 
injury gives rise to neurons and survived for at least one month. However, after 
transplantation 10 days after spinal cord injury, NRPs did not give rise to neurons, 
suggesting that the environment of the injured spinal cord influences the implanted cells 
(Cao 2002). The influence of ES cells due to host environment was also proven in the 
following in vitro experiment. Hereby, we have shown that the extract derived from rat 
brains in the acute phase following TBI impairs survival of undifferentiated murine ES 
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cells and induces rapid differentiation of surviving cells. This observation suggests that 
during the early acute phase of traumatic injury the cerebral environment contains 
detrimental as well as protective signals that may induce neurogenic processes following 
ES cell transplantation (Bentz 2010). However, it is also likely that different cell types will 
have different transplantation time points for optimal survival, migration, and 
proliferation. For example, bone marrow-derived stem cells (BMSCs) have been suggested 
to engraft better as damage progresses in injured tissue (Prockop 2002).  
4. Inflammatory response 
Inflammatory leukocytic recruitment and diffuse neuronal degeneration are pathological 
processes resulting from TBI. While the normal brain is generally considered to be a 
relatively immunologically privileged organ, the injured brain is certainly not. The presence 
of an inflammatory response in the injured parenchyma may increase damage of the host 
brain in the early post-traumatic phase, while becoming more beneficial in the chronic phase 
(Allan 2001, Lenzlinger 2001). The effects of this inflammatory reaction on the graft survival 
following TX are still poorly understood. Our working group examined the time dependent 
fate of ES cells following ipsi- and contralateral implantation into rat brains injured via FP 
injury. Double-staining for GFP and macrophage antigens revealed stem cells phagocytosed 
by infiltrated and activated macrophages, indicating the loss of implanted stem cells was 
due to an early posttraumatic inflammatory response. Macrophage infiltration was shown to 
be less pronounced when stem cells were implanted into completely intact healthy brains. 
We therefore suggested that the massive macrophage infiltration at graft sites might be 
ascribed to the combined stimulus exhibited by the FP brain injury and the cell implantation 
(Molcanyi 2009). 
5. Tumor formation 
It has to be taken into consideration that the highly proliferative characteristics (selfrenewal 
potential) of ES cells combined with the ability to differentiate into all embryonic germinal 
layers (pluripotency) present a potential threat of tumor development (teratoma, 
teratocarcinoma) when they are transplanted into the adult CNS. However, tumorigenesis 
has been observed after implantation of undifferentiated human ESCs into healthy rat 
brains, giving rise to teratomas and malignant teratocarcinomas (Thomson 1998). 
Accordingly, Erdö compared the tumorigenic outcome after implantation of D3, clone BAC-
7 ESCs in a homologous (mouse to mouse) vs. xenogeneic (mouse to rat) stroke model. In 
injured and healthy mouse brains, both transplanted undifferentiated and pre-differentiated 
murine ESCs produced highly malignant teratomas, while mouse ESCs xenotransplanted 
into injured rat brain migrated towards the lesion and differentiated into neurons at the 
border zone of the ischemic infarct, suggesting that tumorigenesis may be related to the host 
animal rather than to the differentiation status of the implanted cells (Erdo 2003)  
Our scientific group has repeated an analogous experiment in the model of traumatic brain 
injury vs. healthy rat brain. After TBI we observed a scarce tumor formation, but in healthy 
rat brains the above mentioned cell line lead to formation of malignant teratocarcinomas in 
the majority of engrafted animals. The absence of tumor formation in animals suffering from 
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to engraft better as damage progresses in injured tissue (Prockop 2002).  
4. Inflammatory response 
Inflammatory leukocytic recruitment and diffuse neuronal degeneration are pathological 
processes resulting from TBI. While the normal brain is generally considered to be a 
relatively immunologically privileged organ, the injured brain is certainly not. The presence 
of an inflammatory response in the injured parenchyma may increase damage of the host 
brain in the early post-traumatic phase, while becoming more beneficial in the chronic phase 
(Allan 2001, Lenzlinger 2001). The effects of this inflammatory reaction on the graft survival 
following TX are still poorly understood. Our working group examined the time dependent 
fate of ES cells following ipsi- and contralateral implantation into rat brains injured via FP 
injury. Double-staining for GFP and macrophage antigens revealed stem cells phagocytosed 
by infiltrated and activated macrophages, indicating the loss of implanted stem cells was 
due to an early posttraumatic inflammatory response. Macrophage infiltration was shown to 
be less pronounced when stem cells were implanted into completely intact healthy brains. 
We therefore suggested that the massive macrophage infiltration at graft sites might be 
ascribed to the combined stimulus exhibited by the FP brain injury and the cell implantation 
(Molcanyi 2009). 
5. Tumor formation 
It has to be taken into consideration that the highly proliferative characteristics (selfrenewal 
potential) of ES cells combined with the ability to differentiate into all embryonic germinal 
layers (pluripotency) present a potential threat of tumor development (teratoma, 
teratocarcinoma) when they are transplanted into the adult CNS. However, tumorigenesis 
has been observed after implantation of undifferentiated human ESCs into healthy rat 
brains, giving rise to teratomas and malignant teratocarcinomas (Thomson 1998). 
Accordingly, Erdö compared the tumorigenic outcome after implantation of D3, clone BAC-
7 ESCs in a homologous (mouse to mouse) vs. xenogeneic (mouse to rat) stroke model. In 
injured and healthy mouse brains, both transplanted undifferentiated and pre-differentiated 
murine ESCs produced highly malignant teratomas, while mouse ESCs xenotransplanted 
into injured rat brain migrated towards the lesion and differentiated into neurons at the 
border zone of the ischemic infarct, suggesting that tumorigenesis may be related to the host 
animal rather than to the differentiation status of the implanted cells (Erdo 2003)  
Our scientific group has repeated an analogous experiment in the model of traumatic brain 
injury vs. healthy rat brain. After TBI we observed a scarce tumor formation, but in healthy 
rat brains the above mentioned cell line lead to formation of malignant teratocarcinomas in 
the majority of engrafted animals. The absence of tumor formation in animals suffering from 
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traumatic brain injury was linked to the already described inflammatory response. As we 
believe, the tumorigenic fraction of implanted graft may have been scavenged by activaed 
macrophages, alongside with concomitant survival of stem cells turning into healthy neural 
phenotypes. Great caution is needed when stem cells are implanted in experimental settings 
of diseases associated with inflammatory response (such as stroke or traumatic brain injury) 
as the tumorigenic threat may stay unveiled (in case tumorigenic fraction is being removed 
by activated immune cells) (Molcanyi 2009). 
6. Functional outcome 
Neurobehavioral assessment of outcome has always played an integral part in traumatic 
brain injury (TBI) research (Hamm 2001).  
After transplantation of the C17.2 Neural Stem Cells intracerebrally in the acute period after 
TBI we were able to show, that these cells survive, differentiate, and attenuate posttraumatic 
neurological deficits in the chronic postinjury period. Brain-injured mice that received NSC 
transplants showed significantly improved performance in the rotating pole test during the 
8-week observation period. In addition, brain-injured animals that received NSCs in the 
ipsilateral hemisphere exhibited improved performance in the rotarod test during the 12-
week observation period. Similar effects were achieved by, transplantation of 
undifferentiated ES cells following experimental traumatic brain injury. Hereby the TX 
significantly attenuates the impairment of motor function. Performance on the rotarod test 
and sensorimotor scores improved significantly when brain injured animals received ES 
cells. This is in accordance with previous brain injury studies that also reported recovery of 
function following cell transplantation. Improved behavioural outcome on sensorimotor 
and locomotor tests in brain injured animals was also demonstrated following 
transplantation of pre-differentiated ES cells, or minced fetal cortical grafts (E16), 
respectively (Hoane  2004).  
But, the effects on neurobehavior outcome can be influenced by the medication the animals 
receive. Cyclosporin A (CsA) is widely used in clinical situations to attenuate graft rejection 
following organ and central nervous system transplantation. Therefore, we evaluated the 
influence of post-injury CsA administration on behavioral recovery after TBI. Hereby we 
found that, injured animals treated with CsA showed a significant improvement in motor 
function and in sensorimotor function, when compared to vehicle treated, injured animals. 
In conclusion, the treatment with CsA improves certain aspects of motor and sensorimotor 
function following experimental TBI. Therefore in animal studies analyzing functional 
outcome, these effects have to be controlled for (Riess 2001). 
However, all the mechanisms of how stem cells attenuate a neurologic impairment are not 
completely clarified, yet. In the light of the recent data, the true cell replacement of 
lost/injured tissue seems to be highly unlikely. Humoral/trophic mechanisms accompanied 
by cell-cell interactions have been proposed to play a central role of stem cell grafting effect. 
Our scientific group has investigated the behaviour of stem cells in-vitro after conditioning 
with the cerebral extract derived from healthy and injured rat brain. Stimulated cells have 
produced statistically significant amounts of various neurotrophic factors, proving this 
phenomena to be possibly one of the regenarative mechanisms following stem cell 
transplantation (Bentz 2007). 
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7. Conclusion and further prospectives 
In the present review we have summarized our experience with in-vivo and in-vitro set-
ups of cell therapy in TBI. Our results demonstrate the influence of brain 
microenvironment on alterations on stem cell fate, the significance of appropriate 
timepoint for TX and the effect of the time dependent inflammatory response following 
TBI. However, despite the promising results concerning functional improvement 
following ES cell TX following TBI the clinical use of ES cells is complicated due to ethical 
and immunological concerns (Molcanyi 2007, Riess 2007, Erdö 2003). These concerns 
might be overcome by using autologous pluripotent stem cells derived from a patient's 
own somatic cells by ectopic expression of pluripotency factors (Hochedlinger 2006). 
These, induced pluripotent stem (iPS) cells are widely recognised as a powerful 
alternative to ES cells as potential therapeutic agents, with unique advantages. Like ES 
cells, they are pluripotent and can be used to obtain tissue-specific cells or progenitors of 
therapeutic interest (such as neurons and their progenitors). But on the other side, iPS 
cells are likely to carry a higher risk of tumorigenicity than ES cells, due to the 
inappropriate reprogramming of these somatic cells, the activation of exogenous 
transcription factors, or other reasons (Tsuji 2010). In a most recent study it has been 
shown that the transplantation of iPS-derived neurospheres into the spinal cord directly 
after contusive injury in mice resulted in cell differentiation into all three neural lineages 
without forming teratomas or other tumors. These cells also participated in remyelination 
and induced the axonal regrowth of host 5HT-positive serotonergic fibers, promoting 
locomotor function recovery. These findings suggest that iPS cell-derived neurospheres 
may be a promising cell source for therapy of spinal cord injury (Tsuji 2010). It is required, 
that the therapeutic potency of these cell-source will also be evaluated in models of TBI to 
prove their effectiveness and safety as a clinical therapy for human after TBI.  
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1. Introduction 
Over the past several decades stem cell therapy has been characterized as having the 
potential to dramatically change the treatment of human disease. Impact of such therapy on 
pulmonary disorders remains unknown. A lack of evidence for a function of exogenous cells 
in lung repair limits our ability to proceed into clinical trials. Therefore we must rely on 
personal experience and case series to better understand the clinical effects of stem cell 
therapy in pulmonary disease. In this report, we discuss four patients with common 
pulmonary diseases who were treated with the direct infusion of peripherally harvested 
autologous stem cells into the pulmonary arteries. Although these four patients were 
followed by Mayo Clinic, the procedure was performed by Regenocyte Therapeutic, a 
privately owned and operated Florida-based enterprise. The procedure is not approved by 
the United States Food and Drug Administration. In addition, it was not performed in the 
context of an approved clinical trial. Each of the patients in this series independently 
pursued and personally paid for this experimental and controversial treatment. Since the 
practice is not approved in the United States, the stem cell infusion was performed at the 
Centro Otorrino Laringologia Hospital in Santo Domingo, Dominican Republic. This report 
summarizes the clinical experience of these patients based on unrelated clinical assessments 
at the Mayo Clinic performed both before and after the procedure.. 
2. Case 1 
2.1 Clinical history and course 
A 44 year-old Caucasian man and former smoker (38 pack years, quit 2004) presented for 
evaluation in December 2006 for symptoms of progressive dyspnea (World Health 
Organization (WHO) functional class III), fatigue, and presyncopal spells. His past medical 
history was significant for mild chronic obstructive pulmonary disease (COPD) and 
pulmonary hypertension (PH) diagnosed in 2004, with right heart catheterization (RHC) 
revealing a mean pulmonary artery pressure (MPAP) of 37 mmHg. Additional PH risk 
factors included obesity (BMI 33.2), and mild obstructive sleep apnea. The patient had 
recently started sildenafil (25mg dose) on an as needed basis and reported some reduction in 
dyspnea after each use.  
His laboratory evaluation at Mayo Clinic was normal except for an elevated hemoglobin 
(17.7 mg/dL). He was hypoxic on room air (pH 7.4, PaO2 49, PaCO2 33, SaO2 90%), and his 
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therapy in pulmonary disease. In this report, we discuss four patients with common 
pulmonary diseases who were treated with the direct infusion of peripherally harvested 
autologous stem cells into the pulmonary arteries. Although these four patients were 
followed by Mayo Clinic, the procedure was performed by Regenocyte Therapeutic, a 
privately owned and operated Florida-based enterprise. The procedure is not approved by 
the United States Food and Drug Administration. In addition, it was not performed in the 
context of an approved clinical trial. Each of the patients in this series independently 
pursued and personally paid for this experimental and controversial treatment. Since the 
practice is not approved in the United States, the stem cell infusion was performed at the 
Centro Otorrino Laringologia Hospital in Santo Domingo, Dominican Republic. This report 
summarizes the clinical experience of these patients based on unrelated clinical assessments 
at the Mayo Clinic performed both before and after the procedure.. 
2. Case 1 
2.1 Clinical history and course 
A 44 year-old Caucasian man and former smoker (38 pack years, quit 2004) presented for 
evaluation in December 2006 for symptoms of progressive dyspnea (World Health 
Organization (WHO) functional class III), fatigue, and presyncopal spells. His past medical 
history was significant for mild chronic obstructive pulmonary disease (COPD) and 
pulmonary hypertension (PH) diagnosed in 2004, with right heart catheterization (RHC) 
revealing a mean pulmonary artery pressure (MPAP) of 37 mmHg. Additional PH risk 
factors included obesity (BMI 33.2), and mild obstructive sleep apnea. The patient had 
recently started sildenafil (25mg dose) on an as needed basis and reported some reduction in 
dyspnea after each use.  
His laboratory evaluation at Mayo Clinic was normal except for an elevated hemoglobin 
(17.7 mg/dL). He was hypoxic on room air (pH 7.4, PaO2 49, PaCO2 33, SaO2 90%), and his 
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pulmonary function test (PFT) revealed mild obstruction with a reduction in diffusing 
capacity for carbon monoxide (DLCO) (Table 1). High-resolution computed tomography 
scan of the chest showed diffuse emphysema. The electrocardiogram was normal and the 
contrast echocardiogram (ECHO) demonstrated mild PH with a right ventricular systolic 
pressure (RVSP) of 49 mmHg and MPAP 31 mmHg. There was mild left-ventricular 
hypertrophy but right-ventricular (RV) size and function were normal with an estimated 
right atrial pressure (RAP) of 5 mmHg. There was no shunt identified (Table 2). A 
ventilation-perfusion (V/Q) lung scan excluded chronic thromboembolic disease (CTED). 
The patient achieved 519 meters in the six-minute walk test (6MWT) performed on 2 liters 
per minute (lpm) oxygen with a nadir saturation of 84%. Overnight oximetry on room air 
demonstrated a low baseline saturation (mean of 87%) and no significant sleep-disordered 
breathing.  
The patient underwent a repeat RHC with cardiopulmonary exercise testing (CPX). The 
RHC revealed mild PH at rest that worsened significantly with exercise (MPAP increased 
from 30 to 58 mmHg) (Table 3). The maximal oxygen consumption was 15.7 mlO2/kg/min 
with an inadequate increase in stroke volume with exercise. Pulmonary arterial vasodilator 
trial revealed no significant response to intravenous epoprostenol. 
His PH was classified as WHO diagnostic group 3 (Simmoneau 2009); therefore, regular 
use of adequate oxygen was recommended. He also started tiotropium inhaler. In 
addition he was instructed to take sildenafil regularly at 20mg three times daily (Alp 
2006). Over the next 9 months the patient reported some improvement; however, he 
remained dyspneic with minimal exertion. Objective measures of his PH remained stable 
(Table 2). Sildenafil use had ceased and he remained non-compliant with oxygen, using it 
only at night or when significantly dyspneic. He was evaluated for possible lung 
transplantation but was not felt to be a good candidate due to noncompliance and his 
body mass index. The recommendations were for weight loss and improved compliance 
with his medical regimen.  
In November 2007, he was seen in follow-up and was again counseled to be more compliant 
with oxygen and to restart sildenafil at 20mg three times daily. The patient had been seen by 
a cardiologist outside our institution for intermittent chest pain and palpitations and had 
been initiated on diltiazem 180mg daily.  
After exploring alternative therapies at a private facility, the patient had blood collected for 
possible stem cell therapy. On March 4, 2008 he traveled to the Dominican Republic where 
he received multiple infusions, of what was reported to be the harvested stem cells, directly 
into the pulmonary arteries.  
Shortly after the infusion, he reported feeling like "Superman," running 1 to 2 hours in the 
first few days. By his report, his room air saturations rose to 99% at 2 weeks, but 
deteriorated subsequently. Other perceived benefits included decreased fatigue, chest pain, 
palpitations, and leg pain and even improved vision and mental acuity. His symptomatic 
improvements persisted at subsequent visits despite becoming more sedentary and gaining 
4.5 kg. Notably, he had become more compliant with the use of oxygen to about 3 lpm by 
nasal cannula at rest. 
Objectively, there were also improvements noted in his 6MWT and in the 
echocardiographic estimates of his pulmonary pressures. (Table 2) These improvements 
were sustained at repeated follow-ups. However, the oxygen requirement remained 8 to 
15 lpm with exertion.  
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During his evaluation in March 2010, the patient reported that many of the initial subjective 
improvements had waned. Overall his objective measures remained relatively stable. (Table 2)  
He had a repeat RHC demonstrating mild resting but severe exercise induced PH (Table 3).  
3. Case 2 
3.1 Clinical history and course 
A 78 year-old Caucasian man presented with dyspnea on exertion (WHO functional class II). 
He had smoked cigars for 19 years and quit 20 years ago. He was diagnosed with moderate 
COPD and was treated with inhaled bronchodilators. A few months prior to his 
presentation at Mayo Clinic, an extensive evaluation including a RHC, a V/Q scan and a 
pulmonary arteriogram demonstrated PH due to CTED. Those studies were reviewed and 
felt to be conclusive. His medications included hydrochlorothiazide, furosemide, and 
warfarin. A PFT demonstrated moderate obstruction, air trapping, a reduced DLCO, and 
oxygen desaturation with exercise (Table 1). The 6MWT and ECHO results are reported in 
Table 2. Arterial blood gas on room air was:  pH 7.47, PaO2 67, PaCO2 37; and the BNP was 
178 pg/mL. Cardiac MRI revealed RV enlargement and hypertrophy with a reduced RV 
ejection fraction to 27%. A repeat RHC was performed, and it was felt the PH was multi-
factorial secondary to COPD, CTED, and mild pulmonary venous hypertension (Table 3).   
Given the patient’s age, minimal symptoms, multiple mechanisms for his PH, and his co-
morbidities, he was considered a high risk for pulmonary endarterectomy, and the patient 
elected for conservative therapy. An inferior vena cava filter was placed and life-long anti-
coagulation was recommended. In addition, supplemental oxygen with exercise and 
sildenafil 20 mg three times daily (Reichenberger 2007) were initiated. 
Six-months later, there was a slight improvement in the 6MWT (Table 2). He was now 
requiring increasing oxygen to maintain saturations at rest (1.5 lpm) and during exertion. 
Given persistently elevated right-heart pressures and RV enlargement and hypokinesis, 
bosentan was added to his regimen. Eight months after adding bosentan, he continued to 
show improvement in the 6MWT but the ECHO was unchanged. Oxygen needs continued 
to increase, now requiring 2 lpm at rest and 15 lpm for the 6MWT (Table 2). 
Three months later, he underwent adult stem infusion. This date corresponded to 18 months 
on sildenafil 20 mg three times daily and 12 months on bosentan at full dose. One week after 
the harvest, he traveled to Santo Domingo for the infusion into his pulmonary arteries via a 
pulmonary artery catheter at Centro Otorrino Laringologia Hospital. Repeat ECHO one 
month later showed a RVSP of 55 mmHg which was exactly the same as his baseline value 
one month prior to the infusion. Another ECHO performed by Regenocyte Therapeutics 
three months after the stem cell infusion demonstrated a RVSP 41 mmHg. A PFT four 
months after stem cell infusion was essentially unchanged (Table 1).  
The patient was seen in follow up at Mayo Clinic approximately 5 and 12 months after his 
stem cell infusion. He stated that he felt neither better nor worse after his stem cell treatment 
and was on 3 lpm oxygen to maintain an adequate resting saturation. His objective 
assessment showed some benefit at 5 months. That benefit had waned one year after stem 
cell infusion. His treatment regimen included diuretics, warfarin, sildenafil 20 mg three 
times daily, bosentan 125 mg twice daily (Jais 2008) and oxygen. He has also been regularly 
participating in a formal pulmonary rehabilitation program. No changes were made in his 
medical regimen. 
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coagulation was recommended. In addition, supplemental oxygen with exercise and 
sildenafil 20 mg three times daily (Reichenberger 2007) were initiated. 
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bosentan was added to his regimen. Eight months after adding bosentan, he continued to 
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Legend: Pulmonary function test results, oxygenation and modified Borg dyspnea score data on four 
patients who had pulmonary artery stem cell infusion. Key:  FEV1 – Forced Expiratory Volume in One 
Second, FVC – Forced Vital Capacity, TLC – Total Lung Capacity, RV – Residual Volume, DLCO – 
Diffusing Capacity of Carbon Monoxide 
* Percent Predicted. **Test performed on oxygen. ***See Table 2. N/A – Not Available 
Table 1. Pulmonary Function and Six-Minute Walk Testing- Pre and Post Stem Cell Infusion 
 




Legend:  Brain natriuretic peptide levels, WHO functional class (1 to 4 scale), six-minute walk distances 
with modified Borg dyspnea score and echocardiography results on Cases 1 and 2 who had pulmonary 
artery stem cell infusion. Key:  BNP – Brain Natriuretic Peptide, WHO – World Health Organization, 
Borg Score – Modified Borg Dyspnea Score on a scale of 0 to 10, Sa02 – Oxygen Saturation, FIO2 – 
Fraction of Inspired Oxygen, RAP – Right Atrial Pressure, TR – Tricuspid Regurgitant (peak), RVSP – 
Right Ventricular Systolic Pressure, MPAP – Mean Pulmonary Artery Pressure, RV – Right Ventricle, 
Normal and Mild describe degree of enlargement and ventricular dysfunction 
* Unable to estimate due to incomplete tricuspid regurgitant jet 
Table 2. Cardiopulmonary Data for Cases 1 and 2 
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1/2007 4 45/25 30 12 5.1/2.1 282 No 58 
 
Follow-up 




10/2007 11 85/34 51 16 5.8/3.2 478 No N/A * 
 Follow-up NOT DONE       
Legend: Hemodynamic data from right heart catheterization on Cases 1 and 2. Key:  RAP – Right Atrial 
Pressure, PAP – Pulmonary Artery Pressure, MPAP – Mean Pulmonary Artery Pressure, PAOP – 
Pulmonary Artery Occlusion Pressure, CO – Cardiac Output, CI – Cardiac Index, PVR – Pulmonary 
Vascular Resistance 
* Exercise study not performed 
Table 3. Baseline and Post Stem Cell Transfusion Right Heart Catheter Data 
4. Case 3 
4.1 Clinical history and course 
A 66-year-old Caucasian man presented in January of 2009 with symptoms of worsening 
dyspnea on exertion. Patient had a past medical history of hypertension and transient 
ischemic attacks. His pulmonary history dates back to 2002 at which time he was told to 
have scarring of his lungs. He had been followed by outside pulmonologist who had 
reported stable “scarring” of his lungs. The patient endorses a history of asbestos exposure, 
as well as a history of being in industrial chemical salesman. He had a less than 5 pack year 
history of smoking and denied any exposure to pets, birds, hot tubs, or other antigens 
suggestive for hypersensitivity pneumonitis.  
Patient underwent extensive testing including high resolution CT scan, which revealed 
extensive upper and lower lobe fibrosis, focal atelectasis and pleural thickening at the left 
base, and extensive linear calcifications in both lungs associated with fibrosis. Comparing 
this study to a previous scan performed in 2002 the findings had progressed slightly. 
Pulmonary function testing was performed with spirometry showing a mixed pattern of 
obstruction and restriction, lung volumes consistent with mild restriction, and a mildly 
reduced DLCO (Table 1). Echocardiogram revealed normal left ventricular function, normal 
diastolic function, normal RV size and function, and indeterminate pulmonary pressures 
secondary to incomplete tricuspid regurgitant jet. Laboratory work was notable for negative 
hypersensitivity panel, fungal serologies, and normal blood counts. Patient underwent 
bronchoscopy for bronchoalveolar lavage and transbronchial biopsies. Cultures were 
negative and pathology of transbronchial biopsy revealed elastic fibrous tissue. Referral to 
cardiothoracic surgery was made for possible open lung biopsy however it was decided that 
the yield would be low given the extensive fibrotic changes and outweigh potential benefits. 
Patient was given a diagnosis of idiopathic pulmonary fibrosis and obstructive lung disease. 
Follow-up chest imaging and pulmonary function testing was planned. Bronchodilator 
therapy was offered, but refused by patient. 
In June of 2009 patient returned with no significant change in his symptoms. A repeat 
CT scan showed stable diffuse fibrotic changes. Pulmonary function testing was 
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performed and found to be essentially unchanged (Table 1). Given the relative stability 
of patient's symptoms and pulmonary function testing further follow-up was 
recommended. At this time, the patient inquired about treatment of his pulmonary 
fibrosis with stem cell therapy. Given the lack of safety and efficacy data in the use of 
stem cell therapy for the patient's disease, treatment with this modality was 
discouraged. 
In January 2010, under the oversight of Regenocyte Therapeutic, the patient underwent a 
bone marrow derived autologous stem cell infusion in the Dominican Republic. He reported 
that stem cells were infused into three different areas of each lung via a pulmonary artery 
catheter. Patient returned to Mayo Clinic in June 2010 for follow-up at which time he 
reported a significant subjective improvement in his symptoms of dyspnea on exertion. 
More specifically he states that immediately after the infusion he noted no change in 
Approximately 3 months after stem cell infusion, he professed to less dyspnea with exercise. 
For example, in the past it would take him approximately one hour to walk 2 miles and 
several months following stem cell therapy he was able to do so in one half hour. The 
patient's subjective improvements were unfortunately not correlated with any improvement 
in his pulmonary function testing (Table 1). CT imaging also remained unchanged showing 
stable diffuse fibrotic lung disease. 
5. Case 4 
5.1 Clinical history and course 
A 30-year-old man, originally from Albania who has lived in the United States for the past 
25 years, presented in June 2010 with a primary complaint of recurrent pneumonias. Patient 
had a history of repeated pneumonias since the age of 2. He had been hospitalized 
numerous times throughout his life secondary to pneumonia. He described outside 
evaluation as including bronchoscopy and nasal endoscopy with biopsy. Suspected 
diagnosis at time of consultation was primary ciliary dyskinesia. Medications at time of 
evaluation included fluticasone/salmeterol 250/50, tiotropium, and oxygen use nightly. 
Past medical history was otherwise negative. The patient has been a lifelong nonsmoker and 
denied any pulmonary family history. 
At Mayo Clinic, he underwent testing to further evaluate his history and suspected 
diagnosis of primary ciliary dyskinesia. CT Scan showed widespread hyperinflation with 
mosaic attenuation, bronchial wall thickening, and bronchiectasis. The distribution of this 
was diffuse and not lobar predominant. Pulmonary function testing revealed severe 
obstruction, hyperinflation, reduction in DLCO, and resting saturation of 86%. The patient 
was able to ambulate 255 meters on 6 minute walk with end-of-walk oxygen saturation 97% 
on 2 L nasal cannula (Table 1). Echocardiogram performed at time of evaluation revealed 
preserved left ventricular systolic and diastolic function, moderate to severe RV 
enlargement as well as decrease in RV systolic function. Right ventricular systolic pressure 
was estimated at 63 mmHg, with a Doppler derived MPAP of 45 mmHg.  The patient was 
diagnosed with severe obstructive lung disease secondary to bronchiectasis, with secondary 
PH (WHO group 3). Primary ciliary dyskinesia was suspected to be the underlying cause. 
Given the severity of patient's disease he was referred to lung transplantation for evaluation. 
In August of 2010 the patient returned for follow-up evaluation. About one month prior to 
this visit he underwent harvesting of stem cells from bone marrow and subsequent infusion 
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performed and found to be essentially unchanged (Table 1). Given the relative stability 
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diagnosis of primary ciliary dyskinesia. CT Scan showed widespread hyperinflation with 
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was diffuse and not lobar predominant. Pulmonary function testing revealed severe 
obstruction, hyperinflation, reduction in DLCO, and resting saturation of 86%. The patient 
was able to ambulate 255 meters on 6 minute walk with end-of-walk oxygen saturation 97% 
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into his pulmonary arteries for treatment of pulmonary hypertension under the direction of 
Regenocyte Therapeutic. Further details of the procedure were not available at the time of 
visit. He did report subjective improvements in cough, improved energy level, and 
decreased utilization of oxygen. He also denied any exacerbations of his bronchiectasis in 
the interim. Repeat pulmonary function testing showed unchanged lung volumes, persistent 
severe obstruction and reduction in DLCO. Interestingly the patient had an improvement in 
his resting oxygen saturation to 92% from previous measure of 86%. 6 minute walk also 
showed an improvement, with patient walking of 341 meters compared to 255 meters, with 
an end-of-walk oxygen saturation of 90% on 2 L nasal cannula (Table 1). Echocardiography 
continued to show preserved left ventricular function with slight improvement in patient's 
RV enlargement as well as right ventricular systolic function. Estimated RVSP was reduced 
to 49 mmHg with a Doppler derived MPAP of 35 mmHg. 
The patient was evaluated by the lung transplantation service; however, he was not 
interested in proceeding given the subjective improvement he had experienced with his 
initial stem cell therapy.  
6. Discussion 
Use of stem cell therapy for the treatment of pulmonary diseases is gaining increasing 
attention. In the past decade, circulating bone marrow–derived cells similar to embryonal 
angioblasts have been identified (Asahara 1997) termed ‘‘endothelial progenitor cells 
(EPC).’’ These cells have the potential to proliferate and differentiate into mature endothelial 
cells. Two major types of these cells in human peripheral blood have been termed “early 
EPC’s” and “late outgrowth EPC’s,” both of which appear to have potential in lung 
microvascular repair and restoring vascular structures of the lung. (Yoon 2005) 
A number of trials are currently underway to evaluate the safety and effectiveness of the 
infusion of stem cells in pulmonary disease. A recently published report out of Brazil 
suggested both safety and improvement in quality of life in patients with severe 
COPD/emphysema (Ribeiro-Paes 2011). An ongoing multi-center trial is currently looking 
at the efficacy of  PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem 
Cells) intravenous infusion for treatment of moderate to severe COPD. A pilot trial of 
autologous EPC administration for idiopathic pulmonary arterial hypertension was 
conducted at Zhejiang University, Hangzhou, China. The trial was a 12 week follow-up of 
patients after systemic administration of autologous EPC’s plus conventional therapy 
compared with patients receiving conventional therapy alone. (Wang 2007)  The results 
included increased six-minute-walk capacity and improved hemodynamic variables, 
including MPAP, pulmonary vascular resistance, and cardiac output. No concerns with the 
safety of the administration of EPC’s were encountered. The Pulmonary Hypertension and 
Cell Therapy (PHACeT) trial by the University of Toronto reported on the administration of 
autologous EPCs transduced to express exogenous nitric oxide synthase. Three patients in 
their initial panel showed a remarkable (nearly 50%) reduction in total pulmonary vascular 
resistance over the course of the 3-day delivery period. Subsequent study in additional 
patients is currently underway. (Weiss 2008) 
In our report, we present four patients who had peripherally harvested autologous stem 
cells infused into the pulmonary arteries. The procedure was not endorsed by or performed 
by Mayo Clinic. In addition, it was not performed in the context of an approved clinical trial. 
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The procedures were performed by Regenocyte Therapeutic. The reported infusion occurred 
at the Centro Otorrino Laringologia Hospital in Santo Domingo, Dominican Republic, as the 
procedure is not approved by the United States Food and Drug Administration.  
A variety of unusual challenges are illustrated by the care and interaction of these four 
patients at Mayo Clinic (Table 4). The inability to control for concomitant therapy 
complicates the interpretation of these patients’ clincial course both pre and post stem cell 
infusion. The first patient (Case 1) reported significant subjective improvement. At the 
time of follow-up many of these improvements had waned; however, there may have 
been mild improvement in both his resting pulmonary pressures by ECHO and 6MWT. 
(Table 2) These reductions in MPAP appeared to be sustained up to 24 months post 
infusion. Unfortunately, these functional and hemodynamic improvements did not 
translate into any significant change in the severe hypoxemia. Case 2 did not have any 
change in his symptoms or WHO functional class. He continued to have increasing 
supplemental oxygen requirements. His six-minute walk distance had slightly improved, 
and his ECHO demonstrated improved RV function.  Case 3 reported significant 
subjective improvement in exercise capacity. Objectively this did not translate into any 
improvement in PFT. Case 4 perhaps seemed to have the most significant improvement in 
objective measures including improvement in resting saturation, six minute walk distance 
and reduction in MPAP as estimated by ECHO.  
Are any of the changes due to the stem cell infusion?  It is impossible to determine in an 
uncontrolled setting. The role of multiple ongoing therapies and the limitations of the 
clinical assessments are particularly challenging to evaluate. Three of the four patients were 
on multiple therapies for treatment of PH and/or COPD at the time they received the stem 
cell infusion. Variations in oxygen requirements and supplementation may be particularly 
confounding since three of the four patients had obstructive lung disease with associated 
PH. Although validated surrogate endpoints in assessing response to therapy remain a 
source of ongoing discussion, measurements such as spirometry, ECHO, six minute walk 
distance, WHO functional class have been validated to monitor disease course, but remain 
imperfect. (Hoeper 2005; Snow 2007; Aduen 2009) 
If there were some benefit, it is unfortunate that it will remain inconclusive. Cases 1 and 3 
had subjective improvement; however, there clinical scenario was complex as outlined 
above. Case 4’s objective improvements are interesting but may represent concomitant 
therapies not disclosed in this uncontrolled setting. These cases present several challenging 
dilemmas for the clinician in this evolving area of science. Short of lung transplantation, 
there are generally no cures for the underlying pulmonary disease. In Cases 1, 3, and 4, we 
informed the patients that the only proven therapy for COPD/IPF in the setting of hypoxia 
was oxygen therapy. (Nocturnal Oxygen Therapy Trial Group 1980; Medical Research 
Council 1981)  Nonetheless, these patients had a difficult time accepting more conventional 
treatment and instead sought experimental therapies.  
The stem cell therapy raised the issue of unproven therapies to a new level as the patients 
personally paid approximately $50,000 for the therapy that was administered outside the 
context of either a clinical or research setting. In addition, the therapy was pursued 
independently of our clinical recommendation or oversight. Also of interest in these 
particular cases, was the potential impact on the relationship between the physician and 
patient since the patients had pursued an unendorsed experimental therapy outside the 
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country. Although our stance on the experimental nature of stem cell therapy for 
pulmonary disease has always been clear, all of these patients researched, pursued and 
financed the therapy on their own accord. The clinician must be prepared for any 
potential conflict that may ensue if the patient seeks an experimental, unapproved 
therapy. In our practice, we maintain that such therapy should only be administered in 
the context of an approved research protocol.  Nonetheless, we felt committed to the 
ongoing management of these patients regardless of their decision to seek unapproved 
stem cell infusion therapy. 
 
Patient-Centered Provider-Centered Knowledge-Centered 
End-stage disease generates 
desperate interest in 
unproven therapies 
Limited time to discuss 
and counsel patients 
regarding unproven 
therapies 
Conventional therapies are 
often of limited value in 
severe pulmonary disease 
Patients may have strong 
desire to receive unproven 
therapies regardless of 
consequences 
Brief, simplistic cautionary 
advice may be insufficient 
to dissuade the patient 
from seeking unproven 
therapy 
Knowledge gap exists by 
definition with unproven 
therapies 
Inability to distinguish 
between for-profit endeavors 
and academically-based 
clinical trials 
Assessment of ethical, 
legal and professional 
nature of extra-mural 
practices often complex 
Provision of unproven 
therapy in uncontrolled 
(non-research) manner 
precludes firm conclusions 
from results 
Patient desires to maintain 
relationship with primary 
physician and to seek 
unconventional and/or 
unproven therapies 
Physician must maintain 
objectivity as well as 
primary role as patient 
advocate and caregiver 
Cooperative interaction 
and research between 
academic centers required 
to advance the science 
Legend:  Important challenges and limitations encountered in this series of 4 patients receiving stem cell 
infusion independent of your care. 
Table 4. Illustrative Lessons 
7. Conclusion 
Stem cell therapy has emerged as an experimental therapy to potentially treat a number of 
diseases, including pulmonary disorders. Current ongoing safety and efficacy trials will 
likely add significantly to our current understanding of the field, with hopes of aiding in 
 
Autologous Stem Cell Infusion for Treatment of Pulmonary Disease 
 
515 
future patient care. In a parallel fashion, patients are pursuing this form of therapy 
outside of controlled research trials. Such practices create significant challenges in 
evaluating efficacy and potentially stress the provider-patient relationship in unique ways 
(Table 4). 
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1. Introduction 
Hematopoietic stem cell transplantation (HSCT) has been used to cure many pediatric 
patients with both malignant and non-malignant diseases in whom conventional therapy 
has failed. HSCT is generally performed after the administration of high sublethal doses of 
chemotherapy or chemoradiotherapy to achieve myeloablation, immunosuppression and 
eradication of abnormal cells. The use of high dose cytotoxic therapy before HSCT places 
children at risk for acute and  long-term side effects which may differ or be more severe 
than those seen in children who did not receive HSCT.  One important organ that may be 
damaged from cytotoxic therapies used to treat recipients of HSCT has been the brain.  
Survival rates for childhood ALL improved after the introduction of treatments to prevent 
the development of central nervous system (CNS) leukemia. During the past 25 years, CNS 
prophylaxis for leukemia has consisted of either intrathecal chemotherapy alone or a 
combination of both chemotherapy and cranial irradiation. There is a wide range of deficits 
associated with this CNS prophylaxis. Neurological sequelae include severe 
leukoencephalopathy to more subtle and mild dysfunction, such as learning disorders and 
abnormalities that can be seen on CT scan or MRI (Packer R 1986, Brouwers P 1985). 
In contrast, patients with malignant brain tumors often present with neurological symptoms 
of their primary disease such as a) increased intracranial pressure b) problems with balance 
and cranial nerve findings, which are associated with infratentorial tumors and  c) seizures, 
which are often seen in those with supratentorial tumors. The treatment of malignant brain 
tumors involves chemoradiotherpay in addition to neurosurgery. The cranial irradiation 
that these children receive is often more than double that received by patients with acute 
leukemias. Therefore, the neurological sequelae of patients with this particular malignancy 
are greater than that seen for patients with a hematological malignancy.  
The neurocognitive sequelae following cranial irradiation and chemotherapy for childhood 
acute leukemia and brain tumors have been well documented  (Fletcher et al 1988, Smibert  
et al 1996, Anderson et al 1997, Stehbens et al 1991, Butler  and Copeland 1993, Moleski  
2000, Ris  and Noll  1994, Mulhern and Butler 2004). However, information regarding the 
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impact of HSCT and the neurocognitive function of HSCT recipients is still emerging, 
especially among patients with genetic diseases and those who have a primary immune 
deficiency.  
The different types of transplants and their complications can add to the neurological 
complications that follow HSCT. In general, there are three different types of HSCT: 1) 
autologous, which is used for the treatment of solid tumors and lymphomas, 2) syngeneic 
and 3) allogeneic, which is used for the treatment of leukemias, genetic diseases and 
immunodeficiencies.    
In this chapter we review both the acute neurological complications that can occur following 
HSCT and the long-term clinical significance of these complications, especially the 
neurocognitive outcomes of this therapy.  
2. Neurological sequelae following HSCT 
Neurological complications following HSCT have not been studied well, especially in the 
pediatric population. The majority of studies have focused upon adult patients A 
prospective study of 180 adult HSCT patient autopsies  (177 allogeneic and 3 autologous) 
detected neuropathologic abnormalities in over 90% of the subjects (Bleggi-Torres et al,  
2000). The most frequent findings in this study were subarachnoid hemorrhage (32%), 
intraparenchymal hemorrhage (27%) and fungal infections (9%). There were no abnormal 
findings in 9% of the autopsies.  A smaller series of autopsy studies showed similar findings 
(Mohrmann et al, 1990). Although there were a high number of patients with nervous 
system involvement following HSCT, we do not know if these findings led to clinically 
significant neurological complications.  
The incidence of clinical neurologic symptoms varies from 10-40%. Weber et al evaluated 
165 pediatric patients following HSCT. Of these patients, 67% were allogeneic and 33% were 
autologous. Of these 165 patients, 24% developed neurologic complications. The cause of the 
neurological complications included: infections (n=10), drug toxicity (n= 5), cerebrovascular 
events (n=2), and CNS relapse (n=2). Among the infections, aspergillus and toxoplasmosis 
were the most frequent pathogens isolated (Weber et al, 2008).  
A study of patients with Hodgkin Disease who received an autologous HSCT showed early 
symptoms of neurological complications such as encephalopathy, seizures, cerebral 
hemorrhage and psychiatric symptoms (Snider et al, 1994). A separate study of a similar 
population showed the incidence of clinically significant neurological complications as 
being 3.2%. (Guerrero et al, 1999).  
The incidence of neurological symptoms varies depending upon 1) the disease and the 
therapies used to treat that disease prior to HSCT, 2) type of transplant (autologous, 
syngeneic and allogeneic and the complications associated with the specific type of 
transplant  3) conditioning therapy (chemotherapy alone versus chemoradiotherapy,  4) 
immunosuppressive therapies and 5) the infections that may occur from being 
immunosuppressed.   
3. Impact of disease  
There are various reasons for patients to receive HSCT. Among the common diseases 
include a) hematological malignancies such as acute leukemia,  b) malignant solid tumors 
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such as brain tumors and c) nonmalignant diseases such as genetic diseases, immune 
deficiencies and hemoglobinopathies.  All of these diseases can have an impact on the 
neurological outcome of patients, even without a transplant.  
Leukemia patients who are either high-risk patients or have CNS disease, often receive 
between 1800 or 2400 cGy cranial irradiation for the prophylaxis or treatment of CNS 
leukemia. Many believe that the threshold between 1400 and 1800 cGy does not have an 
impact upon neurocognitive function. However, it is known that therapies greater than 1800 
cGy appear to affect the neurocognitive function of leukemia patients. In contrast, patients 
with brain tumors, often receive cranial radiation that can be more than twice that 
traditionally given in the treatment of ALL.  Despite differences in the therapy, there are 
similar declines that are seen in the neurocognitive function of both groups of patients, 
especially those who are young at diagnosis.  
For patients with non-malignant diseases, the pre-transplant neurological sequelae are often 
related to the disease. For example, patients with sickle cell disease often have a history of 
strokes prior to HSCT, this can impact a patient’s neurological status prior to coming to 
transplant. In addition, patients with hemoglobinopathies who are on hypertransfusion 
protocols, may have evidence of iron overload that may involve the brain.  Patients with 
genetic diseases such as adrenoleukodystrophy (ALD) and Krabbe’s disease often have 
disease specific neurological findings prior to HSCT. These patients have lesions in their 
CNS that can affect both the motor and mental development of these patients. Although 
there may be some improvement following HSCT, in general these changes do not resolve 
completely.   
Patients with immunodeficiency, such as severe combined immunodeficiency (SCID) or 
Wiskott Aldrich Syndrome, often have had serious life threatening infections prior to their 
diagnosis, which may impact their overall neurological function. Therefore, it is important 
to assess patients both before and after HSCT to really understand the impact of HSCT upon 
neurological function. 
4. Impact of type of transplant 
Patients who receive an allogeneic transplant are thought to have increased neurologic 
side effects compared to those receiving an autologous transplant. However, a 
retrospective study of 425 (mostly adult patients) found that the incidence of neurologic 
complications was similar in both autologous and allogeneic patients (Saiz et al , 2004). 
The complications that were seen varied depending upon the type of disease and type of 
transplant. For example, patients with Acute Myelogenous Leukemia (AML) receiving an 
autologous transplant developed more subdural hematomas due to prolonged 
thrombocytopenia; whereas, patients with central nervous system (CNS) infections were 
more common in those receiving an allogeneic transplant due to prolonged 
immunosuppression.   
Allogeneic transplant recipients are vulnerable to developing graft versus host disease 
(GVHD).  The risk is greatest among patients receiving an unrelated transplant despite the 
stem cell source. There has been one report of possible central nervous system GVHD in two 
patients. Two patients developed hemiparesis, seizure, encephalopathy and MRI findings of 
hyperintense white matter lesions on T-2 weighted images. A brain biopsy on one patient 
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impact of HSCT and the neurocognitive function of HSCT recipients is still emerging, 
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deficiency.  
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syngeneic and allogeneic and the complications associated with the specific type of 
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patients. Two patients developed hemiparesis, seizure, encephalopathy and MRI findings of 
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and an autopsy finding on the other revealed perivascular lymphocytic infiltrates of 
primarily donor origin. It is difficult to make an unequivocal diagnosis of this entity, since 
there are a number of other etiologies that may explain these findings. However,  physicians 
should be made aware of this possibility (Kamble, et al,  2007). 
The source of stem cells may also affect the neurologic outcomes. There are three different 
sources of stem cells: bone marrow, cord blood and peripheralb blood stem cells. Patients 
who receive peripheral blood stem cells often have a delay in platelet recovery, thus 
increasing the risk of subdural hematomas. Alternatively, patients with cord blood 
transplants can have delayed engraftment, thus increasing the period of neutropenia or 
thrombocytopenia. This can either increase the risk of infections or increase the chances of 
CNS bleeding, both of which can increase neurologic complications.   
Neurologic complications have also been reported following the infusion of stem cells. In 
one report of 179 consecutive patients, 3 developed complications following the infusion  of 
cryopreserved stem cells (Hoyt et al, 2000). The symptoms were global amnesia (n=1), 
cerebral infarction (n=2). The patients who developed infarcts showed evidence of a cerebral 
hemorrhage due to thrombocytopenia and the other showed cerebral aspergillus on 
autopsy. Therefore, although there are sporadic reports of complications due to the infusion 
of cells, the risk of the stem cell infusion itself is very low.  
5. Impact of conditioning therapy 
Ther pretransplant conditioning therapy consists of either high doses of chemotherapy or 
total body irradiation (TBI). The high dose chemotherapy often crosses the blood brain 
barrier and the TBI has a direct cytotoxic effect upon the brain. This pretransplant 
conditioning regimen and the therapy used for the prophylaxis against graft versus host 
disease (GVHD) are thought to be responsible for the majority of neurological complications 
following HSCT. The use of various chemotherapy regimens and the use of TBI vary 
depending upon the type of disease that is being transplanted. For example, patients with 
nonmalignant disorders are often treated with high dose busulfan while most patients with 
acute lymphoblastic leukemia are treated with TBI in addition to a chemotherapeutic agent. 
All agents can produce some acute neurotoxicities and may even have some late onset 
neurotoxicities. The most common agents that are used in transplant conditioning regimens 
and their side effects are shown in Table 1.  
The impact of the conditioning regimen generally affects the patients during the first 30 
days post-HSCT, or the acute post-transplant period. Complications during this time period 
include pancytopenia, metabolic abnormalities, coagulopathies, drug toxicities and 
infections due to neutropenia. During this period, subdural hematomas are common due to 
thrombocytopenia and /or platelet refractoriness. Many patients also develop endothelial 
cell damage from alkylators such as cytoxan. This may also increase patient’s risk of 
developing subdural hematomas. Intraparenchymal hemorrhages are less common, but may 
occur as well. These are usually associated with myeloid leukemias.  
During the acute period, patients are severely neutropenic. As a result, HSCT recipients are 
at risk of developing a variety of infections they include bacterial, viral and fungal 
infections.  Table 2 details the most common neurologic complications that occur post-
HSCT. 
 




Drug Neurologic Toxicities 
Busulfan  Reversible encephalopathy with somnolence, confusion, 
decreased alertness, myoclonus, headaches and 
hallucinations. Seizures in approximately 10% of patients. 
Prophylactic use of antiepileptics is recommended. (De La 
Camara et al 1991 and Vassal et al 1990) 
Carboplatin Ototoxicity in over 80% of children with neuroblastoma 
(Parsons et al 1998) 
Carmustine Optic disc and retinal microvaculopathy with variable degrees 
of visual loss.  Very high doses 9> 1,500 mg/ m2) can be 
associated with severe irreversible encephalopathy (Johnson 
et al 1999, Burger et al 1981) 
Cytarabine arabinoside Pancerebellar syndrome+/- diffuse encephalopathy with 
lethary, confusion, and seizures (Baker et al 1991) 
Etoposide  Acute confusional state, somnolence, and seizures, which 
resolve spontaneously (Leff et al 1988) 
Ifosphamide Encephalopathy with lethargy, confusion and seizures in 10-
40% of patients. Visual or auditory hallucinations, myoclonus, 
or muscle rigidity have been reported, which is usually self 
limited, but have been reported to progress to a coma. (Pratt  
et al 1990,   DiMaggio et al 1994) 
Thiotepa Chronic encephalopathy with progressive declines in 
cognitive and behaviorial function 
 
Table 1. Neurologic Toxicity of Commonly Used Drugs in HSCT Conditioning Regimens 
One of the major complications of CNS therapies is the development of  methotrexate 
induced leukoencephalopathy. The dose of intravenous methotrexate (not intrathecal 
methotrexate) correlates with the development of leukoencephalopathy. The incidence of 
this phenomenon is 16-69%. Patients may have no neurological symptoms. Methotrexate 
induced Leukoencephalopathy does not progress to progressive multifocal 
leukoencephalopathy ((Knaap et al 2005, Pande et al 2006, Reddick et al 2005). 
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 < 30 days 30-100 days > 100 days 
Infections Fungus (aspergillus,candida, etc) → →  →→→→ 
 Virus (HHV6  and CMV) Herpes Zoster  
  Toxoplasmosis PML (JCV) 
 Gram negative 
bacteria 













related side effects 
 
→ Multifocal  
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Post-HSCT    1) Post-transplant 
lymphoproliferative 
disease,  
2) relapse or 
3) secondary malignancy 
Causative issue Neutropenia Acute GVHD  
and deficiency of 
cellular 
immunity 
Chronic GVHD and 
deficiency of both cellular 
and humoral immunity 
Table 2. CNS complications following HSCT 
Progressive multifocal leukoencephalopathy is a more devastating complication  that is 
differentiated from methotrexate induced leukoencephalopathy by the presence of more 
extensive areas of white matter disease. Approximately 7% of patients who receive cranial 
irradiation and/ or intrathecal chemotherapy prior to HSCT and intrathecal methotrexate 
following HSCT develop progressive leukoencephalopathy 4-5 months post-HSCT. Clinical 
manifestations of this problem include dysarthria, confusion, seizures, upper motor neuron 
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weakness and coma. Leukoencephalopathy is usually chronic and often fatal.  (Bleyer, 1981, 
Thompson et al, 1986).  Leukoencephalopathy with severe neurological sequelae and death 
have also been attributed to amphotericin B following TBI in transplant recipients (Devinsky 
et al, 1987). Figure 1 shows the presence of progressive multifocal leukoencephalopathy in 
an 18 year old patient with ALL in 3rd remission 4 months following an unrelated BMT. The 
patient had received 1800 cGy of cranial irradiation prior to HSCT for the treatment of his 
ALL and received 1360 cGy of TBI as part of his HSCT conditioning regimen. The patient 
developed seizures and confusion and subsequently went into a coma. Lumbar puncture 
did not reveal any infectious etiology. The MRI shows extensive white matter changes 
consistent with progressive multifocal leukoencephalopathy.   
 
 
Fig. 1. An 18 year old male with ALL in 3rd remission following an unrelated bone marrow 
transplant. His conditioning regimen consisted of TBI 1360cGy. Four months post-HSCT he 
developed seizures and a coma.. An MRI of his head showed bilateral lesions in the deep 
subcortical white matter of the temporal lobes. The MRI findings are consistent with 
progressive multifocal leukoencephalopathy 
Many patients are unable to tolerate the intensive chemotherapies that are used in 
myeloablative transplants. Thus many centers have begun to employ the use of reduced 
intensity conditioning regimens (RIC). RIC often results in increased GVHD, which may 
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also increase the neurological sequelae and this may negate the beneficial long term effects 
that would be seen of decreased drug toxicity. Although it is expected that a RIC will have 
fewer neurological complications, there are no studies that have been completed in this area. 
6. Impact of immunosuppression 
Patients are often very immunosupressed following HSCT. A variety of complications can 
occur due to immunosuppression.  The second period of transplantation occurs during the 
time between 30-100 days. During this period, patients may develop GVHD, due to 
alloreactive donor derived T cells from the graft attacking nonshared recipient alloantigens 
in target tissues such as the skin,  liver and GI tract. During this time, radiation given during 
the conditioning period damages the host tissue from the mucosa, liver and other tissues. 
Activated cells from the damaged recipient tissues secrete inflammatory cytokines, which 
upregulate expression of recipient antigens. Presentation of recipient antigens to donor T 
cells occurs and subsequent proliferation and differentiation of these activated T cells occurs 
during this time. Activated CD4+ T cells expand and generate cytokines promote 
differentiation of CD8+ T cells to cytotoxic T cells, which kill recipient cells and cause 
further tissue damage.  
In order to prevent GVHD, patients are often treated with either Cyclosporin A (CSA) or 
tacrolimus. Both of these agents can cause neurotoxicity. The most frequent complications 
seen in patients receiving these agents  are tremors (40%), paresthesias ( 11%)  [Walker et al 
1988]. Approximately 5% of patients develop isolated seizures. Both of these agents can also 
cause posterior reversible encephalopathy (PRES syndrome).  The pathogenesis of PRES is 
unclear. However, both of these agents disrupt the blood brain barrier or interfere with 
cerbrovascular autoregulation, resulting in vasogenic edema. This process can rarely 
progress to irreversible cytotoxic edema (Hinchey et al  1996, Schwarz et al 1995, Mckinney 
et al 2007). Patients who develop this syndrome develop headache, confusion, blurry vision, 
visual hallucinations, seizures and motor dysfunction.  MRI findings include white matter 
edema which usually affects the parietal-occipital regions symmetrically  and is best seen on 
fluid- attenuated inversion recovery (FLAIR) sequences. PRES can occur despite normal 
drug levels. The symptoms of this condition resolve after discontinuation of the drug. The 
development of PRES does not preclude the safe use of the alternate agent and patients have 
frequently switched back and forth.   
Many HSCT recipients are on corticosteroid therapy, which can also lead to neurological 
complications. One of the major side effects of corticosteroid therapy includes steroid-
induced myopathy, which can occur early in therapy. Steroid-induced myopathy is often 
characterized by proximal muscle weakness, usually in the hip and neck flexors. 
Discontinuation of corticosteroids will improve the condition, but that may take many 
months to achieve. Corticosteroids are also well known to cause a number of psychiatric 
symptoms such a hallucinations, insomnia, anxiety, mood swings and memory problems. 
After one hundred days post-HSCT, chronic GVHD may occur.  The immune system 
generally tends to recover, however if chronic GVHD occurs, there tends to be a 
prolongation of both cellular and humoral recovery. Patients are at high risk of developing 
infections with a variety of infections that can include bacterial, viral and fungal infections. 
Since HSCT recipients are on anti-inflammatory medications such as corticosteroids, it may 
be difficult for patients to display the classic signs of CNS infections such as fever and 
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meningismus. In addition, many patients have other ongoing complications from their 
transplant that CNS infections are not often considered.  
Patients with CNS infections can be grouped into those who have nonfocal generalized CNS 
dysfunction such as headaches and meningismus or into those with focal findings 
suggestive of a mass lesion or stroke. In the first month following HSCT, most patients are 
neutropenic and are at risk of bacterial infections.  In the first month following transplant, 
gram negative bacterial infections are more predominant, but in the later period (30-100 
days) of HSCT, gram positive infections predominate. Methicillin-resistant Staphylococcus 
aureus or epidermidis (MRSA/ MRSE) and Listeria monocytogenes may cause meningitis, 
encephalitis and ventriculitis.  
Viral infections post-HSCT include those who develop adenovirus or Coxsackie virus B4 
can also produce encephalitis (Krouwer et al 2003, Cree et al 2003). Acquired viral 
infections such as with human herpes virus 6 (HHV6) and  cytomegalovirus (CMV) 
infections are also common during this period.  Most children develop primary HHV6 
infection between 6 months and 5 years of age (Yoshikawa et al  2003, Gorniak et al 2006). 
After the primary infection, this virus remains latent in the body and reactivates upon 
immunosuppression of the host. HHV6 often reactivates concurrently with GVHD and 
can develop in approximately 28%-78% of HSCT recipients (Yoshikawa et al 2003, 
Gorniak et al 2006). Symptoms that have been associated with CNS HHV6 infections 
include short-term memory loss, mental status changes, fever and headache.  The 
mortality of HHV6 infections is greater than 50%. Figure 2 shows the MRI of a 14 year old 
female patient with ALL and chronic GVHD. 2 months following HSCT she developed  
fevers, headaches, seizures and confusion. A CT scan was read as normal, however the 
MRI showed hyperintensity in the limbic system. A lumbar puncture revealed HHV6 
infection and she was treated with foscarnet. This patient recovered from her HHV6 
infection, however the mortality of this infection is more than 50% (Yoshikawa et al 2003, 
Gorniak et al 2006).  
Most pediatric patients have indwelling central venous catheters during their transplant. 
These patients are at risk of developing fungal infections due to Candida. Candidemia can 
become disseminated and involve the CNS with septic emboli. Aspergillus infections are the 
most common fungal infection following HSCT. These often occur when patients are either 
neutropenic or when their T cells have not recovered (day 0-100). MRI findings of patients 
with Aspergillus often show ring enhancing lesions that may have hemorrhage surrounding 
the lesion. Aspergillus preferentially occurs in the basal ganglia, cerebral hemispheres, and 
the corpus callosum.   Unfortunately, a biopsy of this area is very difficult and treatment is 
often started empirically.  The treatment is usually liposomal amphotericin, which may add 
to neurological complications post-HSCT. There are newer agents that are also available for 
the treatment of aspergillus. The mortality of cerebral aspergillosis approaches 85-100% 
depending upon the degree of neurological compromise at presentation (Guermazi et al  
2003, Miaux et al 1995).   
The most common parasitic infection following HSCT is Toxoplasma gondii. Patients present 
with focal symptoms and mild to severe encephalopathy. MRI findings on these patients 
show the presence of multiple mass lesions affecting the basal ganglia with minimal to no 
enhancement. Patients who have not received prophylactic antibiotics with trimethoprim 
sulfamethoxazole are at risk of developing this infection.  
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also increase the neurological sequelae and this may negate the beneficial long term effects 
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meningismus. In addition, many patients have other ongoing complications from their 
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Fig. 2. An MRI of a 14 year old female with ALL in 3rd remission following an unrelated 
cord blood transplantation. She developed severe graft versus host disease fever, confusion 
and  seizures. A lumbar puncture revealed the presence of HHV6. Flair T2 demonstrates 
biparietal white matter increased signal intensity more on the left side. This is consistent 
with HHV6 lesion.  
Finally, post-transplant lymphoproliferative disease (PTLD) covers a spectrum that involves 
benign polyclonal lymphoid hyperplasia to malignant monoclonal lymphoma. Often Ebstein 
Barr Virus (EBV) is the infectious etiology of the malignant lymphoma. In children, the risk 
is related to a primary EBV infection in a previously seronegative younger patient (Newell 
et al, 1996). These patients are usually treated with either reduced immunosuppression or 
chemotherapy. When PTLD does involve the CNS, the prognosis is poor. 
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7. Neurocognitive function following HSCT 
The potential impact of the disease, intensive therapy, social isolation and altered family 
dynamics in a young child is uncertain and cannot be studied well in pediatric patients. Pot-
Mees (1989) documented the profound psychosocial effects of HSCT on patients and 
families. Recipients of HSCT, despite the underlying disease for which they are 
transplanted, often face prolonged periods of time in the hospital. Many do not attend 
school on a regular basis. During the time that they are receiving therapy, they often have 
some malnutrition due to nausea and vomiting from the therapy to treat their underlying 
disease. Even after their therapy is completed, some children have an adaptive school 
program. After HSCT, many children do not have a normal immune system for a long 
period after HSCT. As a result, they are not involved with extracurricular activities like 
other age-matched peers.  
One would expect that HSCT would increase the neurocognitive deficits seen in pediatric 
leukemia survivors. The current studies of neurocognitive functioning upon HSCT 
recipients have yielded mixed results. Most studies of neurocognitive function upon HSCT 
recipients contain patients with all diseases (malignant and non-malignant), varying types 
of transplants and conditioning regimens and different age groups. This makes it difficult to 
interpret the impact of HSCT upon specific disease groups.  
Some studies have shown no significant differences in intellectual functioning  in patients 
who are pre-HSCT versus those who are one-year post-HSCT evaluations, except for those 
patients who have been younger at diagnosis (Kaleita et al 1989, Kramer et al 1992, Simms et 
al 1998, Phipps et al 1995, Simms et al 2002, Phipps et al  2000, Chou et al 1996, Phipps et al 
2008). Whereas, other  studies have reported that those patients who receive cranial 
irradiation have declining neurocognitive function in terms of IQ, achievement, memory 
and fine motor skills (Cool et al 1996, Smedler et al 1995, Said et al ,  Kramer et al 1997, Shah 
et al 2008).  
Consistently, all of these previous studies have shown that a younger age at diagnosis and 
treatment have resulted in significant declines in neurocognitive function In addition, 
deficits in fine motor skills appear to be more pronounced in HSCT recipients who received 
cranial irradiation at a younger age than those who received cranial irradiation at an older 
age (Phipps 2000, Cool 1996, Smedler 1990). Since cranial irradiation appears to affect the 
information processing, memory and attention mechanisms of the brain, patients who have 
received cranial irradiation (brain tumor patients and those who had CNS leukemia or 
received propylaxis for CNS leukemia) are at particular risk of developing long-term 
cognitive deficits.  
Phipps et al conducted the largest pediatric trial relating to the neurocognitive function of 
patients post-HSCT. This prospective study had 102 patients, who received a full battery of 
tests for up to 3 years post HSCT. In this study, the neurocognitive function (cognitive and 
academic functioning) was not impacted by HSCT in patients greater than 6 years of age. 
There was no impact of TBI upon neurocognitive function.  The greatest decline in 
neurocognitive function occurred in those < 3 years of age.  A follow up study done in 2008, 
increased the population being evaluated to 268 patients. Although the majority of patients 
had a malignant disease, there were minimal neurocognitive delays. There were subgroups 
of patients that were increased risk of neurocognitive delays. These subgroups included 
those who received TBI, recipients of unrelated transplants, and those who developed graft 
versus host disease (Phipps et al 2008).  
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For patients who received HSCT for genetic diseases of immunodeficiencies, the information 
regarding neurocognitive function post-HSCT is sparser. Most patients with genetic disease 
have problems due to their underlying disease. Following HSCT, the developmental 
outcomes vary depending upon the disease that they were transplanted for and their pre-
HSCT performance scores. Prasad et al transplanted 159 pediatric patients with a variety of 
inherited metabolic disorders.  Among patients with  MPS I (Hurler’s Disease), most  have 
shown continued increases in their neurocognitive skills, with 81% of them being in age 
appropriate classes. However, for patients with MPS III (Krabbe’s disease), there was less of 
an impact of HSCT upon neurocognitive function. Most children with Krabbe’s disease have 
severe neurological complications of this disease. Of the surviving patients with Tay-Sachs, 
there was no impact of HSCT upon their neurocognitive function and the surviving patients 
are severely debilitated (Prasad 2008).  
There have not been any formal studies upon the neurocognitive function of patients with 
hemoglobinopathies following HSCT.  Walters et al recently reported the outcomes of 
patients receiving HSCT for sickle cell disease. In that study of  55 long-term survivors of 
histocompatible HSCT, 19 patients developed neurological complications post HSCT, which 
consisted primarily of seizures. One patient had graft rejection and subsequently developed 
a second thrombotic stroke. However, no formal neurocognitive testing was done on these 
patients to determine the long-term clinical impact of transplant on this group of patients 
(Walters et al, 2009).   
Many patients with immunodeficiencies, present to a doctor only after they have had a life-
threatening illness. Since these children are very young at diagnosis, they are usually 
socially isolated after the diagnosis is made. They are not exposed to their age-matched 
peers. In addition, they often have a history of chronic infections, especially their respiratory 
systems.  
For patients with immunodeficiencies, there have been only 2 major studies that have 
focused on this population alone. First, Titman et al reported the results of formalized 
neurocognitive testing upon 106 patients with immunodeficiencies. This study showed that 
the underlying genetic disease, presence of ADA deficient SCID and consanguinity were 
associate with a worse outcome. Age at transplantation (<  3 years of age versus > 3 years of 
age), length of stay in the hospital, and chemotherapy conditioning regimen were not 
significant factors (Titman, 2008). 
Lin et al performed a prospective study on the neurocognitive function of 16 patients with 
SCID. Although there were significant decreases in the formal neurocognitive test scores, 
the results showed that these children did learn and acquire developmental milestones, but 
at a slower rate than their age matched normal peers. There was no impact of age (< 8 
months versus > 8 months of age), presence of serious infections prior to HSCT, or length of 
stay in the hospital (Lin, 2009).  
8. Conclusion 
Patients who receive HSCT are at great risk of developing neurological sequelae due to 
either their primary disease, the therapies used to treat the disease and the complications of 
these treatments. The complications can be hard to diagnose. These complications can have 
serious implications for the long-term survivor of HSCT. Formal testing of HSCT recipients 
neurocognitive function should be required for patients  
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1. Introduction  
Allogeneic stem cell transplantations (allo-SCT) increase in recipients the risk of life-
threatening opportunistic infections caused by different pathogens. In recent years, 
adenoviruses (AdV) have been recognized as an emerging pathogen causing serious post-
transplant complications with very high mortality (Fowler et al., 2010). Hematopoietic stem 
cell transplantation is a standard treatment in malignant and non-malignant disorders of 
bone marrow, solid tumors, immunodeficiencies, and autoimmune disorders (Gyurkocza et 
al., 2010; Ljungman et al., 2010). Intensive immunosuppressive treatment for prevention 
both of graft rejection and graft-versus-host disease (GvHD) and the therapy of the latter 
one, makes the patients at risk of developing opportunistic infections. The immune 
reconstitution period following hematopoietic transplantation is therefore accompanied by 
high incidence of adenoviral infections due to profound immunodeficiency (Echavarri´a, 
2008; Gyurkocza et al., 2010). Lack of immunological competence caused by invasive cancer 
therapy and conditioning procedures results mainly in lowering the number of CD3+ 
lymphocytes in peripheral blood. Lymphopenia increases patient`s risk for de novo 
infection or reactivation of a latent virus that mainly occurs during the early post-
transplantation period and usually leads to disseminated disease. The time of the infection 
onset is also vital, because AdV infections occurring after day +100 from the transplantation 
do not seem to be associated with life-threatening disease (Lion et al., 2003). According to 
different retrospective and prospective studies, adenovirus has been found to infect from 
just a few percent to a several dozen percent of patient post-HSCT (Akiyama  et al., 2001; 
Arnberg et al., 2002; Benko et al., 2000; Ebner et al., 2005; Howard et al., 1999; Mahr & 
Gooding, 1999; Lauer et al., 2003; Robin et al., 2007; Rutala et al., 2006; Stone et al., 2003; 
Walls  et al., 2003; Watzinger et al., 2004) with mortality in disseminated disease reaching 
even 80% (Akiyama et al., 2001; Mori  et al., 2003; Russell, 2000; Walls et al., 2003; Watzinger 
et al., 2004). Adenoviruses are commonly detected in stool, pharyngeal swabs, urine and 
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1. Introduction  
Allogeneic stem cell transplantations (allo-SCT) increase in recipients the risk of life-
threatening opportunistic infections caused by different pathogens. In recent years, 
adenoviruses (AdV) have been recognized as an emerging pathogen causing serious post-
transplant complications with very high mortality (Fowler et al., 2010). Hematopoietic stem 
cell transplantation is a standard treatment in malignant and non-malignant disorders of 
bone marrow, solid tumors, immunodeficiencies, and autoimmune disorders (Gyurkocza et 
al., 2010; Ljungman et al., 2010). Intensive immunosuppressive treatment for prevention 
both of graft rejection and graft-versus-host disease (GvHD) and the therapy of the latter 
one, makes the patients at risk of developing opportunistic infections. The immune 
reconstitution period following hematopoietic transplantation is therefore accompanied by 
high incidence of adenoviral infections due to profound immunodeficiency (Echavarri´a, 
2008; Gyurkocza et al., 2010). Lack of immunological competence caused by invasive cancer 
therapy and conditioning procedures results mainly in lowering the number of CD3+ 
lymphocytes in peripheral blood. Lymphopenia increases patient`s risk for de novo 
infection or reactivation of a latent virus that mainly occurs during the early post-
transplantation period and usually leads to disseminated disease. The time of the infection 
onset is also vital, because AdV infections occurring after day +100 from the transplantation 
do not seem to be associated with life-threatening disease (Lion et al., 2003). According to 
different retrospective and prospective studies, adenovirus has been found to infect from 
just a few percent to a several dozen percent of patient post-HSCT (Akiyama  et al., 2001; 
Arnberg et al., 2002; Benko et al., 2000; Ebner et al., 2005; Howard et al., 1999; Mahr & 
Gooding, 1999; Lauer et al., 2003; Robin et al., 2007; Rutala et al., 2006; Stone et al., 2003; 
Walls  et al., 2003; Watzinger et al., 2004) with mortality in disseminated disease reaching 
even 80% (Akiyama et al., 2001; Mori  et al., 2003; Russell, 2000; Walls et al., 2003; Watzinger 
et al., 2004). Adenoviruses are commonly detected in stool, pharyngeal swabs, urine and 
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whole blood in HSCT recipients usually causing limited infections of the respiratory tract, 
gastrointestinal system and urinary tract but sometimes progress to disseminated disease 
affecting many organs and whole systems, too (Watcharananan et al., 2010). The diagnosis 
of adenoviral infection can be difficult due to complexity of the multiorgan disease non-
specific symptoms resembling other infections or acute graft versus host disease (aGvHD). 
This review describes adenoviral infections in recipients of hematopoietic stem cell 
transplantations and focuses attention on infection course, risk factors, possible 
complications, diagnostic methods for adenovirus identification and therapy strategies. 
2. Human adenoviruses-general description 
The original virus was isolated in 1953 from surgically removed adenoids from a child by 
Rowe et al. (Huebner et al., 1954; Rowe et al., 1953), thus it has been called adenovirus. 
Adenoviruses are ubiquitous in the environment contaminated with human feces or sewage. 
To date, 54 antigenic types of human adenoviruses belonging to genus Mastadenovirus and 
family Adenoviridae have been described, and over half of them have been recognized as 
pathogenic for humans. They have been divided into seven species (from A to G) on the 
basis of their morphological, hemagglutinating and oncogeneic properties as well as their 
genome size, DNA sequence and electrophoretic mobility of virion polypeptides (Table 1). 
Adenoviruses from species B and D were further subdivided into subspecies: B1, B2 and D1, 
D2 and D3, respectively. In addition to this classification several AdV genotypes can be 
identified within previously mentioned serotypes (Echavarri´a, 2008, 2009; Ebner et al. 2005; 
Stone et al., 2003; Wadell et al., 1980). 
Adenoviruses are non-enveloped, 70-90 nm in diameter particles with icosahedral 
symmetry. The capsid is composed of 252 capsomers: 240 hexamers and 12 pentons (Russell, 
2009; Rux et al., 2003). Several different proteins in AdV particle can be distinguished, but 
three major proteins such as hexon, penton base and fiber protein create the main capsid 
structure. The hexon is a homotrimer of three identical polypeptide chains (pII) formulating 
a triangular vertex of surface loops. It is the most abundant protein in adenoviral particle 
(more than 80% of AdV2 capsid protein) formulating hexon molecules symmetrically 
distributed in the capsid (Burnett, 1999). The hexon possess the group− and type−specific 
determinants which are utilized in diagnostic procedures such as ELISA test, 
hemagglutination inhibition and serum neutralization. Occurrence of these specific antigen 
determinants on a viral surface is determined by the presence of variable and hypervariable 
regions (HVRs) in nucleotide sequence of the hexon gene. Since today, nine hipervariable 
regions (HVR1-HVR9) have been distinguished (Crawford-Miksza & Schnurr, 1996; Rux et 
al., 2003). They are situated within the loops at the top of the hexon molecule, hence can be 
utilized in diagnostic tests. The hexon protein is also an immunodominant T-cell target, 
however other structural components of the virion may also be immunogenic. Twelve 
penton bases (pIII) creating capsid vertex provide the basis for radially projecting trimeric 
fibers (pIV) of different lengths according to the AdV serotype (10-37 nm). The external end 
of the fiber is terminated with a C-terminal knob which posses several antigen determinants 
participating in cell receptors binding, hemagglutination in vitro and virus internalization 
into a host cell (Burmeister et al., 2004; Cusack, 2005; Echavarri´a, 2008). Genetic information 
of adenoviruses is encoded by about 34-36 kb double stranded linear DNA, containing more 
than 50 coding regions (Echavarri´a, 2008). 
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Species Serotypes Features#  
A 12, 18, 31 Highly oncogenic 
GC%: 47-49 
FL: 28-31nm 
HA: rat (incomplete) 
 
B B1: 3, 7, 16, 21, 50† 
B2: 11, 14, 34, 35 
Poorly oncogenic 
GC%: 48-52 
FL: 9-11 nm 
HA: Rhesus 
 
C 1, 2, 5, 6 Nononcogenic 
GC%: 55-59 
FL: 23-31nm 
HA: rat (incomplete) 
 
D D1: 9, 19 
D2: 15, 22 
D3: 8, 10, 13, 17, 20, 23-30, 32, 
33, 36-39, 42-49, 51†, 53, 54* 
Nononcogenic 
GC%: 54-59 
FL: 12-13 nm 
HA: rat, mouse, human, dog, pig, monkey 
 
E 4 Nononcogenic 
GC%: 57 
FL: 17 nm 
HA: Rat (incomplete) 
 
F 40, 41 Nononcogenic 
GC%: 51-59 
FL: 29 nm 
HA: rat (atypic) 
 
G 52 ND  
# Data adopted from references: (Echavarria, 2006; Hierholzer, 1992; Kaneko et al., 2009; Wadell  et al., 
1980; Walsh et al., 2010; and from National Center for Biotechnology Information database 
(http://www.ncbi.nlm.nih.gov); 
† according to  Ebner et al. (2005) serotype 50 was reclassified into species D and serotype 51 into 
species B; 
* firstly described in year 2009, (proposal) (Kaneko et al., 2006); 
ND- not determined, FL-fiber length, HA- hemaglutination; 
Table 1. Adenovirus classification and general features. 
3. Virus transmission in stem cell recipients 
The most common source of adenoviral infection after haematopoietic stem cell 
transplantation is reactivation of a latent virus persisting in lymphocytes of peripheral 
blood, in adenoids, intestines and kidneys through low-grade replication. AdV1, AdV2 and 
AdV5 (C) are the most common serotypes remaining latent after primary exposure in the 
childhood (Lee et al., 2010; Malekshahi et al., 2010). They also play the significant role in 
development of AdV infections after SCT, therefore confirming the role of virus reactivation 
during an early post-transplant period. The next source of AdV infection in stem cell 
recipients might be the virus transmission from the positive donor to the negative recipient. 
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2009; Rux et al., 2003). Several different proteins in AdV particle can be distinguished, but 
three major proteins such as hexon, penton base and fiber protein create the main capsid 
structure. The hexon is a homotrimer of three identical polypeptide chains (pII) formulating 
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(more than 80% of AdV2 capsid protein) formulating hexon molecules symmetrically 
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determinants which are utilized in diagnostic procedures such as ELISA test, 
hemagglutination inhibition and serum neutralization. Occurrence of these specific antigen 
determinants on a viral surface is determined by the presence of variable and hypervariable 
regions (HVRs) in nucleotide sequence of the hexon gene. Since today, nine hipervariable 
regions (HVR1-HVR9) have been distinguished (Crawford-Miksza & Schnurr, 1996; Rux et 
al., 2003). They are situated within the loops at the top of the hexon molecule, hence can be 
utilized in diagnostic tests. The hexon protein is also an immunodominant T-cell target, 
however other structural components of the virion may also be immunogenic. Twelve 
penton bases (pIII) creating capsid vertex provide the basis for radially projecting trimeric 
fibers (pIV) of different lengths according to the AdV serotype (10-37 nm). The external end 
of the fiber is terminated with a C-terminal knob which posses several antigen determinants 
participating in cell receptors binding, hemagglutination in vitro and virus internalization 
into a host cell (Burmeister et al., 2004; Cusack, 2005; Echavarri´a, 2008). Genetic information 
of adenoviruses is encoded by about 34-36 kb double stranded linear DNA, containing more 
than 50 coding regions (Echavarri´a, 2008). 
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Species Serotypes Features#  
A 12, 18, 31 Highly oncogenic 
GC%: 47-49 
FL: 28-31nm 
HA: rat (incomplete) 
 
B B1: 3, 7, 16, 21, 50† 
B2: 11, 14, 34, 35 
Poorly oncogenic 
GC%: 48-52 
FL: 9-11 nm 
HA: Rhesus 
 
C 1, 2, 5, 6 Nononcogenic 
GC%: 55-59 
FL: 23-31nm 
HA: rat (incomplete) 
 
D D1: 9, 19 
D2: 15, 22 
D3: 8, 10, 13, 17, 20, 23-30, 32, 
33, 36-39, 42-49, 51†, 53, 54* 
Nononcogenic 
GC%: 54-59 
FL: 12-13 nm 
HA: rat, mouse, human, dog, pig, monkey 
 
E 4 Nononcogenic 
GC%: 57 
FL: 17 nm 
HA: Rat (incomplete) 
 
F 40, 41 Nononcogenic 
GC%: 51-59 
FL: 29 nm 
HA: rat (atypic) 
 
G 52 ND  
# Data adopted from references: (Echavarria, 2006; Hierholzer, 1992; Kaneko et al., 2009; Wadell  et al., 
1980; Walsh et al., 2010; and from National Center for Biotechnology Information database 
(http://www.ncbi.nlm.nih.gov); 
† according to  Ebner et al. (2005) serotype 50 was reclassified into species D and serotype 51 into 
species B; 
* firstly described in year 2009, (proposal) (Kaneko et al., 2006); 
ND- not determined, FL-fiber length, HA- hemaglutination; 
Table 1. Adenovirus classification and general features. 
3. Virus transmission in stem cell recipients 
The most common source of adenoviral infection after haematopoietic stem cell 
transplantation is reactivation of a latent virus persisting in lymphocytes of peripheral 
blood, in adenoids, intestines and kidneys through low-grade replication. AdV1, AdV2 and 
AdV5 (C) are the most common serotypes remaining latent after primary exposure in the 
childhood (Lee et al., 2010; Malekshahi et al., 2010). They also play the significant role in 
development of AdV infections after SCT, therefore confirming the role of virus reactivation 
during an early post-transplant period. The next source of AdV infection in stem cell 
recipients might be the virus transmission from the positive donor to the negative recipient. 
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There are many reports confirming more than 4-fold increased risk of primary adenoviral 
infections in HSCT recipients grafted from previously infected (seropositive) donors in 
comparison to uninfected donors (Runde et al., 2001; Walls et al., 2003). 
Adenoviruses can spread directly through respiratory droplets hence upper respiratory tract 
infections occur very often. They are able to replicate in the environment of the 
gastrointestinal tract due to their resistance to low pH of a stomach and proteolytic enzymes 
in gastrointestinal secretions, thus allowing the virus to achieve a high viral load in the gut. 
Because viral loads in stool samples of infected patients achieve the highest levels in 
comparison to other clinical materials, it can be suggested that fecal-oral transmission is the 
most common route of infection spread (Baldwin et al., 2000; Chakrabarti et al., 2002; Hale et 
al., 1999; Howard et al., 1999; Jeulin et al., 2011; Lion et al., 2010; Rutala et al, 2006).  
There are also some reports suggesting possible virus spread via unsterile instruments and 
medical equipment, direct staff-to-patient transmission or inadequate air conditioning in the 
post-transplantation ward. Adenoviruses are strongly resistant to chemical or physical 
agents and adverse pH conditions and are able to remain infectious for a long period 
outside of the body, but this route of infection can be prevented by disinfection procedures 
in transplantation units (Artieda et al., 2010; Gerber et al., 2001; Gray, 2006; Leruez-Ville et 
al., 2006; Lessa et al., 2007; Romero et al., 2010). 
4. Pathomechanism and clinical manifestations of adenoviral infections  
Individual serotypes of Adenoviridae family show varied tissue tropism. They infect post-
mitotic cells of even highly differentiated tissues such as skeletal muscles, lungs, brain and 
heart muscle (Russell, 2009; Zhang & Bergelson, 2005). The infection cycle is divided into 
two stages involving virus adsorption and internalization (Figure 1). Attachment to the host 
cell receptor and virus entry occurs via the fibre protein and penton base. Majority of 
adenoviruses (mainly those from species A, C, D, E and F) use the coxackie-adenovirus 
receptor (CAR) which is a member of the immunoglobulin family and is situated on a 
surface of most human tissues such as heart muscle, brain, liver, pancreas, intestines, lungs 
and kidneys (Dechecchi et al, 2001; Raschperger et al., 2006; Russell, 2000, 2009; Rux et al., 
2003; Zhang & Bergelson, 2005). In human cells lacking CAR receptor, other cell molecules 
are used for virus attachment. For example, AdV2 and AdV5 are able to bind the α-domain 
of MHC class I (Major Histocompatibility Complex Class I) molecule or heparan sulfate 
glycosaminoglycans (HS GAG). Additionally, these serotypes are capable to recognize and 
interact with vascular cell adhesion molecule-1 (VCAM-1) which is situated on 
atherosclerotic lesions of vascular endothelium. More rarely, α(2-3)- sialic acid, sBAR and 
sB2AR and CD46, CD80, CD86 are used (mainly serotypes: 3, 7, 8, 11, 14, 16, 19, 21, 37, 34 , 
35 and 50) (Benko  et al., 2000; Burmeister  et al., 2004; Chu  et al., 2001; Sharma et al., 2009; 
Wang et al, 2007; Zhang & Bergelson, 2005). Virus binding to the cell receptor and 
interaction between penton base and integrins on the target cell induce internalization of the 
viral particle into the host cell by clathrin-coated vesicles and endosomes. Several proteins 
and intra-endosomal mechanisms lead to disintegration of virus particle and subsequently 
to viral core release. Viral DNA is transported to the cell nucleus by microtubule-mediated 
transport and undergoes DNA transcription and replication (Cusack, 2005; Kelkar et al., 
2004; Russell, 2000). Replication process is divided into an early and late phase. Sometimes, 
an intermediate phase is also marked out. The early phase (6-8 hours) includes virus 
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penetration into the host cell, transport of viral DNA to cell nucleus and 
transcription/translation of the “early genes” such as E1A, E1B, E2, E3, E4. The products of 
the early genes act as regulatory factors. They change cell functions to facilitate further 
replication of the virus and transactivate other early transcription units. Second phase of 
AdV replication leads to transcription and translation of the “late genes” (L1-L5) encoding 
mainly structural proteins of the virion shell. Assembly and maturation of AdV particles 
take place in the nuclei of infected cells. The whole process usually takes only 4-6 hours 
(Greber et al. 1997, Gonçalves & de Vries, 2006; Matthews & Russell, 1998; Russell, 2000). 
 
 
Fig. 1. AdV infection cycle. An interaction between penton base and α,β integrins induces 
internalization of viral particle into the host cell. Intra-endosomal mechanisms lead to 
disintegration of virion shell. Viral DNA is transported into the cell nucleus providing 
material for DNA replication. The early phase of replication includes expression of the 
“early genes” (E1-E4) acting as regulatory factors and facilitating virus replication. Second 
phase of AdV replication leads to expression of L1-L4 encoding mainly structural proteins 
determining virus assembly and maturation. 
Adenoviral infection and active virus replication in the host cell can exert three different 
cytopathological effects. In most cases AdV infection leads to cell lysis. AdV genome 
contains at least four different coding regions (E1a, E4ORF4, E4ORF6/7 i ADP, which 
products can induce cell death and lysis (Braithwaite & Russell, 2001). Alternatively, after 
acute phase of the infection, the virus might remain in latent phase. Human adenoviruses, 
especially AdV1, AdV2, AdV5 from species C, possess the ability to prolonged persistence 
in adenoids, intestines, renal parenchyma and lymphocytes in peripheral blood with 
 
New Advances in Stem Cell Transplantation 
 
536 
There are many reports confirming more than 4-fold increased risk of primary adenoviral 
infections in HSCT recipients grafted from previously infected (seropositive) donors in 
comparison to uninfected donors (Runde et al., 2001; Walls et al., 2003). 
Adenoviruses can spread directly through respiratory droplets hence upper respiratory tract 
infections occur very often. They are able to replicate in the environment of the 
gastrointestinal tract due to their resistance to low pH of a stomach and proteolytic enzymes 
in gastrointestinal secretions, thus allowing the virus to achieve a high viral load in the gut. 
Because viral loads in stool samples of infected patients achieve the highest levels in 
comparison to other clinical materials, it can be suggested that fecal-oral transmission is the 
most common route of infection spread (Baldwin et al., 2000; Chakrabarti et al., 2002; Hale et 
al., 1999; Howard et al., 1999; Jeulin et al., 2011; Lion et al., 2010; Rutala et al, 2006).  
There are also some reports suggesting possible virus spread via unsterile instruments and 
medical equipment, direct staff-to-patient transmission or inadequate air conditioning in the 
post-transplantation ward. Adenoviruses are strongly resistant to chemical or physical 
agents and adverse pH conditions and are able to remain infectious for a long period 
outside of the body, but this route of infection can be prevented by disinfection procedures 
in transplantation units (Artieda et al., 2010; Gerber et al., 2001; Gray, 2006; Leruez-Ville et 
al., 2006; Lessa et al., 2007; Romero et al., 2010). 
4. Pathomechanism and clinical manifestations of adenoviral infections  
Individual serotypes of Adenoviridae family show varied tissue tropism. They infect post-
mitotic cells of even highly differentiated tissues such as skeletal muscles, lungs, brain and 
heart muscle (Russell, 2009; Zhang & Bergelson, 2005). The infection cycle is divided into 
two stages involving virus adsorption and internalization (Figure 1). Attachment to the host 
cell receptor and virus entry occurs via the fibre protein and penton base. Majority of 
adenoviruses (mainly those from species A, C, D, E and F) use the coxackie-adenovirus 
receptor (CAR) which is a member of the immunoglobulin family and is situated on a 
surface of most human tissues such as heart muscle, brain, liver, pancreas, intestines, lungs 
and kidneys (Dechecchi et al, 2001; Raschperger et al., 2006; Russell, 2000, 2009; Rux et al., 
2003; Zhang & Bergelson, 2005). In human cells lacking CAR receptor, other cell molecules 
are used for virus attachment. For example, AdV2 and AdV5 are able to bind the α-domain 
of MHC class I (Major Histocompatibility Complex Class I) molecule or heparan sulfate 
glycosaminoglycans (HS GAG). Additionally, these serotypes are capable to recognize and 
interact with vascular cell adhesion molecule-1 (VCAM-1) which is situated on 
atherosclerotic lesions of vascular endothelium. More rarely, α(2-3)- sialic acid, sBAR and 
sB2AR and CD46, CD80, CD86 are used (mainly serotypes: 3, 7, 8, 11, 14, 16, 19, 21, 37, 34 , 
35 and 50) (Benko  et al., 2000; Burmeister  et al., 2004; Chu  et al., 2001; Sharma et al., 2009; 
Wang et al, 2007; Zhang & Bergelson, 2005). Virus binding to the cell receptor and 
interaction between penton base and integrins on the target cell induce internalization of the 
viral particle into the host cell by clathrin-coated vesicles and endosomes. Several proteins 
and intra-endosomal mechanisms lead to disintegration of virus particle and subsequently 
to viral core release. Viral DNA is transported to the cell nucleus by microtubule-mediated 
transport and undergoes DNA transcription and replication (Cusack, 2005; Kelkar et al., 
2004; Russell, 2000). Replication process is divided into an early and late phase. Sometimes, 
an intermediate phase is also marked out. The early phase (6-8 hours) includes virus 
 
Adenoviral Infection – Common Complication Following Hematopoietic Stem Cell Transplantation 
 
537 
penetration into the host cell, transport of viral DNA to cell nucleus and 
transcription/translation of the “early genes” such as E1A, E1B, E2, E3, E4. The products of 
the early genes act as regulatory factors. They change cell functions to facilitate further 
replication of the virus and transactivate other early transcription units. Second phase of 
AdV replication leads to transcription and translation of the “late genes” (L1-L5) encoding 
mainly structural proteins of the virion shell. Assembly and maturation of AdV particles 
take place in the nuclei of infected cells. The whole process usually takes only 4-6 hours 
(Greber et al. 1997, Gonçalves & de Vries, 2006; Matthews & Russell, 1998; Russell, 2000). 
 
 
Fig. 1. AdV infection cycle. An interaction between penton base and α,β integrins induces 
internalization of viral particle into the host cell. Intra-endosomal mechanisms lead to 
disintegration of virion shell. Viral DNA is transported into the cell nucleus providing 
material for DNA replication. The early phase of replication includes expression of the 
“early genes” (E1-E4) acting as regulatory factors and facilitating virus replication. Second 
phase of AdV replication leads to expression of L1-L4 encoding mainly structural proteins 
determining virus assembly and maturation. 
Adenoviral infection and active virus replication in the host cell can exert three different 
cytopathological effects. In most cases AdV infection leads to cell lysis. AdV genome 
contains at least four different coding regions (E1a, E4ORF4, E4ORF6/7 i ADP, which 
products can induce cell death and lysis (Braithwaite & Russell, 2001). Alternatively, after 
acute phase of the infection, the virus might remain in latent phase. Human adenoviruses, 
especially AdV1, AdV2, AdV5 from species C, possess the ability to prolonged persistence 
in adenoids, intestines, renal parenchyma and lymphocytes in peripheral blood with 
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periodic shedding of virus in feaces and respiratory secretions (Akiyama et al., 2001; 
Braithwaite & Russell, 2001; Echavarri´a, 2008; Watzinger et al., 2004). The third possible 
outcome of adenoviral infection is an oncogenic transformation of infected cells, that is 
observed in animal models (Russell, 2009). 
Primary adenoviral infections affect predominantly pediatric population with more than 
50% of children infected before the age of five (Cooper et al., 2003). Children are often 
infected with adenovirus types 1, 2, 3, 4, 5, 7 and 30 which are the most common causes of 
tonsillopharyngitis and pneumonia (Carballal et al., 2002; Faden et al., 2005). These antigenic 
types are also the most frequent in recipients of SCT indicating virus reactivation or droplets 
transmission as most reliable routes of virus spread. AdV infections in immunocompetent 
humans are usually asymptomatic, localized and tend to be self-limited. They are restricted 
to the respiratory system, genitourinary and gastrointestinal tract infections, occasionally 
affecting conjunctiva and cornea. Recipients of HSCT and other imunocompromised 
patients present much broader spectrum of clinical manifestations. According to different 
studies, the estimated rate of AdV infection after HSCT ranges from 3–47% (Akiyama  et al., 
2001; Arnberg  et al., 2002; Ebner  et al., 2005; Howard et al, 1999; Lauer et al., 2004; Mahr & 
Gooding, 1999; Rutala et al., 2006; Stone et al., 2003; Walls et al, 2003; Watcharananan et al, 
2010; Watzinger et al., 2004;) with mortality reaching up to 80% in patients with 
disseminated disease (Akiyama  et al., 2001; Kaneko  et al., 2009; Russell, 2000; Walls et al., 
2003; Watzinger  et al., 2004). The wide range in reported AdV incidence can results from 
different diagnostic methods, variety of body sites analyzed as well as demographic 
differences and lack of strict criteria for defining adenovirus infection or disease. AdV 
infections in immunocompromised patients tend to be invasive. The most common are 
infections of AdVs from subgroup C, followed by A, B and D. They cause exudative 
pharyngitis, acute respiratory disease epidemics, febrile laryngitis, conjunctivitis, 
keratoconjunctivitis, necrotizing enterocolitis, pharyngeal−conjunctival fever and 
hemorrhagic cystitis. Less frequent are testitis, nephritis, arthritis, myocarditis and 
pericarditis. Infections of the gastrointestinal tract are especially frequent in young children 
and include gastroenteritis, mesenteric lymphadenitis, intussusception, hepatitis, and 
appendicitis (Table 2) (Akiyama et al., 2001; Arnberg  et al., 2002; Benko, 2000; Chakrabarti 
et al., 2000; Chmielewicz  et al., 2005; Ebner  et al., 2005; Echavarria, 2009;  Ephros et al., 
2009; Howard  et al., 1999; Ison, 2006; Jones  et al., 2007; Kaneko  et al., 2009; Lim et al., 2005; 
Mori et al., 2003; Robin et al., 2007; Runde et al., 2001; Venard et al., 2000;  Walsh  et al, 2009). 
Most adenoviral infections in patients following HSCT occur during an early post-
transplantation period, within 2-3 months (Ephros et al., 2009; Lion et al., 2010; 
Watcharananan et al., 2010). Adenovirus infections in patients after stem cell 
transplantations can occur throughout the year but there are some reports suggesting 
seasonal fluctuations of adenoviral infections indicating greater incidence in autumn and 
winter, 52-70% (Bil-Lula et al., 2010). 
An intensity of virus replication depends on a site of infection. The highest viral loads are 
observed in gastrointestinal tract infections (even more than 108 copies/g of stool) and in 
upper respiratory tract infections (104 -106 copies/ml). Whole blood viraemia remains at a 
moderate level and usually does not exceed 103 – 104 copies per ml, whereas in plasma 
samples only trace amounts of AdV particles can be detected (< 102 copies/ml). Some of 
patients with moderate viraemia are able to self-eliminate of the virus within 2-4 weeks. 
However most patients presenting disseminated infections (> 107 copies/ml) die due to 
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adenoviral infection within short time (Ephros et al., 2009; Heim et al., 2003; Lion et al., 2003; 
Walls et al., 2005). 
 
Clinical symptoms Involved serotypes 
Acute follicular conjunctivitis and keratoconjunctivitis 1, 3, 4, 5, 7, 8, 9, 11, 16, 19, 26, 27, 
30, 37, 53, 54 
Acute hemorrhagic cystitis (HC) 3, 7, 11, 21, 34, 35 
Acute respiratory disease 1, 2, 3, 4, 5, 6, 7, 14, 21, 30 
Exudative pharyngitis 1, 2, 3, 5, 7 
Gastroenteritis 1, 2, 12, 16, 18, 31, 40, 41, 52 
Hepatitis, appendicitis 1, 2, 3, 5, 7 
Intussusception 1, 2, 5 
Meningitis, encephalitis 2, 3, 7, 12, 32 
Myocarditis 7, 21 
Nephritis and kidney damage 11, 14, 34, 35 
Pertussis−like syndrome 5 
Pharyngitis 1, 2, 3, 5, 7 
Pharyngoconjunctival fever (PCF) 3, 4, 7, 14 
Pneumonia 1, 2, 3, 4, 7, 11, 14, 21, 30, 34, 35 
Prolonged diarrhea 40, 41, 52 
Ulcerative changes in the female genital organs, cervicitis 19, 37 
Urethritis 1, 3, 4, 7, 14, 16, 19, 34, 35, 37, 50 
Table 2. Clinical manifestations of adenoviral infection in stem cell transplant recipients 
(summary table). 
5. Anti-viral response and viral immunoavoidance 
Virus penetration into human organism induces both specific and non-specific response to 
infection. Firstly, virus by binding with the cell receptors activates congenital mechanisms of 
anti-viral defense. An induction of the inflammatory response stimulates interferon 
production by both immunocompetent and non-immunocompetent cells. Macrophages, 
natural killers (NK cells) and complement proteins are also involved in anti-adenovirus 
defense indirectly by killing infected cells or due to production of cytokins such as Il-1, Il-6 
and TNF-α. Additionally, Smith et al. (2008) confirmed the role of the epithelial defensins 
which coat the capsid vertex of adenoviral particle and inhibit virus uncoating in cytoplasm 
of infected cell (Smith & Nemerow, 2008). Another way of virus elimination from the 
organism is induction of pro-apoptotic mechanisms in infected cells due to e.g. p53, TNFα 
and Bax proteins (Randall & Goodbourn, 2008; Russell, 2000, 2009; Smith & Nemerow, 
2008). Very important role in viral clearance is played by acquired immunity mechanisms. 
The cellular response is limited to CD3+ cells activation (both helper and cytotoxic 
lymphocytes) which also produce TNFα and INFɣ. Activation of CD8+ cells due to 
presentation of hexon determinants in MHC I complex leads to eradication of infected cells 
by means of cell perforation and lyses. This mechanism prevents virus replication and 
further spread of viral particles. The humoral response is focused on production of 
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periodic shedding of virus in feaces and respiratory secretions (Akiyama et al., 2001; 
Braithwaite & Russell, 2001; Echavarri´a, 2008; Watzinger et al., 2004). The third possible 
outcome of adenoviral infection is an oncogenic transformation of infected cells, that is 
observed in animal models (Russell, 2009). 
Primary adenoviral infections affect predominantly pediatric population with more than 
50% of children infected before the age of five (Cooper et al., 2003). Children are often 
infected with adenovirus types 1, 2, 3, 4, 5, 7 and 30 which are the most common causes of 
tonsillopharyngitis and pneumonia (Carballal et al., 2002; Faden et al., 2005). These antigenic 
types are also the most frequent in recipients of SCT indicating virus reactivation or droplets 
transmission as most reliable routes of virus spread. AdV infections in immunocompetent 
humans are usually asymptomatic, localized and tend to be self-limited. They are restricted 
to the respiratory system, genitourinary and gastrointestinal tract infections, occasionally 
affecting conjunctiva and cornea. Recipients of HSCT and other imunocompromised 
patients present much broader spectrum of clinical manifestations. According to different 
studies, the estimated rate of AdV infection after HSCT ranges from 3–47% (Akiyama  et al., 
2001; Arnberg  et al., 2002; Ebner  et al., 2005; Howard et al, 1999; Lauer et al., 2004; Mahr & 
Gooding, 1999; Rutala et al., 2006; Stone et al., 2003; Walls et al, 2003; Watcharananan et al, 
2010; Watzinger et al., 2004;) with mortality reaching up to 80% in patients with 
disseminated disease (Akiyama  et al., 2001; Kaneko  et al., 2009; Russell, 2000; Walls et al., 
2003; Watzinger  et al., 2004). The wide range in reported AdV incidence can results from 
different diagnostic methods, variety of body sites analyzed as well as demographic 
differences and lack of strict criteria for defining adenovirus infection or disease. AdV 
infections in immunocompromised patients tend to be invasive. The most common are 
infections of AdVs from subgroup C, followed by A, B and D. They cause exudative 
pharyngitis, acute respiratory disease epidemics, febrile laryngitis, conjunctivitis, 
keratoconjunctivitis, necrotizing enterocolitis, pharyngeal−conjunctival fever and 
hemorrhagic cystitis. Less frequent are testitis, nephritis, arthritis, myocarditis and 
pericarditis. Infections of the gastrointestinal tract are especially frequent in young children 
and include gastroenteritis, mesenteric lymphadenitis, intussusception, hepatitis, and 
appendicitis (Table 2) (Akiyama et al., 2001; Arnberg  et al., 2002; Benko, 2000; Chakrabarti 
et al., 2000; Chmielewicz  et al., 2005; Ebner  et al., 2005; Echavarria, 2009;  Ephros et al., 
2009; Howard  et al., 1999; Ison, 2006; Jones  et al., 2007; Kaneko  et al., 2009; Lim et al., 2005; 
Mori et al., 2003; Robin et al., 2007; Runde et al., 2001; Venard et al., 2000;  Walsh  et al, 2009). 
Most adenoviral infections in patients following HSCT occur during an early post-
transplantation period, within 2-3 months (Ephros et al., 2009; Lion et al., 2010; 
Watcharananan et al., 2010). Adenovirus infections in patients after stem cell 
transplantations can occur throughout the year but there are some reports suggesting 
seasonal fluctuations of adenoviral infections indicating greater incidence in autumn and 
winter, 52-70% (Bil-Lula et al., 2010). 
An intensity of virus replication depends on a site of infection. The highest viral loads are 
observed in gastrointestinal tract infections (even more than 108 copies/g of stool) and in 
upper respiratory tract infections (104 -106 copies/ml). Whole blood viraemia remains at a 
moderate level and usually does not exceed 103 – 104 copies per ml, whereas in plasma 
samples only trace amounts of AdV particles can be detected (< 102 copies/ml). Some of 
patients with moderate viraemia are able to self-eliminate of the virus within 2-4 weeks. 
However most patients presenting disseminated infections (> 107 copies/ml) die due to 
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adenoviral infection within short time (Ephros et al., 2009; Heim et al., 2003; Lion et al., 2003; 
Walls et al., 2005). 
 
Clinical symptoms Involved serotypes 
Acute follicular conjunctivitis and keratoconjunctivitis 1, 3, 4, 5, 7, 8, 9, 11, 16, 19, 26, 27, 
30, 37, 53, 54 
Acute hemorrhagic cystitis (HC) 3, 7, 11, 21, 34, 35 
Acute respiratory disease 1, 2, 3, 4, 5, 6, 7, 14, 21, 30 
Exudative pharyngitis 1, 2, 3, 5, 7 
Gastroenteritis 1, 2, 12, 16, 18, 31, 40, 41, 52 
Hepatitis, appendicitis 1, 2, 3, 5, 7 
Intussusception 1, 2, 5 
Meningitis, encephalitis 2, 3, 7, 12, 32 
Myocarditis 7, 21 
Nephritis and kidney damage 11, 14, 34, 35 
Pertussis−like syndrome 5 
Pharyngitis 1, 2, 3, 5, 7 
Pharyngoconjunctival fever (PCF) 3, 4, 7, 14 
Pneumonia 1, 2, 3, 4, 7, 11, 14, 21, 30, 34, 35 
Prolonged diarrhea 40, 41, 52 
Ulcerative changes in the female genital organs, cervicitis 19, 37 
Urethritis 1, 3, 4, 7, 14, 16, 19, 34, 35, 37, 50 
Table 2. Clinical manifestations of adenoviral infection in stem cell transplant recipients 
(summary table). 
5. Anti-viral response and viral immunoavoidance 
Virus penetration into human organism induces both specific and non-specific response to 
infection. Firstly, virus by binding with the cell receptors activates congenital mechanisms of 
anti-viral defense. An induction of the inflammatory response stimulates interferon 
production by both immunocompetent and non-immunocompetent cells. Macrophages, 
natural killers (NK cells) and complement proteins are also involved in anti-adenovirus 
defense indirectly by killing infected cells or due to production of cytokins such as Il-1, Il-6 
and TNF-α. Additionally, Smith et al. (2008) confirmed the role of the epithelial defensins 
which coat the capsid vertex of adenoviral particle and inhibit virus uncoating in cytoplasm 
of infected cell (Smith & Nemerow, 2008). Another way of virus elimination from the 
organism is induction of pro-apoptotic mechanisms in infected cells due to e.g. p53, TNFα 
and Bax proteins (Randall & Goodbourn, 2008; Russell, 2000, 2009; Smith & Nemerow, 
2008). Very important role in viral clearance is played by acquired immunity mechanisms. 
The cellular response is limited to CD3+ cells activation (both helper and cytotoxic 
lymphocytes) which also produce TNFα and INFɣ. Activation of CD8+ cells due to 
presentation of hexon determinants in MHC I complex leads to eradication of infected cells 
by means of cell perforation and lyses. This mechanism prevents virus replication and 
further spread of viral particles. The humoral response is focused on production of 
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neutralizing antibodies. The neutralizing antibodies recognize HVRs and the fiber 
determinants leading to agglutination of virus particles and interrupting infection of new 
cells. The presence of anti-adenoviral antibodies in patient serum grants permanent 
immunity against AdV (Baldwin et al., 2000; Crawford-Miksza & Schnurr, 1994; Leen et al, 
2008; Russel, 2009; Rux et al., 2003; Schilham et al., 2002; Walls et al., 2003). 
Intensity and length of immunosuppressive therapy are tailored to the risk of graft-rejection 
or graft versus host disease.  
The prevention and therapy of GvHD is crucial in allogeneic HSCT recipients, which 
explains its intensity and diversity by combining drugs (cyclosporine, tacrolimus, 
mycophenolate mofetil) with biological agents (OKT-3, alemtuzumab, ATG) or graft 
engineering methods like T-cell depletion/CD34+ positive selection. Immunosupression 
determinates  stable engraftment and prevents from GvHD, but increases risk of disease 
relapse or opportunistic infections, due to depletion of donor lymphocytes necessary for 
graft-versus-tumor (GVT) effects and delayed immune reconstitution (Gyurkocza et al., 
2010). 
Immune defense against adenoviral infections is hampered by viral abilities for avoidance of 
both humoral and cellular host immune response. By means of E1A (early region 1A) and 
VARNAs (virally associated RNAs) they developed the ability to inhibit human interferons 
α and β. The product of E1B inhibits apoptosis of infected cells.  Moreover, product of E3 
coding region can inhibit a transport of MHC I particles to the cell membrane disturbing 
viral antigens presentation to the cytotoxic lymphocytes (CLS) (Braithwaite & Russell, 2001; 
Lauer et al., 2004; Mahr & Gooding, 1999; Russell, 2000; Stone et al., 2003). Some of E3 
products interfere with pro-inflammatory and cytolytic activity of TNF or remove Fas and 
TRAIL receptors from cell surface (Echavarria, 2009). The fact, that these proteins are 
expressed during early stage of transcription, protects infected cells from immune 
surveillance. 
6. Risk factors for development of adenoviral infection after HSCT 
The hematopoietic stem cell transplantation recipients constitute a group of patients with an 
extremely high risk of death due to opportunistic infections, and among them the AdVs are 
accounted to most challenging pathogens responsible for fatal outcome. The problem of 
AdV infections after HSCT is a consequence of different factors affecting recipient`s 
immunity. Development of graft versus host disease and its prophylaxis or therapy with 
potent immunosuppressants  are the reasons  for  numerous opportunistic infections.  The 
anti-leukemic efficacy and early complications of HSCT result from both intensity of the 
conditioning regimen and the graft-versus-leukaemia (GVL) effect. However, conditioning 
strategies with high doses of cytotoxic and immunosupressive drugs lead to tissue damage, 
cytokine storm and profound impairment of patients immunity, thus increasing patient`s 
risk of de novo infection or reactivation of latent adenovirus during a post-transplantation 
period. Reduced-intensity conditioning (RIC) regimens lower the risk for AdV infection due 
decreased organ damage and lower proinflammatory cytokines secretion, hence protecting 
the patient from aGvHD but maintaining an effect of GVL (Couriel et al., 2004; Gyurkocza et 
al., 2010; Hill& Ferrara, 2000; Pérez-Simón et al., 2002, 2005). The clinical course of AdV 
infection after HSCT is different from the one observed in immunocompetent individuals. 
AdVs usually cause permanent and stubborn infections in those patients because 
immunological response to adenoviruses following SCT is very poor. In rare situations, AdV 
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can be responsible for graft rejection or delayed implantation of stem cells (Hierholzer, 1992; 
Ison, 2006).   
Risk factors affecting patient`s susceptibility to adenovirus infections after stem cells 
transplantation are well known (Figure 2). Many reports indicate increased morbidity 
among recipients of allogeneic grafts from matched unrelated donors (MUD) in comparison 
to partially matched family donors (PMFD) (Baldwin et al. 2000; Bruno et al., 2003; Ebner et 
al., 2005; Gu et al., 2003; Hale et al., 1999; Howard et al., 1999; Ison, 2006; Legrand et al., 
2001; Lion et al., 2003). An incidence of AdV infections and patient`s mortality due to 
infection in this group reach about 5-47% and 60%, respectively (Hierholzer, 1992; Howard 
et al., 1999; Leruez-Ville et al., 2006; Lim et al., 2005; Robin et al., 2007; Runde et al., 2001; 
Venard et al., 2000; Walls et al., 2005). In recipients of autologous transplantations AdV 
infections prevalence is much lower, about 1-14% (Baldwin et al., 2000; Bruno et al., 2003; 
Hale et al., 1999; Howard et al., 1999; Teramura et al., 2004). Significant differences in 
occurrence of adenoviral infections are believed to result from more aggressive and longer 
immunosuppressive therapy after allogeneic transplantations (Walls et al., 2003). Lack of 
endogenous T-cell immunity makes patient more predisposing to development of 
adenoviral infection and disseminated disease with fatal outcome (Bil-Lula et al., 2010; 
Feuchtinger et al., 2008; Watcharananan et al., 2010). Therefore, delayed immune recovery 
after stem cell transplantation has critical impact on progression of adenoviral infections. 
Moreover, second allotransplantation also increases patient`s susceptibility to AdV infection 
(Bruno et al., 2003).  
Another risk factor for development of adenoviral infections in HSCT recipients is patient`s 
age. There are many reports confirming that children and adolescents are at greater risk of 
adenovirus infection than adults (Robin et al., 2007; Walls et al., 2005). Greater susceptibility 
of younger patients may results from immaturity and worse efficiency of immune system in 
comparison to older recipients. Moreover, persistent infections are predominantly caused by 
AdV from species C, which are common etiological factor of adenoviral infections in a 
childhood. Combination of immunosupression and young age of graft recipients can lead to 
intensified replication of adenoviruses and to greater viral load in clinical samples (more 
than 105 copies /ml) in comparison to adult recipient (viral load usually not exceeds 103 
copies /ml) (Baldwin et al., 2000; Bruno et al., 2003; Chakrabarti et al., 2002; Howard et al., 
1999; Heim et al., 2003; Ison, 2006; Robin et al., 2007; Walls et al., 2003). 
The role of T-cells in controlling the AdV infection is unquestionable. The graft engineering 
methods involving ex-vivo removal of T-cells by CD34+ positive selection or by lymphocyte 
depletion are very effective in respect of GvHD reduction but cause profound long-term T-
cell deficiency and function impairment. Adenoviral infections due to reactivation of latent 
virus are also reported more frequently (more than 70%) in recipients of manipulated grafts 
in comparison to those who received graft containing donor`s lymphocytes (25%). 
Moreover, some reports suggested delayed recovery and lower overall survival in patients 
undergoing T-cells depletion (Chakrabarti et al, 2002; Ison, 2006; Lion et al., 2003; Venard et 
al., 2000; Walls et al., 2003, 2005). 
The development and severity of graft versus host disease are typically identified 
independent risk factors for progression of adenoviral infection after stem cell 
transplantation. The mechanism of GvHD induction is multifactorial and despite intensive 
research only moderately understood, the incompatibilities in HLA and in minor 
histocompatibility antigens (mHA) are generally recognized causes for its occurrence 
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neutralizing antibodies. The neutralizing antibodies recognize HVRs and the fiber 
determinants leading to agglutination of virus particles and interrupting infection of new 
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can be responsible for graft rejection or delayed implantation of stem cells (Hierholzer, 1992; 
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(Gyurkocza et al., 2010). It was reported that moderate to severe aGvHD and its therapy 
may facilitate virus replication in recipients of SCT (Baldwin et al., 2000; Bil-Lula et al, 2010; 
Bruno et al., 2003; Ison, 2006; Robin et al., 2007; Runde et al., 2001;  Watcharananan  et al., 
2010). GvHD requires immunosuppressive therapy which lowers the number of 
lymphocytes and hampers the immunity of the recipient, thus enabling adenoviral 
infections. A low lymphocyte count due to non-specific T-cell depletion or delayed T-cell 
reconstitution is considered as important predictor for detection of adenoviral infections. An 
inadequate humoral response due to B lymphocyte impairment contributes to greater 
susceptibility to AdV infection (Chakrabarti et al., 2000, 2002; Heemskerk et al., 2005). 
Some authors emphasize that presence of adenovirus in peripheral blood or plasma is an 
indicator of impending symptomatic adenoviral disease and multiorgan failure in patients 
undergoing HSCT. Chakrabarti et al. (2002) and others confirmed a strong correlation 
between the presence of adenovirus in whole blood/plasma and an increased mortality due 
to infection (9-86%) (Chakrabarti et al., 2002; Ebner et al., 2005; Echavarria  et al, 2001; Lion  
 
 
Fig. 2. Risk factors for adenoviral infections in patients after haematopoietic stem cell 
transplantation. 
 
Adenoviral Infection – Common Complication Following Hematopoietic Stem Cell Transplantation 
 
543 
et al., 2003; Robin et al, 2007; Schilham et al., 2002; Watcharananan et al., 2010). High viral 
load in plasma samples (106-107 copies/ml) should be considered as a risk factor for serious 
post-transplantation complications (Ison, 2006; Claas et al., 2005), but the issue is still 
controversial because other authors did not confirm the relationship between viral load and 
severity of infection (Walls et al., 2005). In some studies were reported patients who despite 
high viral load in blood recovered from adenoviral infection without any treatment. It 
suggests that not each adenoviral infection needs antiviral treatment (Lankester et al., 2002; 
Schilham et al., 2002).  
It needs to be mentioned that the source of progenitor cells also plays a significant role in 
development of adenoviral infection. It was confirmed that transplantation of peripheral 
blood progenitor cells (PBPCs) increases an incidence of AdV infections in hematological 
patients in comparison to bone marrow transplantations (BMT) due to high number of 
lymphocytes transferred with the graft. Adenovirus latency in peripheral lymphocytes may 
be a source of infection in those patients (Runde et al., 2001). On the other hand, unrelated 
cord blood transplantations (UCB) are suggested to be an independent risk factor for AdV 
infections (Robin et al., 2007) due to lack of mature lymphocytes in CB regarded as the major 
component of antiviral defense. Therefore it is still controversial issue. 
7. Co-infections in patients undergoing stem cell transplantation 
Recipients of stem cell transplantations with AdV infection are prone to life-threatening 
multiple opportunistic infections. Simultaneous infections of adenoviruses and CMV (4,3- 
73%), EBV (2,8-34%),  polyoma BK (BKV) (1,7-20%),  HSV (6,7-26,6%) or RSV (3,8-13%) are 
most frequently reported (Baldwin et al., 2000; Bruno et al., 2003; Chakrabarti et al., 2002; 
Leruez-Ville et al., 2006; Lion et al., 2003; Myers et al., 2005; Watcharananan et al., 2010). Co-
infections of AdV and BKV are usually detected in urinary tract of immunocompromised 
patients leading to intensification of hemorrhagic cystitis sympthoms (Akiyama et al., 2001). 
It was also found that CMV viraemia leads to more than 4-fold increase in patient`s risk for 
development of AdV infection (Baldwin et al., 2000; Watcharananan et al., 2010). In rare 
cases, co-infections of AdV and other viruses such as: HSV1, RSV, EBV and rotaviruses were 
observed (Legrand et al., 2001; Robin et al., 2007). Many reports suggested that infection of 
one AdV serotype increases patient`s risk for co-infection with second type of human 
adenovirus leading to extensive organ and whole system involvement (Echavarria et al., 
2006; Kroes et al., 2007; Watcharananan et al., 2010). 
8. Diagnostic methods for adenovirus detection and identification 
Permanently growing number of hematopoietic transplantations in recent years and high 
risk of viral complications following this procedure demands an implementation of better 
and more effective diagnostics methods for detection and monitoring of viral infections. 
There are several methods commonly used for adenovirus detection and identification in 
clinical samples. Serological tests, virus isolation in cell culture, microscopic techniques and 
molecular methods found their way into clinical practice.  
Virus isolation in cell culture is still considered a “gold standard” for detection of adenoviral 
infection. Different cell lines like A549, Graham 293 and HEp-2 can be used for virus 
isolation from clinical samples such as stool, throat swabs, conjunctival swabs, urine and 
biopsy specimens. Within several days of culturing, cythopatic effect as clumping and cell 
rounding can be observed (Figure 3). 
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(Gyurkocza et al., 2010). It was reported that moderate to severe aGvHD and its therapy 
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Fig. 3. Microscope image of A549 cells. (A) native culture; (B) cythopatic effect occurring 
within 48 hours since AdV21 infection (species B). Own collection. 
This reference method provides virus identification and typing by means of serum 
neutralization (SN), hemagglutination inhibition (HI) and complement fixation tests. 
Unfortunately, the culture technique is laborious, time-consuming and lacks sensitivity to 
detect virus in the early phase of infection. It can also be inhibited by neutralizing antibodies 
or other interfering substances (Echavarria, 2009; Huang & Turchek, 2000; Raboni et al., 
2003). Nowadays, due to its disadvantages it is replaced by new, more reliable methods like 
molecular tests. 
The next conventional methods for detection of adenoviral infection are serological tests. 
They are used for indirect antigen detection on capsid surface (IFA, RIA) allowing for virus 
identification in highly concentrated samples of respiratory secretion, pharyngeal swabs and 
stool or to confirm AdV infection on the basis of specific antibodies detection. ELISA tests 
are also used for identification of AdV-antibodies in patient`s serum (Echavarria, 2009; 
Hierholzer et al., 1993; Madisch et al., 2005; Raboni et al., 2003). Although serological tests 
are commonly used in routine diagnostics of viral infections they are not recommended in 
adenoviral infections due to their insensitivity, low specificity, false negative results during 
the window period and difficulties arising from virus variability (Chirmule et al., 1999; 
Chmielewicz et al., 2005; Crawford-Miksza & Schnurr, 1994; Echavarria, 2009; Raboni et al., 
2003). Furthermore, serological tests are useless in recipients of SCT due to profound 
immunosuppression and using of anti-viral drugs.  
The characteristic icosahedral morphology of adenoviruses can be utilized in virus detection 
by use of electron microscopy (EM) and other microscopic techniques. Infected cell are 
characterized by presence of enlarged nuclei containing crystalline inclusions of adenoviral 
particles. Nonetheless, this method is limited by access to unique equipment and EM 
requires a large number of viral particles in clinical sample hence it can be mainly used in 
diagnostics of acute gastroenteritis and upper respiratory tract infections (Chirmule et al., 
1999; Roingeard, 2008). 
Numerous limitations of conventional methods make these techniques impractical in 
routine diagnostics. The culture collection, serological tests and microscopic techniques are 
laborious, time-consuming, and insensitive especially in an early phase of the infection. 
Hence in recent years, molecular methods dominate virus detection and identification in 
clinical practice. Identification of adenovirus by polymerase chain reaction (PCR) facilitates 
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accurate and rapid diagnostics and surveillance. PCR is currently the most widespread 
method used for detection of microbial infections. In comparison to conventional techniques 
it offers high sensitivity and specificity as well as possibility to obtain a reliable result within 
several hours. This method allows detecting even small number of viral particles in largely 
cell-free fluids such as plasma, serum, urine (centrifuged), cerebrospinal fluids and others, 
preferably before clinical manifestation and tissue damage (Ephros et al., 2009). It can also 
be implemented for detection of AdV serotypes which are potentially considered as not 
growing in routine cell culture. Moreover, polymerase chain reaction may be employed for 
detection of variance and mutations in virus genome (Powledge, 2004). In combination with 
other methods such as sequencing of hyper variation regions (HVRs) or restriction fragment 
length analysis, PCR may be used for AdV typing. During last years, the quantitative real-
time PCR (RQ-PCR) technique has been successfully implemented more often in viral 
diagnostics (Bil-Lula et al., 2010; Claas et al., 2005; Echavarria et al., 1999, 2001; Gu et al., 
2003; Heim et al., 2003; Hierholzer et al., 1993; Lankester et al., 2002; Lion et al., 2003; 
Watzinger et al., 2004). Use of highly specific probes allows sensitive detection and 
quantification of viral equivalents in clinical samples. Sensitive and reliable monitoring of 
viral replication in immunocompromised patient is extremely important due to possibility 
for dissemination of infection and poor outcome. It has also a prognostic significance for the 
patient. Moreover, monitoring of active replication and increasing viral load in clinical 
samples constitutes the basis for differentiation of active and latent infection in recipients of 
stem cell transplantations. On the other hand, an early detection of adenovirus due to highly 
sensitive RQ-PCR creates the opportunity for reduction of immunosuppressive therapy or 
early initiation of preemptive anti-viral agents before onset of fulminant disease, 
simultaneously determining therapy effectiveness (Mori et al., 2003). It was confirmed that 
weekly surveillance of samples for AdVs and early intervention with anti-AdV agents 
results in significant reduction in the disseminated disease rate and fatal outcomes 
(Sivaprakasam et al., 2007; Yusuf et al., 2006). 
9. Treatment strategies for adenoviral infections 
There are many reports describing treatment trials of adenoviral infections in recent years. 
However, treatment of AdV infections remains a serious problem due to lack of 
unequivocally proven effectiveness of used drugs. Therefore adenoviral infections in 
immunocompromised patients should be considered as a serious, life-threatening 
complication. 
Due to numerous toxicities and limitations, administration of anti-AdV drugs should be 
tailored to the patients situation and risk of dismal outcome.  In severe AdV infections 
usually cidofovir (CDV) or ganciclovir are administered (Bordigoni et al., 2001; Hoffman et 
al., 2001; Legrand et al., 2001). Other anti-viral drugs such as vidarabine and ribavirine may 
be implemented (Bordigoni et al., 2001; Miyamura et al., 2000). It was demonstrated that 
ribavirin (usually used in treatment of HCV and RSV infections) is highly effective in 
treatment of localized AdV infections in urinary tract but is of limited efficacy in 
disseminated infections (Bordigoni et al., 2001; Gavin & Katz, 2002; Hoffman  et al., 2000; 
Lankester et al., 2004). Some studies also confirmed partially the ability to virus elimination 
from urine samples after cidofovir administration in patients suffering from hemorrhagic 
cystitis. Unfortunately, CDV shows numerous side effects such as renal toxicity, 
carcinogenicity and toxic injury of muscles (Bordigoni et al., 2001; Feuchtinger et al., 2006, 
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particles. Nonetheless, this method is limited by access to unique equipment and EM 
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accurate and rapid diagnostics and surveillance. PCR is currently the most widespread 
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length analysis, PCR may be used for AdV typing. During last years, the quantitative real-
time PCR (RQ-PCR) technique has been successfully implemented more often in viral 
diagnostics (Bil-Lula et al., 2010; Claas et al., 2005; Echavarria et al., 1999, 2001; Gu et al., 
2003; Heim et al., 2003; Hierholzer et al., 1993; Lankester et al., 2002; Lion et al., 2003; 
Watzinger et al., 2004). Use of highly specific probes allows sensitive detection and 
quantification of viral equivalents in clinical samples. Sensitive and reliable monitoring of 
viral replication in immunocompromised patient is extremely important due to possibility 
for dissemination of infection and poor outcome. It has also a prognostic significance for the 
patient. Moreover, monitoring of active replication and increasing viral load in clinical 
samples constitutes the basis for differentiation of active and latent infection in recipients of 
stem cell transplantations. On the other hand, an early detection of adenovirus due to highly 
sensitive RQ-PCR creates the opportunity for reduction of immunosuppressive therapy or 
early initiation of preemptive anti-viral agents before onset of fulminant disease, 
simultaneously determining therapy effectiveness (Mori et al., 2003). It was confirmed that 
weekly surveillance of samples for AdVs and early intervention with anti-AdV agents 
results in significant reduction in the disseminated disease rate and fatal outcomes 
(Sivaprakasam et al., 2007; Yusuf et al., 2006). 
9. Treatment strategies for adenoviral infections 
There are many reports describing treatment trials of adenoviral infections in recent years. 
However, treatment of AdV infections remains a serious problem due to lack of 
unequivocally proven effectiveness of used drugs. Therefore adenoviral infections in 
immunocompromised patients should be considered as a serious, life-threatening 
complication. 
Due to numerous toxicities and limitations, administration of anti-AdV drugs should be 
tailored to the patients situation and risk of dismal outcome.  In severe AdV infections 
usually cidofovir (CDV) or ganciclovir are administered (Bordigoni et al., 2001; Hoffman et 
al., 2001; Legrand et al., 2001). Other anti-viral drugs such as vidarabine and ribavirine may 
be implemented (Bordigoni et al., 2001; Miyamura et al., 2000). It was demonstrated that 
ribavirin (usually used in treatment of HCV and RSV infections) is highly effective in 
treatment of localized AdV infections in urinary tract but is of limited efficacy in 
disseminated infections (Bordigoni et al., 2001; Gavin & Katz, 2002; Hoffman  et al., 2000; 
Lankester et al., 2004). Some studies also confirmed partially the ability to virus elimination 
from urine samples after cidofovir administration in patients suffering from hemorrhagic 
cystitis. Unfortunately, CDV shows numerous side effects such as renal toxicity, 
carcinogenicity and toxic injury of muscles (Bordigoni et al., 2001; Feuchtinger et al., 2006, 
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2008). Despite all these side effects, lack of other more effective medicaments dictates the 
application of these drugs in therapy of adenoviral infections of urinary tract, 
gastroenterititis and pneumonia (Bruno et al., 2003; Ebner et al., 2006; Heim et al., 2003; 
Hoffman et al., 2001; Legrand et al., 2001, Uchio et al., 2007). New antiviral agents are under 
development. CMX001 is a new formulation of cidofovir. It is oral lipid conjugate of CDV, 
potentially highly effective against all dsDNA viruses, including adenoviruses (Fowler et al., 
2010; Randhawa et al., 2006). Novel form of cidofovir is characterized by convenient oral 
supply, decreased dose and lack of affinity to kidney tissue. Due to insufficient effectiveness 
of previously used drugs, new clinical trials are still carrying on. New candidates for 
treatment of adenoviral infections are also zalcitabine and stavudine, commonly used as 
anti-HIV agents (Inoue et al., 2009; Romanowski et al., 2009). Zalcitabine is a reverse 
transcriptase inhibitor which may be used in treatment of AdV infections caused by 
serotypes: 2, 3, 4, 8, 19 and 37. Unfortunately, only low dosed of zalcitabine may be 
administrated because of its mitochondrial toxicity and possibility of peripheral neuropathy 
and esophageal varices. Stavudine, in turn, is an analogue of pyrimidine nucleoside which 
inhibits the activity of reverse transcription. It may be potentially used in treatment of AdV3 
and AdV4 infections (Inoue et al., 2009; Romanowski et al., 2009; Uchio et al., 2007). 
Timing of therapeutical intervention plays important role, too. There are many reports 
confirming the significant role of early detection of viraemia before the appearance of 
clinical symptoms (Legrand et al, 2001; Teramura et al., 2004; Watzinger et al., 2004). 
Initiation of antiviral treatment before the onset of invasive disease is beneficial.  It was 
documented that even intravenous supplementation of antiviral agent during active virus 
replication does not result in recovery in some patients (Chakrabarti et al, 1999). Therefore, 
an early diagnosis of infection and adequately early implementation of antiviral therapy can 
significantly reduce the effects of AdV infections (Chakrabarti et al., 2002; Gavin & Katz, 
2002; Sivaprakasam et al., 2007; Walls et al., 2003). Drug cytotoxicity and its limited efficacy 
in adenoviral infections should encourage clinicians to focus on an earlier diagnostics and 
monitoring of adenoviral infections.  
In recent years, immunomodulation has been most frequently proposed as a new 
therapeutic strategy. Adoptive transfer of T-cell immunity from the donor to the recipient 
(DLI) and infusion of donor immunoglobulins (IVIG) combined with reduced 
immunosupression has become a new treatment option for patients with an insufficient 
number of AdV-specific T-cells. It was demonstrated that infusion of donor AdV-specific 
lymphocytes T is well tolerated and may lead to partially reconstruction of recipient`s 
immune system leading to prophylactics or treatment of adenoviral infections (Amrolia et 
al., 2006; Bordigoni et al., 2001; Feuchtinger et al., 2008; Fujita et al., 2008; Ison, 2006; Lion et 
al., 2010). Successful reduction of AdV replication is achieved mainly due to infusion of 
selected AdV-specific lymphocytes. Infusion of unselected donor lymphocytes is associated 
with higher risk of aGvHD due to high alloreactivity which requires more aggressive 
immunosupresive therapy conducing development of viral infections (Walter et al., 1995). 
The sufficient immune response is achieved mainly due to infusion of combined 
CD4+/CD8+ (60%) or solely CD4+ (40%) cells (Feuchtinger et al., 2008). However, 
heterogeneity of Adenoviridae family in the context of immunomodulation is questionable. 
Human immune system recognizes the surface determinants of AdV capsid which are 
highly variable between AdV serotypes. Hence, the success of T-cells administration may be 
dependent on infecting serotype (Ebner et al., 2006). On the other hand, human 
adenoviruses exhibit high cross-reactivity against different clinically relevant species of AdV 
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and therefore there is a large chance that successful DLI may become a new therapeutic 
strategy for treatment of adenoviral infections after SCT, as antiviral therapy has revealed 
limited success (Bordigoni et al, 2001; Feuchtinger et al., 2008; Lion et al., 2010). Lion et al. 
(2010) suggested that initiation of cidofovir/adoptive transfer of AdV-specific T cells may 
reduce proliferation of adenovirus until recovery of host immune system. These 
considerations suggest that simultaneous detection and treatment of adenoviral infection at 
early stage might prevent life-treatening disseminated infections in recipients of 
hematopoietic stem cell.  
Anti-adenovirus treatment needs careful consideration in many clinical aspects. The 
knowledge on AdV pathogeneicity needs more elucidation. The retrospective studies of 
Wall et al. (2005), Hale et al. (2003)  and others proved that there is a possibility for 
elimination of high viraemia without any treatment due to sufficient host T-cell response 
(Ephros et al., 2009). The opportunity for ‘watch and wait’ strategy is a new unexplored 
clinical option, but the identification of patients with benign clinical course is impossible yet.  
10. Conclusion 
Taking into account that more than 50000 of hematopoietic stem cell transplantations are 
performed every year and nearly 10000 originate from unrelated donors, the number of 
patients who may be affected from adenoviral infections seems to be significant. In view of 
worldwide distribution of adenoviruses, numerous routes of infection and limited 
effectiveness of anti-AdV treatment, adenoviral infections in patients undergoing 
hematopoietic stem cell transplantations should be always considered as serious, life-
threatening post-transplant complication which demands rapid and unequivocal diagnosis 
defining patient`s outcome. 
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1. Introduction  
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment. 
More than 15,000 procedures are performed worldwide each year for a number of 
hematological malignancies such as acute myeloid and lymphoid leukemia, and bone 
marrow failure syndromes (Gratwohl et al. 2002; Frassoni, 2004). It is predicted that 
transplantation rates for allo-HSCT will continue at the same or higher level in the 
immediate future (Gratwohl et al. 2002). Despite clinical cure in 20-70% of all patients, 
depending on disease presentation, long term sequelae of immunosuppression, 
chemotherapy toxicities and graft-versus-host disease (GvHD) debilitate a large number of 
patients (Gratwohl et al. 2002). Moderate to severe GvHD develops in 40-50% of patients 
undergoing allo-HSCT (Bearman et al. 1988; Weisdorf et al. 1990; Roy et al. 1992; Hings et al. 
1994). Factors limiting the efficacy of this treatment are death due to recurrence or 
treatment-related death due to infection or organ failure in the cytopenia and later 
immunosuppressed phase immediately post-HSCT. Over the last decades, the cumulative 
effects of improvements in supportive care, drug dosing, stem cell technology and 
prophylaxis of GvHD have led to an increased number of complete remissions (Devergie, 
2004). However, with the increasing number of transplants performed and the growing 
number of survivors, a shift in clinical focus from not only improving survival but also 
improving short and long-term quality of life has emerged (Andrykowski et al. 1995). 
Patients in the treatment and recovery phase of HSCT commonly experience adverse 
physical and emotional reactions. Fatigue and muscle weakness can limit ability to 
accomplish activities of daily living. Additionally, depression, anxiety, fear, and frustration 
add to the difficulties of recovering from HSCT (Syrjala et al. 1993; Andrykowski et al. 1995). 
Several studies confirm that high levels of physical and psychological stress have been 
observed in patients prior to and at the start of HSCT and during follow-up periods (Baker 
et al. 1997; Molassiotis & Morris, 1997; McQuellon et al. 1998; Fife et al. 2000). The 
mechanisms are not fully known, but it is assumed that several factors such as total body 
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Several studies confirm that high levels of physical and psychological stress have been 
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mechanisms are not fully known, but it is assumed that several factors such as total body 
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irradiation (TBI), chemotherapy, GvHD, infections, long-term inactivity or bed rest and side-
effects from medication can contribute to the physical and emotional weakening of the 
patient. Recipients of allo-HSCT with low Vitamin D levels and low bone mineral density 
were likely to have received corticosteroids, have experienced GVHD and an elevated 
parathyroid hormone level (Sproat et al. 2011; Massenkeil et al. 2001). Vitamin D 
insufficiency and deficiency can cause osteomalacia, bone pain, muscle weakness, 
musculoskeletal pain, headache, fatigue, and may precipitate or exacerbate osteopenia and 
osteoporosis and increase risk of skeletal fracture (Knutsen et al. 2010; Sproat et al. 2011). 
Patients that have undergone HSCT experience treatment-related symptoms during and 
after treatment that can affect health related quality of life (HR-QOL). Patients experience 
multiple somatic, affective and cognitive symptoms during and after aggressive cancer 
treatment, where eleven to thirteen simultaneously occurring symptoms have been reported 
(Portenoy et al. 1994). During hospitalization for standard allo-HSCT, patients are typically 
on prolonged bed rest, and experience complications from the myeloablative treatment, ie. 
acute GvHD, side effects from medications (immunosuppression & steroids), frequent 
infections and psychological reactions that can be debilitating. It is reported that HR-QOL is 
lowest during inpatient time (Grulke et al. 2011). The most commonly reported symptoms 
are fatigue, diarrhea, insomnia, poor appetite, diminished concentration, mouth dryness, 
dyspnoea, loss of hair and poor body image perception (Jarden et al. 2009; Molassitis et 
al.1997; Larsen et al. 2007). After HSCT, fatigue, dyspnoea and insomnia remain at elevated 
levels (Grulke et al. 2011). Psychosocial wellbeing after transplant is influenced by mucositis 
toxicity, and other side effects, and psychological factors as anxiety, distress and social 
support have a significant impact on how severely patients experience mouth pain (Schulz-
Kindermann et al. 2002) Fatigue is one of the most frequent and distressful side effects 
reported by patients who have undergone HSCT (Jarden et al. 2009; So et al. 2003), and it 
has been shown that physical activity decreased and this decline coincided with diminished 
physical, emotional, role and cognitive functioning during the initial post transplantation 
period (Danaher et al. 2006). Bevans et al. found that patients experienced multiple 
symptoms and high symptom distress after allo-HSCT conditioning (Bevans et al. 2008) 
Further, fatigue was the main symptom interfering with daily life in 79% of patients 
(Molassiotis & Morris, 1999), and in 11% of patients at 100 days post allo-HSCT (Bevans et 
al. 2008). Loss of physical strength seem to be more pronounced in patients on corticosteroid 
treatment, and the causes of an impairment of physical performance are not fully 
understood, though low activity levels have been suggested to be a substantial contributor 
(Carlson et al. 2006). One study in patients undergoing HSCT showed a correlation between 
the number of symptoms experienced and poor functional status and general health (Larsen 
et al. 2007) and in another study, changes in HRQoL could be explained entirely by changes 
in functional limitations and somatic symptoms (Broers et al. 2000). Further, symptom 
bother from GVHD had a direct effect on functional performance (Mitchell et al. 2010). A 
Danish study found patients prior to allo-HSCT to have lower VO2 max scores and elevated 
fatigue levels than the normal population, and these scores were unchanged six months 
after transplantation (Kalo et al. 2007). Furthermore, persons diagnosed with hematological 
disease have difficulty returning to the work force (deBoer et al. 2008) and have an increased 
risk for early retirement (Carlsen et al. 2008), while unemployed leukaemia patients, 
especially those with lower social support have significantly elevated levels of stress, 
anxiety, and depression (deBoer et al. 2008). In HSCT, predictors of slower return to work 
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include physical dysfunction and female gender (Kirchhoff AC et al. 2010). Maintaining 
daily function and reducing fatigue and treatment-related symptoms can be important goals 
and there is therefore, a continued need for nonpharmacological strategies that address the 
specific impairments experienced by patients undergoing allo-HSCT. 
There is a rapidly increasing literature on the effects of exercise on cancer rehabilitation, 
especially for breast cancer patients, on whom the majority of research has been conducted 
(Courneya et al. 2011, Conn et al. 2006). Despite that physical exercise showed positive 
effects on cardiorespiratory fitness, treatment-related symptoms and physiological effects, 
the extent of these positive results still need to be established. A qualitative and quantitative 
review and meta-analysis found only small to moderate effect of physical activity 
interventions on these outcomes (Schmitz et al. 2005; Conn et al. 2006). Physical activity is 
reported as being well tolerated in cancer survivors during and after treatment, however, 
conclusions about adverse effects are inconclusive (Schmitz et al. 2005). Recent guidelines 
for exercise prescription for cancer survivors from the American College of Sports Medicine 
(Schmitz et al. 2010) report no contraindication for starting an exercise program in patients 
undergoing either autologous or allogeneic HSCT – however, issues regarding, the ideal 
time for starting a program safely and effectively, type of program, frequency, intensity and 
duration is not confirmed, especially in relation to the HSCT treatment trajectory. Exercise 
has been proposed as a nonpharmacologic adjuvant therapy to combat the physiological 
and psychological symptoms of HSCT (Wiskemann & Huber, 2008). However, little work 
exists in utilizing exercise interventions specifically in the allo-HSCT setting. It is 
documented that there is a decline in exercise levels in cancer patients from prediagnosis to 
postdiagnosis (Courneya et al.1997) and more specifically, a low level of “naturally-
occurring” exercise amongst patients undergoing HSCT is reported, suggesting that a 
structured intervention may be necessary in order to promote exercise in this population 
(Courneya et al. 2000). The majority of the earlier research done in adult patients with 
hematological disease is in the context of high dose chemotherapy with stem cell support 
(autologous HSCT or HD-SCS). To date, there are eight published studies that incorporated 
exercise regimes in the high dose chemotherapy-stem cell support context (HD- SCS) 
(Coleman et al. 2003; Decker et al 1989; Hayes et al. 2003, Dimeo et al. 1996, 1997, 1999, 2003, 
including one on-going study (Peerson et al. 2010), and five studies in mixed HD-SCS and 
allo-HSCT populations (Dimeo et al. 1999, Baumann et al. 2005; Wilson et al. 2005, Knols et 
al. 2010, Danaher Hacker et al. 2011). There are however fundamental and important 
differences in the two types of treatment (HD-SCS and allo-HSCT) including the 
conditioning regimes, i.e. total body irradiation in allo-HSCT, and origin of stem cells, i.e. 
patients undergoing HD-SCS are supported with their own stem cells, and therefore the 
donor related challenges (GvHD) in allo-HSCT are not present, and lastly, the overall 
duration of hospitalization for HD-SCS is much shorter compared to allo-HSCT. One 3 year 
prospective study, found that patients undergoing HD-SCS had better self-rated physical 
function (symptomotology, physical status and energy level) as compared to the allo-HSCT 
group (Prieto et al 2005). The HD-SCS and mixed group (HD-SCS and allo-HSCT, and age) 
exercise-based study sizes ranged between 12-70 participants. There are five randomized 
trials (Peerson et al. 2010; Baumann et al. 2005; Coleman et al. 2003; Hayes et al. 2004; Dimeo 
et al. 1996), one study used a minimization procedure (Knols et al. 2010) and six single-
group trials (Danaher Hacker et al. 2011; Wilson et al. 2005; Decker et al 1989; Dimeo et al. 
 
New Advances in Stem Cell Transplantation 
 
558 
irradiation (TBI), chemotherapy, GvHD, infections, long-term inactivity or bed rest and side-
effects from medication can contribute to the physical and emotional weakening of the 
patient. Recipients of allo-HSCT with low Vitamin D levels and low bone mineral density 
were likely to have received corticosteroids, have experienced GVHD and an elevated 
parathyroid hormone level (Sproat et al. 2011; Massenkeil et al. 2001). Vitamin D 
insufficiency and deficiency can cause osteomalacia, bone pain, muscle weakness, 
musculoskeletal pain, headache, fatigue, and may precipitate or exacerbate osteopenia and 
osteoporosis and increase risk of skeletal fracture (Knutsen et al. 2010; Sproat et al. 2011). 
Patients that have undergone HSCT experience treatment-related symptoms during and 
after treatment that can affect health related quality of life (HR-QOL). Patients experience 
multiple somatic, affective and cognitive symptoms during and after aggressive cancer 
treatment, where eleven to thirteen simultaneously occurring symptoms have been reported 
(Portenoy et al. 1994). During hospitalization for standard allo-HSCT, patients are typically 
on prolonged bed rest, and experience complications from the myeloablative treatment, ie. 
acute GvHD, side effects from medications (immunosuppression & steroids), frequent 
infections and psychological reactions that can be debilitating. It is reported that HR-QOL is 
lowest during inpatient time (Grulke et al. 2011). The most commonly reported symptoms 
are fatigue, diarrhea, insomnia, poor appetite, diminished concentration, mouth dryness, 
dyspnoea, loss of hair and poor body image perception (Jarden et al. 2009; Molassitis et 
al.1997; Larsen et al. 2007). After HSCT, fatigue, dyspnoea and insomnia remain at elevated 
levels (Grulke et al. 2011). Psychosocial wellbeing after transplant is influenced by mucositis 
toxicity, and other side effects, and psychological factors as anxiety, distress and social 
support have a significant impact on how severely patients experience mouth pain (Schulz-
Kindermann et al. 2002) Fatigue is one of the most frequent and distressful side effects 
reported by patients who have undergone HSCT (Jarden et al. 2009; So et al. 2003), and it 
has been shown that physical activity decreased and this decline coincided with diminished 
physical, emotional, role and cognitive functioning during the initial post transplantation 
period (Danaher et al. 2006). Bevans et al. found that patients experienced multiple 
symptoms and high symptom distress after allo-HSCT conditioning (Bevans et al. 2008) 
Further, fatigue was the main symptom interfering with daily life in 79% of patients 
(Molassiotis & Morris, 1999), and in 11% of patients at 100 days post allo-HSCT (Bevans et 
al. 2008). Loss of physical strength seem to be more pronounced in patients on corticosteroid 
treatment, and the causes of an impairment of physical performance are not fully 
understood, though low activity levels have been suggested to be a substantial contributor 
(Carlson et al. 2006). One study in patients undergoing HSCT showed a correlation between 
the number of symptoms experienced and poor functional status and general health (Larsen 
et al. 2007) and in another study, changes in HRQoL could be explained entirely by changes 
in functional limitations and somatic symptoms (Broers et al. 2000). Further, symptom 
bother from GVHD had a direct effect on functional performance (Mitchell et al. 2010). A 
Danish study found patients prior to allo-HSCT to have lower VO2 max scores and elevated 
fatigue levels than the normal population, and these scores were unchanged six months 
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al. 2010, Danaher Hacker et al. 2011). There are however fundamental and important 
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prospective study, found that patients undergoing HD-SCS had better self-rated physical 
function (symptomotology, physical status and energy level) as compared to the allo-HSCT 
group (Prieto et al 2005). The HD-SCS and mixed group (HD-SCS and allo-HSCT, and age) 
exercise-based study sizes ranged between 12-70 participants. There are five randomized 
trials (Peerson et al. 2010; Baumann et al. 2005; Coleman et al. 2003; Hayes et al. 2004; Dimeo 
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group trials (Danaher Hacker et al. 2011; Wilson et al. 2005; Decker et al 1989; Dimeo et al. 
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1997, 1999, 2003). Exercise was tested during hospitalization in three studies ( Baumann et 
al. 2005; Dimeo et al. 1996; 2003), one study during hospitalization and continued to out-
patient (Dimeo 1999), and eight studies after hospital discharge (outpatient and home based 
programs) (Wilson et al. 2005; Decker et al 1989; Coleman et al. 2003; Hayes et al. 2004; 
Dimeo et al. 1997, Knols et al. 2010; Peerson et al. 2010; Danaher Hacker et al. 2011). 
Feasibility was established, no adverse events registered and beneficial effects were reported 
on aerobic capacity (Hayes et al. 2004; Dimeo et al. 2003; Dimeo et al. 1996); muscle strength 
(Hayes et al. 2004; Knols et al. 2010), body composition (Coleman et al. 2003; Hayes et al. 
2003), immunological function (Dimeo et al. 1997; Hayes et al. 2003; Knols et al. 2010), 
treatment-related symptoms i.e. fatigue (Dimeo et al. 1999; Wilson et al. 2005) and HRQoL 
(Wilson et al. 2005; Hayes et al. 2004). These positive and potentially important results for 
HD-SCS and mixed groups are encouraging, but we need to look exclusively at the allo-
HSCT adult patient group in order to evaluate the role and impact of exercise rehabilitation 
in this treatment context alone.  
The primary objective of the systematic review is to summarize the exercise-based 
rehabilitative interventions in adults with haematological disease undergoing allogeneic 
hematopoetic stem cell transplantation (allo-HSCT) on feasibility and safety, and 
effectiveness related to physical and functional capacity, health related quality of life, 
treatment-related symptoms and medical related outcomes.  
2. Method  
The systematic literature search is based on PRISMA guidelines (preferred reporting items 
for systematic reviews and metaanalyses) developed from Cochrane Collaboration (Moher 
D et al. 2009).This review includes 1) a systematic literature search with the identification of 
all intervention trials in adult patients in the allo-HSCT setting during the past 25 years, 2) a 
uniform presentation of all trials and a synthesis of the characteristics and findings, 3) an 
appraisal of the methodological quality of the trials, 4) a summary and 5)  conclusions and 
future research.   
2.1 Search strategy and data extraction  
The systematic literature review covers 25 years of research: 1986 – 2011 (Table 1). Searches 
were carried out in MEDLINE and EMBASE using search items bone marrow cell 
transplantation, bone marrow transplantation, stem cell transplantation, physical activity, 
physical fitness and exercise. Identified articles were searched for additional references. The 
search was limited to include randomized controlled trials (RCT), controlled clinical trials, 
adults and English articles. Eligibility criteria are shown in Table 2. Only studies that 
included patients from the allogeneic setting are included in this review. Studies that 
included patients in either the auto-HSCT / HD-SCS setting or mixed settings (both 
autologous and allogeneic) were excluded, though compiled in the literature search for 
background and reference purposes. Full articles were obtained for remaining abstracts and 
information was extracted from identified articles and organized under the following 
headings: authors, sample (n, type of treatment), age, design and study period, exercise-
based intervention, duration, frequency/intensity, and results (Table 3). All articles were 
independently reviewed and appraised for rigor of method and analysis.  
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 Inclusion criteria  Exclusion criteria 
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 Participants >18 years  
 Recipients of allo-HSCT for a hematologic 
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 Published in English between 1986 and 2011 
 Studies that include auto-HSCT/HD-SCT 
 Studies that include a mixed population of 
auto-HSCT and allo-HSCT 
 Review articles or case study 
 Clinical reports  
 Dissertations  
 Conference abstracts 
 Editorials or letters to the editor 
Allo-HSCT indicates allogeneic stem cell transplantation; auto-SCT, autologous stem cell 
transplantation; HD-SCT, high dose chemotherapy with stem cell support 
Table 2. Eligibility criteria  
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Table 3. Physical exercise based studies in allogeneic HSCT on aerobic capacity, muscle 

























































































































































































































































































































































































































































































































































































































































































































A Systematic Review of Nonpharmacological Exercise-Based Rehabilitative  
Interventions in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation  
 
569 
3. Results  
3.1 Exercise-based studies in the allo-HSCT setting 
In this review, 10 studies met the inclusion criteria (Baumann et al. 2011; Carlson et al. 2006; 
Cunningham et al. 1986; Defor et al. 2007; Inoue et al., 2010; Jarden et al., 2009; Kim and Kim 
2006; Mello et al. 2003; Shelton et al. 2009; Wiskemann et al. 2011). Of these, three were from 
the USA and two from Germany, and respectively, one from Brazil, Canada, Denmark, 
Japan and South Korea. Cunningham et al. carried out the very first exercise training trial 
for the allo-HSCT population in 1986 and although the participants included children and 
adults (range 14 – 41 years), this study is included in the review because of its focus being in 
the allo-HSCT setting only. Jarden et al. published three articles and Kim et al. two articles, 
each based on one trial, however each article has a different focus and purpose.  
All studies were designed as prospective intervention trials that tested an exercise-based 
program. The primary and secondary outcomes were study feasibility and safety; 
physiological outcomes i.e. aerobic, muscle strength and function; psychosocial outcomes 
i.e. health-related QoL, emotional wellbeing; treatment-related symptoms i.e. fatigue; and 
hospital or disease-related outcomes i.e. days of hospitalization, creatinine excretion, 
lymphocyte counts. Baseline to post assessment ranged between 4 – 16 weeks [mean 7.3] and 
one study had follow-up tests to 6 months (Jarden et. al. 2009).  
3.2 Sample characteristics  
In all, 406 patients with different haematological diseases (AA,, AML, ALL, CLL , CML, 
CMML, FL, HD, MDS, MF, MM, MPS, NHL, PNH, WM, other lymphomas)1 across 10   
 
 
Table 4. Intervention phase 
                                                 
1 AA indicates aplastic anemia, AML, acute myelogenous leukemia; ALL, acute lymphocytic or 
lymphoblastic leukemia ; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; 
CMML, chronic myelomonocytic leukemia; HD, Hodgkins disease; MDS, myelodysplastic syndrome; 
MF, myelofibrosis; MM,  multiple myeloma; MPS, myeloproliferative syndrome; NHL, Non-Hodgkin 
lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; WM, waldenstrom macroglobulinemia 
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studies are included in this review. The sample size of the studies ranged from 12 to 105 
[Mean 50.7] and the patients were of mixed gender between 14 and 71 years [mean 42.6]. 
Cunningham was the only study that included patients less than 18 years of age. Four 
studies were initiated prior to conditioning and throughout the hospitalization period 
(Baumann et al. 2011; Cunningham et al. 1986; Defor et al. 2007; Jarden et al. 2009; Kim and 
Kim 2006; Wiskemann et al. 2011), two studies after marrow engraftment and throughout 
hospitalization (Mello et al., 2003; Inoue et al., 2010), and three of these continued post allo-
HSCT (Defor et al. 2007; Mello et al. 2003; Wiskemann et al. 2011). Two studies were 
initiated post allo-HSCT in the out-patient or home setting, within 6 and 39 months (range 9-
92), respectively (Shelton et al. 2009; Carlson et al. 2006). The approximate start and 
endpoint of each intervention is illustrated in Table 4.  
3.3 Type of exercise-based interventions 
The duration of the exercise-based interventions ranged between 4-16 weeks [mean 7.3]. 
For interventions initiated prior to and during hospitalization, 6 of the studies were 
supervised (Cunningham et al. 1986; Mello et al. 2003; Kim and Kim 2006; Jarden et al. 
2009; Inoue et al. 2010; Baumann et al. 2011) and 2 were partly supervised (DeFor et al. 
2007, Wiskemann et al. 2011). In the out-patient context, Carlson’s study was fully 
supervised, while Shelton’s study had one supervised and one self-directed study arm. 
The frequency of all interventions ranged between 3 and 5 days/week or daily. When 
reported, the intensity of training in general was between low/mild and comfortable to 
moderate but not exceeding 70-75% of maximum heart rate or in Rate of Perceived 
Exertion (RPE) - being somewhat hard.     
In the in-patient context, one study tested strength resistive training (Cunningham et al. 
1986), one a walking program (treadmill or walking) (Defor et al. 2007) and another mixed-
type low intensity bed exercises of stretching and relaxation breathing (Kim and Kim 2006), 
and 5 studies instituted mixed-type exercise up to moderate intensity (Mello et al. 2003, 
Jarden et al. 2009, Inoue et al. 2010, Wiskemann et al. 2011, Baumann et al. 2011) by 
combining aerobic training (treadmill, cycle, walking or stair climbing) with one or more 
other moderate intensity exercise (range of motion or ADL (activities of daily living), 
coordination exercises, muscle stretching, resistive exercises with free weights or elastic 
bands) and low intensity progressive relaxation training and education (Jarden et al. 2009). 
Three studies (Mello et al. 2003; Wiskemann et al. 2011, Defor et al. 2007) continued the 
programs after hospital discharge. In the out-patient only context, one study tested an 
ergometer cycle program (Carlson et al. 2006), and the other, aerobic (cycle or treadmill) and 
resistive exercises (weight machines) vs. selfdirected walking and resistive exercises 
including patient information regarding exercise safety (Shelton et al. 2009). All in all, three 
studies were unidimensional (one exercise component), of which, two were aerobic training 
(Carlson et al. 2006; DeFor et al. 2007), and one resistance training (Cunningham et al. 1986), 
and seven studies had mixed type training (Baumann et al. 2011; Inoue et al. 2010; Jarden et 
al. 2009; Kim and Kim 2006; Mello et al. 2003; Shelton et al. 2009; Wiskemann 2011), of 
which, one was of low intensity (Kim and Kim 2006), and one study included both low and 
moderate intensity components (Jarden et al. 2009). Only two studies incorporated 
educational (Shelton et al. 2009) or psychoeducational (Jarden et al. 2009) elements in the 
program.    
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3.4 Feasibility and safety  
No adverse events, reactions or injuries were reported, though not all studies reported 
safety outcomes. The overall attrition rates ranged between 0 and 44% (mean 18.7). Program 
compliance was reported by five studies (Carlson et al. 2006; DeFor et al. 2007; Jarden et al. 
2009; Shelton et al. 2009; Wiskemann et al. 2011). Carlson et al. reported an overall 89% 
compliance. Defor et al. reported that 24% of all patients had 100% compliance and that 62% 
of the study’s population exercised at least 5 times/wk for at least 15 min during 
hospitalization and after discharge, respectively. Jarden et al. reported 90% intervention 
compliance (range 67-100), and 83% in-hospital and 87% at-home compliance (Wiskemann 
et al. 2011), while Shelton et al. reported 75% for the supervised intervention, though did not 
report for the self-directed intervention. Some studies had safety screening parameters, in 
which contraindication for exercise included platelet counts <10 and 20 x 109/l 
(Cunningham et al. 1986, Mello et al. 2003, Jarden et al. 2009; Wiskemann et al. 2011, 
Baumann et al. 2011), and haemoglobin <5 g/dl (Jarden et al. 2009), <8 (Wiskemann et al. 
2011, Baumann et al. 2011), and <10 (Mello et al. 2003); temp>38oC (Cunningham et al. 1986; 
Jarden et al. 2009; Wiskemann et al. 2011, Baumann et al. 2011), and adverse symptoms as 
bleeding, petecchiae, pain, nausea, dizziness. Baumann et al. interrupted training during 
cardio and nephrotoxic chemotherapy.  
3.5 Physiological outcomes - aerobic/endurance  
A mixed-type exercise program 5 days/week at moderate intensity during the entire 
hospitalization was able to maintain aerobic capacity, while the control group decreased, 
and this difference was highly significant (p<0.01) (Jarden et al. 2009). Another similar 
mixed-exercise program during hospitalization showed a significant decrease in aerobic 
endurance (p=0.009) in the control group, but no significant difference between intervention 
and control groups (Baumann et al. 2011). A 12 wk. aerobic training program on cycle 
ergometer initiated between 9 and 92 months after HSCT showed cardiovascular effects 
through increased stroke volume (p<0.005) and decreased heart rate (p<0.005), with a 
decreased RPE (p<0.005) (Carlson et al. 2006). 
3.6 Muscle strength 
Mello et al. combined aerobic (treadmill) and ROM exercise program initiated during 
hospitalization and continued into the outpatient facility over 6 weeks showed significant 
decrease in upper and lower extremity strength in the control group, however differences 
between intervention and control groups were not significant.  
During hospitalization, four muscle strength tests (chest press 1 RM, leg extension 1 RM, 
elbow flexor and knee extensor Newton) decreased by 2 - 4 % in the intervention group, 
while decreasing between 19 - 25 % in the control group. This difference was significant 
(p<0.01) (Jarden et al. 2009). Baumann et al., however, did not find a significant difference 
between groups for muscle strength, but the pre to post muscle strength scores decreased 
significantly in the control group (p=0.022).  
3.7 Functional capacity  
Wiskemann et al. maintained the 6 minute walk distance (6MWD) in the intervention group, 
while the control group decreased and the intergroup difference was significant (p=0.02). 
The 2 minute stair climb test in the intervention group decreased by 14 % and for the control 
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92), respectively (Shelton et al. 2009; Carlson et al. 2006). The approximate start and 
endpoint of each intervention is illustrated in Table 4.  
3.3 Type of exercise-based interventions 
The duration of the exercise-based interventions ranged between 4-16 weeks [mean 7.3]. 
For interventions initiated prior to and during hospitalization, 6 of the studies were 
supervised (Cunningham et al. 1986; Mello et al. 2003; Kim and Kim 2006; Jarden et al. 
2009; Inoue et al. 2010; Baumann et al. 2011) and 2 were partly supervised (DeFor et al. 
2007, Wiskemann et al. 2011). In the out-patient context, Carlson’s study was fully 
supervised, while Shelton’s study had one supervised and one self-directed study arm. 
The frequency of all interventions ranged between 3 and 5 days/week or daily. When 
reported, the intensity of training in general was between low/mild and comfortable to 
moderate but not exceeding 70-75% of maximum heart rate or in Rate of Perceived 
Exertion (RPE) - being somewhat hard.     
In the in-patient context, one study tested strength resistive training (Cunningham et al. 
1986), one a walking program (treadmill or walking) (Defor et al. 2007) and another mixed-
type low intensity bed exercises of stretching and relaxation breathing (Kim and Kim 2006), 
and 5 studies instituted mixed-type exercise up to moderate intensity (Mello et al. 2003, 
Jarden et al. 2009, Inoue et al. 2010, Wiskemann et al. 2011, Baumann et al. 2011) by 
combining aerobic training (treadmill, cycle, walking or stair climbing) with one or more 
other moderate intensity exercise (range of motion or ADL (activities of daily living), 
coordination exercises, muscle stretching, resistive exercises with free weights or elastic 
bands) and low intensity progressive relaxation training and education (Jarden et al. 2009). 
Three studies (Mello et al. 2003; Wiskemann et al. 2011, Defor et al. 2007) continued the 
programs after hospital discharge. In the out-patient only context, one study tested an 
ergometer cycle program (Carlson et al. 2006), and the other, aerobic (cycle or treadmill) and 
resistive exercises (weight machines) vs. selfdirected walking and resistive exercises 
including patient information regarding exercise safety (Shelton et al. 2009). All in all, three 
studies were unidimensional (one exercise component), of which, two were aerobic training 
(Carlson et al. 2006; DeFor et al. 2007), and one resistance training (Cunningham et al. 1986), 
and seven studies had mixed type training (Baumann et al. 2011; Inoue et al. 2010; Jarden et 
al. 2009; Kim and Kim 2006; Mello et al. 2003; Shelton et al. 2009; Wiskemann 2011), of 
which, one was of low intensity (Kim and Kim 2006), and one study included both low and 
moderate intensity components (Jarden et al. 2009). Only two studies incorporated 
educational (Shelton et al. 2009) or psychoeducational (Jarden et al. 2009) elements in the 
program.    
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3.4 Feasibility and safety  
No adverse events, reactions or injuries were reported, though not all studies reported 
safety outcomes. The overall attrition rates ranged between 0 and 44% (mean 18.7). Program 
compliance was reported by five studies (Carlson et al. 2006; DeFor et al. 2007; Jarden et al. 
2009; Shelton et al. 2009; Wiskemann et al. 2011). Carlson et al. reported an overall 89% 
compliance. Defor et al. reported that 24% of all patients had 100% compliance and that 62% 
of the study’s population exercised at least 5 times/wk for at least 15 min during 
hospitalization and after discharge, respectively. Jarden et al. reported 90% intervention 
compliance (range 67-100), and 83% in-hospital and 87% at-home compliance (Wiskemann 
et al. 2011), while Shelton et al. reported 75% for the supervised intervention, though did not 
report for the self-directed intervention. Some studies had safety screening parameters, in 
which contraindication for exercise included platelet counts <10 and 20 x 109/l 
(Cunningham et al. 1986, Mello et al. 2003, Jarden et al. 2009; Wiskemann et al. 2011, 
Baumann et al. 2011), and haemoglobin <5 g/dl (Jarden et al. 2009), <8 (Wiskemann et al. 
2011, Baumann et al. 2011), and <10 (Mello et al. 2003); temp>38oC (Cunningham et al. 1986; 
Jarden et al. 2009; Wiskemann et al. 2011, Baumann et al. 2011), and adverse symptoms as 
bleeding, petecchiae, pain, nausea, dizziness. Baumann et al. interrupted training during 
cardio and nephrotoxic chemotherapy.  
3.5 Physiological outcomes - aerobic/endurance  
A mixed-type exercise program 5 days/week at moderate intensity during the entire 
hospitalization was able to maintain aerobic capacity, while the control group decreased, 
and this difference was highly significant (p<0.01) (Jarden et al. 2009). Another similar 
mixed-exercise program during hospitalization showed a significant decrease in aerobic 
endurance (p=0.009) in the control group, but no significant difference between intervention 
and control groups (Baumann et al. 2011). A 12 wk. aerobic training program on cycle 
ergometer initiated between 9 and 92 months after HSCT showed cardiovascular effects 
through increased stroke volume (p<0.005) and decreased heart rate (p<0.005), with a 
decreased RPE (p<0.005) (Carlson et al. 2006). 
3.6 Muscle strength 
Mello et al. combined aerobic (treadmill) and ROM exercise program initiated during 
hospitalization and continued into the outpatient facility over 6 weeks showed significant 
decrease in upper and lower extremity strength in the control group, however differences 
between intervention and control groups were not significant.  
During hospitalization, four muscle strength tests (chest press 1 RM, leg extension 1 RM, 
elbow flexor and knee extensor Newton) decreased by 2 - 4 % in the intervention group, 
while decreasing between 19 - 25 % in the control group. This difference was significant 
(p<0.01) (Jarden et al. 2009). Baumann et al., however, did not find a significant difference 
between groups for muscle strength, but the pre to post muscle strength scores decreased 
significantly in the control group (p=0.022).  
3.7 Functional capacity  
Wiskemann et al. maintained the 6 minute walk distance (6MWD) in the intervention group, 
while the control group decreased and the intergroup difference was significant (p=0.02). 
The 2 minute stair climb test in the intervention group decreased by 14 % and for the control 
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group 38%, and the difference between groups was significant (p<0.01) (Jarden et al. 2009). 
A walking program did not show significant differences between groups for the Karnofsky 
score, though a subgroup analysis of the nonmyeloablative conditioned patients showed 
that this patient group decreased significantly less than the control group (p=0.04) (DeFor et 
al. 2007). There were no significant differences for the 6MWD between a supervised and self 
directed intervention, still both groups significantly improved by 12% (p<0.05) and 9.8% 
(p<0.05), respectively (Shelton et al. 2009). Also, the supervised group improved the 50 foot 
walk time (p=0.05) and maintained other performance tests, though no significance between 
groups.  
3.8 Health-related quality of life 
A bed exercise study with relaxation breathing, ROM and stretching during hospitalization 
decreased depression (BDI) p=0.0001 and anxiety (STAI) p=0.0001 as compared to the 
control group (Kim and Kim 2006). An in- to out-patient walking program showed 
improvements in physical and emotional wellbeing on a self reported score from 1 – 10, 
with 1 being very poor and 10 being very good. At discharge, physical wellbeing was better 
in the exercise group (p<0.01). Among the nonmyeloablative group, emotional wellbeing 
was better in the exercise group (p=0.02) at discharge and at 100 days, physical wellbeing 
was superior in the exercise group (p<0.01) (DeFor et al. 2007). A mixed exercise 
intervention during the entire hospitalization showed no difference in QoL and emotional 
wellbeing between groups (EORTC-QLQ-C30, FACT-An, HADS), though HRQOL was 
maintained in the intervention group at post testing, and there was significant improvement 
in emotional wellbeing at 3 and 6 months, p=0.045 and p=0.012, respectively (FACT-An) and 
significant decrease in anxiety at 3 and 6 months, p=0.021 and p<0.0001, respectively 
(HADS). The control group significantly decreased overall HRQOL p=0.0005 (FACT-An) at 
post testing, and significantly reduced physical functioning (p=0.004) and worsened three 
gastrointestinal symptoms (nausea and vomiting (p=0.048), appetite loss (p=0.004) and 
diarrhea (p=0.011) (EORTC QLQ C-30) (Jarden et al. 2009). Wiskemann et al. study beyond 
discharge showed between group differences in favor of the intervention group in physical 
functioning (p=0.03)(EORTC-QLQ-C30) and decreased depression (p=0.05), though showed 
a significant  increase in anxiety (p=0.01) in the intervention group (HADS). Baumann et al. 
found no significant difference between groups on the EORTC-QLQ-C30, though the pre-
post differences in the intervention and control group decreased significantly for physical 
functioning (p=0.005 and p=0.002). Intervention group improved emotional state (p=0.028), 
but again, no differences between groups (Baumann et al. 2011). Carlson et al.’s out-patient 
endurance program significantly improved intergroup vigor scores (p<0.001) on POMS.  
3.9 Treatment-related symptoms  
There was a decreased symptom prevalence in diminished concentration, memory loss, 
nausea and nervousness (p<0.01) and decreased symptom severity in fatigue, loss of 
appetite, sleep difficulties and nausea (p<0.05) on the SCT-SAS scale (Jarden et al. 2009). 
Further, diarrhea was significantly decreased (EORTC-QLQ-C30) (p=0.014) (Jarden et al. 
2009). Symptom cluster analyses revealed a significant decrease in symptom severity in 
gastrointestinal, cognitive, functional and mucositis clusters over time and up to 6 months 
after allo-HSCT (p<0.01). Wiskemann et al. found a significant decrease between groups in 
both general and physical fatigue (p=0.009, p=0.01) MFI and a significant decrease in fatigue 
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(p=0.01) (POMS). Baumann et al. was unable to show between group differences in fatigue 
scores, but the control group increased fatigue at post testing (p=0.046). Carlson et al. 
showed a significant decrease in fatigue (p<0.001) (BFI and FACT-F). 
3.10 Medical related outcomes 
Cunningham et al. did not find significant changes in body composition, though a 
decreased creatinine excretion in the intervention group (Cunningham et al. 1986). Kim et 
al. tested a bed exercise effect on lymphocyte counts, and reported no significant 
differences between groups, however there was an interaction between groups and times 
(p=0.031), there was also a decrease in lymphocyte count in the control group (p<0.05). 
Jarden et al. reported the intervention group as receiving fewer days of TPN (p=0.019) 
with no changes in BMI between groups at post testing. There were no other differences 
between groups regarding hospitalization days, bone marrow engraftment days, days 
with fever, and though there was a 19% difference in the incidence of GvHD favoring the 
intervention group, this was not statistically different. Defor et al. and Inoue et al. showed 
no difference in days of hospitalization between groups, but Inoue et al. showed that the 
degree of physical activity had a negative correlation with the duration of hospitalization 
(r=-.71; p=0.0071). 
3.11 Methodological quality of the studies 
Seven studies were designed as randomized trials (Cunningham et al. 1986; Mello et al. 
2003; Kim and Kim 2006; Defor et al. 2007; Jarden et al. 2009; Shelton et al. 2009; Baumann et 
al. 2011), one study allocated through the minimization method (Wiskeman et al. 2011), one 
study was a convenience sample studying the effect of the same exercise intervention on 
two different allo-HSCT treatment groups (myeloablative or nonmyeloablative conditioning 
regime) (Inoue et al. 2010) and one study did not have a control group (Carlson et al. 2006). 
Further, Shelton et al. studied the effect of two different interventions (supervised vs. self 
directed) in the outpatient/home setting. The control group was described in most studies 
as receiving standard or usual care, including either no formal training or the hospital units’ 
standard physical therapy (PT). Generally, standard PT was described as being introduced 
later during hospitalization, i.e. after stem cell infusion, and at less frequent intervals and 
lower intensity levels. The study arms were not similar at baseline in two (Kim and Kim 
2006; Baumann et al. 2011) of the eight groups in which there was an intervention and 
control group present. The control group in Kim et al. had a significant higher lymphocyte 
level at baseline compared to the intervention group and Baumann et al. had twice as many 
males as females in the exercise group as compared to the control group at baseline. All 
studies reported the eligibility criteria to which the study population was chosen. Only one 
study stated that the outcome assessor was blinded (DeFor et al. 2007). In the relevant 
studies, none reported blinding of the exercise trainer or the patients. Two studies reported 
performing intention-to-treat analyses (Jarden et al. 2009; Wiskemann et al. 2011).  
4. Summary 
This is the first literature review of exercise-based interventions in the allo-HSCT context. 
The purpose of this systematic review was to summarize the exercise-based rehabilitative 
interventions in adults with haematological disease undergoing allogeneic hematopoetic 
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group 38%, and the difference between groups was significant (p<0.01) (Jarden et al. 2009). 
A walking program did not show significant differences between groups for the Karnofsky 
score, though a subgroup analysis of the nonmyeloablative conditioned patients showed 
that this patient group decreased significantly less than the control group (p=0.04) (DeFor et 
al. 2007). There were no significant differences for the 6MWD between a supervised and self 
directed intervention, still both groups significantly improved by 12% (p<0.05) and 9.8% 
(p<0.05), respectively (Shelton et al. 2009). Also, the supervised group improved the 50 foot 
walk time (p=0.05) and maintained other performance tests, though no significance between 
groups.  
3.8 Health-related quality of life 
A bed exercise study with relaxation breathing, ROM and stretching during hospitalization 
decreased depression (BDI) p=0.0001 and anxiety (STAI) p=0.0001 as compared to the 
control group (Kim and Kim 2006). An in- to out-patient walking program showed 
improvements in physical and emotional wellbeing on a self reported score from 1 – 10, 
with 1 being very poor and 10 being very good. At discharge, physical wellbeing was better 
in the exercise group (p<0.01). Among the nonmyeloablative group, emotional wellbeing 
was better in the exercise group (p=0.02) at discharge and at 100 days, physical wellbeing 
was superior in the exercise group (p<0.01) (DeFor et al. 2007). A mixed exercise 
intervention during the entire hospitalization showed no difference in QoL and emotional 
wellbeing between groups (EORTC-QLQ-C30, FACT-An, HADS), though HRQOL was 
maintained in the intervention group at post testing, and there was significant improvement 
in emotional wellbeing at 3 and 6 months, p=0.045 and p=0.012, respectively (FACT-An) and 
significant decrease in anxiety at 3 and 6 months, p=0.021 and p<0.0001, respectively 
(HADS). The control group significantly decreased overall HRQOL p=0.0005 (FACT-An) at 
post testing, and significantly reduced physical functioning (p=0.004) and worsened three 
gastrointestinal symptoms (nausea and vomiting (p=0.048), appetite loss (p=0.004) and 
diarrhea (p=0.011) (EORTC QLQ C-30) (Jarden et al. 2009). Wiskemann et al. study beyond 
discharge showed between group differences in favor of the intervention group in physical 
functioning (p=0.03)(EORTC-QLQ-C30) and decreased depression (p=0.05), though showed 
a significant  increase in anxiety (p=0.01) in the intervention group (HADS). Baumann et al. 
found no significant difference between groups on the EORTC-QLQ-C30, though the pre-
post differences in the intervention and control group decreased significantly for physical 
functioning (p=0.005 and p=0.002). Intervention group improved emotional state (p=0.028), 
but again, no differences between groups (Baumann et al. 2011). Carlson et al.’s out-patient 
endurance program significantly improved intergroup vigor scores (p<0.001) on POMS.  
3.9 Treatment-related symptoms  
There was a decreased symptom prevalence in diminished concentration, memory loss, 
nausea and nervousness (p<0.01) and decreased symptom severity in fatigue, loss of 
appetite, sleep difficulties and nausea (p<0.05) on the SCT-SAS scale (Jarden et al. 2009). 
Further, diarrhea was significantly decreased (EORTC-QLQ-C30) (p=0.014) (Jarden et al. 
2009). Symptom cluster analyses revealed a significant decrease in symptom severity in 
gastrointestinal, cognitive, functional and mucositis clusters over time and up to 6 months 
after allo-HSCT (p<0.01). Wiskemann et al. found a significant decrease between groups in 
both general and physical fatigue (p=0.009, p=0.01) MFI and a significant decrease in fatigue 
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(p=0.01) (POMS). Baumann et al. was unable to show between group differences in fatigue 
scores, but the control group increased fatigue at post testing (p=0.046). Carlson et al. 
showed a significant decrease in fatigue (p<0.001) (BFI and FACT-F). 
3.10 Medical related outcomes 
Cunningham et al. did not find significant changes in body composition, though a 
decreased creatinine excretion in the intervention group (Cunningham et al. 1986). Kim et 
al. tested a bed exercise effect on lymphocyte counts, and reported no significant 
differences between groups, however there was an interaction between groups and times 
(p=0.031), there was also a decrease in lymphocyte count in the control group (p<0.05). 
Jarden et al. reported the intervention group as receiving fewer days of TPN (p=0.019) 
with no changes in BMI between groups at post testing. There were no other differences 
between groups regarding hospitalization days, bone marrow engraftment days, days 
with fever, and though there was a 19% difference in the incidence of GvHD favoring the 
intervention group, this was not statistically different. Defor et al. and Inoue et al. showed 
no difference in days of hospitalization between groups, but Inoue et al. showed that the 
degree of physical activity had a negative correlation with the duration of hospitalization 
(r=-.71; p=0.0071). 
3.11 Methodological quality of the studies 
Seven studies were designed as randomized trials (Cunningham et al. 1986; Mello et al. 
2003; Kim and Kim 2006; Defor et al. 2007; Jarden et al. 2009; Shelton et al. 2009; Baumann et 
al. 2011), one study allocated through the minimization method (Wiskeman et al. 2011), one 
study was a convenience sample studying the effect of the same exercise intervention on 
two different allo-HSCT treatment groups (myeloablative or nonmyeloablative conditioning 
regime) (Inoue et al. 2010) and one study did not have a control group (Carlson et al. 2006). 
Further, Shelton et al. studied the effect of two different interventions (supervised vs. self 
directed) in the outpatient/home setting. The control group was described in most studies 
as receiving standard or usual care, including either no formal training or the hospital units’ 
standard physical therapy (PT). Generally, standard PT was described as being introduced 
later during hospitalization, i.e. after stem cell infusion, and at less frequent intervals and 
lower intensity levels. The study arms were not similar at baseline in two (Kim and Kim 
2006; Baumann et al. 2011) of the eight groups in which there was an intervention and 
control group present. The control group in Kim et al. had a significant higher lymphocyte 
level at baseline compared to the intervention group and Baumann et al. had twice as many 
males as females in the exercise group as compared to the control group at baseline. All 
studies reported the eligibility criteria to which the study population was chosen. Only one 
study stated that the outcome assessor was blinded (DeFor et al. 2007). In the relevant 
studies, none reported blinding of the exercise trainer or the patients. Two studies reported 
performing intention-to-treat analyses (Jarden et al. 2009; Wiskemann et al. 2011).  
4. Summary 
This is the first literature review of exercise-based interventions in the allo-HSCT context. 
The purpose of this systematic review was to summarize the exercise-based rehabilitative 
interventions in adults with haematological disease undergoing allogeneic hematopoetic 
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stem cell transplantation (allo-HSCT) on feasibility and safety, and effectiveness related to 
physical and functional capacity, health related quality of life, treatment-related symptoms 
and medical related outcomes. To date, 10 intervention studies and 13 articles have been 
published that incorporated exercise-based regimes in the allo-HSCT context, and though 
we have found encouraging and important results, making direct trial comparisons can be a 
challenge due to the small sample sizes, the wide range of different primary and secondary 
outcomes and measurements, varying types of interventions, and different start and end 
points, duration, frequency and intensity of the different exercise components. Most of the 
studies in this review were randomized trials, however, control groups received varying 
standard care regimes, and there was a lack of outcome assessor blinding, trainer blinding 
and patient blinding which decreases the general methodological quality of the studies. 
Taking these methodological limitations into consideration, this review however finds 
important results pertinent to the allo-HSCT clinical setting.  
The results suggest that exercise interventions are feasible and safe. No study reported 
adverse events as a direct result of testing or exercising, though not all studies reported 
safety. Five studies reported safety screening parameters, which may have contributed to 
patients being able to exercise safely. Of the five studies that reported compliance rates, it 
would suggest that patients are capable of participating adequately in a daily exercise 
program during and after allo-HSCT. Two mixed type exercise studies implemented during 
the entire hospitalization suggest a stabilization in aerobic endurance during hospitalization 
(Jarden et al. 2009; Baumann et al. 2011), and one 12 week out-patient endurance study 
found significant positive cardiovascular effects (Carlson et al. 2006). In regards to muscle 
strength, mixed type exercise during hospitalization (Baumann et al. 2011; Jarden et al. 2009) 
and continuing in the outpatient context (Mello et al. 2003) showed significant muscle 
strength decreases in control group, but only one study found significant differences 
between groups (Jarden et al. 2009) suggesting that the loss of muscle strength was 
minimized. Mixed type exercise during hospitalization (Jarden et al. 2009) and continued 
after discharge (Wiskemann et al. 2011) significantly decreased loss of function (2 minute 
stair climb) (Jarden et al. 2009) and significantly maintained function (6MWT) (Wiskemann 
et al. 2011). DeFor et al.’s walking program during and after discharge did not show 
significant differences between groups for Karnofsky score, though a subgroup analysis of 
the nonmyeloablative group showed a significant reduction in loss of performance in the 
intervention group. (DeFor et al. 2007). Both supervised and self directed mixed type 
exercise in the post HSCT was shown to improve function significantly on the 6MWD and 
for the supervised group improvement was reported for the 50 foot walk time (Shelton et al. 
2009). A mixed type low intensity exercise program during hospitalization significantly 
decreased depression (BDI) and anxiety as compared to the control group (Kim and Kim 
2006), while two mixed-type moderate intensity exercise programs during hospitalization 
did not show a significant effect on HR-QoL (Baumann et al. 2011, Jarden et al. 2009), but 
Wiskemann et al.’s mixed type exercise that continued after discharge showed a significant 
improvement in physical functioning and decreased depression, but also a significant 
increase in anxiety (Wiskemann et al. 2011). DeFor’s in- to out-patient walking program 
reported significant improvements in emotional wellbeing among the nonmyeloablative 
patient group at hospital discharge and by 100 days, physical wellbeing was significantly 
improved. Carlson et al.’s 12 week out-patient endurance program significantly increased 
vigor. There was a significant longitudinal decrease in prevalence and intensity of several 
A Systematic Review of Nonpharmacological Exercise-Based Rehabilitative  
Interventions in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation  
 
575 
symptoms and symptom clusters, including fatigue up to 6 months (Jarden et al. 2009) and 
in two studies exercising after discharge, a significant decrease in fatigue scores was 
reported (Wiskemann et al. 2011, Carlson et al. 2006). Hospital or treatment-related 
outcomes as body composition or immunological and infectious parameters i.e. lymphocyte 
counts, days to bone marrow engraftment, days with fever, incidence of GvHD., number of 
transfusions received)  was not affected by exercise. One exercising group received 
significantly fewer days of TPN as compared to the control group (Jarden et al. 2009). There 
was no effect on duration of hospitalization (Inoue et al. 2010, Jarden et al. 2009, Defor et al. 
2007), though Inoue et al. reported that the level of physical activity had a negative 
correlation with the number of hospitalization days (Inoue et al. 2010).   
It is suggested in recent literature that the optimal training program for persons with cancer 
combine both aerobic and muscle strength training (Neiman & Courneya, 2006, Courneya & 
Friedenreich, 2011). A review from 2008 of 15 exercise trials in the in-patient and out-patient 
HSCT setting, included patients in the allo-HSCT and HD-SCS context and resulted in 
tentative recommendations (Wiskemann & Huber, 2008): mixed exercise: endurance (up to 
daily) and resistance training (2-3 x/wk)), from 10 - 30 minutes at moderate intensity (BORG 
scale 12-14, 70-80% maximum HR) before, during and after hospitalization. In Liu et al. 
literature review from 2009 of physical exercise interventions in hæmatological cancer 
patients suggested it feasible to conduct exercise in this patient population, but concluded 
that there was a lack in methodological quality in the physical exercise studies and therefore 
effectiveness could not be established (Liu  et al. ). Recommendations based on a more 
recent review from 2011 of patients with mixed hematologic disease propose ‘supervised’ 
exercise during and after hematological cancer treatments 2 to 5 days per week, with 
adjustment for health conditions. Further, a combination of aerobic and resistance exercise is 
suggested, with a varying intensity between 40-70% of maximum heart rate and full body 
resistance exercises at 8-12 reps and 2-3 sets with slow progression over time. Health and 
neutropenic screening for exercise participation is also recommended according to Jones et 
al. (Battaglini 2011).  
Exercise recommendations, however for patients during and after hospitalization for 
specifically allo-HSCT have not been developed, and in order to determine the appropriate 
and optimal exercise prescription / intervention for patients undergoing allo-HSCT, trials in 
the allo-HSCT context were examined in this review for type, duration, frequency and 
intensity. Taken the methodological limitations into consideration, a partly to fully 
supervised and daily, mixed-type exercise (aerobic and resistant exercises, also ROM and 
stretching) at moderate intensity (70-75% MHR) started at least prior to conditioning and 
carried out during allo-HSCT is feasible and can maintain or decrease loss of aerobic 
capacity, muscle strength and function at hospital discharge. However, continuing the 
program after hospital discharge had further physical, functional and symptom related 
benefits (decrease fatigue, reduced depression). Attaining positive results require a 
relatively high compliance rate, over 85%. Therefore, screening parameters and 
contraindication for training criteria should be instituted to not only keep the patient safe, 
but also enable adequate participation in the program. Based on this review, it can be 
suggested that postponement or modification of training include: platelets < 20 x 109/l, 
haemoglobin < 5-8 g/l, temp > 38oC and adverse symptoms as bleeding, petecchiae, pain, 
nausea, dizziness. It is not clear from this review, whether training during conditioning inkl. 
cardio and nephrotoxic chemotherapy should be postponed, and to what extent, that is, 
during active infusion or hours/days following chemotherapy. We may also consider 
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The results suggest that exercise interventions are feasible and safe. No study reported 
adverse events as a direct result of testing or exercising, though not all studies reported 
safety. Five studies reported safety screening parameters, which may have contributed to 
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and continuing in the outpatient context (Mello et al. 2003) showed significant muscle 
strength decreases in control group, but only one study found significant differences 
between groups (Jarden et al. 2009) suggesting that the loss of muscle strength was 
minimized. Mixed type exercise during hospitalization (Jarden et al. 2009) and continued 
after discharge (Wiskemann et al. 2011) significantly decreased loss of function (2 minute 
stair climb) (Jarden et al. 2009) and significantly maintained function (6MWT) (Wiskemann 
et al. 2011). DeFor et al.’s walking program during and after discharge did not show 
significant differences between groups for Karnofsky score, though a subgroup analysis of 
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intervention group. (DeFor et al. 2007). Both supervised and self directed mixed type 
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Wiskemann et al.’s mixed type exercise that continued after discharge showed a significant 
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reported significant improvements in emotional wellbeing among the nonmyeloablative 
patient group at hospital discharge and by 100 days, physical wellbeing was significantly 
improved. Carlson et al.’s 12 week out-patient endurance program significantly increased 
vigor. There was a significant longitudinal decrease in prevalence and intensity of several 
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symptoms and symptom clusters, including fatigue up to 6 months (Jarden et al. 2009) and 
in two studies exercising after discharge, a significant decrease in fatigue scores was 
reported (Wiskemann et al. 2011, Carlson et al. 2006). Hospital or treatment-related 
outcomes as body composition or immunological and infectious parameters i.e. lymphocyte 
counts, days to bone marrow engraftment, days with fever, incidence of GvHD., number of 
transfusions received)  was not affected by exercise. One exercising group received 
significantly fewer days of TPN as compared to the control group (Jarden et al. 2009). There 
was no effect on duration of hospitalization (Inoue et al. 2010, Jarden et al. 2009, Defor et al. 
2007), though Inoue et al. reported that the level of physical activity had a negative 
correlation with the number of hospitalization days (Inoue et al. 2010).   
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combine both aerobic and muscle strength training (Neiman & Courneya, 2006, Courneya & 
Friedenreich, 2011). A review from 2008 of 15 exercise trials in the in-patient and out-patient 
HSCT setting, included patients in the allo-HSCT and HD-SCS context and resulted in 
tentative recommendations (Wiskemann & Huber, 2008): mixed exercise: endurance (up to 
daily) and resistance training (2-3 x/wk)), from 10 - 30 minutes at moderate intensity (BORG 
scale 12-14, 70-80% maximum HR) before, during and after hospitalization. In Liu et al. 
literature review from 2009 of physical exercise interventions in hæmatological cancer 
patients suggested it feasible to conduct exercise in this patient population, but concluded 
that there was a lack in methodological quality in the physical exercise studies and therefore 
effectiveness could not be established (Liu  et al. ). Recommendations based on a more 
recent review from 2011 of patients with mixed hematologic disease propose ‘supervised’ 
exercise during and after hematological cancer treatments 2 to 5 days per week, with 
adjustment for health conditions. Further, a combination of aerobic and resistance exercise is 
suggested, with a varying intensity between 40-70% of maximum heart rate and full body 
resistance exercises at 8-12 reps and 2-3 sets with slow progression over time. Health and 
neutropenic screening for exercise participation is also recommended according to Jones et 
al. (Battaglini 2011).  
Exercise recommendations, however for patients during and after hospitalization for 
specifically allo-HSCT have not been developed, and in order to determine the appropriate 
and optimal exercise prescription / intervention for patients undergoing allo-HSCT, trials in 
the allo-HSCT context were examined in this review for type, duration, frequency and 
intensity. Taken the methodological limitations into consideration, a partly to fully 
supervised and daily, mixed-type exercise (aerobic and resistant exercises, also ROM and 
stretching) at moderate intensity (70-75% MHR) started at least prior to conditioning and 
carried out during allo-HSCT is feasible and can maintain or decrease loss of aerobic 
capacity, muscle strength and function at hospital discharge. However, continuing the 
program after hospital discharge had further physical, functional and symptom related 
benefits (decrease fatigue, reduced depression). Attaining positive results require a 
relatively high compliance rate, over 85%. Therefore, screening parameters and 
contraindication for training criteria should be instituted to not only keep the patient safe, 
but also enable adequate participation in the program. Based on this review, it can be 
suggested that postponement or modification of training include: platelets < 20 x 109/l, 
haemoglobin < 5-8 g/l, temp > 38oC and adverse symptoms as bleeding, petecchiae, pain, 
nausea, dizziness. It is not clear from this review, whether training during conditioning inkl. 
cardio and nephrotoxic chemotherapy should be postponed, and to what extent, that is, 
during active infusion or hours/days following chemotherapy. We may also consider 
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incorporation of low intensity exercise as relaxation breathing or progressive relaxation in 
the program, especially when a higher exercise intensity level is not possible (Kim and Kim, 
2006; Jarden et al. 2009). Psychosocial, educational and motivational approaches may be 
integrated to maintain compliance levels, support exercise motivation and efficacy and 
increase independent activity and lifestyle changes.  
5. Conclusion and future research 
This chapter is a systematic review of the  rehabilitation  research carried out in the allo-
HSCT context during the past 25 years. These findings, despite a number of methodological 
issues, indicate positive physiological and emotional benefits from exercise in patients 
during and after allo-HSCT. Exercise during treatment may help patients decrease loss of or 
maintain aerobic and functional capacity, and muscle strength, and when exercise is 
continued or instituted in the outpatient/home context there are improvements in aerobic 
and functional capacity. These results also indicate that exercise-based interventions have 
multidimensional benefits, including maintaining or improving HRQOL and reducing the 
most persistent treatment-related symptoms, especially fatigue. This review provides 
general guidelines for exercise in the allo-HSCT context. However, with improved 
methodological approaches, future research may provide clinicians with more specific 
rehabilitation guidelines.   
5.1 Future research  
Future studies are encouraged to institute certain methodological stringencies, including 
inclusion of homogenous groups (same diagnosis or treatment group), larger patient 
populations, perhaps, multi-institutional studies, randomized designs that clearly describe 
treatment allocation and stratification methods, as well as details regarding the control 
group. Further, point estimates for primary outcomes, effect size calculations, as well as 
Intention-to-Treat analyses are recommended. When and if possible, an effort to blind 
outcome assessors, data entry keyers and statisticians would improve methodological 
quality. It is also important that future studies justify the chosen intervention and clearly 
describe the individual exercise components duration, intensity and frequency as well as 
screening parameters for intervention participation, and lastly, documentation of 
compliance rates in order to properly evaluate the effect of the intervention. Decisions 
regarding test time-points and the most relevant and comprehensive outcome 
measurements need to be associated with challenges directly related to allo-HSCT. 
Therefore, GvHD, treatment related symptoms i.e. fatigue, insomnia, pain, gastrointestinal 
complaints, skin and bodily changes, poor physical, functional and muscle capacity, low 
levels of physical activity and decreased bone density, low Vitamin D levels and reduced 
HRQOL including problems with sexuality, body image, social wellbeing and job function 
need to be considered in this treatment group. More studies are needed that examine the 
entire treatment trajectory and continue well into the out-patient and home setting. Research 
that aims to promote multidimensional benefits may consider multimodal interventional 
designs that combine physical exercise with other psychosocial and educational approaches. 
Additionally the role of vitamin D and exposure to sunlight in combination with physical 
exercise on bone health, function and general wellbeing may be warranted. Further, there is 
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a need to study the patients’ own experience as a participant in an exercise-based 
intervention in order to develop programs that are tailored to fit the needs of patients 
during and after allo-HSCT. Finally, translational intervention studies are needed that 
support and improve the ability of patients to cope with their life situation during 
treatment, as well as to function optimally after allo-HSCT in daily life, including return to 
employment.  
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